# Asthma

## Asthma: diagnosis and monitoring of asthma in adults, children and young people

*Clinical Guideline*

*Appendices A - P*

*January 2015*

*Draft for Consultation*

*Commissioned by the National Institute for Health and Care Excellence*

Royal College of Physicians
The Royal College of Surgeons of England
RCGP Royal College of General Practitioners
Royal College of Nursing
NICE accredited
www.nice.org.uk/accreditation

1



**Funding**
National Institute for Health and Care Excellence

# Contents



1

# Appendices

# Appendix A: Scope

FINAL SCOPE

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## SCOPE

### 1 Guideline title

Asthma: diagnosis and monitoring of asthma in adults, children and young people

#### *1.1 Short title*

Asthma: diagnosis and monitoring

### 2 The remit

The Department of Health has asked NICE: 'to prepare a guideline on the diagnosis and management of asthma'.

### 3 Clinical need for the guideline

#### *3.1 Epidemiology*

a) Asthma is a chronic inflammatory respiratory disease that can affect people of any age but often starts in childhood. It is characterised by attacks of breathlessness and wheezing, with the severity and frequency of attacks varying from person to person. The attacks are associated with variable airflow obstruction within the lung, which is often reversible with or without treatment.

b) The World Health Organization estimates that worldwide 235 million people suffer from asthma and that it is the most common chronic condition affecting children. In the UK 5.4 million people are receiving treatment for asthma, including 1.1 million children.

c) Studies of adults diagnosed with asthma suggest that up to 30% do not have clear evidence of asthma. Some may have had asthma in

Asthma: diagnosis and monitoring final scope
Page 1 of 8

the past, but it is likely that many have been given an incorrect diagnosis.

d) The causes of asthma are not well understood. A combination of risk factors is associated with the condition. Risk factors include both genetic (the condition clusters in families) and environmental (such as inhalation of allergens or chemical irritants) influences. Occupational causes of asthma in adults are often unrecognised.

### *3.2 Current practice*

a) Asthma is diagnosed principally on the basis of a careful history taken by an experienced clinician. Initial clinical assessment includes questions about symptoms (wheezing, cough, breathing and chest problems) and any personal or family history of allergies, atopic disorders or asthma. Various tests can be used to support a diagnosis, but there is no single test that serves as a gold standard.

b) A number of methods and assessments are available to determine the likelihood of asthma. These include measures of airflow obstruction (spirometry and peak flow) and measures of reversibility with bronchodilators, both of which are widely used in current practice. However, normal results do not exclude asthma and abnormal results could be indicators of other respiratory diseases.

c) Testing for airway inflammation is increasingly used as a diagnostic strategy in clinical practice. This includes measuring sputum eosinophil counts and fractional exhaled nitric oxide (FeNO). However, there is some uncertainty about both the sensitivity and specificity of FeNO, particularly whether it can distinguish general atopy from asthma.

d) Other diagnostic strategies include blood or skin prick tests to detect allergic reactions to environmental influences, exercise tests to detect evidence of bronchoconstriction, and measures of airway



1

hyper-reactivity, such as histamine/methacholine PC20 and mannitol challenge. However, it is debatable which test or measure, or combination- of them, is the most effective to accurately diagnose asthma.

e) It is recognised that asthma control is suboptimal in many people with asthma. This has an impact on their quality of life, their use of healthcare services and the associated costs. Asthma control can be monitored by measuring airway inflammation and by using validated questionnaires, but the most effective monitoring strategy is uncertain.

## 4 The guideline

The guideline development process is described in detail on the NICE website (see section 6, 'Further information').

This scope defines what the guideline will (and will not) examine, and what the guideline developers will consider.

It is based on the referral from the Department of Health, but now covers the diagnosis and monitoring of asthma and excludes other aspects of management. This is because there is evidence that incorrect diagnosis is a significant problem whereas management of correctly diagnosed asthma is straightforward in most cases. Also, NICE technology appraisal guidance covers some of the available asthma therapies. In the future NICE will consider whether further guidance on asthma covering the aspects omitted from the current scope is needed.

The areas that will be addressed by the current guideline are described in the following sections.



1

## 4.1 Population

### 4.1.1 Groups that will be covered

a) Adults, children and young people who are being investigated for suspected asthma, or who have been diagnosed with asthma and are having their condition monitored.

b) Specific consideration will be given to subgroups based on age, broadly divided into younger children, older children, and older people (aged over 75 years).

## 4.2 Healthcare setting

a) Primary, secondary and community care settings in which NHS-funded care is provided.

## 4.3 Diagnosis and monitoring

### 4.3.1 Key clinical issues that will be covered

**Diagnosis**

*Initial clinical assessment*

a) The value of specific signs and symptoms in making a diagnosis of asthma. For example, wheezing, cough, breathlessness and other respiratory symptoms including diurnal and seasonal variations; symptoms in response to exercise; and symptoms after taking drugs such as aspirin, other non-steroidal anti-inflammatory drugs and beta-blockers.

b) The value of a family or personal history of atopic disorders in making a diagnosis of asthma.

c) Case identification of occupational asthma.

*Objective tests*

The value of the following tests in making a diagnosis of asthma:

d) Measures of lung function and airway obstruction including spirometry/flow volume loop, peak expiratory flow (PEF) variability,



1

bronchodilator response (using PEF or forced expiratory volume in 1 second), and measures of airway hyper-reactivity, such as histamine/methacholine PC20 and mannitol challenge.

e) Biomarkers of airway inflammation and allergy: skin tests for the common aero-allergens, serum total IgE, peripheral blood eosinophil count and FeNO.

f) Measures of exercise-induced bronchoconstriction.

**Monitoring**

g) Assessment of asthma control using self- or parental reports such as symptom scores or diaries, and validated asthma control questionnaires such as the asthma control test (ACT), the children's asthma control test (CACT), the asthma control questionnaire-7 (ACQ-7), and the Royal College of Physicians 3 (RCP3) questions.

h) Use of tele-healthcare as a route for assessment.

i) Monitoring adherence.

j) Inhaler technique.

k) Assessment of asthma control using tests such as measures of pulmonary function (for example, spirometry and peak expiratory flow meters) and measures of airway hyper-reactivity.

l) Assessments of asthma control using tests or measures such as FeNO.

### 4.3.2 Clinical issues that will not be covered

a) Tertiary care setting.

b) Severe, difficult to control asthma.

c) Sputum cell counts.



1

d) Treating asthma.

### 4.4 Main outcomes

a) Objective response to treatment.

b) Accuracy of diagnostic tests.

c) Frequency of asthma attacks.

d) Need for oral corticosteroids and short-acting beta-agonists.

e) Unscheduled use of healthcare services.

f) Health-related quality of life.

g) Time off school or work.

### 4.5 Economic aspects

Developers will take into account both clinical and cost effectiveness when making recommendations involving a choice between interventions. A review of the economic evidence will be conducted and analyses will be carried out as appropriate. The preferred unit of effectiveness is the quality-adjusted life year (QALY), and the costs considered will usually only be from an NHS and personal social services (PSS) perspective. Further detail on the methods can be found in 'The guidelines manual' (see 'Further information').

### 4.6 Status

#### 4.6.1 Scope

This is the final version of the scope.

#### 4.6.2 Timing

The development of the guideline recommendations will begin in August 2013.



1

# 5 Related NICE guidance

## 5.1 Published guidance and quality standards

- Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201) NICE technology appraisal guidance TA278 (2013).
- Quality standard for asthma. NICE quality standard 25 (2013).
- Bronchial thermoplasty for severe asthma. NICE interventional procedure guidance 419 (2012).
- Roflumilast for the management of severe chronic obstructive pulmonary disease. NICE technology appraisal guidance 244 (2012).
- Chronic obstructive pulmonary disease (updated). NICE clinical guideline 101 (2009).
- Respiratory tract infections. NICE clinical guideline 69 (2008).
- Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over. NICE technology appraisal guidance 138 (2008).
- Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. NICE technology appraisal guidance 131 (2007).
- Inhaler devices for routine treatment of chronic asthma in older children (aged 5–15 years). NICE technology appraisal guidance 38 (2002).
- Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. NICE technology appraisal guidance 10 (2000).

## 5.2 Guidance under development

NICE is currently developing the following related guidance (details available from the NICE website).

- Measuring fractional exhaled nitric oxide concentration in asthma – NIOX MINO, NIOX VERO and NObreath. NICE diagnostic assessment programme. Publication expected April 2014.



1

- Bronchiolitis: diagnosis and management of bronchiolitis in children. NICE clinical guideline. Publication expected April 2015.

## 6 Further information

Information on the guideline development process is provided in the following documents, available from the NICE website:

- How NICE clinical guidelines are developed: an overview for stakeholders' the public and the NHS
- The guidelines manual.

Information on the progress of the guideline will also be available from the NICE website.



1

# Appendix B: Declarations of interest

The 2007 version of the NICE code of practice for declaring and dealing with conflicts of interest policy was applied to this guideline.

**Andrew Menzies-Gow (GDG Chair)**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | Received payment for attending advisory boards for Roche, NAPP, Boehringer Ingelheim and Novartis.<br><br>Received lecture fees for presenting and chairing education meetings from Novartis, Glaxo SmithKline and NAPP.<br><br>Royal Brompton and Harefield NHS Foundation Trust has received payment for participation in phase II and III studies on severe asthma where I am the principal investigator from Glaxo SmithKline, Novartis and Roche.<br><br>I hold one current grant from Asthma UK.<br><br>Member of the BTS severe asthma network and BTS asthma SAG.<br><br>I have resigned my position on the BTS/SIGN asthma guidelines. | Non-specific personal pecuniary<br><br>Non-specific non-personal pecuniary – (monitoring questionnaires review) ACT and CACT developed by GSK but both are freely available (non-profit making).<br><br>Personal non-pecuniary | Declare and participate<br><br>Declare and participate<br><br>Declare and participate |
| GDG2 (3.9.13) | Payment for advisory board attendance for Amgen who are trialling a novel monoclonal antibody for use in severe asthma, October 2013. | Non-specific personal pecuniary | Declare and participate |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | Attending advisory boards for Roche on Lebrikizumab in severe asthma, January and February 2014. | Non-specific personal pecuniary | Declare and participate |
| GDG7 (3.3.14) | Presenting on specialist commissioning of severe asthma at 4 meetings for | Non-specific personal pecuniary | Declare and participate |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| | Novartis.<br>Presenting at 2 meetings in Denmark on severe asthma for Novartis.<br>Attending Gulf Thoracic Society in UAE, sponsored by Novartis. | | |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | Two presentations to primary care on the use of Flutiform in asthma, sponsored by NAPP.<br>One presentation on specialist commissioning of severe asthma services sponsored by Novartis. | Non-specific personal pecuniary | Declare and participate |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | I have attended one advisory board for Boehringer Ingelheim discussing the use of Tiotropium in severe asthma.<br>I have received lecture fees from NAPP for talking about the use of Flutiform in asthma.<br>I have received lecture fees from Glaxo SmithKline for talking about Real Life clinical trials and the Salford Lung Study<br>I have received lecture fees from Chiesi for talking about the Management of Severe Asthma | Non-specific personal pecuniary<br>Non-specific personal pecuniary<br>Non-specific personal pecuniary<br>Non-specific personal pecuniary | Declare and participate |
| GDG12 (2.9.14) | Filming for Boehringer Ingelheim on the use of Tiotropium in severe asthma. | Non-specific personal pecuniary | Declare and participate |
| GDG13 (7.10.14) | Lecture fees for a presentation on severe asthma for Boehringer Ingelheim<br>Lecture fees for a pro con debate on severe asthma for Novartis<br>Lecture fees for a presentation on treatment options for severe asthma and severe asthma workshop for severe asthma for Boehringer-Ingelheim | Non-specific personal pecuniary | Declare and participate |
| GDG14 (30.3.15) | | | |

**John Alexander**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | Received lecture fee from GSK for lecture to GPs. | Non-specific personal pecuniary – (monitoring questionnaires review) ACT and CACT developed by GSK but both are freely available (non-profit making). | Declare and participate |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | Paid lecture on RSV for Abbvie.<br><br>Paid advisory board on preventing RSV admissions by Abbvie. | Non-specific personal pecuniary<br><br>Non-specific personal pecuniary | Declare and participate |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Tara Burn**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Erol Gaillard**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | One research grant for £3000 from Novartis.<br><br>Newly appointed member to the SIGN/BTS Asthma Guideline Development Group. | Non-personal pecuniary<br><br>Personal non-pecuniary | Declare and participate |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | I have a research collaboration with MedImmune a biotech firm with links to AstraZeneca. No direct payments to either me or my research group.<br><br>I am a member to the SIGN/BTS Asthma Guideline Development Group. | Personal non-pecuniary<br><br>Personal non-pecuniary | Declare and participate |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Ren Gilmartin**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | Paid honoraria by Teva for position on “Integrated Care advisory board” May 2013.<br><br>Paid honoraria by British Lung Foundation for development of “Train the Trainer COPD and Self Management” programme May / June 2013.<br><br>PCRS-UK executive and PCRS-UK Nurse committee and receive Loss of Earnings payment plus travel expenses. | Non-specific personal pecuniary | Declare and participate |
| | Pending fee from British Lung Foundation for providing COPD training to GPs and Nurses in Hertfordshire.<br><br>Honoraria received from TEVA for attending advisory meeting.<br><br>Honoraria received from Almirall for attending nurse group meeting.<br><br>Pending fee from RTA training for asthma update presentation for school nurses. | Non-specific personal pecuniary | Declare and participate |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Val Hudson**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | Last year my husband was commissioned by North Durham Clinical Commissioning Group (in shadow form) to carry out a piece of work on developing public and patient involvement in the CCG. This has now finished. | Personal family interest | Declare and participate |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | On the 2nd April I attended a Boehringer Ingelheim training event for their medical and marketing staff in Berlin. The company wanted their staff to understand what it was like for someone 'living with asthma.' I was interviewed by a GP and we both then fielded questions from the audience. The session lasted one hour. I received accommodation and travel expenses but no other | Reasonable travel expenses | Declare and participate |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| | reimbursements | | |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Angela Key**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Matthew Masoli**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | I have received support from GSK to attend the EACCI conference in Milan (June 2013) and with Novartis for the ERS annual conference (Sept 2012). Support included registration and accommodation.<br><br>In June 2013 I was paid by GSK to do a talk on 'asthma control' as part of an allergy study day for GP's and practice nurses. | Non-specific personal pecuniary – (monitoring questionnaires review) ACT and CACT developed by GSK but both are freely available (non-profit making). | Declare and participate |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | Speaker fee for an educational talk and workshop to healthcare professionals on 'reducing emergency asthma admissions' for a severe asthma study day sponsored by Novartis. March 2014. | Non-specific personal pecuniary | Declare and participate |
| GDG9 (13.5.14) | Spoken presentation at a severe asthma symposium sponsored by Novartis in March 2014. | Non-specific personal pecuniary | Declare and participate |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Melanie McFeeters**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | I have received speaker fees, expenses and hospitality from the pharmaceutical industry for both speaking & attending meetings that have taken place in the last | Non-specific personal pecuniary – (monitoring questionnaires | Declare and participate |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| | 12 months and which are planned but have not taken place yet. This includes receiving fees for presenting educational talks to other Healthcare Professionals and hospitality for attending meetings and conferences related to the diagnosis and management of asthma. The companies include Abbott, Abbvie, AstraZeneca, GlaxoSmithKline, Novartis, Roche & Schering Plough.<br><br>Member of the British Thoracic Society (BTS) and committee member of the BTS Nurse Advisory Group.<br>Member of the BTS/SIGN 101 British Guideline on the Management of Asthma Guideline Development Group – Organisation and Delivery of Care.<br>RCN Member. | review) ACT and CACT developed by GSK but both are freely available (non-profit making).<br><br>Personal non-pecuniary | |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | Speaker fee received for educational talk to Healthcare Professionals (GP & PN's) on 30/1/14. Meeting sponsored by GSK. Talk presented - Asthma management in children.<br><br>Steering committee/Advisory board meeting attended on 3/2/14 for AbbVie in preparation for the EMBRACE 2014 meeting – Prophylaxis for RSV. | Non-specific personal pecuniary | Declare and participate |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Tahmina Siddiqui**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | None | n/a | n/a |
| GDG2 (3.9.13) | Member of iCOPD template development group in conjunction with PCRS UK, funded by Kendle Healthcare.<br><br>Attended ERS in September 2102, also to attend a iCOPD meeting funded by Kendle Healthcare.<br><br>Lead GP for COPD in Milton Keynes.<br>Long term intervention team (LIT) chairperson Milton Keynes. | Non-specific personal non-pecuniary<br><br>Non-specific personal pecuniary<br><br>Non-specific personal non-pecuniary | Declare and participate |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | Chaired a GP study day COPD Master class on September 2013 sponsored by Almirral.<br><br>Attended 1st COPD world Summit conference in Lisbon Sponsored by Almirral. | Non-specific personal pecuniary | Declare and participate |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Mike Thomas**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | I have received honoraria for attending advisory panels from the following companies manufacturing respiratory products in the last 12 months:<br>GlaxoSmithKline<br>Almirall<br>Novartis.<br><br>I received sponsorship to attend the European Respiratory Society meeting from Napp (standard travel and hotel).<br><br>I have a research study funded by GSK. | Non-specific personal pecuniary – (monitoring questionnaires review) ACT and CACT developed by GSK but both are freely available (non-profit making).<br><br>Non-specific non-personal pecuniary | Declare and participate |
| | I received an honorarium for speaking at the ERS at the Aerocrine sponsored symposium. | Specific personal pecuniary | Declare and withdraw for FeNO |
| | In the last 3 years I have received speaker's honoraria for speaking at sponsored meetings from the following companies marketing respiratory and allergy products:<br>Aerocrine, Astra Zeneca, Boehringer Inglehiem, GSK, MSD, Napp, Schering-Plough, Teva.<br><br>I have received honoraria for attending advisory panels with; Aerocrine, Almirall, Astra Zeneca, BI, Chiesi, GSK, MSD, Merck Respiratory, Schering-Plough, Teva, Novartis.<br><br>I have received sponsorship to attend international scientific meetings from: GSK, MSD, Astra Zeneca, Mundipharma.<br><br>I have received funding for research projects from: GSK, Almirall.<br><br>I am chief medical adviser to the charity Asthma UK, a member of the BTS SIGN Asthma guideline group. I am a member of the EPOS Rhinosinusitis guideline | Specific personal pecuniary<br><br>Non-specific non-personal pecuniary<br><br>Personal non-pecuniary | Declare and withdraw for FeNO |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| | group.<br><br>I have spoken at the ERS on the use of exhaled nitric oxide in the diagnosis and management of asthma and spoke to the NICE team on this topic as an expert witness. | | |
| | My department has received an honorarium for me speaking at the ERS at the Aerocrine sponsored symposium and my department has received honoraria for me attending an advisory board and for giving a talk at a GP educational meeting.<br><br>My department has received honoraria for producing a research study protocol for Novartis. | Specific non-personal pecuniary interest<br><br>Non-specific non-personal pecuniary | Declare and withdraw for FeNO and the HE model but can answer questions on request by the Chair. |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | My department has received an honorarium from Aerocrine (makers of a FENO monitor) for my attendance at an advisory meeting to discuss research needs in the FENO evidence and we are discussing a possible Horizon 2020 grant application for a multinational collaborative EU-Industry funded project.<br><br>In addition, my department has received funding from GSK as I am the Chief Investigator and chair of the steering committee of an international study investigating inhaler device errors. | Specific non-personal pecuniary interest<br><br>Non-specific non-personal pecuniary | Declare and withdraw for FeNO and the HE model but can answer questions on request by the Chair. |

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| | I have received an honorarium from Boehringer Ingelheim for attendance at a meeting organising a collaborative project with the University of Nottingham/PRIMIS to create an asthma electronic audit tool for use in general practice, and from Novartis for speaking at meeting on COPD. | Non-specific personal pecuniary | |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**NCGC team**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| GDG1 (29.7.13) | In receipt of NICE commissions. | n/a | n/a |
| GDG2 (3.9.13) | No change to existing declarations. | n/a | n/a |
| GDG3 (8.10.13) | No change to existing declarations. | n/a | n/a |
| GDG4 (19.11.13) | No change to existing declarations. | n/a | n/a |
| GDG5&6 (27.1.14 & 28.1.14) | No change to existing declarations. | n/a | n/a |
| GDG7 (3.3.14) | No change to existing declarations. | n/a | n/a |
| GDG8 (8.4.14) | No change to existing declarations. | n/a | n/a |
| GDG9 (13.5.14) | No change to existing declarations. | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |
| GDG11 (22.7.14) | No change to existing declarations. | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |
| GDG13 (7.10.14) | No change to existing declarations. | n/a | n/a |
| GDG14 (30.3.15) | | | |

**Cochrane team**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| Initial declaration (Dec 13) | None | n/a | n/a |
| GDG10 (16.6.14) | No change to existing declarations. | n/a | n/a |

**NIHR team**

| Date | Item declared | Classification | Action taken |
|---|---|---|---|
| Initial declaration (May 14) | None | n/a | n/a |
| GDG12 (2.9.14) | No change to existing declarations. | n/a | n/a |

# 1 Appendix C: Review protocols

## 2 C.1 Diagnosis: Signs and symptoms

3 **Table 1: Review protocol: Signs and symptoms for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic accuracy of each of the following signs and symptoms?<br>• wheezing<br>• cough<br>• breathlessness<br>• nocturnal symptoms<br>• diurnal and seasonal variations |
| Objectives | To evaluate the diagnostic accuracy of signs and symptoms in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Signs and symptoms of asthma<br>Each of the following symptoms alone or in combination:<br>• Wheezing (current or persistent or triggered)<br>• Cough (including nocturnal cough)<br>• Breathlessness<br>• Nocturnal symptoms<br>• Diurnal and seasonal variations |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |

| | |
|---|---|
| | In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (sensitivity and specificity) |
| Other exclusions | • Not looking at occupational asthma /allergens<br>• Not looking at factors which influence signs/symptoms<br>• Due to anticipation of there being a large amount of studies retrieved from the search, the inclusion criteria was limited to studies which only look at populations in the UK, USA, Australia, Canada, New Zealand and Western Europe*. These countries were expected to be similar to the UK in terms of how people report symptoms and the impact of language. If relevant studies were identified from other review questions reporting populations outside these countries then these were included. *Western Europe = Austria, Belgium, France, Germany, Liechtenstein, Luxembourg, Monaco, Netherlands, Switzerland |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br><br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards<br>• Combinations of symptoms |

## C.2 Diagnosis: History of atopic disorders

**Table 2: Review protocol: History of atopic disorders for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic accuracy of taking a personal/family history of atopic disorders? |
| Objectives | To evaluate the diagnostic test value of taking a personal/family history of atopic disorders in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |

| | |
|---|---|
| Index test | Personal/family history of atopic disorders.<br>• This is likely to be ascertained by a questionnaire.<br><br>NOTE: personal history is defined as an individual who has had one of the atopic disorders listed below<br>NOTE: family history is defined as: 1st degree relatives.<br>NOTE: atopic disorders are defined as: eczema, hay fever, allergic rhinitis, food allergy, asthma. |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis.<br><br>In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (sensitivity and specificity) |
| Other exclusions | • Not looking at occupational asthma /allergens<br>• Not looking at other factors which influence this |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different reference standards |

1

# C.3 Diagnosis: Symptoms after exercise

**Table 3: Review protocol: Symptoms after exercise for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic accuracy of a clinical history of symptoms in response to exercise? |
| Objectives | To evaluate the diagnostic test value of taking a clinical history of symptoms in response to exercise in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1- <5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Clinical history of symptoms in response to exercise.<br>NOTE: symptoms would be a combination of the following, or individual symptoms – wheezing, cough, breathlessness |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis.<br>In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Statistical measures | Diagnostic accuracy (sensitivity, specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at other factors which influence signs/symptoms (this includes seasonal variation)<br>• Not looking at tests in athletes or professional / specialist sports<br>• Not looking at validation studies, or studies comparing different methods of measuring clinical history of symptoms after exercise. |

| | |
|---|---|
| | Not looking at 'case-control' type studies where the index test is applied in people with confirmed asthma and healthy controls, and where there is no uncertainty about whether the patient has asthma or not. Such studies only include a spectrum of the disease and non-diseased patients and the diagnostic test accuracy may not be applicable to the clinical question. |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis- subgroups to investigate heterogeneity | None |

# C.4 Diagnosis: Symptoms after drugs

**Table 4: Review protocol: Symptoms after drugs for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic accuracy of a clinical history of symptoms after taking the following drugs:<br>a) in adults - beta blockers, aspirin, or other NSAIDs<br>b) in children – ibuprofen? |
| Objectives | To evaluate the diagnostic test value of taking a clinical history of worsening asthma symptoms after taking drugs (aspirin or other NSAIDs and beta blockers)? |
| Study Design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population/ Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old) - for ibuprofen only<br>• Children/young people (5-16 years old) – for ibuprofen only<br>• Adults (>16 years old) – for beta blockers, aspirin or other NSAIDs |
| Setting | Primary, secondary and community care settings |
| Index test | Clinical history of symptoms after taking drugs.<br>NOTE: drugs of interest for the adult population are aspirin and NSAIDs, beta blockers. For children – ibuprofen.<br>NOTE: symptoms would be a combination of the following, or individual symptoms – wheezing, cough, breathlessness, nocturnal symptoms, diurnal and seasonal variations. |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test); |

| Component | Description |
|---|---|
| | • bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Outcomes | Diagnostic accuracy (sensitivity, specificity) |
| Other exclusions | Not occupational asthma /allergens<br>Not looking at other factors which influence signs/symptoms |
| Search strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | None |

# C.5 Diagnosis: Occupational asthma

**Table 5: Review protocol: Occupational asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In adults under investigation for occupational asthma, what is the diagnostic accuracy for case identification, of asking whether their symptoms are better away from work? |
| Objectives | To evaluate the diagnostic test value (for identifying occupational asthma), of asking whether symptoms are better away from work? |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | Adults (>16 years old) with suspected occupational asthma. |
| Setting | Primary, secondary and community care settings |
| Index test | Symptoms are better away from work.<br><br>NOTE: symptoms are defined as – wheezing, cough, breathlessness, nocturnal symptoms, diurnal variations |
| Reference standard | Physician's diagnosis of occupational asthma supported by an objective test (e.g. specific inhalation challenge) |

| | |
|---|---|
| Outcomes | Diagnostic accuracy (sensitivity, specificity) |
| Other exclusions | |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | Occupational differences (different causal agents) |

# C.6 Diagnosis: Spirometry

**Table 6: Review protocol: Spirometry for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of spirometry / flow volume loop measures? |
| Objectives | To evaluate the diagnostic test value of spirometry / flow volume loop measures in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). Ages stratified into the following 2 groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Spirometry measures (report separately)<br>• FEV1/FVC ratio (<70%)<br>• Flow volume loop (graph)<br>• FEV1 (<80%) – if limited evidence from the above two measures<br><br>Pre bronchodilator values (applies for all above measures)<br>FEV1 and FVC should be performed using the following criteria:<br>• Forced expiratory volume (FEV1) - patients perform manoeuvre until 3 readings are within 5% of each other (maximum 8 attempts) the measured value being the best of these 3 readings.<br>• Forced vital capacity (FVC) - patients perform manoeuvre until 3 readings are within 5% of each other (maximum 8 attempts) the measured value being the best of these 3 readings. |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Outcomes | • Diagnostic accuracy (sensitivity and specificity) |

| | |
|---|---|
| Other exclusions | • Not looking at occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different spirometry or flow volume loop measures<br>• Not looking at factors which influence measurements |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different reference standards |

# C.7 Diagnosis: Bronchodilator reversibility

**Table 7: Review protocol: Bronchodilator reversibility for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of bronchodilator response (using PEF or FEV1)? |
| Objectives | To evaluate the diagnostic test value of bronchodilator response (using PEF or FEV1) in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). Ages stratified into the following 2 groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Bronchodilator response, measured using the following<br>• PEF<br>• FEV1<br>  ○ change in FEV1 % initial and change in FEV1 litres<br><br>Exclusions:<br>• Change in FEV1 % initial alone<br>Change in absolute litres alone<br>• Change in FEV1 % predicted (ΔFEV1 %pred)<br>• Standardised residual (SR)-FEV1<br>• Change in FEV1 % of possible maximal response (ΔFEV1 %max) |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Outcomes | • Diagnostic accuracy (sensitivity and specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different methods of measuring the same test |

| | |
|---|---|
| | • Not looking at factors which influence measurements |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards |

# C.8 Diagnosis: PEF variability

**Table 8: Review protocol: Peak expiratory flow (PEF) variability for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of peak expiratory flow (PEF) variability? |
| Objectives | To evaluate the diagnostic test value of PEF variability in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | PEF variability (diurnal variability usually expressed as amplitude (highest – lowest reading) as a percentage of the mean or the highest reading). PEFv values should be recorded as the mean over a period of at least 3 days) |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an |

| | |
|---|---|
| | objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Outcomes | • Diagnostic accuracy (sensitivity, specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different PEF measures<br>• Not looking at factors which influence measurements |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards |

# C.9 Diagnosis: Skin prick tests

**Table 9: Review protocol: Skin prick tests for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of skin prick tests? |
| Objectives | To evaluate the diagnostic test value of skin prick tests in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Skin prick tests for the most common allergens (reported separately)<br>• House dust mites<br>• Cat<br>• Dog<br>• Grass pollen* (native UK grasses)<br>• Tree pollen* (native UK trees) |

| | |
|---|---|
| | • Mixed pollens* (native UK species)<br>• *Aspergillus*<br>• *Alternaria*<br>• *Cladosporium*<br>Cut off values: 3mm WHEAL (skin reaction) greater than the negative control in the presence of a positive control<br><br>* Mainland Europe (including Denmark; excluding Norway, Sweden, Finland, Iceland, Russia, Greece), North America (USA + Canada), Australia, New Zealand (as trees/grasses/pollen similar to UK in included countries but not in other countries) |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis.<br><br>In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (Sensitivity and specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different skin prick methods<br>• Not looking at factors which influence skin prick measurements<br>• Studies in which we are unable to calculate sensitivity and specificity (unless sensitivity/specificity has been reported by the study). |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Search terms | |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information) |

| | |
|---|---|
| | • Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards<br>• Age groups<br>• People with eczema<br>• Personal or family history of atopy |

# 1C.10 Diagnosis: IgE

2 **Table 10: Review protocol: Serum IgE for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of total and specific serum IgE measures? |
| Objectives | To evaluate the diagnostic test value of serum IgE in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Serum IgE<br>• Total IgE<br>• Specific IgE* (including RAST test)<br><br>*Reported separately t for the most common aero-allergens (dust mites, grass pollen, tree pollen, dog, cat, *Aspergillus, Alternaria, Cladosporium*).<br><br>NOTE: serum IgE must have been assessed using ELISA (apart from RAST) as other techniques are not current/no longer used. |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |

| | |
|---|---|
| | In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (Sensitivity and specificity) |
| Other exclusions | • POPULATION:<br>o Occupational asthma /allergens<br>o Mixed populations of asthma with other groups such as rhinitis (unless the results for the subgroup of asthma patients have been reported separately).<br>• TESTS:<br>o Validation studies, or studies comparing different methods of measuring IgE.<br>o Studies that do not use ELISA for determining presence of IgE.<br>• ANALYSIS/RESULTS:<br>o Studies that look at levels of IgE<br>o Studies that assess factors that may influence IgE measurements (eg. smoking, age, gender)<br>o Studies that use IgE predict the development of asthma at a later follow-up time<br>o Studies that look at correlations or agreement between tests, but not numbers of patients who were positive and negative<br>o Studies that look at IgE to in relation to asthma severity<br>• STUDY TYPES:<br>o Case-control studies will be excluded if there are few 'true' diagnostic studies |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards |

1

# 1C.11 Diagnosis: FeNO

2 **Table 11: Review protocol: FeNO for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of fractional exhaled nitric oxide (FeNO) measures? |
| Objectives | To evaluate the diagnostic test value of FeNO in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses)<br>Case-control studies were included for the comparison of FeNO levels only |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Fractional exhaled nitric oxide (FeNO) with a cut-off threshold between 20-50ppb and a flow rate of 50ml/s or equivalent |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis.<br>In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (Sensitivity and specificity)<br>• FeNO levels |
| Other exclusions | • Studies in which >50% of people are on corticosteroid treatment<br>• Not looking at occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different methods of measuring FeNO.<br>• Cross-sectional studies were included if they reported sensitivity or specificity, or the sensitivity and specificity could be calculated.<br>• Case-control studies were only included if they reported levels of FeNO, but they had to have a sample size of N>50. |

| | |
|---|---|
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | Are there any subgroups to consider?<br>• Different test thresholds<br>• Sequence step of the test (eg, first test, second test etc)<br>• Commercially available meters |

# 1C.12 Diagnosis: Peripheral blood eosinophils

2 **Table 12: Review protocol: Peripheral blood eosinophil count for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of eosinophil blood count measures? |
| Objectives | To evaluate the diagnostic test value of eosinophil blood count in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses)<br><br>Case-control studies were included for the comparison of blood eosinophil levels only |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). All ages, stratified into the following 3 different groups:<br>• Children (1- <5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Peripheral blood eosinophil count (may be part of FBC) |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br><br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold. |

| | |
|---|---|
| | Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis.<br><br>In children 1-<5 years, objective tests cannot be performed so the reference standard will be physician diagnosis based on recurrent and persistent wheezing. |
| Outcomes | • Diagnostic accuracy (sensitivity, specificity)<br>• Eosinophil levels |
| Other exclusions | • Not looking at occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different methods of measuring eosinophil blood counts.<br>• Not looking at factors which influence eosinophil measurements<br>• Cross-sectional studies were included if they reported sensitivity or specificity, or the sensitivity and specificity could be calculated. If they reported levels of blood eosinophils, then they were excluded.<br>• Case-control studies were only included if they reported levels of blood eosinophils, but they had to have a sample size of N>50. |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis- subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards<br>• Sequence step of the test (eg, first test, second test etc)<br>• Eosinophil counts: >1, 0.4-0.9, 0.2-0.4 |

1

# 1C.13 Diagnosis: Histamine and methacholine

2 **Table 13: Review protocol: Histamine and methacholine challenge tests for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of airway hyper-reactivity (non-specific bronchial challenge) with histamine and methacholine? |
| Objectives | To evaluate the diagnostic test value of histamine and methacholine PC20 in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). Ages stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | • Histamine PC20 and PD20<br>• Methacholine PC20 and PD20<br>Cut-off threshold of 8mg/ml or a cut-off threshold identified from a ROC curve |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test).<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Statistical measures | • Diagnostic accuracy (sensitivity and specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different methods of measuring the same test<br>• Not looking at factors which influence measurements<br>• Not looking at 'case-control' type studies where the index test is applied in people with confirmed asthma and healthy controls, and where there is no uncertainty about whether the patient has asthma or not. Such studies only include a spectrum of the disease and non-diseased patients and the diagnostic test accuracy may not be applicable to the clinical question. |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II |

| | |
|---|---|
| | checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |

# 1C.14 Diagnosis: Mannitol

2 **Table 14: Review protocol: Mannitol challenge test for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness ofairway hyper-reactivity (non-specific bronchial challenge) with mannitol? |
| Objectives | To evaluate the diagnostic test value ofmannitol in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). Ages stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | • Mannitol |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test)<br>Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Statistical measures | Diagnostic accuracy (sensitivity, specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at validation studies, or studies comparing different methods of measuring the same test<br>• Not looking at factors which influence measurements |

| | |
|---|---|
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Analyse mannitol challenge methods and kits separately (split)<br>• Diagnostic meta-analysis will be conducted where appropriate.<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards |

# 1C.15 Diagnosis: Exercise challenge test

2 **Table 15: Review protocol: Exercise challenge test for asthma diagnosis**

| Component | Description |
|---|---|
| Review question | In people under investigation for asthma, what is the diagnostic accuracy of bronchoconstriction in response to an exercise challenge? |
| Objectives | To evaluate the diagnostic test value of bronchoconstriction in response to an exercise challenge, in diagnosing asthma |
| Study design | Cross sectional studies, cohort studies, case series (including both retrospective and prospective analyses) |
| Population / Target condition | People with suspected asthma (presenting with respiratory symptoms). Ages stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Setting | Primary, secondary and community care settings |
| Index test | Exercise challenge test (>10% FEV1 bronchoconstriction in response to exercise – within 15 mins)<br>1. Change in FEV1 ≥10% post-exercise<br>2. If the study has used a cut-off based on performing a ROC<br>NOTE: usually this is a 6 minute exercise challenge test. |
| Reference standard | Physician diagnosis of asthma based on symptoms plus an objective test from any one of the following:<br><br>• peak flow variability (cut-off value of more than 20% variability as indication of a positive test);<br>• bronchodilator reversibility (cut-off value of an improvement in FEV1 of more than or equal to 12%, and an increase in volume of more than or equal to 200mls as indication of a positive test);<br>• bronchial hyper-responsiveness (histamine or methacholine challenge test, cut-off value of PC20 less than or equal to 8mg/ml as indication of a positive test) |

| | |
|---|---|
| | Where no evidence is available using the cut-off values specified above, evidence will be included from studies using a reference standard of physician diagnosis with an objective test using an alternative threshold.<br>Where no evidence is available from studies using physician diagnosis and an objective test, evidence will be included from studies using physician diagnosis based on symptoms alone, or patient report of a previous physician diagnosis. |
| Outcomes | • Diagnostic accuracy (sensitivity and specificity) |
| Other exclusions | • Not occupational asthma /allergens<br>• Not looking at tests in athletes<br>• Not looking at other factors which influence signs/symptoms |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using the QUADAS-II checklist.<br>Synthesis of data<br>• Diagnostic meta-analysis will be conducted where appropriate.<br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Different test thresholds<br>• Different reference standards |

# C.16 Monitoring: Questionnaires

**Table 16: Review protocol: Symptom scores/diaries or validated questionnaires to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of using symptom scores / diaries or validated questionnaires measuring symptom control (eg ACT, ACQ, CACT, RCP 3 questions) and/or health related quality of life (eg AQLQ, PAQLQ) to monitor asthma? |
| Objectives | To evaluate the clinical and cost-effectiveness of using symptom scores / diaries or validated questionnaires that measure symptoms or HRQoL to monitor asthma?<br>Questionnaires that measure current disease impact and future risk of exacerbation; does measuring symptom control and QoL in asthma patients, improve patient outcomes? |
| Study design | • RCTs<br>• Validation studies (in different age groups) – summarise these narratively. |
| Population / Target condition | People with asthma (defined as physician Dx with objective test or recurrent persistent wheeze in <5 years). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br>All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old) |

| | |
|---|---|
| | • Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Intervention | Monitoring the following, and using the outcomes of scores/questionnaires to adjust management/therapy according to physician decision or personalised treatment plan (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring):<br><br>• Symptom scores or diaries<br>• Symptom/control questionnaires<br>  ○ Asthma Control Test, ACT (including caregivers or paediatric version, CACT)<br>  ○ Asthma Control Questionnaire, ACQ (including mini ACQ or paediatric ACQ)<br>  ○ RCP 3 questions<br>• Quality of life questionnaires (asthma specific)<br>  ○ HS QoL<br>  ○ Asthma Quality of Life Questionnaire, AQLQ (including paeds version, PAQLQ) |
| Comparison | Comparison of adjustment of asthma therapy based on symptom scores or questionnaires to:<br>• Usual care: eg clinical symptoms (with/without spirometry/PEF) according to guidelines (including BTS/SIGN, GINA)<br><br>Comparison of adjustment of asthma therapy based on:<br>• Symptom scores or diaries vs questionnaires<br>• Control questionnaire vs other control questionnaire<br>• QOL questionnaire vs control questionnaire |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points: |

| | |
|---|---|
| | ○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Ethnic groups (e.g. south Asians, African Americans, Hispanics)<br>• Education levels<br>• Language (non English speaking) |

# 1C.17 Monitoring: Lung function tests

2 **Table 17: Review protocol: Lung function tests to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma? |
| Objectives | To evaluate the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma. |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br><br>All ages, stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Intervention | Monitoring lung function using the following tests, and using the outcomes to adjust management/therapy according to physician decision or personalised treatment plan (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring):<br>• Spirometry (FEV1; FEV1/FVC; Flow loop measures)<br>• PEF |
| Comparison | Comparison of adjustment of asthma therapy based on lung function tests to:<br>• Usual care: eg clinical symptoms according to guidelines (including BTS/SIGN, GINA)<br>• Asthma control or QOL questionnaires<br><br>Comparison of adjustment of asthma therapy based on:<br>• Spirometry versus PEF |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of |

| | |
|---|---|
| | hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points:<br>○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis-subgroups | |
| Key papers | |

# 1C.18 Monitoring: FeNO

2 **Table 18: Review protocol: FeNO to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of using fractional exhaled nitric oxide (FeNO) measures for monitoring asthma control? |
| Objectives | To evaluate the clinical and cost-effectiveness of using fractional exhaled nitric oxide (FeNO) for monitoring asthma control? |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test). If insufficient evidence is found we will consider evidence from studies where asthma is defined as |

| | |
|---|---|
| | physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br><br>All ages, stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old)<br><br>The following groups will be included/combined in the analysis (do not subgroup, would not make separate recommendations for these groups):<br>• Smokers<br>• Atopic asthma |
| Intervention | Monitoring FeNO and adjustment of management/therapy according to physician decision or personalised treatment plan (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring)<br><br>Only use validated methods of measuring FeNO (eg 50ml/s flow rate). |
| Comparison | Comparison of adjustment of asthma therapy based on FeNO to:<br>• Usual care: eg clinical symptoms (with or without PEF) according to guidelines (including BTS/SIGN, GINA)<br>• Asthma control questionnaires or QOL questionnaires<br>• Lung function tests (spirometry or PEFv)<br>• Blood eosinophils<br>• Challenge tests<br><br>Comparison of different frequencies of monitoring using FeNO. |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points: |

| | |
|---|---|
| | ○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>Sensitivity analysis:<br>• SUBGROUP: if heterogeneity, subgroup according to the aim of the treatment in the study. Would expect different directions of effect in studies aiming to decrease ICS in controlled patients and studies aiming to increase ICS in uncontrolled patients.<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • SUBGROUP: if heterogeneity, subgroup according to the aim of the treatment in the study. Would expect different directions of effect in studies aiming to decrease ICS in controlled patients and studies aiming to increase ICS in uncontrolled patients. |
| Key papers | |

# 1C.19 Monitoring: Peripheral blood eosinophils

2 **Table 19: Review protocol: Peripheral blood eosinophils to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of using the peripheral blood eosinophil count for monitoring asthma control? |
| Objectives | To evaluate the clinical and cost-effectiveness of using peripheral blood eosinophil count for monitoring asthma control? |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test or recurrent persistent wheeze in <5 years). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br><br>All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old)<br><br>The following groups will be included/combined in the analysis (do not subgroup, would not make separate recommendations for these groups):<br>• Smokers<br>• Atopic asthma |
| Intervention | Monitoring peripheral blood eosinophil count and adjustment of management/therapy according to physician decision or personalised treatment plan (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring). |

| | |
|---|---|
| Comparison | Comparison of adjustment of asthma therapy based on peripheral blood eosinophil count to:<br>• Usual care: eg clinical symptoms (with or without PEF) according to guidelines (including BTS/SIGN, GINA)<br>• Asthma control questionnaires or QOL questionnaires<br>• Lung function tests (spirometry or PEFv)<br>• Challenge tests<br><br>Comparison of different frequencies of monitoring using blood eosinophil count. |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points:<br>○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis- subgroups to | |

| | |
|---|---|
| investigate heterogeneity | |
| Key papers | |

# 1C.20 Monitoring: Challenge tests

2 **Table 20: Review protocol: Challenge tests to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of using indirect challenge tests with mannitol or direct challenge tests with histamine or methacholine for monitoring asthma control? |
| Objectives | To evaluate the clinical and cost-effectiveness of using indirect challenge tests with mannitol, or direct challenge tests with histamine or methacholine PC20 for monitoring asthma control? |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br><br>All ages, stratified into the following 2 different groups:<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Intervention | Monitoring using indirect or direct challenge tests and using the outcomes to adjust management/therapy according to physician decision or personalised treatment plan (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring):<br>• Indirect challenge test with mannitol<br>• Direct challenge test with methacholine or histamine |
| Comparison | Comparison of adjustment of asthma therapy based on indirect or direct challenge tests to:<br>• Usual care: eg clinical symptoms according to guidelines (including BTS/SIGN, GINA)<br>• Asthma control questionnaires or QOL questionnaires<br>• Lung function tests (spirometry or PEFv)<br><br>Comparison of adjustment of asthma therapy based on:<br>• Indirect vs direct challenge tests<br>• Comparison of different frequencies of monitoring using challenge tests |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days) |

| | |
|---|---|
| | • Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points:<br>○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | |
| Key papers | |

# 1C.21 Monitoring: Adherence to treatment

2 **Table 21: Review protocol: Monitoring adherence to treatment**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of monitoring adherence to treatment? |
| Objectives | To evaluate the clinical and cost-effectiveness of monitoring adherence to treatment?<br>Adherence with repeat therapies |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test or recurrent persistent wheeze in <5 years). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br><br>All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old) |

| | |
|---|---|
| | • Adults (>16 years old) |
| Intervention | Monitoring adherence/compliance/concordance using the following methods and provide patient feedback or intervention to improve adherence (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring):<br>• Adherence with repeat therapy (using prescription and refill data)<br>• Electronic monitoring inhalers (to monitor inhaler use)<br>• Prednisolone levels (serum and urine – when on prednisolone)<br>• MARS questionnaire (medication adherence rating scale)<br>• FeNO levels (comes down if patients are taking their inhalers)<br>• Theophylline levels (when on theophylline) |
| Comparison | • No monitoring of adherence<br>• Usual care<br>• Comparison of different frequencies of monitoring adherence |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>• Adherence<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>• Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Search terms | • Adherence<br>• Compliance<br>• Concordance |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points:<br>○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br>If no/insufficient evidence is found we will (in order of preference): |

| | |
|---|---|
| | • Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis-subgroups to investigate heterogeneity | • Socio economic disadvantage<br>• Cognitive function<br>• Some ethnic groups<br>• Disability (esp. use of inhalers)<br>• Near fatal asthma attacks (associated with psychological effects etc) |

# 1C.22 Monitoring: Inhaler technique

2 **Table 22: Review protocol: Monitoring inhaler technique**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the optimal frequency and method for monitoring inhaler technique? |
| Objectives | To evaluate the clinical and cost-effectiveness of the optimal frequency and method for monitoring inhaler technique? |
| Study design | • RCTs |
| Population / Target condition | People with asthma (defined as physician Dx with objective test or recurrent persistent wheeze in <5 years). If insufficient evidence is found we will consider evidence from studies where asthma is defined as physician Dx only or on asthma treatment (give details of how Dx was made). Not including severe asthma.<br>All ages, stratified into the following 3 different groups:<br>• Children (1-<5 years old)<br>• Children/young people (5-16 years old)<br>• Adults (>16 years old) |
| Intervention | Monitoring inhaler technique using the following methods and provide patient feedback or intervention to improve inhaler technique (use of other interventions to be included if equal access in each group, eg both groups receive education in addition to monitoring):<br>• Electronic devices to monitor inhaler technique (devices check the inhaler is being used correctly but this will still be face-to-face monitoring)<br>• Visual monitoring by doctor, nurse or pharmacist (may include use of a checklist to monitor inhaler technique) |
| Comparison | • No monitoring of inhaler technique<br>• Comparison of different frequencies of monitoring inhaler technique<br>• Monitoring using electronic devices vs monitoring by visual inspection |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF) |

| | |
|---|---|
| | • Symptoms (annual symptom free days)<br>• Dose of regular asthma therapy / preventer medication (ICS dose)<br>• Rescue medication (SABA use)<br>• Time off school or work |
| Exclusions | • Exclude observational cohort studies and NRS unless limited evidence from RCTs<br>• Studies not in English<br>• Not occupational asthma /allergens |
| Search Strategy | The database to be searched are Medline, Embase, The Cochrane Library |
| Review Strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br>• Outcomes will be grouped into the following categories based on time-points:<br>○ <6 months (or the one nearest to 6 months if multiple time-points are given)<br>○ ≥6 months (or the longest one if multiple time-points are given)<br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes<br><br>If no/insufficient evidence is found we will (in order of preference):<br>• Consider unpublished or partially published studies (including abstracts – and contact the authors for more information)<br>• Consider observational studies and NRS<br>• Consider prognostic studies<br>• Move to GDG consensus |
| Analysis- subgroups to investigate heterogeneity | |
| Key papers | |

1

# 1C.23 Monitoring: Tele-healthcare

2 **Table 23: Review protocol: Tele-healthcare to monitor asthma control**

| Component | Description |
|---|---|
| Review question | In people with asthma, what is the clinical and cost-effectiveness of tele-healthcare to monitor asthma control? |
| Objectives | To review the efficacy and effectiveness of tele-healthcare to monitor asthma control. |
| Study design | Full reports of randomised controlled trials which compared a tele-healthcare intervention with usual care or any other control intervention. |
| Population | Children and adults with clinician-diagnosed asthma. We included studies conducted in both primary and secondary care settings. We focused on studies which looked exclusively at people with asthma. There were no exclusions on the basis of age, gender, ethnicity or language spoken. |
| Intervention and comparison | Focus on the proactive use of ICT to provide the information the health professional requires to make their decisions and then feedback of their advice to the patient. The study of technology needed to be central and its use sustained. These interventions included the following.<br>• Video or telephone links between patient and healthcare professionals in real time or using store-and-forward technologies.<br>• Systems of care using Internet-based telecommunication; these could be synchronous or asynchronous (e.g. Skype®, messaging, email) with healthcare professionals.<br>• Systems of care using both wired and wireless telemetry for monitoring of Peak Expiratory Flow (PEF), spirometry (Forced Expiratory Volume in 1 second (FEV1); Forced Vital Capacity (FVC) respiratory rate, chest movement and oxygen saturations involving feedback to the patient, which had been processed or authorised by a healthcare professional.<br>• Other systems of remote healthcare incorporating patient self-reporting of symptoms on a questionnaire and information exchange with a professional.<br>• Complex intervention studies, if it was possible to tease out the individual tele-healthcare elements.<br>Professional involvement in care was considered fundamentally important; we thus excluded the following types of interventions.<br>• Remote interventions that were merely educational and so did not include the input of a professional, e.g. electronic information provision in an emergency waiting room. Although this type of passive information provision was excluded, education could have been part of a more complex interactive intervention that might fit the inclusion criteria, e.g. if it included feedback from a professional.<br>• Decision support which functioned without the active input of a healthcare professional.<br>• |
| Outcomes | Critical outcomes:<br>• Mortality<br>• Unscheduled healthcare utilisation (ED/A&E visit; hospital admissions; GP out of hours or walk-in centre)<br>• Exacerbations (defined as need for course of oral steroids)<br>• Asthma control questionnaires (ACT; CACT; ACQ; PACQ; RCP-3)<br>• QoL (AQLQ; pAQLQ; St George's respiratory questionnaire)<br>Important outcomes:<br>• Lung function (FEV1, PEF)<br>Symptoms (annual symptom free days) |

| | |
|---|---|
| Search | Trials were identified using the Cochrane Airways Group Specialised Register of trials, which is derived from systematic searches of bibliographic databases including the Cochrane Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, CINAHL, AMED, and PsycINFO, and hand-searching of respiratory journals and meeting abstracts. All records coded as 'asthma' were searched using the following terms:<br>Telehealth* or tele-health* or telemedicine*¬ or tele-medicine* or internet* or computer* or web* or interactive* or telecommunication* or telephone or phone or SMS or tele-monitor* or telemonitor* or telemanagement or tele-management¬ or teleconsultation or tele-consultation or telecare* or tele-care* or telematic* or telepharmacy or tele-pharmacy or telenurs* or tele-nurs* or video or email or e-mail or "remote consult*" or wireless or Bluetooth or tele-homecare or telehomecare or "remote care" or tele-support or telesupport or "mobile healthcare" or "computer mediated therapy" or ehealth or e-health or mhealth or m-health |
| Review strategy | Stratify by age group<br><br>Appraisal of methodological quality<br>• The methodological quality of each study will be assessed using NICE checklists and the quality of the evidence will be assessed by GRADE for each outcome.<br>Synthesis of data<br>• Meta-analysis will be conducted where appropriate<br><br>Sources of potential heterogeneity will be assessed with subgroup analyses for device (phonecalls, SMS, email, internet software) and study length (<6 months and > 6 months), or summarised narratively where insufficient numbers of studies are found.<br><br>Default MIDs will be used where no MIDs are established: 0.75 and 1.25 for dichotomous outcomes; 0.5 times SD for continuous outcomes |

1

## 2C.24 Health economic review protocols for all review questions

| Review question | All questions – health economic evidence |
|---|---|
| Objectives | To identify economic evaluations relevant to the review questions set out above. |
| Criteria | • Populations, interventions and comparators must be as specified in the individual review protocols above.<br>• Studies must be of a relevant economic study design (cost–utility analysis, cost–benefit analysis, cost-effectiveness analysis, cost–consequence analysis, comparative cost analysis).<br>• Studies must not be an abstract only, a letter, editorial or commentary, or a review of economic evaluations.[(a)] Unpublished reports will not be considered unless submitted as part of a call for evidence.<br>• Studies must be in English. |
| Search strategy | An economic study search will be undertaken using population-specific terms and an economic study filter – see Appendix F. |
| Review strategy | Each study fulfilling the criteria above will be assessed for applicability and methodological limitations using the NICE economic evaluation checklist which can be found in Appendix G of the NICE guidelines manual (2012).[1216]<br><br>**Inclusion and exclusion criteria**<br>• If a study is rated as both 'Directly applicable' and with 'Minor limitations' then it will be included in the guideline. An economic evidence table will be completed and it will be included in the economic evidence profile.<br>• If a study is rated as either 'Not applicable' or with 'Very serious limitations' then it will |

| | |
|---|---|
| | usually be excluded from the guideline. If it is excluded then an economic evidence table will not be completed and it will not be included in the economic evidence profile.<br>• If a study is rated as 'Partially applicable', with 'Potentially serious limitations' or both then there is discretion over whether it should be included.<br><br>**Where there is discretion**<br>The health economist will make a decision based on the relative applicability and quality of the available evidence for that question, in discussion with the GDG if required. The ultimate aim is to include studies that are helpful for decision-making in the context of the guideline and the current NHS setting. If several studies are considered of sufficiently high applicability and methodological quality that they could all be included, then the health economist, in discussion with the GDG if required, may decide to include only the most applicable studies and to selectively exclude the remaining studies. All studies excluded on the basis of applicability or methodological limitations will be listed with explanation as excluded economic studies in Appendix H.<br><br>The health economist will be guided by the following hierarchies.<br>*Setting*:<br>• UK NHS<br>• OECD countries with predominantly public health insurance systems (for example, France, Germany, Sweden)<br>• OECD countries with predominantly private health insurance systems (for example, USA, Switzerland)<br>• non-OECD settings (always 'Not applicable').<br>*Economic study type*:<br>• cost–utility analysis<br>• other type of full economic evaluation (cost–benefit analysis, cost-effectiveness analysis, cost–consequence analysis)<br>• comparative cost analysis<br>• non-comparative cost analyses including cost-of-illness studies (always 'Not applicable').<br>• Year of analysis:<br>• The more recent the study, the more applicable it is.<br>*Quality and relevance of effectiveness data used in the economic analysis*:<br>• The more closely the effectiveness data used in the economic analysis matches with the outcomes of the studies included in the clinical review the more useful the analysis will be for decision-making in the guideline. |

*(a) Recent reviews will be ordered although not reviewed. The bibliographies will be checked for relevant studies, which will then be ordered.*

# 1 Appendix D: Clinical article selection

## 2 D.1 Diagnosis: Signs and symptoms

**Figure 1: Flow diagram of article selection for the review of signs and symptoms**



# D.2 Diagnosis: History of atopic disorders

**Figure 2: Flow diagram of clinical article selection for the review of history of atopic disorders**



# D.3 Diagnosis: Symptoms after exercise

**Figure 3: Flow diagram of clinical article selection for the review of symptoms after exercise**



# D.4 Diagnosis: Symptoms after drugs

**Figure 4: Flow diagram of clinical article selection for the review of symptoms after drugs**



# D.5 Diagnosis: Occupational asthma

**Figure 5: Flow diagram of clinical article selection for the review of occupational asthma**



# D.6 Diagnosis: Spirometry

**Figure 6: Flow diagram of clinical article selection for the review of spirometry**



# D.7 Diagnosis: Bronchodilator reversibility

**Figure 7: Flow diagram of clinical article selection for the review of bronchodilator reversibility**



# D.8 Diagnosis: PEF variability

**Figure 8: Flow diagram of clinical article selection for the review of PEF variability**



# D.9 Diagnosis: Skin prick tests

**Figure 9: Flow diagram of clinical article selection for the review of skin prick tests**



# D.10 Diagnosis: IgE

**Figure 10: Flow diagram of clinical article selection for the review of IgE**



# D.11 Diagnosis: FeNO

**Figure 11: Flow diagram of article selection for the review of FeNO**



# D.12 Diagnosis: Eosinophils

**Figure 12: Flow diagram of clinical article selection for the review of peripheral blood eosinophils**



# D.13 Diagnosis: Histamine and methacoline

**Figure 13: Flow diagram of clinical article selection for the review of histamine and methacholine challenge tests**



# D.14 Diagnosis: Mannitol

**Figure 14: Flow diagram of clinical article selection for the review of mannitol challenge test**



# D.15 Diagnosis: Exercise

**Figure 15: Flow diagram of clinical article selection for the review of exercise challenge test**



# D.16 Monitoring: Questionnaires

**Figure 16: Flow chart of clinical article selection for the review of symptom scores/diaries or validated questionnaires to monitor asthma control**



# D.17 Monitoring: Lung function tests

**Figure 17: Flow chart of clinical article selection for the review of lung function tests to monitor asthma control**



# D.18 Monitoring: FeNO

**Figure 18: Flow chart of clinical article selection for the review of FeNO to monitor asthma control**



# D.19 Monitoring: Peripheral blood eosinophils

**Figure 19: Flow chart of clinical article selection for the review of peripheral blood eosinophils to monitor asthma control**



# D.20 Monitoring: Challenge tests

**Figure 20: Flow chart of clinical article selection for the review of challenge tests to monitor asthma control**



# D.21 Monitoring: Adherence to treatment

**Figure 21: Flow chart of clinical article selection for the review of monitoring adherence to treatment**



# D.22 Monitoring: Inhaler technique

**Figure 22: Flow chart of clinical article selection for the review of monitoring inhaler technique**



# D.23 Monitoring: Tele-healthcare

**Figure 23: Flow chart of clinical article selection for the review of tele-healthcare to monitor asthma control**



# Appendix E: Economic article selection

## E.1 Diagnosis: Signs and symptoms

**Figure 24: Flow chart of economic article selection for the review of signs and symptoms**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.2 Diagnosis: History of atopic disorders

**Figure 25: Flow diagram of economic article selection for the review of history of atopic disorders**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.3 Diagnosis: Symptoms after exercise

**Figure 26: Flow diagram of economic article selection for the review of symptoms in response to exercise**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.4 Diagnosis: Symptoms after drugs

**Figure 27: Flow diagram of economic article selection for the review of history of symptoms after drugs**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.5 Diagnosis: Occupational asthma

**Figure 28: Flow diagram of economic article selection for the review of occupational asthma**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.6 Diagnosis: Spirometry

**Figure 29: Flow diagram of economic article selection for the review of spirometry**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.7 Diagnosis: Bronchodilator reversibility

**Figure 30: Flow diagram of economic article selection for the review of bronchodilator reversibility**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.8 Diagnosis: PEF variability

**Figure 31: Flow chart of economic article selection for the review of peak expiratory flow variability**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.9 Diagnosis: Skin prick tests

**Figure 32: Flow diagram of economic article selection for the review of skin prick tests**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# 1E.10 Diagnosis: IgE

**Figure 33: Flow diagram of economic article selection for the review of IgE**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2
3

# E.11 Diagnosis: FeNO

**Figure 34: Flow chart of economic article selection for the review of FeNO for asthma diagnosis**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.12 Diagnosis: Eosinophils

**Figure 35: Flow diagram of economic article selection for the review of eosinophils**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# 1E.13 Diagnosis: Histamine and methacholine

**Figure 36: Flow diagram of economic article selection for the review of histamine and methacholine challenge tests**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2

3

# E.14 Diagnosis: Mannitol

**Figure 37: Flow chart of economic article selection for the review of mannitol challenge test**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.15 Diagnosis: Exercise challenge test

**Figure 38: Flow diagram of economic article selection for the review of exercise challenge tests**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# 1E.16 Monitoring: Questionnaires

**Figure 39: Flow chart of economic article selection for the review of symptom scores/diaries or validated questionnaires to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2

3

# 1E.17 Monitoring: Lung function tests

**Figure 40: Flow chart of economic article selection for the review of lung function tests to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2

3

# 1E.18 Monitoring: FeNO

**Figure 41: Flow chart of economic article selection for the review of FeNO to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2
3

# 1E.19 Monitoring: Peripheral blood eosinophils

**Figure 42: Flow chart of economic article selection for the review of peripheral blood eosinophils to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2
3

# E.20 Monitoring: Challenge tests

**Figure 43: Flow chart of economic article selection for the review of challenge tests to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# 1E.21 Monitoring: Adherence to treatment

**Figure 44: Flow chart of economic article selection for the review of monitoring adherence to treatment**




* Non-relevant population, intervention, comparison, design or setting; non-English language

2
3

# E.22 Monitoring: Inhaler technique

**Figure 45: Flow chart of economic article selection for the review of monitoring inhaler technique**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# E.23 Monitoring: Tele-healthcare

**Figure 46: Flow chart of economic article selection for the review of tele-healthcare to monitor asthma control**




* Non-relevant population, intervention, comparison, design or setting; non-English language

# Appendix F: Literature search strategies

## Contents

Search strategies used for the asthma guideline are outlined below and were run in accordance with the methodology in the NICE guidelines manual 2012.[1216] All searches were run up to 1 October 2014 unless otherwise stated. Any studies added to the databases after this date (even those published prior to this date) were not included unless specifically stated in the text. We do not routinely search for electronic, ahead of print or "online early" publications. Where possible searches were limited to retrieve material published in English.

**Table 24: Database date parameters**

| Database | Dates searched |
|---|---|
| Medline | 1946—1 October 2014 |
| Embase | 1980 – 1 October 2014 (week 39) |
| The Cochrane Library | Cochrane Reviews to 2014 Issue 10 of 12<br>CENTRAL to 2014 Issue 9 of 12<br>DARE, HTA and NHSEED to 2014 Issue 3 of 4 |

Searches for the **clinical reviews** were run in Medline (OVID), Embase (OVID) and the Cochrane Library (Wiley).

Searches for **intervention and diagnostic studies** were usually constructed using a PICO format where population (P) terms were combined with Intervention (I) and sometimes Comparison (C) terms. An intervention can be a drug, a procedure or a diagnostic test. Outcomes (O) are rarely used in search strategies for interventions. Search filters were also added to the search where appropriate.

Searches for **prognostic studies** were usually constructed combining population terms with prognostic variable terms and sometimes outcomes. Search filters were added to the search where appropriate.

Searches for the **health economic reviews** were run in Medline (OVID), Embase (OVID), the NHS Economic Evaluations Database (NHS EED), the Health Technology Assessment (HTA) database and the Health Economic Evaluation Database (HEED). Searches in NHS EED and HEED were constructed using population terms only. For Medline and Embase an economic filter (instead of a study type filter) was added to the same clinical search strategy.

# F.1 Population search strategies

## F.1.1 Standard population

This population was used in all clinical questions except F.3.5 occupational asthma.

**Medline and Embase search terms**

| | |
|---|---|
| 1. | exp asthma/ |
| 2. | asthma*.ti. |

| | |
|---|---|
| 3. | or/1-2 |

**Cochrane search terms**

| | |
|---|---|
| #1. | MeSH descriptor: [Asthma] explode all trees |
| #2. | asthma*:ti |
| #3. | {or #1-#2} |

# F.2 Study filter search terms

## F.2.1 Systematic review (SR) search terms

**Medline search terms**

| | |
|---|---|
| 1. | meta-analysis/ |
| 2. | meta-analysis as topic/ |
| 3. | (meta analy* or metanaly* or metaanaly*).ti,ab. |
| 4. | ((systematic* or evidence*) adj2 (review* or overview*)).ti,ab. |
| 5. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. |
| 6. | (search strategy or search criteria or systematic search or study selection or data extraction).ab. |
| 7. | (search* adj4 literature).ab. |
| 8. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 9. | cochrane.jw. |
| 10. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab. |
| 11. | or/1-10 |

**Embase search terms**

| | |
|---|---|
| 1. | systematic review/ |
| 2. | meta-analysis/ |
| 3. | (meta analy* or metanaly* or metaanaly*).ti,ab. |
| 4. | ((systematic or evidence) adj2 (review* or overview*)).ti,ab. |
| 5. | (reference list* or bibliograph* or hand search* or manual search* or relevant journals).ab. |
| 6. | (search strategy or search criteria or systematic search or study selection or data extraction).ab. |
| 7. | (search* adj4 literature).ab. |
| 8. | (medline or pubmed or cochrane or embase or psychlit or psyclit or psychinfo or psycinfo or cinahl or science citation index or bids or cancerlit).ab. |
| 9. | cochrane.jw. |
| 10. | ((multiple treatment* or indirect or mixed) adj2 comparison*).ti,ab. |
| 11. | or/1-10 |

## F.2.2 Randomised controlled trials (RCTs) search terms

**Medline search terms**

| | |
|---|---|
| 1. | randomized controlled trial.pt. |
| 2. | controlled clinical trial.pt. |
| 3. | randomi#ed.ab. |
| 4. | placebo.ab. |
| 5. | randomly.ab. |
| 6. | clinical trials as topic.sh. |

| | |
|---|---|
| 7. | trial.ti. |
| 8. | or/1-7 |

**Embase search terms**

| | |
|---|---|
| 1. | random*.ti,ab. |
| 2. | factorial*.ti,ab. |
| 3. | (crossover* or cross over*).ti,ab. |
| 4. | ((doubl* or singl*) adj blind*).ti,ab. |
| 5. | (assign* or allocat* or volunteer* or placebo*).ti,ab. |
| 6. | crossover procedure/ |
| 7. | double blind procedure/ |
| 8. | single blind procedure/ |
| 9. | randomized controlled trial/ |
| 10. | or/1-9 |

## F.2.3 Observational studies (OBS) search terms

**Medline search terms**

| | |
|---|---|
| 1. | epidemiologic studies/ |
| 2. | exp case control studies/ |
| 3. | exp cohort studies/ |
| 4. | cross-sectional studies/ |
| 5. | case control.ti,ab. |
| 6. | (cohort adj (study or studies or analys*)).ti,ab. |
| 7. | ((follow up or observational or uncontrolled or non randomi#ed or nonrandomi#ed or epidemiologic*) adj (study or studies)).ti,ab. |
| 8. | ((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort*)).ti,ab. |
| 9. | or/1-8 |

**Embase search terms**

| | |
|---|---|
| 1. | clinical study/ |
| 2. | exp case control study/ |
| 3. | family study/ |
| 4. | longitudinal study/ |
| 5. | retrospective study/ |
| 6. | prospective study/ |
| 7. | cross-sectional study/ |
| 8. | cohort analysis/ |
| 9. | follow-up/ |
| 10. | cohort*.ti,ab. |
| 11. | 9 and 10 |
| 12. | case control.ti,ab. |
| 13. | (cohort adj (study or studies or analys*)).ti,ab. |
| 14. | ((follow up or observational or uncontrolled or non randomi#ed or nonrandomi#ed or epidemiologic*) adj (study or studies)).ti,ab. |
| 15. | ((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort*)).ti,ab. |

| | |
|---|---|
| 16. | or/1-8,11-15 |

**Cochrane search terms**

| | |
|---|---|
| #1. | case control:ti,ab,kw |
| #2. | (cohort near/2 (study or studies or analys*)):ti,ab,kw |
| #3. | ((follow up or observational or uncontrolled or non randomi?ed or nonrandomi?ed or epidemiologic*) near/2 (study or studies)):ti,ab,kw |
| #4. | ((longitudinal or retrospective or prospective or cross sectional) and (study or studies or review or analys* or cohort*)):ti,ab,kw |
| #5. | {or #1-#4} |

## F.2.4 Diagnostic test accuracy studies (DIAG1) search terms

**Medline search terms**

| | |
|---|---|
| 1. | exp "sensitivity and specificity"/ |
| 2. | (sensitivity or specificity).ti,ab. |
| 3. | ((pre test or pretest or post test) adj probability).ti,ab. |
| 4. | (predictive value* or PPV or NPV).ti,ab. |
| 5. | likelihood ratio*.ti,ab. |
| 6. | likelihood function/ |
| 7. | (ROC curve* or AUC).ti,ab. |
| 8. | (diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. |
| 9. | gold standard.ab. |
| 10. | or/1-9 |

**Embase search terms**

| | |
|---|---|
| 1. | exp "sensitivity and specificity"/ |
| 2. | (sensitivity or specificity).ti,ab. |
| 3. | ((pre test or pretest or post test) adj probability).ti,ab. |
| 4. | (predictive value* or PPV or NPV).ti,ab. |
| 5. | likelihood ratio*.ti,ab. |
| 6. | (ROC curve* or AUC).ti,ab. |
| 7. | (diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. |
| 8. | diagnostic accuracy/ |
| 9. | diagnostic test accuracy study/ |
| 10. | gold standard.ab. |
| 11. | or/1-10 |

**Cochrane search terms**

| | |
|---|---|
| #1. | diagnos*:ti,ab,kw |
| #2. | (sensitivity or specificity):ti,ab,kw |
| #3. | ((pre test or pretest or post test) near probability):ti,ab,kw |
| #4. | (predictive value* or PPV or NPV):ti,ab,kw |
| #5. | likelihood ratio*:ti,ab,kw |
| #6. | (ROC or AUC):ti,ab,kw |
| #7. | gold standard:ti,ab,kw |

| | |
|---|---|
| #8. | Any MeSH descriptor with qualifier(s): [Diagnosis - DI] |
| #9. | {or #1-#8} |

### F.2.5 Diagnostic studies (DIAG2) search terms

The following terms were added to the diagnostic test accuracy search terms in F.2.4 to create a more sensitive search in Medline and Embase only.

**Medline and Embase search terms**

| | |
|---|---|
| 1. | sensitiv*.mp. |
| 2. | diagnos*.mp. |
| 3. | di.fs. |
| 4. | or/1-3 |

### F.2.6 Prognostic studies (PROG) search terms

**Medline search terms**

| | |
|---|---|
| 1. | predict.ti. |
| 2. | (validat* or rule*).ti,ab. |
| 3. | (predict* and (outcome* or risk* or model*)).ti,ab. |
| 4. | ((history or variable* or criteria or scor* or characteristic* or finding* or factor*) and (predict* or model* or decision* or identif* or prognos*)).ti,ab. |
| 5. | decision*.ti,ab. and Logistic models/ |
| 6. | (decision* and (model* or clinical*)).ti,ab. |
| 7. | (prognostic and (history or variable* or criteria or scor* or characteristic* or finding* or factor* or model*)).ti,ab. |
| 8. | (stratification or discrimination or discriminate or c statistic or "area under the curve" or AUC or calibration or indices or algorithm or multivariable).ti,ab. |
| 9. | ROC curve/ |
| 10. | or/1-9 |

**Embase search terms**

| | |
|---|---|
| 1. | predict.ti. |
| 2. | (validat* or rule*).ti,ab. |
| 3. | (predict* and (outcome* or risk* or model*)).ti,ab. |
| 4. | ((history or variable* or criteria or scor* or characteristic* or finding* or factor*) and (predict* or model* or decision* or identif* or prognos*)).ti,ab. |
| 5. | decision*.ti,ab. and statistical model/ |
| 6. | (decision* and (model* or clinical*)).ti,ab. |
| 7. | (prognostic and (history or variable* or criteria or scor* or characteristic* or finding* or factor* or model*)).ti,ab. |
| 8. | (stratification or discrimination or discriminate or c statistic or "area under the curve" or auc or calibration or indices or algorithm or multivariable).ti,ab. |
| 9. | receiver operating characteristic/ |
| 10. | or/1-9 |
| 11. | predict.ti. |

**Cochrane search terms**

| | |
|---|---|
| #1. | predict:ti,ab,kw |

| | |
|---|---|
| #2. | (validat* or rule*):ti,ab,kw |
| #3. | ((history or variable* or criteria or scor* or characteristic* or finding* or factor*) and (model* or decision* or identif* or prognos*)):ti,ab,kw |
| #4. | (decision* and (model* or clinical*)):ti,ab,kw |
| #5. | (prognostic and (history or variable* or criteria or scor* or characteristic* or finding* or factor* or model*)):ti,ab,kw |
| #6. | (stratification or discrimination or discriminate or c statistic or "area under the curve" or calibration or indices or algorithm or multivariable):ti,ab,kw |
| #7. | {or #1-#6} |

## F.2.7 Validation (VAL) studies search terms

**Medline search terms**

| | |
|---|---|
| 1. | validation studies/ |
| 2. | reproducibility of results/ |
| 3. | (valid* or reliab*).ti,ab. |
| 4. | observer variation/ |
| 5. | ((inter* or intra* or observer* or rater*) adj3 (bias* or variation* or agree* or concordan*)).ti,ab. |
| 6. | or/1-5 |

**Embase search terms**

| | |
|---|---|
| 1. | (valid* or reliab*).ti,ab. |
| 2. | ((inter* or intra* or observer* or rater*) adj3 (bias* or variation* or agree* or concordan*)).ti,ab. |
| 3. | validation study/ |
| 4. | exp reliability/ |
| 5. | exp reproducibility/ |
| 6. | exp observer variation/ |
| 7. | or/1-6 |

## F.2.8 Health economics (HE) search terms

**Medline search terms**

| | |
|---|---|
| 1. | economics/ |
| 2. | value of life/ |
| 3. | exp "costs and cost analysis"/ |
| 4. | exp economics, hospital/ |
| 5. | exp economics, medical/ |
| 6. | economics, nursing/ |
| 7. | economics, pharmaceutical/ |
| 8. | exp "fees and charges"/ |
| 9. | exp budgets/ |
| 10. | budget*.ti,ab. |
| 11. | cost*.ti. |
| 12. | (economic* or pharmaco?economic*).ti. |
| 13. | (price* or pricing*).ti,ab. |
| 14. | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |

| | |
|---|---|
| 15. | (financ* or fee or fees).ti,ab. |
| 16. | (value adj2 (money or monetary)).ti,ab. |
| 17. | or/1-16 |

**Embase search terms**

| | |
|---|---|
| 1. | health economics/ |
| 2. | exp economic evaluation/ |
| 3. | exp health care cost/ |
| 4. | exp fee/ |
| 5. | budget/ |
| 6. | funding/ |
| 7. | budget*.ti,ab. |
| 8. | cost*.ti. |
| 9. | (economic* or pharmaco?economic*).ti. |
| 10. | (price* or pricing*).ti,ab. |
| 11. | (cost* adj2 (effective* or utilit* or benefit* or minimi* or unit* or estimat* or variable*)).ab. |
| 12. | (financ* or fee or fees).ti,ab. |
| 13. | (value adj2 (money or monetary)).ti,ab. |
| 14. | or/1-13 |

## F.2.9 Quality of life (QOL) search terms

**Medline search terms**

| | |
|---|---|
| 1. | (euroqol* or eq5d* or eq 5d*).ti,ab. |

**Embase search terms**

| | |
|---|---|
| 1. | (euroqol* or eq5d* or eq 5d*).ti,ab. |

## F.2.10 Excluded study designs and publication types

The following study designs and publication types were removed from retrieved results using the NOT operator.

**Medline search terms**

| | |
|---|---|
| 1. | letter/ |
| 2. | editorial/ |
| 3. | news/ |
| 4. | exp historical article/ |
| 5. | anecdotes as topic/ |
| 6. | comment/ |
| 7. | case report/ |
| 8. | (letter or comment*).ti. |
| 9. | or/1-8 |
| 10. | randomized controlled trial/ or random*.ti,ab. |
| 11. | 9 not 10 |
| 12. | animals/ not humans/ |
| 13. | exp animals, laboratory/ |
| 14. | exp animal experimentation/ |

| | |
|---|---|
| 15. | exp models, animal/ |
| 16. | exp rodentia/ |
| 17. | (rat or rats or mouse or mice).ti. |
| 18. | or/11-17 |

**Embase search terms**

| | |
|---|---|
| 1. | letter.pt. or letter/ |
| 2. | note.pt. |
| 3. | editorial.pt. |
| 4. | case report/ or case study/ |
| 5. | (letter or comment*).ti. |
| 6. | or/1-5 |
| 7. | randomized controlled trial/ or random*.ti,ab. |
| 8. | 6 not 7 |
| 9. | animal/ not human/ |
| 10. | nonhuman/ |
| 11. | exp animal experiment/ |
| 12. | exp experimental animal/ |
| 13. | animal model/ |
| 14. | exp rodent/ |
| 15. | (rat or rats or mouse or mice).ti. |
| 16. | or/8-15 |

# F.3 Searches for specific questions

## F.3.1 Signs and Symptoms

6. In people under investigation for asthma, what is the diagnostic accuracy of each of the following signs and symptoms?
   - wheezing
   - cough
   - breathlessness
   - nocturnal symptoms
   - diurnal and seasonal variations.

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Signs and symptoms of asthma as listed in the question | n/a | The following filters were used in all databases:<br>DIAG1, OBS, PROG | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | *respiratory sounds/ |

| | |
|---|---|
| 2. | *cough/ |
| 3. | *dyspnea/ |
| 4. | exp *periodicity/ |
| 5. | (wheez* or rhonchi or cough* or breathless* or dyspn?ea).ti,ab. |
| 6. | ((difficult* or labo?r* or short*) adj2 breath*).ti,ab. |
| 7. | ((24h* or 24 hour* or 24 hr*) adj2 (rhythm* or varia* or change* or pattern* or symptom* or sign or signs)).ti,ab. |
| 8. | ((season* or diurnal or circadian or nyctohemeral or night* or nocturnal) adj3 (wheez* or rhonchi or cough* or breathless* or dyspn?ea or symptom or symptoms or sign or signs or asthma*)).ti,ab. |
| 9. | or/1-8 |

**Embase search terms**

| | |
|---|---|
| 1. | *wheezing/ |
| 2. | *irritative coughing/ |
| 3. | *chronic cough/ |
| 4. | *coughing/ |
| 5. | *dyspnea/ |
| 6. | *abnormal respiratory sound/ |
| 7. | *seasonal variation/ |
| 8. | exp *periodicity/ |
| 9. | ((difficult* or labo?r* or short*) adj2 breath*).ti,ab. |
| 10. | ((24h* or 24 hour* or 24 hr*) adj2 (rhythm* or varia* or change* or pattern* or symptom* or sign or signs)).ti,ab. |
| 11. | ((season* or diurnal or circadian or nyctohemeral or night* or nocturnal) adj3 (wheez* or rhonchi or cough* or breathless* or dyspn?ea or symptom or symptoms or sign or signs or asthma*)).ti,ab. |
| 12. | (wheez* or rhonchi or cough* or breathless* or dyspn?ea).ti,ab. |
| 13. | or/1-12 |

**Cochrane search terms**

| | |
|---|---|
| #1. | MeSH descriptor: [Respiratory Sounds] this term only |
| #2. | MeSH descriptor: [Cough] this term only |
| #3. | MeSH descriptor: [Dyspnea] this term only |
| #4. | MeSH descriptor: [Periodicity] explode all trees |
| #5. | (wheez* or rhonchi or cough* or breathless* or dyspn?ea):ti,ab,kw |
| #6. | ((difficult* or labo?r* or short*) near/2 breath*):ti,ab,kw |
| #7. | ((24h* or 24 hour* or 24 hr*) near/2 (rhythm* or varia* or change* or pattern* or symptom* or sign or signs)):ti,ab,kw |
| #8. | ((season* or diurnal or circadian or nyctohemeral or night* or nocturnal) near/3 (wheez* or rhonchi or cough* or breathless* or dyspn?ea or symptom or symptoms or sign or signs or asthma*)):ti,ab,kw |
| #9. | {or #1-#8} |

### F.3.2 Personal/family history of atopic disorders

7. In people under investigation for asthma, what is the diagnostic accuracy of taking a personal/family history of atopic disorders?

1 Search constructed by combining the columns in the following table using the AND Boolean operator.
2 Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Personal/family history of atopic disorders | n/a | The following filters were used in all databases:<br>DIAG1, PROG | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

3 **Medline search terms**

| | |
|---|---|
| 1. | medical history taking/ |
| 2. | (histories or history).ti,ab. |
| 3. | exp questionnaires/ |
| 4. | question?aire*.ti,ab. |
| 5. | or/1-4 |
| 6. | (atopic or atopy).ti,ab. |
| 7. | (histor* adj2 (hypersensitiv* or allerg*)).ti,ab. |
| 8. | ((family or familial or relative? or kin or kinship or brother? or sister? or mother? or father? or son? or daughter? or parent?) adj3 (hypersensitiv* or allerg*)).ti,ab. |
| 9. | rhinitis, allergic, seasonal/ |
| 10. | rhinitis, allergic, perennial/ |
| 11. | dermatitis, atopic/ |
| 12. | exp food hypersensitivity/ |
| 13. | ((hypersensitiv* or allerg*) adj2 asthma*).ab. |
| 14. | (hay fever or hayfever or pollinosis).ti,ab. |
| 15. | (pollen* adj2 (sensitiv* or hypersensitiv* or allerg*)).ti,ab. |
| 16. | allergic rhinitis.ti,ab. |
| 17. | eczema.ti,ab. |
| 18. | ((food* or wheat or nut* or peanut* or milk or dairy or egg* or soy* or sesame or seed* or pecan* or pistachio* or walnut* or coconut* or fish or shellfish or seafood* or cereal* or gluten* or barley or corn* or maize) adj2 (sensitiv* or hypersensitiv* or allerg*)).ti,ab. |
| 19. | or/6-18 |
| 20. | 5 and 19 |

4 **Embase search terms**

| | |
|---|---|
| 1. | exp *anamnesis/ |
| 2. | (histories or history).ti,ab. |
| 3. | exp *questionnaire/ |
| 4. | question?aire*.ti,ab. |
| 5. | or/1-4 |
| 6. | (atopic or atopy).ti,ab. |
| 7. | (histor* adj2 (hypersensitiv* or allerg*)).ti,ab. |
| 8. | ((family or familial or relative? or kin or kinship or brother? or sister? or mother? or father? or son? or daughter? or parent?) adj3 (hypersensitiv* or allerg*)).ti,ab. |
| 9. | ((hypersensitiv* or allerg*) adj2 asthma*).ab. |
| 10. | (hay fever or hayfever or pollinosis).ti,ab. |

| | |
|---|---|
| 11. | (pollen* adj2 (sensitiv* or hypersensitiv* or allerg*)).ti,ab. |
| 12. | allergic rhinitis.ti,ab. |
| 13. | eczema.ti,ab. |
| 14. | ((food* or wheat or nut* or peanut* or milk or dairy or egg* or soy* or sesame or seed* or pecan* or pistachio* or walnut* or coconut* or fish or shellfish or seafood* or cereal* or gluten* or barley or corn* or maize) adj2 (sensitiv* or hypersensitiv* or allerg*)).ti,ab. |
| 15. | *atopic dermatitis/ |
| 16. | *atopy/ |
| 17. | exp *allergic rhinitis/ |
| 18. | exp *food allergy/ |
| 19. | or/6-18 |
| 20. | 5 and 19 |

**Cochrane search terms**

| | |
|---|---|
| #1. | (histories or history or question*):ti,ab,kw |
| #2. | (atopic or atopy):ti,ab,kw |
| #3. | (histor* near/2 (hypersensitiv* or allerg*)):ti,ab,kw |
| #4. | ((family or familial or relative? or kin or kinship or brother? or sister? or mother? or father? or son? or daughter? or parent?) near/3 (hypersensitiv* or allerg*)):ti,ab,kw |
| #5. | ((hypersensitiv* or allerg*) near/2 asthma*):ti,ab,kw |
| #6. | (hay fever or hayfever or pollinosis):ti,ab,kw |
| #7. | (pollen* near/2 (sensitiv* or hypersensitiv* or allerg*)):ti,ab,kw |
| #8. | allergic rhinitis:ti,ab,kw |
| #9. | eczema:ti,ab,kw |
| #10. | ((food* or wheat or nut* or peanut* or milk or dairy or egg* or soy* or sesame or seed* or pecan* or pistachio* or walnut* or coconut* or fish or shellfish or seafood* or cereal* or gluten* or barley or corn* or maize) near/2 (sensitiv* or hypersensitiv* or allerg*)):ti,ab,kw |
| #11. | {or #2-#10} |
| #12. | #1 and #11 |

## F.3.3 Symptoms in response to exercise

**8.** In people under investigation for asthma, what is the diagnostic accuracy of a clinical history of symptoms in response to exercise?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | History of symptoms following exercise | n/a | The following filter was used in all databases:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | medical history taking/ |
| 2. | (histories or history).ti,ab. |
| 3. | exp questionnaires/ |

| | |
|---|---|
| 4. | question*.ti,ab. |
| 5. | exp "signs and symptoms, respiratory"/ |
| 6. | (symptom or symptoms).ti,ab. |
| 7. | or/1-6 |
| 8. | exp exercise/ |
| 9. | exp sports/ |
| 10. | (exercise* or sport*).ti,ab. |
| 11. | (physical* adj (train* or exert* or activit*)).ti,ab. |
| 12. | or/8-11 |
| 13. | 7 and 12 |

**Embase search terms**

| | |
|---|---|
| 1. | exp *anamnesis/ |
| 2. | (histories or history).ti,ab. |
| 3. | exp *questionnaire/ |
| 4. | question*.ti,ab. |
| 5. | (symptom or symptoms).ti,ab. |
| 6. | exp *breathing disorder/ |
| 7. | exp *coughing/ |
| 8. | or/1-7 |
| 9. | exp *exercise/ |
| 10. | exp *sport/ |
| 11. | (exercise* or sport*).ti,ab. |
| 12. | (physical* adj (train* or exert* or activit*)).ti,ab. |
| 13. | or/9-12 |
| 14. | 8 and 13 |

**Cochrane search terms**

| | |
|---|---|
| #1. | (histories or history or question*):ti,ab,kw |
| #2. | (symptom or symptoms):ti,ab,kw |
| #3. | {or #1-#2} |
| #4. | (exercise* or sport*):ti,ab,kw |
| #5. | (physical* near/1 (train* or exert* or activit*)):ti,ab,kw |
| #6. | #4or #5 |
| #7. | #3 and #6 |

## F.3.4 Symptoms after drugs

9. In people under investigation for asthma, what is the diagnostic accuracy of a clinical history of symptoms after taking the following drugs:
   - in adults - beta blockers, aspirin, or other NSAIDs
   - in children – ibuprofen?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all | Drugs as listed in | n/a | The following filter was | See Table 24 |

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| ages with asthma or suspected asthma | the question | | used in all databases:<br>DIAG1<br>The following filter was used in Medline and Embase only:<br>DIAG2 | English only<br>Exclusion filter applied in Medline and Embase |

1 **Medline search terms**

| | |
|---|---|
| 1. | ((anti inflamm* or antiinflamm* or anti-inflamm*) adj2 (non- steroid* or nonsteroid* or non-steroid*) adj2 agent*).ti,ab. |
| 2. | ((cox2 or cox-2 or coxii or cox-ii) adj2 inhibitor*).ti,ab. |
| 3. | ((cyclo-oxygenase2 or cyclo-oxygenase-2 or cyclooxygenase-2 or cyclooxygenase2) adj2 inhibitor*).ti,ab. |
| 4. | ((cyclo-oxygenase-ii or cyclo-oxygenaseii or cyclooxygenase-ii or cyclooxygenaseii) adj2 inhibitor*).ti,ab. |
| 5. | (arcoxia or lodine or eccoxolac or mobic or prexige).ti,ab. |
| 6. | (diclofenac or naproxen or tolmetin or ketoprofen or aceclofenac).ti,ab. |
| 7. | (fenbufen or tenoxicam or nabumetone or osmosin or benoxaprofen).ti,ab. |
| 8. | (fenoprofen or azapropazone or aceclofenac or mefenamic acid or dexketoprofen).ti,ab. |
| 9. | (ibuprofen or ibuprufen).ti,ab. |
| 10. | (indometacin or indomethacin).ti,ab. |
| 11. | (parecoxib or deracoxib or cimicoxib or tilmacoxib).ti,ab. |
| 12. | (piroxicam or flurbiprofen or niflumic acid or diflunisal).ti,ab. |
| 13. | (sulindac or meclofenamate or meclofenamic acid).ti,ab. |
| 14. | exp anti-inflammatory agents, non-steroidal/ |
| 15. | celebrex.ti,ab. |
| 16. | celecoxib.ti,ab. |
| 17. | coxib*.ti,ab. |
| 18. | etodolac.ti,ab. |
| 19. | etoricoxib.ti,ab. |
| 20. | exp aspirin/ |
| 21. | aspirin.ti,ab. |
| 22. | exp cyclooxygenase 2 inhibitors/ |
| 23. | exp diclofenac/ |
| 24. | exp diflunisal/ |
| 25. | exp etodolac/ |
| 26. | exp fenoprofen/ |
| 27. | exp flurbiprofen/ |
| 28. | exp ibuprofen/ |
| 29. | exp indomethacin/ |
| 30. | exp ketoprofen/ |
| 31. | exp meclofenamic acid/ |
| 32. | exp mefenamic acid/ |
| 33. | exp naproxen/ |
| 34. | exp niflumic acid/ |

| | |
|---|---|
| 35. | exp piroxicam/ |
| 36. | exp sulindac/ |
| 37. | exp tolmetin/ |
| 38. | flosulide.ti,ab. |
| 39. | iguratimod.ti,ab. |
| 40. | meloxicam.ti,ab. |
| 41. | nimesulide.ti,ab. |
| 42. | nsaid*.ti,ab. |
| 43. | tiaprofenic acid.ti,ab. |
| 44. | (isoxicam or zomepirac or carprofen or proquazone or lornoxicam).ti,ab. |
| 45. | (propranolol or angilol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab. |
| 46. | (beta adj3 block*).ti,ab. |
| 47. | (b adj3 block*).ti,ab. |
| 48. | (beta adj2 antagonist*).ti,ab. |
| 49. | ((beta-adrenoceptor or b-adrenoceptor or beta-adrenergic) adj3 (blockade or blocker*or blocking or antagonist*)).ti,ab. |
| 50. | exp adrenergic beta-antagonists/ |
| 51. | or/1-50 |
| 52. | medical history taking/ |
| 53. | (histories or history).ti,ab. |
| 54. | exp drug hypersensitivity/ |
| 55. | ((drug or medication* or medicine*) adj2 (allerg* or hypersensitivity or sensitivity or intolerance)).ti,ab. |
| 56. | exp questionnaires/ |
| 57. | question*.ti,ab. |
| 58. | exp "signs and symptoms, respiratory"/ |
| 59. | (symptom or symptoms).ti,ab. |
| 60. | or/52-59 |
| 61. | 51 and 60 |

1 **Embase search terms**

| | |
|---|---|
| 1. | ((anti inflamm* or antiinflamm* or anti-inflamm*) adj2 (non- steroid* or nonsteroid* or non-steroid*) adj2 agent*).ti,ab. |
| 2. | ((cox2 or cox-2 or coxii or cox-ii) adj2 inhibitor*).ti,ab. |
| 3. | ((cyclooxygenase-2 or cyclooxygenase2 or cyclooxygenase 2) adj2 inhibitor*).ti,ab. |
| 4. | ((cyclooxygenase-ii or cyclooxygenaseii or cyclooxygenase ii) adj2 inhibitor*).ti,ab. |
| 5. | (arcoxia or lodine or eccoxolac or prexige or mobic).ti,ab. |
| 6. | (diclofenac or naproxen or tolmetin or ketoprofen or aceclofenac).ti,ab. |
| 7. | (fenbufen or tenoxicam or nabumetone or osmosin or benoxaprofen).ti,ab. |
| 8. | (fenoprofen or azapropazone or aceclofenac or mefenamic acid or dexketoprofen).ti,ab. |
| 9. | (ibuprofen or ibuprufen).ti,ab. |
| 10. | (indometacin or indomethacin).ti,ab. |

| | |
|---|---|
| 11. | (isoxicam or zomepirac or carprofen or proquazone or lornoxicam).ti,ab. |
| 12. | (parecoxib or deracoxib or cimicoxib or tilmacoxib).ti,ab. |
| 13. | (piroxicam or flurbiprofen or niflumic acid or diflunisal).ti,ab. |
| 14. | (sulindac or meclofenamate or meclofenamic acid).ti,ab. |
| 15. | celebrex.ti,ab. |
| 16. | celecoxib.ti,ab. |
| 17. | coxib*.ti,ab. |
| 18. | etodolac.ti,ab. |
| 19. | etoricoxib.ti,ab. |
| 20. | exp *aceclofenac/ |
| 21. | exp *aspirin/ |
| 22. | exp *azapropazone/ |
| 23. | exp *benoxaprofen/ |
| 24. | exp *carprofen/ |
| 25. | exp *celecoxib/ |
| 26. | exp *cyclooxygenase 2 inhibitor/ |
| 27. | exp *dexketoprofen/ |
| 28. | exp *diclofenac/ |
| 29. | exp *diflunisal/ |
| 30. | exp *etodolac/ |
| 31. | exp *etoricoxib/ |
| 32. | exp *fenbufen/ |
| 33. | exp *fenoprofen/ |
| 34. | exp *flosulide/ |
| 35. | exp *flurbiprofen/ |
| 36. | exp *ibuprofen/ |
| 37. | exp *iguratimod/ |
| 38. | exp *indomethacin/ |
| 39. | exp *ketoprofen/ |
| 40. | exp *lornoxicam/ |
| 41. | exp *lumiracoxib/ |
| 42. | exp *meclofenamic acid/ |
| 43. | exp *mefenamic acid/ |
| 44. | exp *meloxicam/ |
| 45. | exp *nabumetone/ |
| 46. | exp *naproxen/ |
| 47. | exp *niflumic acid/ |
| 48. | exp *nimesulide/ |
| 49. | exp *parecoxib/ or exp *tilmacoxib/ |
| 50. | exp *piroxicam/ |
| 51. | exp *proquazone/ |
| 52. | exp *sulindac/ |
| 53. | exp *tenoxicam/ |
| 54. | exp *tiaprofenic acid/ |
| 55. | exp *tolmetin/ |

| | |
|---|---|
| 56. | exp *zomepirac/ |
| 57. | flosulide.ti,ab. |
| 58. | iguratimod.ti,ab. |
| 59. | lumiracoxib.ti,ab. |
| 60. | meloxicam.ti,ab. |
| 61. | nimesulide.ti,ab. |
| 62. | exp *nonsteroid antiinflammatory agent/ |
| 63. | nsaid*.ti,ab. |
| 64. | tiaprofenic acid.ti,ab. |
| 65. | aspirin.ti,ab. |
| 66. | exp *beta adrenergic receptor blocking agent/ |
| 67. | exp *bisoprolol/ or exp *bisoprolol fumarate/ or exp *bisoprolol fumarate plus hydrochlorothiazide/ or exp *carvedilol/ or exp *metoprolol/ or exp*metoprolol fumarate/ or exp *metoprolol succinate/ or exp *metoprolol tartrate/ or exp *nebivolol/ |
| 68. | (propranolol or angilol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim).ti,ab. |
| 69. | (beta adj3 block*).ti,ab. |
| 70. | (b adj3 block*).ti,ab. |
| 71. | (beta adj2 antagonist*).ti,ab. |
| 72. | ((beta-adrenoceptor or b-adrenoceptor or beta-adrenergic) adj3 (blockade or blocker* or blocking or antagonist*)).ti,ab. |
| 73. | or/1-72 |
| 74. | exp *anamnesis/ |
| 75. | (histories or history).ti,ab. |
| 76. | exp *questionnaire/ |
| 77. | question*.ti,ab. |
| 78. | exp *drug hypersensitivity/ |
| 79. | ((drug or medication* or medicine*) adj2 (allerg* or hypersensitivity or sensitivity or intolerance)).ti,ab. |
| 80. | (symptom or symptoms).ti,ab. |
| 81. | exp *breathing disorder/ |
| 82. | exp *coughing/ |
| 83. | or/74-82 |
| 84. | 73 and 83 |

1 **Cochrane search terms**

| | |
|---|---|
| #1. | ((anti inflamm* or antiinflamm* or anti-inflamm*) near/2 (non- steroid* or nonsteroid* or non-steroid*)):ti,ab,kw |
| #2. | ((cox2 or cox-2 or coxii or cox-ii) near/2 (inhibitor*)):ti,ab,kw |
| #3. | ((cyclooxygenase-2 or cyclooxygenase2 or cyclooxygenase 2) near/2 (inhibitor*)):ti,ab,kw |
| #4. | ((cyclo-oxygenase2 or cyclo-oxygenase-2 or cyclooxygenase-2 or cyclooxygenase2) near/2 (inhibitor*)):ti,ab,kw |
| #5. | ((cyclooxygenase-ii or cyclooxygenaseii) near/2 (inhibitor*)):ti,ab,kw |
| #6. | ((cyclo-oxygenase-ii or cyclo-oxygenaseii or cyclooxygenase-ii or cyclooxygenaseii) near/2 |

| | |
|---|---|
| | (inhibitor*)):ti,ab,kw |
| #7. | (aceclofenac or arcoxia or aspirin or azapropazone or benoxaprofen or carprofen or celebrex or celecoxib or cimicoxib or coxib* or deracoxib or dexketoprofen or diclofenac or diflunisal or eccoxolac or etodolac or etoricoxib or fenbufen or fenoprofen or flosulide or flurbiprofen or ibuprofen or ibuprufen or iguratimod or indometacin or indomethacin or isoxicam or ketoprofen or lodine or lornoxicam or lumiracoxib or meclofenam* or mefenamic acid or meloxicam or mobic or nabumetone or naproxen or niflumic acid or nimesulide or nsaid* or osmosin or parecoxib or piroxicam or prexige or proquazone or sulindac or tenoxicam or tiaprofenic acid or tilmacoxib or tolmetin or zomepirac):ti,ab,kw |
| #8. | (propranolol or angilol or angilol or inderal-la or half-inderal or inderal or bedranol or prograne or slo-pro or acebutolol or sectral or atenolol or tenormin or bisoprolol or cardicor or emcor or carvedilol or eucardic or celiprolol or celectol or co-tenidone or tenoret or tenoretic or esmolol or brevibloc or labetalol or trandate or metoprolol or betaloc or lopresor or nadolol or corgard or nebivolol or nebilet or hypoloc or oxprenolol or trasicor or slow-trasicor or pindolol or visken or sotalol or beta-cardone or sotacor or timolol or betim):ti,ab,kw |
| #9. | (beta or b) near/3 (block* or antagonist*):ti,ab,kw |
| #10. | ((beta-adrenoceptor or b-adrenoceptor or beta-adrenergic) near/3 (blockade or blocker*or blocking or antagonist*)):ti,ab,kw |
| #11. | {or #1-#10} |
| #12. | (histories or history or question*):ti,ab,kw |
| #13. | ((drug or medication* or medicine*) near/2 (allerg* or hypersensitivity or sensitivity or intolerance)):ti,ab,kw |
| #14. | (symptom or symptoms):ti,ab,kw |
| #15. | {or #12-#14} |
| #16. | #11 and #15 |

### F.3.5 Occupational asthma

10. In adults under investigation for occupational asthma, what is the diagnostic accuracy for case identification, of asking whether their symptoms are better away from work?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| Adults under investigation for occupational asthma | Symptom history | n/a | The following filters were used in Medline and Embase only:<br>DIAG1, OBS, RCT, SR | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | asthma, occupational/ |
| 2. | ((occupation* or work* or job* or employ*) adj2 asthma*).ti,ab |
| 3. | or/1-2 |
| 4. | *occupational diseases/ |
| 5. | exp asthma/ |
| 6. | 4 and 5 |
| 7. | 3 or 6 |
| 8. | medical history taking/ |
| 9. | (histories or history).ti,ab. |

| | |
|---|---|
| 10. | questionnaires/ |
| 11. | question*.ti,ab. |
| 12. | (holiday* or weekend* or vacation*).ti,ab. |
| 13. | ((away or absent* or leave*) adj3 (work* or job* or employ* or occupation*)).ti,ab. |
| 14. | or/8-13 |
| 15. | 7 and 14 |

**Embase search terms**

| | |
|---|---|
| 1. | ((occupation* or work* or job* or employ*) adj2 asthma*).ti,ab. |
| 2. | *occupational asthma/ |
| 3. | or/1-2 |
| 4. | *occupational disease/ |
| 5. | exp *asthma/ |
| 6. | 4 and 5 |
| 7. | 3 or 6 |
| 8. | exp *anamnesis/ |
| 9. | (histories or history).ti,ab. |
| 10. | exp *questionnaire/ |
| 11. | question*.ti,ab. |
| 12. | (holiday* or weekend* or vacation*).ti,ab. |
| 13. | ((away or absent* or leave*) adj3 (work* or job* or employ* or occupation*)).ti,ab. |
| 14. | or/8-13 |
| 15. | 7 and 14 |

**Cochrane search terms**

| | |
|---|---|
| #1. | ((occupation* or work* or job* or employ*) near/2 asthma*):ti,ab,kw |
| #2. | (histories or history or question* or holiday* or weekend* or vacation*):ti,ab,kw |
| #3. | ((away or absent* or leave*) near/3 (work* or job* or employ* or occupation*)):ti,ab,kw |
| #4. | #2 or #3 |
| #5. | #1 and #4 |

### F.3.6 Spirometry/flow volume loop measures

11. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of spirometry / flow volume loop measures?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Spirometry / flow volume loop measures | n/a | The following filter was used in all databases:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | vital capacity/ |

| | |
|---|---|
| 2. | forced expiratory volume/ |
| 3. | (FEV1 or FEV 1 or FVC).ti,ab. |
| 4. | (flow volume adj (loop* or curve* or graph*)).ti,ab. |
| 5. | (forced expiratory volume* adj6 ("1" or one)).ti,ab. |
| 6. | ((force* or time*) adj vital capacit*).ti,ab. |
| 7. | spirometry.ti. |
| 8. | or/1-7 |

**Embase search terms**

| | |
|---|---|
| 1. | vital capacity/ |
| 2. | forced expiratory volume/ |
| 3. | lung flow volume curve/ |
| 4. | (FEV1 or FEV 1 or FVC).ti,ab. |
| 5. | (flow volume adj (loop* or curve* or graph*)).ti,ab. |
| 6. | (forced expiratory volume* adj6 ("1" or one)).ti,ab. |
| 7. | ((force* or time*) adj vital capacit*).ti,ab. |
| 8. | spirometry.ti. |
| 9. | or/1-8 |

**Cochrane search terms**

| | |
|---|---|
| #1. | MeSH descriptor: [Vital Capacity] this term only |
| #2. | MeSH descriptor: [Forced Expiratory Volume] this term only |
| #3. | (FEV1 or "FEV 1" or FVC):ti,ab |
| #4. | (flow volume near/2 (loop* or curve* or graph*)):ti,ab |
| #5. | (forced expiratory volume* near/6 ("1" or one)):ti,ab |
| #6. | ((force* or time*) near/2 vital capacit*):ti,ab |
| #7. | spirometry:ti |
| #8. | {or #1-#7} |

### F.3.7 Bronchodilator response

12. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of bronchodilator response (using PEF or FEV1)?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Bronchodilator response | n/a | The following filter was used in Medline and Cochrane:<br>DIAG1<br>The following filter was used in Medline only:<br>DIAG2 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | exp bronchodilator agents/du |
| 2. | bronchoreversibility.ti,ab. |
| 3. | ((bronchodilator* or bronchial dilat* or broncholytic*) adj3 (test* or revers* or respons* or |

| | |
|---|---|
| | respond*)).ti,ab. |
| 4. | (BDR or BDT).ti,ab. |
| 5. | or/1-4 |

**Embase search terms**

| | |
|---|---|
| 1. | bronchoreversibility.ti,ab. |
| 2. | ((bronchodilator* or bronchial dilat* or broncholytic*) adj3 (test* or revers* or respons* or respond*)).ti,ab. |
| 3. | (BDR or BDT).ti,ab. |
| 4. | bronchoreversibility.ti,ab. |
| 5. | or/1-4 |
| 6. | exp "sensitivity and specificity"/ |
| 7. | (sensitivity or specificity).ti,ab. |
| 8. | ((pre test or pretest or post test) adj probability).ti,ab. |
| 9. | (predictive value* or PPV or NPV).ti,ab. |
| 10. | likelihood ratio*.ti,ab. |
| 11. | (ROC curve* or AUC).ti,ab. |
| 12. | (diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. |
| 13. | diagnostic accuracy/ |
| 14. | diagnostic test accuracy study/ |
| 15. | gold standard.ab. |
| 16. | sensitiv*.mp. |
| 17. | diagnos*.mp. |
| 18. | di.fs. |
| 19. | or/6-18 |
| 20. | 5 and 19 |
| 21. | exp *bronchodilating agent/ |
| 22. | or/6-15 |
| 23. | 21 and 22 |
| 24. | 20 or 23 |

**Cochrane search terms**

| | |
|---|---|
| #1. | ((bronchodilator* or bronchial dilat* or broncholytic*) near/3 (test* or revers* or respons* or respond*)):ti,ab,kw |
| #2. | bronchoreversibility:ti,ab,kw |
| #3. | (BDR or BDT):ti,ab,kw |
| #4. | MeSH descriptor: [Bronchodilator Agents] explode all trees and with qualifiers: [Diagnostic use - DU] |
| #5. | {or #1-#4} |

### F.3.8 Peak expiratory flow

13. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of peak expiratory flow (PEF) variability?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Peak expiratory flow (PEF) variability | n/a | The following filter was used in all databases:<br>DIAG1<br>The following filter was used in Medline and Embase only:<br>DIAG2 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | PEFV.ti,ab. |
| 2. | ((diurnal* or circadian or variation* or variability or fluctuat* or alter* or increas* or decreas* or chang*) adj3 (PEF or PEFR or PFR or peak expiratory flow* or peak flow*)).ti,ab. |
| 3. | peak expiratory flow rate/ |
| 4. | exp circadian rhythm/ |
| 5. | 3 and 4 |
| 6. | 1 or 2 or 5 |

**Embase search terms**

| | |
|---|---|
| 1. | PEFV.ti,ab. |
| 2. | ((diurnal* or circadian or variation* or variability or fluctuat* or alter* or increas* or decreas* or chang*) adj3 (PEF or PEFR or PFR or peak expiratory flow* or peak flow*)).ti,ab. |
| 3. | peak expiratory flow/ |
| 4. | circadian rhythm/ |
| 5. | 3 and 4 |
| 6. | 1 or 2 or 5 |

**Cochrane search terms**

| | |
|---|---|
| #1. | pefv:ti,ab,kw |
| #2. | ((diurnal* or circadian or variation* or variability or fluctuat* or alter* or increas* or decreas* or chang*) near/3 (PEFR or PFR or peak expiratory flow* or peak flow*)):ti,ab,kw |
| #3. | {or #1-#2} |

### F.3.9 Skin prick test

14. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of skin prick tests?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Skin prick test | n/a | The following filter was used in Medline and Embase only:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | ((dust or housedust) adj mite*).ti,ab. |

| | |
|---|---|
| 2. | (dermatophagoides or euroglyphus).ti,ab. |
| 3. | pyroglyphidae/ |
| 4. | (cat or cats or feline*).ti,ab. |
| 5. | cats/ |
| 6. | (dog or dogs or canine*).ti,ab. |
| 7. | dogs/ |
| 8. | pollen*.ti,ab. |
| 9. | pollen/ |
| 10. | exp aspergillus/ |
| 11. | aspergillus.ti,ab. |
| 12. | alternaria/ |
| 13. | alternaria.ti,ab. |
| 14. | cladosporium/ |
| 15. | cladosporium.ti,ab. |
| 16. | ((air* or aero*) adj allergen*).ti,ab. |
| 17. | aeroallergen*.ti,ab. |
| 18. | or/1-17 |
| 19. | exp skin tests/ |
| 20. | skin prick*.ti,ab. |
| 21. | skin scratch*.ti,ab. |
| 22. | prick* test*.ti,ab. |
| 23. | scratch* test*.ti,ab. |
| 24. | skin test*.ti,ab. |
| 25. | or/19-24 |
| 26. | 18 and 25 |

1 **Embase search terms**

| | |
|---|---|
| 1. | ((dust or housedust) adj mite*).ti,ab. |
| 2. | (dermatophagoides or euroglyphus).ti,ab. |
| 3. | (cat or cats or feline*).ti,ab. |
| 4. | (dog or dogs or canine*).ti,ab. |
| 5. | pollen*.ti,ab. |
| 6. | aspergillus.ti,ab. |
| 7. | alternaria.ti,ab. |
| 8. | cladosporium.ti,ab. |
| 9. | exp *dermatophagoides/ |
| 10. | *cat/ |
| 11. | *dog/ |
| 12. | *grass pollen/ |
| 13. | *pollen/ |
| 14. | exp *aspergillus/ |
| 15. | exp *alternaria/ |
| 16. | exp *cladosporium/ |
| 17. | ((air* or aero*) adj allergen*).ti,ab. |
| 18. | aeroallergen*.ti,ab. |

| | |
|---|---|
| 19. | or/1-18 |
| 20. | exp *skin test/ |
| 21. | skin prick*.ti,ab. |
| 22. | skin scratch*.ti,ab. |
| 23. | prick* test*.ti,ab. |
| 24. | scratch* test*.ti,ab. |
| 25. | skin test*.ti,ab. |
| 26. | or/20-25 |
| 27. | 19 and 26 |

**Cochrane search terms**

| | |
|---|---|
| #1. | (skin prick* or skin scratch* or prick* test* or scratch* test* or skin test*):ti,ab,kw |
| #2. | ((dust or housedust) near/1 mite*):ti,ab,kw |
| #3. | (dermatophagoides or euroglyphus or cat or cats or feline* or dog or dogs or canine* or pollen or aspergillus or alternaria or cladosporium or pyroglyphidae):ti,ab,kw |
| #4. | ((air* or aero*) near/1 allergen*):ti,ab |
| #5. | aeroallergen*:ti,ab |
| #6. | {or #2-#5} |
| #7. | #1 and #6 |

## F.3.10 IgE

15. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of total and specific serum IgE measures?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Serum IgE | n/a | The following filters were used in Medline and Embase only:<br>DIAG1, OBS, RCT, SR | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline and Embase search terms**

| | |
|---|---|
| 1. | *radioallergosorbent test/ |
| 2. | (RAST or radioallergosorbent).ti. |
| 3. | *immunoglobulin E/ |
| 4. | (immunoglobulin E or IgE).ti. |
| 5. | or/1-4 |

**Cochrane search terms**

| | |
|---|---|
| #1. | (immunoglobulin E or IgE or RAST or radioallergosorbent):ti,kw |

## F.3.11 FeNO

16. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of fractional exhaled nitric oxide (FeNO) measures?

1 Search constructed by combining the columns in the following table using the AND Boolean operator.
2 Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Fractional exhaled nitric oxide (FeNO) | n/a | The following filter was used in Medline and Embase only:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

3 **Medline search terms**

| | |
|---|---|
| 1. | FeNO.ti,ab. |
| 2. | ((Fe or exhal* or fraction*) adj2 (NO or nitric or nitrogen)).ti,ab. |
| 3. | or/1-2 |
| 4. | nitric oxide/ |
| 5. | biological markers/ |
| 6. | breath tests/ |
| 7. | exhalation/ |
| 8. | or/5-7 |
| 9. | 4 and 8 |
| 10. | 3 or 9 |

4 **Embase search terms**

| | |
|---|---|
| 1. | FeNO.ti,ab. |
| 2. | ((Fe or exhal* or fraction*) adj2 (NO or nitric or nitrogen)).ti,ab. |
| 3. | or/1-2 |
| 4. | *nitric oxide/ |
| 5. | *breath analysis/ |
| 6. | *expired air/ |
| 7. | *biological marker/ |
| 8. | *exhalation/ |
| 9. | or/5-8 |
| 10. | 4 and 9 |
| 11. | 3 or 10 |

5 **Cochrane search terms**

| | |
|---|---|
| #1. | FeNO:ti,ab,kw |
| #2. | ((Fe or exhal* or fraction*) near/2 (NO or nitric or nitrogen)):ti,ab,kw |
| #3. | ((NO or nitric or nitrogen) near/2 (marker* or biomarker* or breath* or |
| #4. | {or #1-#3} |
| #5. | test* or exhal* or expir*)):ti,ab,kw |
| #6. | MeSH descriptor: [Nitric Oxide] explode all trees |
| #7. | MeSH descriptor: [Biological Markers] explode all trees |
| #8. | MeSH descriptor: [Breath Tests] explode all trees |
| #9. | MeSH descriptor: [Exhalation] explode all trees |
| #10. | {or #6-#9} |
| #11. | #5 and #10 |

| | |
|---|---|
| #12. | #4 or #11 |

### F.3.12 Peripheral blood eosinophil count

17. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of eosinophil blood count measures?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Eosinophil blood count measures | n/a | The following filter was used in Medline and Embase only:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | *eosinophils/ |
| 2. | *eosinophilia/ |
| 3. | (blood* adj2 (eosinophil* or acidophil*)).ti,ab. |
| 4. | or/1-3 |

**Embase search terms**

| | |
|---|---|
| 1. | *eosinophil/ |
| 2. | *eosinophil count/ |
| 3. | *eosinophilia/ |
| 4. | (blood* adj2 (eosinophil* or acidophil*)).ti,ab. |
| 5. | or/1-4 |

**Cochrane search terms**

| | |
|---|---|
| #1. | eosinophil*:kw |
| #2. | (blood* near/2 (eosinophil* or acidophil*)):ti,ab |
| #3. | {or #1-#2} |

### F.3.13 Bronchial challenge test: histamine, methacholine, mannitol

Searches for the following two questions were run as one search:

18. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of airway hyper-reactivity (non-specific bronchial challenge) with histamine and methacholine?

19. In people under investigation for asthma, what is the diagnostic test accuracy and cost-effectiveness of airway hyper-reactivity (non-specific bronchial challenge) with mannitol?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or | Bronchial challenge tests using histamine and | n/a | The following filter was used in all databases:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter |

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| suspected asthma | methacholine or mannitol | | | applied in Medline and Embase |

1 **Medline search terms**

| | |
|---|---|
| 1. | exp mannitol/ |
| 2. | exp histamine/ |
| 3. | methacholine chloride/ |
| 4. | (mannitol* or histamine* or methacholine*).ti,ab. |
| 5. | or/1-4 |
| 6. | bronchial provocation tests/ |
| 7. | (inhalation or provocation or provoke* or challenge*).ti,ab. |
| 8. | (hyperresponsiv* or hyperreactiv*).ti,ab. |
| 9. | bronchial hyperreactivity/ |
| 10. | or/6-9 |
| 11. | 5 and 10 |

2 **Embase search terms**

| | |
|---|---|
| 1. | mannitol/ |
| 2. | histamine/ |
| 3. | methacholine/ |
| 4. | (mannitol* or histamine* or methcholine*).ti,ab. |
| 5. | or/1-4 |
| 6. | inhalation test/ |
| 7. | provocation test/ |
| 8. | bronchus hyperreactivity/ |
| 9. | (inhalation or provocation or provoke* or challenge*).ti,ab. |
| 10. | (hyperresponsiv* or hyperreactiv*).ti,ab. |
| 11. | or/6-10 |
| 12. | 5 and 11 |

3 **Cochrane search terms**

| | |
|---|---|
| #1. | MeSH descriptor: [Mannitol] explode all trees |
| #2. | MeSH descriptor: [Histamine] explode all trees |
| #3. | MeSH descriptor: [Methacholine Chloride] explode all trees |
| #4. | (mannitol or histamine or methacholine):ti,ab |
| #5. | {or #1-#4} |
| #6. | MeSH descriptor: [Bronchial Provocation Tests] explode all trees |
| #7. | MeSH descriptor: [Bronchial Hyperreactivity] explode all trees |
| #8. | (inhalation or provocation or provoke* or challenge*):ti,ab |
| #9. | (hyperresponsiv* or hyperreactiv*):ti,ab |
| #10. | {or #6-#9} |
| #11. | 5 and 10 |

## 1F.3.14 Bronchial challenge test: exercise

2 20. In people under investigation for asthma, what is the diagnostic accuracy of bronchoconstriction
3 in response to an exercise challenge?

4 Search constructed by combining the columns in the following table using the AND Boolean operator.
5 Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Clinical history of symptoms in response to exercise | n/a | The following filter was used in all databases:<br>DIAG1 | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

6 **Medline search terms**

| | |
|---|---|
| 1. | exp exercise/ |
| 2. | exp sports/ |
| 3. | (exercise* or sport*).ti,ab. |
| 4. | (physical* adj (train* or exert* or activit*)).ti,ab. |
| 5. | or/1-4 |
| 6. | medical history taking/ |
| 7. | (histories or history).ti,ab. |
| 8. | exp questionnaires/ |
| 9. | question*.ti,ab. |
| 10. | exp "signs and symptoms, respiratory"/ |
| 11. | (symptom or symptoms).ti,ab. |
| 12. | or/6-11 |
| 13. | 5 and 12 |

7 **Embase search terms**

| | |
|---|---|
| 1. | exp *exercise/ |
| 2. | exp *sport/ |
| 3. | (exercise* or sport*).ti,ab. |
| 4. | (physical* adj (train* or exert* or activit*)).ti,ab. |
| 5. | or/1-4 |
| 6. | exp *anamnesis/ |
| 7. | (histories or history).ti,ab. |
| 8. | exp *questionnaire/ |
| 9. | question*.ti,ab. |
| 10. | (symptom or symptoms).ti,ab. |
| 11. | exp *breathing disorder/ |
| 12. | exp *coughing/ |
| 13. | or/6-12 |
| 14. | 5 and 13 |

8 **Cochrane search terms**

| | |
|---|---|
| #1. | (exercise* or sport*):ti,ab,kw |

| | |
|---|---|
| #2. | (physical* near/1 (train* or exert* or activit*)):ti,ab,kw |
| #3. | {or #1-#2} |
| #4. | (histories or history or question*):ti,ab,kw |
| #5. | (symptom or symptoms):ti,ab,kw |
| #6. | #4 or #5 |
| #7. | #3 and #6 |

## 1F.3.15 Questionnaires

2 21. In people with asthma, what is the clinical and cost-effectiveness of using symptom scores/diaries
3 or validated questionnaires measuring symptom control (e.g. ACT, ACQ, cACT, RCP 3 questions)
4 and/or health related quality of life (e.g. AQLQ, pAQLQ) to monitor asthma?

5 Search constructed by combining the columns in the following table using the AND Boolean operator.
6 Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Validated questionnaires | n/a | The following filters were used in Medline and Embase only:<br>OBS, RCT, VAL | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

7 **Medline search terms**

| | |
|---|---|
| 1. | (diary or diaries).ti,ab. |
| 2. | (symptom* adj2 scor*).ti,ab. |
| 3. | or/1-2 |
| 4. | (measur* or assess* or monitor* or evaluat*).ti,ab. |
| 5. | 3 and 4 |
| 6. | (CACT or ACQ 6 or ACQ 7 or ACQ6 or ACQ7 or PACQ or RCP-3 or RCP3 or PAQLQ or AQLQ or PACQLQ).ti,ab. |
| 7. | asthma control test*.ti,ab. |
| 8. | asthma control questionnaire*.ti,ab. |
| 9. | (rcp3 question* or rcp 3 question* or rcp three question* or royal college of physician*3 question* or royal college of physician* three question*).ti,ab. |
| 10. | asthma quality of life questionnaire*.ti,ab. |
| 11. | ((p?ediatric or caregiver* or care giver* or carer*) adj3 quality of life questionnaire*).ti,ab. |
| 12. | or/6-11 |
| 13. | 5 or 12 |

8 **Embase search terms**

| | |
|---|---|
| 1. | (diary or diaries).ti,ab. |
| 2. | (symptom* adj2 scor*).ti,ab. |
| 3. | or/1-2 |
| 4. | (measur* or assess* or monitor* or evaluat*).ti,ab. |
| 5. | 3 and 4 |
| 6. | (CACT or ACQ 6 or ACQ 7 or ACQ6 or ACQ7 or PACQ or RCP-3 or RCP3 or PAQLQ or AQLQ or PACQLQ).ti,ab. |
| 7. | asthma control test*.ti,ab. |

| | |
|---|---|
| 8. | asthma control questionnaire*.ti,ab. |
| 9. | (rcp3 question* or rcp 3 question* or rcp three question* or royal college of physician*3 question* or royal college of physician* three question*).ti,ab. |
| 10. | asthma quality of life questionnaire*.ti,ab. |
| 11. | ((p?ediatric or caregiver* or care giver* or carer*) adj3 quality of life questionnaire*).ti,ab. |
| 12. | or/6-11 |
| 13. | 5 or 12 |

**Cochrane search terms**

| | |
|---|---|
| #1. | (diary or diaries):ti,ab |
| #2. | (symptom* near/2 scor*):ti,ab |
| #3. | {or #1-#2} |
| #4. | (measur* or assess* or monitor* or evaluat*):ti,ab |
| #5. | #3 and #4 |
| #6. | (CACT or ACQ 6 or ACQ 7 or ACQ6 or ACQ7 or PACQ or RCP-3 or RCP3 or PAQLQ or AQLQ or PACQLQ):ti,ab |
| #7. | asthma control test*:ti,ab |
| #8. | asthma control questionnaire*:ti,ab |
| #9. | (rcp3 question* or rcp 3 question* or rcp three question* or royal college of physician*3 question* or royal college of physician* three question*):ti,ab |
| #10. | asthma quality of life questionnaire*:ti,ab |
| #11. | ((p?ediatric or caregiver* or care giver* or carer*) near/3 "quality of life questionnaire*"):ti,ab |
| #12. | {or #6-#11} |
| #13. | #5 or #12 |

## F.3.16 Lung functions tests

22. In people with asthma, what is the clinical and cost-effectiveness of using measures of pulmonary function assessing asthma control (for example, spirometry and peak expiratory flow) to monitor asthma?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Lung function tests | n/a | The following filter was used in Medline and Embase only:<br>RCT | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | vital capacity/ |
| 2. | forced expiratory volume/ |
| 3. | (FEV1 or FEV 1 or FVC).ti,ab. |
| 4. | (flow volume adj (loop* or curve* or graph*)).ti,ab. |
| 5. | (forced expiratory volume* adj6 ("1" or one)).ti,ab. |
| 6. | ((force* or time*) adj vital capacit*).ti,ab. |
| 7. | spirometry.ti. |

| | |
|---|---|
| 8. | or/1-7 |
| 9. | PEFV.ti,ab. |
| 10. | (PEF or PEFR or PFR or peak expiratory flow* or peak flow*).ti,ab. |
| 11. | peak expiratory flow rate/ |
| 12. | or/9-11 |
| 13. | 8 or 12 |
| 14. | monitoring, physiologic/ |
| 15. | monitor*.ti,ab. |
| 16. | self care/ |
| 17. | plan*.ti,ab. |
| 18. | or/14-17 |
| 19. | 13 and 18 |

1 **Embase search terms**

| | |
|---|---|
| 1. | vital capacity/ |
| 2. | forced expiratory volume/ |
| 3. | lung flow volume curve/ |
| 4. | (FEV1 or FEV 1 or FVC).ti,ab. |
| 5. | (flow volume adj (loop* or curve* or graph*)).ti,ab. |
| 6. | (forced expiratory volume* adj6 ("1" or one)).ti,ab. |
| 7. | ((force* or time*) adj vital capacit*).ti,ab. |
| 8. | spirometry.ti. |
| 9. | or/1-8 |
| 10. | PEFV.ti,ab. |
| 11. | (PEF or PEFR or PFR or peak expiratory flow* or peak flow*).ti,ab. |
| 12. | peak expiratory flow/ |
| 13. | or/10-12 |
| 14. | (monitor* or plan*).ti,ab. |
| 15. | exp monitoring/ |
| 16. | self care/ |
| 17. | or/14-16 |
| 18. | 9 or 13 |
| 19. | 17 and 18 |

2 **Cochrane search terms**

| | |
|---|---|
| #1. | MeSH descriptor: [Vital Capacity] this term only |
| #2. | MeSH descriptor: [Forced Expiratory Volume] this term only |
| #3. | (FEV1 or "FEV 1" or FVC):ti,ab |
| #4. | (flow volume near/2 (loop* or curve* or graph*)):ti,ab |
| #5. | (forced expiratory volume* near/6 ("1" or one)):ti,ab |
| #6. | ((force* or time*) near/2 vital capacit*):ti,ab |
| #7. | spirometry:ti |
| #8. | {or #1-#7} |
| #9. | PEFV:ti,ab |
| #10. | (PEF or PEFR or PFR or peak expiratory flow* or peak flow*):ti,ab,kw |
| #11. | #9 or #10 |

| | |
|---|---|
| #12. | #8 or #11 |
| #13. | (monitor* or plan*):ti,ab,kw |
| #14. | MeSH descriptor: [Self Care] explode all trees |
| #15. | #13 or #14 |
| #16. | #12 and #15 |

### F.3.17 FeNO (monitoring)

For search terms see F.3.11

23. In people with asthma, what is the clinical and cost-effectiveness of using fractional exhaled nitric oxide (FeNO) measures for monitoring asthma control?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Fractional exhaled nitric oxide (FeNO) | n/a | The following filters were used in Medline and Embase only:<br>OBS, RCT, SR | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

### F.3.18 Peripheral blood eosinophil count (monitoring)

For search terms see F.3.12

24. In people with asthma, what is the clinical and cost-effectiveness of using the peripheral blood eosinophil count for monitoring asthma control?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Eosinophil blood count measures | n/a | The following filters were used in Medline and Embase only:<br>OBS, RCT | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

### F.3.19 Airway hyper-reactivity measures

For search terms see F.3.13

25. In people with asthma, what is the clinical and cost-effectiveness of using indirect challenge tests with mannitol or direct challenge tests with histamine or methacholine for monitoring asthma control?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all | Bronchial challenge | n/a | The following filter was | See Table 24 |

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| ages with asthma or suspected asthma | tests using histamine and methacholine or mannitol | | used in Medline and Embase only:<br>RCT | English only<br>Exclusion filter applied in Medline and Embase |

## F.3.20 Adherence to treatment

26. In people with asthma, what is the clinical and cost-effectiveness of monitoring adherence to treatment?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Strategies to monitor or interventions to increase adherence | n/a | The following filters were used in Medline and Embase only:<br>OBS, RCT | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | (adheren* or complian* or concordan* or nonadheren* or noncomplian*).ti,ab. |
| 2. | exp patient compliance/ |
| 3. | or/1-2 |
| 4. | FeNO.ti,ab. |
| 5. | nitric oxide/ |
| 6. | biological markers/ |
| 7. | breath tests/ |
| 8. | exhalation/ |
| 9. | or/6-8 |
| 10. | 5 and 9 |
| 11. | ((Fe or exhal* or fraction*) adj2 (NO or nitric or nitrogen)).ti,ab. |
| 12. | 4 or 10 or 11 |
| 13. | prescription*.ti,ab. |
| 14. | exp pharmaceutical services/ |
| 15. | or/13-14 |
| 16. | ((electronic adj2 inhaler*) or smartinhaler* or smart inhaler*).ti,ab. |
| 17. | prednisolone.ti,ab. |
| 18. | theophylline.ti,ab. |
| 19. | (MARS or (medication adherence adj2 scale*)).ti,ab. |
| 20. | exp adrenal cortex hormones/ |
| 21. | administration, inhalation/ |
| 22. | 20 and 21 |
| 23. | (inhal* and (corticosteroid* or steroid* or corticoid* or glucocorticoid* or gluco-cortico*)).ti,ab. |

| | |
|---|---|
| 24. | 22 or 23 |
| 25. | or/12,15-19,24 |
| 26. | exp monitoring, physiologic/ |
| 27. | monitor*.ti,ab. |
| 28. | or/26-27 |
| 29. | 25 or 28 |
| 30. | 3 and 29 |

1 **Embase search terms**

| | |
|---|---|
| 1. | (adheren* or complian* or concordan* or nonadheren* or noncomplian*).ti,ab. |
| 2. | exp *patient compliance/ |
| 3. | or/1-2 |
| 4. | FeNO.ti,ab. |
| 5. | ((Fe or exhal* or fraction*) adj2 (NO or nitric or nitrogen)).ti,ab. |
| 6. | *nitric oxide/ |
| 7. | *breath analysis/ |
| 8. | *expired air/ |
| 9. | *biological marker/ |
| 10. | *exhalation/ |
| 11. | or/7-10 |
| 12. | 6 and 11 |
| 13. | 4 or 5 or 12 |
| 14. | prescription*.ti,ab. |
| 15. | *pharmacy/ |
| 16. | *prescription/ |
| 17. | ((electronic adj2 inhaler*) or smartinhaler* or smart inhaler*).ti,ab. |
| 18. | prednisolone.ti,ab. |
| 19. | theophylline.ti,ab. |
| 20. | *prednisolone/ |
| 21. | *theophylline blood level/ |
| 22. | (MARS or (medication adherence adj2 scale*)).ti,ab. |
| 23. | exp *corticosteroid/ih |
| 24. | (inhal* and (corticosteroid* or steroid* or corticoid* or glucocorticoid* or gluco-cortico*)).ti,ab. |
| 25. | or/13-24 |
| 26. | exp *monitoring/ |
| 27. | monitor*.ti,ab. |
| 28. | or/26-27 |
| 29. | 3 and (25 or 28) |

2 **Cochrane search terms**

| | |
|---|---|
| #1. | (adheren* or complian* or concordan* or nonadheren* or noncomplian*):ti,ab |
| #2. | [mh ^"patient compliance"] |
| #3. | {or #1-#2} |
| #4. | FeNO:ti,ab |
| #5. | ((Fe or exhal* or fraction*) near/2 (NO or nitric or nitrogen)):ti,ab |

| | |
|---|---|
| #6. | ((NO or nitric or nitrogen) near/2 (marker* or biomarker* or breath* or test* or exhal* or expir*)):ti,ab |
| #7. | [mh ^"Nitric Oxide"] |
| #8. | [mh ^"Biological Markers"] |
| #9. | [mh ^"Breath Tests"] |
| #10. | [mh ^Exhalation] |
| #11. | {or #8-#10} |
| #12. | #7 and #11 |
| #13. | {or #4-#6, #12} |
| #14. | prescription*:ti,ab |
| #15. | [mh ^"pharmaceutical services"] |
| #16. | ((electronic near/2 inhaler*) or smartinhaler* or smart inhaler*):ti,ab |
| #17. | prednisolone:ti,ab |
| #18. | theophylline:ti,ab |
| #19. | (MARS or medication adherence):ti,ab |
| #20. | [mh ^"adrenal cortex hormones"] |
| #21. | [mh "administration, inhalation"] |
| #22. | (inhal* and (corticosteroid* or steroid* or corticoid* or glucocorticoid* or gluco-cortico*)):ti,ab |
| #23. | #20 and #21 |
| #24. | {or #13-#19, #22-#23} |
| #25. | [mh ^"Monitoring, Physiologic"] |
| #26. | monitor*:ti,ab |
| #27. | {or #25-#36} |
| #28. | #3 and (#24 or #27) |

## F.3.21 Inhaler technique

27. In people with asthma, what is the optimal frequency and method for monitoring inhaler technique?

Search constructed by combining the columns in the following table using the AND Boolean operator. Exclusion filter applied using NOT Boolean operator.

| Population | Intervention or exposure | Comparison | Study design filter | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | Monitoring inhaler technique | n/a | The following filters were used in Medline and Embase only:<br>OBS, RCT | See Table 24<br>English only<br>Exclusion filter applied in Medline and Embase |

**Medline search terms**

| | |
|---|---|
| 1. | ((nebuliser* or nebulizer* or vaporiser* or vaporizer* or atomiser* or atomizer* or inhal* or aerosol* or device*) adj5 (technique* or competen* or efficien* or inefficien* or misuse* or check* or correct* or incorrect* or evaluat* or adher*)).ti,ab. |

**Embase search terms**

| | |
|---|---|
| 1. | ((nebuliser* or nebulizer* or vaporiser* or vaporizer* or atomiser* or atomizer* or inhal* or aerosol* or device*) adj5 (technique* or competen* or efficien* or inefficien* or misuse* or |

| | |
|---|---|
| | check* or correct* or incorrect* or evaluat* or adher*)).ti,ab. |

**Cochrane search terms**

| | |
|---|---|
| #1. | ((nebuliser* or nebulizer* or vaporiser* or vaporizer* or atomiser* or atomizer* or inhal* or aerosol* or device*) near/5 (technique* or competen* or efficien* or inefficien* or misuse* or check* or correct* or incorrect* or evaluat* or adher*)):ti,ab |

### F.3.22 Tele-healthcare

Searches for the following question were undertaken by the Cochrane Airways Group using the Cochrane Airways Group Specialised Register of trials. Full search methodology is provided in the published Cochrane review.[1123,1123]

28. In people with asthma, what is the clinical and cost-effectiveness of tele-healthcare to monitor asthma control?

## F.4 Health economics search

### F.4.1 Health economic reviews

Economic searches were conducted in Medline, Embase, HEED and CRD for NHS EED and HTA.

| Population | Intervention or exposure | Comparison | Study design filters | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | n/a | n/a | The following filters were used in Medline and Embase only:<br>HE | Medline and Embase 2012–1 October 2014<br>CRD EED and HTA All dates to 1 October 2014<br>English only |

**Medline and Embase search terms**

| | |
|---|---|
| 4. | exp asthma/ |
| 5. | asthma*.ti.ab. |
| 6. | or/1-2 |

**Cochrane search terms**

| | |
|---|---|
| #4. | MeSH descriptor: [Asthma] explode all trees |
| #5. | asthma*:ti,ab. |
| #6. | {or #1-#2} |

**CRD search terms**

| | |
|---|---|
| #1. | MeSH DESCRIPTOR Asthma EXPLODE ALL TREES |
| #2. | (asthma*) |
| #3. | #1 OR #2 |

**HEED search terms**

| | |
|---|---|
| 1. | AX=asthma* |

### F.4.2 Quality of life reviews

Quality of life searches were conducted in Medline and Embase only

| Population | Intervention or exposure | Comparison | Study design filters | Date parameters and other limits |
|---|---|---|---|---|
| People of all ages with asthma or suspected asthma | n/a | n/a | The following filters were used in Medline and Embase only:<br>QOL | Medline 1948-02/10/2014<br>Embase 1980–02/10/2014<br>English only |

1

# Appendix G: Clinical evidence tables

## G.1 Signs and symptoms for diagnosis

**Table 25: CHOI 2007[318]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Choi et al., 2007. Easy diagnosis of asthma: computer-assisted, symptom-based diagnosis. Journal of Korean Medical Science: 22: 832-838.<br><br>REF ID: CHOI2007 | Study type:<br>Diagnostic cross sectional study<br><br>Setting:<br>Hospital outpatient dept.<br><br>Country:<br>Korea<br><br>Recruitment:<br>Consecutive or random patient selection | N = 302<br>Adults<br>Inclusion criteria:<br>• Respiratory symptoms such as dyspnoea, cough or wheezing<br><br>Exclusion criteria: | Male:Female<br>127:175<br><br>Mean age:<br>Asthma: 46.8 (16.8)<br>Non-asthma: 47.8 (15.6)<br><br>Medications:<br>Not reported<br><br>Smokers:<br>Asthma: 36.7%<br>Non-asthma: 21.4% | Index test<br>Questionnaire consisting of 11 questions regarding symptoms within 1 year:<br>Q1 = Have you had wheezing associated with dyspnoea? (score 2)<br>Provoking factors:<br>• Nocturnal aggravation (score 1)<br>• Cold air (score 1)<br>• Exercise (score 1)<br>• Upper respiratory infection (score 1)<br>• Smoke or air pollution (score 1)<br>• Concurrently with coughing (score 1)<br>Q2 = Have you had paroxysmal coughing? (score 1)<br>Q3 = Have you had dyspnoea without wheezing? (score 1)<br>Q4 = Have you had wheezing without dyspnoea? (score 1)<br>Q5 = Have you had fluctuation of | a) only sn/sp values reported, not number of TN, FN, TP and FP.<br>Cut-off ≥3: Sn = 92.4%; Sp = 3.3%<br>Cut-off ≥4: Sn = 85.2%; Sp = 25.0%<br>Cut-off ≥5: Sn = 74.3%; Sp = 47.8%<br>Cut-off ≥6: Sn = 59.5%; Sp = 66.3%<br>Cut-off ≥7: Sn = 40.0%; Sp = 83.7%<br>Cut-off ≥8: Sn = 21.4%; Sp = 89.1%<br>Cut-off ≥9: Sn = 14.3%; Sp = 95.7%<br>Cut-off ≥10: Sn = 8.6%; Sp = 96.7%<br>Cut-off ≥11: Sn = 4.3%; Sp = 98.9%<br><br>AUC total symptom score: 0.647 (0.033)<br><br>b)<br><br>Index test +: Ref std + = 86; Ref std - = 71; Total = 157<br>Index test -: Ref std + = 124; Ref std - = 21; Total = 145<br>Total: Ref std + = 210; Ref std - = 92; Total = 302 | Source of funding:<br>Korea Asthma Allergy Foundation Research Grant and Korea Health 21 R&D Project, Ministry of Health<br>Limitations:<br>• No drop-outs<br>• Consecutive or random patient selection not mentioned<br>• time between IT and RS unclear but same time |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | not reported | | | exacerbation and improvement? (score 2)<br><br>a) Total symptom score<br>b) Responded yes to Q1 (all provoking factors)<br>c) Responded yes to Q2<br>d) Responded yes to Q3<br>e) Responded yes to Q4<br>f) Responded yes to Q5<br><br>Cut-off: various total symptom score cut-off scores reported. ROC analysis of total symptom scores. With an increase in cut-off, sensitivity decreased and specificity increased. Cut-off value of ≥4 associated with highest combination of sn and sp. Even within a total symptom score of ≥4, the sn/sp varied with the combination of symptoms (reported in paper Table 6)<br><br><u>Reference standard</u><br>Physician Dx with objective test (patients with an FEV1 >70% had MCT, all other patients had BDR to short-acting beta2-agonist). Definite Dx of asthma made using test (MCh PC20 <16mg/ml or BDR FEV1 increase >12% and 200ml) | Sensitivity 41.0%<br>Specificity 22.8%<br>PPV / NPV 54.8% / 14.5%<br><br>c)<br>Ref std +<br>Ref std -<br>Total<br>Index test +<br>34<br>53<br>87<br>Index test -<br>176<br>39<br>215<br>Total<br>210<br>92<br>302<br><br>Sensitivity 16.2%<br>Specificity 42.4%<br>PPV / NPV 39.1% / 18.1%<br><br>d)<br>Ref std +<br>Ref std -<br>Total<br>Index test +<br>24<br>27<br>51<br>Index test -<br>186<br>65<br>251<br>Total<br>210<br>92<br>302<br><br>Sensitivity 11.4%<br>Specificity 70.7%<br>PPV / NPV 47.1% / 25.9%<br><br>e)<br>Ref std +<br>Ref std -<br>Total<br>Index<br>18<br>19<br>37 | suggested<br><u>Additional data:</u><br>Symptoms and provoking factors with high prevalence in those Dx with asthma: wheezing with dyspnoea (86%); nocturnal aggrevation (64%); fluctuation (64%); upper respiratory infection (50%); cold air (44%); exercise (40%). |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | test + | | | | |
| | | | | Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Asthma | Index test - | 192 | 73 | 265 | |
| | | | | | Total | 210 | 92 | 302 | |
| | | | | | Sensitivity<br>Specificity | | 9.0%<br>79.3% | | |
| | | | | | f) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 64 | 59 | 123 | |
| | | | | | Index test - | 146 | 33 | 179 | |
| | | | | | Total | 210 | 92 | 302 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 30.5%<br>35.9%<br>52.0% / 18.4% | | |

**Table 26: SCHLEICH 2012[1530]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Schleich FN, Asandei R, Manise M, Sele J, Seidel L, Louis R. Is FENO50 | <u>Study type:</u><br>Prospective study<br><br><u>Data source:</u><br>Collected for study | N = 174<br><br><u>Inclusion criteria:</u><br>Patients referred to chest physicians for methacholine challenge for asthma diagnosis; | <u>Male: Female</u><br>72: 102<br><br><u>Mean (SD) age:</u><br>41 (16) yrs | <u>Index test</u><br>Questionnaire concerning symptoms:<br>a) diurnal cough<br>b) nocturnal cough<br>c) diurnal wheezing<br>d) nocturnal wheezing<br>e) dyspnoea | a) | Ref std + | Ref std - | Total | <u>Source of funding:</u><br>Interuniversity Attraction Poles Project<br><br><u>Limitations:</u> |
| | | | | | Index test + | 54 | 68 | 122 | |
| | | | | | Index test - | 28 | 24 | 52 | |
| | | | | | Total | 82 | 92 | 174 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| useful diagnostic tool in suspected asthma? International Journal of Clinical Practice. 2012; 66(2):158-165. *(Guideline Ref ID SCHLEICH 2012)* | Setting:<br>Department of Pulmonary Medicine<br><br>Country:<br>Belgium<br><br>Recruitment:<br>March 13, 2009 to December 30, 2009 | bronchodilator test failed to show reversible airway obstruction or baseline spirometry normal<br><br>Exclusion criteria:<br>Patients already receiving inhaled corticosteroids | | Reference standard<br>Methacholine challenge<br><br>Cut off PC20 <16mg/mL<br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma (methacholine challenge positive) vs. methacholine negative<br><br>FeNO levels: methacholine challenge positive vs. methacholine negative | Sensitivity<br>Specificity<br>PPV / NPV | | 65.9<br>26.1<br>44.3 / 46.2 | | Additional data:<br>None |
| | | | | | b) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 30 | 32 | 62 | |
| | | | | | Index test - | 52 | 60 | 112 | |
| | | | | | Total | 82 | 92 | 174 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 36.6<br>65.2<br>48.4 / 53.4 | | |
| | | | | | c) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 47 | 35 | 82 | |
| | | | | | Index test - | 35 | 57 | 92 | |
| | | | | | Total | 82 | 92 | 174 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 57.3<br>62.0<br>57.3 / 62.0 | | |
| | | | | | d) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 46 | 19 | 65 | |
| | | | | | Index test - | 36 | 73 | 109 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Total | 82 | 92 | 174 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 56.1<br>79.3<br>70.8 / 67.0 | | |
| | | | | | e) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 60 | 41 | 101 | |
| | | | | | Index test - | 22 | 51 | 73 | |
| | | | | | Total | 82 | 92 | 174 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 73.2<br>55.4<br>59.4 / 69.9 | | |

**Table 27: SCHNEIDER 2009A[1535]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Schneider A et al. 2009. Diagnostic accuracy of spirometry in primary | Study type:<br>Cross-sectional study<br>Setting:<br>Index test in primary care, 14 GPs in 10 practices | N = 219<br>Adults<br>Inclusion criteria:<br>• Visiting GP for the first time with complaints of suggested obstructive airway disease (OAD). | Male: Female<br>92:127<br><br>Mean (SD) age:<br>43.8 (15.6)<br><br>% of symptomatic | Index test:<br>Medical history taken with a structured questionnaire:<br>a) 'Do you sometimes suffer from shortness of breath?'<br>b) 'Have you suffered from wheezing in your chest?'<br>c) 'Do you often suffer from cough?' | a) | Ref st + | Ref st - | Total | Source of funding:<br>Federal ministry of education and research (BMBF), Germany.<br>Limitations: |
| | | | | | Index test + | 55 | 80 | 135 | |
| | | | | | Index test - | 35 | 49 | 84 | |
| | | | | | Total | 90 | 129 | 219 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| care. BMC Pulmonary Medicine: 9: 31.<br><br>REF ID: SCHNEIDER2009A | Country:<br>Germany<br>Recruitment:<br>Consecutive recruitment | • Symptoms such as dyspnoea, coughing, or expectoration<br>Exclusion criteria:<br>• Previous Dx for OAD<br>• Previous anti-obstructive medicine<br>• Contraindications for BDR of challenge testing (untreated hyperthyreosis, unstable coronary artery disease, cardiac arrhythmia)<br>• Pregnancy | patients with positive/abnormal spirometry:<br>35.6%<br><br>Medications:<br>None prior to spirometry at GP. If necessary, therapy initiated by GP for asthma or COPD but stopped 12 hours prior to lung function lab. | d) 'Do you often suffer from expectoration?'<br>e) 'Have you been woken up with a feeling of tightness in your chest?'<br>f) 'Have you been woken up by an attack of shortness of breath?'<br><br>Reference standard<br>LUNG FUNCTION LAB: Dx by pneumologist based on whole-body plethysmography (FEV1/VC ≤70% or FEV1 <80%) followed by either BDR if obstruction is present (FEV1 ≥12% and ≥200ml) or methacholine if obstruction is not present (PC20 ≤16mg/ml or extreme increase in airway resistance accompanied by clinical symptoms in two patients)<br><br>Time between index test and reference standard: unclear<br><br>Target condition<br>OAD: Asthma or COPD | Sensitivity<br>Specificity<br>PPV/NPV | | 61.1<br>38.0<br>40.7/58.3 | | Additional data:<br>3 lost to follow-up |
| | | | | | b) | Ref st + | Ref st - | Total | |
| | | | | | Index test + | 47 | 60 | 107 | |
| | | | | | Index test - | 43 | 69 | 112 | |
| | | | | | Total | 90 | 129 | 219 | |
| | | | | | Sensitivity<br>Specificity<br>PPV/NPV | | 52.2<br>53.5<br>43.9 / 61.6 | | |
| | | | | | c) | Ref st + | Ref st - | Total | |
| | | | | | Index test + | 39 | 87 | 126 | |
| | | | | | Index test - | 51 | 42 | 93 | |
| | | | | | Total | 90 | 129 | 219 | |
| | | | | | Sensitivity<br>Specificity<br>PPV / NPV | | 43.3<br>32.6<br>31.0 / 45.2 | | |
| | | | | | d) | Ref st + | Ref st - | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Index test + | 22 | 52 | 74 | |
| | | | | | Index test - | 68 | 77 | 145 | |
| | | | | | Total | 90 | 129 | | |
| | | | | | Sensitivity<br>Specificity<br>PPV/NPV | | 24.4<br>59.7<br>29.7 / 53.1 | | |
| | | | | | e) | Ref st + | Ref st - | Total | |
| | | | | | Index test + | 27 | 22 | 49 | |
| | | | | | Index test - | 63 | 107 | 170 | |
| | | | | | Total | 90 | 129 | | |
| | | | | | Sensitivity<br>Specificity<br>PPV/NPV | | 30.0<br>82.9<br>55.1 / 62.9 | | |
| | | | | | f) | Ref st + | Ref st - | Total | |
| | | | | | Index test + | 27 | 24 | 51 | |
| | | | | | Index test - | 63 | 105 | 168 | |
| | | | | | Total | 90 | 129 | | |
| | | | | | Sensitivity<br>Specificity | | 30.0<br>81.4 | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | PPV / NPV | 52.9 / 62.5 | |

**Table 28: SCHNEIDER 2012[1533]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Antonius Schneider, Mehtap Ay, Bernhard Faderl, Klaus Linde, and Stefan Wagenpfeil. Diagnostic accuracy of clinical symptoms in obstructive airway diseases varied within different health care sectors. | Study type:<br>Cross-sectional study<br><br>Setting:<br>3 parts /settings:<br>1. GPs<br>2. Referral practice (pneumologists)<br>• Hospital (Pts in rehab after long-term respiration, or after weaning from artificial respiration, or pts with severe COPD | N = 778 adults<br>(GP: n=219; pneumologists: n=259; hospital: n=300).<br><br>Inclusion criteria:<br>**1. GPs:**<br>• first time visit with complaints of suggested OAD or RAD<br>• symptoms for >2 months<br>**2. Pneumologists:**<br>• 1st visit for Dx work-up to include or exclude OAD or RAD<br>• Other criteria as for GPs<br>**3. Hospital**<br>• Pts with suspected OAD who were hospitalised for the | Female<br>GP: 58%<br>Referral: 60%<br>Hospital: 36%<br><br>Mean age:<br>GP: 43.8<br>Referral: 46.3<br>Hospital: 65.3<br><br>% of symptomatic patients Dx with asthma:<br>GP: 90 (41%)<br>Referral: 84 (32%)<br>Hospital: 25 (8.3%)<br><br>Medications:<br>Not mentioned. | Index test:<br>Medical history taken with a structured questionnaire:<br>a) Self-reported wheezing<br>b) Coughing<br>c) Dyspnoea attacks<br>d) Dyspnoea going upstairs<br>e) Dyspnoea when walking<br>f) Dyspnoea on minimal exercise<br>g) Expectoration<br>h) Tightness of chest<br><br>Reference standard<br>Symptoms + LUNG FUNCTION LAB: Dx by pneumologist based on whole-body plethysmography (FEV1/VC ≤70% or FEV1 <80%) followed by either BDR if obstruction is | **GP (sens/spec)**<br>NOTE: some outcome data was previously reported in Schneider 2009A.<br>a) Self-reported wheezing (52.2 / 53.1)<br>b) Coughing (43.8 / 31.5)<br>c) Dyspnoea attacks (40.0 / 78.4)<br>d) Dyspnoea going upstairs (47.1 / 49.6)<br>e) Dyspnoea when walking (4.8 / 93.2)<br>f) Dyspnoea on minimal exercise (2.5 / 94.1)<br>g) Expectoration (25.3 / 58.7)<br>h) Tightness of chest (31.4 / 82.7)<br><br>**Pneumologists (sens/spec)**<br>a) Self-reported wheezing (52.4 / 65.6)<br>b) Coughing (52.5 / 63.9)<br>c) Dyspnoea attacks (8.9 / 88.2)<br>d) Dyspnoea going upstairs (54.6 / 40.6)<br>e) Dyspnoea when walking (25.0 / 78.4)<br>f) Dyspnoea on minimal exercise (14.5 / 84.9)<br>g) Expectoration (40.0 / 74.1)<br>h) Tightness of chest (31.7 / 74.7) | Source of funding:<br>Federal ministry of education and research (BMBF), Germany.<br><br>Limitations:<br><br>Additional data:<br>None. |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| *J.Clin.Epidemiol.* 65 (8):846-854, 2012.<br><br>REF ID: SCHNEIDER2012 | needing respiration at home or severe asthma)<br><br>Country:<br>Germany (multicentre)<br><br>Recruitment:<br>Consecutive recruitment | first time.<br><br>Exclusion criteria:<br>**1. GPs:**<br>• Respiratory infections in prior 6 wks<br>• Previous Dx of OAD.<br>**2. Pneumologists:**<br>• As above.<br>**3. Hospital**<br>• None reported. | | present (FEV1 ≥12% and ≥200ml) or methacholine if obstruction is not present (PC20 ≤16mg/ml). Most asthma pts were identified by the BPT.<br><br>Time between index test and reference standard:<br>unclear<br><br>Target condition<br>OAD: Asthma or COPD | **Hospital (sens/spec)**<br>a) Self-reported wheezing (76.0 / 33.6)<br>b) Coughing (48.0 / 51.8)<br>c) Dyspnoea attacks (32.0 / 81.6)<br>d) Dyspnoea going upstairs (88.0 / 6.7)<br>e) Dyspnoea when walking (36.0 / 32.3)<br>f) Dyspnoea on minimal exercise (32.0 / 42.9)<br>g) Expectoration (41.7 / 51.1)<br>h) Tightness of chest (44.0 / 53.5) | |

**Table 29: TOMITA 2013[1773]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Tomita et al., 2013. A scoring algorithm for predicting the presence of adult asthma: a prospective | Study type:<br>Cross-sectional study<br>Setting:<br>Outpatient clinic, University Hospital<br>Country:<br>Japan | N = 566<br>Adults<br>Inclusion criteria:<br>• Adult outpatients with non-specific repiratory symptoms including wheeze, shortness of breath, and cough.<br>Exclusion criteria: | Male: Female<br>221:345<br><br>Median (range) age: 52 years (18-88)<br><br>Medications:<br>Could be | Index test<br>Five additional questions at routine interview, including:<br>a) 'Have you ever had any experiences of wheezing?'<br>b) 'Did your symptoms occur in the early morning or at night (diurnal variation)?'<br>c) 'Have you had similar episodes of respiratory symptoms (recurrent episodes)?' | a) | Ref st + | Ref st - | Total | Source of funding:<br>None. None of the authors had a financial relationship with a commercial entity<br>Limitations:<br>• Time |
| | | | | | Index test + | 110 | 26 | 136 | |
| | | | | | Index test - | 257 | 173 | 430 | |
| | | | | | Total | 367 | 199 | 566 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| derivation study. Primary care respiratory journal: 22: 51-58<br><br>REF ID: TOMITA2013 | <u>Recruitment:</u><br>All eligible patients between Jan 2008 and Sept 2011 (unclear) | • Abnormal x-ray findings and other causes<br>• Pregnant/ breastfeeding<br>• Current Dx of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, other lower respiratory abnormality.<br>• Systemic or inhaled CS, beta-blockers or angiotensin converting enzyme inhibitors<br>• Symptoms of chest pain or haemosputum. | started on ICS at first visit before MCT | <u>Reference standard</u><br>Relevant symptom history (all patients) and BDR (FEV1 <200ml and 12%) and/or BHR (methacholine PC20 <8mg/ml)<br><br>NB. 64/367 patients Dx had clinically Dx asthma (responsive to ICS with neither BDR or BHR)<br><br>Time between index test and reference standard: within 8 weeks<br><br><u>Target condition</u><br>Asthma | Sensitivity 30.0%<br>Specificity 86.9%<br>PPV / NPV 80.9% / 40.2%<br><br>b)<br>Ref std +<br>Ref std -<br>Total<br>Index test + 198 62 260<br>Index test - 169 137 306<br>Total 367 199 566<br><br>Sensitivity 54.0%<br>Specificity 68.8%<br>PPV / NPV 76.2% / 44.8%<br><br>c)<br>Ref std +<br>Ref std -<br>Total<br>Index test + 107 18 125<br>Index test - 260 181 441<br>Total 367 199 566<br><br>Sensitivity 29.2%<br>Specificity 91.0% | between tests 8 weeks, but could be started on ICS at first visit<br>• 813 consented but only 566 performed MCT (others declined participation or no AHR)<br><u>Additional data:</u> |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | PPV / NPV | 85.6% / 41.0% | |

**Table 30: WEVERHESS 1999[1908]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Wever-hess et al., 1999. Prognostic characteristics of asthma diagnosis in early childhood in clinical practice. Acta Paediatric a: 88: 827-834.<br><br>REF ID: WEVERHESS1999 | <u>Study type:</u><br>Longitudinal prognostic study<br><br><u>Setting:</u><br>Outpatient department, Children's Hospital<br><u>Country:</u><br>Netherlands<br><u>Recruitment:</u><br>All children from Jan 1991 to Jan 1993 | N = 188 (including aged 2-4yr subgroup only)<br><br><u>Inclusion criteria:</u><br>Aged 0-4 years with symptoms that were suggestive of asthma<br><br><u>Exclusion criteria:</u><br>Symptoms that could be explained by other respiratory disorders, such as respiratory syncytial virus bronchiolitis, cystic fibrosis, gastro-oesophageal reflux | <u>Male: Female</u><br>108:80<br><br><u>Mean (SD) age:</u><br>37 (8.4) months<br><br>Medications at initial visit:<br>Beta-agonists 42%, deptropine 10%, anticholinergics 3%, antihistamines 20%, anti-inflammatory 5%, antibiotics 49%. | <u>Index test</u><br>Symptoms (visit and questionnaire):<br>a) cough<br>b) wheeze<br>c) cough and wheeze<br>d) shortness of breath<br><br><u>Reference standard</u><br>Dx taken from medical notes at follow-up (2 years later). Dx made by a paediatrician on clinical grounds, based on recurrence of symptoms and need for and response to therapy according to the guidelines for diagnosis of asthma in young children (follow up statement from the International Paediatric Asthma Consensus Group). | a) | Ref st + | Ref st - | Total | <u>Source of funding:</u><br>Supported financially by Stichting Astmabestrijding, Amsterdam<br><u>Limitations:</u><br>Follow up at 2 years, prognostic design<br><br><u>Additional data:</u><br>Data provided from children aged 0-1 year separately but does not match protocol. |
| | | | | | Index test + | 127 | 41 | 168 | |
| | | | | | Index test - | 17 | 3 | 20 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sens / Spec<br>PPV / NPV | | 88.2% / 6.8%<br>75.6% / 15.0% | | |
| | | | | | | | | | |
| | | | | | b) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 78 | 19 | 97 | |
| | | | | | Index test - | 66 | 25 | 91 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sens / Spec<br>PPV / NPV | | 54.2% / 56.8%<br>80.4% / 27.5% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | <u>Time between index test and reference standard:</u><br>2 years<br><br><u>Target condition</u> | c) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 70 | 18 | 88 | |
| | | | | | Index test - | 74 | 26 | 100 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sens / Spec<br>PPV / NPV | | 48.6% / 59.1%<br>79.5% / 26.0% | | |
| | | | | | d) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 109 | 21 | 130 | |
| | | | | | Index test - | 35 | 23 | 58 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sens / Spec<br>PPV / NPV | | 75.7% / 52.3%<br>83.8% / 39.7% | | |
| | | | | | **PROGNOSTIC DATA (multivariate):**<br>**Predictors of Asthma Dx 2 years later (n=188)**<br>• Shortness of breath was a prognostic factor (OR 3.10, 95% CI 1.49-6.47)<br>• Wheeze was not a prognostic factor | | | | |

# G.2 History of atopic disorders

**Table 31: CORDIERO 2011[365]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Cordiero et al., 2011. Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy and Asthma Proceedings: 32: 119-126.<br><br>REF ID: CORDIERO 2011 | Study type:<br>Cross-sectional observational study<br>Setting:<br>General outpatient allergy clinic<br>Country:<br>The Netherlands<br>Recruitment:<br>All from January 2007 to September 2007 | N = 114<br>Adults and children/young people<br>Inclusion criteria:<br>• New referrals to outpatient allergy clinic<br>• Symptoms of nasal or ocular complaints; pulmonary complaints; skin complaints and general complaints.<br>Exclusion criteria:<br>• Patients using inhaled corticosteroids or oral corticosteroids within 6 weeks | Male: Female<br>43:71<br><br>Median (range) age:<br>38.5 (7-87)<br><br>Medications:<br>Treatment with short acting bronchodilators allowed up to 8 hours before and long acting bronchodilators and antihistamines up to 48 hours before. | Index test<br>Family history (unclear if first degree relatives and if history of asthma or atopy)<br><br>Reference standard<br>History of typical respiratory symptoms and FEV1 improvement >12% and >200mL with salbutamol 400µg or PC20 histamine ≤8mg/mL according to GINA.<br><br>Time between index test and reference standard: 6 weeks<br><br>Target condition<br>Asthma diagnosis vs. non-asthma (Allergic rhinitis, non-allergic rhinitis, eczema, urticarial, other analysed all together) | | Ref st + | Ref st - | Total | Source of funding:<br>Not stated<br>Limitations:<br>• Family history (unclear if first degree relatives and if history of asthma or atopy).<br>Additional data: |
| | | | | | Index test + | 25 | 32 | 57 | |
| | | | | | Index test - | 17 | 40 | 57 | |
| | | | | | Total | 42 | 72 | 114 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 59.5%<br>55.6%<br><br>43.9%<br>70.2% | | |

**Table 32: DEILAMI 2009[413]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Deilami et al., 2009. Evaluation of methacholine challenge test results in chronic cough patients referring to clinic of pulmonary disease. Acta Medica Iranica: 47: 175-179.<br><br>REF ID: DEILAMI2009 | Study type:<br>Cross sectional study<br>Setting:<br>Hospital pulmonary disease clinic<br>Country:<br>Iran<br>Recruitment:<br>All patients who were not excluded (unclear) | N = 81<br><br>Inclusion criteria:<br>• Suffering from cough for at least 8 weeks and went to the pulmonary disease clinic.<br>• Normal spirometry<br>Exclusion criteria:<br>• Patients with PND<br>• Patients of GERD who were untreated<br>• Respiratory infection within the last 3 weeks or contraindication to methacholine. | Male: Female<br>45:36<br><br>Mean age:<br>32.5 (13.1)<br><br>Medications:<br>n=7 smokers | Index test<br>Personal history of allergy<br><br>NB Family history of asthma sens/spec data was not extracted as was not first class relatives only<br><br>Reference standard<br>Methacholine challenge test: concentrations of 0.03, 0.06, 0.125, 0.25, 0.5, 1, 2, 4, 8 and 16mg/ml, until FEV1 drop of 20% or more.<br><br>Cut-off: PC20 ≤4mg/ml<br><br>Time between index test and reference standard:<br><br>Target condition<br>Asthma | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>•<br>•<br>Additional data: |
| | | | | | Index test + | 13 | 15 | 28 | |
| | | | | | Index test - | 11 | 42 | 53 | |
| | | | | | Total | 24 | 57 | 80 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 54.2%<br>73.7%<br><br>46.4%<br>20.8% | | |

**Table 33: TOMITA 2013[1773]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Tomita et al., 2013. A scoring algorithm for predicting the presence of adult asthma: a prospective derivation study. Primary care respiratory journal: 22: 51-58<br><br>REF ID: TOMITA2013 | Study type:<br>Cross-sectional study<br>Setting:<br>Outpatient clinic, University Hospital<br>Country:<br>Japan<br>Recruitment:<br>All eligible patients between Jan 2008 and Sept 2011 (unclear) | N = 566<br>Adults<br>Inclusion criteria:<br>• Adult outpatients with non-specific respiratory symptoms including wheeze, shortness of breath, and cough.<br>Exclusion criteria:<br>• Abnormal x-ray findings and other causes<br>• Pregnant/ breastfeeding<br>• Current Dx of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, chronic bronchitis, other lower respiratory abnormality.<br>• Systemic or inhaled CS, beta-blockers or angiotensin converting enzyme inhibitors<br>• Symptoms of chest pain or | Male: Female<br>221:345<br><br>Median (range) age: 52 years (18-88)<br><br>Medications:<br>Could be started on ICS at first visit before MCT | Index test<br>Routine interview including following questions:<br>a) Personal history: 'Have you had any medical history of allergic diseases such as asthma, atopic dermatitis, and allergic rhinitis?'<br>b) Family history: 'Do you have any close relatives with allergic disease?'<br><br>Reference standard<br>Relevant symptom history (all patients) and BDR (FEV1 <200ml and 12%) and/or BHR (methacholine PC20 <8mg/ml)<br><br>NB. 64/367 patients Dx had clinically Dx asthma (responsive to ICS with neither BDR or BHR)<br><br>Time between index test and reference standard: within 8 weeks<br><br>Target condition<br>Asthma | a) | Ref st + | Ref st - | Total | Source of funding:<br>None. None of the authors had a financial relationship with a commercial entity<br>Limitations:<br>• Time between tests 8 weeks, but could be started on ICS at first visit<br>• 813 consented but only 566 performed MCT (others declined participation or no AHR)<br>Additional data: |
| | | | | | Index test + | 202 | 64 | 266 | |
| | | | | | Index test - | 165 | 135 | 300 | |
| | | | | | Total | 367 | 199 | 566 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 55.0%<br>67.8%<br><br>75.9%<br>45.0% | | |
| | | | | | | | | | |
| | | | | | b) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 95 | 34 | 129 | |
| | | | | | Index test - | 272 | 165 | 437 | |
| | | | | | Total | 367 | 199 | 566 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | haemosputum. | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | 25.9%<br>82.9%<br><br>73.6%<br>37.8% | |

**Table 34: WEVERHESS 1999[1908]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Wever-hess et al., 1999. Prognostic characteristics of asthma diagnosis in early childhood in clinical practice. | <u>Study type:</u><br>Longitudinal prognostic study<br><u>Setting:</u><br>Outpatient department, Children's Hospital<br><u>Country:</u><br>Netherlands | N = 188 (including aged 2-4yr subgroup only)<br><br><u>Inclusion criteria:</u><br>• Aged 0-4 years with symptoms that were suggestive of asthma<br><u>Exclusion criteria:</u> | <u>Male: Female</u><br>108:80<br><br><u>Mean (SD) age:</u><br>37 (8.4) months<br><br>Medications at initial visit:<br>Beta-agonists 42%, | <u>Index test</u><br>History taken at initial visit:<br>a) Past or present rhinitis<br>b) past or present eczema<br>c) family history<br><br><u>Reference standard</u><br>Dx taken from medical notes at follow-up (2 years later). Dx made by a paediatrician on clinical | a) | Ref st + | Ref st - | Total | <u>Source of funding:</u><br>Supported financially by Stichting Astmabestrijding, Amsterdam<br><br><u>Limitations:</u> |
| | | | | | Index test + | 89 | 35 | 124 | |
| | | | | | Index test - | 55 | 9 | 64 | |
| | | | | | Total | 144 | 44 | 188 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Acta Paediatrica: 88: 827-834.<br><br>REF ID: WEVERHESS1999 | <u>Recruitment:</u><br>All children from Jan 1991 to Jan 1993 | • Symptoms that could be explained by other respiratory disorders, such as respiratory syncytial virus bronchiolitis, cystic fibrosis, gastro-oesophageal reflux | deptropine 10%, anticholinergics 3%, antihistamines 20%, anti-inflammatory 5%, antibiotics 49%. | grounds, based on recurrence of symptoms and need for and response to therapy according to the guidelines for diagnosis of asthma in young children (follow up statement from the International Paediatric Asthma Consensus Group).<br><br>Time between index test and reference standard: 2 years<br><br><u>Target condition</u> | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 61.8%<br>20.5%<br><br>71.8%<br>14.1% | | <u>Additional data:</u><br>Data provided from children aged 0-1 year separately but does not match protocol. |
| | | | | | | | | | |
| | | | | | b) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 67 | 11 | 78 | |
| | | | | | Index test - | 77 | 33 | 110 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 46.5%<br>75.0%<br><br>85.9%<br>30.0% | | |
| | | | | | c) | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 63 | 19 | 82 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Index test - | 81 | 25 | 106 | |
| | | | | | Total | 144 | 44 | 188 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 43.8%<br>56.8%<br><br>76.8%<br>23.6% | | |

**Table 35: VANDERMARK 2014[1823]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Predicting asthma in preschool children at high risk presenting in primary care: development of a clinical asthma prediction score. | Study type:<br>Longitudinal prognostic study (demographic data and clinical history obtained from questionnaire. Sensitivity and specificity calculated from for Dx | N = 771 (438 had information for diagnosis at age 6 years)<br><br>Inclusion criteria:<br>Aged 1-5 years.<br>Presented in primary care in the previous 12 months with current coughing (≥2 visits), wheezing (≥1 visits), and/or shortness of breath (≥1 visits) (only those | Male: Female<br>249:189<br><br>Mean (SD) age:<br>At baseline for study: 3.0 (1.3).<br>Note: diagnosis made at aged 6 years<br><br>Medications:<br>unclear | Index test<br>Questionnaire administered at baseline and at 6 years:<br>a) Family history of asthma (parents and/or siblings)<br><br>Reference standard<br>At age 6 years, spirometry and BHR obtained in children with wheezing, shortness of breath, recurrent coughing or use of asthma medication during the previous 12 | a) | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br><br>Limitations:<br><br>Additional data: |
| | | | | | Index test + | 80 | 76 | 156 | |
| | | | | | Index test - | 107 | 175 | 282 | |
| | | | | | Total | 187 | 251 | 438 | |
| | | | | | Sens<br>Spec | | 43.8%<br>69.7% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Primary Care Respiratory Journal. 2014; 68(1):52-59.<br><br>REF ID: VANDERMARK2014 | at 6 years of age)<br><br><u>Setting:</u><br>Primary care<br><br><u>Country:</u><br>Netherlands<br><br><u>Recruitment:</u><br>Children participating in the ARCADE prospective cohort study | with symptoms in the past year included in asthma Dx at age 6 years).<br><br><u>Exclusion criteria:</u> | | months.<br>Dx defined as having persistent symptoms and/or using asthma medication in the last year in combination with BHR (methacholine <8mg.ml) or BDR (>10% increase in FEV1).<br><br><u>Time between index test and reference standard:</u><br>Unclear if index test (clinical history) was taken at baseline or at 6 years.<br><br><u>Target condition</u><br>Asthma | | |

# G.3 Symptoms after exercise

**Table 36: Choi 2007[318,319]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Choi et al., 2007. Easy diagnosis of asthma: computer-assisted, symptom-based diagnosis. Journal of Korean Medical Science: 22: 832-838.<br><br>REF ID: CHOI2007 | <u>Study type:</u><br>Diagnostic cross sectional study<br><br><u>Setting:</u><br>Hospital outpatient dept.<br><br><u>Country:</u><br>Korea<br><br><u>Recruitment:</u><br>Consecutive or random patient selection not reported | N = 302<br>Adults<br><u>Inclusion criteria:</u><br>• Respiratory symptoms such as dyspnoea, cough or wheezing<br><br><u>Exclusion criteria:</u> | <u>Male:Female</u><br>127:175<br><br><u>Mean age:</u><br>Asthma: 46.8 (16.8)<br>Non-asthma: 47.8 (15.6)<br><br>Medications:<br>Not reported<br><br>Smokers:<br>Asthma: 36.7%<br>Non-asthma: 21.4% | <u>Index test</u><br>Questionnaire consisting of 11 questions regarding symptoms. Q3 = Have you had wheezing associated with dyspnoea (provoking factor – exercise)?<br><br>Cut-off: affirmative answer to Q3<br><br><u>Comparator test</u><br>n/a<br><br><u>Reference standard</u><br>Physician Dx with objective test (patients with an FEV1 >70% had MCT, all other patients had BDR to short-acting beta2-agonist). Definite Dx of asthma made using test (MCh PC20 <16mg/ml or BDR FEV1 increase >12% and 200ml)<br><br>Time between index test and reference standard: unclear | | Ref std + | Ref std - | Total | <u>Source of funding:</u><br>Korea Asthma Allergy Foundation Research Grant and Korea Health 21 R&D Project, Ministry of Health<br><u>Limitations:</u><br>• No drop-outs<br>• Consecutive or random patient selection not mentioned<br>• time between IT and RS unclear but same time suggested<br><u>Additional data:</u> |
| | | | | | Index test + | 84 | 20 | 104 | |
| | | | | | Index test - | 126 | 72 | 198 | |
| | | | | | Total | 210 | 92 | 302 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 40.0%<br>78.3%<br><br>80.8%<br>36.4% | | |
| | | | | | | | | | |
| | | | | | | Ref std + | Ref std - | Total | |
| | | | | | Index test + | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | Target condition<br>Asthma | Index test - | | | | |
| | | | | | Total | | | | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | | | |
| | | | | | | | | | |

## G.4 Occupational asthma

**Table 37: BAUR 1998[129]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Baur X et al. Relation between occupatio | Study type:<br>Diagnostic Cross-sectional study | N = 62 healthcare workers (airborne latex; 12 asthma) | Male: Female<br>Not stated<br><br>Mean age: | Index test Asking whether their symptoms are better away from work | **Occupational asthma: health care workers (latex)** | Ref std + | Ref std – | Total | Source of funding:<br>None stated |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| nal asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. Am J Industr Med 1998; 33: 114-122.<br><br>BAUR1998 | <u>Data source:</u><br>Industrial medicine institute<br><br><u>Setting:</u><br>Symptomatic<br><br><u>Country:</u><br>Germany<br><br><u>Recruitment:</u><br>1992 to 1997 | 28 bakers (flour, baking enzymes; 7 asthma)<br><br>114 isocyanate workers (isocyanates; 21 asthma)<br><br><u>Inclusion criteria:</u><br>Healthcare workers with contact with latex gloves, bakers or isocyanate workers presenting with suspected occupational asthma<br><u>Exclusion criteria:</u><br>Challenge tests contraindicated or declined | Healthcare workers 31 (8.1); bakers 32 (11.9); isocyanate workers 39 (11.1) years | **CUT-OFF:** positive = Reversible airways narrowing (SOB, wheeze) causally related to exposure in the working environment occurred repeatedly<br><br><u>Reference standard</u> **Clinical Dx** including objective test: Specific conductance ($sG_{aw}$) dropped ≥40% from baseline and absolute value ≤0.5$(kPa*s)^{-1}$<br><br>Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Occupational asthma | Question + | 11 | 34 | 45 | <u>Limitations:</u><br><br><u>Additional data:</u><br>Sensitivity etc calculated |
| | | | | | Question - | 1 | 16 | 17 | |
| | | | | | Total | 12 | 50 | 62 | |
| | | | | | Sensitivity<br>Specificity | | 92%<br>32% | | |
| | | | | | PPV<br>NPV | | 24%<br>94% | | |
| | | | | | **Occupational asthma: bakers (flour/enzyme)** | Ref std + | Ref std – | Total | |
| | | | | | Question + | 7 | 8 | 15 | |
| | | | | | Question - | 0 | 13 | 13 | |
| | | | | | Total | 7 | 21 | 28 | |
| | | | | | Sensitivity<br>Specificity | | 100%<br>62% | | |
| | | | | | PPV<br>NPV | | 47%<br>100% | | |
| | | | | | **Occupational asthma:** isocyanate workers | Ref std + | Ref std – | Total | |
| | | | | | Question | 14 | 32 | 46 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | + | | | | |
| | | | | | Question - | 7 | 61 | 68 | |
| | | | | | Total | 21 | 93 | 114 | |
| | | | | | Sensitivity<br>Specificity | | 67%<br>66% | | |
| | | | | | PPV<br>NPV | | 30%<br>90% | | |

**Table 38: Malo 1991[1079]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Malo J-L et al. Is the clinical history a satisfactory means of diagnosing occupational asthma? Am Rev Respir Dis 1991; 143: 528-532. | Study type: Diagnostic Cross-sectional study<br><br>Data source: Chest clinic<br><br>Setting: Symptomatic<br><br>Country: Canada | N = 162<br><br>Inclusion criteria: Consecutive cases referred for possible occupational asthma<br><br>Exclusion criteria: None given | Male: Female 125:37<br><br>Mean age: 39.6 (11.8) years | Index test Asking whether their symptoms are better away from work<br><br>**CUT-OFF:** positive = Whether symptoms worse during or after work and improved during weekends and holidays – history "very likely" or "likely"<br><br>Reference standard **Clinical Dx** including objective test: Final diagnosis including specific inhalation challenges, serial monitoring of peak flow at work and away from work or both. Fall in FEV1 > 20% (or ≥15% in late component of dual reactions) on specific challenge | **Occupational asthma** | Ref std + | Ref std – | Total | Source of funding: Not stated<br><br>Limitations:<br><br>Additional data: PPV and NPV reported; sensitivity and specificity calculated |
| | | | | | Question + | 65 | 39 | 104 | |
| | | | | | Question - | 10 | 48 | 58 | |
| | | | | | Total | 75 | 87 | 162 | |
| | | | | | Sensitivity<br>Specificity | | 87%<br>55% | | |
| | | | | | PPV<br>NPV | | 63%<br>83% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| MALO 1991 | Recruitment: 1987 to 1989 | | | or patterns suggestive of work-related asthma using graphs of individual, mean, maximum and minimum daily values using Burge criteria<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Occupational asthma (isocyanates, flour, grain dust, red and white cedar, pharmaceutical products, sawmills, laboratory animals) | | | |

**Table 39: Vandenplas 2001[1842]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Vandenplas O et al. Occupational asthma in symptomatic workers exposed to natural rubber latex: | Study type: Diagnostic Cross-sectional study<br><br>Data source: Chest clinic<br><br>Setting: Symptomatic | N = 45<br><br>Inclusion criteria: Consecutive patients referred for investigation of possible OA caused by latex; exposed at work to airborne natural rubber latex (NRL) allergens from NRL gloves. | Male: Female 2:43<br><br>Mean age: 33.6 years | Index test Asking whether their symptoms are better away from work<br><br>**CUT-OFF:** positive = Symptoms present only on work days<br><br>Reference standard **Clinical Dx** including objective test: SICs with NRL gloves; FEV1 fell by more than 20% | **Occupational asthma (latex)** | Ref std + | Ref std – | Total | Source of funding: Programme d'appui scientifique à la protection des travailleurs, Services fédéraux des affaires scientifiques, techniques et |
| | | | | | Question + | 15 | 4 | 19 | |
| | | | | | Question - | 16 | 10 | 26 | |
| | | | | | Total | 31 | 14 | 45 | |
| | | | | | Sensitivity<br>Specificity | | 48%<br>71% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Evaluation of diagnostic procedures. J Allergy Clin Immunol 2001; 107(3): 542-547.<br><br>VANDENPLAS 2001 | <u>Country:</u><br>Belgium<br><br><u>Recruitment:</u><br>1993 to 1998 | <u>Exclusion criteria:</u><br>None given | | Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Occupational asthma (latex) | PPV<br>NPV | 79%<br>38% | culturelles<br><br><u>Limitations:</u><br><br><u>Additional data:</u><br>Sensitivity and specificity etc calculated |

**Table 40: Vandenplas 2005[1842]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| What are the questionnaire items most useful in identifying subjects with occupational asthma? European Respirator | <u>Study type:</u><br>Diagnostic Cross-sectional study<br><br><u>Data source:</u><br>Chest clinic<br><br><u>Setting:</u><br>Symptomatic | N = 212<br><br><u>Inclusion criteria:</u><br>Prospectively assessed in outpatient clinics of four hospital centres and who underwent objective testing with specific inhalation challenges. | <u>Male: Female</u><br>125:87<br><br><u>Mean age:</u><br>38.8 (10.7) years | <u>Index test:</u> Asking whether their symptoms are better away from work<br><br>• **CUT-OFF:** positive = a) Improvement or disappearance of symptoms at weekends<br>• b) Improvement or disappearance of symptoms during vacations<br><br><u>Reference standard</u> **Clinical Dx** | **Occupational asthma – Question a** | Ref std + | Ref std – | Total | <u>Source of funding:</u><br><u>Actions de Recherche Concertées, Communauté Française de Belgique, Belgium.</u> |
| | | | | | Question + | 55 | 64 | 119 | |
| | | | | | Question - | 17 | 76 | 93 | |
| | | | | | Total | 72 | 140 | 212 | |
| | | | | | Sensitivity<br>Specificity | | 76%<br>54% | | <u>Limitations:</u> |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| y Journal. 2005; 26(6):1056-1063<br><br>VANDENPLAS 2005 | Country:<br>Belgium, Canada, Italy, Spain<br><br>Recruitment:<br>not stated | Exclusion criteria:<br>None given | | including objective test: specific inhalation challenge; a sustained fall in forced expiratory volume in one second of 20%<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Occupational asthma (flour and cereals, latex, isocyanates, other chemicals, wood dust, laboratory animals, persulfate, resins and glues, various proteins, metals) | PPV<br>NPV | | 41%<br>80% | | Additional data:<br>Sensitivity and specificity etc reported; raw data calculated |
| | | | | | **Occupational asthma – question b** | Ref std + | Ref std – | Total | |
| | | | | | Question + | 53 | 60 | 113 | |
| | | | | | Question - | 19 | 80 | 99 | |
| | | | | | Total | 72 | 140 | 212 | |
| | | | | | Sensitivity<br>Specificity | | 74%<br>57% | | |
| | | | | | PPV question<br>NPV | | 57%<br>74% | | |

## G.5 Spirometry/flow volume loop measures

**Table 41: FORTUNA 2007[511]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Fortuna et al., 2007. Diagnostic utility of inflammatory | Study type:<br>Cross sectional study<br>Setting:<br>Referred to | N = 50<br>Adults<br>Inclusion criteria:<br>• Referred with a clinical history suggestive of | Male: Female<br>21:29<br><br>Age range:<br>18-68 | Index test<br>Spirometry was performed following international guidelines with a Datospir 120 (Sibelmed, Barcelona, Spain). A FEV1 ≥80% of predicted and/or a ratio of | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>• RS objective MCT is |
| | | | | | Index test + | 5 | 0 | 5 | |
| | | | | | Index test - | 17 | 22 | 39 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count. Respiratory Medicine: 101: 2416-2421<br><br>REF ID: FORTUNA | hospital based outpatient clinic<br>Country:<br>Spain<br>Recruitment:<br>Consecutive | asthma (dry cough, wheezing, and shortness of breath)<br>Exclusion criteria:<br>• Conditions that could affect FENO or Eos% measurement for reasons other than asthma: subjects with symptoms of respiratory tract infection in the previous 6 weeks or with systemic manifestations of atopy (rash, digestive | % of symptomatic patients with positive/abnormal spirometry (FEV1/FVC<75% or FEV1 <80%): 10%<br><br>Medications: no CS within the last 4 weeks | FEV1/FVC ≥75% were considered to lie within normal limits.<br><br>Cut-off: Obstruction: FEV1 <80%<br><br>Comparator test<br>n/a<br><br>Reference standard<br>Methacholine challenge test (PD20 ≤16mg/ml) following guidelines of the GINA<br><br>Time between index test and reference standard: 1 day | Total | 22 | 22 | 44 | 16mg/ml<br>• Unclear why 6 patients not included in analysis of sn/sp<br>• Suggests IT is FEV1<80% and unclear if also includes FEV1/FVC<br>Additional data:<br>7 of original 57 patients excluded as on CS treatment<br><br>6 out of the 50 |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV<br><br>AUC FEV1/FVC | | 22.7%<br>100%<br><br>100%<br>56.4%<br><br>0.64 (95% CI, 0.49–0.77; p<0.008)<br><br>0.63 (95% CI, 0.48–0.76; p<0.006) | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| 2007 | | symptoms, etc.)<br>• Received treatment with inhaled or oral corticosteroids in the last 4 weeks | | <u>Target condition</u><br>Asthma | | patients not included in analysis of sn/sp for spirometry and not mentioned |

**Table 42: PINO 1996[1365]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Pino et al., 1996. | <u>Study type:</u><br>Cross- | N = 84<br>Adults | <u>Male: Female</u><br>53:31 | <u>Index test</u><br>Spirometry: Pneumoscreen II | | Ref st +<br> | Ref st -<br> | Total<br> | <u>Source of funding:</u> |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Value of the peak expiratory flow in bronchodynamic tests. Allergologia et Immunopathologia: 24: 54-57<br><br>REF ID: PINO1996 | sectional study<br><br><u>Setting:</u><br>University hospital<br><br><u>Country:</u><br>Spain<br><br><u>Recruitment:</u><br>Not stated | <u>Inclusion criteria:</u><br>• Clinically suspected of bronchial asthma<br><u>Exclusion criteria:</u><br>• Worsening of symptoms in the preceding 2 months<br>• A respiratory infection in the lower or upper tract in the preceding 6 weeks<br>• Vaccination with live attenuated virus 6 weeks prior to the test<br>• The existence of a recurrent pathology<br>• Cases of whistling in observed in pulmonary auscultation were excluded from the bronchial provocation test. | <u>Mean age:</u><br>46.5 (13.7)<br><br>Medications:<br>Smoking prohibited 2 hours before the study; discontinuation 48 hours in advance of beta-agonists; theophyllines; anticholinergics; antihistamines; nedochromil; chromoglicate. | (Jagger) according to ATS criteria<br><br>Cut-off: FEV1/FVC<70% and FEV1<80%<br><br><u>Comparator test</u><br>n/a<br><br><u>Reference standard</u><br>If obstructive spirometry: performed BDR (400µg salbutamol; FEV1 >15% initial)<br>If normal spirometry: methacholine challenge test five breaths of 5mg/ml and five breaths of 25mg/ml, test positive if a 20% drop in FEV1<br><br>Time between index test and reference standard:<br><br><u>Target condition</u> | Index test + | 20 | 24 | 44 | Not reported<br><u>Limitations:</u><br>• Unclear of the directness of the population as few details reported<br>• Unclear time between RS and IT<br>• Random or consecutive recruitment not reported<br>• Patients have different RS objective tests depending on if they were negative or positive to IT<br>• Unclear if suitable cut-off used for MCT<br><u>Additional data:</u> |
| | | | | | Index test - | 23 | 17 | 40 | |
| | | | | | Total | 43 | 41 | 84 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 46.5%<br>41.5%<br><br>45.5%<br>42.5% | | |
| | | | | | | | | | |
| | | | | | | Ref std + | Ref std - | Total | |
| | | | | | Index test + | | | | |
| | | | | | Index test - | | | | |
| | | | | | Total | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | |
| | | | | | | | |

**Table 43: POPOVIC 2012[1381]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Popovic-Grle et al., 2002. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung | Study type:<br>Cross-sectional study<br>Setting:<br>Outpatient department, University Hospital<br>Country:<br>Croatia | N = 195<br>Adults<br>Inclusion criteria:<br>• Referred by GP with suspected asthma and symptoms of breathlessness / dyspnoea.<br>Exclusion criteria:<br>• Serious diseases of | Male, %<br>51% of those given an asthma Dx<br><br>Mean age:<br>36.5 (6.2) in those given an asthma Dx (n=141) | Index test<br>Spirometry: measured at least 3 times by forced expiration on Vitalograph apparatus with a pneumotachograph. Best attempt recorded.<br><br>Cut-off: FEV1 <80% predicted<br><br>Comparator test<br>n/a | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>• Details of reference standard objective test not given<br>• Unclear if RS results |
| | | | | | Index test + | 63 | 37 | 100 | |
| | | | | | Index test - | 78 | 17 | 95 | |
| | | | | | Total | 141 | 54 | 195 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| function in the diagnosis of asthma in persons with dyspnoea. Collegium Antropologicum: 26 Suppl: 119-127<br><br>REF ID: POPOVIC 2002 | <u>Recruitment:</u><br>Random | other organ systems or the lungs (apart from those of an obstructive and/or allergic nature) | Medications:<br>Not reported | <u>Reference standard</u><br>Dx made on the basis of questionnaire, with typical medical history data of occasional asthma attacks with wheezing and nocturnal awakening because of dyspnoea, and reversible bronchial obstruction after salbutamol test (no further details stated)<br><br>Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Asthma | Sensitivity<br>Specificity<br><br>PPV<br>NPV | 44.7%<br>31.5% | | | interpreted without knowledge of the IT results<br>• Unclear if IT results interpreted without knowledge of the RS results (but objective)<br><br><u>Additional data:</u> |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | | | | | |

**Table 44: SCHNEIDER 2009A[1535]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | Comments |
|---|---|---|---|---|---|---|---|---|
| Schneider A et al. 2009. Diagnostic accuracy of spirometry in primary care. BMC Pulmonary Medicine: 9: 31.<br><br>REF ID: SCHNEIDER2009A | <u>Study type:</u><br>Cross-sectional study<br><u>Setting:</u><br>Index test in primary care, 14 GPs in 10 practices<br><u>Country:</u><br>Germany<br><u>Recruitment:</u><br>Consecutive recruitment | N = 219<br>Adults<br><u>Inclusion criteria:</u><br>• Visiting GP for the first time with complaints of suggested obstructive airway disease (OAD).<br>• Symptoms such as dyspnoea, coughing, or expectoration<br><u>Exclusion criteria:</u><br>• Previous Dx for OAD<br>• Previous anti-obstructive medicine<br>• Contraindications | <u>Male: Female</u><br>92:127<br><br><u>Mean (SD) age:</u><br>43.8 (15.6)<br><br><u>% of symptomatic patients with positive/abnormal spirometry:</u><br>35.6%<br><br><u>Medications:</u><br>None prior to spirometry at GP. If necessary, therapy initiated by GP for asthma or | <u>Index test: Spirometry at GP</u><br>Electronic spirometer (Medikro Spirostar USB). Best of 3 consecutive spirometric values used in accordance with European Respiratory Society (ERS). Max inspiratory and expiratory flow volume curves generated by forced deep inspiration and expiration with intervening periods of tidal breathing.<br><br>Cut-off: OAD if FEV1/VC ≤70% and/or FEV1 <80%<br><br><u>Comparator test</u><br>None<br><br><u>Reference standard</u><br>LUNG FUNCTION LAB: Dx by | | Ref st + | Ref st - | Total | <u>Source of funding:</u><br>Federal ministry of education and research (BMBF), Germany.<br><u>Limitations:</u><br>• Spirometry performed with full adherence to ERS guidelines in 39.8% of cases and moderate adherence in 38% of cases. ERS criteria |
| | | | | | Index test + | 26 | 52 | 78 | |
| | | | | | Index test - | 63 | 75 | 138 | |
| | | | | | Total | 89 | 127 | 216 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 29.2%<br>59.1%<br><br>33.3%<br>54.3% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | for BDR of challenge testing (untreated hyperthyreosis, unstable coronary artery disease, cardiac arrhythmia)<br>• Pregnancy | COPD but stopped 12 hours prior to lung function lab. | pneumologist based on whole-body plethysmography (FEV1/VC ≤70% or FEV1 <80%) followed by either BDR if obstruction is present (FEV1 ≥12% and ≥200ml) or methacholine if obstruction is not present (PC20 ≤16mg/ml or extreme increase in airway resistance accompanied by clinical symptoms in two patients)<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>OAD: Asthma or COPD | | | | | not fulfilled in 22.2% of cases.<br>• Unclear time between IT and RS; 74 patients from original 293 only wanted the IT and did not have RS<br>• RS objective MCT is 16mg/ml<br><u>Additional data:</u><br>3 lost to follow-up<br><br>Gives sn/sp of spirometry for asthma and COPD separately (data combined here to include all patients presenting with respiratory symptoms regardless of their final Dx) |

**Table 45: SIVAN 2009[1619]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Sivan et al., 2009. The use of exhaled nitric oxide in the diagnosis of asthma in school children. Journal of Pediatrics: 155: 211-216<br><br>REF ID: SIVAN2009 | Study type:<br>Cross-sectional study<br>Setting:<br>Outpatient paediatric pulmonary clinic, Children's Hospital<br>Country:<br>Israel<br>Recruitment:<br>Consecutive | N = 150 (113 excluding those on ICS from analysis)<br>Children<br>Inclusion criteria:<br>• Non-specific respiratory symptoms suggestive of asthma for at least 3 months, including cough, wheezing and shortness of breath with or without trials of treatment with bronchodilators and ICS.<br>• Follow-up for at least 1 year<br>Exclusion criteria:<br>• Symptoms of unresolved respiratory tract infection<br>• Systemic clinical manifestations of atopy such as anaphylaxis, angioedema, food allergy, urticarial, systemic or inflammatory disease | Male: Female<br>~56% male<br><br>Age range:<br>5-18yrs (mean 12)<br><br>Medications:<br>Withheld bronchodilators for 24 hours. Unclear if on medications for 18 months between IT and RS. | Index test<br>Spirometry: hand-held spirometer (Micro-lab ML3500/S, Micro-Medical, UK).<br><br>Cut-off: FEV1 <80%<br><br>Reference standard<br>Made by paediatric pulmonologist after 18 months follow-up. Based on history of 2 or more clinical exacerbations of wheezing documented by a physician; dyspnoea or cough relived by bronchodilators; documented variability in FEV1 ≥15% in response to bronchodilators at any time during the follow-up period; OR documented variability in FEV1 ≥15% over time with or without controller medications (ICS or montelukast). Results of provocation tests included when available.<br><br>Time between index test and reference standard: 18 months | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>• Recruited 150 patients but excluded 37 on ICS from analysis<br>• Time between IT and RS = 18 months<br>• Unclear if all had objective test with RS<br>• Interpretation of RS not done blinded to results of spirometry IT<br>Additional data: |
| | | | | | Index test + | 36 | 12 | 48 | |
| | | | | | Index test - | 33 | 32 | 65 | |
| | | | | | Total | 69 | 44 | 113 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 52%<br>72%<br><br>75%<br>48% | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | Target condition<br>Asthma | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

**Table 46: SMITH 2004[1630]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Smith et al., 2004. Clinical usefulness of fractional exhaled nitric | Study type:<br>Cross-sectional study<br>Setting:<br>Referred to hospital pulmonary | N = 47<br>Adults and children (8-75 years)<br>Inclusion criteria:<br>• Referred to hospital pulmonary function lab by GP for possible asthma | Male: Female<br><br>Mean age:<br><br>Medications: | Index test<br>Spirometry<br><br>Cut-off:<br>FEV1 <90% predicted<br>FEV1 <80% predicted<br>FEV1/FVC <80% | **FEV1/FVC <70%** | Ref st + | Ref st - | Total | Source of funding:<br>Supported by Otago Medical Research Foundation and the Otago respiratory |
| | | | | | Index test + | 6 | 0 | 6 | |
| | | | | | Index test - | 11 | 30 | 41 | |
| | | | | | Total | 17 | 30 | 47 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| oxide for diagnosing prolonged cough. Respiratory Medicine: 102: 1452-1459.<br><br>REF ID: SMITH2004 | function lab<br>Country:<br>New Zealand<br>Recruitment:<br>Consecutive | • Respiratory symptoms for a minimum of 6 weeks<br>Exclusion criteria:<br>• Used ICS in the preceding 4 weeks<br>• Typical respiratory tract infection in the preceding 6 weeks | Short-acting beta-agonists and anticholinergic inhalers permitted during the study period but withheld for a minimum of 6 hours before the study visit. | FEV1/FVC <70%<br><br>Comparator test<br>n/a<br><br>Reference standard<br>Relevant symptom history (all patients) and a positive hypertonic saline challenge test (PD15<20ml) or BDR increase in FEV1 ≥12%<br><br>Time between index test and reference standard: 2 weeks<br><br>Target condition<br>Asthma | Sensitivity 35.3%<br>Specificity 100%<br>PPV 100%<br>NPV 73.2%<br><br>AUC FEV1/FVC 0.678<br><br>**FEV1/FVC <80%** / Ref st + / Ref st - / Total<br>Index test + 8 / 6 / 14<br>Index test - 9 / 24 / 33<br>Total 17 / 30 / 47<br><br>Sensitivity 47.1%<br>Specificity 80.0%<br>PPV 57.1%<br>NPV 72.7%<br><br>**FEV1 <80% pred** / Ref st + / Ref st - / Total<br>Index test + 5 / 0 / 5<br>Index test - 12 / 30 / 42<br>Total 17 / 30 / 47<br><br>Sensitivity 29.4%<br>Specificity 100%<br>PPV 100%<br>NPV 72.4% | research trust. GSK personal education grant to one author.<br>Limitations:<br>•<br>•<br>Additional data:<br>4 of the original 51 patients withdrew after first study visit due to time commitments. |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | AUC FEV1%pred | | 0.804 | | |
| | | | | | **FEV1 <90% pred** | Ref st + | Ref st - | Total | |
| | | | | | Index test + | 6 | 2 | 8 | |
| | | | | | Index test - | 11 | 28 | 39 | |
| | | | | | Total | 17 | 30 | 47 | |
| | | | | | Sensitivity | | 35.3% | | |
| | | | | | Specificity | | 93.3% | | |
| | | | | | PPV | | 75%% | | |
| | | | | | NPV | | 71.8% | | |

## G.6 Bronchodilator reversibility

**Table 47: BRAND 1992[211]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Brand PLP et al. Interpretation of bronchodilator response | Study type:Diagnostic cross-sectional study | N = 150<br><br>Inclusion criteria:<br>• Adults with chronic respiratory symptoms (asthma | Male: Female<br>Not stated<br><br>Mean age:<br>18-60 years; mean not stated | Index testBronchodilator reversibility: Response to inhaled terbutaline 1000µg a) change [Δ]FEV1 % init; b) ΔFEV1[l] i.e. absolute value in litres; c) ΔFEV1 % init and ΔFEV1[l]; d) ΔFEV1 %pred; e) standardised residual [SR]-FEV1; | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>Some |
| | | | | | Bronchodilator reversibility | 68 | 24 | 92 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| in patients with obstructive airways disease. Thorax 1992; 47: 429-436.<br><br>BRAND1992 | <u>Data source:</u><br>University hospital outpatients departments<br><br><u>Setting:</u><br>Secondary care<br><br><u>Country:</u><br>The Netherlands<br><br><u>Recruitment:</u><br>Not stated. | or COPD) in university hospital outpatients departments; baseline FEV1 >1.2 litres and 1.64-4.5 residual standard deviations below predicted value, or FEV1/inspiratory vital capacity ratio >1.64 RSD below predicted; hyperresponsive to inhaled histamine<br><br><u>Exclusion criteria:</u><br>Pregnant women; history of occupational asthma or other serious diseases (e.g. TB, MI, malignancy); oral corticosteroids, beta-blockers, nitrates or anticoagulants; continuous antibiotics. | Tx was withdrawn for 14days and BD Tx for 12 days. | f) FEV1 post-bronchodilator [pb] %pred<br><br>**CUT-OFF:** positive = a) ΔFEV1 % init >15%; b) ΔFEV1[l] > 0.200; **c) ΔFEV1 % init >15% and ΔFEV1[l] > 0.200;** d) ΔFEV1 %pred >9%; e) SR-FEV1 > 0.5; f) FEV1 pb %pred >80%<br><br><u>Reference standard</u>**Clinical Dx**<br>Standardised history using criteria of American Thoracic Society: asthma = attacks of breathlessness and wheeze (asthma attacks) without chronic (>3 months/year) cough or sputum production; COPD = Current or former smokers without a history of asthma attacks reporting either chronic cough +/- sputum production, or dyspnoea when walking quietly on level ground, or both<br>Plus hyper-responsiveness to inhaled histamine<br><br>Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Asthma | (a) + | | | | exclusions may limit generalisability<br><br><u>Additional data:</u><br>Raw data not stated; calculated from sensitivity and specificity |
| | | | | | Bronchodilator reversibility (a) - | 31 | 27 | 58 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity (a)<br>Specificity (a) | | 68.7%<br>52.9% | | |
| | | | | | Likelihood ratio (a) | | 1.459 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (b) + | 87 | 33 | 120 | |
| | | | | | Br. rev. (b) - | 12 | 18 | 30 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity (b)<br>Specificity (b) | | 87.9%<br>35.3% | | |
| | | | | | Likelihood ratio (b) | | 1.359 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (c) + | 68 | 23 | 91 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Br. rev. (c) - | 31 | 28 | 59 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity (c)<br>Specificity (c) | | 68.7%<br>54.9% | | |
| | | | | | Likelihood ratio (c) | | 1.523 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (d) + | 73 | 22 | 95 | |
| | | | | | Br. rev. (d) - | 26 | 29 | 55 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity (d)<br>Specificity (d) | | 73.7%<br>56.9% | | |
| | | | | | Likelihood ratio (d) | | 1.710 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (e) + | 80 | 28 | 108 | |
| | | | | | Br. rev. (e) - | 19 | 23 | 42 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity(e)<br>Specificity (e) | | 80.8%<br>45.1% | | |
| | | | | | Likelihood ratio (e) | | 1.472 | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (f) + | 45 | 16 | 61 | |
| | | | | | Br. rev. (f) - | 54 | 35 | 89 | |
| | | | | | Total | 99 | 51 | 150 | |
| | | | | | Sensitivity (f)<br>Specificity (f) | | 45.5%<br>68.6% | | |
| | | | | | Likelihood ratio (f) | | 1.449 | | |

**Table 48: CHHABRA 2005[313]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. J Asthma 2005; 42: | Study type:Diagnostic cross-sectional study<br><br>Data source:<br>Outpatient clinic<br><br>Setting:<br>Secondary care<br><br>Country: | N = 354<br><br>Inclusion criteria:<br>• Clinical diagnosis of asthma (non-smokers) or COPD; stable clinical state with no history of acute exacerbation in previous 4 weeks; acceptable performance of spirometry; FEV1/FVC ratio 70% or less | Male: Female<br>Asthma: 122:78; COPD: 149:5<br><br>Mean age:<br>Asthma mean 35.60 (12.47); COPD mean 56.28 (9.57) years<br><br>Participants were already on (and remained on) | Index testBronchodilator reversibility: Response to inhaled salbutamol 200µg: a) absolute change in FEV1 (ΔFEV1); b) ΔFEV1%init; c) ΔFEV1%pred; d) ΔFEV1≥0.2l and ΔFEV1%init ≥12%<br><br>**CUT-OFF:** positive = a) absolute change in FEV1 (ΔFEV1) a1: 0.2l; a2: 0.3l; a3: 0.4l; b) ΔFEV1%init b1: 12%; b2: 15%; b3: 20%; c) ΔFEV1%pred c1: 9%; c2: 15%; **d) ΔFEV1≥0.2l and ΔFEV1%init ≥12%**<br><br>Reference standard**Clinical Dx** | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>Time between index test and reference standard: unclear. Some exclusions may limit generalisability<br><br>Additional data: |
| | | | | | Bronchodilator reversibility (a1) + | 146 | 31 | 177 | |
| | | | | | Bronchodilator reversibility (a1) - | 54 | 123 | 177 | |
| | | | | | Total | 200 | 154 | 354 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| 367-372.<br><br>CHHABRA 2005 | India<br><br><u>Recruitment:</u><br>Not stated. | <u>Exclusion criteria:</u><br>Smokers with asthma; any other concurrent pulmonary or systemic disease | corticosteroid treatment. BD Tx was withdrawn for 12 hrs. | Physician diagnosis based on clinical criteria suggested by the National Institute of Health Global Strategy for Asthma Management and Prevention (asthma = recurrent episodes of breathlessness and wheezing, with or without cough and phlegm, with seasonal and diurnal variations and any identifiable trigger factors) and the Global Initiative for Chronic Obstructive Lung Disease (COPD = history of smoking >10 pack-years, cough with expectoration for at least 3 consecutive months in a year for 2 years or more and progressive dyspnoea on exertion).<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Asthma | Sensitivity (a1)<br>Specificity (a1) | | 73%<br>80% | | Raw data not stated; calculated from sensitivity and specificity |
| | | | | | PPV (a1)<br>NPV (a1)<br>Likelihood ratio (a1) | | 82%<br>69%<br>3.60 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (a2) + | 106 | 20 | 126 | |
| | | | | | Br. rev. (a2) - | 94 | 134 | 228 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity(a2)<br>Specificity (a2) | | 53%<br>87% | | |
| | | | | | PPV (a2)<br>NPV (a2)<br>Likelihood ratio (a2) | | 84%<br>59%<br>4.08 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (a3) + | 68 | 8 | 76 | |
| | | | | | Br. rev. (a3) - | 132 | 146 | 278 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (a3)<br>Specificity (a3) | | 34%<br>95% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | PPV (a3)<br>NPV (a3)<br>Likelihood ratio (a3) | | 91%<br>53%<br>7.37 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (b1) + | 150 | 62 | 212 | |
| | | | | | Br. rev. (b1) - | 50 | 92 | 142 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (b1)<br>Specificity (b1) | | 75%<br>60% | | |
| | | | | | PPV (b1)<br>NPV (b1)<br>Likelihood ratio (b1) | | 71%<br>65%<br>1.88 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (b2) + | 132 | 48 | 170 | |
| | | | | | Br. rev. (b2) - | 68 | 106 | 174 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (b2)<br>Specificity (b2) | | 66%<br>69% | | |
| | | | | | PPV (b2)<br>NPV (b2)<br>Likelihood ratio | | 73%<br>61%<br>2.12 | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | (b2) | | | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (b3) + | 106 | 34 | 140 | |
| | | | | | Br. rev. (b3) - | 94 | 120 | 214 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (b3)<br>Specificity (b3) | | 53%<br>78% | | |
| | | | | | PPV (b3)<br>NPV (b3)<br>Likelihood ratio (b3) | | 76%<br>56%<br>2.42 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (c1) + | 126 | 25 | 151 | |
| | | | | | Br. rev. (c1) - | 74 | 129 | 203 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (c1)<br>Specificity (c1) | | 63%<br>84% | | |
| | | | | | PPV (c1)<br>NPV (c1)<br>Likelihood ratio (c1) | | 84%<br>64%<br>4.03 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Br. rev. (c2) + | 76 | 8 | 84 | |
| | | | | | Br. rev. (c2) - | 124 | 146 | 270 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (c2)<br>Specificity (c2) | | 38%<br>95% | | |
| | | | | | PPV (c2)<br>NPV (c2)<br>Likelihood ratio (c2) | | 92%<br>54%<br>8.36 | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (d) + | 130 | 29 | 159 | |
| | | | | | Br. rev. (d) - | 70 | 125 | 195 | |
| | | | | | Total | 200 | 154 | 354 | |
| | | | | | Sensitivity (d)<br>Specificity (d) | | 65%<br>81% | | |
| | | | | | PPV (d)<br>NPV (d)<br>Likelihood ratio (d) | | 81%<br>64%<br>3.34 | | |

**Table 49: KIM 2012[870]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kim T-B et al. The reality of an intermediate type between asthma and COPD in practice. Respir Care 2012; 57: 1248-1253.<br><br>KIM2012 | Study type:Diagnostic cross-sectional study<br><br>Data source:<br>Disease cohorts<br><br>Setting:<br>Secondary care<br><br>Country:<br>Republic of Korea<br><br>Recruitment:<br>Not stated | N = 514<br><br>Inclusion criteria:<br>• Adults with chronic obstructive airways disorders included in an asthma cohort or a COPD cohort; all had at least one chronic persistent respiratory symptom (dyspnoea, cough, sputum production or wheeze) for >3 months or repetition of the symptom for >3 months<br><br>Exclusion criteria:<br>Patients with tuberculous destroyed lungs, bronchiectasis or lung resection | Male: Female<br>49% male in asthma group and 91.7% in COPD group<br><br>Mean age:<br>48 (16) years for asthma and 65 (8) years for COPD | Index testBronchodilator reversibility: Bronchodilator response to albuterol 400µg<br><br>**CUT-OFF:** positive = **Increase in FEV1 >200mL and >12% above baseline**<br><br>Reference standard**Clinical Dx**<br>Clinical decision (no definite diagnostic criteria) by specialists in allergy or pulmonary departments<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Korea Healthcare Technology Research and Development Project, Ministry of Health and Welfare, Republic of Korea<br><br>Limitations:<br>No definite diagnostic criteria used; unclear if index test could be part of diagnostic criteria. Some exclusions may limit generalisability<br><br>Additional data:<br>None |
| | | | | | Bronchodilator reversibility + | 62 | 56 | 118 | |
| | | | | | Bronchodilator reversibility - | 307 | 89 | 396 | |
| | | | | | Total | 369 | 145 | 514 | |
| | | | | | Sensitivity<br>Specificity | | 16.8%<br>61.4% | | |
| | | | | | PPV<br>NPV | | 52%<br>22% | | |

**Table 50: QUADRELLI 1999[1417]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Quadrelli SA et al. Evaluation of bronchodilator response in patients with airway obstruction. Respir Med 1999; 93: 630-636.<br><br>QUADRELLI1999 | Study type: Diagnostic cross-sectional study<br><br>Data source: University hospital<br><br>Setting: Secondary care<br><br>Country: Argentina<br><br>Recruitment: Not stated | N = 119 (subset of 61 patients with asthma with FEV1<55% from overall sample 142 asthma patients, plus all 58 patients with COPD)<br><br>Inclusion criteria:<br>• Patients with previously diagnosed airways obstruction; present baseline spirometry: FEV1/FVC relationship 1.64 SEE below predicted value or lower; people with asthma had FEV1 <55% predicted (to match with COPD patients' baseline lung function)<br><br>Exclusion criteria: | Male: Female<br>Overall: asthma 74:68; COPD 46:12<br><br>Mean age:<br>Overall asthma: 55.4 (19.0) years; COPD 67.3 (7.0) years | • Index testBronchodilator reversibility: Response to inhaled salbutamol 200µg a) ΔFEV1[L]; b) ΔFEV1%init; c) ΔFEV1[L] plus ΔFEV1%init; d) ΔFEV1%pred; e) ΔFEV1%max (% of maximal possible response)<br><br>**CUT-OFF:** positive = a) ΔFEV1[L]: 200mL; b) ΔFEV1%init: 15%; **c) ΔFEV1[L] >200mL plus ΔFEV1%init >15%;** d) ΔFEV1%pred: 9%; e) ΔFEV1%max (% of maximal possible response): 50%<br><br>Positive and negative predictive values calculated for two arbitrary prevalences of asthma A] prevalence of asthma 30% and B] prevalence of asthma 70%<br><br>Reference standard**Clinical Dx**<br>Clinical diagnosis: asthma = attacks of breathlessness or wheeze according to ATS criteria (smokers excluded) and at least 2 of: 1; | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>Time between index test and reference standard: unclear. Some exclusions may limit generalisability<br><br>Additional data:<br>Raw data not stated; calculated from sensitivity and specificity |
| | | | | | Br. rev. (a) + | 43 | 17 | 60 | |
| | | | | | Br. rev. (a) - | 18 | 41 | 59 | |
| | | | | | Total | 61 | 58 | 119 | |
| | | | | | Sensitivity (a) | | 70.4% | | |
| | | | | | Specificity(a) | | 70.6% | | |
| | | | | | PPV(a) [A] [B] | | 50.5% 84.8% | | |
| | | | | | NPV (a) [A] [B] | | 84.7% 50.6% | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (b) + | 52 | 29 | 81 | |
| | | | | | Br. rev. (b) - | 9 | 29 | 38 | |
| | | | | | Total | 61 | 58 | 119 | |
| | | | | | Sensitivity (b) | | 85.2% | | |
| | | | | | Specificity(b) | | 50.0% | | |
| | | | | | PPV(b) [A] | | 39.4% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | Those mentioned in inclusion and reference standard sections, plus patients not clearly classified as either asthma or COPD, or those under current treatment with systemic steroids | | history of symptoms since childhood or adolescence; 2. symptomatic-free periods of >3 months; 3. spontaneous variations in FEV1 during the year of >20% of baseline value; 4. histamine challenge test <8mg/mL. COPD = heavy current or ex-smokers with no history of asthma reporting chronic cough or sputum (non-smokers excluded)<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Asthma | [B]<br>NPV (b) [A]<br>[B] | | 78.0%<br>82.9%<br>47.3% | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (c) + | 42 | 17 | 59 | |
| | | | | | Br. rev. (c) - | 19 | 41 | 60 | |
| | | | | | Total | 61 | 58 | 119 | |
| | | | | | Sensitivity (c)<br>Specificity(c) | | 68.8%<br>70.6% | | |
| | | | | | PPV(c) [A]<br>[B]<br>NPV(c) [A]<br>[B] | | 48.1%<br>83.5%<br>81.9%<br>45.5% | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (d) + | 41 | 17 | 58 | |
| | | | | | Br. rev. (d) - | 20 | 41 | 61 | |
| | | | | | Total | 61 | 58 | 119 | |
| | | | | | Sensitivity (d)<br>Specificity(d) | | 67.2%<br>70.6% | | |
| | | | | | PPV(d) [A]<br>[B]<br>NPV (d) [A] | | 49.2%<br>84.1%<br>83.1% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | [B] | | 47.5% | | |
| | | | | | **Asthma** | Ref std + | Ref std – | Total | |
| | | | | | Br. rev. (e) + | 4 | 1 | 5 | |
| | | | | | Br. rev. (e) - | 57 | 57 | 114 | |
| | | | | | Total | 61 | 58 | 119 | |
| | | | | | Sensitivity (e) | | 6.5% | | |
| | | | | | Specificity(e) | | 98.2% | | |
| | | | | | PPV(e) [A] | | 75.5% | | |
| | | | | | [B] | | 94.5% | | |
| | | | | | NPV (e) [A] | | 72.3% | | |
| | | | | | [B] | | 32.4% | | |

## G.7 PEF variability

**Table 51: BROUWER 2010[232,233]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Brouwer AFJ, Visser CAN, Duiverman EJ, | Study type:Diagnostic Cross-sectional study | N = 61<br><br>Inclusion criteria:<br>Children with non-specific respiratory | Male: Female<br>27:34<br><br>Mean age:<br>6 to 16 years; | Index testPEF variation amp%mean<br>**CUT-OFF:** positive = >95$^{th}$ centile for healthy children i.e. ≥12.3% | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>AstraZeneca NL<br><br>Limitations: |
| | | | | | PEF + | 10 | 11 | 21 | |
| | | | | | PEF - | 10 | 28 | 38 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Roorda RJ, and Brand PLP. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatric Pulmonology2010; 45: 326-332<br>REF ID: **BROUWER2010**. | <u>Data source:</u><br>Paediatric asthma clinic<br><br><u>Setting:</u><br>Secondary care<br><br><u>Country:</u><br>The Netherlands<br><br><u>Recruitment:</u><br>Not stated. | symptoms such as cough and breathlessness in whom GP uncertain of diagnosis referred to hospital-based paediatric asthma clinic<br><br><u>Exclusion criteria:</u><br>Straightforward diagnosis of asthma based on classical respiratory symptoms; referred for poorly controlled asthma; systemic corticosteroids or long-acting beta-2 agonists in last 4 weeks | mean 10.4 years | <u>Reference standard</u>**Clinical Dx**including objective test: Asthma diagnosed by paediatric pulmonologist including history. physical examination and lung function tests including methacholine challenge<br><br>Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Asthma | Total | 20 | 39 | 59 | Home spirometry data lost for 2 patients due to battery failure of the device<br><br><u>Additional data:</u><br><u>None</u> |
| | | | | | Sensitivity | | 50% | | |
| | | | | | Specificity | | 72% | | |
| | | | | | PPV | | 48% | | |
| | | | | | NPV | | 74% | | |
| | | | | | Likelihood ratio | | 1.77 | | |

**Table 52: DEN OTTER 1997[422]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| den Otter JJ, Reijnen GM, van den Bosch | <u>Study type:</u>Diagnostic Cross-sectional | N = 323<br><br><u>Inclusion criteria:</u><br>adults between 25 | <u>Male: Female</u><br>135:188<br><u>Mean age:</u> | <u>Index test</u>PEF variability = ($PEF_{highest}$ – $PEF_{lowest}$)/ $PEF_{mean}$ x 100% (mean over 21 days' readings) | **Asthma** | Ref std + | Ref std – | Total | <u>Source of funding:</u><br>Not stated. |
| | | | | | PEF var >15% | 6 | 4 | 10 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| WJ, van Schayck CP, Molema J, Van Weel C. Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability ? British Journal of General Practice. 1997; 47(421):487-492<br>DENOTTE R1997 | study<br><br>Data source:<br>Population screening<br><br>Setting:<br>General population<br><br>Country:<br>The Netherlands<br>Recruitment:<br>Not stated. | and 70 years old with signs or symptoms indicating asthma (persistent or recurrent respiratory symptoms or signs of reversible bronchial obstruction)<br><br>Exclusion criteria:<br>None given | 43 (12) years | **CUT-OFF:** positive = >5% or 10% or 15%<br><br>Reference standard**Clinical Dx**including objective test: Reference standard = BHR, defined as a PC20 histamine of ≤8 mg/ml<br><br>Time between index test and reference standard: unclear<br><br>Target condition<br>Asthma | PEF var ≤15% | 124 | 184 | 308 | Limitations:<br>None<br><br>Additional data:None |
| | | | | | Total | 130 | 188 | 318 | |
| | | | | | Sensitivity<br>Specificity | | 5%<br>97% | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 60%<br>60% | | |
| | | | | | | Ref std + | Ref std – | Total | |
| | | | | | PEF var >10% | 18 | 8 | 26 | |
| | | | | | PEF var ≤10% | 112 | 180 | 292 | |
| | | | | | Total | 130 | 188 | 318 | |
| | | | | | Sensitivity<br>Specificity | | 14%<br>96% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 69%<br>62% | | |
| | | | | | | Ref std + | Ref std – | Total | |
| | | | | | PEF var >5% | 73 | 58 | 131 | |
| | | | | | PEF var ≤5% | 57 | 130 | 187 | |
| | | | | | Total | 130 | 188 | 318 | |
| | | | | | Sensitivity | | 56% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | Specificity | 69% | |
| | | | | | PPV<br>NPV<br>PLR and NL | 56%<br>66% | |

**Table 53: THIADENS 1998[1746,1746]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Thiadens HA, De Bock GH, Dekker FW, Huysman JA, Van Houwelingen JC, Springer MP et al. Value of measuring diurnal peak flow variability in the recognition of asthma: a study in general practice. | Study type:Diagnostic Cross-sectional study<br><br>Data source: Community<br><br>Setting: Primary care<br><br>Country: The Netherlands<br><br>Recruitment: January 1994 – March 1995 | N = 170<br><br>Inclusion criteria:18–75 yrs of age, who consulted their GP with coughing that had lasted for at least 2 weeks<br><br>Exclusion criteria: Already had a diagnosis of asthma or COPD, pregnant, or had a cardiovascular or concomitant pulmonary disease | Male: Female<br>61: 109<br><br>Mean age:<br>44 (16) years | Index test:<br>PEF variability (DPV) = ($PEF_{highest}$ – $PEF_{lowest}$)/ $PEF_{highest}$ x 100%<br>= amplitude % highest<br>(a) MDPV = mean over 2 week period<br>(b) DPV more than threshold on 4 days or more<br>(c) DPV more than threshold on 3 days or more<br><br>**CUT-OFF:**<br>(a) MDPV > 10% and MDPV >15%<br>(b) DPV >15% on 4 days or more<br>(c) DPV >20% on 3 days or more<br><br>Reference standard**Clinical Dx**including objective test: A patient was considered to have asthma if there had been a | | Ref std + | Ref std – | Total | Source of funding: GlaxoWellcome BV, Medical Division, The Netherlands.<br><br>Limitations: Sensitivity etc calculated<br><br>Additional data: None |
| | | | | | MDPV (a) >10% + | 10 | 3 | 13 | |
| | | | | | MDPV - | 59 | 98 | 157 | |
| | | | | | Total | 69 | 101 | 170 | |
| | | | | | Sensitivity<br>Specificity | | 14.5%<br>97.0% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 76.9%<br>62.4% | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | Ref std + | Ref std – | Total | |
| | | | | | MDPV (a) 15% + | 2 | 1 | 3 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| European Respiratory Journal. 1998; 12(4):842-847<br><br>THIADENS 1998 | | | | previous period of respiratory symptoms for >3 weeks in the last year, accompanied by a provocative dose causing a 20% fall in FEV1 (PD20) ≤15.6 µmol methacholine and/or reversibility ≥9% of predicted<br><br>Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Asthma | MDPV - | 67 | 100 | 167 | |
| | | | | | Total | 69 | 101 | 170 | |
| | | | | | Sensitivity<br>Specificity | | 2.9%<br>99.0% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 66.7%<br>59.9% | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | Ref std + | Ref std – | Total | |
| | | | | | DPV(b) >15% ≥4 days + | 14 | 3 | 17 | |
| | | | | | PEF - | 55 | 98 | 153 | |
| | | | | | Total | 69 | 101 | 170 | |
| | | | | | Sensitivity<br>Specificity | | 20.3%<br>97.0% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 82.4%<br>64.1% | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | Ref std + | Ref std – | Total | |
| | | | | | DPV (c) | 8 | 1 | 9 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | >20% on ≥3 days + | | | | |
| | | | | | PEF - | 61 | 100 | 161 | |
| | | | | | Total | 69 | 101 | 170 | |
| | | | | | Sensitivity<br>Specificity | | 11.6%<br>99.0% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 88.9%<br>62.1% | | |

**Table 54: ULRIK 2005**[1809,1810]

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Ulrik CS, Postma DS, Backer V. Recognition of asthma in adolescents and young adults: which objective measure is best? Journal of | Study type: Diagnostic Cross-sectional study<br><br>Data source: Community survey<br><br>Setting: Community<br><br>Country: | N = 74 people with asthma out of sample of 609 adolescents and young adults in survey<br><br>Inclusion criteria: Children and adolescents born between 1969 and 1979 in central Copenhagen<br><br>Exclusion criteria: None given | Male: Female 37:37<br><br>Mean age: 18.5 (2.8) years | Index testPEF variability (amp%mean)<br><br>**CUT-OFF:** positive = PEF amp%mean ≥20%<br><br>Reference standard**Clinical Dx**including objective test:<br>1) Histamine challenge test; cut off PC20 <16.0mg/mL histamine (airways hyper-responsiveness)<br>2) Bronchodilator reversibility: change in FEV1 (ΔFEV1%post) >10% | **Asthma** | Ref std (1) + | Ref std (1) – | Total | Source of funding: Danish Lung Association<br><br>Limitations: Asthma patients only<br><br>Additional data: None |
| | | | | | PEF + | 32 | 1 | 33 | |
| | | | | | PEF - | 37 | 4 | 41 | |
| | | | | | Total | 69 | 5 | 74 | |
| | | | | | Sensitivity<br>Specificity | | 46.4%<br>80.0% | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 97.0%<br>9.8% | | |
| | | | | | AUC | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Asthma. 2005; 42(7):549-554<br><br>ULRIK2005 | Denmark<br><br><u>Recruitment:</u><br>1992. | | | Time between index test and reference standard: same time<br><br><u>Target condition</u><br>Asthma | Diagnostic yield | | | | |
| | | | | | | Ref std (2) + | Ref std (2) – | Total | |
| | | | | | PEF + | 5 | 28 | 33 | |
| | | | | | PEF - | 2 | 39 | 41 | |
| | | | | | Total | 7 | 67 | 74 | |
| | | | | | Sensitivity<br>Specificity | | 71.4%<br>58.2% | | |
| | | | | | PPV<br>NPV<br>PLR and NL | | 15.2%<br>95.1% | | |
| | | | | | AUC | | | | |
| | | | | | Diagnostic yield | | | | |

# G.8 Skin prick tests

**Table 55: DRKULEC 2013[455]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Sensitization profile in differential diagnosis: allergic | <u>Study type:</u><br>Diagnostic Cross-sectional study<br><br><u>Data source:</u> | N = 131<br>(N=71 asthma)<br><br><u>Inclusion criteria:</u><br>• 1-15 year olds in Zagreb | <u>Male: Female</u><br>89:32<br><br><u>Mean age:</u><br>7.5 years | <u>Index test</u> **SPT**<br>• Allergopharma (Croatia)<br>• Allergens:<br>• SPT for *Dermatophagoides pteronyssinus* (house dust | **Der P** | Asthma | Chronic cough | Total | <u>Source of funding:</u><br>Departmental sources |
| | | | | | SPT + | 59 | 17 | 76 | |
| | | | | | SPT - | 12 | 43 | 55 | |
| | | | | | Total | 71 | 60 | 131 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| asthma vs. chronic (nonspecific) cough syndrome. Medical science monitor: 19: 409-415<br>Drkulec V, Nogalo B, Perica M, Plavec D, Pezer M, and Turkalj M 2013.<br>REF ID: DRKULEC2013. | Clinic<br><br>Setting: Patients attending Department of Allergology<br><br>Country: Croatia<br><br>Recruitment: 6 month period (date not stated) | • Respiratory symptoms<br>• Sent to department for diagnosis<br><br>Exclusion criteria:<br>None given | | mite)<br>• *Ambrosia artemisifoliae* (common ragweed)<br>• *Phleum pratense* (timothy grass)<br>**CUT-OFF:** not stated.<br><br>Reference standard **Clinical Dx**<br>At least 3 episodes of wheezing and/or positive bronchodilatation test<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Allergic asthma (vs. chronic cough, i.e. <3 episodes of wheezing, with persistent cough >6 weeks) | **Der P**<br>Sensitivity<br>Specificity | | <br>83.6% (72.4, 90.8)<br>71.4% (59.9, 80.7) | | Limitations: none<br><br>Additional data: Raw data calculated not presented |
| | | | | | PPV<br>NPV<br>Likelihood + test<br>Likelihood - test | | 71.8% (60.5, 80.9)<br>83.3% (71.9, 90.7)<br>2.9 (2.6, 3.3)<br>0.23 (0.19, 0.28) | | |
| | | | | | Diagnostic accuracy | | 77.1% (69.2, 83.5) | | |
| | | | | | Diagnostic odds | | 12.8 (5.4, 29.9) | | |
| | | | | | **Amb A** | Asthma | Chronic cough | Total | |
| | | | | | SPT + | 47 | 31 | 78 | |
| | | | | | SPT - | 24 | 29 | 53 | |
| | | | | | Total | 71 | 60 | 131 | |
| | | | | | **Amb A**<br>Sensitivity<br>Specificity | | 66.7% (46.7, 82.0)<br>48.6% (39.3, 57.9) | | |
| | | | | | PPV<br>NPV<br>Likelihood + test<br>Likelihood - test | | 22.5% (14.4, 33.5)<br>86.7% (75.8, 93.1)<br>1.30 (1.18, 1.4)<br>0.69 (0.52, 0.91) | | |
| | | | | | Diagnostic accuracy | | 51.9% (43.4, 60.3) | | |
| | | | | | Diagnostic odds | | 1.89 (0.75, 4.8) | | |
| | | | | | **Phl P** | Asthma | Chronic cough | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | SPT + | 47 | 30 | 77 | |
| | | | | | SPT - | 24 | 30 | 54 | |
| | | | | | Total | 71 | 60 | 131 | |
| | | | | | **Phl P**<br>Sensitivity<br>Specificity | | 66.7% (48.8, 80.8)<br>49.5% (39.9, 59.1) | | |
| | | | | | PPV<br>NPV<br>Likelihood + test<br>Likelihood - test | | 28.2% (19.0, 39.5)<br>83.3% (71.9, 90.7)<br>1.3 (1.2, 1.4)<br>0.67 (0.53, 0.85) | | |
| | | | | | Diagnostic accuracy | | 53.4% (44.9, 61.8) | | |
| | | | | | Diagnostic odds | | 1.96 (0.84, 4.60) | | |
| | | | | | **≥1 allergens** | Asthma | Chronic cough | Total | |
| | | | | | SPT + | 56 | 5 | 61 | |
| | | | | | SPT - | 15 | 55 | 70 | |
| | | | | | Total | 71 | 60 | 131 | |
| | | | | | **SPT to ≥1 allergen**<br>Sensitivity<br>Specificity | | 78.8% (68.9, 86.2)<br>91.3% (79.7, 96.6) | | |
| | | | | | PPV<br>NPV<br>Likelihood + test<br>Likelihood - test | | 94.4% (86.4, 97.8)<br>70% (57.5, 80.1)<br>9.1 (5.5, 14.9)<br>0.23 (0.21, 0.26) | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | Diagnostic accuracy | 83.21% (75.88, 88.64) | |
| | | | | | Diagnostic odds | 39.1 (12.4, 123.4) | |

**Table 56: Gaig 1999[539]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Asthma, mite sensitization, and sleeping in bunks. Annals of allergy, asthma and immunology: 82: 531-533<br>Gaig P, Enrique E, Garcia-Ortega P, Olona M, del Mar San Miguel M, and Richart C 1999. | Study type:<br>Cross-sectional study<br><br>Data source:<br>Clinic<br><br>Setting:<br>Outpatient allergy clinic<br><br>Country:<br>Spain<br><br>Recruitment:<br>Consecutive patients, date not stated | N = 94 (47 sibling pairs); (N=41 asthma)<br><br>Inclusion criteria:<br>Patients attending outpatient allergy clinic who had been sharing a bunk with a sibling for >6 months, occupying always the same position (top or bottom bunk)<br><br>Exclusion criteria:<br>not stated | Male: Female<br>43:51<br><br>Mean age:<br>16 years | Index test **SPT**<br>• ALK Abelló (Madrid, Spain)<br>• Allergens:<br>• *Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*<br>**CUT-OFF:** skin wheal diameter to at least one of the two mites 3mm larger than control<br><br>Reference standard **Clinical Dx**<br>Clinical history and current symptoms (asthma or rhinitis)<br><br>Time between index test and reference standard: not stated<br><br>Target condition<br>Allergic asthma (vs. rhinits) | **Der P/ Der F** | Asthma | Rhinitis | Total | Source of funding:<br>ALK Abelló (Madrid, Spain) supported antibody testing<br><br>Limitations:<br>No mention of objective test for asthma; study not designed to assess diagnostic test<br><br>Additional data:<br>Sensitivity etc calculated from 2 x 2 table |
| | | | | | SPT + | 35 | 17 | 52 | |
| | | | | | SPT - | 6 | 9 | 15 | |
| | | | | | Total | 41 | 26 | 67 | |
| | | | | | Mite Sensitivity | | 85.4% | | |
| | | | | | Specificity | | 34.6% | | |
| | | | | | PPV | | 67.3% | | |
| | | | | | NPV | | 60% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| REF ID: GAIG1999. | | | | | | | |

**Table 57: May 1990[1108]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Allergy to Artemisia vulgaris in the region of Warsaw. Allergologia et Immunopathologia: 18: 57-60 May KL 1990. REF ID: MAY1990. | Study type: Diagnostic Cross-sectional study<br><br>Data source: Clinic<br><br>Setting: Allergology clinic<br><br>Country: Poland<br>Recruitment: consecutive patients, date not stated | N = 446 (N=190 asthma)<br><br>Inclusion criteria: Consecutive unselected patients for allergological consultation for conjunctivitis, rhinitis and/or asthma which appeared or deteriorated in late spring and summer<br><br>Exclusion criteria: None stated | Male: Female 256:190<br><br>Mean age: Range 6 to 56 years, mean not stated | Index test **SPT**<br>• Haarlem-Holland<br>• Allergens:<br>• *Gramineae* (grasses both wild and cultivated)<br>• *Artemisia vulgaris* (weed: mugwort)<br>**CUT-OFF:** 3+ or 4+<br><br>Reference standard **Clinical Dx**<br>Clinically evident bronchial symptoms<br><br>Time between index test and reference standard: not stated<br><br>Target condition<br>Asthma with or without | **Gramineae** | Asthma with or without rhinitis and with or without conjunctivitis | Rhinitis with or without conjunctivitis | Total | Source of funding: Not stated<br><br>Limitations: No mention of objective test for asthma |
| | | | | | SPT + | 170 | 228 | 398 | |
| | | | | | SPT - | 20 | 28 | 48 | |
| | | | | | Total | 190 | 256 | 446 | |
| | | | | | **Gramineae**<br>Sensitivity<br>Specificity | | 89.5%<br>10.9% | | Additional data: Sensitivity etc calculated from 2 x 2 table |
| | | | | | PPV<br>NPV | | 42.7%<br>58.3% | | |
| | | | | | **Artemisia vulgaris** | Asthma | Rhinitis | Total | |
| | | | | | SPT + | 92 | 95 | 187 | |
| | | | | | SPT - | 98 | 161 | 259 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | rhinitis and with or without conjunctivitis (vs. rhinitis with or without conjunctivitis.) | Total | 190 | 256 | 446 | |
| | | | | | **Artemisia vulgaris**<br>Sensitivity<br>Specificity | | 48.4%<br>62.9% | | |
| | | | | | PPV<br>NPV | | 49.2%<br>62.2% | | |

**Table 58: Miraglia del Giudice 2002[1156]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Atopy and house dust mite sensitization as risk factors for asthma in children. Allergy: 57: 169-172<br>Miraglia Del Giudice M, Pedulla M, Piacentini GL, | Study type:<br>Diagnostic Cross-sectional study<br><br>Data source:<br>Clinic<br><br>Setting:<br>Paediatric Asthma and Allergy clinic<br><br>Country:<br>Italy | N = 1426<br>(N=925 asthma)<br><br>Inclusion criteria:<br>Children referred to our Paediatric Asthma and Allergy Centre because of allergic symptoms (see reference standard)<br><br>Exclusion criteria:<br>Children without a confirmed | Male: Female<br>814:612<br><br>Mean age:<br>Range 0 to 12 years, mean not stated | Index test **SPT**<br>• Bayer DHS Diagnostics, Epernon Cedex-France<br>• Allergens:<br>• house dust mites (HDM) (*Dermatophagoides pteronyssinus, D. farinae*), *Parietaria officinalis* (lichwort, in the nettle family), grasses (*Dactylis glomerata, Lolium perenne, Phaleum pratense*), moulds (*Alternaria, Aspergillus, Cladosporium*), dog fur, cat fur, egg albumin, and cow's milk<br>**CUT-OFF:** wheal was at least 3 mm in diameter<br><br>Reference standard **Clinical Dx**<br>Clinical diagnosis: asthma, allergic | **≥1 test +ve** | Asthma | Chronic cough | Total | Source of funding:<br>None stated |
| | | | | | SPT + | 411 | 218 | 629 | |
| | | | | | SPT - | 514 | 283 | 797 | |
| | | | | | Total | 925 | 501 | 1426 | |
| | | | | | **≥1 test +ve**<br>Sensitivity<br>Specificity | | 44%<br>56% | | Limitations:<br>No mention of objective test for asthma<br><br>Additional data:<br>Sensitivity, |
| | | | | | PPV<br>NPV | | 65%<br>36% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Capristo C, Brunese FP, Decimo F, Maiello N, and Capristo AF 2002. REF ID: MIRAGLIA DELGIUDICE2002. | Recruitment: January–December 1998 | diagnosis | | rhinoconjunctivitis, atopic dermatitis and food allergy was confirmed by a paediatric allergologist.<br><br>**Bronchial asthma** defined as ≥3 episodes of wheezing < 2 years of age, or 1 episode from 2 years of age, or any episode of wheezing independent of age, if combined with atopic symptoms in the family or other atopic symptoms in the child.<br>**Allergic rhino-conjunctivitis:** sneezing, nasal obstruction, watery rhinorrhea, nasal itching, conjunctival hyperemia and photophobia at least twice after exposure to a particular allergen and unrelated to infection.<br>**Food allergy:** acute onset of symptoms e.g. skin reactions, wheezing, oral allergic symptoms, vomiting or diarrhoea on >1 occasion after ingestion of, or oral contact with, a particular type of food.<br>**Atopic dermatitis:** defined according to Hanifin and assessed with the Scorad index<br><br>Time between index test and reference standard: not stated<br><br>Target condition<br>Allergic asthma (vs. allergic rhinoconjunctivitis, atopic dermatitis or | | | specificity calculated |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | | | | food allergy) | | | |

**Table 59: Popovic 2002[1381]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| S. Popovic-Grle, M. Mehulic, F. Pavicic, I. Babic, and Z. Beg-Zec. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung function in the diagnosis of asthma in persons with dyspnea. *Coll.Antro* | Study type: Cross-sectional study<br><br>Data source: Random sample<br><br>Setting: Outpatient allergy department<br><br>Country: Croatia<br><br>Recruitment: Just says 'sample' of patients, date not stated | N = 195<br>(N=141 asthma, n=17 COPD, n=29 rhinitis/sinusitis, n=8 unsolved)<br><br>Inclusion criteria:<br>• Pts with dyspnoea<br>• Treated for breathlessness in the Outpt dept of Allergology<br>• Referred by GPs due to suspected asthma<br><br>Exclusion criteria:<br>• All serious diseases of other organ systems or the lungs (apart from those of an obstructive and/or | **ASTHMA PTS:**<br><br>Male: Female<br>51%:49%<br><br>Mean age:<br>36.5 years | Index test **SPT**<br>• House dust<br>• *D. pteronyssinus*<br>• Grass pollen<br>• Weed pollen<br>• Tree pollen<br>• Animal dander<br>• Cat fur<br>• Dog fur<br>• Feathers<br>• Fungi mixture<br>• Insect antigens<br>**CUT-OFF:** skin wheal diameter ≥3mm.<br><br>Reference standard **Clinical Dx (with obj test)**<br>Questionnaire of clinical history of occasional asthma attacks with wheezing and nocturnal awakening because of dyspnoea, and BDR test with salbutamol. | **≥1 aeroallergen** | Asthma | Non-asthma | Total | Source of funding: None reported<br><br>Limitations: No major ones identified |
| | | | | | SPT + | 87 | 20 | 1074 | |
| | | | | | SPT - | 54 | 34 | 88 | |
| | | | | | Total | 141 | 54 | 195 | |
| | | | | | Sensitivity<br>Specificity | | 62%<br>63% | | |
| | | | | | PPV<br>NPV | | 81%<br>61% | | |
| | | | | | | | | | Additional data: n/a |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| *pol.* 26 Suppl:119 -127, 2002.<br><br>REF ID: POPOVIC 2002. | | allergic nature) | | Time between index test and reference standard: not stated<br><br><u>Target condition</u><br>Allergic asthma (vs. rhinitis/sinusitis, COPD or unsolved) | | | |

**Table 60: Soriano 1999A[1645]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| JB Soriano, JM. Anto, J. Sunyer, A. Tobias, M. Kogevinas, E. Almar, N. Muniozguren, JL. Sanchez, L. Palenciano, P. Burney, J. Martinez-Moratalla et al. Risk of asthma in the general Spanish | <u>Study type:</u><br>Cross-sectional study<br><br><u>Data source:</u><br>Sub sample of general population reporting respiratory symptoms<br><br><u>Setting:</u><br>General population | N = 1816 (N=136 asthma)<br><br><u>Inclusion criteria:</u><br>• Subsample of pts from a general population, who reported respiratory symptoms in a screening questionnaire.<br><br><u>Exclusion criteria:</u><br>• Already selected in | <u>Male: Female</u><br>48%:52%<br><br><u>Mean age:</u><br>32 years | <u>Index test</u> **SPT**<br>• *D. pteronyssinus*<br>• *Cladosporium*<br>• *Alternaria*<br>• Timothy grass<br>• Olive<br>• Birch<br>• Parieta or ragweed<br>**CUT-OFF:** skin wheal diameter ≥3mm.<br><br><u>Reference standard</u> **Clinical Dx with objective test**<br>Clinical history and current symptoms (woken up by attack of | **≥1 allergen +ve** | Asthma | Non-asthma | Total | <u>Source of funding:</u><br>Fondo de Investigaciones Sanitarias, Madrid and Generalitat de Catalunya. |
| | | | | | SPT + | 60.7% (n=83) | 31.4% (n=528) | 611 | |
| | | | | | SPT - | 39.3% (n=53) | 68.6% (n=1152) | 1205 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 60.7%<br>68.6% | | |
| | | | | | PPV<br>NPV | | -<br>- | | |
| | | | | | **Alternaria** | Asthma | Non-asthma | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| population attributable to specific immunoresponse. *Int.J.Epidemiol.* 28 (4):728-734, 1999.<br><br>REF ID: SORIANO 1999A. | <u>Country:</u><br>Spain<br><br><u>Recruitment:</u><br>date not stated | an earlier random sample | | shortness of breath during last 12 months, or having an attack of asthma during last 12 months, or currently taking medication for asthma) – using questionnaire, plus methacholine challenge for bronchoresponsiveness (BR).<br><br>Asthma defined as symptomatic BR.<br><br>Time between index test and reference standard: not stated<br><br><u>Target condition</u><br>Allergic asthma | SPT + | 6.7% (n=9) | 1.4% (n=24) | 33 | |
| | | | | | SPT - | 93.3% (n=127) | 98.6% (n=1656) | 1783 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 6.7%<br>98.6% | | |
| | | | | | **Birch** | Asthma | Non-asthma | Total | |
| | | | | | SPT + | 5.9% (n=8) | 1.6% (n=27) | 35 | |
| | | | | | SPT - | 94.1% (n=128) | 98.4% (n=1653) | 1781 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 5.9%<br>98.4% | | |
| | | | | | **Cat** | Asthma | Non-asthma | Total | |
| | | | | | SPT + | 20.7% (n=28) | 6.3% (n=106) | 134 | |
| | | | | | SPT - | 79.3% (n=108) | 93.7% (n=1574) | 1682 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 20.7%<br>93.7% | | |
| | | | | | **Cladosporium** | Asthma | Non-asthma | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | SPT + | 7.4% (n=10) | 2.8% (n=47) | 57 | |
| | | | | | SPT - | 92.6% (n=126) | 97.2% (n=1633) | 1759 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 7.4%<br>97.2% | | |
| | | | | | **Dust mite** | Asthma | Non-asthma | Total | |
| | | | | | SPT + | 39.3% (n=53) | 20.0% (n=336) | 389 | |
| | | | | | SPT - | 60.7% (n=83) | 80.0% (n=1344) | 1427 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 39.3%<br>80.0% | | |
| | | | | | **Timothy grass** | Asthma | Non-asthma | Total | |
| | | | | | SPT + | 31.9% (n=43) | 13.3% (n=223) | 266 | |
| | | | | | SPT - | 68.1% (n=93) | 86.7% (n=1457) | 1550 | |
| | | | | | Total | 136 | 1680 | 1816 | |
| | | | | | Sensitivity<br>Specificity | | 31.9%<br>86.7% | | |

# G.9 IgE

**Table 61: ABRAHAM 2007[8]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| CM. Abraham, DR Ownby, EL Peterson, G Wegienka, EM Zoratti, LK Williams, CLM Joseph, and C Cole Johnson. The relationship between seroatopy and symptoms of either allergic rhinitis or asthma. *J.Allergy Clin.Immunol.* 119 (5):1099-1104, 2007. | Study type:Diagnostic Cross-sectional study<br><br>Data source: Information from a regional survey of pregnant women in a primary care practice, and subsequent interview and blood test.<br><br>Setting: Primary care<br><br>Country:USA<br><br>Recruitment: Dates not | N = 702<br><br>Inclusion criteria:<br>• Pregnant women in second trimester or later<br>• Age 21-49 years<br><br>Exclusion criteria:<br>None given | Male: Female<br>0 : 100%<br><br>Mean age:<br>29 years<br><br>Dx of asthma:<br>N=140 self-reported, N=138 physician provided Dx. | Index test**Specific IgE**<br>• Pharmacia UniCAP system<br>• Allergens:<br>○ Dust mite (American) *D. farinae*<br>○ Dust mite (European) *D. pteronyssinus*<br>○ Cat<br>○ Dog<br>○ Cockroach<br>○ Ragweed<br>○ Grass (timothy)<br>○ Egg<br>○ *Alternaria*<br><br>**CUT-OFF:** positive = ≥0.35 kU/l.<br><br>Reference standard**Clinical Dx**<br>Physician Dx of asthma (by answer to questionnaire).<br><br>Time between index test | **Dust mite (Ameri) asthma** | Ref std + | Ref std – | Total | Source of funding: National Institute of Allergy and Infectious Diseases and by the Fund for Henry Ford Health System, Detroit.<br><br>Limitations: High IgE cut off, pregnant women only, consecutive recruitment; Unclear time between Ref standard and Index test |
| | | | | | IgE + | | | | |
| | | | | | IgE - | | | | |
| | | | | | Total | | | | |
| | | | | | Sensitivity<br>Specificity | | | | |
| | | | | | **Dust mite (Euro) asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 37.9% (~n=47) | 21.8% (~n=90) | | |
| | | | | | IgE - | 62.1% (~n=77) | 78.2% (~n=403) | | |
| | | | | | Total | N=124 | N=493 | N=617 | |
| | | | | | Sensitivity<br>Specificity | | 37.9 (47/124)<br>78.2 (97/493) | | |
| | | | | | **Grass (tim)** | Ref std + | Ref std – | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| ABRAHAM 2007 | given | | | and reference standard:Index done much later<br>(because physican Dx was determined by people answering a questionnaire, so the Dx could have been made any previous time)<br><br>Target condition<br>Allergic asthma | **asthma** | | | | Additional data: |
| | | | | | IgE + | 33.3% (~n=41) | 19.5% (~n=96) | | |
| | | | | | IgE - | 66.7% (~n=83) | 80.5% (~n=397) | | |
| | | | | | Total | N=124 | N=493 | N=617 | |
| | | | | | Sensitivity<br>Specificity | | 33.3 (41/124)<br>80.5 (397/493) | | |
| | | | | | ***Alternaria*asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 33.9% (~n=42) | 14.4% (~n=71) | | |
| | | | | | IgE - | 66.1% (~n=82) | 85.6% (~n=422) | | |
| | | | | | Total | N=124 | N=493 | N=617 | |
| | | | | | Sensitivity<br>Specificity | | 33.9 (167/124)<br>85.6 (106/493) | | |
| | | | | | **Cat asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 39.8% (~n=49) | 12.2% (~n=60) | | |
| | | | | | IgE - | (~n=75) | 87.8% (~n=433) | | |
| | | | | | Total | N=124 | N=493 | N=617 | |
| | | | | | Sensitivity<br>Specificity | | 39.8%<br>87.87% | | |
| | | | | | **Dog asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 33.9% | 12.3% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | (~n=42) | (~n=61) | | |
| | | | | | IgE - | 66.1% (~n=82) | 88% (~n=432) | | |
| | | | | | Total | N=124 | N=493 | | |
| | | | | | Sensitivity<br>Specificity | | 33.9%<br>88% | | |

**Table 62: LINNEBERG 2006[1027]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| A. Linneberg, L. Husemoen, N. Nielsen, F. Madsen, L. Frolund, and N. Johansen. Screening for allergic respiratory disease in the general population with the ADVIA Centaur Allergy Screen Assay. *Allergy* 61 (3):344-348, 2006. | Study type:Diagnostic Cross-sectional study<br><br>Data source: Random sample from a prospective cohort study (Copenhagen Allergy Study).<br><br>Setting: General population<br><br>Country:Denmark | N = 709<br><br>Inclusion criteria:<br>• 15-69 year olds in Copenhagen<br>• Participants in the study who responded at follow-up<br>• Random group and a respiratory symptom group were used for analysis | Male: Female<br>Not reported<br><br>Mean age:<br>Not reported | Index test**Specific IgE**<br>• ADIVA Centaur immunoassay<br>• Allergens:<br>○ Birch<br>○ Grass (timothy)<br>○ Mugwort<br>○ Mammals (includes dog, cat, horse, hamster and others)<br>○ Dust mite<br>**CUT-OFF:** positive = >0.35 kU/l.<br><br>Reference standard**Clinical Dx**<br>Allergic asthma clinical Dx by presence of positive symptoms (via questionnaire) and positive SPT.<br><br>Time between index test and | **Pollen asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>Unclear time between Ref standard and Index test |
| | | | | | IgE + | 49 | 238 | 287 | |
| | | | | | IgE - | 2 | 420 | 422 | |
| | | | | | Total | 51 | 658 | 709 | |
| | | | | | Sensitivity<br>Specificity | | 96.1 (49/51)<br>63.8 (420/658) | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 17.1 (49/287)<br>99.5 (420/658)<br>- | | |
| | | | | | **Dust mite asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 27 | 260 | 287 | |
| | | | | | IgE - | 5 | 417 | 422 | |
| | | | | | Total | 32 | 677 | 709 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| LINNEBERG 2006 | Recruitment:<br>Oct 1997-Nov 1998 | Exclusion criteria:<br>None given | | reference standard: unclear<br><br>Target condition<br>Allergic asthma | Sensitivity<br>Specificity | | 84.4 (27/32)<br>62.0 (417/677) | | Additional data: |
| | | | | | PPV<br>NPV | | 9.4 (27/287)<br>61.5 (417/677) | | |
| | | | | | **ALL allergic asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 79 | 208 | 287 | |
| | | | | | IgE - | 6 | 416 | 422 | |
| | | | | | Total | 85 | 624 | 709 | |
| | | | | | Sensitivity<br>Specificity | | 92.9 (79/85)<br>66.7 (416/624) | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 27.5 (79/287)<br>98.6 (416/422)<br>- | | |

**Table 63: PLASCHKE 1999A[1368]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| P. Plaschke, C. Janson, E. Norrman, E. Björnsson, S. Ellbjär, and B. Järvholm. Association between atopic sensitization | Study type:DiagnosticCross-sectional study<br><br>Data source:<br>Random sample(1800 men, 1800 women) from population registers. | N = 1572 in final analysis.<br><br>Inclusion criteria:<br>• Aged 20-44 years<br>• Responded to questionnaire and agreed to | Male: Female<br>46: 54%<br><br>Mean age:<br>33 years<br><br>Current smokers:<br>30% | Index test**Specific IgE**<br>• Pharmacia CAP system<br>• Allergens:<br>○ Cat<br>○ Dust mite *D. pteronyssinus*<br>○ Grass<br>○ Birch | **Dust mite (Euro) asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Fondo de Investigaciones Sanitarias, Madrid and Generalitat de Catalunya. |
| | | | | | IgE + | 18.8% (~n=16) | 5.8% (~n=86) | 102 | |
| | | | | | IgE - | 81.2% (~n=68) | 94.2% (~n=1402) | 1470 | |
| | | | | | Total | N=84 | N=1488 | N=1572 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| and asthma and bronchial hyperresponsiveness in swedish adults: pets, and not mites, are the most important allergens. *J.Allergy Clin.Immunol*. 104 (1):58-65, 1999.<br><br>PLASCHKE 1999A | Postal questionnaire (modified ECRHS) was sent and had an 86% response rate. 89.2% of those who answered, agreed to participate in clinical examinations.<br><br>Setting: General population<br><br>Country:<br>Sweden<br><br>Recruitment:<br>Feb 1991 – June 1992 | have clinical examination and perform SPT, RAST and bronchial methacholine challenge.<br><br>Exclusion criteria:<br>None given | Dx of asthma:<br>N=84 (according to symptoms and previous Dx ascertained by questionnaire). | ○ *Cladosporium*<br><br>**CUT-OFF:** positive = class ≥2 (≥0.7 kU/l).<br><br>Reference standard**Clinical Dx**<br>Dx of asthma (by answer to questionnaire)<br><br>Time between index test and reference standard:Not mentioned.<br><br>Target condition<br>Allergic asthma | Sensitivity<br>Specificity | | 18.8 (16/84)<br>94.2 (1402/1488) | | |
| | | | | | **Grass asthma** | Ref std + | Ref std – | Total | Limitations:<br>High IgE cut off; Unclear time between Ref standard and Index test |
| | | | | | IgE + | 35.3% (~n=30) | 12.6% (~n=187) | 217 | |
| | | | | | IgE - | 64.7% (~n=54) | 87.3% (~n=1301) | 1355 | |
| | | | | | Total | N=84 | N=1488 | N=1572 | |
| | | | | | Sensitivity<br>Specificity | | 35.3 (30/84)<br>87.3 (1301/1572) | | Additional data: |
| | | | | | **Birch asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 29.4% (~n=25) | 10.4% (~n=155) | 180 | |
| | | | | | IgE - | 70.6% (~n=59) | 89.6% (~n=1333) | 1392 | |
| | | | | | Total | N=84 | N=1488 | N=1572 | |
| | | | | | Sensitivity<br>Specificity | | 29.4 (25/84)<br>89.6 (1333/1488) | | |
| | | | | | ***Cladosporium* asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 3.5% (~n=3) | 1.0% (~n=15) | 18 | |
| | | | | | IgE - | 96.5% (~n=81) | 99.0% (~n=1473) | 1554 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | Total | N=84 | N=1488 | N=1572 | |
| | | | | | Sensitivity<br>Specificity | | 3.5 (3/84)<br>99.0 (1473/1488) | | |
| | | | | | **Cat asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 40% (~n=34) | 9.4% (~n=140) | | |
| | | | | | IgE - | 60% (~n=50) | 90.6% (~n=1348) | | |
| | | | | | Total | N=84 | N=1488 | | |
| | | | | | Sensitivity<br>Specificity | | 40%<br>90.6% | | |

**Table 64: SORIANO 1999[1644]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| J. B. Soriano, J. M. Anto, J. Sunyer, A. Tobias, et al. Risk of asthma in the general Spanish population attributable to | Study type:DiagnosticCross-sectional study<br><br>Data source: Info from a 20% random subsample of a qu'aire | N = 1816<br><br>Inclusion criteria:<br>• Aged 20-44 years<br>• Responded to questionnaire and provided blood samples, had SPTs and spirometry as | Male: Female<br>48 : 52%<br><br>Mean age:<br>32 years<br><br>Current smokers:<br>52% | Index test**Specific IgE or SPT**<br>• Pharmacia CAP system<br>• Allergens:<br>○ Cat<br>○ *Cladosporium*<br>○ Dust mite *D. pteronyssinus*<br>○ Grass (timothy)<br>○ *Parietaria*<br>○ *Alternaria* (SPT only) | ***Cladosporium* asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Fondo de Investigaciones Sanitarias, Madrid and Generalitat de Catalunya. |
| | | | | | IgE + | 7.4% (~n=10) | 2.8% (~n=47) | 57 | |
| | | | | | IgE - | 92.6% (~n=126) | 97.2% (~n=1633) | 1759 | |
| | | | | | Total | N=136 | N=1680 | N=1816 | |
| | | | | | Sensitivity / Specificity | | 7.0 and 97.2 | | |
| | | | | | **Dust mite asthma** | Ref std + | Ref std – | Total | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| specific immunoresponse. Spanish Group of the European Community Respiratory Health Survey. *Int.J.Epidemiol.* 28 (4):728-734, 1999.<br><br>SORIANO 1999 | given toa random sample (N=16844) of general pop. aged 20-44 yrs in 5 areas of Spain.<br><br><u>Setting:</u> General population<br><br><u>Country:</u>Spain<br><br><u>Recruitment:</u> Dates not given | well as methacholine challenge test.<br><br><u>Exclusion criteria:</u> None given | <u>Dx of asthma:</u> N=136 (according to symptoms and BR results) performed by the study and questionnaire. N=1689 (not asthma). | ○ Birch (SPT only)<br>○ Olive Ragweed (SPT only)<br>**CUT-OFF:** positive = >0.35 kU/l.<br><br><u>Reference standard</u>**Clinical Dx** Dx of asthma (by answer to questionnaire and BR results).<br><br><u>Time between index test and reference standard:</u>Index done same time as BR tests<br><br><u>Target condition</u> Allergic asthma | IgE + | 39.3% (~n=53) | 20.0% (~n=336) | 389 | <u>Limitations:</u> Unclear time between Ref standard and Index test; results mix of IgE + SPT.<br><br><u>Additional data:</u> |
| | | | | | IgE - | 60.7% (~n=83) | 80.0% (~n=1344) | 1427 | |
| | | | | | Total | N=136 | N=1680 | N=1816 | |
| | | | | | Sensitivity<br>Specificity | | 39.3 (53/136)<br>80.0 (1344/1680) | | |
| | | | | | **Grass timothy asthma** | Ref std + | Ref std – | Total | |
| | | | | | Index test + | 31.9% (~n=93) | 13.3% (~n=223) | 316 | |
| | | | | | Index test - | 68.1% (~n=43) | 86.7% (~n=1457) | 1500 | |
| | | | | | Total | N=136 | N=1680 | N=1816 | |
| | | | | | Sensitivity<br>Specificity | | 68.0 (93/136)<br>86.7 (1457/1680) | | |
| | | | | | **Cat asthma** | Ref std + | Ref std – | Total | |
| | | | | | IgE + | 20.7% (~n=27) | 6.3% (~n=106) | | |
| | | | | | IgE - | 79.3% (~n=109) | 93.7% (~n=1574) | | |
| | | | | | Total | 136 | 1680 | | |
| | | | | | Sensitivity<br>Specificity | | 20.7%<br>94% | | |

**Table 65: TSCHOPP 1998[1788]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| J. M. Tschopp, D. Sistek, C. Schindler, P. Leuenberger, A. P. Perruchoud, B. Wuthrich, M. Brutsche, J. P. Zellweger, W. Karrer, and O. Brandli. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on | Study type:DiagnosticCross-sectional study<br><br>Data source: Information from a random sample of residents (part of the SAPALIDA study) from the general population aged 18-60 yrs.<br><br>Setting: General population | N = 8329<br><br>Inclusion criteria:<br>• Aged 18-60<br>• Undertaken the 3 atopic tests (total IgE, SPT and Phadiatop)<br><br>Exclusion criteria:<br>• Not done the 3 atopic | Male: Female<br>Data in another publication – ON ORDER<br><br>Mean age:<br>Data in another publication – ON ORDER<br><br>Current smokers:<br>Data in another publication – ON ORDER<br><br>Dx of asthma (in N=8329):<br>DA (DrDx): N=566,<br>CA (current asthma): N=208,<br>CAA (current allergic asthma): N=153,<br>CAR (current allergic | Index test **Total IgE**<br>• Pharmacia CAP FEIA technology<br><br>**CUT-OFF:** positive = ≥100 kU/l.<br><br>Index test**Specific IgE**<br>• Phadiatop fluoroenzyme immunoassay<br>• Allergens:<br>○ Pollens<br>○ House dust mite<br>○ Moulds<br>○ Cat – total IgE only<br>NOT USING DATA AS RESULTS ARE COMBINED<br>**CUT-OFF:** positive = above the reference serum value.<br><br>Reference standard**Clinical Dx**<br>Dx of current allergic asthma (by qu'aire results: CA + respiratory symptoms related to common allergy exposure in the last 12 mths asthma. | **Current allergic asthma** | Ref std + | Ref std – | Total | Source of funding: Swiss National Science Foundation and Federal Office of Education and Science.<br><br>Limitations: High cut off; Unclear time between Ref standard and Index test |
| | | | | | Total IgE + | 87 | 1807 | 1894 | |
| | | | | | Total IgE - | 66 | 6369 | 6435 | |
| | | | | | Total | 153 | 8176 | 8329 | |
| | | | | | Sensitivity<br>Specificity | | 56.9<br>77.9 | | |
| | | | | | PPV, NPV | | 4.6, 99.0 | | |
| | | | | | **Current allergic asthma (all allergens)** | Ref std + | Ref std – | Total | |
| | | | | | Sp IgE + | NR | NR | NR | |
| | | | | | Sp IgE - | NR | NR | NR | |
| | | | | | Total | NR | NR | 8329 | |
| | | | | | Sensitivity<br>Specificity | | 72.5<br>71.9 | | |
| | | | | | PPV, NPV<br>PLR and NLR | | 4.6, 99.3<br>- | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Air Pollution and Lung Diseases in Adults. *Allergy* 53 (6):608-613, 1998.<br><br>TSCHOPP 1998 | Country:Switzerland<br><br>Recruitment:<br>1 year period | tests. | rhinitis): N=1361,<br>CAA and/or CAR: N=1422,<br>Phadiatop: N=2410,<br>SPT+: N=1912,<br>IgE+: N=1890. | Time between index test and reference standard:<br>not reported (likely to be different time as one was based on questionnaire results).<br><br>Target condition<br>Current allergic asthma.<br>DATA NOT GIVEN FOR DA (Dr Dx asthma). | | | Additional data: |

# G.10 FeNO for diagnosis

**Table 66: BERLYNE 2000[160]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| G. S. Berlyne, K. Parameswaran, D. Kamada, A. Efthimiadis, and F. E. Hargreave. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. *J.Allergy Clin.Immunol.* 106 (4):638-644, 2000. | Study type:<br>Case-control study<br><br>Data source:<br>clinic pts<br><br>Setting:<br>Chest allergy clinic pts<br><br>Country:<br>Canada<br><br>Recruitment:<br>Not reported | N = 131 adults<br>- n=38 asthma – steroid naiive (1)<br>- n=35 asthma – steroid Tx (2)<br>- n=8 eosinophilic bronchitis (3)<br>- n=28 healthy controls - atopic (4)<br>- n=22 healthy controls – nonatopic (5)<br><br>Inclusion criteria:<br>(1): Asthma (steroid naiive). Symptoms of wheeze, breathlessness or cough in past year plus MCT PC20 <8 mg/ml if the FEV1/VC >70%; or a post-BD FEV1 >15% if the FEV1/VC was <70%. Not received ICS in previous month.<br>(2): Asthma (steroid-Tx). As above but receiving regular ICS Tx.<br>(3): Eosinophilic bronchitis without asthma. Cough in the past yr, FEV1/VC >80%, MCT PC20 >16 mg/ml, and induced sputum eos count >5% of total squamous cell count (above the 90th percentile for sputum eos).<br>(4): Healthy controls - atopic. No symptoms. FEV1/VC >70% and MCT PC20 >16 mg/ml. Positive SPT to at least 1 common allergen.<br>(5): Healthy controls -nonatopic. As | Male: Female<br>43%/57%<br><br>Mean age:<br>39 years | Index test<br>FeNO: chemiluminescence analyser; fixed flow rate 45 ml/s. Sievers 240 device.<br><br>Target condition<br>FeNO levels asthma vs. healthy vs. eosinophilic bronchitis (separately) | **Median (IQR) FeNO levels:**<br>1. Asthma – steroid naiive: 39 (43) ppb<br>2. Asthma – steroid Tx: 17 (12) ppb<br>3. Eosinophilic bronchitis: 65 (92) ppb<br>4. Healthy - atopic: 11 (6) ppb<br>5. Healthy - nonatopic: 9 (7) ppb<br>- median of healthy = 10<br><br>The median FeNO was SS differenet between the groups.<br><br>Median FeNO was SS higher in the group with asthma (steroid naiive) vs. healthy controls (p<0.001)<br><br>Median FeNO was SS lower in the group with asthma (steroid Tx) vs. steroid naiive (p<0.001)<br><br>Median FeNO was SS lower in the group with asthma (steroid Tx) vs. Eosinophilic bronchitis. | Source of funding:<br>Not reported<br><br>Limitations:<br>-<br><br>Additional data:<br>None |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| BERLYNE 2000 | | above but negative SPT to at least 1 common allergen.<br><br>Exclusion criteria:<br>• Current smokers (as reduces ENO levels)<br>• Ex-smokers <1 year<br>• Symptoms of RTI in 4 wks before study or other complicating respiratory disease | | | There was NS difference in median FeNO levels between the control groups (ie. atopic status does not matter). | |

**Table 67: CARDINALE 2005[270]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| F. | Study type: | N = 175 children (mean 10 years) | Male: Female | Index test | **Median (IQR) FeNO levels:** | Source of |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Cardinale, F. M. De Benedictis, V. Muggeo, P. Giordano, M. S. Loffredo, G. Iacoviello, and L. Armenio. Exhaled nitric oxide, total serum IgE and allergic sensitization in childhood asthma and allergic rhinitis. *Pediatr.Allergy Immunol.* 16 (3):236-242, 2005. | Case-control study<br><br>Data source:<br>Pts from clinic<br><br>Setting:<br>Paediatric allergy clinic<br><br>Country:<br>Italy<br><br>Recruitment:<br>No detail if consecutive. Nov 2002 - Sept 2003. | - n=109 asthma (83.4% were allergic – SPT+; 51% of all asthma had additional allergic rhinitis (1a and 1b = atopic/nonatopic asthma)<br>- n=41 allergic rhinitis, moderate persistent (2)<br>- n=25 healthy controls (3)<br><br>Inclusion criteria:<br>(1): mild intermittent asthma. History of symptoms, pulmonary function tests and response to inhaled beta-adrenergic agents according to international guidelines. History of at least 1 episode of asthma in past year and stable at time of study.<br>(2): moderate persistent allergic rhinitis. Clinical history and positive SPT to common allergens. None had ever had wheezing or received asthma medication. Steriod Tx or antihistamine had to be withdrawn >3 months before study.<br>(3): Healthy controls. Non-atopic (absence of allergic symptoms in history and negative SPT), no history of airway disease, allergy or significant medical illness and not taking any medication.<br><br>Exclusion criteria: | 1:2 (overall)<br><br>Mean age:<br>10 years (overall) | FeNO: chemiluminescence analyser; flow rate 50 ml/s. NOA Tm280 Sievers device<br><br>Target condition<br>FeNO levels asthma vs. allergic rhinitis vs. healthy controls (separately) | 1. All asthma: 22.7 (9.1 - 48) ppb<br>1a. n=91 Asthma atopic: 25.6 (11.4 – 56.2) ppb<br>1b. n=18 Asthma non-atopic: 11.5 (5.4 - 15.5) ppb<br>2. Allergic rhinitis: 15.3 (9.4 – 31.0)<br>3. Healthy: 5.9 (3.4 – 9.3)<br><br>Asthma pts and allergic rhinitis has SS higher FeNO levels than controls (p=0.0001 and p=0.016)<br><br>The mean eNO was SS higher in allergic vs. non-allergic asthma (p<0.001)<br><br>There was NS difference in eNO between the non-allergic asthma pts vs. healthy controls.<br><br>There was NS difference in eNO between all asthma pts vs. allergic rhinitis.<br><br>The median FeNO level was SS higher in allergic asthma vs. allergic rhinitis. (p=0.03) | funding:<br>Not reported<br><br>Limitations:<br>-<br><br>Additional data:<br>None |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| CARDINAL E 2005 | | History of significant medical illness, previous or current allergen hyposensitisation, history or signs of RTI in 4 wks before study, tobacco smoke exposure in the family. | | | | |

**Table 68: CHATKIN 1999[306]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Chatkin JM, Ansarin K, Silkoff PE, McClean P, Gutierrez C, Zamel N et al. Exhaled | Study type: Cross-sectional observational study<br><br>Data source: | N = 38 chronic cough + 23 healthy controls<br><br>Inclusion criteria: Chronic cough (>3 weeks) of unknown cause referred for | Male: Female 11:27 chronic cough plus 8:15 controls<br><br>Mean age: Adult: asthma: | Index test FeNO: chemiluminescence analyser (Sievers 280 device); mouth pressure 20mm Hg. Flow rate 45ml/s Optimal cut-off 30ppb | | Ref std + | Ref std - | Total | Source of funding: Dr Chatkin recipient of a grant from CAPES |
| | | | | | Index test + | 6 | 4 | 10 | |
| | | | | | Index test - | 2 | 26 | 28 | |
| | | | | | Total | 8 | 30 | 38 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| nitric oxide as a noninvasive assessment of chronic cough. American Journal of Respiratory and Critical Care Medicine. 1999; 159(6):1810-1813. *(Guideline Ref ID CHATKIN1999)* | Data collected for this study<br><br>Setting:<br>Asthma centre (tertiary referral centre) or affiliated community respiratory clinics<br><br>Country:<br>Canada<br><br>Recruitment:<br>Not stated | diagnosis; normal CXR and FEV1 >80% predicted<br><br>Exclusion criteria:<br>Use of codeine or any other medication for chronic cough, upper respiratory infection within 4 weeks; use of corticosteroids within 6 weeks; current smoking; any significant medical conditions; contra-indications to methacholine challenge. | 41 (12) yr; chronic cough non-asthma: 47 (15) yr; healthy controls: 38 (8)<br><br>Non-asthma = chronic cough (mean 53.8 weeks) but methacholine negative | Reference standard<br>Positive to methacholine challenge (PC20 ≤8mg/mL)<br>Tests done within 24 hours<br><br>Target condition<br>Asthma diagnosis vs. chronic cough non-asthma<br>FeNO levels asthma vs. chronic cough non-asthma or vs. healthy controls | Sensitivity<br>Specificity | 75%<br>87% | Limitations:<br>None<br><br>Additional data:<br>None |
| | | | | | PPV<br>NPV<br>PLR / NLR | 60%<br>93%<br>5.8 / 0.3 | |
| | | | | | AUC | Not stated | |
| | | | | | Median (25th to 75th percentile) FeNO levels: asthma (chronic cough and methacholine positive): 75.0 (34.1 to 104.0) ppb n=8, p=0.0014 vs. non-asthma, p=0.007 vs. controls | Non-asthma (chronic cough and methacholine negative): 16.7 (11.0 to 21.7) ppb n=30<br><br>Healthy controls: 28.3 (23 to 30) ppb, n=23 | |

**Table 69: CIPRANDI 2013[338]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Giorgio | Study type: | N = 330 children (median 12 years) | Male: Female | Index test | **Median (IQR) FeNO levels:** | Source of |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Ciprandi, Maria Angela Tosca, and Michele Capasso. High exhaled nitric oxide levels may predict bronchial reversibility in allergic children with asthma or rhinitis. *J.Asthma* 50 (1):33-38, 2013.<br><br>CIPRANDI 2013 | Case-control study<br><br>Data source:<br>Hospital pts<br><br>Setting:<br>Hospital<br><br>Country:<br>Italy<br><br>Recruitment:<br>Not reported | - n=180 allergic intermittent asthma (1)<br>- n=150 allergic rhinitis (2)<br><br>Inclusion criteria:<br>(1): allergic asthma. Paediatrician using validated criteria (GINA). Consistent symptoms and signs, lung function impairment and BDR. BDR FEV1>12%. Allergy by SPT for common aeroallergens.<br>(2): rhinitis. Paediatrician using validated criteria (GINA).<br><br>Exclusion criteria:<br>Negative SPT<br>Acute or chronic uRTI<br>Anatomical or nasal disorders<br>Previous or current immunotherapy<br>Use of CS, nasal or oral vasoconstrictors, LABA anti-leukotrienes or antihistamines in previous 4 weeks. | 56%/44%<br><br>Median age:<br>(1) children 13 yrs<br>(2) children 10 yrs | FeNO: chemiluminescence analyser; flow rate 50 ml/s. Sievers 280 device.<br><br>Target condition<br>FeNO levels allergic asthma vs. rhinitis (separately) | 1. Asthma allergic: 34 (29 - 381) ppb<br>2. Rhinitis: 27 (21 - 35)<br><br>The median FeNO was SS higher in the allergic asthma vs. rhinitis group (p<0.001) | funding:<br>No sponsorship.<br><br>Limitations:<br>-<br><br>Additional data:<br>None |

**Table 70: CORDEIRO 2011[365]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Cordeiro D, Rudolphus A, Snoey E, Braunstahl GJ. Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy and Asthma Proceedings. 2011; 32(2):119-126. *(Guideline Ref ID CORDEIRO2011)* | Study type: Cross-sectional observational study<br><br>Data source: Routine prospective database<br><br>Setting: General outpatient allergy clinic<br><br>Country: The Netherlands<br><br>Recruitment: January 2007 to September 2007 | N = 114<br><br>Inclusion criteria: New referrals to outpatient allergy clinic<br><br>Exclusion criteria: Patients using inhaled corticosteroids or oral corticosteroids within 6 weeks | Male: Female<br>43: 71<br><br>Median age:<br>Asthma: 39 (range 7-83); non-asthma 38 (7-87) | Index test<br>FeNO: measured online at constant flow rate 50mL/s (Niox-Flex device)<br>Optimal cut off 27ppb. Flow rate 50ml/s<br><br>Reference standard<br>History of typical respiratory symptoms and FEV1 improvement >12% and >200mL with salbutamol 400µg or PC20 histamine ≤8mg/mL<br><br>Time between index test and reference standard: within 6 weeks<br><br>Target condition<br>Asthma diagnosis vs. non-asthma (Allergic rhinitis, non-allergic rhinitis, eczema, urticarial, other analysed all together); raw data calculated from sensitivity/ specificity<br><br>FeNO levels:<br>Asthma vs. Allergic rhinitis, non-allergic rhinitis, eczema, urticarial, other analysed all together<br>Asthma vs. allergic rhinitis | | Ref std + | Ref std - | Total | Source of funding: Not stated<br><br>Limitations: Unclear if pts treated with asthma medication apart from corticosteroids (steroid-naiive)<br><br>Additional data: None |
| | | | | | Index test + | 33 | 6 | 39 | |
| | | | | | Index test - | 9 | 66 | 75 | |
| | | | | | Total | 42 | 72 | 114 | |
| | | | | | Sensitivity<br>Specificity | | 78%<br>92% | | |
| | | | | | PPV / NPV | | 86% / 87% | | |
| | | | | | AUC | | 0.88 | | |
| | | | | | Median (range) FeNO levels: Asthma: 44 (6-290) ppb, n=42 | | Non-asthma (all diagnoses): 17 (5-45) ppb, n=72 p<0.001<br>Allergic rhinitis only (sub-group of above): 21 ppb, n=32 p<0.001 | | |

**Table 71: DEYKIN 2002[433]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Deykin et al., 2002. Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. American Journal of Respiratory and Critical Care Medicine: 165: 1597-1601<br><br>REF ID: DEYKIN2002 | Study type:<br>Prospective case-control study<br><br>Data source:<br>Collected for study<br><br>Setting:<br>Pulmonary and Critical Care Division, Department of Medicine<br><br>Country:<br>US<br>Recruitment:<br>Not stated | N = 62<br><br>Inclusion criteria:<br>• Adult nonsmokers with and without asthma<br>• Those with asthma had a history of asthma, with either a 12% improvement in FEV1 after inhalation of a beta-agonist or a methacholine PC20 of 8 mg/ml or less<br>• Those without asthma had no history of asthma, normal spirometry, and a methacholine PC20 more than 8 mg/ml.<br>• Free of upper respiratory infection for at least 6 weeks<br>Exclusion criteria:<br>Systemic or inhaled corticosteroids used within 8 weeks | Male: Female<br>26:36<br><br>Mean (SEM) age:<br>People with asthma (n=34) 29.6 (1.6)<br>Healthy (n=28) 27.3 (1.3)<br><br>Medications:<br>No asthma medications except for short-acting bronchodilators, which were withheld for at least 8 hours before all testing | Index test<br>FeNO: chemiluminescence analyser (NOA 280 Sievers device); triplicate recordings.<br><br>Target condition<br>FeNO levels asthma vs. healthy controls | <table><tr><td></td><td>Ref std +</td><td>Ref std -</td><td>Total</td></tr><tr><td>Index test +</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Index test -</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Total</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Sensitivity<br>Specificity</td><td colspan="2"></td><td>-<br>-</td></tr></table>Various flow rates reported:<br>50ml/s: Asthma: 57.9 (6.5) Healthy: 26.3 (2.2);<br><br>(p<0.001 for comparison) | Source of funding:<br>Supported by the National Institutes of Health (P50-HL-56383) and an educational grant from Merck USHH<br>Limitations:<br><br>Additional data:<br>Other flow rates reported but not relevant |

**Table 72: FUKUHARA 2011[535]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Fukuhara et al., 2011. Validation study of asthma screening criteria based on subjective symptoms and fractional exhaled nitric oxide. Annals of Allergy, Asthma and Immunology: 107: 480-486<br><br>REF ID: FUKUHARA2011 | Study type:<br>Cross-sectional study<br><br>Setting:<br>Outpatients, Dept. of Pulmonary Medicine, University Hospital<br><br>Country:<br>Japan<br>Recruitment:<br>Not reported | N = 61<br>Adults<br><br>Inclusion criteria:<br>• At least 1 of the subjective symptoms: recurrent cough, wheezing or dyspnoea (including chest tightness)<br>•<br>Exclusion criteria:<br>• Prior history of asthma<br>• Taking oral or inhaled steroids or anti-leukotriene agents | Male: Female<br>31:30<br><br>Mean age (range):<br>55.6 (17-81)<br><br>Medications:<br><br>6 current smokers and 13 former smokers | Index test<br>FeNO level: measured using online method in accordance with American Thoracic Society/European Respiratory Society and a chemiluminescence analyser (NA623N, Chest MI, Japan). Information on the compatibility with other NO analysers provided. FeNO level measured 3 times with differences within 10%, mean of 3 measurements used. Flow rate 50ml/s.<br><br>Cut-off: ≥40ppb<br><br>Comparator test<br>n/a<br><br>Reference standard<br>At least 2 of the following: induced sputum eosinophilia, airway hyperresponsiveness, reversible airway obstruction. Airway reversibility defined as a change in FEV1 of 200ml or ≥12% after short-acting β-agonist or after 2-4 weeks treatment with ICS or bronchodilator. Airway | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>• Consecutive or random recruitment not reported<br>• 97 patients with symptoms gave consent but 36 were unable to undergo testing (reasons not reported)<br>Additional data: |
| | | | | | Index test + | 33 | 2 | 35 | |
| | | | | | Index test - | 9 | 17 | 26 | |
| | | | | | Total | 42 | 19 | 61 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 78.6%<br>89.5%<br><br>94.3%<br>65.4% | | |
| | | | | | FeNO levels, mean (95% CI), ppb<br>Asthma 90.1 (65.9 -114.3)<br>Non-asthma (with symptoms): 40.1 (21.8 – 58.5) | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | | | hyperresponsiveness defined as dose of MCh at which airway resistance began to rise (cut-off <12.5U). And other diseases ruled out using chest radiography, computed tomography and other lab tests.<br><br>Time between index test and reference standard: FeNO measured before other pulmonary function tests<br><br><u>Target condition</u><br>Asthma | | |

**Table 73: HEFFLER 2006[657]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Heffler E, Guida G, Marsico P, Bergia R, Bommarito L, Ferrero N et al. | <u>Study type:</u><br>Prospective study<br><br><u>Data source:</u><br>Collected for study | N = 48 symptomatic + 30 healthy controls<br><br><u>Inclusion criteria:</u><br>Patients referred to allergy department for diagnostic evaluation of | <u>Male: Female</u><br>21:27<br><br><u>Mean age:</u><br>Asthma: 42.33 (range 17-69) yr; non-asthma: 38.73 (11-75) yr | <u>Index test</u><br>FeNO: chemiluminescence analyser (Niox device); mouth pressure 10 cm $H_2O$; exhalation rate 50mL/s; mean of 3 recordings.<br><br>Different cut offs used: optimal cut off for highest combination of | | Ref std + | Ref std - | Total | <u>Source of funding:</u><br>Regione Peimonte-Ricerca Sanitaria Finalizzata 2003 |
| | | | | | Index test + | 14 | 12 | 26 | |
| | | | | | Index test - | 4 | 18 | 22 | |
| | | | | | Total | 18 | 30 | 48 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms. Respiratory Medicine. 2006; 100(11):1981-1987. *(Guideline Ref ID HEFFLER2006)* | Setting:<br>Allergy outpatients clinic<br><br>Country:<br>Italy<br><br>Recruitment:<br>Not stated | persistent rhinitis and asthma-like lower airways symptoms (cough, dyspnoea, chest tightness and wheezing) during the last 2 months<br><br>Exclusion criteria:<br>Use of steroids or any other anti-inflammatory medications in last 2 months, current smoking (in previous 12 months), previous diagnosis of asthma, respiratory infection in last 6 weeks | | sensitivity and specificity was 36ppb<br><br>Reference standard<br>Typical symptoms and significant response to bronchodilator (≥12% improvement in FEV1 with salbutamol) or airway hyper-responsiveness to methacholine (PD20 FEV1 ≤800µg)<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma vs. no asthma (not meeting criteria for diagnosis of asthma but final diagnoses not reported); raw data calculated from sensitivity/specificity<br><br>FeNO levels: asthma vs. no asthma (symptomatic) or healthy controls | Sensitivity<br>Specificity | 77.8%<br>60.0% | Limitations:<br>None<br><br>Additional data:<br>None |
| | | | | | PPV / NPV<br>Accuracy | 54.0% / 81.8%<br>66.67% | |
| | | | | | AUC | 0.78 | |
| | | | | | Geometric mean (95% CI) FeNO levels: asthma 59.7 (50.2 to 89.0) ppb, n=18 | Non-asthma (symptomatic): 30.4 (28.1 to 45.1) ppb, n=30, p=0.001 vs. asthma<br><br>Healthy controls: 12.2 (11.1 to 15.1) ppb, n=30, p<0.001 vs. asthma | |

**Table 74: KOSTIKAS 2008[916]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kostikas K, Papaioannou AI, Tanou K, Koutsoker | Study type:<br>Prospective study<br><br>Data source: | N = 149 symptomatic + 70 healthy controls<br><br>Inclusion criteria:<br>Subjects with at least | Male: Female<br>76: 73 symptomatic + 37:33 controls | Index test<br>FeNO: exhalation flow rate 50mL/s (NIOX MINO device)<br><br>Optimal cut off 19ppb | | Ref std + | Ref std - | Total | Source of funding:<br>Not stated<br><br>Limitations: |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| a A, Papala M, Gourgoulianis KI. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest. 2008; 133(4):906-913. *(Guideline Ref ID KOSTIKAS 2008)* | Collected for the study<br><br>Setting:<br>University students<br><br>Country:<br>Greece<br><br>Recruitment:<br>Spring 2006 | one asthma symptom on a screening questionnaire among students<br><br>Exclusion criteria:<br>Previous diagnosis of asthma or rhinitis treated with anti-inflammatory medication (inhaled or nasal corticosteroids, long-acting β-agonists, leukotriene modifiers, antihistamines or methylexanthines); respiratory tract infection in past 6 weeks; recent smoking cessation (<2 months prior to study) | Mean age:<br>Asthma: 21.6 (2.7) yr; allergic rhinitis: 21.8 (3.0) yr; non-specific symptoms: 22.1 (3.1) yr; healthy controls: 21.4 (2.3) yr | Reference standard<br>History + significant bronchodilator reversibility, positive methacholine challenge test, or clinical or spirometric response to a 4-week trial of inhaled corticosteroids<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma vs. Allergic rhinitis (raw data calculated from sensitivity/ specificity)<br><br>FeNO levels: Asthma vs. Allergic rhinitis or non-specific respiratory symptoms or healthy controls (separately) | Index test + | | | | Population symptomatic but had not presented to healthcare professionals<br><br>Additional data:<br>None |
| | | | | | Index test - | | | | |
| | | | | | Total | | | | |
| | | | | | Sensitivity<br>Specificity | | Not used as calculated including healthy control group | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR | | | | |
| | | | | | AUC | | 0.544 | | |
| | | | | | Median (IQR) FeNO levels: Asthma: 20.0 (14.0 to 31.0), n=63 | | Allergic rhinitis: 17.0 (12.5 to 23.0), n=57, p=0.28 vs. asthma<br>Non-specific symptoms: 11.0 (8.5 to 12.5), n=29, p<0.0001 vs. asthma<br>Healthy controls: 10.5 (7.0 to 13.0), n=70, | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | p<0.0001 vs. asthma | | | |

**Table 75: KOWAL 2009[924]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kowal K, Bodzenta-Lukaszyk A, Zukowski S. Exhaled nitric oxide in evaluation of young adults with chronic cough. Journal of Asthma 2009; 46(7):692-698. *(Guideline Ref ID KOWAL2009)* | Study type: Prospective study<br><br>Data source: Collected for study<br><br>Setting: Asthma clinic<br><br>Country: Poland<br><br>Recruitment: September 2000 to November 2006 | N = 540 symptomatic + 100 healthy controls<br><br>Inclusion criteria: Young adult patients with chronic cough (at least 8 weeks) referred to asthma clinic for evaluation<br><br>Exclusion criteria: Use of any anti-asthma medication, treatment with angiotensin converting enzyme inhibitors, use of codeine or other cough suppressant, upper respiratory tract infection within 4 weeks before study, presence of any systemic disease, contra-indications to | Male: Female<br>Not stated<br><br>Mean age:<br>Symptomatic: 26.5 (range 18-45) years; healthy controls: 24 (18-39) years | Index test<br>FeNO: chemiluminescence analyser (NOA 280 Sievers device); fixed expiratory resistance 16cm $H_2O$; exhalation flow rate 50mL/s; mean of 3 recordings<br><br>Optimal cut off 40ppb<br><br>Reference standard<br>Significant diurnal changes in PEF or significant improvement of FEV1 with 200µg salbutamol over next 6 months<br><br>Time between index test and reference standard: up to 6 months<br><br>Target condition<br>Asthma vs. Rhinitis/sinusitis or gastroesophageal reflux; raw data calculated from sensitivity/ specificity<br><br>FeNO levels: Asthma vs. | | Ref std + | Ref std - | Total | Source of funding: Medical University of Bialystok<br><br>Limitations: None<br><br>Additional data: None |
| | | | | | Index test + | 157 | 63 | 220 | |
| | | | | | Index test - | 21 | 299 | 320 | |
| | | | | | Total | 178 | 362 | 540 | |
| | | | | | Sensitivity<br>Specificity | | 88.3%<br>82.6% | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR | | 72.6%<br>94%<br>5.08<br>0.14 | | |
| | | | | | AUC | | 0.924 | | |
| | | | | | Median (95% CI) FeNO levels: asthma: 86ppb (95% CI 72 to 94.5), n=178 | | Rhinitis/sinusitis: 37ppb (95% CI 35.6 to 42.9), n=211, p<0.0001 Gastroesophageal reflux: 14.8ppb (95% CI 13.3 to 16.2), | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | bronchial histamine test; people with seasonal allergies if cough appeared in pollen season or up to 4 weeks after the season | | Rhinitis/sinusitis; gastroesophageal reflux; healthy controls (separately) | | n=108, p<0.0001 vs. asthma<br>Healthy controls: 13ppb (95% CI 11 to 15), n=100, p<0.0001 vs. asthma | |

**Table 76: LOUHELAINEN 2008[1041]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Louhelainen N, Rytila P, Obase Y, Makela M, Haahtela T, Kinnula VL et al. The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma. Journal of | Study type:<br>Prospective study<br><br>Data source:<br>Collected for study<br><br>Setting:<br>Division of Pulmonary Medicine<br><br>Country:<br>Finland<br><br>Recruitment:<br>Not stated | N = 37 asthma + 11 COPD + 28 healthy controls<br><br>Inclusion criteria:<br>Patients with newly-diagnosed asthma (wheezing, prolonged cough and shortness of breath plus significant bronchial reversibility i.e. reduction in post-exercise PEF and/or FEV1 ≥15% or improvement in FEV1 ≥12% after bronchodilator or PD15 of histamine | Male: Female<br>Asthma: 17:20<br>COPD: 7:4<br>Healthy controls: 11:17<br><br>Mean age:<br>Patients with asthma and healthy controls grouped by age (adult asthma mean 38 yr, range 16-72 yrs; adult control mean 40, range 19 to 56 yr; asthma child mean 10, range | Index test<br>FeNO: chemiluminescence analyser (Niox device); exhalation flow rate 50mL/s; mean of 3 recordings<br><br>Reference standard<br>BDR ≥12%, Exercise challenge test ≥15% or histamine challenge test PD15 <0.4mg<br><br>Target condition<br>FeNO levels: Asthma vs. healthy controls (COPD not reported) | | Ref std + | Ref std - | Total | Source of funding:<br>Finnish Tuberculosis Association Foundation, funding of the Helsinki University Hospital (EVO), the Sigrid Juselius Foundation, the Ida Montin Foundation, an unrestricted research grant from GSK |
| | | | | | Index test + | - | - | - | |
| | | | | | Index test - | - | - | - | |
| | | | | | Total | - | - | - | |
| | | | | | Sensitivity<br>Specificity | | - | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| Asthma. 2008; 45(2):149-154. *(Guideline Ref ID LOUHELAINEN2008A)* | | <0.4mg or ≥20% diurnal variation in PEF values and/or ≥15% improvement in PEF after bronchodilator at home)<br>COPD exacerbation<br>Healthy controls<br><br><u>Exclusion criteria:</u><br>Not stated | 7-14 yr; healthy child mean 11, range 8-14 yrs); COPD all adult (mean 72, range 54 to 85) | | PPV<br>NPV<br>PLR<br>NLR | - | <u>Limitations:</u><br>None<br><br><u>Additional data:</u><br>None |
| | | | | | AUC | - | |
| | | | | | Median FeNO levels:<br>Asthma children: 35.5ppb, n unclear – between 19 and 23<br><br>Asthma adults: 81.8ppb, n unclear – between 5 and 14 | Healthy children: 11.9ppb, n unclear – between 9 and 13, p<0.001 vs. children with asthma<br>Healthy adults: 16.6ppb, n unclear – between 6 and 15, p=0.025 vs. adults with asthma | |

**Table 77: SATO 2008[1515]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Sato S, Saito J, Sato Y, Ishii T, Xintao W, Tanino Y et al. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough. Respiratory Medicine. 2008; 102(10):1452-1459. *(Guideline Ref ID SATO2008)* | Study type: Prospective<br><br>Data source: Collected for study<br><br>Setting: Department of Pulmonary Medicine<br><br>Country: Japan<br><br>Recruitment: January 2004 to January 2007 | N = 71<br><br>Inclusion criteria: Prolonged cough or wheezing >3 weeks attending Department of Pulmonary Medicine; age 20-78 years; no abnormalities on CXR or CT scan; no prior history of treatment for pulmonary disease; never used oral or inhaled corticosteroids<br><br>Exclusion criteria: None apart from above | Male: Female<br>Bronchial asthma: 20:10<br>Cough variant asthma: 7:11<br>Eosinophilic bronchitis without asthma: 4:4<br>Others: 8:7<br><br>Mean (95% CI) age:<br>Bronchial asthma: 55.5 (48.9 to 62.5)<br>Cough variant asthma: 48.2 (39.4 to 57.0)<br>Eosinophilic bronchitis without asthma: 45.3 (33.3 to 57.2)<br>Others: 55.5 (47.5 to 63.5) | Index test<br>FeNO: chemiluminescence analyser (Device from Kimoto, Japan - no further details given); exhalation flow rate 50mL/s; mouth pressure 16 cm $H_2O$; mean of 3 recordings<br><br>Optimal cut off 38.8ppb<br><br>Reference standard<br>Bronchial asthma (BA): cough and wheezing for 3 weeks or longer, sputum eosiniophilia and positive airway hyper-responsiveness (methacholine <12.5 units) or reversible airflow limitation (improvement in FEV1 of 200mL and ≥12% from baseline after salbutamol 200µg or long-acting β2-agonist).<br>Cough variant asthma (CVA): As above except without wheezing<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma group = bronchial asthma + cough variant asthma together; compared with non-asthma group = eosinophilic bronchitis without asthma (EB), post-infectious cough, post-nasal drip, COPD, chronic bronchitis, cough | | Ref std + | Ref std - | Total | Source of funding: Not stated<br><br>Limitations: None<br><br>Additional data: None |
| | | | | | Index test + | 38 | 2 | 40 | |
| | | | | | Index test - | 10 | 21 | 31 | |
| | | | | | Total | 48 (BA + CVA) | 23 (EB + other) | 71 | |
| | | | | | Sensitivity<br>Specificity | | 79.2%<br>91.3% | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | Mean (95% CI) FeNO levels: Bronchial asthma: 93.5 (72.5 to 120.7) ppb, n=30, p=0.001 vs. CVA group, p<0.001 vs. EB group, p<0.001 vs. others<br><br>Cough variant asthma: 46.7 (33.6 to 64.8) ppb, n=18, p<0.001 vs. EB | | Eosinophilic bronchitis without asthma: 16.4 (10.9 to 24.8) ppb, n=8, NS vs. others<br><br>Other = post-infectious cough, post-nasal drip, COPD, chronic bronchitis, cough with GERD or ino-bronchial syndrome: 21.2 (15.1 to 29.7) ppb, n=15 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | with GERD or sino-bronchial syndrome (i.e. one comparator group); raw data calculated from sensitivity/ specificity<br><br>FeNO levels: Bronchial asthma and cough variant asthma (separately); compared with a) eosinophilic bronchitis without asthma, and b) other = post-infectious cough, post-nasal drip, COPD, chronic bronchitis, cough with GERD or sino-bronchial syndrome (i.e. two comparator groups) | group, p<0.001 vs. others | | |

**Table 78: SHIMODA 2013[1580]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Shimoda T, Obase Y, Kishikawa R, Iwanaga T, Miyatake A, Kasayama S. The fractional exhaled nitric oxide and | Study type:<br>Prospective study, case-control<br><br>Data source:<br>Collected for study<br><br>Setting:<br>Department of respiratory | N = 90 cough variant asthma + 92 bronchial asthma + 90 healthy controls<br><br>Inclusion criteria:<br>Both patients with cough variant asthma and bronchial asthma were to be free of attacks and newly diagnosed.<br>The diagnoses of cough variant asthma | Male: Female<br>Bronchial asthma: 44:48<br>Cough variant asthma: 32:58<br>Controls: 47:43<br><br>Mean age:<br>Bronchial asthma: 38.6 (13.8) yr<br>Cough variant asthma: 44.7 | Index test<br>FeNO: chemiluminescence analyser (NOA 280 Sievers device); mouth pressure 16 cm $H_2O$; flow rate 50mL/s; mean of 3 recordings<br><br>Cut off: n/a (case-control study for levels only)<br><br>Reference standard<br>Newly diagnosed asthma (bronchial or cough variant) using GINA guidelines:<br>Cough variant asthma: chronic cough | | Ref std + | Ref std - | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>Patient groups not comparable at baseline<br><br>Additional data:<br>None |
| | | | | | Index test + | | | | |
| | | | | | Index test - | | | | |
| | | | | | Total | | | | |
| | | | | | Sensitivity<br>Specificity | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| serum high sensitivity C-reactive protein levels in cough variant asthma and typical bronchial asthma. Allergology International. 2013; 62(2):251-257. *(Guideline Ref ID SHIMODA 2013)* | medicine<br><br><u>Country:</u><br>Japan<br><br><u>Recruitment:</u><br>Not stated | and bronchial asthma were based on the GINA guidelines<br>Healthy subjects had no past history of asthma, atopic diseases, or other respiratory diseases and had no current respiratory symptoms<br><br><u>Exclusion criteria:</u><br>Treated with any type of steroid; concurrent hypertension, diabetes mellitus, hyperlipidaemia; cough too severe to measure bronchial hypersensitivity | (14.7) yr<br>Controls: 37.4 (11.5) yr; p=0.004 between groups<br><br>Symptom duration: bronchial asthma: 6.0 (8.8) yr; cough variant asthma: 2.5 (4.4) yr, p=0.001 | persisting for longer than 8 weeks but without wheezing or dyspnoea; no past history of asthma or other respiratory diseases; wheeze or rhonchi not audible on chest auscultation; BHR to inhaled acetylcholine; bronchodilators effective against their coughs; normal chest radiograph results.<br>Bronchial asthma: history of episodic dyspnoea, wheezing and cough; at least 15% reversibility in FEV1 after inhalation of 200 µg of salbutamol and/or BHR to acetylcholine.<br><br>Time between index test and reference standard: n/a<br><br><u>Target condition</u><br>Bronchial asthma vs. cough variant asthma<br>FeNO levels: Each type of asthma compared separately with healthy controls. | Mean (SD) FeNO levels: bronchial asthma: 92.6 (85.5) ppb, n=92, p<0.001 vs. controls | Healthy controls: 18.0 (6.4) ppb, n=90<br><br>Cough variant asthma: 35.6 (43.3) ppb, n=90,<br><br>p<0.001 vs. bronchial asthma, p<0.001 vs. controls | |

**Table 79: SHOME 2006[1585]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Shome GP, Starnes III | <u>Study type:</u><br>Prospective study | N = 19 asthma (11 mild; 8 moderate to severe) + 17 healthy | <u>Male: Female</u><br>Not stated | <u>Index test</u><br>FeNO: 10cm H2O resistance; flow rate 50mL/s (CLD 88sp, EcoPhysics | | Ref std + | Ref std - | Total | <u>Source of funding:</u><br>Department of |
| | | | | | Index | - | - | - | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| JD, Shearer M, Kennedy R, Way A, Arif A et al. Exhaled nitric oxide in asthma: Variability, relation to asthma severity, and peripheral blood lymphocyte cytokine expression. Journal of Asthma. 2006; 43(2):95-99. *(Guideline Ref ID SHOME2006)* | <u>Data source:</u> Collected for study<br><br><u>Setting:</u> Division of Allergy and Immunology<br><br><u>Country:</u> USA<br><br><u>Recruitment:</u> Not stated | controls<br><br><u>Inclusion criteria:</u> Patients with newly-diagnosed asthma (symptoms, signs and spirometry according to National Heart, Lung and Blood Institute) plus increase ≥12% after albuterol 2.5mg; untreated at baseline<br><br><u>Exclusion criteria:</u> COPD, CF, lupus pneumonitis, sepsis, respiratory infection in previous 6 weeks, congestive heart failure, smoking, other systemic diseases with pulmonary symptoms | <u>Mean (SEM) age:</u> Mild asthma: 52.36 (17.10) yr; moderate to severe asthma: 38.25 (8.52) yr; controls: 38.71 (13.04) yr, mild vs. control: p<0.05 | device)<br><br><u>Reference standard</u> BDR ≥12%<br><br><u>Target condition</u> FeNO levels: asthma vs. healthy controls. Patients with asthma grouped by mild versus moderate/ severe disease | test + \| \| \| <br>Index test - \| - \| - \| -<br>Total \| - \| - \| <br>Sensitivity Specificity \| \| - \| <br><br>Mean (SEM) FeNO levels: Moderate to severe asthma: 18.53 (2.00) ppb, n=8, p<0.001 vs. controls<br>Mild asthma: 6.27 (3.79) ppb, n=11, NS vs. controls<br><br>MEDIAN OF BOTH ASTHMA = 24.8ppb<br><br>Healthy controls: 5.90 (0.90) ppb, n=17 | Internal Medicine, Texas Tech University Health Sciences Center<br><br><u>Limitations:</u> Groups not comparable at baseline<br><br><u>Additional data:</u> None |

**Table 80: VOUTILAINEN 2013[1879]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Voutilainen M, Malmberg LP, Vasankari T, Haahtela T. Exhaled nitric oxide indicates poorly athlete's asthma. Clinical Respiratory Journal. 2013; 7(4):347-353. (Guideline Ref ID VOUTILAINEN2013) | Study type:<br>Cross-sectional observational study<br><br>Setting:<br>Allergy and asthma clinic<br><br>Country:<br>Finland<br><br>Recruitment:<br>Not stated | N = 87<br>(study also included a group of elite athletes N=87, not included in this review)<br><br>Inclusion criteria:<br>Sedentary patients remitted to an allergy and asthma clinic because of respiratory symptoms (cough, dyspnoea or wheeze)<br><br>Exclusion criteria:<br>History of sports at a competitive level | Male:<br>Female<br>26:61<br><br>Mean age:<br>23 (14-31)<br><br>Medications:<br>No subjects on ICS at the time of the study and beta-agonists withheld accordingly | Index test<br>FeNO: measured using online single exhalation method recommended by ATS (Niox device)<br>Cut off 30ppb.<br><br>Reference standard<br>Based on general guidelines including typical symptoms and the objective confirmation of variable airway obstruction documented in hospital records. Such evidence was based either on BDR ≥12%, PEFv ≥20%, BDR of PEF ≥15%, exercise challenge test ≥15% or BHR MCh PD20 or hist PD15 ≤0.4mg<br><br>Time between index test and reference standard: 1 day<br><br>Target condition<br>Asthma<br><br>FeNO levels:<br>Asthma vs. non-asthma dx (final dx not stated) | <table><tr><td></td><td>Ref std +</td><td>Ref std -</td><td>Total</td></tr><tr><td>Index test +</td><td></td><td></td><td></td></tr><tr><td>Index test -</td><td></td><td></td><td></td></tr><tr><td>Total</td><td></td><td></td><td></td></tr><tr><td colspan="2">Sensitivity<br>Specificity</td><td colspan="2">43%<br>89%</td></tr><tr><td colspan="2">PPV / NPV</td><td colspan="2">-</td></tr><tr><td colspan="2">AUC</td><td colspan="2">0.79</td></tr><tr><td colspan="4">FeNO levels: Asthma: 29.7ppb<br>Non-asthma: 14.6ppb<br>P<0.001</td></tr></table> | Source of funding:<br>Supported by the Vaino and Laina Kivi foundation (study sponors did not have invlolvment in study design, collection, analysis or interpretation of data).<br><br>Limitations:<br>Random or consecutive recruitment of patients not stated<br><br>Additional data:<br>study also included a group of elite athletes N=87, not included in this review |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | | | | | |

**Table 81: WOO 2012[1937]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide (F(E)NO) measurements in diagnosing asthma. Respiratory Medicine. 2012; 106(8):1103-1109. | Study type: Prospective study<br><br>Data source: Collected for study<br><br>Setting: Department of Paediatrics<br><br>Country: Korea<br><br>Recruitment: Not stated | N = 245<br><br>Inclusion criteria: Children 8- 16 years old, presenting with non-specific respiratory symptoms e.g. cough, wheezing, shortness of breath, referred to paediatric outpatients for evaluation of asthma<br><br>Exclusion criteria: Receiving inhaled short-acting β2 agonist in previous 8 hours; receiving regular treatment with controller medications for 3 | Male: Female<br>Overall: 163:82<br>Atopic asthma: 92:37; atopic non-asthma: 42:18; non-atopic asthma: 20:18; non-atopic non-asthma: 9:9<br><br>Mean age:<br>Atopic asthma: 11.7 (2.4) yr; atopic non-asthma: 12.6 (2.6) yr; non-atopic asthma: 11.6 (2.7) yr; non-atopic non-asthma 11.4 (2.0) yr | Index test<br>FeNO: chemiluminescence (NIOX MINO device); flow rate 50mL/s; mean of 2 values.<br><br>Optimal cut off 22ppb<br><br>Reference standard<br>History + reversible airflow obstruction (≥12% improvement in FEV1 with inhaled β-agonist) and/or airway hyper-responsiveness (methacholine PC20 ≤8mg/mL)<br><br>Time between index test and reference standard: same time<br><br>Target condition<br>Asthma vs. non-asthma (not airway hyper-responsiveness (cut off for | Total study population | Ref std + | Ref std - | Total | Source of funding: Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology<br><br>Limitations: Unclear if treatment naive<br><br>Additional data: None |
| | | | | | Index test + | 95 | 10 | 105 | |
| | | | | | Index test - | 72 | 68 | 140 | |
| | | | | | Total | 167 | 78 | 245 | |
| | | | | | Sensitivity<br>Specificity | | 56.9%<br>87.2% | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR<br>Accuracy | | 90.5%<br>48.6%<br><br><br>64.5% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| *(Guideline Ref ID WOO2012 )* | | month or more before enrolment | | methacholine PC20 of 8mg/mL) or reversible airflow obstruction (12% improvement in FEV1 with inhaled β-agonist); final diagnoses not stated.<br>Asthma and non-asthma groups also sub-divided by atopic vs. non-atopic | AUC | | 0.76, p<0.001 | | |
| | | | | | Atopic only | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 93 | 9 | 102 | |
| | | | | | Index test - | 36 | 51 | 87 | |
| | | | | | Total | 129 | 60 | 189 | |
| | | | | | Sensitivity<br>Specificity | | 72.1%<br>85.0% | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR<br>Accuracy | | 91.2%<br>58.6% | | |
| | | | | | AUC | | 0.85, p<0.001 | | |
| | | | | | Geometric mean FeNO levels: asthma: 23.4 ppb (95% CI 20.9 to 26.2), n=167 | | Non-asthma: 12.6 ppb (95% CI 10.9 to 14.5), n=78, p<0.001 | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | | | vs. asthma | |
| | | | | | Atopic asthma sub-group: 29.6 (26.6 to 32.8) ppb, n=129, p<0.001 vs. atopic non-asthma, non-atopic asthma and non-atopic non-asthma<br><br>Non-atopic asthma sub-group: 10.6 (8.6 to 13.0) ppb, n=38 | Atopic non-asthma sub-group: 13.6 (11.6 to 15.9) ppb, n=60, p<0.05 vs. non-atopic asthma and non-atopic no asthma<br><br>Non-atopic non-asthma sub-group: 9.7 (7.1 to 13.3) ppb, n=18 | |

**Table 82: ZIETKOWSKI 2006A[1980]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| Zietkowski et al., 2006. Comparison of exhaled nitric oxide measurem | Study type:<br>Case-control study<br>Data source:<br>Collected for this study<br><br>Setting:<br>Medical | N = 140 (inc. 39 healthy controls)<br><br>Inclusion criteria:<br>• Steroid-naïve patients with mild to moderate asthma (56 allergic and 45 nonallergic)<br>• Asthma Dx according to GINA<br>• Stable condition free from | Male: Female<br>57:83<br><br>Mean () age:<br>Allergic asthma (n=56)<br>32 (12)<br><br>Non-allergic | Index test<br>FeNO: chemiluminescence analyser; measurements were performed at an expiratory flow of 50 mL/s. Repeat measurements were performed until the 3 values agreed to within 10% of the mean. The mean value of the 3 measurements was recorded | **FeNO levels**<br><br>Allergic asthma: 84.0±51.4<br>Non-allergic asthma: 45.8±32.6<br>MEDIAN OF BOTH ASTHMA = 64.9ppb<br><br>Healthy controls: 12.9 ±4.6 | Source of funding:<br>Not reported<br><br>Limitations:<br><br>Additional data: |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| ent with conventional tests in steroid-naive asthma patients. Journal of Investigational Allergology and Clinical Immunology: 16: 239-246<br><br>REF ID: ZIETKOWSKI 2006A | University<br><br><u>Country:</u><br>Poland<br><br><u>Recruitment:</u><br>Not stated | acute exacerbations and respiratory tract infections during the previous 2 months<br>• Healthy controls had an FEV1 greater than 80% of predicted. They were free of respiratory tract infection for 2 months prior to the study and from other significant illnesses known to affect FENO measurements (smoking, nitrate-rich diet, allergic rhinitis).<br><u>Exclusion criteria:</u><br>• Patients with asthma who had been treated with inhaled steroids in the past<br>• Other factors that could alter FENO—such as smoking and nitrate–rich diet, but not asthma, features of atopy, or allergic rhinitis<br>• Smokers | asthma (n=45)<br>40 (12)<br><br>Healthy (n=39 )<br>33.5 (15.2)<br><br>Medications:<br>Refrain from use of inhaled bronchodilators for at least<br>6 and 12 hours for short- and long-acting ß2-agonists, respectively | <u>Reference standard</u><br>None (levels only)<br><br><u>Target condition</u><br>FeNO levels asthma vs. healthy controls | p<0.0001 for comparison | |

# G.11 Eosinophils for diagnosis

**Table 83: BACKER 2002[90]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Backer V, Nepper-Christensen S, Ulrik CS, von Linstow ML, Porsbjerg C. Factors associated with asthma in young Danish adults. Ann Allergy Asthma Immunol. 2002 Aug;89(2):148-54.<br><br>BACKER2002 | Study type:<br>Cross-sectional<br><br>Data source:<br>Registry<br><br>Setting: General population<br><br>Country:<br>Denmark<br><br>Recruitment:<br>Children and adolescents living in the area surrounding Rigshospitalet were drawn from the civil registration list who were born between 1969 and 1979. | N = 624<br>103 people with asthma and 521 people who do not have asthma<br><br>Inclusion criteria:<br>Children and adolescents<br><br>Exclusion criteria: Not to use theophylline or antihistamine for at least 24 hours before the test, not to use astemizole for 6 weeks before testing, oral beta-2-agonist for 12 hours before the tests. Pregnant women and breast feeding mothers were excluded from the histamine challenge and pregnant women did not undergo skin prick testing. | Male N=279<br>Female N=345<br><br>Age:<br>19 to 29 years<br><br>Severity of asthma:<br>Current asthma vs. those who do not have asthma.<br><br>Current smokers:<br>35 to 53%<br><br>Current anti-asthma<br>Inhaled or oral corticosteriod<br><br>Drop-outs/missing values:<br>940 were eligible; 624 participated. | Index test **Peripheral blood eosinophils**<br>• Venous blood sample and put into a tube containing EDTA, and the number of eosinophil leukocytes was counted in billions per litre.<br><br>Reference standard<br>N/A<br><br>Target condition<br>NA | **Blood eosinophil count. (Factor associated with asthma in young adults).** Billions per litre. | **Non-asthma:** 0.19 (0.1) **versus. Asthma** 0.26 (0.2)<br>• P<0.01 different between two groups. | Source of funding:<br>Danish Lung Association. Glaxo Wellcome and ALK-Abello.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data<br>Those that had asthma had higher eosinophil counts. |

**Table 84: HALVANI 2012[634]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Abolhasan Halvani, Fatemeh Tahghighi, and Hossein Hadi Nadooshan. Evaluation of correlation between airway and serum inflammatory markers in asthmatic patients. *Lung India* 29 (2):143-146, 2012.<br><br>HALVANI 2012 | Study type:<br>Case-control<br><br>Data source:<br>Asthma pts from clinic – details not reported, and age and sex matched healthy controls.<br><br>Setting:<br>Outpatients (secondary care).<br><br>Country:<br>Iran<br><br>Recruitment:<br>Not reported. | N = 98 (includes 37 healthy)<br><br>Inclusion criteria:<br>• Mild to moderate persistent asthma (GINA criteria)<br>• Non-smokers without history of RTI or exacerbation of asthma during previous 6 weeks.<br>• Healthy: no history of smoking, heart disease or other diseases; normal pulmonary function tests.<br><br>Exclusion criteria:<br>• Heart disease<br>• Diabetes<br>• Cancer<br>• Obesity<br>• Systemic inflammatory disorders. | Male: Female<br>55%/45%<br><br>Mean age:<br>37.8 years.<br><br>Diagnoses:<br>• 1. Healthy controls: n=37<br>• 2. Asthma ICS user: n=31<br>• 3. Asthma non-ICS user: n=30.<br><br>Current smokers:<br>None reported.<br><br>Current anti-asthma Tx:<br>N=31 ICS users.<br><br>Drop-outs/missing values:<br>None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Not reported.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Asthma. | **Population (baseline)** | **Eosinophils, median**<br>**No./µL** | Source of funding:<br>None reported.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Healthy controls | **211** | |
| | | | | | Asthma – ICS user | **402** | |
| | | | | | Asthma – non-ICS user | **517** | |
| | | | | | | | |
| | | | | | | | |
| | | | | | • **Asthma non-ICS user group: SS more PBE than asthma ICS users and healthy controls.** | | |

**Table 85: HUNTER 2002[721]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| C. J. Hunter, C. E. Brightling, G. Woltmann, A. J. Wardlaw, and I. D. Pavord. A comparison of the validity of different diagnostic tests in adults with asthma. *Chest* 121 (4):1051-1057, 2002.<br><br>HUNTER 2002 | Study type: Case-control<br><br>Data source: Patients attending Dept of Respiratory medicine, staff, and volunteers.<br><br>Setting: Patients (secondary care) and general population.<br><br>Country: UK<br><br>Recruitment: Dates not reported. | N = 110 (includes n=21 healthy controls)<br><br>Inclusion criteria:<br>• Asthma: consistent clinical features, symptomatic, FEV1 >65% predicted, and one or more of other criteria.<br>• Healthy controls: no symptoms suggesting past or current asthma, non-smokers.<br>• Pseudoasthma: people referred to hospital with Dx of asthma by GP, clinical features considered atypical and symptoms not deteriorate upon withdrawal of Tx. Symptoms improved after Tx of underlying condition.<br><br>Exclusion criteria: None reported. | Male: Female<br>47%:53%<br><br>Mean age:<br>39 years (range 14-76).<br><br>Diagnoses:<br>• Asthma: n=69<br>• Pseudoasthma: n=20<br>• Healthy control: n=21<br><br>Current smokers:<br>8%<br><br>Current anti-asthma Tx:<br>28%. Mean Tx time = 2 years (0-29 yrs).<br><br>Drop-outs/missing values:<br>None reported. | Index test **Peripheral blood eosinophils**<br>• Standard haematological techniques.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>• Asthma.<br>• Physician Dx based on clinical features and tests. | **Population**<br>Healthy controls<br>Pseudoasthma<br>Asthma<br><br>**Test results for eosinophil vs. healthy controls:**<br>• Normal range = <6.3%<br>• sens 21% (11-31)<br>• spec 100<br><br>**Most tests were less specific when the reference population consisted of people with pseudoasthma.** | **Eosinophils, mean (SEM)**<br>**%**<br>1.9 (0.6)<br>2.0 (0.3)<br>4.3 (0.6) | Source of funding: None reported.<br><br>Limitations: Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |

**Table 86: KHAKZAD 2009[856]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| M. R. Khakzad, M. Mirsadraee, M. Sankian, A. Varasteh, and M. Meshkat. Is serum or sputum eosinophil cationic protein level adequate for diagnosis of mild asthma? *Iran.J.Allergy Asthma Immunol.* 8 (3):155-160, 2009.<br><br>KHAKZAD 2009 | Study type: Case-control<br><br>Data source: Subjects with asthma and controls (no other details reported).<br><br>Setting: Not reported.<br><br>Country: Iran<br><br>Recruitment: Not reported. | N = 62 (includes 12 healthy)<br><br>Inclusion criteria:<br>• Asthma: history of cough, dyspnoea, wheeze and airway hyperresponsiveness; symptoms increased during nights and some seasons; Spirometry showing obstructive pattern with >12% increase with bronchodilator or PC20 <8 mg/ml.<br>• All were new cases or pts who had withheld their drugs for a long time.<br>• Healthy: no history of asthma or other allergic disorders; PC20 >8 mg/ml.<br><br>Exclusion criteria:<br>• Healthy people with : evidence of peripheral blood eosinophilia, abnormal chest X-ray, history of smoking, systemic or ICS usage, recent infection. | Male: Female 40%/60%<br><br>Mean age: 39.5 years (range 9-76).<br><br>Diagnoses (GINA criteria):<br>• 1. Healthy controls: n=12<br>• 2. Asthma Mild intermittent: n=6.<br>• 3. Asthma mild persistent: n=16.<br>• 4. Asthma moderate persistent: n=13<br>• 5. Asthma severe: n=15<br><br>Current smokers: None reported.<br><br>Current anti-asthma Tx: None reported.<br><br>Drop-outs/missing values: None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Automated cell counter (Sysmex).<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>• Asthma. | **Population (baseline)** | **Eosinophils, median %** | Source of funding: Islamic Azad University.<br><br>Limitations: Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |
| | | | | | Healthy controls | **1.2** | |
| | | | | | All asthma | **1.0** | |
| | | | | | Asthma Mild intermittent | **2.0** | |
| | | | | | Asthma mild persistent | **3.6** | |
| | | | | | Asthma moderate persistent | **3.2** | |
| | | | | | Asthma severe | **3.2** | |
| | | | | | • Asthma: SS higher PBE than healthy controls. | | |

**Table 87: KOTANIEMI 2002[917]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Anne Kotaniemi-Syrjanen, Tiina M. Reijonen, Kaj Korhonen, and Matti Korppi. Wheezing requiring hospitalization in early childhood: predictive factors for asthma in a six-year follow-up. *Pediatr.Allergy Immunol.* 13 (6):418-425, 2002.<br><br>KOTANIEMI 2002 | Study type:<br>Case series (prospective)<br><br>Data source:<br>Prospective study: 6-year follow-up of children with infection-related wheeze; data used for 6 years only to see at 6 years the % who have asthma.<br><br>Setting: Outpatients (secondary care)<br><br>Country:<br>Finland<br><br>Recruitment:<br>6 year follow-up data January to March 1999 (original baseline study December 1992-1993) | N = 82<br>(**FINAL Dx: N=33 asthma; N=49 non-asthma)**<br><br>Inclusion criteria:<br>• Children from previous study who were available for follow-up.<br><br>Exclusion criteria: None reported. | Male: Female<br>74%:26%<br><br>Median age:<br>7.2 (5.6 - 8.8 years)<br><br>Current smokers:<br>N/A<br><br>Current anti-asthma Tx:<br>30/33 asthma pts used cromones (n=18) or inhaled steroids (n=12) for maintenance medication for asthma.<br><br>Drop-outs/missing values:<br>N=18 from the original 100 | Index test **Peripheral blood eosinophils**<br>• Method not reported.<br>**CUT-OFF:** ≥0.45 x $10^9$/l.<br><br>Reference standard<br>**Clinical Dx – clinical history and questionnaire (symptoms), and exercise challenge test** (pulmonary testing before and after exercise using flow-volume spirometry and $FEV_1$ – positive = auscultatory wheezing post-exercise and/or ≥15% fall in $FEV_1$).<br>**Asthma diagnosed if:**<br>1. On continuous maintenance Tx-asthma<br>2. suffered from repeated (≥2) episodes of wheezing and/or prolonged cough (≥4 wks) apart from infection during previous 12 months reported by parents.<br>3. positive exercise challenge test.<br>**Non-Asthma diagnosed if:**<br>wheezing or prolonged cough but negative exercise challenge OR positive exercise test but no asthma symptoms.<br><br>Time between index test and reference standard: unclear<br><br>Target condition: Asthma. | **Population**<br><br>False positives: 8, false negatives: 15, true positives: 18, true negatives: 41<br><br>Sensitivity: 18/33<br>Specificity: 41/49<br>PPV: 18/26 (69% reported in the paper)<br>NPV: 41/56 | **% with Eosinophil counts ≥0.45 x $10^9$/l** | Source of funding:<br>Ida Montin Foundation, Kerttu and kale Viik Fund, Kuopio University Hospital.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |

**Table 88: KROEGEL 1998[930]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| C. Kroegel, M. Schuler, M. Forster, R. Braun, and P. R. Grahmann. Evidence for eosinophil activation in bronchiectasis unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy between blood eosinophil counts and serum eosinophil cationic protein levels. *Thorax* 53 (6):498-500, 1998.<br><br>KROEGEL 1998 | Study type:<br>Case-control<br><br>Data source:<br>Consecutive pts with bronchiectasis, plus age and sex matched control groups (allergic asthma, COPD and healthy).<br><br>Setting:<br>Secondary care.<br><br>Country:<br>Germany<br><br>Recruitment:<br>Jan 1992 – August 1994. | N = 56 (n=14 asthma)<br><br>Inclusion criteria:<br>• Proven or new bronchiectasis (persistent cough, recurrent pneumonias and frequent haemoptysis, large quantities of partially foul purulent sputum production, positive sputum cultures>3 years, and radiological evidence of bronchiectasis)<br>• COPD or asthma (diagnostic criteria previously published)<br>• All pts without clinical signs of current infectiou exacerbation in previous 4 weeks<br>• Healthy controls – no pulmonary disease.<br>• No family history of similar lung disease.<br><br>Exclusion criteria:<br>• None reported. | Male: Female<br>N=8/N=6<br><br>Mean age:<br>54.8 years (range 31-78).<br><br>Diagnoses:<br>• 1. Healthy controls: n=14<br>• 2. Bronchiectasis: n=14<br>• 3. COPD: n=14<br>• 4. Allergic asthma: n=14.<br><br>Current smokers:<br>None reported.<br><br>Current anti-asthma Tx:<br>Not reported.<br><br>Drop-outs/missing values:<br>None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Standard cytometry.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Allergic asthma. | **Population (baseline)** | **Eosinophils, median**<br>**x10$^7$/l** | Source of funding:<br>County of Thuringia, Germany.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Healthy controls | **10.1 (range 1.6-21.4)** | |
| | | | | | Bronchiectasis | **10.2 (1.0-32.0)** | |
| | | | | | COPD | **11.7 (range 0.6-31.5)** | |
| | | | | | Allergic asthma | **30.5 (range 12.3-69.3)** | |
| | | | | | | | |
| | | | | | • **Allergic asthma: SS more PBE than all other groups**<br>• **NS difference in PBE count between bronchiectasis and healthy controls or COPD.** | | |

**Table 89: LABBE 2001[954]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| A. Labbe, B. Aublet-Cuvelier, L. Jouaville, G. Beaugeon, L. Fiani, I. Petit, L. Ouchchane, and M. Doly. Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough. *Pediatr.Pulmonol.* 31 (5):354-362, 2001.<br><br>LABBE 2001 | Study type:<br>Case-control<br><br>Data source:<br>Children seen in outpts by paediatric pulmonologist.<br><br>Setting:<br>Outpatients (secondary care).<br><br>Country:<br>France<br><br>Recruitment:<br>Feb 1997-March 1999. | N = 143 (N=88 asthma, N=22 severe)<br><br>Inclusion criteria:<br>• Asthma: a) recent onset, not receiving any Tx except B-2 agonists if needed. b) severe asthma, taking ICS regularly for at least 12 months.<br>• Healthy: admitted to dept for non-infectious, non-respiratory disorder. No history of asthma or atopic disease.<br>• Chronic cough: referred for chronic cough (>3months duration/year), or recurrent cough (>3 episodes/year, each lasting >15 days). Experienced no episodes of wheezing or dyspnoea.<br><br>Exclusion criteria:<br>• None reported. | Male: Female<br>64%/36%<br><br>Mean age:<br>7.0 years (range 1.1 - 16.5).<br><br>Diagnoses (GINA criteria):<br>• 1. Healthy controls: n=34.<br>• 2. Chronic cough: n=21.<br>• 3. Asthma: n=88<br><br>Current smokers:<br>N/A.<br><br>Current anti-asthma Tx:<br>Some pts.<br><br>Drop-outs/missing values:<br>None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Method not reported.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Asthma. | **Population (baseline)** | **Eosinophils, median** x$10^9$/L | Source of funding:<br>Pharmacia.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Healthy controls | **0.25** | |
| | | | | | Chronic cough | **0.21** | |
| | | | | | Asthma | **0.40** | |
| | | | | | • Asthma: SS higher PBE than healthy controls and chronic cough groups (p<0.01). | | |

**Table 90: METSO 2000[1139]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Metso T, Kilpiö K, Björkstén F, Kiviranta K, Haahtela T. Detection and treatment of early asthma. Allergy. 2000 May;55(5):505-9.<br><br>METSO 2000 | Study type: Case-control study (pt groups within this were randomly assigned to Tx groups for 6 weeks)).<br><br>Data source: Hospital staff recruited patients<br><br>Setting: Hospital<br><br>Country: Finland<br><br>Recruitment: 80 consecutive patients | N = 190<br>(N=30 control and N=160 asthma – N=39 budesonide, N=39 terbutaline).<br><br>Inclusion criteria:<br>Subjective symptoms for <1 year. At least one of the following lung-function test outside the reference range:<br>FEV1 improvement >15% after inhaled beta2 agonist<br>PEF diurnal variation >15% and PEF increase of >15% after inhaled beta2-agonist at least once during a 2 week period<br><br>Exclusion criteria: treatment with anti-inflammatory medication, lung diseases other than asthma, and respiratory tract infection in the previous 4 weeks. Past and present long-term respiratory diseases including asthma, respiratory tract infections and preceding 4 weeks and hyper responsiveness to histamine. | Male: Female<br>Budesonide<br>32/7<br>Terbutaline<br>31/10<br>Controls<br>28/2<br><br>Age:<br>16-60<br><br>Severity of asthma:<br>Mild/Moderate<br>Budesonide<br>31/8<br>Terbutaline 30/11<br>Controls 0/0<br><br>Current smokers:<br>Budesonide 14<br>Terbutaline 9<br>Controls 0<br><br>Current a-asthma Tx:<br><br>Drop-outs/missing values: NA | Index test<br>**Peripheral blood eosinophils**<br><br>**CUT-OFF:** NA<br><br>Reference standard<br>N/A<br><br>Target condition<br>NA | **Blood eosinophils $10^9$/L** | **Control:**<br>0.13<br><br>**Budesonide group:**<br>**Pre-Tx:**0.20<br>**Post-Tx (6 wks):** 0.11**<br><br>**Terbutaline group**<br>**Pre-Tx:** 0.16<br>**Post-Tx (6 wks):** 0.14<br><br>**Post-Tx (6 wks terbutaline + 2 ks budesonide):** 0.12**<br><br>** p<0.05 vs baseline | Source of funding: Research institute of Helsinki University Central Hospital and the Finnish Allergy Research Foundation.<br><br>Limitations: Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |

**Table 91: NORDLUND 2012[1257]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Nordlund B, Konradsen JR, Kull I, Borres MP, Önell A, Hedlin G, Grönlund H. IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma. Allergy. 2012 May;67(5):661-9.<br><br>NORDLUND 2012 | Study type:<br>Case-series<br><br>Data source:<br>Hospital based paediatric clinics<br><br>Setting:<br>Outpatients (secondary care)<br><br>Country:<br>Denmark<br><br>Recruitment:<br>Hospital based paediatric clinics | N = 39 (mild to moderate)<br><br>Inclusion criteria:<br>Children from 7 to 18 years of age with diagnosed asthma according to the Global initiative for asthma (GINA). At least 6months of regular treatment with ICS, min 800 microgram of budesonide or equivalent for problematic severe asthma and 100-400 microgram budesonide or equivalent for children with mild to moderate asthma.<br>Physician diagnosed asthma.<br><br>Exclusion criteria: children with lung or neurological diseases, as well as those born prematurely (gestational age <36 weeks) were excluded. | Male:female<br>59: 41<br>Age:<br>13.8±2.9 years<br><br>Severity of asthma:<br>Controlled mild to moderate. And severe patients were included.<br><br>Current smokers:<br>35 to 53%<br><br>Current anti-asthma<br>Inhaled or oral corticosteriod<br><br>Drop-outs/missing values:<br>Unclera | Index test **Peripheral blood eosinophils**<br>• Venous blood sample and the number of eosinophil were measured.<br><br>Reference standard<br>N/A<br><br>Target condition<br>NA | **Blood count of eosinophils ($10^9$ x $1^{-1}$, mean SD)** | • Mild to moderate asthma<br>0.25± 0.19 | Source of funding:<br>Freemason Child House Foundation<br>Swedish Asthma and Allergy Associations Research Fund and Swedish Heart and Lung Foundation<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |

**Table 92: PIIPPOSAVOLAINEN 2007[1358]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| E Piippo-Savolainen, S Remes, and M Korppi. Does blood eosinophilia in wheezing infants predict later asthma? A prospective 18-20-year follow-up. *Allergy Asthma Proc.* 28 (2):163-169, 2007.<br><br>PIIPPOSAVOLAINEN 2007 | Study type: Case-series (prospective)<br><br>Data source: Infants hospitalised for bronchiolitis.<br><br>Setting: Hospital (secondary care).<br><br>Country: Finland.<br><br>Recruitment: 1981-1982. | N = 83<br><br>Inclusion criteria:<br>• Infants (<2 years) hospitalised for broncholitis<br>• Bronchiolitis: respiratory wheezing and/or prolonged expirum during lower respiratory infection.<br><br>Exclusion criteria: None reported. | Male: Female<br>Not reported.<br><br>Mean age:<br><2 years (mean or range not given).<br><br>Diagnoses:<br>N/A at baseline.<br><br>Current smokers:<br>N/A<br><br>Current anti-asthma Tx:<br>Not reported.<br><br>Drop-outs/missing values:<br>None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Fuchs-Rosenthal counting chamber.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>• Asthma | **BASELINE VALUES Population: wheezing** | **Eosinophils, median (25th-75th percentile)**<br>**counts** | Source of funding:<br>None reported.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Wheezing (all 83 pts) | $0.1 \times 10^9$/L (0.028 – 0.321) | |

**Table 93: POPOVIC 2002[1381]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| S. Popovic-Grle, M. Mehulic, F. Pavicic, I. Babic, and Z. Beg-Zec. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung function in the diagnosis of asthma in persons with dyspnea. *Coll.Antropol.* 26 Suppl:119-127, 2002.<br><br>POPOVIC 2002 | <u>Study type:</u><br>Diagnostic Cross-sectional study<br><br><u>Data source:</u><br>Outpatients with dyspnoea, treated for breathlessness; referred by GP due to suspected asthma.<br><br><u>Setting:</u><br>Outpatients (secondary care)<br><br><u>Country:</u><br>Croatia<br><br><u>Recruitment:</u><br>Not reported | N =195<br>(**FINAL Dx:** N=141 asthma, N=17 COPD, N=29 rhinitis/sinusitis, N=8 unsolved so further examined)<br><br><u>Inclusion criteria:</u><br>• Outpatients treated for breathlessness<br><br><u>Exclusion criteria:</u><br>• None reported. | **ASTHMA pts**<br><br><u>Male: Female</u><br>48%:52%<br><br><u>Mean age:</u><br>39 years<br><br><u>Current smokers:</u><br>20%<br><br><u>Current anti-asthma Tx:</u><br>Not mentioned<br><br><u>Drop-outs/missing values:</u><br>None | <u>Index test</u> **Peripheral blood eosinophils**<br>• Method not mentioned<br><br>**CUT-OFF:** positive = not reported.<br><br><u>Reference standard</u><br>**Physician Dx (pulmonologist)**<br>Based on questionnaire (medical history of occasional asthma attacks with wheezing and nocturnal wakening due to dyspnoea), and on the basis of bronchodilation test (reversible obstruction) with salbutamol.<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Asthma. N=141 were people with diagnosed asthma. | **Asthma** | Ref std + | Ref std – | Total | <u>Source of funding:</u><br>Not reported.<br><br><u>Limitations:</u><br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br><u>Additional data:</u><br>N/A |
| | | | | | Eosin + | 21 | 33 | 54 | |
| | | | | | Eosin - | 120 | 21 | 141 | |
| | | | | | Total | 141 | 54 | 195 | |
| | | | | | Sensitivity<br>Specificity | | 15% (21/141)<br>39% (21/54) | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 64% (21/33)<br>74% (120/162)<br>- | | |
| | | | | | AUC | | - | | |
| | | | | | % eosinophils in asthma pts, mean (SD) | | Not reported | | |

**Table 94: POSTMA 1995[1385]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| D. S. Postma and M. D. Lebowitz. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. *Arch.Intern. Med.* 155 (13):1393-1399, 1995.<br><br>POSTMA 1995 | Study type:<br>Diagnostic Cross-sectional study<br><br>Data source:<br>Adults from an epidemiologic study of obstructive airway disease.<br><br>Setting:<br>General population<br><br>Country:<br>USA<br><br>Recruitment:<br>Original study: 1972-1985 | N =2169<br>(N=2130 had Dx data)<br>(**FINAL Dx:** N=345 any asthma, N=303 emphysema and/or chronic bronchitis, N=124 Low 1st FEV1, N=1358 none)<br><br>Inclusion criteria:<br>Age ≥20 years<br><br>Exclusion criteria:<br>None reported. | **Reported in a separate publication (Lebowitz 1989)**<br><br>Male: Female<br>-<br><br>Mean age:<br>Adults (details not reported)<br><br>Current smokers:<br>-<br><br>Current anti-asthma Tx:<br>-<br><br>Drop-outs/missing values:<br>- | Index test **Peripheral blood eosinophils**<br>Stained slides counted from the 1st and 6th surveys.<br><br>**CUT-OFF:** eosinophilia (positive) = ≥5% 1st survey, or ≥3% 6th survey. Based on distribution of all values in either survey.<br><br>R eference standard **Physician Dx**<br>Based on questionnaire (symptoms) and clinical evaluations (including FVC, and reversibility of airways obstruction (FEV1 before and after 5 mins after inhalation of 2 puffs of isoproterenol hydrochloride from a metered dose inhaler.<br><br>Time between index test and reference standard: unclear<br><br>Target condition<br>Asthma. N=345 were people with diagnosed asthma. | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Dutch Asthma fund and National Heart, Lung and Blod Institute, USA.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Eosin + | 103 | - | - | |
| | | | | | Eosin - | 242 | - | - | |
| | | | | | Total | 345 | 1989 | 2130 | |
| | | | | | Sensitivity<br>Specificity | | 30% (103/345)<br>- | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | -<br>-<br>- | | |
| | | | | | AUC | | - | | |
| | | | | | % eosinophils in asthma pts, mean (SD) | | Not reported | | |

**Table 95: RYTILA 2000[1496]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| P. Rytila, T. Metso, K. Heikkinen, P. Saarelainen, I. J. Helenius, and T. Haahtela. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. *Eur.Respir.J.* 16 (5):824-830, 2000.<br><br>RYTILA 2000 | Study type: Case-control<br><br>Data source: Consecutive pts with respiratory symptoms, and healthy controls.<br><br>Setting: Outpatients (secondary care).<br><br>Country: Finland<br><br>Recruitment: Oct 1996-March 1997. | N = 68 (includes n=43 healthy controls)<br><br>Inclusion criteria:<br>• Pts with respiratory symptoms suggestive of asthma.<br>• At least 2/6 respiratory symptoms for >2 months and <1 year.<br>• Healthy – no respiratory symptoms or history of chronic pulmonary diseases.<br><br>Exclusion criteria:<br>• Pts treated with a-inflammatory asthma medication.<br>• Pts or healthy pple who had clinically diagnosed respiratory infection 8 wks before study.<br>• Pts who had used histamine H2 blockers. | Male: Female<br>41%: 59%<br><br>Mean age:<br>37.7 years (range 15-75).<br><br>Diagnoses:<br>• 1. Healthy controls (normal lung function tests): n=43<br>• 2. Respiratory symptoms (no significant airflow variability, and not hyperresponsive): n=36<br>• 3. Asthma (FEV1 increase ≥12% 15 mins after SABA, or PEF varied by >12% from morning to evening for ≥3 days during 2-week follow-up. Had increased bronchial responsiveness to inhaled histamine): n=25<br><br>Current smokers: 31%<br>Current anti-asthma Tx:<br>Not reported.<br><br>Drop-outs/missing values: None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Method not reported.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Asthma. | **Population (baseline)** | **Eosinophilsmean $x10^9/l$** | Source of funding: None reported.<br><br>Limitations: Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |
| | | | | | Healthy controls | **0.11** | |
| | | | | | Respiratory Symptoms | **0.17** | |
| | | | | | Asthma | **0.41** | |
| | | | | | Atopic asthma | 0.51 | |
| | | | | | Non-atopic asthma | 0.27 | |
| | | | | | • **Asthma: SS more PBE than respiratory symptom pts (p=0.002) and healthy pple (p<0.0001).**<br>• **Respiratory symptoms: SS more PBE than healthy pple (p=0.01).**<br>• **Atopic asthma: SS more PBE than non-atopic asthma pts p=0.04)** | | |

**Table 96: SHIELDS 1999[1579]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Shields MD, Brown V, Stevenson EC, Fitch PS, Schock BC, Turner G, Taylor R, Ennis M. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clin Exp Allergy. 1999 Oct;29(10):1382-9.<br><br>SHIELDS1999 | <u>Study type:</u><br>Cross sectional study<br><br><u>Data source:</u><br>Wheezing children undergoing an elective surgical procedure for a non-inflammatory condition at the Hospital<br><br><u>Setting:</u><br>Hospital<br><br><u>Country:</u><br>Northern Ireland<br><br><u>Recruitment:</u><br>- | N = 137<br><br><u>Inclusion criteria:</u><br>• History of wheezing in the previous year<br>• Free from recent respiratory infection.<br><br><u>Exclusion criteria:</u><br>Alternative causes of wheezing. | Male N=48<br>Female N=29<br><br><u>Age:</u><br>1-15 years (mean not reported)<br><br><u>Severity of asthma:</u><br>Atopic asthma<br><br><u>Current smokers:</u><br>N/A<br><br><u>Current anti-asthma Tx:</u> 43 were taking anti-inflammatory therapy, however there was no effect on blood eosinophil counts.<br><br><u>Drop-outs/missing values:</u> | <u>Index test</u> **blood eosinophils**<br>• Blood sample taken pre-surgery. Eosinophil counts obtained from blood smears by routine methods.<br><br>**CUTOFF positive** = 4% and 8% (elevated).<br><br><u>Reference standard</u><br>**Physican Dx** Detailed asthma and allergy history.<br><br>Diagnoses:<br>1. Atopic asthma – symptoms triggered by known aeroallergens, who had other personal atopic features, strong family background of atopy or elevated serum IgE compared to normal values.<br>2. Viral-associated wheezing – no personal or family background of atopy, wheezing predominantly in winter and solely in association with viral upper RTI.<br><br><u>Target condition</u><br>Asthma (N=60 atopic asthma diagnosed). | **Blood eosinophil %**<br><br>**Area under curve for predicting airways inflammation**<br><br>**Blood eosinophils**<br>**>4%**<br>**>8%** | **All patients** N=77<br>4 (0-25)<br>**People with atopic asthma** n=60<br>4.10 (1-25)<br><br>**Log serum ECP concentration** = 0.75<br>**Log blood eosinophil %** = 0.76<br><br>**>4%**<br>**Sensitivity** 62%<br>**Specificity** 67%<br>**PPV %** 56%<br>**PLR** 1.9<br><br>**>8%**<br>**Sensitivity** 38%<br>**Specificity** 93%<br>**PPV %** 78%<br>**PLR** 5.4 | <u>Source of funding:</u><br>National Asthma Campaign and the Northern Ireland Chest Heart and Stroke Association.<br><br><u>Limitations:</u><br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br><u>Additional data:</u><br>Serum eosinophil percentages in BAL and blood were lowest (NS) when last symptoms occurred more than 12 weeks previously |

**Table 97: SILVESTRI 2001A[1600]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|
| M. Silvestri, F. Sabatini, D. Spallarossa, L. Fregonese, E. Battistini, M. G. Biraghi, and G. A. Rossi. Exhaled nitric oxide levels in non-allergic and allergic mono- or polysensitised children with asthma. *Thorax* 56 (11):857-862, 2001.<br><br>SILVESTRI 2001A | Study type:<br>Case-control<br><br>Data source:<br>Children with asthma referred to outpatient department.<br><br>Setting:<br>Outpatients (secondary care)<br><br>Country:<br>Italy<br><br>Recruitment:<br>Dates not reported. | N = 112 (N=26 additional healthy controls, but data not given).<br><br>Inclusion criteria:<br>• Children<br>• History of mild asthma<br>• Positive response to methacholine challenge<br>• Stable clinical condition<br>• Not taken inhaled steroids at least in the year before the study<br><br>Exclusion criteria:<br>None reported. | Male: Female<br>58%:42%<br><br>Mean age (SD):<br>10.6 (0.3), range 0-18 years.<br><br>Types of asthma:<br>• Non-allergic: n=56<br>• Sensitised: n=56<br>○ Monosensitised (dust mites): n=23<br>○ Polysensitised (dust mites and at least one other allergen class): n=33<br><br>Current smokers:<br>N/A<br><br>Current anti-asthma Tx:<br>None reported.<br><br>Drop-outs/missing values:<br>None reported. | Index test<br>**Peripheral blood eosinophils**<br>• Technicon H6000.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>Asthma. | **Population: asthma** | **Eosinophils, % and median (IQR)** | | Source of funding:<br>None reported.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |
| | | | | | | **%** | **Cells/mm$^3$** | |
| | | | | | All allergic | 7.5 (5.0-11.8) | 500 (370-855) | |
| | | | | | Mono-sensitised | 6.9 (5.3-13.7) | 500 (370-893) | |
| | | | | | Poly-sensitised | 8.3 (4.9-10.0) | 500 (263-750) | |
| | | | | | Non-allergic | 2.5 (1.6-4.2) | 125 (100-300) | |
| | | | | | **Children with allergic asthma had SS higher blood eosinophilia - % and absolute numbers:**<br>• median difference %: 4.6, 95% CI 3.2-5.9; p=0.0001<br>• median difference cells/mm$^3$: 375, 95% CI 237.9 – 512.1, p=0.0001<br><br>**There was NS difference between mono- and poly-sensitised children (p>0.1).** | | | |

**Table 98: SILVESTRI 2003[1603]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| M Silvestri, F Sabatini, R Sale, AC Defilippi, L Fregonese, E Battistini, MG Biraghi, and GA Rossi. Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals. *Pediatr.Pulmonol.* 35 (5):358-363, 2003.<br><br>SILVESTRI 2003 | Study type:<br>Case-control<br><br>Data source:<br>Children with atopic asthma and age/gender matched children with non-atopic asthma referred to outpatient department.<br><br>Setting:<br>Outpatients (secondary care)<br><br>Country:<br>Italy<br><br>Recruitment:<br>Dates not reported. | N = 92<br><br>Inclusion criteria:<br>• Children<br>• History of mild asthma<br>• Atopic or non-atopic<br>• Not have upper or lower RTIs 2 months before study<br>• Not taken anti-asthma Tx (except for $\beta_2$-agonists as necessary – which were avoided 12hrs before study).<br><br>Exclusion criteria:<br>None reported. | Male: Female<br>65%:35%<br><br>Mean age (SD):<br>10.7 (0.3) years.<br><br>Types of asthma:<br>• Atopic: n=66<br>• Non-atopic: n=26<br><br>Current smokers:<br>N/A<br><br>Current anti-asthma Tx:<br>None reported.<br><br>Drop-outs/missing values:<br>None reported. | Index test **Peripheral blood eosinophils**<br>• Technicon H6000.<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>• Asthma.<br>• Atopic/non-atopic diagnosed according to SPT to common aeroallergens (those sensitised to pollen were tested outside of the pollen season) | **Population: asthma** | **% eosinophils, Median (IQR)**<br>**%** | Source of funding:<br>None reported.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | All | 5.5 (3.0-9.8) | |
| | | | | | Atopic | 6.7 (4.6-10.7) | |
| | | | | | Non-atopic | 3.0 (1.8-4.3) | |
| | | | | | **Children with atopic asthma had SS higher blood eosinophilia than non-atopic (p=0.001).**<br><br>**Within the atopic group, there was NS difference between mono- and poly-sensitised children (p>0.05).** | | |

**Table 99: TILEMANN 2011[1756]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| L Tilemann, L Gindner, F Meyer, J Szecsenyi, and A Schneider. Differences in local and systemic inflammatory markers in patients with obstructive airways disease. *Prim.care respir.j.* 20 (4):407-414, 2011.<br><br>TILEMANN 2011 | Study type: Diagnostic Cross-sectional study<br><br>Data source: Consecutive pts with suspected obstructive airways disease (OAD).<br><br>Setting: Primary care<br><br>Country: Germany<br><br>Recruitment: Dates not mentioned. | N = 210<br>(**FINAL Dx:** N=86 asthma, N=36 COPD, N=13 partial reversibility, N=75 No OAD)<br><br>Inclusion criteria:<br>• Pts presenting for first time to GP with complaints suggestive of OAD<br>• Symptoms: dyspnoea, coughing and/or expectoration persisting for at least 2 months.<br><br>Exclusion criteria:<br>• Respiratory tract infections in the previous 6 weeks<br>• Well-known contraindications for bronchodilator reversibility testing or bronchial provocation – pregnancy, untreated hyperthyroidism, unstable coronary artery disease, and cardiac arrhythmia. | Male: Female<br>45%:55%<br><br>Mean age:<br>49 years<br><br>Current smokers:<br>39%<br><br>Current anti-asthma Tx:<br>5.2% (inhaled corticosteroids)<br><br>Drop-outs/missing values:<br>• Eosinophils: N=13<br>• FeNO: N=54<br><br>Pts were instructed not to use any bronchodilator or inhaled steroid and to stop smoking 12 hrs before assessments. | Index test **Peripheral blood eosinophils**<br>• Flow cytometry (ADVIA system)<br><br>**OPTIMAL CUT-OFF:** positive = 4.15%.<br><br>Reference standard **Bronchodilation test (salbutamol)** Pts with $FEV^1$ <80% predicted received BDT with additional whole body plethysmography 20 mins after inhaling 400µg salbutamol. If no obstruction in the first lung function test, a BPT with methacholine was performed.<br>Diagnoses:<br>• COPD (irreversible OAD): FEV1 <12% and <200mL compared to baseline,).<br>• Asthma: (fully reversible OAD): reversibility in FEV1 >12% and >200mL | **Asthma** | Ref std + | Ref std – | Total | Source of funding: Federal Ministry of Education and Research, Germany.<br><br>Limitations: Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |
| | | | | | Eosin + ≥4.15% | - | - | - | |
| | | | | | Eosin - ≥4.15% | - | - | - | |
| | | | | | Total | 86 | 124 | 210 | |
| | | | | | Sensitivity<br>Specificity | | 36%<br>83% | | |
| | | | | | PPV<br>NPV<br>PLR and NLR | | 59%<br>65%<br>- | | |
| | | | | | AUC | | 0.602<br>(95% CI 0.50–0.68) | | |
| | | | | | % eosinophils in asthma pts, mean (SD) | | 4.1 (3.1);<br>95% CI 3.3-4.7.<br>Median 3.2 | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | | | | compared to baseline).<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Asthma. N=86 were diagnosed with asthma. | | | |

**Table 100: TOMASIAKLOZOWSKA 2012[1771]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| MM Tomasiak-Lozowska, Z Zietkowski, K Przeslaw, M Tomasiak, R Skiepko, and A Bodzenta-Lukaszyk. Inflammatory markers and | <u>Study type:</u><br>Case-control<br><br><u>Data source:</u><br>Pts and healthy volunteers.<br><br><u>Setting:</u><br>Not | 110 (N=91 asthma)<br><br><u>Inclusion criteria:</u><br>• Asthma (mild allergic – all atopic and sensitised to common inhaled allergens by SPT).<br>• Healthy controls: | <u>Male: Female:</u> 50%/50%<br><u>Mean age:</u> 38 years<br><u>Current smokers:</u> None.<br><br><u>Diagnoses (GINA criteria):</u><br>• 1. Healthy controls: n=19.<br>• 2. Stable* asthma, steroid naïve (no ICS Tx in past 3 mths): n=22.<br>• 3. Stable* asthma, ICS Tx (mild to | <u>Index test</u><br>**Peripheral blood eosinophils**<br>• Haematologic analyser (Coulter).<br><br>**CUT-OFF:** N/A | **Population (baseline)**<br><br>Healthy controls<br><br>Stable asthma (no ICS) | **Eosinophils, mean**<br>cells/$mm^3$<br>**32.0**<br><br>**29.5** | <u>Source of funding:</u><br>Grant number given but details not specified.<br><br><u>Limitations:</u><br>Overall - LOW/UNCLEAR |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients. *Int.Arch.Allergy Immunol.* 159 (2):121-129, 2012.<br><br>TOMASIAKLOZOWSKA 2012 | reported.<br><br>Country:<br>Poland.<br><br>Recruitment:<br>Not reported. | free of RTIs within past 3 months and other significant illness known to affect FeNO mmmts.<br><br>Exclusion criteria:<br>• Asthma exacerbation<br>• Respiratory disease<br>• Concomitant heart, renal, liver or collagen disease<br>• RTI in the mouth. | moderate, low to medium ICS dose at constant dose for ≥3 mths): n=35.<br>• 4. Severe, unstable asthma, ICS Tx (required ≥1 hospitalisations for asthma and >3 oral steroid bursts in previous year. Taking high doses of ICS and LABA ≥6 mths): n=34.<br><br>*stable asthma = minimal need for rescue medication (SABA), no exacerbations and no use of systemic steroids in past 12 mths.<br><br>Current anti-asthma Tx:<br>Mild to moderate asthma pts had been Tx with constant low to medium doses of ICS for ≥3 mths.<br><br>Drop-outs/missing values: None reported. | Reference standard<br>N/A<br><br>Time between index test and reference standard: N/A<br><br>Target condition<br>• Asthma. | Stable asthma (ICS) | **42.4** | RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | Unstable asthma (ICS) | **49.8** | |
| | | | | | No other details of results reported for eosinophil counts. | | |

**Table 101: TUCHINDA 1987[1797]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| M. Tuchinda, S. Habananada, J. Vareenil, N. Srimaruta, | Study type:<br>Case series (prospective)<br><br>Data source: | N = 1000 measured for blood eosinophils (N=2000 whole study) | Male: Female<br>61%:39%<br><br>Age:<br><13 years | Index test **Peripheral blood eosinophils**<br>• Method not reported.<br><br>**CUT-OFF:** Not reported. | **Eosinophil counts (cells/mm$^3$)** | **%** | Source of funding:<br>None reported. |
| | | | | | 0 - 500 | 39.8 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| and K. Piromrat. Asthma in Thai children: a study of 2000 cases. *Ann.Allergy* 59 (3):207-211, 1987.<br><br>TUCHINDA 1987 | Prospective study of 2000 children with asthma<br><br>Setting:<br>Outpatients (secondary care)<br><br>Country:<br>Thailand<br><br>Recruitment:<br>December 1972-1985 | Inclusion criteria:<br>• Age <13 years<br>• Diagnosis of bronchial asthma.<br><br>Exclusion criteria:<br>None reported. | Severity of asthma:<br>• Mild: 29%<br>• Moderate: 61%<br>• Severe: 9.6%<br><br>Current smokers:<br>N/A<br><br>Current anti-asthma Tx: 7% previous CS treatment; and 23% had been hospitalised with asthma.<br><br>Drop-outs/missing values:<br>Not reported | Reference standard :<br>N/A<br><br>Time between index test and reference standard: unclear<br><br>Target condition<br>Asthma. 63% of pts had other allergic diseases. | 501 - 1000<br>1001 - 1500<br>1501 - 2000<br>>2000 | 29.4<br>15.7<br>8.6<br>6.5 | Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data: N/A |

**Table 102: VILA-INDURAIN 1999[1865]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| B. Vila-Indurain, F. Munoz-Lopez, and M. Martin- | Study type:<br>Case-control<br><br>Data source: | N = 57 (includes n=21 healthy controls) | Male: Female<br>Not reported.<br><br>Mean age: | Index test<br>**Peripheral blood eosinophils**<br>• Flow cytometry. | **Population (baseline – pre BPT)**<br><br>Healthy controls | **Eosinophils, mean (SD)**<br>**Cells/mm$^3$**<br><br>161 (77) | Source of funding:<br>None reported.<br><br>Limitations: |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Mateos. Evaluation of blood eosinophilia and the eosinophil cationic protein (ECP) in the serum of asthmatic children with varying degree of severity. *Allergol.Immunopathol.(Madr).* 27 (6):304-308, 1999.<br><br>VILA-INDURAIN 1999 | Selection of children with asthma and control healthy children.<br><br>Setting: Not reported.<br><br>Country: Spain<br><br>Recruitment: Dates not reported. | Inclusion criteria:<br>• Children age 8-18 years with asthma or healthy controls.<br><br>Exclusion criteria: None reported. | Range 8-18 years.<br><br>Diagnoses:<br>• 1. Healthy controls (negative allergy and respiratory function tests): n=21<br>• 2. Asthma (favourably evolving, with normal $FEV_1$): n=19<br>• 3. Asthma (below normal $FEV_1$ that normalised with salbutamol): n=13<br>• 4. Asthma (below normal $FEV_1$ that did not recover after bronchodialtion test): n=14<br><br>Current smokers:<br>N/A<br>Current anti-asthma Tx:<br>Not reported.<br>Drop-outs/missing values:<br>None reported. | **CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Asthma. | 1. Asthma – normal $FEV_1$ | 509 (311) | Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |
| | | | | | 2. Asthma – below normal $FEV_1$ normalised with SABA | 397 (230) | |
| | | | | | 3. Asthma – below normal $FEV_1$ not normalise after SABA | 319 (152) | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

**Table 103: ZIETKOWSKI 2006A[1980]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Z. Zietkowski, | Study type: | 140 (N=101 asthma) | Male: Female | Index test | **Population** | **Eosinophils,** | Source of |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| A. Bodzenta-Lukaszyk, M. M. Tomasiak, R. Skiepko, and M. Szmitkowski. Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naive asthma patients. *J.Investig.Allergol.Clin.Immunol.* 16 (4):239-246, 2006.<br><br>ZIETKOWSKI 2006A | Case-control<br><br>Data source:<br>Asthma pts and healthy volunteers.<br><br>Setting:<br>Not reported.<br><br>Country:<br>Poland.<br><br>Recruitment:<br>Not reported. | Inclusion criteria:<br>• Asthma: stable condition, free from acute exacerbations and RTIs in previous 2 mths.<br>• Healthy: FEV1 > 80% predicted. Free of RTIs for 2 mths before study and from other significant illnesses known to affect FeNO mmts.<br><br>Exclusion criteria:<br>• Factors that could alter FeNO (such as smoking and nitrate rich diet, but not asthma)<br>• Features of atopy or allergic rhinitis<br>• Tx with ICS in the past. | 41%/59%<br><br>Mean age:<br>35.2 years.<br><br>Diagnoses (GINA criteria and history of symptoms and SPT for allergic rhinitis):<br>• 1. Healthy controls: n=39.<br>• 2. Allergic asthma: n=56.<br>• 3. Non-allergic asthma: n=45.<br><br>Current smokers: Not reported.<br><br>Current anti-asthma Tx:<br>Prior to study, pts allowed to take SABA and LABA.<br><br>Drop-outs/missing values:<br>None reported. | **Peripheral blood eosinophils**<br>• Haematologic analyser (Coulter).<br><br>**CUT-OFF:** N/A<br><br>Reference standard<br>N/A<br><br>Time between index test and reference standard:<br>N/A<br><br>Target condition<br>• Asthma. | **(baseline)**<br>Healthy controls<br>Allergic asthma<br>Non-allergic asthma<br><br>• Asthma: SS higher PBE than healthy controls (P<0.05)<br>• Allergic asthma: NS higher PBE than non-allergic asthma. | **mean** cells/mm$^3$<br>**119**<br>**247**<br>**211** | funding:<br>None reported.<br><br>Limitations:<br>Overall - LOW/UNCLEAR RIK OF BIAS.<br><br>Additional data:<br>N/A |

# G.12 Histamine and methacholine challenge tests for diagnosis

**Table 104: ANDERSON 2009[44,48]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Anderson et al. 2009. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Resp Res 10: 4.[44,48] | Study type:<br>Diagnostic cross sectional study<br><br>Recruitment:<br>Not mentioned | N = 391 (16 not included in PP analysis reported N=375)<br>Adults and children/youngpeople.<br>Sn/sp given for:<br>• all ages<br>• <18 yrs only<br>Inclusion criteria:<br>Aged 6-50 yrs (BMI<35) with signs and symptoms suggestive of asthma according to the NIH questionnaire.<br>• At least step 1 symptoms according to the NAEPPII asthma severity grading (symptoms ≤2 times per week; asymptomatic between exacerbations; exacerbations of only a few hrs to a few days; night time symptoms ≤2 times | Male: Female<br>182/193<br><br>Mean age:<br>24.3 (10.2)<br>range 6-50<br>Children n=96<br>Adults n=279<br><br>Medications:<br>Withholding periods of medications summarised in table in paper for inhaled agents, oral BD, CS, other medications, foods, strenuous exercise and tobacco. | Index test<br>MCT – methacholine (Provocholine, CA) delivered from a nebulizer (DeVilbiss 646) by the dosimeter method. Concentrations were 0.0312, 0.0625, 0.125, 0.25, 0.5, 1, 2, 4, 8, 16mg/ml administered (each conc required 5 inhalations and spirometry performed within 3 minutes). PC20 calculated<br><br>Cut-off: 16mg/ml<br><br>Comparator test<br>Mannitol: mannitol test kit as per standard protocol (Aridol or Osmohale Pharmaxis Ltd). FEV1 measured 60s after each dose: 0, 5, 10, 20, 40, 80, 160, 160, 160mg). 60s after the 0mg capsule, the FEV1 was measured in duplicate at the highest value taken as baseline. PD15 calculated<br><br>Cut-off: ≥15% fall in FEV1 ≤635mg | | Ref std + | Ref std - | Total | Source of funding:<br>Phase III clinical trial funded by Pharmaxis Ltd and involved in the design and statistics<br>Limitations:<br>• Indirect population: reported ages 6-50 yrs together. Children reported separately but age 6-18, not age 5-16 as in protocol.<br>• Not all patients included in analysis.<br>• Consecutive or random patient selection not reported. |
| | | | | | Index test + | 122 | 34 | 156 | |
| | | | | | Index test - | 118 | 101 | 219 | |
| | | | | | Total | 240 | 135 | 375 | |
| | | | | | Sensitivity<br>Specificity | | 50.8%<br>74.8% | | |
| | | | | | PPV<br>NPV | | 78.2%<br>46.1% | | |
| | | | | | | Mann + | Mann - | Total | |
| | | | | | Index test + | 104 | 52 | 156 | |
| | | | | | Index test - | 64 | 155 | 219 | |
| | | | | | Total | 168 | 207 | 375 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | per month)<br>• FEV1 ≥70% predicted at screening<br>Exclusion criteria:<br>• Firm diagnosis of asthma or an exclusion of the Dx of asthma<br>• Other pulmonary disease<br>• Smoked >1 cigarette per week in the past yr or a ≥10pack year smoking history<br>• Respiratory tract infection within the last 4 weeks<br>• Skin test positive to aeroallergens present in the environment during enrolment or reported worsening symptoms when exposed to these during the study<br>• Dx at screening visit as definitively having asthma (95-100% likelihood) or not having asthma (0-5% likelihood)<br>• Abnormal chest x-ray or ECG | | or 10% fall between consecutive doses.<br><br>Reference standard<br>Clinical Dx with objective test: made by respiratory physician at visit 5 with access to data on exercise challenge, history, examination, skin tests and BDR but not methacholine and mannitol challenge tests.<br><br>Time between index test and reference standard: unclear<br><br>Target condition<br>Asthma | Sensitivity 62%<br>Specificity 75%<br>PPV 66.7%<br>NPV 70.8%<br><br>**Children <18 yrs (n=115)**<br>MCT vs reference standard<br>• Sensitivity = 66.2%<br>• Specificity = 62.9% | • Unclear time between IT and RS<br>Additional data:<br>Consisted of 5 study visits. Objective tests performed on first visit and physician assigned one of 6 asthma likelihood – those with 5-95% likelihood included. Visit 2 and 3 confirmed spirometry at screening and an exercise test. Visit 4 and 5 was randomised crossover of either mannitol or methacholine. Likelihood of asthma determined again after visit 5 – but Dx of asthma for ref standard determined by physician blinded to challenge tests. |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | • Failure to observe washout of medications | | | | |

**Table 105: HEDMAN 1998[656,656]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Hedman et al. 1998. A rapid dosimetric methacholine challenge in asthma diagnostic: a clinical study of 230 patients with dyspnoea, wheezing or a cough of unknown cause. | Study type:<br>Diagnostic cross sectional study<br><br>Setting:<br>Hospital pulmonary department<br>Country:<br>Finland<br>Recruitment:<br>Consecutive patients tested with the MCT from May to Sept 1994 | N = 230<br>Adults<br>Inclusion criteria:<br>Referred due to dyspnoea, wheezing or a cough of unknown cause<br><br>Exclusion criteria:<br>Previous asthma Dx; use of inhaled steroids during the preceding 4 weeks<br><br>FEV1 of at least 65% before challenge test and no respiratory infection during previous 4 weeks. | Male: Female<br>90/140<br><br>Mean age:<br>44.3 (16)<br>Current smokers n=39<br><br>Medications:<br>- Beta2-agonist used by 58% patients with a positive MCT and 32% of patients with a negative MCT<br>- anticholinergic drug used by 5% patients with a | Index test<br>RAPID dosimetric MCT performed with a pocket turbine spirometer (MicroSpirometer, Micro Medical Instruments). An automatic, inhalation synchronised dosimeter jet nebuliser (Spira Elektro 2, Respiratory Care Centre, Finland)used for MCh delivery. After nebulisation of 33g isotonic saline, MCh delivered in four doses 80, 400, 1700, 6900µg. FEV1 measured 90s after each dose. The concentrations were 2.5, 10, 40 and 160 mg/ml. PD20 calculated<br><br>Cut-off PD20≤6900µg<br><br>Comparator test<br>None | | Ref std + | Ref std - | Total | Source of funding:<br>Not reported<br><br>Limitations:<br>• Unclear time between IT and RS<br>Additional data: |
| | | | | | Index test + | 47 | 31 | 78 | |
| | | | | | Index test - | 14 | 138 | 152 | |
| | | | | | Total | 61 | 169 | 230 | |
| | | | | | Sensitivity<br>Specificity | | 77.0%<br>81.7% | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR | | 60.3%<br>90.8% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| Resp Med 92: 32-39.[656,656] | | | positive MCT and 21% of patients with a negative MCT<br><br>No use of beta2-agonists for 12hrs prior to MCT, or any other asthma or antihistamine drug for 48hrs (terfenadine for 1 week and astemitsole for 4 weeks) | <u>Reference standard</u><br>Physician Dx with objective test (according to guidelines of the American Thoracic Society). The person who classified the patients as having or not having asthma was blinded to MCT results. Patients had to have a documented variation in FEV or PEF of 15% or greater after medication, or repeatedly a 20% or greater spontaneous daily variation in PEF monitoring during a period of 2 weeks. In addition, a 15% or greater decrease in FEV, after a specific allergen provocation or during an exercise test was a criterion for diagnosing bronchial asthma.<br><br>Time between index test and reference standard: unclear<br><br><u>Target condition</u><br>Bronchial asthma | AUC | | |

**Table 106: KOSKELA 2003** [915,915]

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Koskela et al. | <u>Study type:</u> | N=42 | <u>Male: Female</u> | <u>Index test</u> | PD15 ≤1mg/ml | Ref std + | Ref std - | Total | <u>Source of funding:</u> |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Responsiveness to three bronchial provocation tests in patients with asthma. Chest 2003: 124(6):2171.<br><br>915,915 | Comparative test vs test study<br>Data source:<br><br>Setting:<br>Outpatient clinic<br>Country:<br>Finland<br>Recruitment:<br>Consecutive patients with a new diagnosis of asthma over an 18 month period | Consecutive patients with a new Dx of asthma over a 18 month period<br>Inclusion criteria:<br>Asthma Dx based on patient history and clinical examination, including objective evidence of reversible airway obstruction (postitive exercise challenge; BDR; PEFV or PEF improvement with BD) according to the Finnish Social Insurance Institute criteria.<br><br>Exclusion criteria:<br>Previous usage of inhaled or oral CS; febrile respiratory tract infection within 4 weeks; FEV1<50% predicted; if staff physician considered COPD the most probable diagnosis. | 21/16<br>Mean age:<br>49 (44-54)<br><br>Current smokers n=6<br><br>Medications: subjects refrained from taking short-acting beta2-agonists for 6 hrs, inhaled anti-cholinergic drugs for 8 hrs, and theophylline for 24 hrs prior to HCT. | HCT – administered using Spiro Elektro 2 dosimeter nebuliser (Respiratory Care Centre, Finland) . Nebulisation time 0.4s, set to start 100ms after beginning of inspiration. Starting dose 25µg with 4-fold increases until the FEV1 fallen by 15% or max dose of 1600µg administered<br><br>Cut-off: PD15 ≤1mg and PD15 ≤0.4mg<br><br>Reference standard<br>Mannitol – spray dried powder packed in gelatin capsules containing 5, 10, 20 and 40mg (inhaled in doubling doses up to 160mg and repeated 3 times using an Inhalator). Test until 15% fall in FEV1 or cumulative dose of 635mg reached<br><br>Cut-off: >15% fall in FEV1 regardless of dose<br><br>Time between index test and reference standard: 2 days to 2 weeks.<br><br>Target condition<br>Asthma (with +ve mannitol | Index test + | 19 | 11 | 30 | Not reported<br><br>Limitations:<br>Comparator test used as reference standard as all people had asthma<br><br>Additional data:<br>Mannitol, cold air and histamine tests given in random order within 2 weeks and at least 2 days before challenges (within 3 weeks of asthma Dx). |
| | | | | | Index test - | 0 | 7 | 7 | |
| | | | | | Total | 19 | 18 | 37 | |
| | | | | | Sensitivity<br>Specificity | | 100%<br>38.9% | | |
| | | | | | PPV<br>NPV | | 63.3%<br>100% | | |
| | | | | | PD15 ≤0.4mg/ml | Ref std + | Ref std - | Total | |
| | | | | | Index test + | 16 | 2 | 18 | |
| | | | | | Index test - | 3 | 16 | 19 | |
| | | | | | Total | 19 | 18 | 37 | |
| | | | | | Sensitivity<br>Specificity<br>PPV<br>NPV | | 84.2%<br>88.9%<br>88.9%<br>84.2% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | | | | response) | | | |

**Table 107: KOWAL 2009[924,924]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kowal et al. Exhaled Nitric Oxide in Evaluation of Young Adults with Chronic Cough. 2009. Journal of Asthma 46: 692-698.[924,924] | Study type: Diagnostic cross sectional study<br>Data source: (if it comes from records for instance)<br><br>Setting: Asthma Clinic<br>Country: Poland<br>Recruitment: Patients referred by family doctors to the clinic between Sept 2000 | N = 540<br><br>Inclusion criteria: Patients referred to the asthma clinic for evaluation of chronic cough<br>Non smokers with non-productive cough of at least 8 weeks in duration, no abnormalitiy on chest radiograph and baseline lung function within normal limits<br>Exclusion criteria: Use of anti-asthma medication before the study; treatment with ACE inhibitors; use of codeine or other cough | Male: Female<br><br>Mean age: 26.5 range 18-45 years<br><br>Other Dx made were rhinitis; GERD | Index test<br>HCT – doubling concentrations of histamine (aerosol generated using a DeVilbis 646 nebuliser attached to a Rosenthal French dosimeter). Five inspiratory capacity breaths of each conc. FEV1 measured 90s after each fifth inhalation. Starting at 0.62mg/ml until 20% decrease or concentration of 32mg/ml reached.<br><br>Cut-off: 8mg/ml<br><br>Comparator test<br>FENO<br><br>Reference standard<br>Significant diurnal changes in PEF or significant improvement of FEV1 on administration of 200µg of | | Ref std + | Ref std - | Total | Source of funding:<br><br>Limitations:<br>• Consecutive or random patient selection not reported<br>• RS 6 months after IT<br>• Unclear if reference standard performed without knowledge of the results of the Index test<br>Additional data:<br>Data provided on a healthy |
| | | | | | Index test + | 166 | 0 | 166 | |
| | | | | | Index test - | 12 | 362 | 374 | |
| | | | | | Total | 178 | 362 | 540 | |
| | | | | | Sensitivity<br>Specificity | | 93.3%<br>100% | | |
| | | | | | PPV<br>NPV<br>PLR<br>NLR | | 100%<br>96.8% | | |
| | | | | | AUC | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| | and Nov2006 | suppressant; upper respiratory tract infection within 4 weeks of the study; presence of any systemic disease; contradictions to HCT. | | salbutamol according to the Global Initiative of Asthma (GINA) guidelines.<br><br>Time between index test and reference standard: 6 months (observed for 6 months after HCT before Dx)<br><br><u>Target condition</u><br>Bronchial asthma | | | control group but not included here for calculation of sn/sp |

**Table 108: NIEMINEN 1992[1241,1241]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Nieminen M.M. Unimodal Distribution of Bronchial Hyperresponsiveness to Methacholine in Asthmatic Patients. Chest: 102 (5): 1537- | <u>Study type:</u><br>Diagnostic cross sectional study<br><br><u>Data source:</u><br><br><u>Setting:</u><br>Pulmonary Department, University Hospital | N = 791<br>Adults<br><u>Inclusion criteria:</u><br>dyspnoea, wheezing, prolonged cough, or a history of asthma. referred to the clinic and tested with methacholine challenge<br><u>Exclusion criteria:</u> | <u>Male: Female</u><br>319/472<br><u>Mean age:</u><br>43.2 (SD 14.0)<br><br>179 current smokers<br><br>Oral beta-agonists and inhaled anti-cholinergic drugs were withheld for 12 | <u>Index test</u><br>MCT performed using a dosimeter technique with tidal breathing. An automatic, inhalation synchronised dosimeter jet nebuliser (Spira Elektro 2, Respiratory Care Centre, Finland) used for MCh delivery. Nebulisation time 0.5s, set to start 100ms after beginning of inspiration. After nebulisation of saline, MCh delivered in five cumulative doses of 18, 72, 270, 810, and 2,600 µg (concentration of MCh was 2.5 mg/ml for the doses 18 to 270µg and 25 mg/ml | | Ref std + | Ref std - | Total | <u>Source of funding:</u><br>Supported by a grant from Suomen Astra Ltd.<br><br><u>Limitations:</u><br>• Unclear if reference standard performed without knowledge of |
| | | | | | Index test + | 283 | 114 | 397 | |
| | | | | | Index test - | 36 | 358 | 394 | |
| | | | | | Total | 319 | 472 | 791 | |
| | | | | | Sensitivity<br>Specificity | | 88.7%<br>75.8% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | Comments |
|---|---|---|---|---|---|---|---|
| 1543[1241,1241] | Country:<br>Finland<br><br>Recruitment:<br>consecutive patients referred to pulmonary department with respiratory symptoms. March 1988 – Sept 1989 | | hours, inhaled beta-agonists for 8 hours and theophylline compounds for 48 hours before the MCT | for the doses 810 to 2,600µg). FEV1 PD20 calculated<br><br>Cut-off: 2,600µg<br><br>Comparator test<br>None<br><br>Reference standard<br>Clinical Dx according to the guidelines defined by the American Thoracic Society, a typical history with chronic or repeated symptoms, and a documented variation in FEV1 or in PEFR of more than 15 percent after medication, or repeatedly 20 percent spontaneous daily variation in PEFR monitoring during a period of two weeks. In addition, a 15 percent decrease in air flow after specific allergen provocation or in an exercise test was a criterion for diagnosing bronchial asthma.<br><br>Time between index test and reference standard: unlcear<br><br>Target condition<br>Bronchial asthma | PPV<br>NPV<br>PLR<br>NLR | 71.3%<br>90.9% | the results of the Index test.<br>• Unclear time between IT and RS<br>Additional data:<br>Data provided on a healthy control group but not included here for calculation of sn/sp |
| | | | | | AUC | | |
| | | | | | | | |

**Table 109: POPOVIC 2012[1381]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Popovic-Grle et al., 2002. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung function in the diagnosis of asthma in persons with dyspnea. Collegium Antropologicum: 26 Suppl: 119-127<br><br>REF ID: POPOVIC 2002 | Study type:<br>Cross-sectional study<br>Setting:<br>Outpatient department, University Hospital<br>Country:<br>Croatia<br>Recruitment:<br>Random | N = 195<br>Adults<br>Inclusion criteria:<br>• Referred by GP with suspected asthma and symptoms of breathlessness / dyspnoea.<br>Exclusion criteria:<br>• Serious diseases of other organ systems or the lungs (apart from those of an obstructive and/or allergic nature) | Male, %<br>51% of those given an asthma Dx<br><br>Mean age:<br>36.5 (6.2) in those given an asthma Dx (n=141)<br><br>Medications:<br>Not reported | Index test<br>Methacholine Challenge test (initial concentration of 0.03mg/ml, increased by doubling concentrations to 8mg/ml)<br><br>Cut-off: 8mg/ml suggested as highest concentration given<br><br>Comparator test<br>n/a<br><br>Reference standard<br>Dx made on the basis of questionnaire, with typicalmedical history data of occasional asthma attacks with wheezing and nocturnal awakening because of dyspnoea, and reversible bronchial obstruction after salbutamol test (no further details stated)<br><br>Time between index test and reference standard: same time<br><br>Target condition | | Ref st + | Ref st - | Total | Source of funding:<br>Not reported<br>Limitations:<br>• Details of reference standard objective test not given<br>• Unclear if RS results interpreted without knowledge of the IT results<br>• Unclear if IT results interpreted without knowledge of the RS results (but objective)<br>• Value reported in text for positive MCT result do not match other |
| | | | | | Index test + | 137 | 9 | 146 | |
| | | | | | Index test - | 4 | 45 | 49 | |
| | | | | | Total | 141 | 54 | 195 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 97.2%<br>83.3%<br><br>93.8%<br>91.8% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | Asthma | | | | | results<br><br>Additional data: |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |

## G.13 Mannitol challenge test for diagnosis

**Table 110: ANDERSON 2009[48]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Anderson et al. 2009. Comparison of mannitol and | Study type:<br>Diagnostic cross sectional study | N = 391 (16 not included in PP analysis reported N=375)<br>Adults and children/youngpeo | Male: Female<br>182/193<br><br>Mean age:<br>24.3 (10.2) range 6-50 | Index test<br>Mannitol: mannitol test kit as per standard protocol (Aridol or Osmohale Pharmaxis Ltd). FEV1 measured 60s after each dose: 0, 5, 10, 20, 40, 80, 160, 160, 160mg). 60s after the 0mg capsule, the | | Ref std + | Ref std - | Total | Source of funding:<br>Phase III clinical trial funded by Pharmaxis Ltd and involved in the design and |
| | | | | | Index test + | 134 | 34 | 168 | |
| | | | | | Index test - | 106 | 101 | 207 | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | | | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Resp Res 10: 4.[48] | Recruitment:<br>Not mentioned | ple. Sn/sp given for:<br>• all ages<br>• <18 yrs only<br>Inclusion criteria:<br>Aged 6-50 yrs (BMI<35) with signs and symptoms suggestive of asthma according to the NIH questionnaire.<br>• At least step 1 symptoms according to the NAEPPII asthma severity grading (symptoms ≤2 times per week; asymptomatic between exacerbations; exacerbations of only a few hrs to a few days; night time symptoms ≤2 times per month)<br>• FEV1 ≥70% predicted at screening<br>Exclusion criteria:<br>• Firm diagnosis of asthma or an | Children n=96<br>Adults n=279<br><br>Medications:<br>Withholding periods of medications summarised in table in paper for inhaled agents, oral BD, CS, other medications, foods, strenuous exercise and tobacco. | FEV1 was measured in duplicate at the highest value taken as baseline. PD15 calculated<br><br>Cut-off: ≥15% fall in FEV1 ≤635mg or 10% fall between consecutive doses.<br><br>Comparator test<br>Exercise: running on a treadmill whilst breathing medical grade dry air to 80-90% predicted HR (220-age) and sustained for 6 minutes. FEV1 measured 5, 10, 15 and 30 mins after and % fall in FEV1 calculated by subtracting lowest value after exercise from pre-exercise value<br><br>Cut-off: positive if fall in FEV1 ≥10%<br><br>Reference standard<br>Clinical Dx with objective test: made by respiratory physician at visit 5 with access to data on exercise challenge, history, examination, skin tests and BDR but not mannitol challenge tests.<br><br>Time between index test and reference standard: unclear | Total | 240 | 135 | 375 | statistics<br>Limitations:<br>• Indirect population: reported ages 6-50 yrs together. Children reported separately but age 6-18, not age 5-16 as in protocol.<br>• Not all patients included in analysis.<br>• Consecutive or random patient selection not reported.<br>• Unclear time between IT and RS<br>Additional data:<br>Consisted of 5 study visits. Objective tests performed on |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 55.8%<br>74.8%<br><br>79.8%<br>48.8% | | |
| | | | | | | | | | |
| | | | | | | Ex + | Ex - | Total | |
| | | | | | Index test + | 95 | 73 | 168 | |
| | | | | | Index test - | 68 | 136 | 204 | |
| | | | | | Total | 163 | 209 | 372 | |
| | | | | | Sensitivity<br>Specificity<br><br>PPV<br>NPV | | 58.6%<br>65.2%<br><br>56.5%<br>66.7% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | exclusion of the Dx of asthma<br>• Other pulmonary disease<br>• Smoked >1 cigarette per week in the past yr or a ≥10pack year smoking history<br>• Respiratory tract infection within the last 4 weeks<br>• Skin test positive to aeroallergens present in the environment during enrolment or reported worsening symptoms when exposed to these during the study<br>• Dx at screening visit as definitively having asthma (95-100% likelihood) or not having asthma (0-5% likelihood)<br>• Abnormal chest x-ray or ECG<br>• Failure to observe washout of | | <u>Target condition</u><br>Asthma | **Children <18 yrs (n=115)**<br>Mannitol vs reference standard<br>• Sensitivity = 63.2%<br>• Specificity = 81.4%<br><br>Mannitol vs Exercise<br>• Sensitivity = 60.1%<br>• Specificity = 58.5% | first visit and physician assigned one of 6 asthma likelihood – those with 5-95% likelihood included. Visit 2 and 3 confirmed spirometry at screening and an exercise test. Visit 4 and 5 was randomised crossover of either mannitol or methacholine. Likelihood of asthma determined again after visit 5 – but Dx of asthma for ref standard determined by physician blinded to challenge tests. |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Statistical measures and 2x2 tables | Comments |
|---|---|---|---|---|---|---|
| | | medications | | | | |

## G.14 Exercise challenge test for diagnosis

**Table 111: AVITAL2000[81,82]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| **Exercise, methacholine, and adenosine 5'-monophosphate challenges in children with asthma: relation to severity of the disease.** | Study type: Diagnostic Cross-sectional study<br><br>Data source: Paediatric pulmonology clinic<br><br>Setting: Secondary care<br><br>Country: | N = 135<br><br>Inclusion criteria:<br>• American Thoracic Society definition of asthma;<br><br>Exclusion criteria:<br>Upper or lower respiratory tract infection in last 4 weeks | Male: Female<br>Not stated<br><br>Mean age:<br>12.4 (3.9) range 6 to 25 years | Index test Exercise test 6 minute treadmill<br><br>**CUT-OFF:** positive = minimum fall in FEV1 of 8.2%<br><br>Reference standard **Clinical Dx**<br>Methacholine challenge (PC20 ≤8mg/mL)<br><br>Time between index test and reference standard: within 30 days<br><br>Target condition<br>Asthma | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>None<br><br>Additional data:<br>None |
| | | | | | Exercise + | 95 | 1 | 96 | |
| | | | | | Exercise - | 37 | 2 | 39 | |
| | | | | | Total | 132 | 3 | 135 | |
| | | | | | Sensitivity<br>Specificity | | 72%<br>67% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Pediatric Pulmonology: 30: 207-214<br>Avital A, Godfrey S, and Springer C 2000.<br>REF ID: **AVITAL2000.** | Israel<br><br>Recruitment:<br>Not stated | | | | | | |

**Table 112: EGGLESTON1979**[468,468]

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| **A comparison of the asthmatic response to methacholine and exercise**. Journal of Allergy and Clinical Immunology: 63: 104-110 | Study type:<br>Diagnostic Cross-sectional study<br><br>Data source:<br>University School of Medicine<br><br>Setting:<br>Secondary care | N = 45<br><br>Inclusion criteria:<br>• Young adults with asthma<br><br>Exclusion criteria:<br>None given | Male: Female<br>27:18<br><br>Mean age:<br>Range 16 to 30 years | Index test Exercise test 5 minutes treadmill<br><br>**CUT-OFF:** positive = ΔFEV1 ≥18% (cut off for 2SD from mean normal response)<br><br>Reference standard **Clinical Dx**<br>Methacholine<br><br>Time between index test and reference standard: same time<br><br>Target condition | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Not stated<br><br>Limitations:<br>No patients were methacholine-negative so specificity cannot be calculated<br><br>Additional data:<br>None |
| | | | | | Exercise + | 36 | 0 | 36 | |
| | | | | | Exercise - | 9 | 0 | 9 | |
| | | | | | Total | 45 | 0 | 45 | |
| | | | | | Sensitivity<br>Specificity | | 80%<br>Not estimable | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Eggleston PA 1979.<br>REF ID: **EGGLESTON1979**. | Country:<br>USA<br><br>Recruitment:<br>Not stated | | | Asthma | | | |

**Table 113: KERSTEN2009[852,852]**

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| Kersten ETG et al. Mannitol and exercise challenge tests in asthmatic children. Pediatric Pulmonology 2009; 44: 655-661.<br><br>KERSTEN2009 | Study type:<br>Diagnostic Cross-sectional study<br><br>Data source:<br>Outpatients<br><br>Setting:<br>Secondary care<br><br>Country:<br>The Netherlands<br><br>Recruitment: | N = 25<br><br>Inclusion criteria:<br>• Children with a history of allergic asthma and exercise induced bronchoconstriction recruited from outpatient clinic; clinically stable, otherwise healthy; FEV1 at least 70% predicted normal value; able to run on treadmill and perform reproducible spirometry | Male: Female<br>17: 8<br><br>Mean age:<br>Mean 12.4 (2.0) years | Index test Exercise challenge running with nose clip on treadmill in cold air at ice ring (temperature 1°C) for 6 minutes<br><br>**CUT-OFF:** positive = ΔFEV1%init >15% for both tests<br><br>Reference standard Mannitol challenge up to cumulative dose 6.35mg<br><br>Time between index test and reference standard: within 4 weeks<br><br>Target condition<br>Asthma | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>Pediatric Research Foundation Enschede, The Netherlands<br><br>Limitations:<br>None<br><br>Additional data:<br>None |
| | | | | | Cold air exercise + | 9 | 1 | 10 | |
| | | | | | Cold air exercise - | 4 | 11 | 15 | |
| | | | | | Total | 13 | 12 | 25 | |
| | | | | | Sensitivity<br>Specificity | | 69%<br>92% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | Not stated | <u>Exclusion criteria:</u><br>None given | | | | | |

**Table 114: KLEPACPULANIC2004**[887]

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| **Exercise and allergic diseases**. Arhiv Za Higijenu Rada i Toksikologiju: 55: 197-204<br>Klepac-Pulanic T, Macan J, Plavec D, and Kanceljak-Macan B 2004.<br>REF ID: **KLEPACPULANIC2004**. | <u>Study type:</u><br>Diagnostic Cross-sectional study<br><br><u>Data source:</u><br>Institute for Medical Research and Occupational Health<br><br><u>Setting:</u><br>Secondary care<br><br><u>Country:</u><br>Croatia<br><br><u>Recruitment:</u> | N = 35<br><br><u>Inclusion criteria:</u><br>• GINA definition of asthma; asthma symptoms and/or taking asthma medication; all positive to histamine; all met EAACI definition of allergic asthma and had positive skin prick tests to at least 1 inhalatory allergen. Allergic rhinitis patients met EAACI definition; negative to histamine; positive skin prick tests to at least 1 | <u>Male: Female</u><br>Not stated<br><br><u>Mean age:</u><br>Asthma: range 15 to 48 years; allergic rhinitis: range 15 to 45 years | <u>Index test</u> Exercise test (6 minute treadmill)<br><br>**CUT-OFF:** positive = ΔFEV1 ≥10%<br><br><u>Reference standard</u> **Clinical Dx**<br>GINA definition of asthma; asthma symptoms and/or taking asthma medication; all positive to histamine; all met EAACI definition of allergic asthma and had positive skin prick tests to at least 1 inhalatory allergen. Allergic rhinitis patients met EAACI definition; negative to histamine; positive skin prick tests to at least 1 inhalatory allergen<br>Time between index test and reference standard: same time<br><br><u>Target condition</u> | **Asthma** | Ref std + | Ref std – | Total | <u>Source of funding:</u><br>Not stated<br><br><u>Limitations:</u><br>None<br><br><u>Additional data:</u><br>None |
| | | | | | Exercise + | 5 | 0 | 5 | |
| | | | | | Exercise - | 14 | 16 | 30 | |
| | | | | | Total | 19 | 16 | 35 | |
| | | | | | Sensitivity<br>Specificity | | 26%<br>100% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| | Not stated | inhalatory allergen<br><br>Exclusion criteria:<br>Exercise test or histamine challenge contra-indicated; upper respiratory viral infection within 3 weeks | | Asthma | | | |

**Table 115: LIN1991**[1018,1018]

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | | Effect sizes | | Comments |
|---|---|---|---|---|---|---|---|---|---|
| **A bronchial response comparison of exercise and methacholine in asthmatic subjects**. Journal of Asthma: 28: 31-40 Lin CC, Wu JL, Huang WC, and | Study type:<br>Diagnostic Cross-sectional study<br><br>Data source:<br>Department of Internal Medicine Chest section<br><br>Setting:<br>Secondary care<br><br>Country: | N = 22<br><br>Inclusion criteria:<br>• People with stable unmedicated asthma; FEV1 >75% normal<br><br>Exclusion criteria:<br>None given | Male: Female<br>12:10<br><br>Mean age:<br>Range 20 to 40 years | Index test Exercise test (10 minute treadmill)<br><br>**CUT-OFF:** positive = ΔFEV1%init >20%<br><br>Reference standard **Clinical Dx**<br>Methacholine challenge<br><br>Time between index test and reference standard: Up to 3 weeks<br><br>Target condition<br>Asthma | **Asthma** | Ref std + | Ref std – | Total | Source of funding:<br>The National Science Council of China<br><br>Limitations:<br>None<br><br>Additional data:<br>None |
| | | | | | Exercise + | 9 | 0 | 9 | |
| | | | | | Exercise - | 12 | 1 | 13 | |
| | | | | | Total | 21 | 1 | 13 | |
| | | | | | Sensitivity<br>Specificity | | 43%<br>100% | | |

| Reference | Study type | Number of patients | Patient characteristics | Index test(s) and reference standard + target condition | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|
| Lin CY 1991.<br>REF ID: **LIN1991**. | Taiwan<br><br>Recruitment:<br>July 1985 to December 1988 | | | | | | |

# G.15 Questionnaires to monitor asthma control

**Table 116: MEER 2009[1818,1824]**

| Study (subsidiary papers) | SMASHING trial: Van 2009[1818,1824] (Van der meer 2010[1126,1126]) |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=200) |
| Countries and setting | Conducted in Netherlands; Setting: GP and outpatient clinic, multicentre |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Physician Dx asthma, coded according to International Classification of Primary Care |
| Stratum | Adults and young people overall: Asthma patients 18- 50 years with ICS prescription, not receiving OCS |
| Subgroup analysis within study | Not stratified but pre-specified: Level of baseline control |
| Inclusion criteria | age 18-50 years; prescription of ICS for at least 3 months in the previous year; no serious cormorbid conditions interfering with asthma treatment; access to the internet at home; Dutch language. |
| Exclusion criteria | Receiving maintenance OCS treatment. |
| Recruitment/selection of patients | September 2005 to September 2006 |

| | |
|---|---|
| Age, gender and ethnicity | Age - Range: 18-50 years. Gender (M:F): 61/139. Ethnicity: |
| Further population details | 1. Education level: Moderate/high level of education (>50% with high education level). 2. Language: Non English speaking (Dutch speaking). |
| Extra comments | Baseline data: age mean (range): Monitoring 36 (19-50); UC 37 (18-50); FEV1%pred Monitoring 88 (34-133); UC 90 (53-118); AQLQ Monitoring 5.73 (3.66-6.94); UC 5.79 (3.03-7.00); ACQ Monitoring 1.12 (0.07-3.22); UC 1.11 (0-3.86); ICS 100%; ICS/LABA 60%. |
| Indirectness of population | No indirectness |
| Interventions | (n=101) Intervention 1: Monitoring asthma control + treatment - Monitoring control questionnaires + treatment. Weekly completion of electronic ACQ and instant feedback of asthma control along with advice on how to adjust treatment according to predefined algorithm and treatment plan (treatment steps according to GINA). - Four consecutive scores ≤0.5 : decrease treatment according to plan- Two scores >0.5 but <1: increase treatment according to plan- One score ≥1 but <1.5: immediately increase according to plan- One score >1.5: immediately increase treatment and contact nurse.. Duration 12 months. Concurrent medication/care: Intervention group only - online education, face-to-face group education (two 60 min sessions) and web communications with an asthma nurseBoth groups received a prior basic education session about core information on asthma, action of medications and inhaler technique instructions. All trained to measure FEV1 daily and report highest value of 3 measurements before medications. Reported daytime and nightime symptoms and ACQ weekly. No feedback provided on ACQ or lung function.<br>Further details: 1. Additional education training : Additional education in both groups 2. Duration of study: >= 6 months<br><br>(n=99) Intervention 2: Usual care. Asthma care according to Dutch guidelines (based on GINA), recommend medical review and treatment adjustment every 2 to 4 weeks in unstable asthma and once or twice yearly for controlled asthma. Control patients had access to the part of the website on which a diary of symptoms and exacerbations was kept, but not ACQ.. Duration 12 months. Concurrent medication/care: Both groups received a prior basic education session about core information on asthma, action of medications and inhaler technique instructions. All trained to measure FEV1 daily and report highest value of 3 measurements before medications. Reported daytime and nightime symptoms and ACQ weekly. No feedback provided on ACQ or lung function.<br>Further details: 1. Additional education training : Additional education in both groups 2. Duration of study: >= 6 months |
| Funding | Academic or government funding (Netherlands organisation for health research and development, ZonMw, and Netherland Asthma Foundation) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ONGOING MANAGEMENT BASED ON ACQ SCORE versus USUAL CARE | |

| | |
|---|---|
| Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people overall: AQLQ at 12 months; MD 0.38 (95%CI 0.2 to 0.56) (P<0.001 ) AQLQ 1-7 Top=High is good outcome; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people overall: Emergency treatment, hospitalisation or OCS course at 12 months; HR 1.18 (95%CI 0.51 to 2.74) Reported; Risk of bias: High; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 3: Asthma control questionnaires at End of Treatment<br>- Actual outcome for Adults and young people overall: ACQ at 12 months; MD -0.47 (95%CI -0.64 to -0.3) (P<0.001 ) ACQ 0-6 Top=High is poor outcome; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people with uncontrolled asthma: ACQ at 12 months; MD -0.82 (95%CI -1.1 to 0.55) ACQ 0-6 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Adults and young people overall: Mean daily ICS use, µg at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people with controlled asthma: Mean daily ICS use, µg at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people with uncontrolled asthma: Mean daily ICS use, µg at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people overall: FEV1 L at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Symptom free days at End of Treatment<br>- Actual outcome for Adults and young people overall: % symptom free days in previous 2 weeks at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Rescue medication at End of Treatment; Time of school/work at End of Treatment |

**Table 117: MEHUYS 2008[1128,1128]**

| **Study** | **Mehuys 2008[1128,1128]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |

| | |
|---|---|
| Number of studies (number of participants) | 1 (n=201) |
| Countries and setting | Conducted in Belgium; Setting: Pharmacy, multicentre |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 6 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Asthma patients |
| Stratum | Adults and young people overall: Asthma patients treated for asthma for ≥12 months (not including fully controlled or severely uncontrolled) |
| Subgroup analysis within study | Not applicable: na |
| Inclusion criteria | Aged 18-50 years; treated for asthma for ≥12 months; using controller medication; regular visitor to the pharmacy. |
| Exclusion criteria | Smoking history of >10 pack-years; suffering from another severe disease and ACT at screening of <15 (indicating seriously uncontrolled asthma) or equalling 25 (complete asthma control). |
| Recruitment/selection of patients | Consecutive recruitment in 66 pharmacies from Jan 2006 - April 2006. |
| Age, gender and ethnicity | Age - Range: 18-50. Gender (M:F): 94/107. Ethnicity: |
| Further population details | 1. Education level: Not applicable / Not stated / Unclear 2. Language: Non English speaking (Non English speaking but Dutch version of ACT used). |
| Extra comments | Baseline data: Mean (range) age: Monitoring: 35.2 (19-51); Usual care: 36.3 (17-51). ACT mean (range): Monitoring: 19.7 (11-25); Usual care: 19.3 (10-25). ICS %: Monitoring: 25%; Usual care: 23.1%; LABA/ICS %: Monitoring: 64.5%; Usual care: 70.8%. |
| Indirectness of population | No indirectness |
| Interventions | (n=107) Intervention 1: Monitoring asthma control + treatment - Monitoring control questionnaires + treatment. Pharmacist intervention including initial education on inhaler technique, asthma, medication. Pharmacist advice at 1 month and 3 months based on ACT score of the patient (direct physician feedback). -ACT <15 (uncontrolled asthma): immediate referral to GP or specialist-ACT 15-19 (insufficiently controlled asthma): review inhaler technique and check controller adherence-ACT >19 (well-controlled): no advice, inform patient asthma is well-controlled. Duration 6 months. Concurrent medication/care: Education session from pharmacist at the start of the intervention in the intervention group<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Duration of study: >= 6 months<br><br>(n=94) Intervention 2: Usual care. Usual pharmacist care. Duration 6 months. Concurrent medication/care: No education at start of study as in intervention group. |

| | |
|---|---|
| | Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Duration of study: >= 6 months |
| Funding | Funding not stated |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ONGOING MANAGEMENT BASED ON ACT SCORE versus USUAL PHARMACIST CARE

Protocol outcome 1: Quality of life at End of treatment
- Actual outcome for Adults and young people overall: AQLQ at 6 months; Group 1: mean 6 (SD 0.7); n=80, Group 2: mean 5.8 (SD 0.9); n=70; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people overall: Exacerbation (ER visit, hospitalisation or course of OCS) at 6 months; Group 1: 10/80, Group 2: 8/70; Risk of bias: Very high; Indirectness of outcome: Serious indirectness

Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment
- Actual outcome for Adults and young people overall: ER visit or hospitalisation at 6 months; Group 1: 1/80, Group 2: 5/70; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Asthma control questionnaires at End of Treatment
- Actual outcome for Adults and young people overall: ACT final values at 3 months; Group 1: mean 20.3 (SD 3.2); n=99, Group 2: mean 20 (SD 3.8); n=84; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT final values at 6 months; Group 1: mean 20.2 (SD 3.5); n=80, Group 2: mean 19.7 (SD 4.8); n=70; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients controlled (score 20-25) at 3 months; Group 1: 61/99, Group 2: 52/84; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients controlled (score 20-25) at 6 months; Group 1: 54/80, Group 2: 42/70; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients partially controlled (score 15-19) at 3 months; Group 1: 32/99, Group 2: 23/84; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients partially controlled (score 15-19) at 6 months; Group 1: 19/80, Group 2: 17/70; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients uncontrolled (score <15) at 3 months; Group 1: 5/99, Group 2: 9/84; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people overall: ACT, no. of patients uncontrolled (score <15) at 6 months; Group 1: 7/80, Group 2: 11/70; Risk of bias: Very high; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcome 5: Rescue medication at End of Treatment<br>- Actual outcome for Adults and young people overall: puffs/day final values at 3 months; Group 1: mean 0.68 puffs/day (SD 1.16); n=99, Group 2: mean 1.3 puffs/day (SD 2.55); n=84; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people overall: puffs/day final values at 6 months; Group 1: mean 0.67 puffs/day (SD 1.33); n=80, Group 2: mean 0.9 puffs/day (SD 1.36); n=70; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 118: RIKKERSMUTSAERTS 2012[1464]**

| **Study** | **SMASHING trial: Rikkers-mutsaerts 2012[1464]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=90) |
| Countries and setting | Conducted in Netherlands; Setting: Primary and Secondary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Doctor Dx of mild to severe persistant asthma; not well controlled asthma as assessed by ACQ>0.75 and/or ATAQ <1.0 |
| Stratum | Children 5 -<16 with uncontrolled asthma: Children 12-18 years, asthma not well controlled asthma as assessed by ACQ>0.75 and/or ATAQ <1.0 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Aged 12-18 years; prescription of ICS for more than 3 months in the previous year; access to the internet; Dutch language |
| Exclusion criteria | Receiving maintenance OCS treatment; relevant co-morbidity. |
| Age, gender and ethnicity | Age - Range: 12-18 years. Gender (M:F): 45/45. Ethnicity: |
| Further population details | 1. Education level: Not applicable / Not stated / Unclear 2. Language: Non English speaking (Dutch speaking). |
| Extra comments | Baseline data: Age mean (range) Monitoring: 13.4 (12-17), UC: 13.8 (12-17); FEV1%pred Monitoring: 88 (49-151), UC: 92 (49-164); AQLQ Monitoring: 5.6 (3.12-6.97), UC: 5.68 (2.87-7.0); ACQ Monitoring: 1.29 (0.22-3.0), UC: 1.19 (0-3.43); % |

| | |
|---|---|
| | ICS Monitoring: 100%, UC: 100%; % ICS/LABA Monitoring: 60.5%, UC: 65%. |
| Indirectness of population | Serious indirectness: Age group indirect to protocol (12-18 years); not well controlled asthma includes partially controlled and uncontrolled (not uncontrolled alone) |
| Interventions | (n=46) Intervention 1: Monitoring asthma control + treatment - Monitoring control questionnaires + treatment. Weekly asthma control monitoring (according to ACQ score) and treatment advice. Monitoring through website, use of internet based treatment plan, online education, web communications with an asthma nurse. Weekly completion of electronic ACQ and instant feedback of asthma control along with advice on how to adjust treatment according to predefined algorithm and treatment plan (treatment steps according to GINA). Patients attended their own physician, as they would normally do, every 3–6 months and extra when needed if their asthma was deteriorating).. Duration 12 months. Concurrent medication/care: Intervention group only: online education, face-to-face group education (two 60 min sessions) and web communications with an asthma nurse.Both groups received prior basic education about asthma, medications and inhaler technique. All trained to measure FEV1 daily and report highest value of 3 measurements before medications. Reported ACQ weekly. No feedback provided on ACQ or lung function.<br>Further details: 1. Additional education training : Additional education in both groups 2. Duration of study: >= 6 months<br><br>(n=44) Intervention 2: Usual care. Usual care. Adolescents in the usual care group received care by their physician according to the Dutch guidelines on asthma management in children in general practice and in hospitals. Commonly, they visited their general practitioner or paediatrician every 3 months or twice per year once control of asthma had been achieved.. Duration 12 months. Concurrent medication/care: Both groups received prior basic education about asthma, medications and inhaler technique. All trained to measure FEV1 daily and report highest value of 3 measurements before medications. Reported ACQ weekly. No feedback provided on ACQ or lung function.<br>Further details: 1. Additional education training : Additional education in both groups 2. Duration of study: >= 6 months |
| Funding | Academic or government funding (Netherlands Asthma Foundation) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ONGOING MANAGEMENT BASED ON ACQ SOCRE versus USUAL CARE + TREATMENT

Protocol outcome 1: Quality of life at End of treatment
- Actual outcome for Children 5 -<16 with uncontrolled asthma: PAQLQ at 3 months; MD 0.4 (95%CI 0.17 to 0.62) (P<0.05 ) PAQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Children 5 -<16 with uncontrolled asthma: PAQLQ at 12 months; MD -0.05 (95%CI -0.5 to 0.41) (P=0.85 ) PAQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Exacerbation (need for OCS) at End of treatment

| | |
|---|---|
| - Actual outcome for Children 5 -<16 with uncontrolled asthma: Exacerbation requiring OCS for 3 days or more at 12 months; Group 1: 6/35, Group 2: 6/40; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Asthma control questionnaires at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: ACQ at 3 months; MD -0.32 (95%CI -0.56 to -0.079) (P<0.01 ) ACQ 0-6 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: ACQ at 12 months; MD -0.05 (95%CI -0.35 to 0.25) (P=0.75 ) ACQ 0-6 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Mean daily ICS use µg at 3 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Mean daily ICS use µg at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: FEV1 L at 3 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: FEV1 L at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Symptom free days at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Proportion of symptom free days in the previous 2 weeks at 3 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Proportion of symptom free days in the previous 2 weeks at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Rescue medication at End of Treatment; Time of school/work at End of Treatment |

# G.16 Lung function tests to monitor asthma control

**Table 119: Adams 2001[15]**

| **Study** | **Adams 2001[15]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=N=172 (no. randomised to each group not reported and also high attrition from ACA numbers - high ROB)) |

| | |
|---|---|
| Countries and setting | Conducted in Australia; Setting: Secondary care (university public teaching hospital) |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Physician's diagnosis of asthma defined by American Thoracic Society |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Age 17 to 70 years; physician's diagnosis of asthma defined by American Thoracic Society; demonstrated ability to use PFM; telephone access at home; could read and sign consent form in English |
| Exclusion criteria | Previous life-threatening attack of asthma, current or previous written asthma action plan based on symptoms or PEF; pregnancy; poor perception of bronchoconstriction during histamine inhalation test; baseline FEV1 <1.5L preventing histamine inhalation test |
| Recruitment/selection of patients | Recruited from inpatient and outpatient clinics |
| Age, gender and ethnicity | Age - Range of means: PFM group 37.3, symptoms group 35.5 years. Gender (M:F): 52:82. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=73) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Self-management action plan activated by decrease in PEF explained by specialist pulmonologist; reinforced monthly by study coordinator. Duration 12 months. Concurrent medication/care: Started or continued on appropriate dose of inhaled corticosteroids; instructed to use bronchodilator as required<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=61) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Self-management action plan activated by increase in symptoms explained by specialist pulmonologist; reinforced monthly by study coordinator. Duration 12 months. Concurrent medication/care: Started or continued on appropriate dose of inhaled corticosteroids; instructed to use bronchodilator as required<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Academic or government funding (University of Adelaide, The Queen Elizabeth Hospital Research Foundation) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT

| | |
|---|---|
| | Protocol outcome 1: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Hospitalisation days at 12 months; Group 1: mean 0.07 days (SD -0.3); n=48, Group 2: mean 0.1 days (SD 0.5); n=40; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): ED visits at 12 months; Group 1: mean 0.11 (SD 0.4); n=48, Group 2: mean 0.15 (SD 0.4); n=40; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Asthma control questionnaires at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Severity self-rating at 12 months; Group 1: mean 3.46 None (SD 3.3); n=48, Group 2: mean 3.48 None (SD 2.5); n=40; Self-rating asthma severity 0-10 Top=High is poor outcome; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Pre-bronchidilator FEV1 at 12 months; Group 1: mean 2.45 L (SD 0.82); n=48, Group 2: mean 2.71 L (SD 0.86); n=40; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Time of school/work at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Days off work at 12 months; Group 1: mean 5 days (SD 11); n=48, Group 2: mean 2.3 days (SD 4); n=40; Risk of bias: Very high; Indirectness of outcome: No indirectness |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment |

**Table 120: Buist 2006[243]**

| **Study** | **Buist 2006[243]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=296) |
| Countries and setting | Conducted in USA; Setting: Community |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 2 years |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Physician-diagnosed asthma and had medication use suggestive of moderate-to-severe asthma; bronchodilator reversibility (> 8% of baseline FEV1) |

| | |
|---|---|
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Aged 50 to 92 yr, recruited from a large managed-care organization; physician-diagnosed asthma and medication use suggestive of moderate-to-severe asthma; none was using a peak flow meter; screening criteria included bronchodilator reversibility (>8% of baseline FEV1) and demonstrated ability to keep a daily symptom diary. |
| Exclusion criteria | None apart from above |
| Recruitment/selection of patients | Screening criteria included bronchodilator reversibility (> 8% of baseline FEV1) and demonstrated ability to keep a daily symptom diary. |
| Age, gender and ethnicity | Age - Mean (SD): 66 (9.4) years. Gender (M:F): 142:154. Ethnicity: 94% were white, not of Hispanic origin; others not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=149) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Peak flow rate (twice daily or “as needed”) for asthma monitoring; four 90-min small-group classes. Development of a personalised action plan and review of the subjects’ asthma diaries; instructed in proper use of metered dose inhalers (MDIs). Interventionists also met with participants semiannually to review MDI and peak flow technique, review daily diaries, and discuss participants’ action plans. In between these meetings, they phoned participants quarterly to review diaries and answer questions . Duration 2 years. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training :<br><br>(n=147) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Symptoms for asthma monitoring; four 90-min small-group classes. Development of a personalised action plan and review of the subjects’ asthma diaries; instructed in proper use of metered dose inhalers (MDIs). Interventionists also met with participants semiannually to review MDI and peak flow technique, review daily diaries, and discuss participants’ action plans. In between these meetings, they phoned participants quarterly to review diaries and answer questions . Duration 2 years. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : |
| Funding | Academic or government funding (National Heart, Lung, and Blood Institute) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT | |

| | |
|---|---|
| Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): AQLQ increase >0.5 points at 2 years; Group 1: 52/134, Group 2: 50/128; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): AQLQ decrease >0.5 points at 2 years; Group 1: 16/134, Group 2: 11/128; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Total asthma-related health care utilisation at 2 years; Group 1: mean 1.39 Events per person-year of follow-up (SD 1.98); n=148, Group 2: mean 1.5 Events per person-year of follow-up (SD 2.23); n=146; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 121: Charlton 1990[304]**

| **Study** | **Charlton 1990[304]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=115 Patients (46 children and 69 adults)) |
| Countries and setting | Conducted in United Kingdom; Setting: General practice |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Patients on the repeat prescribing register who were receiving prophylactic treatment for asthma. |
| Stratum | Adults and young people (16 years and over) |

| | |
|---|---|
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients on the repeat prescribing register who were receiving prophylactic treatment for asthma. |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | Patients on the repeat prescribing register who were receiving prophylactic treatment for asthma. |
| Age, gender and ethnicity | Age - --: Not stated. Gender (M:F): Not stated. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=51) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Peak flow self-management plan. The first interview usually took 45 minutes. One week later the patients were reviewed by the nurse for a further 15 minutes, when spirometry was again performed and inhaler technique checked. Progress with self monitoring and self management were checked and treatment altered, if necessary, after discussion with the patient's general practitioner. Topics such as smoking, holidays, provoking factors, and emergency treatments were discussed in the course of the follow up visits. All the patients were reviewed every eight weeks by the nurse or more often if she considered it necessary.. Duration 12 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=64) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Symptoms self-management plan. The first interview usually took 45 minutes. One week later the patients were reviewed by the nurse for a further 15 minutes, when spirometry was again performed and inhaler technique checked. Progress with self monitoring and self management were checked and treatment altered, if necessary, after discussion with the patient's general practitioner. Topics such as smoking, holidays, provoking factors, and emergency treatments were discussed in the course of the follow up visits. All the patients were reviewed every eight weeks by the nurse or more often if she considered it necessary.. Duration 12 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Academic or government funding (Clare Wand fund, the Scientific Foundation of the Royal College of General |

| | |
|---|---|
| | Practitioners, and Vitalograph) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Receiving oral steroids at 12 months; Group 1: 14/27, Group 2: 7/33; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : Receiving oral steroids at 12 months; Group 1: 7/19, Group 2: 0/27; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Rescue medication at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Requiring nebulised salbutamol at 12 months; Group 1: 3/28, Group 2: 2/37; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : Requiring nebulised salbutamol at 12 months; Group 1: 2/17, Group 2: 0/27; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 122: Cote 1997[369]**

| **Study** | **Cote 1997[369]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=188) |
| Countries and setting | Conducted in Canada; Setting: Three tertiary care hospitals |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: The diagnosis had to be confirmed by either a documented reversibility greater than 15% in FEV1 or a methacholine PC20<8mg/ml |

| | |
|---|---|
| Stratum | Adults and young people (16 years and over): Aged 16 years or older |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Presence of moderate to severe asthma; aged 16 years or older; the need to take daily anti-inflammatory agents (ICS, cromoglycate or nedocromil). |
| Exclusion criteria | Current or ex-smokers 40 years of age or older in whom the best FEV1 after salbutamol was <80% predicted; patients with significant concurrent diseases; tose requiring >7.5mg/day of prednisone to control asthma symptoms, those having taken part in an asthma educational program. Subjects in whom regular OCS were needed to obtain good asthma control during the run-in period were excluded. |
| Recruitment/selection of patients | At time of hospitalisation or visit to the clinic between April and December 1993 |
| Age, gender and ethnicity | Age - Range: ≥16 years. Gender (M:F): 37/58. Ethnicity: |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=50) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Self-management based on twice daily PEF. - Step 1: green zone, morning PEF ≥85% best, continue maintenance treatment- Step 2: yellow zone, for past 24 hours PEF 60-85% best, increase BDP to 4 puffs twice daily (2000mcg/day) until PEF % best returns, or if there is no increase in PEF within 48 hours proceed to step 3.- Step 3: red zone, for past 12 hours PEF <60% best, inform physician and start OCS- Step 4: red extra zone, PEF <50% best, visit physician or ER.. Duration 12 months. Concurrent medication/care: 2-6 week run-in period when medication adjusted according to the International Consensus on asthma therapy. In patients receiving budesonide, this was replaced by an equivalent dose of inhaled beclomethasone dipropionate (BDP). In patients considered unstable during run-in period (nighttime symptoms, four or more puffs/day of inhaler beta-agonist, PEFv>15%, post-BD FEV1<85%, mean PEF <85%) the dose of BDP could be doubled or theophyllines added. Subjects in whom regular OCS were needed to obtain good asthma control were excluded. Both groups received counselling with an educator during a 1 hour session.<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=45) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Self-management based on symptoms. - Step 1: green zone, not awakened at night, using usual SABA and able to perform usual activities, continue maintenance treatment- Step 2: yellow zone, for previous 24 hours using twice as much SABA, awakened at night and unusual breathlessness with exercise, increase BDP to 4 puffs twice daily (2000mcg/day) until PEF % best returns, or if there is no increase in PEF within 48 hours proceed to step 3.- Step 3: red zone, for past 24 hours SABA relieving symptoms for <4 hours or more than 10puffs/day, inform physician and start OCS- Step 4: red extra zone, SABA relieving symptoms for <2 hours and difficulty talking, inform physician and visit ER.. Duration 12 months. Concurrent |

| | |
|---|---|
| | medication/care: 2-6 week run-in period when medication adjusted according to the International Consensus on asthma therapy. In patients receiving budesonide, this was replaced by an equivalent dose of inhaled beclomethasone dipropionate (BDP). In patients considered unstable during run-in period (nighttime symptoms, four or more puffs/day of inhaler beta-agonist, PEFv>15%, post-BD FEV1<85%, mean PEF <85%) the dose of BDP could be doubled or theophyllines added. Subjects in whom regular OCS were needed to obtain good asthma control were excluded. Both groups received counselling with an educator during a 1 hour session.<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Study funded by industry (Supported by a grant from Glaxo Canada, Mississauga (Ontario)) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): OCS courses at 12 months; Group 1: mean 0.7 number of events (SD 1.4); n=50, Group 2: mean 0.9 number of events (SD 1.3); n=45; Risk of bias: Very high; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 2: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Hospitalisation at 12 months; Group 1: mean 0.04 number of events (SD 0.28); n=50, Group 2: mean 0.09 number of events (SD 0.27); n=45; Risk of bias: Very high; Indirectness of outcome: Serious indirectness<br>- Actual outcome for Adults and young people (16 years and over): ER visits at 12 months; Group 1: mean 0.7 number of events (SD 1.4); n=50, Group 2: mean 0.7 number of events (SD 1.3); n=50; Risk of bias: Very high; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 3: Time of school/work at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Mean number of days lost from school or work at 12 months; Group 1: mean 2.2 number of days lost (SD 12.7); n=50, Group 2: mean 2.9 number of days lost (SD 12.7); n=45; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment |

**Table 123: Cowie 1997[374]**

| **Study** | **Cowie 1997[374]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |

| | |
|---|---|
| Number of studies (number of participants) | 1 (n=150) |
| Countries and setting | Conducted in Canada; Setting: Secondary care |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 6 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Adult and adolescent patients who had received urgent treatment for their asthma in the preceding 12 months and used asthma medication |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Adult and adolescent patients who had received urgent treatment for their asthma in the preceding 12 months and used asthma medication |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | Subjects were recruited by contacting those who had been treated for an exacerbation of asthma in an emergency department in one of the teaching hospitals in the city of Calgary. Subjects were also recruited from those attending a university asthma clinic when they gave a history of having received urgent treatment for their asthma in the previous 12 months. |
| Age, gender and ethnicity | Age - Range of means: 36.4 to 39.1 years. Gender (M:F): 56:83. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=48) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Patients were given a peak flowmeter and brief instructions in its use and in recording the data. Their action plan included peak flow measurements that were estimated from their measured and predicted peak expiratory flows. Peak flow readings at or below which each step should be initiated were written into each subject's action plan. Doubling of their inhaled corticosteroid was recommended when the peak expiratory flow was <70% of their estimated best reading or when the diurnal variation was >20%. Initiation of the third step (prednisone) was advised at <50%, and the fourth step (urgent treatment in an emergency department) at <30% of their estimated best peak expiratory flow.. Duration 6 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training :<br><br>(n=50) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. The instructions for the symptom-based plan listed common symptoms of asthma, including waking at night or a persistent cough and |

| | |
|---|---|
| | symptoms of a common cold as indications for doubling their inhaled corticosteroid. The third step required the introduction of prednisone if their relief following the use of a bronchodilator lasted <2 h or if they became short of breath doing their normal daily activities. The fourth step required them to seek urgent treatment if their bronchodilator provided relief for <30 min or if their breathing made it difficult for them to speak.. Duration 6 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : |
| Funding | Academic or government funding (Foothills Hospital Calgary) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Visits for urgent treatment of asthma at 6 months; Group 1: 5/46, Group 2: 14/45; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Hospital admissions at 6 months; Group 1: 2/46, Group 2: 2/45; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 124: Kaya 2009[835]**

| **Study** | **Kaya 2009[835]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=63) |
| Countries and setting | Conducted in Turkey; Setting: Secondary care |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Patients with persistent asthma; had been receiving care for at least 1 year in specific asthma clinic; classified by GINA guidelines on illness severity |

| | |
|---|---|
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients with persistent asthma; had been receiving care for at least 1 year in specific asthma clinic; classified by GINA guidelines on illness severity |
| Exclusion criteria | Significant co-morbid conditions; illiteracy; hearing and visual defects; mental retardation; psychotic disorders |
| Recruitment/selection of patients | Specific asthma clinic |
| Age, gender and ethnicity | Age - Mean (SD): 43 (10.48) years. Gender (M:F): 13:50. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=31) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. PEF-based self-management. Duration 12 months. Concurrent medication/care: Standard education programme on asthma self-management prepared according to GINA recommendations given to patients with booklet for keeping daily reords<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=32) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Symptom-based self-monitoring. Duration 12 months. Concurrent medication/care: Standard education programme on asthma self-management prepared according to GINA recommendations given to patients with booklet for keeping daily reords<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Funding not stated |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT

Protocol outcome 1: Quality of life at End of treatment
- Actual outcome for Adults and young people (16 years and over): SF-36 physical score at 3 months; Group 1: mean 58.81 None (SD 21.98); n=31, Group 2: mean 65.3 None (SD 21.31); n=32; SF-36 Physical 0-100 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people (16 years and over): SF-36 mental score at 3 months; Group 1: mean 62.39 None (SD 19.1); n=31, Group 2: mean 74.17 None (SD 15.51); n=32; SF-36 Mental 0-100 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Lung Function at End of Treatment
- Actual outcome for Adults and young people (16 years and over): FEV1 (%) at 6 months; Group 1: mean 87.74 % (SD 19.02); n=31, Group 2: mean 87.35 % (SD 21.25); n=32; Risk of bias: Very high; Indirectness of outcome: No indirectness

| | |
|---|---|
| - Actual outcome for Adults and young people (16 years and over): PEF (% personal best) at 6 months; Group 1: mean 84.93 % (SD 14.32); n=31, Group 2: mean 79.62 % (SD 14.92); n=32; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 125: Letz 2004[996]**

| **Study** | **Letz 2004[996]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=50) |
| Countries and setting | Conducted in USA; Setting: Allergy, asthma and immunology clinic |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 3 month |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Diagnosed with mild to severe persistent asthma (symptoms at least 2 times per week, FEV1<80% and FEV1 or PEF variability 12% or greater). Diagnosis made on the basis of history, examination and pre/post-BD lung function testing. |
| Stratum | Children 5 -<16 : 6-12 years |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | 6-12 years, diagnosed with mild to severe persistent asthma (symptoms at least 2 times per week, FEV1<80% and FEV1 or PEF variability 12% or greater), new diagnosis and initiation of daily ICS. |
| Exclusion criteria | nr |
| Recruitment/selection of patients | Consecutive recruitment at 2 week follow up after diagnosis and initiation of ICS. |
| Age, gender and ethnicity | Age - Range of means: 8.9-9.4. Gender (M:F): 32/18. Ethnicity: Caucasian |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=26) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Action plan based on |

| | |
|---|---|
| | patient's measured and predicted PEF values. Yellow zone recommended when PEF 60-80%, red zone when PEF <60%. Best of 3 consecutive PEF readings recorded daily. Baseline therapy with ICS (green zone), step-up of ICS and beta-agonists used every 4 hours (yellow zone), call office or present to emergency room (red zone). . Duration 3 months. Concurrent medication/care: All provided with asthma education session from a nurse including use of the action plan. Further details: 1. Additional education training : Additional education in both groups<br><br>(n=25) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Action plan based on symptoms only. Common symptoms including persistent cough, symptoms of common cold, dyspnoea as indications for initiating yellow zone. Red zone if relief following a BD lasted less than 2 hours. Baseline therapy with ICS (green zone), step-up of ICS and beta-agonists used every 4 hours (yellow zone), call office or present to emergency room (red zone).. Duration 3 months. Concurrent medication/care: All provided with asthma education session from a nurse including use of the action plan.<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Funding not stated |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 : Required a course of OCS at 3 month; Group 1: 1/12, Group 2: 1/12; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 126: Lopez-vina 2000[1039]**

| **Study** | **Lopez-vina 2000[1039]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=150) |
| Countries and setting | Conducted in Spain |

| | |
|---|---|
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 12 month |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Satisfied the ATS definition of asthma, with symptoms of episodic wheezing, cough and shortness of breath responding to bronchodilators, and reversible airflow obstruction documented on at least one previous pulmonary function study (>20% increase in FEV1 or PEF following salbutamol 0.2mg). In patients with normal spirometry and lac of functional assessment of asthma previously, a methacholine test was performed. |
| Stratum | Adults and young people (16 years and over): 17-65 years of age |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | 17-65 years of age; required treatment in an ED of acute-care hospitals over an 18-month period because of an episode of acute asthma exacerbation; symptomatic disease during the previous year; satisfied the ATS definition of asthma with BDR or BHR. |
| Exclusion criteria | Concurrent chronic diseases (COPD, emphysema, cystic fibrosis, severe rheumatoid arthritis, neoplasia etc) |
| Recruitment/selection of patients | Consecutive patients who required treatment in an ED over an 18-month period |
| Age, gender and ethnicity | Age - Range: 17-65. Gender (M:F): 49/51. Ethnicity: |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=75) Intervention 1: Monitoring lung function + treatment - Monitoring PEF and symptoms + treatment. Self-management plan with a card of colour codes based on symptoms, medication and PEF. Physician assessment at 15 days, 1 month and then every 3 months at which treatment adjusted according to symptoms, spirometric data and variability in PEF (less than 10% variability considered irrelevant). Duration 12 months. Concurrent medication/care: Medical regimes tailored to each patient and included the administration of beta-agonists when needed in mild asthma; inhaled salbutamol 0.2mg or terbutaline 0.5mg and budesonide 400mcg every 12 hours in moderate to severe asthma with FEV1>80%; and inhaled salbutamol 0.2mg or terbutaline 0.5mg and budesonide 800mcg every 8 hours or when needed and prednisone 40mg/day for 14 days in moderate to severe asthma with FEV1<80%. Patients in both groups received asthma education.<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=75) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Self-management plan based on symptoms only. Physician assessment at 15 days, 1 month and then every 3 months at which treatment adjusted according to symptoms and spirometric data only.. Duration 12 months. Concurrent medication/care: Medical regimes tailored to each patient and included the administration of beta-agonists when needed in mild asthma; inhaled |

| | |
|---|---|
| | salbutamol 0.2mg or terbutaline 0.5mg and budesonide 400mcg every 12 hours in moderate to severe asthma with FEV1>80%; and inhaled salbutamol 0.2mg or terbutaline 0.5mg and budesonide 800mcg every 8 hours or when needed and prednisone 40mg/day for 14 days in moderate to severe asthma with FEV1<80%. Patients in both groups received asthma education.<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Academic or government funding (Supported in part by grant FISS 92/372) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF, MEDICATION AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Number of patients with visits to an emergency ward at 12 months; Group 1: 3/56, Group 2: 0/44; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Number of patients with a hospital admission at 12 months; Group 1: 2/56, Group 2: 0/44; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): FEV1% predicted at 12 months; Group 1: mean 80.9 % (SD 2.3); n=56, Group 2: mean 80.8 % (SD 2.8); n=44; FEV1 %pred 0-100 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Time of school/work at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Number of patients with absenteeism school/work at 12 months; Group 1: 2/56, Group 2: 0/44; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment |

**Table 127: Turner 1998[1803]**

| **Study** | **Turner 1998[1803]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=117) |

| | |
|---|---|
| Countries and setting | Conducted in Canada; Setting: Primary care |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 6 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: PC20 methacholine < 8 mg/ml |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Between 18 and 55 yr of age with moderate to moderately severe asthma. The authors defined asthma severity by including only patients with a baseline PC20 methacholine < 8 mg/ml and a daily requirement for inhaled corticosteroids to manage their asthma symptoms. Patients were either newly prescribed inhaled corticosteroids independently by their family physician or were currently using inhaled corticosteroids. |
| Exclusion criteria | Exclusion criteria included significant comorbid conditions that would impact on QOL measurements, current use of a PFM, inability to use a PFM, and inability to communicate in English. |
| Recruitment/selection of patients | Potential study patients were identified from the clinic computer database, and the clinic physicians were encouraged to refer patients meeting study criteria. The authors displayed a poster board and flyer advertisements in the clinic to encourage volunteers. All patients had written permission from their physician to participate. |
| Age, gender and ethnicity | Age - Mean (SD): PEF group: 34.1 (10.5); symptoms group: 34.1 (9.4) years. Gender (M:F): 43:49. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=53) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. The asthma nurse reviewed patients monthly for 6 mo after the initial visit (seven total visits). The self-management plans and use of a PFM were reviewed in detail after randomization. Monthly visits documented morbidity outcomes, reinforced and evaluated use of the self-management plan, and provided ongoing education. Duration 6 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training :<br><br>(n=64) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. The asthma nurse reviewed patients monthly for 6 mo after the initial visit (seven total visits). The self-management plans were reviewed in detail after randomization. Monthly visits documented morbidity outcomes, reinforced and evaluated use of the self-management plan, and provided ongoing education. Duration 6 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : |

| | |
|---|---|
| Funding | Study funded by industry (Glaxo Wellcome Canada Inc.) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Asthma Quality of Life Questionnaire at 6 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Prednisone treatments at 6 months; Group 1: 3/44, Group 2: 6/48; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Unscheduled doctor visits at 6 months; Group 1: 17/44, Group 2: 12/48; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Hospitalisation at 6 months; Group 1: 0/44, Group 2: 1/48; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): ED visits at 6 months; Group 1: 6/44, Group 2: 2/48; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): FEV1 % pred at 6 months; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): PEF at 6 months; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Time of school/work at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Time off school/work at 6 months; Group 1: 9/44, Group 2: 8/48; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment |

**Table 128: Wensley 2004[1906]**

| **Study** | **Wensley 2004[1906]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |

| | |
|---|---|
| Number of studies (number of participants) | 1 (n=90) |
| Countries and setting | Conducted in United Kingdom; Setting: Recruitment in primary care and secondary care. |
| Line of therapy | Not applicable |
| Duration of study | Intervention time: 12 weeks |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Physician-diagnosed asthma and at least step 2 of the British Thoracic Society Guidelines for Asthma Management (regular inhaled corticosteroid therapy) |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Inclusion criteria were (1) age 7–14 years, (2) physician-diagnosed asthma, (3) at least step 2 of the British Thoracic Society Guidelines for Asthma Management (regular inhaled corticosteroid therapy), (4) stable treatment for 1 month, (5) no other respiratory problem, (6) competent at spirometry, and (7) a successful 4-week run-in period. |
| Exclusion criteria | None stated |
| Recruitment/selection of patients | Withdrawals after run-in phase (n=27) due to refusal, poor comprehension or poor compliance, technical problems, equipment failure or GP advice |
| Age, gender and ethnicity | Age - Median (range): Symptoms group: 12 (7–14); PEF group: 11 (7–14) years. Gender (M:F): 48:42. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=44) Intervention 1: Monitoring lung function + treatment - Monitoring PEF + treatment. Group PF based on symptoms plus PEF. A written symptom diary was completed each morning, and spirometry was performed twice daily. The spirometers of those children randomized to the PF group were reprogrammed so that the PEF value for any maneuver (but not other spirometric values) was visible to them at any time. The child and the main caregiver were taught self-management at a training session, which also included training in spirometry and symptom recording and which lasted 30–90 minutes according to need. A printed plan incorporating the child's own medication regime was color coded: green, PEF more than 70%, few symptoms (carry on as usual); yellow, PEF 50–70% after beta2 agonist (double-inhaled corticosteroid as well as taking additional beta2-agonist therapy); and red, PEF less than 50% after taking additional inhaled beta2 agonist, severe symptoms (commence oral prednisolone and/or seek medical help). The PEF levels for action were based on the child's best previous PEF.. Duration 12 weeks. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : |

| | |
|---|---|
| | (n=46) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Group S based on symptoms alone; the S group did not have access to any lung function results throughout the study.. Duration 12 weeks.<br>Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : |
| Funding | Study funded by industry (United Kingdom National Asthma Campaign and Glaxo SmithKline, United Kingdom.) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Emergency GP visits at 12 weeks; Group 1: 10/44, Group 2: 11/45; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : Hospital admissions at 12 weeks; Group 1: 1/44, Group 2: 0/45; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : Attendance at A&E at 12 weeks; Group 1: 1/44, Group 2: 0/45; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : FEV1 at 12 weeks; Group 1: mean 87.3 % of best value (SD 1.33); n=44, Group 2: mean 86.9 % of best value (SD 1.54); n=45; Percentage 0-100% Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : PEF at 12 weeks; Group 1: mean 83.4 % (SD 1.39); n=44, Group 2: mean 80.6 % (SD 1.74); n=45; Percentage 0-100% Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Symptom free days at End of Treatment<br>- Actual outcome for Children 5 -<16 : Proportion of symptom-free days at 12 weeks; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Time of school/work at End of Treatment<br>- Actual outcome for Children 5 -<16 : Time off school at 12 weeks; Group 1: 15/44, Group 2: 13/45; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment |

**Table 129: Yoos 2002[1963]**

| Study | Yoos 2002[1963] |
|---|---|

| | |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=168) |
| Countries and setting | Conducted in USA; Setting: 11 primary care settings |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: All school-aged children who carried a diagnosis of asthma |
| Stratum | Children 5 -<16 : Aged 6-19 years |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Aged 6-19 years with a diagnosis of asthma, more that 3 asthma-related healthcare visits in the previous 12 months, English speaking, the child had not used a PEF meter in the previous 6 months. |
| Exclusion criteria | Children with mild asthma who were rarely symptomatic (had not had more than 3 asthma related healthcare visits in the previous 12 months). |
| Recruitment/selection of patients | All school-aged children who carried a diagnosis of asthma identified through computerised data sets. |
| Age, gender and ethnicity | Age - Range: 6-19 years. Gender (M:F): 99/69. Ethnicity: |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=57) Intervention 1: Monitoring lung function + treatment - Monitoring PEF and symptoms + treatment. Personal action plan zones based on symptoms and PEF. Green zone, yellow zone (rescue medication) and red zone (contact healthcare provider).. Duration 3 months. Concurrent medication/care: Both groups received asthma education and a personal action plan. Two week run-in period with allocated self-management method and at the end of this period the nurse estabilised zones based on PEF best and developed a personal action plan based on PEF and symptoms.<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=56) Intervention 2: No lung function monitoring + treatment - Monitoring symptoms + treatment. Personal action plan zones based on symptoms only. Green zone, yellow zone (rescue medication) and red zone (contact healthcare provider).. Duration 3 months. Concurrent medication/care: Both groups received asthma education and a personal action plan.Two week run-in period with allocated self-management method and at the end of this period the nurse estabilised zones based on symptoms and developed a personal action plan based on symptoms.<br>Further details: 1. Additional education training : Additional education in both groups |

| | |
|---|---|
| Funding | Academic or government funding (Supported by NIH grants) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING PEF AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : FEV1 % predicted at 3 months; Group 1: mean 88 % (SD 20.6); n=57, Group 2: mean 90 % (SD 21); n=56; FEV1 %pred 0-100 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

# G.17 FeNO to monitor asthma control

**Table 130: Calhoun 2012[264]**

| **Study** | **BASALT trail trial: Calhoun 2012[264]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=342) |
| Countries and setting | Conducted in USA; Setting: Secondary - adjustments of inhalled corticosteroids made at outpatient visits |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 9 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: All patients had a physician diagnosis of asthma, and either reversible airflow limitation (≥12% improvement in forced expiratory volume in the first second of expiration [FEV1] after 360 mcg of albuterol), or airway hyperresponsiveness (provocative concentration of methacholine [<8mg/ml] causing a 20% drop in FEV1) |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Mild to moderate persistent asthma, acceptable control of asthma (i.e. a score of 0 or 1 on each of the 3 |

| | |
|---|---|
| | questions on the Asthma Evaluation Questionnaire and predicted bronchodilator FEV1 >70%), and patients who demonstrated at least 75% adherence (i.e. those patients that could tolerate 2 puffs twice daily of beclomethasone HFA (40 mch/puff)) during the run-in period |
| Exclusion criteria | Poorly controlled, severe asthma |
| Recruitment/selection of patients | Participants were recruited cooperatively with a concurrent Asthma Clinical Research Network trial |
| Age, gender and ethnicity | Age - Mean (SD): 35 (11.83). Gender (M:F): 105/237. Ethnicity: White: 216, Black: 69, Hispanic: 38, Asian/Pacific Islander:13, Other: 5, American Indian/Alaska Native: 1 |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=114) Intervention 1: No FeNO monitoring + treatment - Monitoring symptoms and lung function + treatment. Dose of inhaled coriticosteroids was adjusted by an investigator according to a strategy based on National Heart, Lung, and Blood Institute guidelines (PABA). Dose adjustments of inhaled corticosteroids were made at the time of clinic visits (every 6 weeks). Treatment step down - PABA: Physician assessment-based adjustment, inhaler A (1). Fev1 ≥85% at baseline, plus symptoms in past 2 wk ≤2 d/wk (all AEQ of 0); control status: well controlled; inhaler dose change: down 1 level. (2). Fev1 ≥85% at baseline, plus symptoms no worse than mild (AEQ scores of 0 or 1 on each question); control status: controlled; inhaler dose change: maintain current level. (3). Fev1 <85% at baseline, moderate symptoms (any AEQ score of 2 or 3), or meets criteria for treatment failure; control status: under controlled; inhaler dose change: up 1 level. . Duration 9 months. Concurrent medication/care: During the prerandomisation period, patients were given 3 inhalers coded as A, B, and C. Inhaler A contained beclomethasone HFA (40 mcg/puff), and inhalers B and C contained placebo. An albuterol inhaler was provided for use as needed for asthma symptoms. Participants were instructed to use 2 puffs twice daily from inhalers A and B, and to use 2 puffs from inhaler C each time they used 2 puffs of albuterol for symptom relief. Participants who demonstrated 75% adherence were randomised to one of the adjustment strategies (PABA, BBA, or SBA (occurrence of symptoms - data not extracted)). Beclomethasone HFA was provided at a dosage of 2 puffs twice daily (40 mcg/puff) before randomisation, corresponding to level 3 treatment. Hence, inhaled corticosteroid therapy could be intensified or deintensified during the trail. Following randomisation, beclomethasone HFA was contained only in inhaler A for PABA participants, only in inhaler B for BBA patients, and only in inhaler C for SBA participants. Thereafter, inhalers were adjusted according to the strategy assigned (i.e. PABA or BBA). Subsequent visits occurred at 2, 4, 6, 12, 18, 24, 30, and 36 weeks after randomisation.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients (To evaluate different approaches to dose adjustment of inhaled corticosteroids in a 3-group trial during 9 months in adults with mild to moderate asthma that was well controlled with low-dose inhaled corticosteroids). |

| | |
|---|---|
| | (n=115) Intervention 2: Monitoring FeNO + treatment. Dose of inhaled coriticosteroids was adjusted by an investigator according to exhaled nitric oxide (BBA). Dose adjustments of inhaled corticosteroids were made at the time of clinic visits (every 6 weeks). BBA: Biomarker-based adjustment, inhaler B. Fraction of exhaled nitric oxide, ppb: (1). <22; control status: well controlled; inhaler dose change: down 1 level. (2). 22-35; control status: controlled; inhaler dose change: maintain current level. (3). >35; control status: under controlled; inhaler dose change: up 1 level. Inhaled corticosteroids dose level: (1) none, na; (2) 80 (2 puffs), once daily (am); (3) 160 (2 puffs), twice daily; (4) 320 (4 puffs), twice daily; (5) 640 (8; 4 puffs at double strength), twice daily.. Duration 9 months. Concurrent medication/care: During the prerandomisation period, patients were given 3 inhalers coded as A, B, and C. Inhaler A contained beclomethasone HFA (40 mcg/puff), and inhalers B and C contained placebo. An albuterol inhaler was provided for use as needed for asthma symptoms. Participants were instructed to use 2 puffs twice daily from inhalers A and B, and to use 2 puffs from inhaler C each time they used 2 puffs of albuterol for symptom relief. Participants who demonstrated 75% adherence were randomised to one of the adjustment strategies (PABA, BBA, or SBA (occurrence of symptoms - data not extracted)). Beclomethasone HFA was provided at a dosage of 2 puffs twice daily (40 mcg/puff) before randomisation, corresponding to level 3 treatment. Hence, inhaled corticosteroid therapy could be intensified or deintensified during the trail. Following randomisation, beclomethasone HFA was contained only in inhaler A for PABA participants, only in inhaler B for BBA patients, and only in inhaler C for SBA participants. Thereafter, inhalers were adjusted according to the strategy assigned (i.e. PABA or BBA). Subsequent visits occurred at 2, 4, 6, 12, 18, 24, 30, and 36 weeks after randomisation.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients (To evaluate different approaches to dose adjustment of inhaled corticosteroids in a 3-group trial during 9 months in adults with mild to moderate asthma that was well controlled with low-dose inhaled corticosteroids). |
| Funding | Academic or government funding (Study was conducted with the support of the Institute for Translational Sciences at the University of Texas Medical Branch, supported in part by a Clinical and Translational Science Award from the National Center for Advancing Translational Sciences, National Institutes of Health. The study was also supported by National Institutes of Health grants that were awarded by the National Heart, Lung, and Blood Institute. Teva Pharmaceuticals provided the study drug and matching placebo.) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT<br><br>Protocol outcome 1: Quality of life at End of treatment | |

| | |
|---|---|
| - Actual outcome for Adults and young people (16 years and over): AQLQ at 9 months; MD 0.00 (SE 0.11); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Asthma exacerbation (including multiple epsiodes) at 36 weeks; HR lnHR -0.095 (SE 0.429); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Asthma control questionnaires at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): ACQ at 9 months; MD -0.04 (SE 0.08); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Rescue medication at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Rescue medication - albuterold rescue use (puffs) at 9 months; MD -0.06 (SE 0.034119); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Dose of regular asthma therapy (ICS, beclomethasone HFA (40 mcg/puff)) at 36 weeks; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Lung function - am peak flow 2-week average prior to visit 4, L/min at 9 months; MD 2.3 (SE 7.2); Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Lung function - pm peak flow 2-week average prior to visit 4, L/min at 9 months; MD 3.8 (SE 7.04); Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Lung function - prebronchodilator FEV1 at 9 months; MD 0.98 (SE 0.96); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 7: Time of school/work at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Time off school/work (no. of patients) at 36 weeks; OR lnOR 0.693 (SE 0.273); Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Symptom free days at End of Treatment |

**Table 131: de Jongste 2009[402]**

| Study | CHARISM (Children with Asthma subjected to Respiratory Inflammatory Status Monitoring) trial: De jongste 2009[402] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=151) |
| Countries and setting | Conducted in Netherlands; Setting: Secondary (clinic visits, data transmitted daily to centre, telephone contact). |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 30 weeks |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Diagnosed according to GINA guidelines |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Age: 6-18 years; stable mild-moderate atopic asthma, diagnosed according to GINA guidelines; treatment with 200-1000 mcg of inhaled budesonide or equivalent daily for 2 months before randomisation; and RAST class 2 or higher or a positive skin prick test for at least one airborne allergen. |
| Exclusion criteria | Exclusion criteria were as follows: active smoking, previous admission to an intensive care unit for asthma, and concomitant disease that might affect FeNO. |
| Recruitment/selection of patients | Participants were recruited from 5 academic centres and 12 general hospitals. |
| Age, gender and ethnicity | Age - Mean (SD): 11.7 (3.538). Gender (M:F): 100/51. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=77) Intervention 1: Monitoring FeNO + treatment - Monitoring FeNO and symptoms + treatment. Children in the FeNO group received an airway inflammation monitor (NIOX MINO; Aerocrine, Solna, Sweden) that measures FeNO. Measurements were performed daily. Measurement time was recorded by the device. Data was transmitted to the coordinating centre. All parents were phoned every 3 weeks between visits, and medication was adapted according to geometric mean FeNO over the preceding 3 weeks and cumulative symptom scores. Algorithm: (a) symptom score, high; FeNO, high; adjustment, increase; (b) symptom score, high; FeNO, low; adjustment, no change; (c) symptom score, low; FeNO, high; adjustment, increase; (d) symptom score, low; FeNO, low; adjustment, decrease or discontinue. Cut-off level for symptom score - high score: >60, low score ≤60 cumulative in 3 weeks. Cut-off levels for FeNO were 20 ppb for children aged 6-10 years and 25 ppb for older children. . Duration 30 weeks. Concurrent medication/care: Monitored children with atopic asthma for 30 weeks. Children were randomised at first visit, stratified by centre. ICS doses were adjusted every 3 weeks on the basis of either FeNO and symptoms, or symptom |

| | |
|---|---|
| | scores alone. All children recorded asthma symptoms in a palmtop diary. Entries were transmitted daily to the coordinating centre. Children in both groups were seen at randomisation and at 3, 12, 21, and 30 weeks. Doses were changed according to predefined steps for each type of inhaled steroid, for example, budesonide at 100, 200, 400, 800, and 1,200 mcg. Maximal allowed dose: 1200 mcg of budesonide or equivalent. If a combination of ICS and long-acting beta-agonist (LABA) was used, the LABA was stopped whenever decrease was required at the lowest ICS dose, before stopping ICS. Steroids were stopped for 6 weeks with low symptom scores at the lowest steroid dose level.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=74) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms + treatment. All parents were phoned every 3 weeks between visits. Algorithm: symptom score: above average (adjustment - increase); in range (no change); below range (decrease or discontinue). Cut-off level: the "normal range" was 10-60. Duration 30 weeks. Concurrent medication/care: Monitored children with atopic asthma for 30 weeks. Children were randomised at first visit, stratified by centre. ICS doses were adjusted every 3 weeks on the basis of either FeNO and symptoms, or symptom scores alone. All children recorded asthma symptoms in a palmtop diary. Entries were transmitted daily to the coordinating centre. Children in both groups were seen at randomisation and at 3, 12, 21, and 30 weeks. Doses were changed according to predefined steps for each type of inhaled steroid, for example, budesonide at 100, 200, 400, 800, and 1,200 mcg. Maximal allowed dose: 1200 mcg of budesonide or equivalent. If a combination of ICS and long-acting beta-agonist (LABA) was used, the LABA was stopped whenever decrease was required at the lowest ICS dose, before stopping ICS. Steroids were stopped for 6 weeks with low symptom scores at the lowest steroid dose level.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (Supported by a research grant from Aerocrine AB (Solna, Sweden). Conflict of interest statement: authors received travel grants, research grants and lectured at scientific meetings for the following: GlaxoSmithLine, Merck Sharp & Dohme, Altana Pharma, Aerocrine, Abbott, Valeas, Chiesi and Roche. Also note that the Department of Paediatrics/Erasmus MC Holding received research grants from GlaxoSmithKline, AstraZeneca, Aerocrine, Roche, Freisland Foods, Transave, Chiron, and Pfizer.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT

Protocol outcome 1: Quality of life at End of treatment
- Actual outcome for Children 5 -<16 : PACQLQ(S) - Paediatric Asthma Caregiver Quality of Life Questionnaire with Standardised Activities at 30 weeks; Group 1: mean

| | |
|---|---|
| 6.2 (SD 0.8); n=75, Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 : Exacerbation - OCS, prednisone course at 30 weeks; Group 1: 9/75, Group 2: 12/72; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Children 5 -<16 : UHU at 30 weeks; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Rescue medication at End of Treatment<br>- Actual outcome for Children 5 -<16 : Rescue medication - beta agonist puffs per 3 weeks at 30 weeks; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Dose of regular therapy - ICS, budesonide at 30 weeks; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : Lung function - FEV1 at 30 weeks; Group 1: mean 95 % (SD 14); n=75, Group 2: mean 94 % (SD 14); n=72; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 7: Symptom free days at End of Treatment<br>- Actual outcome for Children 5 -<16 : % symptom free days over last 12 weeks at 30 weeks; MD 0.3 (95%CI -10 to 11); Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Asthma control questionnaires at End of Treatment; Time of school/work at End of Treatment |

**Table 132: Fritsch 2006[528]**

| **Study** | **Fritsch 2006[528]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=47) |
| Countries and setting | Conducted in Austria; Setting: Secondary care - Paediatric Pulmonology outpatient clinic |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 6 months |

| | |
|---|---|
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: A paediatrician, trained in paediatric pulmonology and allergology, diagnosed participants asthma according to ATS criteria. |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients aged 6-18 years, with mild to moderate persistent asthma. All participants had a positive skin prick test or radioallergosorbent test (RAST >1) to at least one of seven common aeroallergens (cat, dog, house dust mite, alternaria, birch-, hazelnut-, and mixed grass-pollen) in their past medical history or at the time of recruitment. |
| Exclusion criteria | Participants who had received oral or IV steroid treatment 4 weeks prior to the first visit were excluded from the study. |
| Recruitment/selection of patients | Recruited from the Paediatric Pulmonology outpatient clinic of the University Children's Hospital Vienna. |
| Age, gender and ethnicity | Age - Mean (SD): 11.73 (3.121). Gender (M:F): 28/19. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=25) Intervention 1: No FeNO monitoring + treatment - Monitoring symptoms and lung function + treatment. Children in the control group were treated considering parameters of asthma control (symptoms, short-acting beta agonist use, and lung function) recommended in current asthma guidelines. A step down in therapy was performed if FEV1 % predicted was ≥80% and there was no or mild symptoms over the last 4 weeks and beta agonist use was <6 puffs over the last 12 days. A step up was performed in every other case. . Duration 6 months. Concurrent medication/care: Following a run-in period of 4 weeks participants were randomly assigned to a control group or a FeNO group at the first visit. The trail included five visits (6 weeks intervals) over a period of 6 months. Doses - Low dose ICS: (2X 100 mcg fluticasone or 2x 200 mcg budesonide); Low dose ICS + leukotriene receptor agonists: (2x 100 mcg fluticasone or 2x 200 mcg budesonide + 5 mg montelukast once daily p.o.); Low dose ICS + long acting beta-agonist (2x 100 mcg fluticasone + 2x 50 mcg salmeterol or 2x 200 mcg Budesonide + 2x 12 mcg formeterol); High dose ICS + leukotriene receptor agonist (2x 250 mcg fluticasone or budesonide 2x 400 mcg + 1 daily 5 mg montelukast p.o.); High dose ICS + long acting beta-agonist (2x 250 mcg fluticasone + 2x 50 mcg salmeterol or 2x 400 mcg budesonide + 2x 12 mcg formeterol).<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=22) Intervention 2: Monitoring FeNO + treatment - Monitoring FeNO, symptoms and lung function + treatment. FeNO group therapy was based on symptoms, beta agonist use, lung function, and FeNO. A step down in therapy was performed if FEV1 % predicted was ≥80% and there was no or mild symptoms over the last 4 weeks and beta agonist use was <6 puffs over the last 14 days. A step up was performed in every other case. Treatment was further adjusted |

| | |
|---|---|
| | according the FeNO cut-off point, >20 ppb. In participants with stable asthma increased FeNO was considered a sign of insufficient anti-inflammatory treatment. These patients were provided with 2-week diary cards to record daily symptoms, beta agonists use and controller medication requirement, and telephone calls were regularly performed to check adherence to therapy. Asymptomatic patients on therapy with beta-agonist on demand only, with normal lung function but increased FeNO were prescribed low dose steroids. Step up was performed irrespective of FeNO level if FEV1% predicted was <80% and/or there were severe symptoms over the last 4 weeks and/or beta-agonist use was ≥6 puffs over the last 14 days. If FeNO was raised in these patients, they received 2-week diary cards as well. Step down was performed if FEV1% predicted was ≥80% and there were no or mild symptoms over the last 4 weeks and beta-agonist use was <6 puffs over the last 14 days and FeNO was ≤20 ppb.. Duration 6 months. Concurrent medication/care: Following a run-in period of 4 weeks participants were randomly assigned to a control group or a FeNO group at the first visit. The trail included five visits (6 weeks intervals) over a period of 6 months. Doses - Low dose ICS: (2X 100 mcg fluticasone or 2x 200 mcg budesonide); Low dose ICS + leukotriene receptor agonists: (2x 100 mcg fluticasone or 2x 200 mcg budesonide + 5 mg montelukast once daily p.o.); Low dose ICS + long acting beta-agonist (2x 100 mcg fluticasone + 2x 50 mcg salmeterol or 2x 200 mcg Budesonide + 2x 12 mcg formeterol); High dose ICS + leukotriene receptor agonist (2x 250 mcg fluticasone or budesonide 2x 400 mcg + 1 daily 5 mg montelukast p.o.); High dose ICS + long acting beta-agonist (2x 250 mcg fluticasone + 2x 50 mcg salmeterol or 2x 400 mcg budesonide + 2x 12 mcg formeterol).<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (Aerocine provided technical support and help with data analyses) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO, SYMPTOMS AND LUNG FUNCTION + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT<br><br>Protocol outcome 1: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 : Exacerbation - OCS at 6 months; Group 1: 2/22, Group 2: 2/25; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Dose of regular treatment - ICS dose at 6 months; Other: ; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 133: Honkoop 2014[700]**

| Study | Asthma Control Cost-Utility Randomised Trial Evaluation (ACCURATE) trial: Honkoop 2014[700] |
|---|---|
| Study type | RCT (Cluster randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=647) |
| Countries and setting | Conducted in Netherlands; Setting: Primary |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Doctor diagnosed asthma according to Dutch national guidelines |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | 18-50 years old, doctor-diagnosed asthma according to the Dutch national guidelines, a prescription for ICSs for at least 3 months in the previous year, and asthma being managed in primary care |
| Exclusion criteria | Significant comorbidity (at the GPs discretion), inability to understand Dutch, and a prescription for oral corticosteroids in the previous month |
| Recruitment/selection of patients | General practices from both rural and urban areas in The Netherlands were invited to participate |
| Age, gender and ethnicity | Age - Mean (SD): 39.42 (9.633). Gender (M:F): 191/420 . Ethnicity: Not specified |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=205) Intervention 1: Monitoring FeNO + treatment - Monitoring FeNO and symptoms + treatment. Treatment strategy: aiming at FeNO-driven controlled asthma (FCa strategy). In all strategies, patients visited the practice nurse of their general practice every 3 months over the course of 1 year. During these visits, the practice nurse assessed current medication use and asthma control status by using the 7-item asthma control questionnaire that includes lung function. In addition, FeNO measurement was performed in the FCa strategy. Duration 12 months. Concurrent medication/care: At each visit, a patient's asthma control status was classified based on the ACQ score as controlled (ACQ score ≤0.75), partly controlled (0.75 <ACQ ≤1.5), or uncontrolled (ACQ score >1.5); and additionally in the FCa strategy as 3 subcategories of FeNO: low/absence of airway inflammation for values at 25 ppb or less, intermediate at 26 to 50 ppb, and high/presence of airway inflammation at greater than 50 ppb. Treatment decisions were based on a dedicated algorithm for each strategy. (1)Strategy aimed at Ca = asthma controlled status Ca (ACQ ≤0.75): 3mo: no change, 6mo: step down; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, treatment choice open; asthma |

| | |
|---|---|
| | controlled status uncontrolled (ACQ >1.5): step up, treatment choice open. (2)Strategy aimed at FCa, low FeNO (<25 ppb) = asthma controlled status Ca (ACQ ≤0.75): step down, treatment choice open; asthma controlled status PCa (0.75 > ACQ ≤1.5): 3 mo: no change/change within current step to LABA, 6mo: step down to ICS; asthma controlled status uncontrolled (ACQ >1.5): 3 mo: step up LABA, 6mo: revise asthma diagnosis. (3)Strategy aimed at FCa, intermediate FeNO (25-50 ppb) = asthma controlled status Ca (ACQ ≤0.75): no change; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, treatment choice open; asthma controlled status uncontrolled (ACQ >1.5): treatment choice open. (4)Strategy aimed at FCa, high FeNO (>50 ppb) = asthma controlled status Ca (ACQ ≤0.75): step up/change within current step to ICS; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, 1 X ICS; asthma controlled status uncontrolled (ACQ >1.5): step up, 2 X ICS. Current medication use and all measurements were entered into an online decision support tool, which subsequently automatically generated treatment advice based on the appropriate algorithm for each of the treatment strategies. Patients' current medication use was classified as an asthma treatment step ranging from 0 (only short-acting beta agonists) to 5 (oral prednisone) based on the US National Asthma Education and Prevention Programe guideline. When treatment was to be adjusted, in the Ca strategy professionals and patients could choose any (combination of) type or types of asthma medication they preferred within a certain treatment step, whereas the FCa strategy offered more guidance toward adding/removing LABAS or ICSs.<br>Further details: 1. Additional education training : No education in both groups 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=210) Intervention 2: No FeNO monitoring + treatment - Monitoring symptom control questionnaires + treatment. Treatment strategy: aiming at controlled asthma (Ca strategy). In all strategies, patients visited the practice nurse of their general practice every 3 months over the course of 1 year. During these visits, the practice nurse assessed current medication use and asthma control status by using the 7-item asthma control questionnaire that includes lung function. . Duration 12 months. Concurrent medication/care: At each visit, a patient's asthma control status was classified based on the ACQ score as controlled (ACQ score ≤0.75), partly controlled (0.75 <ACQ ≤1.5), or uncontrolled (ACQ score >1.5); and additionally in the FCa strategy as 3 subcategories of FeNO: low/absence of airway inflammation for values at 25 ppb or less, intermediate at 26 to 50 ppb, and high/presence of airway inflammation at greater than 50 ppb. Treatment decisions were based on a dedicated algorithm for each strategy. (1)Strategy aimed at Ca = asthma controlled status Ca (ACQ ≤0.75): 3mo: no change, 6mo: step down; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, treatment choice open; asthma controlled status uncontrolled (ACQ >1.5): step up, treatment choice open. (2)Strategy aimed at FCa, low FeNO (<25 ppb) = asthma controlled status Ca (ACQ ≤0.75): step down, treatment choice open; asthma controlled status PCa (0.75 > ACQ ≤1.5): 3 mo: no change/change within current step to LABA, 6mo: step down to ICS; asthma controlled status uncontrolled (ACQ >1.5): 3 mo: step up LABA, 6mo: revise asthma diagnosis. (3)Strategy aimed at FCa, intermediate FeNO (25-50 ppb) = asthma controlled status Ca (ACQ ≤0.75): no change; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, treatment choice open; asthma controlled status uncontrolled (ACQ >1.5): treatment choice open. (4)Strategy aimed at FCa, high FeNO (>50 ppb) = |

| | |
|---|---|
| | asthma controlled status Ca (ACQ ≤0.75): step up/change within current step to ICS; asthma controlled status PCa (0.75 > ACQ ≤1.5): step up, 1 X ICS; asthma controlled status uncontrolled (ACQ >1.5): step up, 2 X ICS. Current medication use and all measurements were entered into an online decision support tool, which subsequently automatically generated treatment advice based on the appropriate algorithm for each of the treatment strategies. Patients' current medication use was classified as an asthma treatment step ranging from 0 (only short-acting beta agonists) to 5 (oral prednisone) based on the US National Asthma Education and Prevention Programe guideline. When treatment was to be adjusted, in the Ca strategy professionals and patients could choose any (combination of) type or types of asthma medication they preferred within a certain treatment step, whereas the FCa strategy offered more guidance toward adding/removing LABAs or ICSs.<br>Further details: 1. Additional education training: No education in both groups 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (Study was funded by the Netherlands Organisation for Health Research and Development and the Netherlands Asthma Foundation, and nonfinancial support was received from Aerocrine. Author holds stock in Grace Bros and received consultancy fees from Astra-Zeneca, GlaxoSmithKline, and Novartis, as well as grants funding from ACME Pharmaceutical.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOM CONTROL QUESTIONNAIRES + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people (16 years and over): Exacerbation (severe, defined as hospitalisation, emergency care or use of OCS) at 12 months; Risk of bias: High; Indirectness of outcome: Serious indirectness

Protocol outcome 2: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment
- Actual outcome for Adults and young people (16 years and over): UHU - hospitalisation (from the exacerbation outcome) at 12 months; Group 1: 1/189, Group 2: 2/203; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people (16 years and over): UHU - ED visit (from the exacerbation outcome) at 12 months; Group 1: 2/189, Group 2: 3/203; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Asthma control questionnaires at End of Treatment
- Actual outcome for Adults and young people (16 years and over): ACQ-7 score at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Lung Function at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Lung function (FEV1 % predicted) at 12 months; Risk of bias: High; Indirectness of outcome: No

| | |
|---|---|
| indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 134: Peirsman 2013[1331]**

| **Study** | **Peirsman 2013[1331]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=99) |
| Countries and setting | Conducted in Belgium; Setting: Secondary |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Method of assessment /diagnosis not stated: Not stated - children with persistent allergic asthma |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Children with persistent allergic asthma. Mild to severe persistent asthma according to GINA guidelines, for a period of at least 6 months, and allergic sensitisation (i.e., a positive skin prick test and/or specific IgE antibodies against nihalant allergens). |
| Exclusion criteria | Exclusion criteria comprised significant comorbidity, an acute exacerbation or the administration of experimental medication 4 weeks prior to the screening visit, hospitalisation and/or systematic corticosteroids 12 weeks prior to the screening visit or oral corticosteroids dependence. |
| Recruitment/selection of patients | Secondary - visits were organised by physicians from seven Belgian hospitals. |
| Age, gender and ethnicity | Age - Mean (SD): 10.65 (2.151). Gender (M:F): 66/33. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=49) Intervention 1: Monitoring FeNO and symptoms + treatment. In the intervention group, FeNO measurements were primarily used to adjust the treatment. Goal was to keep FeNO below 20 ppb, the rounded 95% upper limit of |

| | |
|---|---|
| | FeNO values in healthy children, deduced from previous trials. Controlled asthma = NO ≤20 ppb and controlled; ICS (dosage in budesonide or equivalent) = ICS step down - 100 mcg/day, below 100 mcg/day: stop and add LTRA; LTRA = stay the same; ICS + LTRA = ICS step down: -100 mcg/day, below 100 mcg/day: stop ICS; ICS + LABA = stop LABA. Partly controlled asthma = NO ≤20 ppb and partly controlled or uncontrolled; ICS (dosage in budesonide or equivalent) = consider + LTRA; consider + ICS 100 mcg/day (max 200 mcg/day); ICS + LTRA = consider ICS step up + 100 mcg/day (max 400 mcg/day, then add LABA); ICS + LABA = consider + LTRA. Uncontrolled asthma = NO >20 ppb regardless of symptoms; ICS (dosage in budesonide or equivalent) = +LTRA; LTRA = +ICS 100 mcg/day (max 200 mcg/day); ICS + LTRA = ICS step up: 100 mcg/day, (max 400 mcg/day, then add LABA); ICS + LABA = replace LABA with LTRA.. Duration 12 months. Concurrent medication/care: Five visits, one every 3 months.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=50) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms and lung function + treatment. In the control group, control and treatment adjustments during each visit were determined by the reporting of symptoms (i.e., limitation of activities, daytime and nocturnal symptoms), the need for rescue treatment during the two preceding weeks and spirometry (FEV1), based on GINA guidelines.. Duration 12 months. Concurrent medication/care: Five visits, one every 3 months.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (Research supported in part by a research grant from the Investigator Initiated Studies Program of Merck & Co., Inc. NO analysers were provided by Aerocrine, Solna, Sweden.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Children 5 -<16 : exacerbation (OCS) at 12 months; Group 1: 2/49, Group 2: 3/50; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment
- Actual outcome for Children 5 -<16 : UHU - number of unscheduled asthma-related contacts at 12 months; Group 1: 6/44, Group 2: 15/43; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Children 5 -<16 : UHU - number of children with ≥1 hospital admission at 12 months; Group 1: 1/43, Group 2: 1/43; Risk of bias: Very high; Indirectness of outcome: No indirectness
- Actual outcome for Children 5 -<16 : UHU - number of children with ≥1 emergency room admission at 12 months; Group 1: 2/45, Group 2: 4/46; Risk of bias: Very

| | |
|---|---|
| high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Dose of regular therapy - change in daily ICS dose at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : lung function - FEV1 (mean % predicted) [≥6mo] at 12 months; Group 1: mean 93.9 mean % predicted (SD 15.5); n=49, Group 2: mean 91.2 mean % predicted (SD 12.3); n=50; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 : lung function - FEV1 (mean % predicted) [<6mo] at 3 months; Group 1: mean 92.2 (SD 14.1); n=49, Group 2: mean 90.7 (SD 13.2); n=50; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Symptom free days at End of Treatment<br>- Actual outcome for Children 5 -<16 : % symptom free days at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Time of school/work at End of Treatment<br>- Actual outcome for Children 5 -<16 : time off school/work - number of children missed school at 12 months; Group 1: 10/46, Group 2: 12/46; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment |

**Table 135: Petsky 2014[1354]**

| **Study** | **Petsky 2014[1354]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=63) |
| Countries and setting | Conducted in Australia, Hong Kong (China); Setting: Secondary care |
| Line of therapy | Unclear |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Under the care of a paediatrician |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Children aged >4 years with persistent asthma, prescribed anti-inflammatory asthma treatment, and receiving their |

| | |
|---|---|
| | care primarily through the clinical service at Royal Children's Hospital, Brisbane or Prince of Wales Hospital, Hong Kong. |
| Exclusion criteria | Children who had underlying cardio-respiratory illness such as bronchiectasis or tracheomalacia, inability to take ICS or long acting beta-2-agonists (LABA) or previous poor adherence to medications (as documented in clinic notes). |
| Recruitment/selection of patients | Not stated |
| Age, gender and ethnicity | Age - Median (IQR): 10.17 (6.56,12.69) years FeNO; 10.08 (6.25, 12.44) years controls. Gender (M:F): 31:32. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=31) Intervention 1: Monitoring FeNO + treatment. Management based on FeNO levels and atopic status. If FeNO was low for two consecutive visits, medications were stepped down. Elevated FeNO was defined ≥10ppb in children with no positive skin prick test (SPT), ≥12ppb in children with one positive SPT, and ≥20ppb in children with ≥2 positive SPT. Treatment steps were modified from the Australian National Asthma Council guidelines and GINA guidelines.. Duration 1 year. Concurrent medication/care: 2-week run-in period when the children were maintained on their current treatment. If they were unstable (based on clinician review and diary cards) their medications were adjusted by their treating physician and a further run-in period was undertaken<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=32) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms + treatment. Management based on clinical symptoms. Treatment decisions were made on symptoms as recorded on the asthma symptom diary card. Control was considered inadequate and treatment increased if scores increased by more than or equal to 15% since the previous visit. Treatment was stepped down if the child's scores totalled <10 in recent week. Treatment steps were modified from the Australian National Asthma Council guidelines and GINA guidelines.. Duration 1 year. Concurrent medication/care: 2-week run-in period when the children were maintained on their current treatment. If they were unstable (based on clinician review and diary cards) their medications were adjusted by their treating physician and a further run-in period was undertaken<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Academic or government funding (Asthma Foundation of Queensland 2008, Royal Children's Hospital Foundation, NHMRC) |
| | |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS + TREATMENT | |

| | |
|---|---|
| Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Children 5 -<16 : Asthma QOL score at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 : 1 or more exacerbations at 12 months; Group 1: 6/27, Group 2: 15/28; Risk of bias: Low; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Hospitalisation at 12 months; Group 1: 0/27, Group 2: 0/28; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Fluticasone dose at 12 months; Risk of bias: Low; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : FEV1 % predicted at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 136: Pijnenburg 2005[1359]**

| **Study** | **Pijnenburg 2005[1359]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=85) |
| Countries and setting | Conducted in Netherlands |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: States participants were children with atopic asthma, and fulfilled ATS criteria for asthma. |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients had been using inhaled corticosteroids (ICS) at a constant dose for at least 3 months preceding the study. All |

| | |
|---|---|
| | patients were atopic, defined as RAST class 2 or higher for at least 1 airborne allergen ever. |
| Exclusion criteria | None specified. |
| Recruitment/selection of patients | Participants were recruited from the outpatient clinic of Erasmus MC - Sophia Children's Hospital. |
| Age, gender and ethnicity | Age - Mean (SD): 12.28 (2.868). Gender (M:F): 55/30. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=42) Intervention 1: Monitoring FeNO + treatment - Monitoring FeNO and symptoms + treatment. In the intervention group, ICS doses were determined by FeNO and symptoms according to the following algorithm: FeNO >30ppb, regardless of symptoms = ICS increased; FeNO ≤30ppb AND symptoms > 14 = ICS stays same; FeNO ≤30 AND symptoms ≤14 = ICS decreased.. Duration 12 months. Concurrent medication/care: After a 2-week run-in period, participants were randomly allocated to one of two groups stratified for baseline FeNO (≥ 30 or <30 ppb) and dose of ICS (≥ 400 or <400 mcg budesonide or equivalent daily dose). Study duration was 12 months, with five visits at 3-month intervals. FeNO was measured at each visit, and the ICS dose was then adapted to FeNO and/or symptom scores recorded during the previous 2 weeks. Throughout the study, 2000 mcg per day budesonide (or equivalent dose of other ICS) was the maximum allowed dose. The study design was such that the patients' physician was allowed to deviate from the recommended ICS dose. Lung function and bronchoprovocation tests with methacholine were performed at visits 1 and 5. At all visits, inhaler technique was checked and optimised. ICS doses: 100 mcg: increase to 200 mcg, decrease to 0 mcg; 200 mcg: increase to 400 mcg, decrease to 100 mcg; 400 mcg: increase to 800 mcg, decrease to 200 mcg; 500 mcg: increase to 1000 mcg, decrease to 250 mcg; 800 mcg: increase to 1200 mcg, decrease to 400 mcg; 1000 mcg: increase to 1500 mcg, decrease to 500 mcg; 1200 mcg: increase to 1600 mcg, decrease to 800 mcg; 1600 mcg: increase to 2000 mcg, decrease to 1200 mcg; 2000 mcg: no further increase, decrease to 1000 mcg.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=47) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms + treatment. In the control group, only symptoms influenced ICS dosing. Symptoms >14 = ICS increased; symptoms ≤ 14, first time = ICS stays same; symptoms ≤14, second time = ICS decreased. . Duration 12 months. Concurrent medication/care: After a 2-week run-in period, participants were randomly allocated to one of two groups stratified for baseline FeNO (≥ 30 or <30 ppb) and dose of ICS (≥ 400 or <400 mcg budesonide or equivalent daily dose). Study duration was 12 months, with five visits at 3-month intervals. FeNO was measured at each visit, and the ICS dose was then adapted to FeNO and/or symptom scores recorded during the previous 2 weeks. Throughout the study, 2000 mcg per day budesonide (or equivalent dose of other ICS) was the maximum allowed dose. The study design was such that the patients' physician was allowed to deviate from the recommended ICS dose. Lung function and bronchoprovocation tests with |

| | |
|---|---|
| | methacholine were performed at visits 1 and 5. At all visits, inhaler technique was checked and optimised. ICS doses: 100 mcg: increase to 200 mcg, decrease to 0 mcg; 200 mcg: increase to 400 mcg, decrease to 100 mcg; 400 mcg: increase to 800 mcg, decrease to 200 mcg; 500 mcg: increase to 1000 mcg, decrease to 250 mcg; 800 mcg: increase to 1200 mcg, decrease to 400 mcg; 1000 mcg: increase to 1500 mcg, decrease to 500 mcg; 1200 mcg: increase to 1600 mcg, decrease to 800 mcg; 1600 mcg: increase to 2000 mcg, decrease to 1200 mcg; 2000 mcg: no further increase, decrease to 1000 mcg.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Other (Supported by grant from the Kroger Foundation/Sophia Children's Hospital Foundation. Authors note in conflict of interest statement that the Department of Paediatrics of Erasmus University received research grants and payments for consultancy services from Aerocine (manufacturer of NO analysers).) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Children 5 -<16 : Exacerbation - need for OCS (prednisone course) at 12 months; Group 1: 7/39, Group 2: 10/46; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome for Children 5 -<16 : Dose of regular treatment (mean daily ICS dose score, at 3 months) at 3 months; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Lung Function at End of Treatment
- Actual outcome for Children 5 -<16 : Lung function - FEV1 at 12 months; MD 2.3 (95%CI -1.8 to 6.3); Risk of bias: Very high; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 137: Pike 2012[1360]**

| Study | Pike 2012[1360] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=90) |
| Countries and setting | Conducted in United Kingdom; Setting: Secondary - hospital |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Asthma diagnosis was based upon a history of typical symptoms, ≥15% icreas i FEV1 wih bronchodilator or diurnal PEF variability of ≥15%. |
| Stratum | Children 5 -<16 |
| Subgroup anaysis within study | Not applicable |
| Inclusion criteria | Participants were age 6-17 years, clinical diagnosis of asthma and treatment with ≥400 mcg/day beclomethasone/budesonide or ≥200 mcg/day fluticasone. |
| Exlusion criteria | Inability to preform spirometry or FeNO measurement, cigarette soking, poor treatment adherence, life-threatening excerbation or need for maintenance oral prednisolone. |
| Recruitment/election of patients | Participants were recruited from outpatient clinics at Southampton University Hospital; St Mary's Hospital, Portsmouth; St Mary's Hospital, Isle of Wight; and, the Royal Hampshire County Hospital, Winchester. |
| Age, gender and ethnicity | Age - Mean (SD): 10.98 (2.695). Gender (M:F): 51/39. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=44) Intervention 1: No FeNO monitoring + treatment - Monitoring symptoms, BD use and lung function + treatment. Therapy decisions were taken by an independent clinician following a simple algorithm reflecting symptom control for standard management subjects. Under standard management, therapy was increased if symptoms were poorly controlled and decreased if symptoms were well controlled for 3 months as per the SIGN/BTS (Scottish Intercollegiate Guidelines Network/British Thoracic Society) guidelines. Algorithm for managing asthma: Standard management group: (a) poorly controlled asthma - increase inhaled corticosteroids or add LABA and/or LTRA as directed by stepwise approach to therapy SIGN/BTS; (b) asthma controlled – no change in inhaled corticosteroids; (c) well-controlled asthma – if well-controlled for 3 months reduced if inhaled corticosteroids if dose ≤400 mcg, reduce LABA.. Duration 12 months. Concurrent medication/care: Participants asthma was stabilised if necessary over 4-16 weeks prior to randomisation. Participants were assessed 2 monthly for 12 months. Participants' asthma was |

| | |
|---|---|
| | categorised as well controlled (symptoms and reliever inhaler <1 per week and FEV1 ≥90% predicted); controlled (symptoms or reliever inhaler use 1-2 days per week or FEV1 ≥80% predicted); or poorly controlled (symptoms or reliever inhaler use >2 days per week or FEV1 <80% predicted). Step 1: no inhaled corticosteroid (option 1); no inhaled corticosteroid (option 2); no inhaled corticosteroid (option 3). Step 2: Beclometasone 50 mcg twice a day via spacer (option 1); Budesonide 50 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 50 mcg once a day via spacer (or accuhaler) (option 3). Step 3: Beclometasone 100 mcg twice a day via spacer (option 1); Budesonide 100 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 50 mcg twice a day via spacer (or accuhaler) (option 3). Step 4: Beclometasone 200 mcg twice a day via spacer (option 1); Budesonide 200 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 100 mcg once a day via spacer (or accuhaler) (option 3). Step 5: Trial of LABA, if ineffective consider trial of LTRA (options 1, 2, 3). Step 6: Fluticasone 125 mcg twice a day via spacer (options 1, 2, 3). Step 7: Fluticasone 250 mcg twice a day via spacer (options 1, 2, 3). Step 8: Consider a short course of prednisolone or other therapeutic options (options 1, 2, 3).<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear<br><br>(n=46) Intervention 2: Monitoring FeNO + treatment - Monitoring FeNO and symptoms + treatment. Therapy decisions were taken by an independent clinician following a simple algorithm reflecting FeNO measurements in addition to symptom control for FeNO group. ICS was decreased if FeNO ≤15 ppb and symptoms were controlled or well controlled for 3 months in similar steps as for the standard management group. Where asthma was poorly controlled and FeNO was <25ppb in the FeNO group, long-acting beta-agonist (LABA) therapy was maximised before ICS was increased. ICS was increased if FeNO ≥25 ppb or FeNO doubled from baseline. If FeNO remained raised after increasing by two SIGN/BTS steps, ICS was not further increased unless participants were poorly controlled. Algorithm for managing asthma: FeNO group: (a) ≥25 ppb or FeNO more than twice baseline: poorly controlled asthma - increase inhaled corticosteroids or add LTRA if already at SIGN/BTS step 4 (if after increasing by two SIGN/BTS steps FeNO remains high do not increase therapy further); asthma controlled/well-controlled asthma – increase inhaled corticosteroids or add LTRA if already at SIGN/BTS step 4. (b) >15 to <25 ppb: poorly controlled asthma - increase LABA therapy (if dose maximal, increase corticosteroids or add LTRA if already at SIGN/BTS step 4); asthma controlled/well-controlled asthma – continue current treatment. (c) ≤15 ppb: poorly controlled asthma – increase LABA (if does maximal, increase corticosteroids or add LTRA if already at SIGN/BTS step 4); asthma controlled/well-controlled asthma – if asthma controlled for 3 months, reduce inhaled corticosteroids (if dose ≤400 mcg, reduce LABA).. Duration 12 months. Concurrent medication/care: Participants asthma was stabilised if necessary over 4-16 weeks prior to randomisation. Participants were assessed 2 monthly for 12 months. Participants' asthma was categorised as well controlled (symptoms and reliever inhaler <1 per week and FEV1 ≥90% predicted); controlled (symptoms or reliever inhaler use 1-2 days per week or FEV1 ≥80% predicted); or poorly controlled (symptoms or reliever inhaler use >2 days per week or FEV1 <80% predicted). Step 1: no inhaled corticosteroid (option 1); no inhaled corticosteroid (option 2); no inhaled corticosteroid (option 3). Step 2: Beclometasone 50 mcg twice a day via spacer |

| | |
|---|---|
| | (option 1); Budesonide 50 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 50 mcg once a day via spacer (or accuhaler) (option 3). Step 3: Beclometasone 100 mcg twice a day via spacer (option 1); Budesonide 100 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 50 mcg twice a day via spacer (or accuhaler) (option 3). Step 4: Beclometasone 200 mcg twice a day via spacer (option 1); Budesonide 200 mcg twice a day via spacer (or tubohaler) (options 2); Fluticasone 100 mcg once a day via spacer (or accuhaler) (option 3). Step 5: Trial of LABA, if ineffective consider trial of LTRA (options 1, 2, 3). Step 6: Fluticasone 125 mcg twice a day via spacer (options 1, 2, 3). Step 7: Fluticasone 250 mcg twice a day via spacer (options 1, 2, 3). Step 8: Consider a short course of prednisolone or other therapeutic options (options 1, 2, 3).<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Not applicable / Not stated / Unclear |
| Funding | Other (Funding was provided by Sparks) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT<br><br>Protocol outcome 1: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Children 5 -<16 : UHU - severe, requiring ≥8 hr hospital admission at 12 months; Group 1: 5/46, Group 2: 3/44; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : Dose of regular therapy - final inhaled corticosteroid dose at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 138: Shaw 2007[1574]**

| Study | Shaw 2007[1574] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=118) |
| Countries and setting | Conducted in United Kingdom; Setting: Secondary - visits took place at hospital |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Participants had a diagnosis of asthma recorded in their general practitioner's (GP) notes. Participants attended hospital for tests to characterise their asthma: exhaled nitric oxide levels measured at flow of 50 ml/second, FEV1, and forced vital capacity (FVC), methacholine challenge test to determine the concentration of methacholine required to provoke a 20% fall in FEV1, induced sputum analysis, and skin prick tests. |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | GP diagnosis of asthma. Participants were eligible if they had received at least one prescription for any antiasthma medication in the last 12 months. Study was restricted to current non-smokers with a past smoking history of less than 10 packs-years. |
| Exclusion criteria | Participants were excluded if they were considered by their physician to be poorly compliant or had had a severe asthma exacerbation, requiring a course of prednisolone, within 4 weeks of study entry. |
| Recruitment/selection of patients | Recruited from primary care - all suitable participants on the registers (held in general practices around Leicester, UK) who responded to an invitation from their GP to be contacted by the research team were invited to participate in the study. |
| Age, gender and ethnicity | Age - Mean (range): Intervention group: 50 (20-75). Control group: 52 (24-81).. Gender (M:F): 54/64. Ethnicity: Not specified |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=58) Intervention 1: Monitoring FeNO + treatment - Monitoring FeNO and symptoms + treatment. At each visit, patients asthma control was determined using a validated Juniper asthma control questionnaire, which scores asthma control from 0 to 6; a score of greater than 1.57 was used to identify poorly controlled asthma. Assessment of asthma control was made per protocol by investigators who were unaware of the participants' randomisation status. In the |

| | |
|---|---|
| | FeNO group, treatment was adjusted following a set protocol according to both the FeNO and Juniper scores. If the FeNO was greater than 26 ppb, inhaled corticosteroid treatment was increased; if it was less than 16 ppb or less than 26 ppb on two consecutive occasions, treatment was decreased. Bronchodilator therapy was increased if symptoms were uncontrolled, despite a FeNO of less than 26 ppb. *Hierarchy of Anti-Inflammatory Treatment: 1) Low dose inhaled steroid (100-200µg BDP bd). 2) Moderate dose inhaled steroid (200-800µg BDP bd). 3) High dose inhaled steroid (800-2000µg BDP bd). 4) High dose inhaled steroid (800-2000µg BDP bd) plus leukotriene antagonist. 5) Higher dose inhaled steroid (2000µg BDP bd) plus leukotriene antagonist. 6) Higher dose inhaled steroid (2000µg BDP bd) plus leukotriene antagonist plus oral Prednisolone 30mg. 2/52, then titrating dose reducing by 5mg/week **Hierarchy of Bronchodilator Treatment: 1) PRN short acting β2-agonists. 2) Long acting β2 agonist. 3) Long acting β2 agonist plus theophylline. 4) Long acting β2-agonist plus theophylline plus nebulised bronchodilator.. Duration 12 months. Concurrent medication/care: Participants were seen 2 weeks following characterisation of their asthma, and then every month for 4 months; they were seen every 2 months for a further 8 months. Each visit occurred at the same time of day and consisted of assessment of exhaled nitric oxide, spirometry, and post-bronchodilator FEV1, 20 minutes after 400 mcg albuterol at the end of every visit. Peak flow and symptom diaries were analysed and compliance assessed by monitoring adherence to prescription script collection. Participants were issued with self-management plans based on their baseline peak flow from the first 2 weeks of the study; if their peak flow fell to less than 70% of their best peak flow for 48 hours during the study, or their asthma deteriorated, they were asked to attend the hospital where they were assessed by a physician.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients<br><br>(n=60) Intervention 2: No FeNO monitoring + treatment - Monitoring symptom control questionnaires + treatment. At each visit, patients asthma control was determined using a validated Juniper asthma control questionnaire, which scores asthma control from 0 to 6; a score of greater than 1.57 was used to identify poorly controlled asthma. Assessment of asthma control was made per protocol by investigators who were unaware of the participants' randomisation status. In the control group, treatment was doubled if the score was more than 1.57, and treatment was halved if the score was less than 1.57 for 2 consecutive months. Step 1: SABA as required. Step 2: Add inhaled steroid 200 to 800mcg/day BDP equivalent. Step 3: Add inhaled LABA. Step 4: Increase ICS up to 2000mcg/day and addition of 4th drug, e.g. LTRA, theophylline, LABA. Step 5: Oral prednisolone, high does ICS, refer to specialist care.. Duration 12 months. Concurrent medication/care: Participants were seen 2 weeks following characterisation of their asthma, and then every month for 4 months; they were seen every 2 months for a further 8 months. Each visit occurred at the same time of day and consisted of assessment of exhaled nitric oxide, spirometry, and post-bronchodilator FEV1, 20 minutes after 400 mcg albuterol at the end of every visit. Peak flow and symptom diaries were analysed and compliance assessed by monitoring adherence to prescription script collection. Participants were issued with self-management plans based on their baseline peak flow from the first 2 weeks of the study; if their peak flow fell to less than 70% of their best peak flow for 48 hours during the study, or their asthma deteriorated, they |

| | |
|---|---|
| | were asked to attend the hospital where they were assessed by a physician.<br>Further details: 1. Additional education training: Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients |
| Funding | Academic or government funding (Trial supported by a grant from Asthma UK. Conflict of interest statement: authors received grants (research and travel) from Glaxo SmithKline and lecture fees from Astra eneca.) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO AND SYMPTOMS + TREATMENT versus MONITORING SYMPTOM CONTROL QUESTIONNAIRES + TREATMENT<br><br>Protocol outcome 1: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Exacerbation - course of oral steroids or antibiotics at 12 months; Group 1: 12/58, Group 2: 19/60; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Dose of regular therapy - ICS, expressed as equivalent dose to BDP at 12 months; MD -338 (95%CI -640 to -37); Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 139: Smith 2005[1628]**

| Study | Smith 2005[1628] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=110) |
| Countries and setting | Conducted in New Zealand; Setting: Primary care |
| Line of therapy | Unclear |
| Duration of study | Intervention time: Phase 1 stabilisation on optimum therapy (mean 22 and 25 weeks in the 2 groups); phase 2 dose adjustment using FeNO or control: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Chronic asthma |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | 12 to 75 years of age with chronic asthma, managed in primary care, regular inhaled corticosteroids for six months or more with no change in dose in last 6 weeks |
| Exclusion criteria | Four or more courses of oral prednisone in the previous 12 months; admission to the hospital because of asthma in the previous 6 months or to the intensive care unit because of asthma at any time in the past; and cigarette smoking, either current or past, with a history of more than 10 pack-years. |
| Recruitment/selection of patients | Not stated |
| Age, gender and ethnicity | Age - Mean (range): 44.8 (12 to 73) years. Gender (M:F): 41:69. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=48) Intervention 1: Monitoring FeNO + treatment. Dose adjustment based on FeNO. Visits every 2 months for 1 year. Cut-off 15ppb (at an exhaled flow rate of 250 ml per second), above which an increase in the dose of inhaled corticosteroid was prescribed; this FeNO value is equivalent to 35 ppb at a flow rate of 50 ml per second. Subjects in the FeNO group had a predetermined “safety buffer” by which an upward (one-step) adjustment in the dose was provided to deal with deteriorating asthma in the absence of a rise in measured FeNO. Duration 12 months. Concurrent medication/care: 5 patients on LABA. Two-week run-in period. At the second visit, all patients were started on inhaled fluticasone. During phase 1, the dose of inhaled fluticasone was titrated downward in a stepwise manner until the optimal dose was deemed to have been achieved. Subjects received 750 µg per day to start (or 500 µg per day if their inhaled-corticosteroid requirement before enrolment was less than 200 µg per day of fluticasone or the equivalent). |

| | |
|---|---|
| | Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to increase ICS in uncontrolled patients<br><br>(n=49) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms, BD use and lung function + treatment. Dose adjustments were based on predetermined thresholds in regard to symptoms, bronchodilator use, diurnal peak flows, and spirometry with an algorithm based on Global Initiative for Asthma 2002 criteria. Visits every 2 months for 1 year.. Duration 12 months. Concurrent medication/care: 8 patients on LABA. Two-week run-in period. At the second visit, all patients were started on inhaled. During phase 1, the dose of inhaled fluticasone was titrated downward in a stepwise manner until the optimal dose was deemed to have been achieved. Subjects received 750 µg per day to start (or 500 µg per day if their inhaled-corticosteroid requirement before enrolment was less than 200 µg per day of fluticasone or the equivalent).<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to increase ICS in uncontrolled patients |
| Funding | Academic or government funding (Otago Medical Research Foundation, Dunedin School of Medicine, University of Otago) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people (16 years and over): Number of patients requiring at least one course of OCS at 12 months; Group 1: 13/46, Group 2: 15/48; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Rescue medication at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Bronchodilator mean puffs/day (past 7 days) at 12 months; Group 1: mean 0.4 puffs/day (SD 1.04); n=46, Group 2: mean 0.4 puffs/day (SD 0.88); n=48; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Dose of fluticasone at 12 months; Group 1: mean 370 microg/day (SD 370); n=46, Group 2: mean 641 microg/day (SD 407); n=48; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Lung Function at End of Treatment
- Actual outcome for Adults and young people (16 years and over): FEV1 % predicted at 12 months; MD 3.8 (SE 4.4); Risk of bias: High; Indirectness of outcome: No indirectness

| | |
|---|---|
| - Actual outcome for Adults and young people (16 years and over): PEF am (mean previous 7 days) at 12 months; MD 1.0 (SE 13.2); Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Symptom free days at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Percentage of symptom-free days at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Time of school/work at End of Treatment |

**Table 140: Syk 2013[1711]**

| Study | Syk 2013[1711] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=181) |
| Countries and setting | Conducted in Sweden; Setting: Primary care. |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Physician's diagnosis of asthma, had been on prescribed ICS treatment for at least 6 months, and had confirmed IgE sensitisation to at least 1 major airborne perennial allergen (dog, cat, or mite). |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Eligible participants had a physician's diagnosis of asthma, had been on prescribed ICS treatment for at least 6 months, and had confirmed IgE sensitisation to at least 1 major airborne perennial allergen (dog, cat, or mite). In addition: age 18-64 years old, non-smokers since at least 1 year earlier and with a smoking history of <10 packs years. |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | Participants recruited from 17 primary health care centres in 7 different autonomous health care regions in central and southern Sweden. |
| Age, gender and ethnicity | Age - Mean (SD): 41 (12.4). Gender (M:F): 94/87. Ethnicity: Not stated |

| | |
|---|---|
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=93) Intervention 1: Monitoring FeNO + treatment. In the FeNO-guided group, the anti-inflammatory treatment (ICS and leukotriene receptor antagonist [LTRA]) was adjusted according to an algorithm based on exhaled NO levels (FeNO <19ppb (men), <21ppb (women) - decrease one step; FeNO 19-23 (men), 21-25 (women) - no change; FeNO ≥24ppb (men), ≥26ppb (women) - increase one step (no change in treatment step if on step 4 or 5 and using ≤i2 inhalations of short-acting beta2 agonist per week); FeNO ≥30ppb (men), ≥32ppb (women)- increase two steps (only if one treatment step 1); grey zone of 5ppb applied to avoid frequent dose changes) and 6 fixed treatment steps (Steps 1-6: Budesonide (mcg/day): 0, 200, 400, 800, 800+LTRA, 1600+LTRA; Fluticasone (mcg/day): 0, 100, 250, 500, 500+LTRA; 1000+LTRA; Mometasone (mcg/day): 0, 100, 200, 400, 400+LTRA, 800+LTRA).. Duration 12 months. Concurrent medication/care: Capillary blood was sampled to confirm perennial allergy by using ImmunoCAP Rapid Wheeze/Rhinitis Child. All participants currently being treated with combination inhalers (corticosteroid plus LABA) were required to switch to the corresponding single corticosteroid inhaler to withdraw the LABA component. All patients switched SABA to a salbutamol inhaler which incorporates a dose counter. Venous blood was sampled for serum IgE All participants received a logbook to take home, in which they noted contacts with health care, changes in drug therapy, sick leave, or other problems between scheduled visits.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients (The goal of the asthma treatment was to achieve and maintain clinical control, which implies that the patients should be free from symptoms; maintain normal activity levels, including physical exercise; maintain pulmonary function as close to normal as possible; avoid adverse effects of asthma medication; and have little or no need for reliever medication, all according to the Swedish Medical Product Agency recommendations.).<br><br>(n=88) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms, BD use and lung function + treatment. In the control group, FeNO measurement was done but blinded to both operator and patient, and treatment was adjusted according to usual care, that is, based on patient-reported symptoms, SABA use, physical examination, and results of pulmonary function tests. In the control group, only the treatment steps (as described for the intervention group) were allowed, but changes in treatment steps were entirely at the discretion of the treating physician, and immediate changes over several steps were allowed. Permissible treatment steps (as described for the intervention group) basically followed the prevailing national guidelines at the time of the study start, issued in 2002 by the Swedish Medical Product Agency, with the exception that only LTRA was used as an add-on treatment.. Duration 12 months. Concurrent medication/care: Capillary blood was sampled to confirm perennial allergy by using ImmunoCAP Rapid Wheeze/Rhinitis Child. All participants currently being treated with combination inhalers (corticosteroid plus LABA) were required to switch to the corresponding single corticosteroid inhaler to withdraw the LABA component. All patients switched SABA to a salbutamol inhaler which incorporates a dose counter. Venous |

| | |
|---|---|
| | blood was sampled for serum IgE analysis. All participants received a logbook to take home, in which they noted contacts with health care, changes in drug therapy, sick leave, or other problems between scheduled visits.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to decrease ICS in controlled patients (The goal of the asthma treatment was to achieve and maintain clinical control, which implies that the patients should be free from symptoms; maintain normal activity levels, including physical exercise; maintain pulmonary function as close to normal as possible; avoid adverse effects of asthma medication; and have little or no need for reliever medication, all according to the Swedish Medical Product Agency recommendations.). |
| Funding | Academic or government funding (Study was funded by the Stockholm country council (PickUp), Centre for Allergy Research, Korlinska Institutet, and the Research Foundation of the Swedish Asthma and Allergy Association. Support also from Aerocine AB (NIOX MINO instruments), Phadia AB (ImmuncoCAP Rapid), Meda AB (Buventol Easyhaler), and MSD Sweden (small grant). Authors not conflicts of interest: grants from Aerocrine AB and Research Council for Working Life and Social Research; stock/stock options as employee and co-founder of Aerocine, etc.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people (16 years and over): Exacerbation - severe (≥1 event, course of OCS) at 12 months; Group 1: 8/93, Group 2: 6/88; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Asthma control questionnaires at End of Treatment
- Actual outcome for Adults and young people (16 years and over): ACQ - clinically important improvement (≥0.5) at 12 months; Group 1: 29/81, Group 2: 19/74; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 3: Rescue medication at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Rescue medication (SABA use per week, at 8-12 months, i.e. ≥6 months) at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Dose of regular therapy (Budesonide equivalent dose) at 12 months; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 5: Lung Function at End of Treatment

| | |
|---|---|
| - Actual outcome for Adults and young people (16 years and over): Lung function - FEV1 (litres) at 12 months; Group 1: mean -0.034 litres (SD 0.28); n=88, Group 2: mean -0.006 litres (SD 0.28); n=78; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 141: Szefler 2008[1712]**

| Study | Szefler 2008[1712] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=546) |
| Countries and setting | Conducted in USA; Setting: 10 centres |
| Line of therapy | Unclear |
| Duration of study | Intervention time: 46 weeks |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Physician diagnosis |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Aged 12 to 20 years, with asthma; residents of urban census tracts in which at least 20 percent of households had incomes below the federal poverty threshold. Individuals receiving long-term control therapy were required to have symptoms of persistent asthma or evidence of uncontrolled disease. Individuals not receiving long-term control therapy were required to have both symptoms of persistent asthma and evidence of uncontrolled disease defined by NAEPP guidelines |
| Exclusion criteria | Excluded after the run-in if controller adherence was <25%. Participants with a urinary cotinine >100 excluded (active smokers) |
| Recruitment/selection of patients | Not stated |
| Age, gender and ethnicity | Age - Mean (SD): 14.4 ± 2.1 years in each group. Gender (M:F): 288:258. Ethnicity: Black: 347/546 (64%); Hispanic: 125/546 (23%); other/mixed: 74/546 (13%) |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=276) Intervention 1: Monitoring FeNO, lung function, BD use and symptoms + treatment. Exhaled nitric oxide |

| | |
|---|---|
| | (eNO) added to guideline-based care. FENO was measured for each participant at every visit, but only influenced treatment of the FENO Group. Control level and FENO data were entered into a computer program which generated two treatment options for the blinded physician, one for the Reference Group and another for the FENO Group. The treatment options were derived from protocol-defined treatment steps. Duration 46 weeks. Concurrent medication/care: For safety reasons, FENO was not allowed to increase treatment on the third consecutive visit without elevated symptoms. Also low FENO alone was not allowed to reduce therapy without a corresponding reduction in symptoms.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to increase ICS in uncontrolled patients<br><br>(n=270) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms, BD use and lung function + treatment. Based on National Asthma Education and Prevention Program (NAEPP) guidelines. Duration 46 weeks. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear 2. Aim of intervention: Aim to increase ICS in uncontrolled patients |
| Funding | Academic or government funding (National Institute of Allergy and Infectious Diseases, National Institutes of Health and National Centre for Research Resources, National Institutes of Health) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Children 5 -<16 : OCS at 46 weeks; Group 1: 89/250, Group 2: 113/244; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 2: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment
- Actual outcome for Children 5 -<16 : Hospitalisation at 46 weeks; Group 1: 9/250, Group 2: 11/244; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Children 5 -<16 : Unscheduled visits at 46 weeks; Group 1: 59/250, Group 2: 61/244; Risk of bias: Low; Indirectness of outcome: No indirectness

Protocol outcome 3: Asthma control questionnaires at End of Treatment
- Actual outcome for Children 5 -<16 : Poor control at >20% of visits at 46 weeks; Group 1: 59/267, Group 2: 63/267; Risk of bias: Low; Indirectness of outcome: No indirectness
- Actual outcome for Children 5 -<16 : Asthma Control Test score in last month at 46 weeks; Group 1: mean 21.89 Not stated (SD 1.9); n=250, Group 2: mean 21.83 Not stated (SD 1.87); n=244; Asthma Control Test Not stated Top=High is good outcome; Risk of bias: Low; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Children 5 -<16 : ICS daily dose (fluticasone) at 46 weeks; MD 118.9 (95%CI 48.5 to 189.3); Risk of bias: Low; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 5: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16 : FEV1 % pred at 46 weeks; MD 0.8 (95%CI -0.51 to 2.07); Risk of bias: Low; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Symptom free days at End of Treatment<br>- Actual outcome for Children 5 -<16 : Number of symptom-days in last 2 weeks at 46 weeks; Group 1: mean 1.93 days (SD 1.42); n=250, Group 2: mean 1.89 days (SD 1.41); n=244; Risk of bias: Low; Indirectness of outcome: No indirectness<br><br>Protocol outcome 7: Time of school/work at End of Treatment<br>- Actual outcome for Children 5 -<16 : School days missed in last 2 weeks at 46 weeks; Group 1: mean 0.19 days (SD 0.47); n=250, Group 2: mean 0.23 days (SD 0.47); n=244; Risk of bias: Low; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Rescue medication at End of Treatment |

**Table 142: Verini 2010[1857]**

| Study | Verini 2010[1857] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=64) |
| Countries and setting | Conducted in Italy; Setting: Secondary care |
| Line of therapy | Unclear |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Diagnosis was made by a paediatric respiratory physician on the basis of clinical history of repeated episodes of coughing, dyspnoea, and wheezing, according to ATS-ERS criteria |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Children with allergic asthma; age 6-17 years; referred to the Allergological and Pneumological Unity of the Paediatric Department, University of Chieti, Italy, between January 2005 and January 2006. |
| Exclusion criteria | Not stated |

| | |
|---|---|
| Recruitment/selection of patients | Not stated |
| Age, gender and ethnicity | Age - Mean (SD): FeNO group: 10.7 ± 2.4 years; GINA group: 11.3 ± 2.1 years, range 6-17 years. Gender (M:F): 36:28. Ethnicity: Caucasian |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=32) Intervention 1: Monitoring FeNO + treatment. Therapy was based on symptoms, short acting β2-agonist use, and lung function and FeNO measurements. Duration 12 months. Concurrent medication/care: Not stated<br>Further details: 1. Additional education training : 2. Aim of intervention:<br><br>(n=32) Intervention 2: No FeNO monitoring + treatment - Monitoring symptoms and lung function + treatment. Therapy was based on symptoms, short acting β2-agonist use, and lung function. Duration 12 months. Concurrent meication/care: ot stated<br>Further details:1. Additional education training : 2. Aim of intervention: |
| Funding | Funding not stated |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING FENO + TREATMENT versus MONITORING SYMPTOMS AND LUNG FUNCTION + TREATMENT

Protocol outcome 1: Rescue medication at End of Treatment
- Actual outcome for Children 5 -<16 : Number of patients with exacerbations (defined as the number of episodes of coughing, dyspnoea, and wheezing, according to ATS-ERS criteria, requiring short-acting β2-adrenergic agonist) at 12 months; Group 1: 16/32, Group 2: 26/32; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome fo Children 5 -<16 : Number of patients not using inhaled corticosteroids or anti-leukotrienes at 12 months; Group 1: 2/32, Group 2: 6/32; Risk of bias: High; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

# G.18 Challenge tests to monitor asthma control

**Table 143: Koenig 2008[895]**

| Study | Koenig 2008[895] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=466) |
| Countries and setting | Conducted in Latvia, Multiple countries, USA; Setting: 50 sites in the US, three sites in Latin American, and two sites in Latvia. |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 40 weeks |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Either historical documentation of reversible airways disease within the last 24 months or an increase in FEV1 of at least 12% within 30 min of inhalation of 2 puffs (180 mcg) of albuterol. |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Male and female patients, 12 years of age and older; asthma for at least 3 months and had been treated during the previous month with short-acting beta2-agonists, anticholinergics, or ICS (p250 mcg daily of fluticasone propionate (FP) or equivalent). At the screening visit, all patients were required to have a forced expiratory volume in 1 s (FEV1) between 60% and 95% of predicted normal |
| Exclusion criteria | Pregnancy; lifethreatening asthma, hospitalization attributable to asthma within the last 6 months, current smoker or a >10 pack-year history of smoking, a recent (within 2 weeks) upper or lower respiratory tract infection, or significant concurrent diseases. Medications that could confound the evaluation of the study treatments or treatment strategies were prohibited before and throughout the study, including inhaled (up to 250 mcg FP allowed prior to randomization), oral, or parenteral corticosteroids (with the exception of protocol defined use of oral corticosteroids following second consecutive assignment to the highest dose of FP), theophylline or other bronchodilators, leukotriene modifiers, anticholinergics, cromolyn, and nedocromil |
| Recruitment/selection of patients | Patients underwent physical examination, pulmonary function testing, and other pre-study procedures at the screening visit |
| Age, gender and ethnicity | Age - Mean (range): 34.8 (12–81), 34.8 (12–81) and 33.2 (12–72) years in the three groups. Gender (M:F): 85:115. Ethnicity: White FSCBHR 124 (79%), FPBHR 120 (77%), FPREF 124 (81%); Black FSCBHR 18 (12%), FPBHR 24 (15%), FPREF 16 (10%); Other FSCBHR 14 (9%), FPBHR 12 (8%), FPREF 14 (9%) |

| | |
|---|---|
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=156) Intervention 1: Monitoring challenge tests + treatment - Monitoring direct challenge tests + treatment. Starting dose of treatment and adjustment of dose (at each 8 week visit for 40 weeks) based on severity class or BHR. Severity class included 4 treatment steps based on control over the past 14 days based on the highest of the following clinical measures (symptoms, BD use, PEFv, FEV1) or BHR. Treatment steps 1-no ICS (placebo); 2-FSC 100/50mcg BID; 3-FSC 250/50mcg BID; 4-500/50mcg BID. For BHR (methacholine PC20) severity class one >4mg/ml; two 1.1-4mg/ml; three 0.25-1mg/ml; four <0.25mg/ml.. Duration 40 weeks. Concurrent medication/care: SABA replaced by albuterol for study duration. ICS was fluticasone propionate using the DISKUS. If patient remained in step 4 for 2 or more visits they were given OCS.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear<br><br>(n=154) Intervention 2: No challenge test monitoring + treatment - Monitoring symptoms, lung function and BD use + treatment. Starting dose of treatment and adjustment of dose (at each 8 week visit for 40 weeks) based on severity class (without BHR as a clinical measure). Severity class included 4 treatment steps based on control over the past 14 days based on the highest of the following clinical measures (symptoms, BD use, PEFv, FEV1). Treatment steps 1-no ICS (placebo); 2-FSC 100/50mcg BID; 3-FSC 250/50mcg BID; 4-500/50mcg BID. . Duration 40 weeks. Concurrent medication/care: SABA replaced by albuterol for study duration. ICS was fluticasone propionate using the DISKUS. If patient remained in step 4 for 2 or more visits they were given OCS.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (GlaxoSmithKline, Research Triangle Park, NC.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING DIRECT CHALLENGE TESTS + TREATMENT versus MONITORING SYMPTOMS, LUNG FUNCTION AND BD USE + TREATMENT

Protocol outcome 1: Mortality at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Death at 40 weeks; Group 1: 1/105, Group 2: 0/107; Risk of bias: Very high; Indirectness of outcome: No indirectness

Protocol outcome 2: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people (16 years and over): Asthma exacerbation (not defined) at 40 weeks; Group 1: 22/105, Group 2: 26/107; Risk of bias: Very high; Indirectness of outcome: Exacerbations not defined, serious indirectness.

| | |
|---|---|
| Protocol outcome 3: Rescue medication at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Albuterol use (puff/day) at 40 weeks; Group 1: mean -0.8 puffs/day (SD 1.8); n=105, Group 2: mean -0.7 puffs/day (SD 1.8); n=107; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): Mean inhaled corticosteroid daily dose over treatment period (mcg) at 40 weeks; MD 131.2 (95%CI 83.2 to 178.5) (P=0.037 van Elteren tests ); Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 5: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): AM PEF at 40 weeks; Group 1: mean 16.9 L/min (SD 92.2); n=105, Group 2: mean 25.5 L/min (SD 92.1); n=107; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): PM PEF at 40 weeks; Group 1: mean 16.4 L/min (SD 89.1); n=105, Group 2: mean 22.4 L/min (SD 88.9); n=107; Risk of bias: High; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Pre-dose FEV1 at 40 weeks; Group 1: mean 0.06 L (SD 0.51); n=105, Group 2: mean 0.11 L (SD 0.52); n=107; Risk of bias: High; Indirectness of outcome: No indirectness<br><br>Protocol outcome 6: Symptom free days at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): % symptom-free days at 40 weeks; Group 1: mean 13 % (SD 56.2); n=105, Group 2: mean 18.1 % (SD 54.9); n=107; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Time of school/work at End of Treatment |

**Table 144: Lipworth 2012[1030]**

| **Study** | **STAMINA trial: Lipworth 2012[1030]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=157) |
| Countries and setting | Conducted in United Kingdom; Setting: Primary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: History of mild to moderate persistent asthma |

| | |
|---|---|
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Between 18 and 65 years of age and with a history of mild to moderate persistent asthma; prebronchodilator FEV 1 was required to be > 60% predicted for the purposes of challenge testing. |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | At the time of patients' entry into the study, AHR was established through a provocative dose of mannitol causing a 10% fall in FEV 1 (PD 10) ≤ 635 mg at the end of the step-down period. Patients initially underwent step-down of their existing treatment with follow-up every 2 weeks. Patients on combination inhalers were switched to an equivalent dose of the same ICS only. The dose of ICS was then halved every 2 weeks until patients were taking 200 m g/d beclomethasone dipropionate equivalent or they became clinically unstable. Once unstable, patients were stepped back up to the last stable dose of ICS. All patients were then converted to an equivalent dose of the reference ICS, namely ciclesonide, to be taken throughout the rest of the study. |
| Age, gender and ethnicity | Age - Mean (SD): Control 53.7 (1.7); intervention 53.2 (1.6) years. Gender (M:F): Not stated. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | Serious indirectness: Patients initially underwent step-down of their existing treatment. Patients on combination inhalers were switched to an equivalent dose of the same ICS only (unclear whether LABA was continued) |
| Interventions | (n=80) Intervention 1: Monitoring challenge tests + treatment - Monitoring indirect challenge tests + treatment. Treatment adjusted based on mannitol AHR only, every 2 months for 12 months. ICS dose increased by one step every 2 months until they became unresponsive to mannitol (PD10>635mg). Treatment steps: ciclesonide, step 1: 80mcg once daily, step 2: 160mcg once daily, step 3: 320mcg once daily, step 4: 160mcg and 320mcg BID, step 5: 320mcg BID.. Duration 12 months. Concurrent medication/care: Initial step-down of existing treatment and those on combination inhalers switched to same ICS only. Dose of ICS halved every 2 weeks until taking 200ug/d beclomethasone dipropionate or equivalent or became unstable - put back to last stable ICS dose. All then converted to equivalent ciclesonide. Further details: 1. Additional education training : Not applicable / Not stated / Unclear<br><br>(n=77) Intervention 2: No challenge test monitoring + treatment - Monitoring symptoms, lung function and BD use + treatment. Treatment adjusted according to BTS guidelines every 2 months for 12 months. ICS dose increased by one step if 1. fall in PEF >20% baseline; 2. fall in FEV1 >20% baseline; 3. BD use more than 0.5puffs/day; 4. symptom score >0.5. Treatment steps: ciclesonide, step 1: 80mcg once daily, step 2: 160mcg once daily, step 3: 320mcg once daily, step 4: 160mcg and 320mcg BID, step 5: 320mcg BID.. Duration 12 months. Concurrent medication/care: Initial step-down of existing treatment and those on combination inhalers switched to same ICS only. Dose of ICS halved every 2 weeks until taking 200ug/d beclomethasone dipropionate or equivalent or became unstable - put back to last stable ICS dose. All |

| | |
|---|---|
| | then converted to equivalent ciclesonide.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear |
| Funding | Study funded by industry (University Departmental grants as well as by Pharmaxis, who supplied mannitol as a gift and donated an unrestricted educational grant. Nycomed supplied the ciclesonide inhalers as a gift and also provided an unrestricted educational grant.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING INDIRECT CHALLENGE TESTS + TREATMENT versus MONITORING SYMPTOMS, LUNG FUNCTION AND BD USE + TREATMENT

Protocol outcome 1: Quality of life at End of treatment
- Actual outcome for Adults and young people (16 years and over): mini AQLQ at 12 months; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Adults and young people (16 years and over): Severe exacerbations requiring oral corticosteroids at 12 months; Group 1: 12/61, Group 2: 13/58; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Rescue medication at End of Treatment
- Actual outcome for Adults and young people (16 years and over): Reliever use (puffs/day) at 12 months; MD 0.31 (95%CI -0.12 to 0.73) (P=0.16 ) (final value is lower in the intervention group, therefore mean difference analysed as -0.31); Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome for Adults and young people (16 years and over): ciclesonide dose mcg at 12 months; MD 306 (95%CI 241.6 to 370.2); Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 5: Lung Function at End of Treatment
- Actual outcome for Adults and young people (16 years and over): AM PEF at 12 months; MD 1.5 (95%CI -37.7 to 34.7) (P=0.93 ); Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people (16 years and over): FEV1% at 12 months; Group 1: mean 2 % (SD 22.3); n=61, Group 2: mean 1.7 % (SD 24.9); n=58; % 0-100 Top=High is good outcome; Risk of bias: High; Indirectness of outcome: No indirectness
- Actual outcome for Adults and young people (16 years and over): PEF% at 12 months; Group 1: mean 3.1 % (SD 25.9); n=61, Risk of bias: High; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcomes not reported by the study | Mortality at End of Treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of |

| | |
|---|---|
| | Treatment |

**Table 145: Nuijsink 2007[1260]**

| **Study** | **Children Asthma Therapy Optimal (CATO) Study trial: Nuijsink 2007[1260]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=210) |
| Countries and setting | Conducted in Netherlands; Setting: 15 centres; secondary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 2 years |
| Method of assessment of guideline condition | Adequate method of assessment/diagnosis: Documented clinical history of moderate persistent asthma, according to GINA guidelines. |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Children with clinically stable asthma living in the Netherlands, aged 6–16 yrs and with a documented clinical history of moderate persistent asthma, according to GINA guidelines. All patients gave a positive, class ≥1, radioallergosorbent test result for one or more airborne allergens and used ≥200 µg/day fluticasone or an equivalent dose of other ICS.<br><br>In children treated with 500 mg/day fluticasone who did not meet the criteria for randomisation after 1 month, the dose of ICS was tapered down to 200 mg/day fluticasone for a further 2 months before randomisation. After run-in, children were randomised into one of two treatment strategy arms if they showed a cumulative symptom score ≥14 during the last 2 weeks of the run-in period and/or a PD20<150mg. |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | Selected on the basis of symptom scores and/or the presence of airway hyper-responsiveness |
| Age, gender and ethnicity | Age - Mean (SD): Intervention: 10.8+/-2.4 years; control: 10.9+/-2.5 years. Gender (M:F): 117:89. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | Serious indirectness: Patients initially underwent step-down of their existing treatment. |
| Interventions | (n=102) Intervention 1: Monitoring challenge tests + treatment - Monitoring direct challenge tests + treatment. Treatment adjusted on the basis of AHR and symptom score according to a three step medication level algorithm. AHR methacholine dosimeter method PD20.- Increase by 1: PD20<100mcg and SS<14 or PD20<300mcg and SS>=14- No |

| | |
|---|---|
| | change: PD20 100-300mcg and SS<14 or PD20>=300mcg and SS>=14- Decrease by 1: PD20>300mcg and SS<14.. Duration 2 years. Concurrent medication/care: During run-in patients put on 100 or 250 FP BID depending on equivalent treatment before run-in.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear<br><br>(n=104) Intervention 2: No challenge test monitoring + treatment - Monitoring symptoms + treatment. Treatment adjusted on the basis of symptom score only according to a three step medication level algorithm. Symptoms from diary 2 weeks before visit. - Increase by 1: SS>=14- No change: SS 0-14- Decrease by 1: SS=0. Duration 2 years. Concurrent medication/care: During run-in patients put on 100 or 250 FP BID depending on equivalent treatment before run-in.<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear |
| Funding | Funding not stated |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING DIRECT CHALLENGE TESTS + TREATMENT versus MONITORING SYMPTOMS + TREATMENT

Protocol outcome 1: Exacerbation (need for OCS) at End of treatment
- Actual outcome for Children 5 -<16 : At least one exacerbation at 2 years; Group 1: 16/102, Group 2: 17/104; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 2: Dose of regular asthma treatment (SABA, ICS) at End of Treatment
- Actual outcome for Children 5 -<16 : Mean daily ICS dose for treatment period at 2 years; Group 1: mean 562 mcg/day (SD 239); n=85, Group 2: mean 478 mcg/day (SD 256); n=90; Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 3: Lung Function at End of Treatment
- Actual outcome for Children 5 -<16 : FEV1 % at 2 years; MD 6.0 (95%CI 1.2 to 10.8); Risk of bias: High; Indirectness of outcome: No indirectness

Protocol outcome 4: Symptom free days at End of Treatment
- Actual outcome for Children 5 -<16 : % symptom-free days (in last 3 months) at 2 years; Risk of bias: High; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Time of school/work at End of Treatment |

**Table 146: Sont 1999[1642]**

| Study | AMPUL trial: Sont 1999[1642] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=75) |
| Countries and setting | Conducted in Netherlands; Setting: Secondary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 2 years |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: History of episodic chest tightness and wheezing in the previous year and visiting a chest physician for their asthma. |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients who were visiting a chest physician for their asthma at one of the outpatient clinics of four hospitals in the Leiden area; history of episodic chest tightness and wheezing in the previous year; AHR was established through a 20% decrease in FEV1 in response to a provocative concentration of inhaled methacholine (PC20) of < 8 mg/ml; nonsmokers at the time of recruitment (> 1 yr; < 5 pack-yr), and were atopic, between 18 and 50 yr of age, and had had a history of episodic chest tightness and wheezing in the previous year. Atopy was assessed through a positive skin-prick test (> 3 mm wheal) to one or more common airborne allergen extracts. Prebronchodilator FEV1 was more than 50% predicted and > 1.5 L, whereas postbronchodilator FEV1 was within the normal range (> 80% predicted). Subjects were eligible when they had used no other medication than regular inhaled steroids and/or beta-agonists as needed for their asthma during the 6 mo before entry. All subjects gave their written informed consent |
| Exclusion criteria | Not stated |
| Recruitment/selection of patients | Outpatient clinics of four hospitals in the Leiden area |
| Age, gender and ethnicity | Age - Mean (SD): Intervention 31.5 (1.7); control 28.2 (1.3) years. Gender (M:F): 37:38. Ethnicity: Not stated |
| Further population details | |
| Indirectness of population | No indirectness |
| Interventions | (n=34) Intervention 1: Monitoring challenge tests + treatment - Monitoring direct challenge tests + treatment. Treatment adjusted at each 3 month visit based on severity class or AHR. Severity class included 4 treatment steps based on the highest of the following clinical measures (symptoms, BD use, PEFv, FEV1 or BHR). Treatment steps 1-no ICS; 2-low dose ICS; 3-intermediate dose ICS; 4-hig dose ICS plus OCS course. For AHR (methacholine PC20) severity class one |

| | |
|---|---|
| | >4mg/ml; two 1.0-4mg/ml; three 0.25-1mg/ml; four <0.25mg/ml.. Duration 2 years. Concurrent medication/care: SABA used as needed<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear<br><br>(n=41) Intervention 2: No challenge test monitoring + treatment - Monitoring symptoms, lung function and BD use + treatment. Treatment adjusted at each 3 month visit based on severity class ONLY. Severity class included 4 treatment steps based on the highest of the following clinical measures (symptoms, BD use, PEFv, FEV1). Treatment steps 1-no ICS; 2-low dose ICS; 3-intermediate dose ICS; 4-hig dose ICS plus OCS course. . Duration 2 years. Concurrent medication/care: SABA use as needed<br>Further details: 1. Additional education training : Not applicable / Not stated / Unclear |
| Funding | Academic or government funding (The Netherlands Asthma Foundation) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: MONITORING DIRECT CHALLENGE TESTS + TREATMENT versus MONITORING SYMPTOMS, LUNG FUNCTION AND BD USE + TREATMENT<br><br>Protocol outcome 1: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): FEV1 L at 2 years; Group 1: mean 78 mL/year (SD 34); n=32, Group 2: mean -7 mL/year (SD 36); n=35; Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

## G.19 Monitoring adherence to treatment

**Table 147: BURGESS 2010[246]**

| **Study** | **Burgess 2010[246]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |

| | |
|---|---|
| Number of studies (number of participants) | 1 (n=26) |
| Countries and setting | Conducted in Australia; Setting: Paediatric asthma clinic, outer metropolitan general hospital |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 4 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Dx with asthma |
| Stratum | Children 5 -<16 with uncontrolled asthma: Children 6-14 years, asthma not well controlled despite preventative medication ('unstable asthma') |
| Subgroup analysis within study | Not applicable: |
| Inclusion criteria | Aged 6-14 years; asthma not well controlled (based on a reported history of asthma symptoms occuring more than twice a week and requiring reliever medication and/or lung function FEV1 <80%) |
| Exclusion criteria | nr |
| Recruitment/selection of patients | nr |
| Age, gender and ethnicity | Age - Range: 6-14 years. Gender (M:F): 17/9. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Near fatal asthma attacks: Not applicable / Not stated / Unclear 4. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness |
| Interventions | (n=14) Intervention 1: Adherence monitoring + treatment - Adherence monitoring and feedback + treatment. Electronic monitoring device (Smartinhaler, Nexus 6; counts number of doses). Adherence calculated at each monthly review as a % of the number of prescribed doses registered by the smartinhaler. Adherence shared with child and carer and incorporated into the management plan (direct feedback from respiratory physician). Duration 4 months. Concurrent medication/care: In both groups: personalised asthma education and generic written information. Personalised asthma management plan devised, assessment of inhaler technique.<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=12) Intervention 2: Usual care + treatment - Usual care (no adherence feedback) + treatment. Adherence remains unknown to physician. Duration 4 months. Concurrent medication/care: In both groups: personalised asthma education and generic written information. Personalised asthma management plan devised, assessment of inhaler technique.<br>Further details: 1. Additional education training : Additional education in both groups |

| | |
|---|---|
| Funding | Funding not stated |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ADHERENCE MONITORING AND FEEDBACK + TREATMENT versus USUAL CARE (NO ADHERENCE FEEDBACK) + TREATMENT<br><br>Protocol outcome 1: Adherence at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: % of prescribed doses measured by the electronic inhaler at 4 months; Group 1: mean 84.2 % (SD 26.3); n=14, Group 2: mean 55.3 % (SD 26.3); n=12; % of prescribed doses measured by the electronic inhaler 0-100 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Acute exacerbation at 4 months; Group 1: 3/14, Group 2: 1/12; Risk of bias: Very high; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 3: Rescue medication at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Reliever medication 3 or more times a week at 4 months; Group 1: 2/14, Group 2: 0/12; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 148: ONYIRIMBA 2003[1282]**

| Study | Onyirimba 2003[1282] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=30) |
| Countries and setting | Conducted in USA; Setting: hospital asthma centre |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 10 weeks |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Adults with moderate to severe asthma; referred to hospital asthma centre |
| Stratum | Adults and young people with uncontrolled asthma: Adults with moderate to severe asthma |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Adults with moderate to severe asthma; referred to hospital asthma centre; low socioeconomic status; FEV1 <80% predicted and BDR of ≥15%; regular use of ICS (LABA, OCS and theophylline permissible); smokers not excluded. |
| Exclusion criteria | nr |
| Recruitment/selection of patients | nr |
| Age, gender and ethnicity | Age - Range: >18 years. Gender (M:F): 3/16. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Near fatal asthma attacks: Not applicable / Not stated / Unclear 4. Social economic disadvantage: Low social economic status |
| Indirectness of population | Serious indirectness: Includes severe asthma |
| Interventions | (n=15) Intervention 1: Adherence monitoring + treatment - Adherence monitoring and feedback + treatment. Electronic monitoring device (MDI Chronologs and electronic recording of actuations for 10 weeks). Received direct feedback on ICS use from the clinician investigator and discussion of techniques to improve adherence (in addition to standard asthma care). Duration 10 weeks. Concurrent medication/care: In both groups: If necessary, ICS switched to a twice daily regime; 3 week intensive asthma education (four 30-60min sessions) by a nurse and/or respiratory therapist blinded to the patient group (goals of therapy, signs of worsening asthma, medications, importance of prophylactic medication, MDI technique and PEF). Physician input, therapy adjustment and implementation of a management plan based on PEF or symptoms at these sessions<br>Further details: 1. Additional education training : Additional education in both groups |

| | |
|---|---|
| | (n=15) Intervention 2: Usual care + treatment - Usual care (no adherence feedback) + treatment. Adherence data not provided to physician. Standard asthma care only. Duration 10 weeks. Concurrent medication/care: In both groups: If necessary, ICS switched to a twice daily regime; 3 week intensive asthma education (four 30-60min sessions) by a nurse and/or respiratory therapist blinded to the patient group (goals of therapy, signs of worsoning asthma, medications, importance of prophylactic medication, MDI technique and PEF). Physician input, therapy adjustment and implementation of a management plan based on PEF or symptoms at these sessions<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Funding not stated |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ADHERENCE MONITORING AND FEEDBACK + TREATMENT versus USUAL CARE (NO ADHERENCE FEEDBACK) + TREATMENT<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people with uncontrolled asthma: AQLQ at 10 weeks; Group 1: mean change score 1.13 (SD 0.31); n=10, Group 2: mean change score 0.76 (SD 0.33); n=9; AQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people with uncontrolled asthma: FEV1 % at 10 weeks; Group 1: mean 0.04 L (SD 0.11); n=10, Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Adherence at End of Treatment; Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 149: OTSUKI 2009[1292]**

| **Study** | **Otsuki 2009[1292]** |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=250) |
| Countries and setting | Conducted in USA; Setting: Community; recruited from paediatric ED |
| Line of therapy | Mixed line |

| | |
|---|---|
| Duration of study | Intervention time: 18 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Phys Dx asthma |
| Stratum | Children 5 -<16 with uncontrolled asthma: Children 2-12 years with asthma recruited from ED discharge records; 2 ED visits or 1 hospitalisation for asthma in previous year |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Children with asthma recruited from ED discharge records; 2-12 years old; had Phys Dx asthma; 2 ED visits or 1 hospitalisation for asthma in previous year; prescribed an asthma controller medication) |
| Exclusion criteria | nr |
| Recruitment/selection of patients | 2001-2003 |
| Age, gender and ethnicity | Age - Range: 2-12 years. Gender (M:F): 106/61. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Near fatal asthma attacks: Not applicable / Not stated / Unclear 4. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness: Mean age within 5-16 year age group |
| Interventions | (n=83) Intervention 1: Adherence monitoring + treatment - Adherence monitoring and feedback + treatment. Feedback of adherence (electronic medication monitors), goal-setting and reinforcement of adherence goals and strategies for self-monitoring of med use plus home-based education as in the control group. Duration 18 months. Concurrent medication/care: In both groups: Five 30min home visits by trained asthma educators<br>Further details: 1. Additional education training : Additional education in both groups<br><br>(n=84) Intervention 2: Usual care + treatment - Usual care (no adherence feedback) + treatment. Home-based asthma education programme alone (review of asthma regime; training in inhaler technique; development of asthma action plan and other education materials). Duration 18 months. Concurrent medication/care: In both groups: Five 30min home visits by trained asthma educators<br>Further details: 1. Additional education training : Additional education in both groups |
| Funding | Academic or government funding (National Heart Lung and Blood Institute) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ADHERENCE MONITORING AND FEEDBACK + TREATMENT versus USUAL CARE (NO ADHERENCE FEEDBACK) + TREATMENT

| | |
|---|---|
| Protocol outcome 1: Adherence at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: % self-reported adherence in previous 6 months at 18 months; Group 1: mean 87.33 % (SD 25.24); n=76, Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Number of canister refills (100% adherence = 3.0) at 18 months; Group 1: mean 0.58 (SD 0.86); n=76, Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Courses of OCS in previous 6 months at 18 months; Group 1: mean 0.96 (SD 1.59); n=76, Risk of bias: High; Indirectness of outcome: Serious indirectness<br><br>Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Children 5 -<16 with uncontrolled asthma: Hospitalisation in previous 6 months at 18 months; Group 1: mean 12 (SD 15.8); n=76, Risk of bias: High; Indirectness of outcome: Serious indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

**Table 150: WILLIAMS 2010[1922]**

| **Study** | **Williams 2010[1922]** |
|---|---|
| Study type | RCT (Cluster randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=2698) |
| Countries and setting | Conducted in USA; Setting: Primary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 12 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: at least one physician Dx of asthma and no Dx of COPD or congestive heart failure |
| Stratum | Adults and young people overall: Age 5-56 years wtih ICS prescription |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Age 5-56 years; an electronic prescription for an ICS between Jan 2005 and April 2007; at least one physician Dx of asthma and no Dx of COPD or congestive heart failure; at least one visit to primary care provider in the previous year |

| | |
|---|---|
| Exclusion criteria | nr |
| Recruitment/selection of patients | August 2007 to July 2008 |
| Age, gender and ethnicity | Age - Range: 5-56 years. Gender (M:F): Define. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Near fatal asthma attacks: Not applicable / Not stated / Unclear 4. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness: Mean age within adult and young person age group |
| Interventions | (n=1335) Intervention 1: Adherence monitoring + treatment - Adherence monitoring and feedback + treatment. Physicians provided with adherence information (from refill data) when reviewing and writing prescriptions. Adherence calculated from prescription and refill data and uploaded onto the ePrescribing system every 2 weeks and could be viewed by physicians. General and detailed adherence information could be viewed. Physicians also received specific instructions on how to intepret the adherence data.. Duration 12 months. Concurrent medication/care: GP practices in both groups received information on the most recent asthma guidelines, and methods for discussing nonadherence with their patients.<br>Further details: 1. Additional education training : No education in both groups<br><br>(n=1363) Intervention 2: Usual care + treatment - Usual care (no adherence feedback) + treatment. GP used e Prescribing system but could not view asthma patient's adherence data.. Duration 12 months. Concurrent medication/care: GP practices in both groups received information on the most recent asthma guidelines, and methods for discussing nonadherence with their patients.<br>Further details: 1. Additional education training : No education in both groups |
| Funding | Academic or government funding (Grants from National Heart Lung and Blood Institute, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes for Health, Fund for Henry Ford Hospital, American Asthma Foundation.) |

RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: ADHERENCE MONITORING AND FEEDBACK + TREATMENT versus USUAL CARE (NO ADHERENCE FEEDBACK) + TREATMENT

Protocol outcome 1: Adherence at End of Treatment
- Actual outcome for Adults and young people overall: % adherence to prescription refills in previous 3 months at 12 months;  Risk of bias: Very high; Indirectness of outcome: No indirectness

| | |
|---|---|
| Protocol outcome 2: Exacerbation (need for OCS) at End of treatment<br>- Actual outcome for Adults and young people overall: OCS use at 12 months; HR 1.07 (95%CI 0.89 to 1.29) Reported; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people overall: OCS use at 12 months; RR Adjusted RR 1.11 (95%CI 0.92 to 1.34) (P=0.28 (negative binomial regression model) ); Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 3: UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment<br>- Actual outcome for Adults and young people overall: Asthma-related Hospitalisation at 12 months; HR 0.86 (95%CI 0.32 to 2.29) Reported; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people overall: Asthma-related Hospitalisation at 12 months; RR Adjusted RR 0.87 (95%CI 0.33 to 2.29) (P=0.77 (negative binomial regression model) ); Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people overall: Asthma-related ED visit at 12 months; HR 1.22 (95%CI 0.83 to 1.78) Reported; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people overall: Asthma-related ED visit at 12 months; RR Adjusted RR 1.12 (95%CI 0.74 to 1.69) (P=0.60 (negative binomial regression model) ); Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Quality of life at End of treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Lung Function at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |



1

# 1G.20 Monitoring inhaler technique

| Study | Al-showair 2007[29] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | (n=71) |
| Countries and setting | Conducted in United Kingdom; Setting: Secondary care - patients attending an outpatient clinic |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 6 weeks |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Patients with asthma attending an outpatient clinic and receiving ICS |
| Stratum | Adults and young people (16 years and over) |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients with asthma attending an outpatient clinic; receiving ICS from an MDI without a spacer; identified with poor inhaler technique (good coordination but inhaled too fast IFR ≥90l/min). |
| Exclusion criteria | Experienced an acute exacerbation of asthma within 4 weeks prior to recruitment; hearing problems and/or unable to distinguish between one and two tones produced by the 2TT tool; patients who started to inhale before actuating a dose (poor coordination). |
| Recruitment/selection of patients | nr |
| Age, gender and ethnicity | Age - Mean (SD): Verbal group 52.6 (15.7); Verbal+2TT group 58.3 (13.7). Gender (M:F): 27/44. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness |
| Interventions | (n=36) Intervention 1: Monitoring inhaler technique + feedback - Monitoring using electronic devices + feedback. Verbal training on the most desirable inhalation technique with emphasis on breathing out slowly as far as comfortable and actuating a dose at or soon after the start of a slow inhalation. Also trained on how to use the 2Tone Trainer every morning and night to obtain the one-tone sound and to use the same inhalation procedure when using their MDI.. Duration 6 weeks. Concurrent medication/care: nr<br>Further details: 1. Additional education training : Additional education in both groups (Counselled on compliance with the prescribed medication). |

| | |
|---|---|
| | (n=36) Intervention 2: Monitoring inhaler technique + feedback - Visual monitoring + feedback. Verbal training on the most desirable inhalation technique with emphasis on breathing out slowly as far as comfortable and actuating a dose at or soon after the start of a slow inhalation.. Duration 1 visit (6 weeks follow-up). Concurrent medication/care: nr Further details: 1. Additional education training : Additional education in both groups (Counselled on compliance with the prescribed medication). |
| Funding | Other (2 Tone trainers donated by Canday Medical Ltd.) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: VERBAL TRAINING PLUS ELECTRONIC DEVICE TO PRACTICE versus VERBAL TRAINING<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): mini AQLQ at 6 weeks; Group 1: mean 4.6 (SD 1); n=36, Group 2: mean 4.2 (SD 1); n=35; mini AQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): FEV1 L at 6 weeks; Group 1: mean 1.93 L (SD 0.63); n=36, Group 2: mean 2.16 L (SD 0.74); n=35; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

| Study | Ammari 2013-1[43] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | (n=34) |
| Countries and setting | Conducted in United Kingdom; Setting: Primary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 6 weeks |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Patients with asthma who collected their MDI prescriptions from community pharmacies |
| Stratum | Adults and young people (16 years and over): |
| Subgroup analysis within study | Stratified then randomised: Adults and children |
| Inclusion criteria | Aged 4-45 years; prescribed at least one MDI without a spacer device including a preventer; identified with poor inhaler technique (defined as poor hand-lung coordination and an IFR ≥90l/min). |
| Exclusion criteria | Experienced an acute exacerbation of asthma or received OCS within 4 weeks prior to recruitment; had other illnesses adversely affecting their respiratory system; hearing problems and/or unable to distinguish between one and two tones produced by the 2TT tool. |
| Recruitment/selection of patients | nr |
| Age, gender and ethnicity | Age - Mean (SD): 40.7 (9.7). Gender (M:F): 11/23. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness |
| Interventions | (n=17) Intervention 1: Monitoring inhaler technique + feedback - Monitoring using electronic devices + feedback. All patients selected due to a fast inhalation (most common inhaler technique problem). Verbal training + the 2 tone trainer (2TT) to achieve a slow inhalation flow rate by encouraging patients to increase the length of their inhalation period. The 2TT is an MDI-like tool without a canister that is designed to give an audible feedback depending on the inhalation speed (a high pitched two tone noise if inhalation is too fast >60l/min). Patients then simulate this technique when using their own MDI. . Duration 6 weeks. Concurrent medication/care: Instucted to practice using the 2TT twice daily before taking their MDI<br>Further details: 1. Additional education training : No education in both groups |

| | |
|---|---|
| | (n=17) Intervention 2: Monitoring inhaler technique + feedback - Visual monitoring + feedback. All patients selected due to a fast inhalation (most common inhaler technique problem). Verbal training to achieve a slow inhalation flow rate by encouraging patients to increase the length of their inhalation period.. Duration 1 visit (6 week follow-up).<br>Concurrent medication/care: nr<br>Further details: 1. Additional education training : No education in both groups |
| Funding | Principal author funded by industry (Author received sponsorship to carry out studies from several pharmaceutical companies. Research sponsorship also received from EPSRC and MRC) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: VERBAL TRAINING PLUS ELECTRONIC DEVICE TO PRACTICE versus VISUAL TRAINING<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): mini AQLQ at 6 weeks; Group 1: mean -0.409 (SD 1.05); n=17, Group 2: mean -0.748 (SD 1.31); n=17; miniAQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): FEV1 % pred at 6 weeks; Group 1: mean 96.3 % (SD 17.6); n=17, Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

| Study | Ammari 2013-2[43] |
|---|---|
| Study type | RCT (Patient randomised; Parallel) |
| Number of studies (number of participants) | 1 (n=12) |
| Countries and setting | Conducted in United Kingdom; Setting: Primary care |
| Line of therapy | Mixed line |
| Duration of study | Intervention + follow up: 6 weeks |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Patients with asthma who collected their MDI prescriptions from community pharmacies |
| Stratum | Children 5 -<16 |
| Subgroup analysis within study | Stratified then randomised: Adults and children |
| Inclusion criteria | Aged 4-45 years; prescribed at least one MDI without a spacer device including a preventer; identified with poor inhaler technique (defined as poor hand-lung coordination and an IFR ≥90l/min). |
| Exclusion criteria | Experienced an acute exacerbation of asthma or received OCS within 4 weeks prior to recruitment; had other illnesses adversely affecting their respiratory system; hearing problems and/or unable to distinguish between one and two tones produced by the 2TT tool. |
| Recruitment/selection of patients | nr |
| Age, gender and ethnicity | Age - Mean (SD): 10.2 (3.2). Gender (M:F): 8/4. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness |
| Interventions | (n=6) Intervention 1: Monitoring inhaler technique + feedback - Monitoring using electronic devices + feedback. All patients selected due to a fast inhalation (most common inhaler technique problem). Verbal training + the 2 tone trainer (2TT) to achieve a slow inhalation flow rate by encouraging patients to increase the length of their inhalation period. The 2TT is an MDI-like tool without a canister that is designed to give an audible feedback depending on the inhalation speed (a high pitched two tone noise if inhalation is too fast >60l/min). Patients then simulate this technique when using their own MDI.. Duration 1 visit (6 week follow-up). Concurrent medication/care: Instructed to practice using the 2TT twice daily before taking their MDI<br>Further details: 1. Additional education training : No education in both groups |

| | |
|---|---|
| | (n=6) Intervention 2: Monitoring inhaler technique + feedback - Visual monitoring + feedback. All patients selected due to a fast inhalation (most common inhaler technique problem). Verbal training to achieve a slow inhalation flow rate by encouraging patients to increase the length of their inhalation period.. Duration 1 visit (6 week follow-up). Concurrent medication/care: nr<br>Further details: 1. Additional education training : No education in both groups |
| Funding | Principal author funded by industry (Author received sponsorship to carry out studies from several pharmaceutical companies. Research sponsorship also received from EPSRC and MRC) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: VERBAL TRAINING PLUS ELECTRONIC DEVICE TO PRACTICE versus VERBAL TRAINING<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Children 5 -<16: PAQLQ at 6 weeks; Group 1: mean -0.362 (SD 0.52); n=6, Group 2: mean -0.391 (SD 0.69); n=6; PAQLQ 1-7 Top=High is good outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Children 5 -<16: FEV1 % pred at 6 weeks; Group 1: mean 90.9 % (SD 14.3); n=6, Risk of bias: High; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

| Study (subsidiary papers) | Basheti 2007[122] (Basheti 2008[119]) |
|---|---|
| Study type | RCT (Cluster randomised; Parallel) |
| Number of studies (number of participants) | (n=) |
| Countries and setting | Conducted in Australia; Setting: Community - pharmacy education |
| Line of therapy | Mixed line |
| Duration of study | Intervention time: 6 months |
| Method of assessment of guideline condition | Partially adequate method of assessment/diagnosis: Doctor Dx asthma and use of ICS |
| Stratum | Adults and young people (16 years and over): Aged ≥14 years |
| Subgroup analysis within study | Not applicable |
| Inclusion criteria | Patients presenting with Turbuhaler or Diskus prescriptions for asthma; age ≥14 years; doctor diagnosed asthma; use of ICS with Turbuhaler or Diskus with or without LABA; no change in asthma medication or dose for 1 month. |
| Exclusion criteria | Did not self-adminisater their own medication; did not speak or understand English. |
| Recruitment/selection of patients | April 2003 - 2004 |
| Age, gender and ethnicity | Age - Range: ≥14 years. Gender (M:F): nr. Ethnicity: |
| Further population details | 1. Cognitive function: Not applicable / Not stated / Unclear 2. Disability: Not applicable / Not stated / Unclear 3. Social economic disadvantage: Not applicable / Not stated / Unclear |
| Indirectness of population | No indirectness |
| Interventions | (n=56) Intervention 1: Monitoring inhaler technique + feedback - Visual monitoring + feedback. Pharmacy trained to deliver education on peak flow meter technique and inhaler technique. Assessed inhaler technique using checklists and then educated using 'show and tell' for each step on the checklist. Incorrect steps on the checklist were highlighted and attached to the patient's inhaler using a label. This was repeated at 1, 2, 3 and 6 months.. Duration 6 months.<br>Concurrent medication/care: nr<br>Further details: 1. Additional education training : No education in both groups<br><br>(n=56) Intervention 2: No monitoring . Pharmacy trained to deliver education on peak flow meter technique only. Duration 1 visit (6 month follow-up). Concurrent medication/care: nr<br>Further details: 1. Additional education training : No education in both groups |

| | |
|---|---|
| Funding | Principal author funded by industry (Author grant support from GSK and AstraZenica) |
| RESULTS (NUMBERS ANALYSED) AND RISK OF BIAS FOR COMPARISON: VISUAL MONITORING + FEEDBACK versus NO MONITORING OF INHALER TECHNIQUE<br><br>Protocol outcome 1: Quality of life at End of treatment<br>- Actual outcome for Adults and young people (16 years and over): Marks AQLQ at 3 months; Group 1: mean 0.8 (SD 0.5); n=53, Group 2: mean 1.35 (SD 0.6); n=44; Marks AQLQ 0-10 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): Marks AQLQ at 6 months; Group 1: mean 0.8 (SD 0.6); n=53, Group 2: mean 1.3 (SD 0.6); n=44; Marks AQLQ 0-10 Top=High is poor outcome; Risk of bias: Very high; Indirectness of outcome: No indirectness<br><br>Protocol outcome 2: Lung Function at End of Treatment<br>- Actual outcome for Adults and young people (16 years and over): PEFv (Min%Max) at 3 months; Group 1: mean 83.8 % (SD 8.3); n=53, Risk of bias: Very high; Indirectness of outcome: No indirectness<br>- Actual outcome for Adults and young people (16 years and over): PEFv (Min%Max) at 6 months; Group 1: mean 78.9 % (SD 9.7); n=53, Group 2: mean 74.4 % (SD 8.9); n=44; Risk of bias: Very high; Indirectness of outcome: No indirectness | |
| Protocol outcomes not reported by the study | Mortality at End of Treatment; Exacerbation (need for OCS) at End of treatment; UHU (ED visit, hospitalisation, GP out-of-hours centre) at End of Treatment; Asthma control questionnaires at End of Treatment; Rescue medication at End of Treatment; Dose of regular asthma treatment (SABA, ICS) at End of Treatment; Symptom free days at End of Treatment; Time of school/work at End of Treatment |

## G.21 Tele-healthcare to monitor asthma control

**Table 151: Baptist 2013[100,100]**

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baptist, A. P., et al. (2013). A randomized controlled trial of a self-regulation intervention for older adults with asthma. May. *Journal of the American Geriatrics Society, 61*(5), 747-753 | RCT<br><br>1 tertiary care centre in USA | N=70<br><br>**Tele:** N=34<br><br>**Control:** N=36 | | **Tele** | **Control** | 3 in-person group sessions and 3 one-on-one telephone sessions. Group sessions included seven participants and a health educator who served as the leader. A health educator conducted all group and telephone sessions. | 3 phone calls not related to asthma self-management. An allergist called participants randomized to the control group 1 and 2 weeks after enrolment to address any inquiries regarding information received during the asthma education session. | 6 and 12 months | Hospital visits | T:0/34<br>C:4/36 | **Funding:** American Academy of Allergy Asthma and Immunology<br><br>**Risk of bias:**<br>• Randomised with number generator<br>• Participants, physicians and assessors were blind<br>• 90% included in final analysis<br>• ACQ continuous data not reported |
| | | | Age, yrs | 72.8 | 73.8 | | | | GP visits | T: 6/34<br>C: 14/36 | |
| | | | % male: | 32.4 | 13.9 | | | | FEV1 % predicted | T: 84.6<br>C: 76.3<br>P=0.17 | |
| | | | % pred. FEV1 | 84.2 | 80.9 | | | | | | |
| | | | **Inclusion criteria**:<br>• Outpatients aged 65 and older<br>• Physician diagnosis of asthma<br>• Daily controller medication<br>• Access to a home telephone<br><br>**Exclusion criteria**:<br>• COPD or any other primary pulmonary disorder<br>• Current smokers or smoking history of > 20 pack-years<br>• Mental impairment | | | | | | | | |

**Table 152: Barbanel 2003**[105,105]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Barbanel, D., Eldridge, S., & Griffiths, C. (2003). Can a | RCT<br><br>Deprived area | N=24<br><br>**Tele:** | | **Tele** | **Control** | After a 3-day training course on asthma care, patients were | The control group received no input from | 6 months | North of England Asthma Scale – not | N/A | **Funding:** Not stated |
| | | | Age, yrs | 45 | 47 | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. *Thorax, 58*(10), 851-854. | of London | N=12<br><br>**Control:** N=12 | % male: | 50 | 41.7 | allocated to a pharmacist for a 45 min educational session and weekly follow-up calls for 3 months. Education included inhaler technique and PEF meter use. Patients were also given supporting literature and a management plan. | the pharmacist. | | meta-analysed | | • **Risk of bias:** Sequence generation unclear but concealed allocation<br>• Blinding was not possible<br>• One dropout in control was imputed |
| | | | **Inclusion criteria:**<br>• Adults aged 18-65 years<br>• Maintenance ICS<br><br>**Exclusion criteria:**<br>• Recently attended secondary care with acute asthma<br>• Recent medication change<br>• Acute respiratory infection | | | | | | | | |

**Table 153: Bender 2010[150,150]**

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| **Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma**. Journal of the American | RCT | N=50 (25 in each group)<br>18 to 65 years; physician-diagnosed asthma for which they were prescribed daily inhaled corticosteroid treatment.<br>Exclusion criteria: (1) any | Mean age treatment: 39.6 (12.8) years; control 43.5 (14.3) years. % male: 40% and 32%. White 56% and 60%; Hispanic 24% and 12%; African American 20% and 20%; | 2 automated interactive voice response telephone calls separated by one month, with one additional call if they reported recent symptoms of poorly controlled disease or failure to fill a prescription. Calls were completed in | Participants in the control group received no calls. | 10 weeks | Mean ICS adherence (dividing the number of inhaler puffs taken by the number of puffs prescribed to be taken each day and then averaged over the 10-week interval) was | 64.5 (17.2) % vs. 49.1 (16.8) %, p=0.0032 | Investigator-Sponsored Study Program of AstraZeneca | Randomisation and allocation concealment unclear (random table generated before study initiation); investigator blind; no attrition; no selective |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| Board of Family Medicine: 23: 159-165<br><br>Bender BG, Apter A, Bogen DK, Dickinson P, Fisher L, Wamboldt FS, and Westfall JM 2010. | | significant disease or disorder that, in the opinion of the investigator, might influence the results of the study or the patient's ability to participate in the study (including other chronic health disorders, current substance abuse or dependence, mental retardation, or psychiatric disorder); and (2) current participation in any other asthma-related research or clinical trial. | Asian 0% and 8%. All not significantly different. | < 5 minutes and included content designed to inquire about asthma symptoms, deliver core educational messages, encourage refilling of inhaled corticosteroid prescriptions, and increase communication with providers | | | higher in the group receiving IVR intervention than in the control group | | | reporting; groups comparable at baseline |
| | | | | | | | Change in Beliefs about Medications Questionnaire (scores above 0 indicate more positive beliefs and scores below 0 indicate more negative beliefs): the group receiving IVR intervention demonstrating a greater upward shift in positive medication beliefs | 0.248 (1.07) vs. -0.508 (0.913), p=0.007 | | |
| | | | | | | | Change in Asthma Quality of Life Questionnaire | -0.152 (0.92) vs. -0.381 | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | (higher scores indicate better quality of life) | (1.06), not signifi cant | | |
| | | | | | | | Change in Asthma Control Test (higher scores indicate better control of asthma symptoms) | -1.120 (3.90) vs. -1.840 (4.14), not signifi cant | | |

**Table 154: Chan 2007**[298,299]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chan, D. S., et al (2007). Internet-based home monitoring and education of children with asthma is comparable to ideal office-based | RCT<br><br>Child clinic in Hawaii army centre | N=120<br><br>**Tele:** N=60<br><br>**Control:** N=60 | | **Tele:** | **Control:** | Virtual group patients received computers, internet connections, and in-home, Internet-based case | Office-based group patients received traditional in-person education and case management. | 12 m | Hospital visits | T: 1/60<br>C: 1/60 | **Funding:** US Army Medical Research Acquisition Activity<br><br>**Risk of bias:** |
| | | | Age, yrs | 10.2 | 9 | | | | ED visits | T: 4/60<br>C: 2/60 | |
| | | | % male | 61.7 | 63.3 | | | | PAQLQ child | T: 6.1 (1.1)<br>C: 5.8 (1.2) | |
| | | | **Inclusion criteria:**<br>• Children/teens aged 6-17 | | | | | | PAQLQ parent | T: 6.4 (1)<br>C: 6.2 (0.8) | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| care: results of a 1-year asthma in-home monitoring trial. *Pediatrics, 119*(3), 569-578. | | | • Persistent asthma<br>• Dependent of active duty or retired military personnel<br>• Could receive cable modem<br>• Willing to complete questionnaires<br><br>**Exclusion criteria:**<br>• Not stated | management and received education through the study website. | | | FEV1 % predicted | T: 97.4 (19.2)<br>C: 92.7 (18.1) | • Random numbers table<br>• Un-blinded<br>• Dropout much higher in tele-health group (23%) than office group (8%) |

**Table 155: Chatkin 2006[306,307]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Chatkin, J. M., et al. (2006). Impact of a low-cost and simple intervention in enhancing treatment adherence in a Brazilian asthma sample. *Journal of Asthma, 43*(4), 263-266. | RCT<br><br>Physicians from all over Brazil were invited to include their patients | N=271<br><br>**Tele:** N=140<br><br>**Control:** N=131 | | **Tele** | **Control** | Participants received 10 minute telephone calls every two weeks to provide asthma education with emphasis on treatment adherence. A specifically trained nursing student conducted the calls. | Routine care with a call at the beginning and end of the study to collect data. | Unknown follow-up | Adherence measures | None of interest | **Funding:** GSK Brazil<br><br>**Risk of bias:**<br>• Minimal information regarding randomisation<br>• 10 patients were not included because they did not return their |
| | | | Age, yrs | 43.3 | 44.4 | | | | | | |
| | | | % male | 25.7 | 29 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults/adolescents<br>• 12+ years<br>• Mod./severe asthma according to GINA<br><br>**Exclusion criteria:**<br>• Mild persistent asthma | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | • Pregnancy or breast-feeding<br>• Recent alcohol or drug abuse<br>• Active medical condition | | | | | | drug disks and 8 for not responding to the telephone calls |

**Table 156: Christakis 2012[325,325]**

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| **Improving parental adherence with asthma treatment guidelines: a randomized controlled trial of an interactive website**. Academic pediatrics: 12: 302-311<br><br>Christakis DA, Garrison MM, Lozano P, | RCT | N=603; 283 intervention; 320 control.<br>Parents of children aged 2 to 10 years with asthma (at least 1 clinical encounter – clinic visit, emergency room or inpatient admission – or two prescription refills for bronchodilato | 29% had mild to severe persistent asthma; 71% had mild intermittent asthma; 54% on at least one controller medication and of these, 61% took controller 5 or more days per week. Among controller users, 60% adherent in control arm and 61% in | Web-based intervention: gathers information from parents (day and night time symptoms, quick-reliever use), applies algorithm to determine asthma severity, home care practices (controller use and adherence), functional status, parental beliefs (outcomes expectation and | Control parents had similar intervention around reducing media usage among their children. | 12 months | Appropriate controller use: non-users converted to controller use at 6 months | 15.69% control vs. 15.79% int'n, p=0.98 (denominators unclear) | National Heart, Lung and Blood Institute | Computer randomisation; 85% completed 6-month assessment and 80% at 12 months; no selective reporting; groups comparable at baseline |
| | | | | | | | Patients who should have been on controllers at baseline (i.e. persistent asthma) but were not, who were on controllers at 6 | 7/19 (36.84%) int'n; 5/30 (16.7%) cont; OR 2.85, 95% CI 0.63 to 14.04, | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| Meischke H, Zhou C, and Zimmerman FJ 2012. | | rs in the last year) in an HMO and a primary care clinical practice network. Had to have convenient access to internet-enable computer, speak English at home. | intervention arm at baseline. | self-efficacy), feedback on child's asthma (recommendations regarding controller use and other aspects of asthma care), allowed parent to set goals relevant to their situation. Monthly email reminders to log on. Intervention 6 months, then opt-in for further 6 months | | | months | p=0.17 | | |
| | | | | | | | Persistent asthma on controllers at baseline but discontinued at 6 months | 6/42 (14%) int'n; 3/58 (5%) cont; OR 0.33, 95% CI 0.05 to 1.67, p=0.16 | | |
| | | | | | | | Adherence at 6 months (5 or more days per week) to controllers for those who were prescribed them at 6 months | 72% int'n vs. 62% cont, OR 1.54, 95% CI 0.90 to 2.63, p=0.10 | | |
| | | | | | | | Adherence at 6 months (5 or more days per week) to controllers for the persistent asthma subgroup who were | 77% vs. 50%, OR 3.33, 95% CI 1.20 to 10.07, p=0.01 (denominators | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | prescribed them at baseline and 6 months | unclear) | | |
| | | | | | | | Outcome expectations at 6 months: positive: no difference between groups; negative: lower in intervention arm. | Positive: 124/241 (51%) int'n; 122/274 (44%) cont, p=0.12.<br>Negative: 145/241 (60%) int'n vs. 190/274 (69%) cont, p=0.03 | | |
| | | | | | | | Parental self-efficacy (parents somewhat or strongly agreeing that they can give their child controller medication daily) at 6 | 217/241 (90%) int'n vs. 218/274 (80%) cont, p=0.001 | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | months | | | |
| | | | | | | | Asthma symptoms and severity at 6 and 12 months: Proportions of children with stable or improved symptoms not significantly differed between groups | Data not shown | | |
| | | | | | | | Proportion of children on controllers at 12 months | 50% int'n vs. 57% cont, p=0.17 (denominators unclear) | | |
| | | | | | | | Of those who met severity criteria for controllers at baseline, number on them at 12 months | 34/53 (64%) int'n, 50/82 (60%) cont, p=0.86 | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Source of funding | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | Adherence 5 or more days/week at 12 months | 69/105 (66%) int'n, 88/140 (63%) cont, p=0.69 | | |

**Table 157: Deschildre 2012[431,431]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deschildre, A., et al. (2012). Home telemonitoring (forced expiratory volume in 1 s) in children with severe asthma does not reduce exacerbations. *European respiratory journal, 39*(2), 290-296. | RCT<br><br>4 paediatric clinics in France | N=50<br><br>**Tele:** N=25<br><br>**Control:** N=25 | | **Tele** | **Control** | Daily home spirometry transmitted to the physician via modem, and medical feedback. Depending on FEV1 results, the GP or hospital paediatrician was contacted. | Conventional treatment | 12 m | Hospital visits | T: 2/21<br>C: 2/23 | **Funding:** French Ministry of Health<br>**Risk of bias:**<br>• Unclear randomisation procedures<br>• Un-blinded<br>• Unbalanced attrition (higher in tele group)<br>• Analysed with non-parametric tests |
| | | | Age, yrs (median) | 11.0 | 11.2 | | | | Oral steroids | T: 19/21<br>C: 21/23 | |
| | | | % male | 72 | 76 | | | | | | |
| | | | FEV1 % predicted (median) | 87.4 | 83.3 | | | | | | |
| | | | **Inclusion criteria:**<br>• Children/teens aged 6-16<br>• Severe allergic asthma (3rd Paediatric Asthma Consensus)<br>• Frequent exacerbations<br>• reversibility of > 12%and/or | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | an increase of at least 200 mL<br>• All taking LABA/ICS combo<br><br>**Exclusion criteria:**<br>• Congenital or acquired illness other than asthma | | | | | | |

**Table 158: Donald 2008[447,447]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Donald, K. J., McBurney, H., Teichtahl, H., & Irving, L. (2008). A pilot study of telephone based asthma management. *Australian Family Physician, 37*(3), 170-173. | RCT<br><br>2 teaching hospitals in Australia | N=71<br><br>**Tele**: N=36<br><br>**Control**: N=35 | | **Tele:** | **Control:** | 6 follow-up calls from the nurse educator about current asthma symptoms, with management advice. Patients were given a PEF meter and recording instructions, a face-to-face session with an asthma nurse educator, advice on medications, triggers and management, and an Asthma Action Plan. | The control group was encouraged to continue with self-management and usual GP care | 12 m | Hospital visits | T: 1/31<br>C: 6/29 | **Funding:** Unclear<br>**Risk of bias:**<br>• Unclear randomisation procedures<br>• Researcher blinded, patients and nurses not<br>• Low questionnaire response rate |
| | | | Age, years | 36.2 | | | | | ED visits | T: 7/36<br>C: 5/35 | |
| | | | % male | 23.9 | | | | | GP visits | T: 22/31<br>C: 16/29 | |
| | | | **Inclusion criteria:**<br>• Adults aged 18-55<br>• Previous asthma admission<br>• Primary diagnosis of asthma<br><br>**Exclusion criteria:**<br>• Other chronic respiratory or unstable medical condition<br>• Cognitive disability<br>• Psychiatric illness | | | | | | Oral steroids<br><br>Absence (days) | T: 22/31<br>C: 21/29<br><br>T: 2.81 (6.26)<br>C: 5.22 (8.38) | |

**Table 159: Gruffydd-Jones 2005[603]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gruffydd-Jones, K., et al (2005). Targeted routine asthma care in general practice using telephone triage. *British Journal of General Practice, 55*(521), 918-923. | RCT<br><br>1 general practice in England | N=194<br><br>**Tele**: N=97<br><br>**Control**: N=97 | | **Tele:** | **Control:** | Contacted by telephone every 6-months by a trained asthma nurse and asked the RCPs 'three questions' plus two extra questions related to a high risk of asthma death. The nurse formulated an individualised asthma action plan with the patient. | Usual care by 6-monthly check up with an asthma nurse. Symptom scores, inhaler technique, and PEF were checked and all patients issued with an asthma action plan. | 6 and 12 m | AQLQ | T: 5.93 (1.64)<br>C: 5.79 (0.90) | **Funding:** Asthma UK<br><br>**Risk of bias:**<br>• Random number tables<br>• Un-blinded<br>• Unbalanced attrition (higher in usual care) |
| | | | Age, years | 50.8 | 49.6 | | | | ACQ | T:-0.18 (95% CI) (-0.38 to 0.02)<br>C: -0.11 (-0.32 to 0.11) | |
| | | | % male | 51.5 | 39.2 | | | | Costs | T: 210.4(95% CI) (208.9 to 211.8)<br>C: 332.7 (329.5 to 335.9) | |
| | | | **Inclusion criteria**:<br>• Adults aged 17-70<br>• On the practice asthma list<br><br>**Exclusion criteria**:<br>• Housebound or no phone | | | | | | | | |

**Table 160: Guendelman 2002[609,609]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Guendelman, S., et al (2002). Improving asthma outcomes and self-management behaviors of | RCT<br><br>1 clinic in California, USA | N=134<br><br>**Tele**: N=66<br><br>**Control**: N=68 | | Tele: | Control: | Internet-based asthma self-management and education program with feedback (Health Buddy) which asked | Paper asthma diary. All children returned for 2 follow-up visits at 6 and 12 weeks when they received | 3 m | Hospital visits | T: 4/62<br>C: 1/60 | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Unclear sequence generation, |
| | | | Age, years | 12.0 | 12.2 | | | | ED visits | T: 6/62<br>C: 11/60 | |
| | | | % male | 61 | 54 | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| inner-city children: a randomized trial of the Health Buddy interactive device and an asthma diary. *Archives of Pediatrics & Adolescent Medicine., 156*(2), 114-120. | | | **Inclusion criteria**:<br>• Children/teens aged 8-16<br>• Persistent asthma<br>• English speaking with a telephone in the house<br><br>**Exclusion criteria**:<br>• In another asthma study<br>• Mental or physical challenges that affected the program<br>• Co-morbid conditions that might affect quality of life | every day about asthma status, PEF and medication. Responses were downloaded to the nurse co-ordinator overnight. | further standardised teaching from the nurse co-ordinator | | | | concealed with envelopes<br>• Un-blinded<br>• Low attrition |

**Table 161: Gustafson 2012**[617,617]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gustafson, D., et al (2012). The effects of combining web-based eHealth with telephone nurse case management for pediatric asthma control: A randomized | RCT<br><br>USA | N=301<br><br>**Tele**: N=132<br><br>**Control**: N=127 | | **Tele:** | **Control:** | Automated management software with monthly calls from nurse (CHESS+CM). Based on self-determination theory and designed to improve competence, social support, | Treatment as usual plus asthma information | 12 m | ACQ | MD -0.31; 95% CI -0.56 to -0.06; 0=0.01 | **Funding:** National Institute of Nursing Research<br>**Risk of bias:**<br>• Sequence generation fine and well concealed<br>• Un-blinded |
| | | | Age, years | 7.7 | 8.2 | | | | | | |
| | | | % male | 66 | 57 | | | | | | |
| | | | Baseline ACQ | 2.49 | 2.32 | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| controlled trial. [References]. *Journal of medical Internet research, 14*(4), 41-59. | | | **Inclusion criteria**:<br>• Children aged 4-12<br>• Diagnosis of asthma or wheezing<br>• Controller meds and poor adherence<br>**Exclusion criteria**:<br>• Not described | and intrinsic motivation of parents and children. | | | | | • Balanced attrition |

**Table 162: Halterman 2012[633,633]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Halterman Jill, S. et al (2012). Working toward a sustainable system of asthma care: Development of the School-Based Preventive Asthma Care Technology (SB-PACT) trial. *49*, 395-400 | RCT<br><br>19 inner-city schools in New York, USA | N=100<br><br>**Tele**: N=48<br><br>**Control**: N=51 | | **Tele:** | **Control:** | 'SB-PACT' intervention: web-based screening, electronic communication with primary care providers, online prescription of medications, direct nurse observation of adherence in schools, assessment of symptoms online | In addition to usual care, families in both groups were provided with written educational hand-outs on asthma triggers, treatment, and local asthma resources | 8 m | Hospital visits | T: 1/48<br>C: 1/51 | **Funding:** National Heart, Lung, and Blood Institute of the National Institutes of Health<br><br>**Risk of bias:**<br>• Sequence generation fine and well concealed<br>• Families not blind, but assessors were |
| | | | Age, years | 7.5 | 7.0 | | | | ED visits | T: 4/48<br>C: 3/51 | |
| | | | | | | | | | GP visits | T: 6/48<br>C: 8/51 | |
| | | | % male | 52 | 63 | | | | AQLQ | T: 6.46 (0.7)<br>C: 6.31 (0.9) | |
| | | | **Inclusion criteria:**<br>• Children aged 3-10 years<br>• Persistent asthma (physician diagnosed base on NHLBI)<br>**Exclusion criteria:**<br>• Non English speaking, no access to phone<br>• Other significant conditions | | | | | | School absence | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | • No dropout |

**Table 163: Jan 2007[757,757]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jan, R. L., et al. (2007). An internet-based interactive telemonitoring system for improving childhood asthma outcomes in Taiwan. Telemedicine Journal and e-Health, 13(3), 257-268. | RCT<br><br>1 university medical center in Taiwan | N=164<br><br>**Tele**: N=88<br><br>**Control**: N=76 | | **Tele:** | **Control:** | "Blue Angel for Asthma Kids", an Internet-based paediatric asthma monitoring program children and parents. Included symptom and PEF diaries and Asthma Action Plans based on the GINA. Data could be shared with the physician who gave feedback by phone/email. | Traditional treatment in an outpatient allergy and asthma clinic accompanied by a PEF meter and diary. Also received verbal and printed asthma education and an Action Plan as part of usual care. | 3 m | PEF morning | T: 18.7 (49.4)<br>C: 10.9 (40) | **Funding:** National Science Council and Bureau of Health Promotion<br><br>**Risk of bias:**<br>• Unclear sequence generation, concealed with envelopes<br>• Un-blinded<br>• Low attrition |
| | | | Age, years | 10.9 | 9.9 | | | | PEF evening | T: 23.1 (56.5)<br>C: 11.1 (41.6) | |
| | | | % male | 39.7 | 36.8 | | | | | | |
| | | | **Inclusion criteria:**<br>• Children aged 6-12 years<br>• Access to internet<br>• Physician-diagnosed asthma<br><br>**Exclusion criteria:**<br>• Other chronic conditions such as broncho-pulmonary dysplasia | | | | | | | | |

**Table 164: Khan 2004**[858,858]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Khan, M. S. R., et al (2004). Randomized controlled trial of asthma education after discharge from an emergency department. Journal of Paediatrics & Child Health, 40(12), 674-677. | RCT<br><br>1 centre in Sydney, Australia | N=310<br><br>**Tele**: N=155<br><br>**Control**: N=155 | | **Tele:** | **Control:** | Parents received a telephone call by an asthma nurse educator within 2 weeks of discharge to reiterate advice given at discharge. Calls lasted an average of 13 min (range 5 to 44 minutes). | All parents received written materials with facts about asthma, use of spacers, management of exercise induced asthma and when to contact a doctor. | 6 m | Hospital visits | T: 0/136<br>C: 0/130 | **Funding:** Financial Markets Foundation for Children<br><br>**Risk of bias:**<br>• Random numbers table<br>• Assessors blind<br>• Possible attrition bias |
| | | | Age, years | 4.9 | | | | | ED visits | T: 1/136<br>C: 0/130 | |
| | | | % male | 65.5 | | | | | | | |
| | | | **Inclusion criteria:**<br>• Children aged 1-15 years<br>• Recent ED discharge<br><br>**Exclusion criteria:**<br>• Non English speaking | | | | | | | | |

**Table 165: Liu 2011**[1031,1032]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Liu, W. T., et al (2011). A mobile telephone-based interactive self-care system improves asthma control. | RCT<br><br>Clinics at a teaching hospital in Taiwan | N=89<br><br>**Tele**: N=60<br><br>**Control**: N=60 | | **Tele:** | **Control:** | Mobile phone-based software: with electronic diary to record symptom score, reliever use, and lung function. Staff reviewed data uploaded to website and gave advice in | Written asthma diary and action plan. All subjects received asthma education, self-management plan, and | 6 m | Mortality | T: 0/43<br>C: 0/46 | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Allocation not described<br>• Un-blinded<br>• High attrition |
| | | | Age, years | 50.4 | 54 | | | | Hospital visits | T: 0/43<br>C: 1/46 | |
| | | | % male | 51.2 | 47.8 | | | | ED visits | T: 2/43<br>C: 12/46 | |
| | | | **Inclusion criteria:**<br>• Adults | | | | | | FEV1 % predicted | T: 65.2 (21)<br>C: 56.5 (19) | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| *European respiratory journal, 37*(2), 310-317 | | | • Moderate/severe asthma | accordance with GINA guidelines. Data were given to the doctors to adjust treatment plans. | standard treatment | | PEF L/min | T: 382.7 (56)<br>C: 343.5 (52) | |

**Table 166: Ostojic 2005**[1291,1291]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ostojic, V., et al. (2005). Improving asthma control through telemedicine: A study of short-message service. *Telemedicine Journal & E-Health, 11*(1), 28-35. | RCT<br><br>1 clinic in Croatia | N=16<br><br>**Tele**: N=8<br><br>**Control**: N=8 | | **Tele:** | **Control:** | Paper diary for PEF, medication use and symptoms. PEF (3 times a day), sent results to a computer in the asthma centre and received weekly text instructions from an asthma specialist about therapy or the need for extra office visits. | Both groups were treated according to GINA guidelines. Controls also kept a daily diary of PEF and symptoms, but results were only reviewed by the physician at the end of the study period. | 4 m | Hospital visits | T: 2/8<br>C: 7/8 | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Computer randomised<br>• Un-blinded<br>• No dropouts |
| | | | Age, years | 24.8 | 24.5 | | | | FEV1 % predicted | T: 81.3 (17.3)<br>C: 78.3 (21.1) | |
| | | | % male | 63 | 50 | | | | | | |
| | | | % predicted FEV1 | 77.6 | 78.9 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults with moderate asthma<br>• All using LABA/ICS<br><br>**Exclusion criteria:**<br>• Adults with moderate asthma<br>• All using LABA/ICS | | | | | | | | |

**Table 167: Pinnock 2003**[1362,1362]

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pinnock, H., et al (2003). Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. *BMJ, 326*(7387), 477-479. | RCT<br><br>4 UK GPs | N=278<br><br>**Tele**: N=137<br><br>**Control**: N=141 | | **Tele:** | **Control:** | Telephone review with the asthma nurse. The nurse tried up to 4 times to contact the patients. | Face-to-face reviews in the surgery also with the asthma nurse, one invitation was sent in the usual manner. Content of the review was as the nurse deemed appropriate. | Variable follow-up, pragmatic design | Hospital visits | T: 0/137<br>C: 0/141 | **Funding:** Educational grant from AstraZeneca<br><br>**Risk of bias:**<br>• Centrally randomised<br>• Un-blinded |
| | | | Age, years | 54.6 | 56.4 | | | | ED visits | T: 0/137<br>C: 0/141 | |
| | | | % male | 41 | 42 | | | | Oral steroid use | T: 5/137<br>C: 3/141 | |
| | | | Baseline AQLQ | 5.17 | 5.16 | | | | GP visits | T: 27/137<br>C: 34/141 | |
| | | | **Inclusion criteria**:<br>• Adults aged 18+<br>• Asthma for 1 year +<br>• Bronchodilator prescription in previous 6 months<br>**Exclusion criteria**:<br>• COPD<br>• Communication difficulties | | | | | | AQLQ | T: 5.15 (1.28)<br>C: 5.52 (1.14) | |

**Table 168: Pinnock 2007**[1361,1362]

| Reference | Study type | Number of patients | Patient characteristics | | | | Intervention | Comparisons | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pinnock H., et al (2007). Accessibility, clinical effectiveness and practice costs of providing a telephone | RCT<br><br>1 UK GP over 3 sites | N=1728<br><br>**Tele**: N=554<br><br>**Control1**: N=515 | | **Tele** | **Cont 1** | **Cont 2** | Sent 3 invitations over the study period to book either a phone or face-to-face review both at a pre-arranged | 1) Usual care maintained their well-established asthma clinic but no re call was undertaken.<br><br>2) Patients were recalled to face- | 12 m | AQLQ | T: 5.29 (1.2)<br>C1: 5.27 (1.2)<br>C2: 5.31 (1.2) | **Funding:** Scientific Foundation Board of the RCGP<br><br>**Risk of bias:**<br>• Randomised |
| | | | Age, yrs | 43 | 45.4 | 42.3 | | | | ACQ | T: 1.20 (1)<br>C1: 1.24 (1)<br>C2:1.33 (1.1) | |
| | | | % male | 44.2 | 44.7 | 44.9 | | | | Cost total | T: £3982<br>C1: £3340 | |

| Reference | Study type | Number of patients | Patient characteristics | | | | Intervention | Comparisons | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| option for routine asthma reviews: phase IV controlled implementation study. *British Journal of General Practice*, *57*(542): 714–722 | | **Control2**: N=659 | | | | | time. Patients who did not respond to the 3 invitations were phoned and reviewed opportunistically | to-face reviews using invitations by post or with repeat prescriptions. There was no option for a phone review and no attempt to contact non-attenders. | | | C2: £4485 | with coin toss<br>• Un-blinded |
| | | | % with COPD | 6.5 | 7.2 | 8.5 | | | | Cost per review | T: £10.03<br>C1: £11.85<br>C2: £12.74 | |
| | | | **Inclusion criteria:**<br>• Adults aged 12+ years<br>• Prescription in previous year<br>**Exclusion criteria:**<br>• Diagnosis of COPD | | | | | | | | | |

**Table 169: Prabhakaran 2009[1392,1392]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Prabhakaran, L., et al (2010). The use of text messaging to improve asthma control: A pilot study using the mobile phone short messaging service (SMS). *Journal of telemedicine and telecare, 16*(5), 286-290 | RCT<br><br>Hospital in Singapore and location | N=120<br><br>**Tele**: N=60<br><br>**Control**: N=60 | | **Tele:** | **Control:** | SMS monitoring to assist with the management of their asthma control for three months. | All patients were seen by a trained asthma nurse educator who assessed their asthma control, compliance and inhaler technique prior to asthma education. The 60 patients in the control group were left to self-manage their asthma for | 3 m | Mortality | T: 0/60<br>C: 0/60 | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Randomised with slips of paper<br>• Un-blinded<br>• Low dropout |
| | | | Age, years | 37 | 40 | | | | Dichot. ACT, can't use | | |
| | | | % male | 35 | 47 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults aged 21+ years<br>• Previous asthma admission<br>• English speaking and able to use a mobile phone<br><br>**Exclusion criteria:**<br>• Significant co-morbidity | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| | | | • Mild asthma | | three months | | | | |

**Table 170: Rasmussen 2005**[1435,1436]

| Reference | Study type | Number of patients | Patient characteristics | | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rasmussen, L. et al. (2005). Internet-based monitoring of asthma: A long-term, randomized clinical study of 300 asthmatic subjects. *Journal of Allergy & Clinical Immunology, 115*(6), 1137-1142. | RCT<br><br>Copenhagen Denmark | N=300<br><br>**Tele**: N=100<br><br>**Control1**: N=100<br><br>**Control2**: N=100 | | **Tele** | **Cont 1** | **Cont 2** | Electronic diary, an asthma action plan and a decision support system for the physician. Patients were given a PEF Meter and taught how to fill in a daily diary and respond to the computer's advice. Physicians gave instructions via e-mail or telephone. | 1) Specialists taught patients how to adjust medication on the basis of a PEF meter and written action plan<br><br>2) Patients were asked to contact their GP and pass on a letter describing the study and giving the test results. GPs in Copenhagen had been sent a circular about asthma and GINA guidelines. | 12 m | Hospital visits | T: 0/85<br>C1: 1/88<br>C2: 0/80 | **Funding:** Grants from H:S Corporation of University Hospital of Copenhagen, AstraZeneca, and private funds<br><br>**Risk of bias:**<br>• Randomised consecutively with sealed envelopes<br>• Un-blinded<br>• Unbalanced dropout<br>• Some selective reporting |
| | | | Age, yrs | 28 | 30 | 30 | | | | ED visits | T: 2/85<br>C1: 0/88<br>C2: 1/80 | |
| | | | % male | 31.8 | 34.1 | 37.5 | | | | GP visits | T: 3/85<br>C1: 2/88<br>C2: 1/810 | |
| | | | % pred FEV1 | 91 | 93 | 92 | | | | | | |
| | | | Baseline AQLQ | 6.2 | 6.2 | 6.1 | | | | FEV1 change (mL) | T: 187 (369)<br>C1: 35 (281)<br>C2: 4 (268) | |
| | | | **Inclusion criteria:**<br>• Adults aged 18-45 years<br>• Asthma according to ATS<br><br>**Exclusion criteria:**<br>• Not described | | | | | | | | | |

**Table 171: Ryan 2012**[1493,1493]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ryan, D., et al (2012). Clinical and cost-effectiveness of mobile phone supported self-monitoring of asthma: multicentre randomised controlled trial. *BMJ (Online), 344*(7854), e1756. | RCT<br><br>32 GPs in England | N=288<br><br>**Tele**: N=145<br><br>**Control**: N=143 | | **Tele:** | **Control:** | Twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback prompting action according to an agreed plan | Paper-based monitoring with the same clinical care as the intervention group (BTS/SIGN based). Both groups also received a 30 minute education session from the practice nurse before randomisation . | 6 m | Hospital visits | T: 3/140<br>C: 1/141 | **Funding:** Asthma UK<br><br>**Risk of bias:**<br>• Centrally randomised<br>• Blinded outcome assessment |
| | | | Age, years | 46.6 | 51.5 | | | | ED visits | T: 3/140<br>C: 0/141 | |
| | | | % male | 33.8 | 41.3 | | | | GP visits | T: 51/140<br>C: 41/141 | |
| | | | Baseline ACQ | 2.32 | 2.29 | | | | Oral steroid use | T: 28/140<br>C: 30/141 | |
| | | | **Inclusion criteria:**<br>• Adults aged 12+<br>• Poorly controlled asthma<br><br>**Exclusion criteria:**<br>• Other lung disease or other clinical/social problems | | | | | | AQLQ | T: 5.00 (1.32)<br>C: 4.99 (1.34) | |
| | | | | | | | | | ACQ | T: 1.57 (0.99)<br>C: 1.56 (1.09) | |

**Table 172: Seid 2012**[1557,1557]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Seid, M., et al (2012). The In Vivo adherence intervention for at risk adolescents with asthma: Report of a randomized | RCT<br><br>1 site in Cincinnati, USA | N=26<br><br>**Tele**: N=14<br><br>**Control**: N=14 | | **Tele:** | **Control:** | Asthma education, in-person motivational interviewing and problem solving skills training, cell phone with | Asthma education and cell phone without tailored text messaging | 1 and 3 m | None of interest | N/A | **Funding:** National Institutes of Health<br><br>**Risk of bias:**<br>• Random number tables |
| | | | % male | 41.7 | 21.4 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adolescents aged 12-18 years<br>• Moderate/severe asthma | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| pilot study. *Journal of pediatric psychology, 37*(4), 390-403 | | | (NHLBI)<br>• Symptoms in past 2 weeks<br><br>**Exclusion criteria:**<br>• Co-morbid conditions<br>• Non English speaking | tailored text messages | | | | | • Blinded outcome assessment<br>• Pilot study |

**Table 173: van der Meer 2009[1824]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Van Der Meer, V., et al (2010). Self-management for asthma on the Internet: A randomized study. *Nederlands tijdschrift voor geneeskunde, 154*(9), 403-409. | RCT<br><br>37 GPs in Holland | N=200<br><br>**Tele**: N=101<br><br>**Control**: N=99 | | **Tele:** | **Control:** | Website to record FEV1 (daily), ACQ (weekly), and symptoms via internet or text. Also included asthma treatment plan and online education. Patients could contact an asthma nurse when needed. The ACQ score fed into an algorithm and patients received one of 4 treatment messages. | Control patients had access to the part of the website on which a diary of symptoms and exacerbations was kept. | 12 m | AQLQ change with 95% CI | T: 0.56 (0.43 to 0.68)<br>C: 0.18 (0.05 to 0.31) | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Computer randomisation<br>• Un-blinded<br>• Completer analysis |
| | | | Age, years | 36 | 37 | | | | ACQ change with 95% CI | T: -0.54 (-0.65 to -0.42)<br>C: -0.06 (-0.18 to 0.05) | |
| | | | % male | 32 | 29 | | | | | | |
| | | | % predicted FEV1 | 88 | 90 | | | | | | |
| | | | Baseline ACQ | 1.12 | 1.11 | | | | | | |
| | | | % taking LABA/ICS | 59 | 60 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults aged 18-50 years<br>• ICS for > 3 months in the past year<br><br>**Exclusion criteria:**<br>• Currently on oral steroids | | | | | | | | |

**Table 174: Vollmer 2006[1873,1873]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Vollmer, W. M., et al (2006). Use and impact of an automated telephone outreach system for asthma in a managed care setting. *American Journal of Managed Care, 12*(12), 725-733. | RCT<br><br>Large group health organisation in Oregon, USA | N=6948<br><br>**Tele**: N=3389<br><br>**Control**: N=3367 | | **Tele:** | **Control:** | Three phone calls 5 months apart with tailored advice to address recent ED care, asthma control and medication use. Optional tailored feedback. The call generated alerts for the provider as to which patients were at high risk of exacerbations. | Routine care with no telephone calls | 10 m | AQLQ (in a subset of patients) | T: 5.2 (1.2)<br>C: 5.1 (1.2) | **Funding:** Centres for Disease Control and Prevention and the Kaiser Permanente Care management Institute<br>**Risk of bias:**<br>• No details about randomisation or blinding<br>• Some data only collected from a subset of patients |
| | | | Age, years | 51.8 | 51.4 | | | | Hospital visit *or* ED visit | T: 132/3220<br>C: 121/3033 | |
| | | | % male | 35 | 35 | | | | | | |
| | | | Baseline AQLQ | 5.0 | 5.2 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults aged 18+ years<br>• At least 180 days of asthma medication dispensed<br><br>**Exclusion criteria:**<br>• COPD | | | | | | | | |

**Table 175: Willems 2007[1917,1918]**

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Willems, D. C., et al (2007). Process evaluation of a nurse-led telemonitoring | RCT<br><br>Single centre in the Netherl | N=109<br><br>**Tele**: N=55 (26 adults, 29 | | **Tele:** | **Control:** | Asthma tele-monitoring via home modem. Patients were asked to perform daily | Regular outpatient care: 3 to 6-monthly medical check-ups by | 12 m | AQLQ | T: 5.73 (1.09)<br>C: 5.48 (1.18) | **Funding:** Unclear<br><br>Baseline characteristics reported for |
| | | | Age, years | 27.2 | 28.4 | | | | ED visits | T: 0/55<br>C: 4/54 | |

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| programme for patients with asthma. *Journal of Telemedicine & Telecare, 13*(6), 310-317. | ands | children)<br><br>**Control**: N=54 (27 adults, 27 children) | % male | 58.2 | 44.4 | PEFR and more often in exacerbations. The nurse could increase and decrease asthma medication and involve a doctor if necessary. | their lung specialist or paediatrician | | | | children and adults separately, but not outcome data<br>**Risk of bias:**<br>• Random number list, stratified by age<br>• Un-blinded<br>• Compliance for AQLQ and PEF was low |
| | | | % predicted FEV1 | 94.9 | 96.0 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults and children aged 7+<br>• Stage I to III GINA<br><br>**Exclusion criteria:**<br>• Severe co-morbidity | | | | | | | | |

**Table 176: Xu 2011**[1948,1949]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Xu, C., et al (2010). A randomized controlled trial of an interactive voice response telephone system and specialist nurse support for childhood | RCT<br><br>Child hospitals in Australia | N=121 (82) in relevant groups)<br><br>**Tele**: N=41<br><br>**Control**: N=41 | | **Tele:** | **Control:** | 1) Interactive Voice Response<br><br>2) The nurse support group received follow-up calls from one Nurse Specialist every 2 weeks. Where families | Patients' primary care physicians were notified and continued to provide primary asthma care. All families had the same initial asthma education with | 6 m | Hospital visits | T1: 4/39<br>T2: 4/38<br>C: 4/40 | **Funding:** Unclear<br><br>**Risk of bias:**<br>• Randomisation unclear<br>• Un-blinded<br>• Low dropout |
| | | | Age, years | T1: 7.0<br>T2: 6.5 | 7.4 | | | | ED visits | T1: 6/39<br>T2: 8/39<br>C: 5/40 | |
| | | | % male | T1: 56.4<br>T2: 51.2 | 51.2 | | | | Oral steroid use | T1: 16/39<br>T2: 22/41<br>C: 21/40 | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| asthma management. *Journal of asthma, 47*(7), 768-773 | | | **Inclusion criteria:**<br>• Children/teens aged 3-16<br>• Recent exacerbation<br><br>**Exclusion criteria:**<br>• Not described | preferred email contact, the nurse used email to collect the same data and offer education and advice on asthma.<br>2) | the same Specialist Nurse. | | School days lost (yes/no) | T1: 20/38<br>C: 22/39 | |
| | | | | | | | Parent work days lost (yes/no) | T1: 13/39<br>C: 13/39 | |
| | | | | | | | AQLQ (child), mean (SD) | T1: 1.1 (1.1)<br>C: 0.5 (0.9) | |
| | | | | | | | AQLQ (carer), mean (SD) | T1: 1.2 (1.6)<br>C: 1.0 (1.5) | |
| | | | | | | | | | |

**Table 177: Young 2012**[1964,1964]

| Reference | Study type | Number of patients | Patient characteristics | | | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Young, H. N., et al (2012). Patient and phaRmacist telephonic encounters (PARTE) in an underserved rural patient population with | RCT<br><br>Wisconsin, USA | N=98<br><br>**Tele**: N=49<br><br>**Control**: N=49 | | **Tele:** | **Control:** | Telephone consultation from pharmacists regarding their asthma self-management and medication use. Five pharmacists | Usual care, which included mail receipt of a prescription refill with written medication use instructions. | Unknown follow-up | None of interest | N/A | **Funding:** National Centre for Research Resources, National Institutes of Health<br><br>**Risk of bias:** |
| | | | Age, years | 45.4 | 43.7 | | | | | | |
| | | | % male | 26.5 | 20.4 | | | | | | |
| | | | **Inclusion criteria:**<br>• Adults aged 19+<br>• Community Health Access | | | | | | | | |

| Reference | Study type | Number of patients | Patient characteristics | Intervention | Comparison | Length of follow-up | Outcome measures | Effect sizes | Comments |
|---|---|---|---|---|---|---|---|---|---|
| asthma: results of a pilot study. *Telemedicine journal and e-health, 18*(6), 427-433 | | | program (uninsured or underinsured people)<br>• Diagnosis of asthma and 1+ asthma medications within 6 months<br><br>**Exclusion criteria:**<br>• Enrolment in the FHC pharmacy program | incorporated the intervention into their usual practice. | | | | | • No randomisation details<br>• Blinded assessment<br>• Balanced dropout<br>• No relevant outcomes |

# Appendix H: Economic evidence tables

## H.1 Monitoring: Tele-healthcare

**Table 178: Gruffydd-Jones 2005[603]**

| Gruffydd-Jones K, Hollinghurst S, Ward S, Taylor G. Targeted routine asthma care in general practice using telephone triage. British Journal of General Practice. 2005; 55:918-923. | | | | |
|---|---|---|---|---|
| **Study details** | **Population & interventions** | **Costs** | **Health outcomes** | **Cost-effectiveness** |
| **Economic analysis:** CCA (health outcome: Mini-AQLQ scores)<br><br>**Study design:** Within-trial analysis (RCT)<br><br>**Approach to analysis:** Analysis of individual level data for asthma control and resource use with unit costs applied.<br><br>**Perspective:** UK NHS<br>**Time horizon:** 12 months<br>**Treatment effect duration:** 12 months<br>**Discounting:** Not Applicable | **Population:** Adult Asthma Patients<br><br>**Patient characteristics:**<br>N (control): 62<br>N (intervention): 84<br><br>Mean age (control): 49.6 (SD: 16.1)<br>Mean age (intervention): 50.8 (SD: 15.4)<br><br>Male (control): 39%<br>Male (intervention): 51%<br><br>**Intervention 1:**<br>Clinic Group: Patients received 'usual' care by 6 monthly check-up via dedicated asthma nurse.<br><br>**Intervention 2:** | **Total costs (mean per patient):**<br>Intervention 1: £333.85 (SD: 410.64)<br>Intervention 2: £209.85 (SD: 220.94)<br>Incremental (2−1):<br>Bootstrapped cost difference: £122.35 (p-value: 0.071)<br><br>**Currency & cost year:**<br>2004 UK pounds<br><br>**Cost components incorporated:**<br>Total routine care (minutes)<br>Number of inhalers<br>Number of tablets<br>Non-routine consultations<br>Length of inpatient stays | **Mini-AQLQ score (median per patient at 12 months):**<br>Intervention 1: 5.93 (IQR: 2.07)<br>Intervention 2: 6.47 (IQR: 1.22)<br>Incremental (2−1):<br>NR, though the difference in health was not clinically significant | **ICER (Intervention 2 versus Intervention 1):**<br>Telephone reviews dominated clinical reviews (lower costs and higher health outcomes)<br><br>**Analysis of uncertainty:** NR |

| | | | | |
|---|---|---|---|---|
| | Telephone group: patients contacted by telephone at 6 monthly intervals by one or two trained asthma nurses. Patient was asked RCP Morbidity Index and if 'yes' was answered to any of the three questions a clinical asthma review was arranged. If asthma was deemed stable for 3 months telephone interviews were resumed. | | | |

**Data sources**

**Health outcomes:** Mini AQLQ score.

**Quality-of-life weights:** NR

**Cost sources:** Resource use from within RCT;

resources use priced using: BNF; NHS Reference costs; PSSRU 2003

**Comments**

**Source of funding:** Research grant from Asthma UK. **Limitations:** Short time horizon of 12 months may not be long enough to capture adverse health impacts and therefore not give an accurate representation of long term health and cost outcomes. Health was also not measured using QALYs, only quality of life not length was considered. Lack of any sensitivity analysis reduces robustness of results.

**Overall applicability[(a)]: Partially applicable Overall quality[(b)]: Potentially serious limitations**

*Abbreviations: CCA: cost–consequence analysis; CI: 95% confidence interval; ICER: incremental cost-effectiveness ratio; NR: not reported; QALYs: quality-adjusted life years, SD: Standard Deviation*

*(a) Directly applicable / Partially applicable / Not applicable*

*(b) Minor limitations / Potentially serious limitations / Very serious limitations*

### Table 179: Ryan 2012[1493,1493]

**Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D et al. Clinical and cost-effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ. 2012; 344:e1756.**

| Study details | Population & interventions | Costs | Health outcomes | Cost-effectiveness |
|---|---|---|---|---|
| **Economic analysis:** CCA (health outcome: changes in scores on asthma control questionnaire and self-efficacy )<br><br>**Study design:** One year multicentre randomised controlled trial conducted in a UK primary care setting - Within trial analysis<br><br>**Approach to analysis:** Economic evaluation based on the results of the randomised controlled trial<br><br>**Perspective:** UK NHS<br>**Time horizon:** 12 months<br>**Treatment effect duration:** 12 months<br>**Discounting:** NA | **Population:**<br>288 adolescents and adults with poorly controlled asthma (ACQ score ≥ 1.5)<br><br>**Patient characteristics:**<br>N (control) =142<br>N (intervention) =145<br><br>Mean age (control): 51.5 (SD: 17.7)<br>Mean age (intervention): 46.6 (SD: 18)<br><br>Male (control): 34%<br>Male (intervention): 41%<br>**Intervention 1:**<br>Mobile phone monitoring: Twice daily recording and mobile phone based transmission of symptoms, drug use, and peak flow with immediate feedback (through t+ Asthma mobile application) prompting action to agreed plan.<br><br>**Intervention 2:**<br>Patients asked to keep a paper diary, recording the same information gathered from intervention 1 | **Total costs (mean per patient):**<br>Intervention 1: £315 (SD: 226)<br>Intervention 2: £245 (SD: 201)<br><br>Incremental (2−1): £70<br>(CI: £20 to £121; p = 0.006)<br><br>**Currency & cost year:**<br>2008-2009 UK pounds<br>**Cost components incorporated:**<br>Cost of delivering intervention<br>Nursing costs<br>Tele-monitoring service costs<br>Cost of healthcare provision<br>GP respiratory consultations<br>Practice nurse respiratory consultations<br>Secondary care costs (outpatient and admissions)<br>Emergency services<br>Total cost of prescriptions from respiratory drugs | **QALYs (mean per patient):**<br>There was no significant change in asthma control or self-efficacy between the two interventions | **ICER (Intervention 2 versus Intervention 1):**<br>NR<br><br>**Analysis of uncertainty:** No sensitivity analysis was conducted |

| | | | | |
|---|---|---|---|---|
| | (symptoms, drug use, and peak flow readings twice daily). | | | |
| **Data sources** | | | | |
| **Health outcomes:** Self-reported from patients who participated in the trial.<br>**Cost sources:** Unit costs for all resources used by patients in the randomized controlled trial were obtained from the data sources in the UK including the NHS Reference costs (2007-2008), the Personal Social Services Research Unit (2008) and the British National Formulary (BNF 2008). | | | | |
| **Comments** | | | | |
| **Source of funding:** Asthma UK. **Limitations:** Short time horizon of 12 months may not be long enough to capture adverse health impacts and therefore not give an accurate representation of long term health and cost outcomes. Health was also not measured using QALYs, only quality of life not length was considered. Lack of any sensitivity analysis reduces robustness of results. | | | | |
| **Overall applicability[(a)]:** partially applicable **Overall quality[(b)]:** potentially serious limitations | | | | |

*Abbreviations: CCA: cost–consequence analysis; 95% CI: 95% confidence interval; ICER: incremental cost-effectiveness ratio; NR: not reported; pa: probabilistic analysis; QALYs: quality-adjusted life years*

*(a) Directly applicable / Partially applicable / Not applicable*

*(b) Minor limitations / Potentially serious limitations / Very serious limitations*

**Table 180: Willems 2007[1918,1919]**

| **Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost-effectiveness and Resource Allocation. Netherlands 2007; 5:10.** | | | | |
|---|---|---|---|---|
| **Study details** | **Population & interventions** | **Costs** | **Health outcomes** | **Cost-effectiveness** |
| **Economic analysis:** CUA (health outcome: QALYs )<br><br>**Study design:** One year single centre randomised controlled trial – Within trial analysis<br>**Approach to analysis:** | **Population:** Outpatients with asthma<br>**Patient characteristics:**<br>N (Control ) = 53<br>N (Intervention) = 56<br><br>Mean age (control over 18 years old): 45.9 (SD: 15.9)<br>Mean age (intervention over | **Total costs (mean per patient):**<br>Intervention 1 (over 18 years old): £1,197 (SD: £1212)<br>Intervention 1 (between 7 and 18 years old): £409 (SD: £591)<br><br>Intervention 2 (over 18 years old): £1,550 (SD: £1,101) | **QALYs (mean per patient):**<br><br>Intervention 1 (between 7 and 18 years old): 0.0 (95% CI: 0.00 to 0.02)<br><br>Incremental (2−1) (Over 18 years old): 0.03 (95% CI: 0.00 to 0.07) | **ICER (Intervention 2 versus Intervention 1) (over 18 years old):**<br>£10693 per QALY gained (pa)<br>95% CI: NR<br>Probability Intervention 2 (adults) cost-effective (£20K/30K threshold): NR<br><br>**ICER (Intervention 2 versus Intervention 1) (between 7 and 18 years old):**<br>£40865 per QALY gained (pa) |

| | | | | |
|---|---|---|---|---|
| Comparison of health outcomes and costs between tele-monitoring and usual care.<br><br>**Perspective:** Dutch societal or healthcare perspective (only healthcare perspective results shown)<br><br>**Time horizon:** 12 months<br><br>**Treatment effect duration:** 12 months<br>**Discounting:** NR | 18 years old): 45.65 (SD: 11.3)<br>Mean age (control between 7 and 18 years old): 10.85 (SD: 2.3)<br>Mean age (intervention between 7 and 18 years old): 10.57 (SD: 2.1)<br><br>Male (control over 18 years old): 33.3%<br>Male (intervention over 18 years old): 42.3%<br>Male (control between 7 and 18 years old): 55.6%<br>Male (intervention between 7 and 18 years old): 72.4%<br><br>**Intervention 1:**<br>Regular outpatient care. Three to six monthly medical check-ups by their lung specialist or paediatrician. For exacerbations patients received additional care by GP and/or outpatient care.<br><br>**Intervention 2:**<br>Patients received an asthma monitor and had a hospital based nurse practitioner as the main caregiver. Patients were instructed to perform daily lung function tests in | Intervention 2 (between 7 and 18 years old): £830 (SD: £405)<br><br>Incremental (2−1) (over 18 years old):<br>£353<br>(95% CI: -£114 to £1118; p=NR)<br><br>Incremental (2−1) (between 7 and 18 years old):<br>£421<br>(95% CI: £319 to £862; p=NR)<br><br>**Currency & cost year:**<br>2002 Euros (presented here as 2002 UK pounds[(a)])<br><br>**Cost components incorporated:**<br>General practitioner practice: (GP visit, GP telephone visit, assistant visit, assistant telephone visit, nurse practitioner visit)<br>Hospital care: (day admission, emergency room visit, surgical procedures, diagnostic procedures, laboratory research, lung specialist outpatient visit, paediatric lung specialist | Incremental (2−1) (between 7 and 18 years old): 0.01 (95% CI: 0.00 to 0.02)<br><br>Incremental (2−1) (Over 18 years old): 0.03 (95% CI: 0.00 to 0.07) | 95% CI: NR<br>Probability Intervention 2 (children) cost-effective (£20K/30K threshold): NR<br><br>**Analysis of uncertainty:**<br>Using SF-36 instead of EQ-5D leads to drastically different results making the intervention dominated for adults; SF-6D was not assessed in children.<br>Sensitivity analysis was conducted by excluding monitor device costs from the intervention (monitor, modem, batteries and insurance) which equated to £313. This reduced the ICER for adults to £1224 and for children to £10502. This shows that initial capital costs significantly drive the cost-effectiveness result. Therefore in the long run assuming recurrent capital costs will fall the ICER will fall over time, all other things remaining equal. |

| | | | | |
|---|---|---|---|---|
| | the morning and evening and more often when they were having symptoms. Patients asked to transfer data once a month or more with symptoms. Based on data nurse was able to decrease asthma medication (after three months of stable asthma) or increase (if asthma was unstable) by one step. | outpatient visit, asthma nurse practitioner outpatient visit, other medical specialists outpatient visit)<br>Other healthcare professional costs: (speech therapist, homoeopath, company medical officer)<br>Prescribed medication: (medication, pharmacist fee)<br>Professional home care<br>Intervention costs | | |
| **Data sources** | | | | |
| **Health outcomes:** Taken from the results from the in-trial randomized controlled trial. **Quality-of-life weights:** EQ-5D, UK tariff. **Cost sources:** Volumes of hospital care were obtained from the hospital billing system of the university hospital Maastricht. All other resource costs use obtained from cost diaries. Dutch manual for cost research used for unit prices. | | | | |
| **Comments** | | | | |
| **Source of funding:** NR. **Limitations:** The costs are not from a UK perspective and therefore may not be generalizable. The time horizon is also very short at 12 months; this may not be enough time to capture rare adverse events that would have a differential probability of occurring across the two groups. The results are extremely sensitive to the choice of HRQoL measure used. | | | | |
| **Overall applicability[(a)]: Partially applicable Overall quality[(b)]: Potentially serious limitations** | | | | |

*Abbreviations: 95% CI: 95% confidence interval; CUA: cost–utility analysis; EQ-5D: Euroqol 5 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death); HRQoL: Health related quality of life; ICER: incremental cost-effectiveness ratio; NR: not reported; QALYs: quality-adjusted life years; SF-6D: Short form 6 dimensions (scale: 0.0 [death] to 1.0 [full health], negative values mean worse than death)*

*(a) Converted using 2002 purchasing power parities*[1284]

*(b) Directly applicable / Partially applicable / Not applicable*

*(c) Minor limitations / Potentially serious limitations / Very serious limitations*

# Appendix I: GRADE tables

## I.1 Monitoring: Questionnaires

**Table 181: Clinical evidence profile: Children (5-16 years) with uncontrolled asthma: Monitoring questionnaires + treatment vs UC + treatment.**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Children with uncontrolled asthma: Monitoring control + treatment | UC + treatment | Relative (95% CI) | Absolute | | |
| **QOL (< 6months) (follow-up 3 months; measured with: PAQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 46 | 44 | - | MD 0.4 higher (0.17 to 0.63 higher) | ⊕OOO VERY LOW | CRITICAL |
| **QOL (≥ 6months) (follow-up 12 months; measured with: PAQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 46 | 44 | - | MD 0.05 lower (0.5 lower to 0.4 higher) | ⊕⊕OO LOW | CRITICAL |
| **Exacerbations (≥ 6months) (follow-up 12 months; assessed with: Course of OCS)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[3] | none | 6/35 (17.1%) | 15% | RR 1.14 (0.41 to 3.22) | 21 more per 1000 (from 89 fewer to 333 more) | ⊕OOO VERY LOW | CRITICAL |
| **Asthma control (< 6months) (follow-up 3 months; measured with: ACQ; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised | very | no serious | no serious | no serious | none | 46 | 44 | - | MD 0.32 lower (0.56 to 0.08 | ⊕⊕OO | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | trials | serious[1] | inconsistency | indirectness | imprecision | | | | | lower) | LOW | |
| **Asthma control (≥ 6months) (follow-up 12 months; measured with: ACQ; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 46 | 44 | - | MD 0.05 lower (0.35 lower to 0.25 higher) | ⊕⊕OO LOW | CRITICAL |
| **Lung function (< 6months) (follow-up 3 months; measured with: FEV1 L; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 46 | 44 | - | MD 0.23 higher (0.08 to 0.38 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Lung function (≥ 6months) (follow-up 12 months; measured with: FEV1 L ; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 46 | 44 | - | MD 0.1 higher (0.11 lower to 0.31 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Symptom free days (< 6months) (follow-up 3 months; measured with: % over 2 weeks ; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[4] | none | 46 | 44 | - | MD 1.5 lower (14.5 lower to 11.5 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Symptom free days (≥ 6months) (follow-up 12 months; measured with: % over 2 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[4] | none | 46 | 44 | - | MD 4 higher (9.7 lower to 17.7 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **ICS use (< 6months) (follow-up 3 months; measured with: mean daily dose ug; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[4] | none | 46 | 44 | - | MD 14 higher (79 lower to 107 higher) | ⊕OOO VERY LOW | IMPORTANT |

| ICS use (≥ 6months) (follow-up 12 months; measured with: mean daily dose ug; Better indicated by lower values) | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[4] | none | 46 | 44 | - | MD 14 higher (75 lower to 103 higher) | ⊕OOO VERY LOW | IMPORTANT |

*1 The majority of the evidence was from studies at very high risk of bias*
*2 95% CI crosses one MID*
*3 95% CI for the absolute effect crosses one MID*
*4 95% CI crosses both MIDs*

**Table 182: Clinical evidence profile: Adults and young people (>16 years) overall: Monitoring questionnaires + treatment vs UC + treatment.**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Adults overall: Monitoring control + treatment | UC + treatment | Relative (95% CI) | Absolute | | |
| **QOL (≥ 6months) (follow-up 6-12 months; measured with: AQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 171 | 162 | - | MD 0.32 higher (0.17 to 0.47 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **Exacerbations (≥ 6months) (follow-up 12 months; assessed with: course of OCS)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 11/91 (12.1%) | 10.9% | HR 1.18 (0.51 to 2.73) | 18 more per 1000 (from 52 fewer to 161 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations (≥ 6months) (follow-up 6-12 months; assessed with: ER, hospitalisation or OCS )** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | no serious inconsistency | serious[3] | serious[4] | none | 21/171 (12.3%) | 11.2% | RR 1.1 (0.61 to 1.99) | 11 more per 1000 (from 44 fewer to 111 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU (≥ 6months) (follow-up 6 months; assessed with: ER or hospitalisation)** | | | | | | | | | | | | |
| 1 | randomised | very | no serious | no serious | serious[4] | none | 1/80 | 7.1% | RR 0.17 | 59 fewer per 1000 | ⊕OOO | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | trials | serious[5] | inconsistency | indirectness | | | (1.3%) | | (0.02 to 1.46) | (from 70 fewer to 33 more) | VERY LOW | |
| **Asthma control (< 6months) (follow-up 3 months; measured with: ACT; range of scores: 5-25; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 99 | 84 | - | MD 0.3 higher (0.73 lower to 1.33 higher) | ⊕⊕OO LOW | CRITICAL |
| **Asthma control (≥ 6months) (follow-up 12 months; measured with: ACQ ; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[6] | none | 91 | 92 | - | MD 0.47 lower (0.64 to 0.3 lower) | ⊕⊕OO LOW | CRITICAL |
| **Asthma control (≥ 6months) (follow-up 6 months; measured with: ACT; range of scores: 5-25; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 80 | 70 | - | MD 0.5 higher (0.86 lower to 1.86 higher) | ⊕⊕OO LOW | CRITICAL |
| **Lung function (≥ 6months) (follow-up 12 months; measured with: FEV1 L; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[6] | none | 91 | 92 | - | MD 0.25 higher (0.03 to 0.47 higher) | ⊕⊕OO LOW | IMPORTANT |
| **Symptom free days (≥ 6months) (follow-up 12 months; measured with: % over 2 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[6] | none | 91 | 92 | - | MD 10.9 higher (0.05 to 21.75 higher) | ⊕⊕OO LOW | IMPORTANT |
| **ICS use (≥ 6months) (follow-up 12 months; measured with: mean daily dose ug; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 91 | 92 | - | MD 57 higher (38 lower to 152 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Rescue medication (< 6months) (follow-up 3 months; measured with: puffs/day; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[6] | none | 99 | 84 | - | MD 0.62 lower (1.21 to 0.03 lower) | ⊕⊕OO LOW | IMPORTANT |
| **Rescue medication (> 6months) (follow-up 6 months; measured with: puffs/day; Better indicated by lower values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 80 | 70 | - | MD 0.23 lower (0.66 lower to 0.2 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |

*1 The majority of the evidence was from studies at high risk of bias*
*2 95% CI crosses both the MIDs*
*3 Evidence from one study with an indirect outcome (ER, hospitalisation or OCS)*
*4 95% CI for the absolute effect crosses one MID*
*5 The majority of the evidence was from studies at very high risk of bias*
*6 95% CI crosses one MID*

# I.2 Monitoring: Lung function tests

**Table 183: Clinical evidence profile: Adults: Monitoring PEF versus symptom monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | PEF versus symptoms monitoring: adults | Control | Relative (95% CI) | Absolute | | |
| **QOL ≥6 months (follow-up 2 years; assessed with: AQLQ increase >0.5 points)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 52/134 (38.8%) | 39.1% | RR 0.99 (0.73 to 1.35) | 4 fewer per 1000 (from 106 fewer to 137 more) | ⊕OOO VERY LOW | CRITICAL |
| **QOL ≥6 months (follow-up 2 years; assessed with: AQLQ decrease >0.5 points )** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2,3] | none | 16/134 (11.9%) | 8.6% | RR 1.39 (0.67 to 2.88) | 34 more per 1000 (from 28 fewer to 162 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation ≥6 months (follow-up 6-12 months; assessed with: need for OCS)** | | | | | | | | | | | | |
| 2 | randomised | very | serious[4] | no serious | very serious[3] | none | 17/71 | 16.9% | RR 1.28 (0.29 to | 47 more per 1000 (from 120 fewer to | ⊕OOO | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | trials | serious[1] | | indirectness | | | (23.9%) | | 5.57) | 772 more) | VERY LOW | |
| **Exacerbations ≥6 months (follow-up 12 months; measured with: number of OCS courses; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 50 | 45 | - | MD 0.20 lower (0.74 lower to 0.34 higher) | ⊕⊕OO LOW | CRITICAL |
| **UHU ≥6 months (follow-up 2 years; measured with: Total asthma-related health care utilisation; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 148 | 146 | - | MD 0.11 lower (0.59 lower to 0.37 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU ≥6 months (follow-up 6-12 months; assessed with: Hospitalisation)** | | | | | | | | | | | | |
| 3 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | very serious[3] | none | 4/146 (2.7%) | 2.2% | RR 1.17 (0.31 to 4.43) | 4 more per 1000 (from 15 fewer to 75 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ≥6 months (follow-up 12 months; measured with: Number of hospital admissions; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 50 | 45 | - | MD 0.05 lower (0.16 lower to 0.06 higher) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ≥6 months (follow-up 12 months; measured with: days hospitalisation; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 48 | 40 | - | MD 0.03 lower (0.21 lower to 0.15 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU ≥6 months (follow-up 6-12 months; assessed with: ED visits)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 9/100 (9%) | 2/92 (2.2%) | RR 3.78 (0.96 to 14.93) | 60 more per 1000 (from 1 fewer to 303 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ≥6 months (follow-up 12 months; measured with: Mean number of ED visits ; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 98 | 85 | - | MD 0.04 lower (0.2 lower to 0.12 higher) | ⊕⊕⊕O MODERATE | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **UHU ≥6 months (follow-up 6 months; assessed with: Unscheduled doctors visit)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[5] | very serious[6] | no serious indirectness | very serious[3] | none | 22/90 (24.4%) | 28.1% | RR 0.77 (0.18 to 3.34) | 65 fewer per 1000 (from 230 fewer to 658 more) | ⊕OOO VERY LOW | CRITICAL |
| **Rescue medication ≥6months (follow-up 12 months; assessed with: requiring nebulised salbutamol)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 3/28 (10.7%) | 5.4% | RR 1.98 (0.35 to 11.08) | 53 more per 1000 (from 35 fewer to 544 more) | ⊕OOO VERY LOW | IMPORTANT |
| **FEV1 L ≥6 months (follow-up 12 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 48 | 40 | - | MD 0.26 lower (0.61 lower to 0.09 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **FEV1 % ≥6 months (follow-up 6-12 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 87 | 76 | - | MD 0.10 higher (0.92 lower to 1.12 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF % best ≥6 months (follow-up 6 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 31 | 32 | - | MD 5.31 higher (1.91 lower to 12.53 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Time off school/work ≥6 months (follow-up 6-12 months)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 11/100 (11%) | 8.3% | RR 1.41 (0.62 to 3.21) | 34 more per 1000 (from 32 fewer to 183 more) | ⊕OOO VERY LOW | IMPORTANT |
| **Mean days off work ≥6 months (follow-up 12 months; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised | very | no serious | no serious | serious[2] | none | 98 | 85 | - | MD 2.5 higher (1.27 | ⊕OOO | IMPORTANT |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | trials | serious[1] | inconsistency | indirectness | | | | | | to 3.74 higher) | VERY LOW | |

[1] The majority of the evidence was from studies at very high risk of bias
[2] 95% CI crosses one MID
[3] 95% CI crosses two MIDs
[4] Heterogeneity in the point estimates, I2=52%
[5] The majority of the evidence was from studies at high risk of bias
[6] Heterogeneity in the point estimates, I2=86%

**Table 184: Clinical evidence profile: Children: Monitoring PEF versus symptom monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | PEF versus symptoms monitoring: children | Control | Relative (95% CI) | Absolute | | |
| **Exacerbations <6months (follow-up 3 months; assessed with: OCS)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 1/12 (8.3%) | 8.3% | RR 1.00 (0.07 to 14.21) | 0 fewer per 1000 (from 77 fewer to 1000 more)[3] | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations ≥6months (follow-up 12 months; assessed with: OCS)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 7/19 (36.8%) | 0% | OR 16.34 (3.25 to 82.24) | 370 more per 1000 (from 150 more to 590 more)[3] | ⊕⊕OO LOW | CRITICAL |
| **UHU <6 months (follow-up 12 weeks; assessed with: Hospitalisation)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | very serious[2] | none | 1/44 (2.3%) | 0% | OR 7.56 (0.15 to 381.04) | 20 more per 1000 (from 40 fewer to 80 more)[3] | ⊕OOO VERY LOW | CRITICAL |
| **UHU <6 months (follow-up 12 weeks; assessed with: Attendance at A&E)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | very serious[2] | none | 1/44 (2.3%) | 0% | OR 7.56 (0.15 to 381.04) | 20 more per 1000 (from 40 fewer to 80 more)[3] | ⊕OOO VERY LOW | CRITICAL |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| **UHU(<6 months) (follow-up 12 weeks; assessed with: Emergency GP visits )** | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | very serious[2] | none | 10/44 (22.7%) | 24.4% | RR 0.93 (0.44 to 1.97) | 17 fewer per 1000 (from 137 fewer to 237 more) | ⊕OOO VERY LOW | CRITICAL |
| **Rescue meds ≥6 months (follow-up 12 months; assessed with: requiring nebulised salbutamol)** | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[5] | none | 2/17 (11.8%) | 0% | OR 14.15 (0.79 to 252.1) | 120 more per 1000 (from 50 fewer to 280 more)[3] | ⊕OOO VERY LOW | IMPORTANT |
| **FEV1 % best (<6 months) (follow-up 12 weeks; Better indicated by higher values)** | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 101 | 101 | - | MD 0.39 higher (0.21 lower to 0.98 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF % best (<6 months) (follow-up 12 weeks; Better indicated by higher values)** | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 44 | 45 | - | MD 2.8 higher (2.15 to 3.45 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Time off school (<6 months) (follow-up 12 weeks)** | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 15/44 (34.1%) | 28.9% | RR 1.18 (0.64 to 2.18) | 52 more per 1000 (from 104 fewer to 341 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] The majority of the evidence was from studies at very high risk of bias
[2] 95% CI crosses 2 MIDs
[3] Manual risk difference calculation due to no events in one group
[4] The majority of the evidence was from studies at high risk of bias
[5] 95% CI crosses one MID

# I.3 Monitoring: FeNO

**Table 185: Clinical evidence profile: FeNO versus Conventional Monitoring Adults**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | FeNO versus conventional monitoring ADULTS | Control | Relative (95% CI) | Absolute | | |
| **UHU (ED visit) ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 2/205 (0.98%) | 1.4% | OR 0.68 (0.12 to 3.98) | 4 fewer per 1000 (from 12 fewer to 39 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU (hospitalisation) ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 1/205 (0.49%) | 1% | OR 0.52 (0.05 to 5.07) | 5 fewer per 1000 (from 9 fewer to 39 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation (OCS) ≥6 months (follow-up mean 52 weeks)** | | | | | | | | | | | | |
| 3 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 33/197 (16.8%) | 31.3% | RR 0.84 (0.56 to 1.26) | 50 fewer per 1000 (from 138 fewer to 81 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation (OCS) ≥6 months (follow-up mean 9 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | - | - | HR 0.91 (0.39 to 2.11) | -[3] | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation (OCS) ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | - | - | OR 0.64 (0.27 to 1.56) | -[3] | ⊕OOO VERY LOW | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **AQLQ (≥ 6months) (follow-up mean 6 weeks; measured with: Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 115 | 112 | - | MD 0 higher (0.22 lower to 22 higher)[5] | ⊕⊕OO LOW | CRITICAL |
| **ACQ ≥6 months (follow-up 9-12 months; measured with: Asthma Control Questionnaire; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 320 | 324 | - | MD 0.05 lower (0.13 lower to 0.04 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **ACQ (clinically important improvement, ≥0.5) ≥6 months (follow-up mean 12 months; assessed with: Asthma Control Questionnaire)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 29/81 (35.8%) | 25.7% | RR 1.39 (0.86 to 2.26) | 100 more per 1000 (from 36 fewer to 324 more) | ⊕OOO VERY LOW | CRITICAL |
| **FEV1 %pred (follow-up 9-12 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 3 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 366 | 370 | - | MD 0.45 higher (0.69 lower to 1.59 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **FEV1, litres ≥6 months (follow-up mean 12 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 88 | 78 | - | MD 0.03 lower (0.11 lower to 0.06 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF am (L/min) ≥6 months (follow-up 9-12 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 161 | 160 | - | MD 2 higher (10.39 lower to 14.39 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF pm (L/min) ≥6 months (follow-up mean 9 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 115 | 112 | - | MD 3.8 higher (10 lower to 17.6 higher) | ⊕⊕OO LOW | IMPORTANT |
| **ICS use ≥6 months (follow-up mean 12 months; measured with: fluticasone or BDP equivalent; Better indicated by lower values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | randomised trials | serious[1] | no serious inconsistency | serious[6] | serious[2] | none | 104 | 108 | - | SMD 0.53 lower (0.8 to 0.25 lower) | ⊕OOO VERY LOW | IMPORTANT |
| **Rescue medication (puffs/day) ≥6 months (follow-up 9-12 months; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | serious[6] | no serious imprecision | none | 161 | 160 | - | MD 0.06 lower (0.12 lower to 0 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **% symptom free days ≥6 months (follow-up 12 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 46 | 48 | - | MD 5.6 higher (8.51 lower to 19.71 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Time of work (number of people) ≥6 months (follow-up 9 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | - | - | OR 2 (1.17 to 3.41) | -[3] | ⊕OOO VERY LOW | IMPORTANT |

[1] Downgraded by one increment if the majority of the evidence was at high risk of bias, and downgraded by two increments if the majority of the evidence was at very high risk of bias
[2] Downgraded by one increment if the confidence interval crossed one MID or by two increments if the confidence interval crossed both MIDs
[3] Control group event rate not reported
[5] 97.5% CI reported and extracted
[6] Downgraded by one/two increments because: the majority of the evidence had indirect outcomes

## Table 186: Clinical evidence profile: FeNO versus Conventional Monitoring Children

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **FeNO versus conventional monitoring CHILD** | **Control** | **Relative (95% CI)** | **Absolute** | | |
| **UHU (unscheduled visits) ≥6 months (follow-up 46-52 weeks)** | | | | | | | | | | | | |
| 2 | randomised trials | no serious risk of bias | serious[1] | no serious indirectness | very serious[2] | none | 65/294 (22.1%) | 29.9% | RR 0.67 (0.29 to | 99 fewer per 1000 (from 212 fewer to | ⊕OOO VERY LOW | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | | | | | | | | 1.55) | 164 more) | | |
| **UHU (hospitalisation) ≥6 months (follow-up 46-52 weeks)** | | | | | | | | | | | | |
| 4 | randomised trials | serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 15/366 (4.1%) | 3.4% | RR 0.97 (0.48 to 1.95) | 1 fewer per 1000 (from 18 fewer to 32 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU (number of children ≥1 emergency room admin) ≥6 months (follow-up mean 52 weeks)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 2/45 (4.4%) | 8.7% | RR 0.51 (0.1 to 2.65) | 43 fewer per 1000 (from 78 fewer to 144 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation (OCS) ≥6 months (follow-up mean 43 weeks)** | | | | | | | | | | | | |
| 6 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[2] | none | 115/462 (24.9%) | 19.2% | RR 0.74 (0.61 to 0.9) | 50 fewer per 1000 (from 19 fewer to 75 fewer) | ⊕⊕⊕O MODERATE | CRITICAL |
| **Asthma control (ACT score) ≥6 months (follow-up mean 46 weeks; measured with: ACT; range of scores: 5-25; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 250 | 244 | - | MD 0.06 higher (0.27 lower to 0.39 higher) | ⊕⊕⊕⊕ HIGH | CRITICAL |
| **PACQLQ (Pediatric Asthma Caregiver) ≥6 months (follow-up mean 30 weeks; measured with: Pediatric Asthma Care Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 75 | 72 | - | MD 0 higher (0.24 lower to 0.24 higher) | ⊕⊕OO LOW | CRITICAL |
| **FEV1 % pred ≥6 months (follow-up 46-52 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[2] | none | 289 | 290 | - | MD 0.94 higher (0.31 lower to 2.19 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **ICS dose ≥6 months (follow-up 46 weeks; measured with: fluticasone; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | serious[4] | no serious imprecision | none | 250 | 244 | - | MD 118.9 higher (48.5 to 189.3 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **% symptom free days ≥6 months (follow-up 30 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 75 | 72 | - | MD 0.3 higher (10 lower to 10.6 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Number of symptom days in last 2 weeks; ≥6 months (follow-up mean 46 weeks; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 250 | 244 | - | MD 0.04 higher (0.21 lower to 0.29 higher) | ⊕⊕⊕⊕ HIGH | IMPORTANT |
| **Number of patients not using inhaled corticosteroids or anti-leukotrienes ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 2/32 (6.3%) | 18.8% | RR 0.33 (0.07 to 1.53) | 126 fewer per 1000 (from 175 fewer to 100 more) | ⊕OOO VERY LOW | IMPORTANT |
| **Rescue medication (no. of patients needed beta-agonist due to symptoms) ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | serious[2] | none | 16/32 (50%) | 81.3% | RR 0.62 (0.42 to 0.9) | 309 fewer per 1000 (from 81 fewer to 472 fewer) | ⊕OOO VERY LOW | IMPORTANT |
| **Number of school days missed in last 2 weeks; ≥6 months (follow-up mean 46 weeks; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 250 | 244 | - | MD 0.04 lower (0.12 lower to 0.04 higher) | ⊕⊕⊕⊕ HIGH | IMPORTANT |
| **Time off (school/work - number of children missed school) ≥6 months (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 10/46 (21.7%) | 26.1% | RR 0.83 (0.4 to 1.73) | 44 fewer per 1000 (from 157 fewer to 191 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] Downgraded by one/two increments because: heterogeneity, I2=50%, p=0.04
[2] Downgraded by one increment if the confidence interval crossed one MID or by two increments if the confidence interval crossed both MIDs
[3] Downgraded by one increment if the majority of the evidence was at high risk of bias, and downgraded by two increments if the majority of the evidence was at very high risk of bias
[4] Downgraded by one/two increments because: the majority of the evidence had indirect outcomes

# I.4 Monitoring: Challenge tests

**Table 187: Clinical evidence summary: ADULTS Methacholine challenge test versus no challenge test for asthma monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ADULTS Methacholine challenge test versus no challenge test | Control | Relative (95% CI) | Absolute | | |
| **Mortality (≥6 months) (follow-up 40 weeks)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 1/105 (0.95%) | 0% | OR 7.53 (0.15 to 379.61) | 10 more per 1000 (from 20 fewer to 40 more)[3] | ⊕OOO VERY LOW | CRITICAL |
| **Asthma exacerbations (≥6 months) (follow-up 40 weeks)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | serious[4] | very serious[2] | none | 22/105 (21%) | 24.3% | RR 0.86 (0.52 to 1.42) | 34 fewer per 1000 (from 117 fewer to 102 more) | ⊕OOO VERY LOW | CRITICAL |
| **Rescue medications (≥6 months) (follow-up 40 weeks; measured with: Albuterol puffs/day; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 105 | 107 | - | MD 0.1 lower (0.58 lower to 0.38 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **ICS use >6months (follow-up 40 weeks; measured with: mean daily dose (mcg; fluticasone propionate); Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 105 | 107 | - | MD 131.2 higher (83.57 to 178.83 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **FEV1 (≥6 months) (follow-up 40-104 weeks; measured with: L; Better indicated by higher values)** | | | | | | | | | | | | |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 | randomised trials | serious[5] | serious[6] | no serious indirectness | no serious imprecision | none | 137 | 142 | - | MD 0.04 lower (0.09 lower to 0.16 higher) | ⊕⊕OO LOW | IMPORTANT |
| **% symptom free days (≥6 months) (follow-up 40 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 105 | 107 | - | MD 5.1 lower (20.06 lower to 9.86 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **PEF am (≥6 months) (follow-up 40 weeks; measured with: L/min; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 105 | 107 | - | MD 8.6 lower (17.20 lower to 0 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **PEF pm (≥6 months) (follow-up 40 weeks; measured with: L/min; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[5] | no serious inconsistency | no serious indirectness | serious[7] | none | 105 | 107 | - | MD 6 lower (29.96 lower to 17.96 higher) | ⊕⊕OO LOW | IMPORTANT |

[1] The majority of the evidence was from studies at very high risk of bias due to allocation concealment and missing data
[2] 95% CI crosses 2 MIDs
[3] Manual calculation of absolute effect as zero events in the control group
[4] Evidence from one study - exacerbations not defined
[5] The majority of the evidence was from studies at high risk of bias due to allocation concealment
[6] Point estimates show statistical heterogeneity I2=72% P<0.06. Only 2 studies so random effects model used.
[7] 95% CI crosses one MID

**Table 188: Clinical evidence summary: ADULTS Mannitol challenge test versus no challenge test for asthma monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ADULTS Mannitol challenge test versus no challenge test | Control | Relative (95% CI) | Absolute | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **AQLQ (≥6 months) (follow-up 52 weeks; measured with: mini AQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | no serious imprecision | none | 61 | 58 | - | MD 0.06 higher (0.3 lower to 0.42 higher) | ⊕⊕OO LOW | CRITICAL |
| **Asthma exacerbations (≥6 months) (follow-up 52 weeks)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[3] | no serious inconsistency | serious[2] | very serious[4] | none | 12/61 (19.7%) | 22.4% | RR 0.88 (0.44 to 1.76) | 27 fewer per 1000 (from 125 fewer to 170 more) | ⊕OOO VERY LOW | CRITICAL |
| **Rescue medications (≥6 months) (follow-up 52 weeks; measured with: Albuterol puffs/day; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | serious[5] | none | 61 | 58 | - | MD 0.31 lower (0.73 lower to 0.11 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **ICS use >6months (follow-up 52 weeks; measured with: mean daily dose (mcg; ciclesonide); Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | no serious imprecision | none | 61 | 58 | - | MD 306 higher (241.71 to 370.29 higher) | ⊕⊕OO LOW | IMPORTANT |
| **FEV1% (≥6 months) (follow-up 52 weeks; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1,6] | no serious inconsistency | serious[2] | no serious imprecision | none | 61 | 58 | - | MD 0.3 higher (8.21 lower to 8.81 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF% (≥6 months) (follow-up 52 weeks; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | no serious imprecision | none | 61 | 58 | - | MD 2.7 lower (13.17 lower to 7.77 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF am (≥6 months) (follow-up 52 weeks; measured with: L/min; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | very serious[4] | none | 61 | 58 | - | MD 1.5 higher (34.7 lower to 37.7 higher) | ⊕OOO VERY LOW | IMPORTANT |

[1] The majority of the evidence was from studies at high risk of bias due to blinding
[2] Patients initially underwent step-down of their existing treatment. Patients on combination inhalers were switched to an equivalent dose of the same ICS only (unclear whether LABA was continued).
[3] The majority of the evidence was from studies at high risk of bias due to missing data
[4] 95% CI crosses 2 MIDs
[5] 95% CI crosses one MID
[6] The majority of the evidence was from studies at high risk of bias due to baseline differences

**Table 189: Clinical evidence profile: CHILDREN Challenge test versus no challenge test for asthma monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | CHILDREN Challenge test versus no challenge test | Control | Relative (95% CI) | Absolute | | |
| **Asthma exacerbations (≥6 months) (follow-up 2 years; assessed with: OCS course)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | serious[2] | very serious[3] | none | 16/102 (15.7%) | 16.4% | RR 0.96 (0.51 to 1.79) | 7 fewer per 1000 (from 80 fewer to 130 more) | ⊕OOO VERY LOW | CRITICAL |
| **ICS dose (follow-up 2 years; measured with: Mean daily dose for treatment period; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | serious[2] | serious[5] | none | 85 | 90 | - | MD 84 higher (10.66 to 157.34 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **FEV1% (≥6 months) (follow-up 2 years; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | serious[2] | no serious imprecision | none | 93 | 92 | - | MD 6 higher (1.2 lower to 10.8 higher) | ⊕⊕OO LOW | IMPORTANT |
| **% symptom free days (≥6 months) (follow-up 2 years; measured with: in last 3 months of treatment; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | serious[2] | very serious[3] | none | 85 | 90 | - | MD 1.1 lower (10.1 lower to 7.9 higher) | ⊕OOO VERY LOW | IMPORTANT |

[1] No explanation was provided
[2] Patients initially underwent step-down of their existing treatment.
[3] 95% CI crosses both MIDs
[4] The majority of the evidence was at high risk of bias due to allocation concealment and baseline differences
[5] 95% CI crosses one MID

# I.5 Monitoring adherence to treatment

**Table 190: Clinical evidence profile: Children with uncontrolled asthma: Monitoring adherence + treatment vs UC + treatment for asthma**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Children with uncontrolled asthma: Monitoring adherence + treatment | UC + treatment | Relative (95% CI) | Absolute | | |
| **Adherence <6months (follow-up 4 months; measured with: % of prescribed doses measured by the electronic inhaler; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 14 | 12 | - | MD 28.9 higher (8.62 to 49.18 higher) | ⊕OOO VERY LOW | CRITICAL |
| **Adherence ≥6months (follow-up 18 months; measured with: Number of canister refills (100% adherence = 3.0); range of scores: 0-3; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 76 | 81 | - | MD 0.02 lower (0.29 lower to 0.25 higher) | ⊕⊕OO LOW | CRITICAL |
| **Adherence (self-reported) ≥6months (follow-up 18 months; measured with: % self-reported adherence in previous 6 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 76 | 81 | - | MD 1.95 higher (5.87 lower to 9.77 higher) | ⊕⊕OO LOW | CRITICAL |
| **Exacerbation < 6months (follow-up 4 months; assessed with: need for OCS)** | | | | | | | | | | | | |

| | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 3/14 (21.4%) | 8.3% | RR 2.57 (0.31 to 21.59) | 130 more per 1000 (from 57 fewer to 1000 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation ≥6 months (follow-up 18 months; measured with: no. of OCS courses in 6 months; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 76 | 81 | - | MD 0.22 higher (0.19 lower to 0.63 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU ≥6 months (follow-up 18 months; measured with: Hospitalisations in previous 6 months ; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 76 | 81 | - | MD 0 higher (4.8 lower to 4.8 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **Rescue medication < 6months (follow-up 4 months; assessed with: Reliever medication 3 or more times a week)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 2/14 (14.3%) | 0% | OR 6.92 (0.41 to 118.14) | 140 more per 1000 (from 7 more to 360 more)[5] | ⊕OOO VERY LOW | IMPORTANT |

[1] The majority of the evidence was from studies at very high risk of bias
[2] 95% CI crosses one MID
[3] 95% CI crosses both MIDs
[4] The majority of the evidence was from studies at high risk of bias
[5] Manual calculation of absolute risk difference as no events in the control group

**Table 191: Clinical evidence profile: Adults overall: Monitoring adherence + treatment vs UC + treatment for asthma**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Adults overall: Monitoring adherence + | UC + treatment | Relative (95% CI) | Absolute | | |

| | | | | | | | treatment | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Adherence ≥6months (follow-up 12 months; measured with: % adherence to prescription refills in previous 3 months; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 0 | - | - | MD 2 lower (8.61 lower to 4.61 higher) | ⊕OOO VERY LOW | CRITICAL |
| **QOL <6months (follow-up 10 weeks; measured with: AQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | serious[4] | serious[5] | none | 10 | 9 | - | MD 0.37 higher (0.08 to 0.66 higher) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbation ≥6months (follow-up 12 months; assessed with: course of OCS)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 307/1335 (23%) | 22% | HR 1.07 (0.89 to 1.29) | 13 more per 1000 (from 22 fewer to 54 more) | ⊕⊕OO LOW | CRITICAL |
| **UHU (hospitalisation) ≥6months (follow-up 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[6] | none | 10/1335 (0.75%) | 0.81% | HR 0.86 (0.32 to 2.31) | 1 fewer per 1000 (from 6 fewer to 11 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU (ED visit) ≥6months (follow-up 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[5] | none | 127/1335 (9.5%) | 8.1% | HR 1.22 (0.83 to 1.79) | 17 more per 1000 (from 13 fewer to 59 more) | ⊕OOO VERY LOW | CRITICAL |
| **Lung function <6months (follow-up 10 weeks; measured with: FEV1 L; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | serious[4] | very serious[2] | none | 10 | 9 | - | MD 0.12 lower (7.31 lower to 7.07 higher) | ⊕OOO VERY LOW | IMPORTANT |

*1 The majority of the evidence was from studies at very high risk of bias*

*2 95% CI crosses both MIDs*
*3 The majority of the evidence is from studies at very high risk of bias*
*4 Population indirectness: includes severe asthma*
*5 95% CI crosses one MID*
*6 95% CI crosses both the MIDs but only downgraded by one as the 95% CI for the absolute effect is small*

# I.6 Monitoring inhaler technique

**Table 192: ADULTS: Monitoring inhaler technique vs no monitoring for asthma**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ADULTS: Monitoring inhaler technique | No monitoring | Relative (95% CI) | Absolute | | |
| **Lung function <6 months (follow-up 3 months; measured with: PEF Min%Max (higher is less variability); range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 53 | 44 | - | MD 6.2 higher (2.68 to 9.72 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Lung function ≥6 months (follow-up 6 months; measured with: PEF Min%Max (higher is less variability); range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 53 | 44 | - | MD 4.5 higher (0.79 to 8.21 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **QOL <6 months (follow-up 3 months; measured with: Marks AQLQ; range of scores: 0-10; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 53 | 44 | - | MD 0.55 lower (0.77 to 0.33 lower) | ⊕⊕OO LOW | CRITICAL |
| **QOL ≥6 months (follow-up 6 months; measured with: Marks AQLQ; range of scores: 0-10; Better indicated by lower values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 53 | 44 | - | MD 0.5 lower (0.74 to 0.26 lower) | ⊕OOO VERY LOW | CRITICAL |

[1] The evidence was from one study at very high risk of bias for this outcome
[2] 95% CI crosses one MID

**Table 193: ADULTS: Monitoring (verbal and electronic) vs verbal monitoring only for asthma**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | ADULTS: Monitoring (verbal and electronic) | Verbal monitoring only | Relative (95% CI) | Absolute | | |
| **QOL <6 months (follow-up 6 weeks; measured with: mini AQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 53 | 52 | - | MD 0.38 higher (0.02 lower to 0.79 higher) | ⊕OOO VERY LOW | CRITICAL |
| **Lung function <6 months (follow-up 6 weeks; measured with: FEV1 L; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 36 | 35 | - | MD 0.23 lower (0.55 lower to 0.09 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Lung function <6 months (follow-up 6 weeks; measured with: FEV1 % pred; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[3] | no serious inconsistency | no serious indirectness | serious[2] | none | 17 | 17 | - | MD 9.1 higher (3.71 lower to 21.91 higher) | ⊕⊕OO LOW | IMPORTANT |

[1] The majority of the evidence was from studies at very high risk of bias for this outcome
[2] 95% CI crosses one MID
[3] The majority of the evidence was from studies at high risk of bias for this outcome

**Table 194: CHILDREN: Monitoring (verbal and electronic) vs verbal monitoring only for asthma**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | CHILDREN: Monitoring (verbal and electronic) | Verbal monitoring only | Relative (95% CI) | Absolute | | |
| **Lung function <6 months (follow-up 6 weeks; measured with: FEV1 % pred; range of scores: 0-100; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[2] | none | 6 | 6 | - | MD 3.2 lower (15.27 lower to 8.87 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **QOL <6 months (follow-up 6 weeks; measured with: PAQLQ; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[3] | no serious inconsistency | no serious indirectness | very serious[2] | none | 6 | 6 | - | MD 0.03 higher (0.66 lower to 0.72 higher) | ⊕OOO VERY LOW | CRITICAL |

[1] The evidence was from one study at high risk of bias for this outcome
[2] 95% CI crosses both MIDs
[3] No explanation was provided

# I.7 Monitoring: Tele-healthcare

**Table 195: Adult comparison 1: tele-health services vs face-to-face equivalents**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Tele-health services | face-to-face equivalents | Relative (95% CI) | Absolute | | |
| **Quality of life (follow-up mean 12 months; measured with: Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 491 | 469 | - | MD 0.01 lower (0.17 lower to 0.14 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU hospitalisation (follow-up mean 6 months[2])** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1,3] | no serious inconsistency | no serious indirectness | very serious[4] | none | 0/222 (0%) | 0.6% | OR 0.14 (0 to 7.06)[5] | 5 fewer per 1000 (from 6 fewer to 35 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ED visit (follow-up mean 6 months[2])** | | | | | | | | | | | | |
| 2 | randomised trials | very serious[1,3] | no serious inconsistency | no serious indirectness | very serious[4] | none | 2/222 (0.9%) | 0% | OR 7.75 (0.48 to 124.9)[5] | - | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations requiring oral steroids** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[4] | none | 5/137 (3.6%) | 2.1% | RR 1.72 (0.42 to 7.04) | 15 more per 1000 (from 12 fewer to 127 more) | ⊕OOO VERY LOW | CRITICAL |
| **Asthma control (follow-up mean 12 months; measured with: Asthma Control Questionnaire; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 354 | 328 | - | MD 0.11 lower (0.27 lower to 0.04 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU GP visits (follow-up mean 6 months[2])** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1,6] | no serious inconsistency | no serious indirectness | serious[4] | none | 30/222 (13.5%) | 13.2% | RR 0.86 (0.56 to 1.32) | 18 fewer per 1000 (from 58 fewer to 42 more) | ⊕⊕OO LOW | CRITICAL |
| **Change in FEV1 (mL) (follow-up mean 6 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,3] | no serious inconsistency | no serious indirectness | serious[7] | none | 85 | 88 | - | MD 152 higher (54 to 250 higher) | ⊕OOO VERY LOW | IMPORTANT |
| **Withdrawal (follow-up 6-12 months)** | | | | | | | | | | | | |
| 3 | randomised trials | no serious risk of bias | serious[8] | no serious indirectness | very serious[4] | none | 35/334 (10.5%) | 12% | RR 0.78 (0.32 to 1.9) | 26 fewer per 1000 (from 82 fewer to 108 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] Studies could not use blinding to control for performance or detection bias
[2] Pinnock 2003 was a pragmatic trial of variable intervention duration, but did not contribute any events to the analysis
[3] Evidence of sub-optimal randomisation procedures and imputation of missing values, and selective reporting
[4] 95% CI crosses both the MIDs
[5] Very rare events - Peto odds ratio used
[6] While there were several issues with one of the studies in the analysis, it only accounted for 6.6% of the analysis weight.
[7] 95% CI crossed an MID
[8] Heterogeneity was high (I squared = 79%)

**Table 196: Adult comparison 2: tele-monitoring vs paper-based monitoring**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Tele-monitoring | Paper-based monitoring | Relative (95% CI) | Absolute | | |
| **Quality of life (follow-up 6-12 months; measured with: Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | serious[2] | no serious indirectness | serious[3] | none | 188 | 196 | - | MD 0.21 higher (0.09 lower to 0.5 higher) | ⊕OOO VERY LOW | CRITICAL |
| **UHU hospitalisation (follow-up 4-6 months)** | | | | | | | | | | | | |
| 3 | randomised trials | serious[4] | serious[5] | no serious indirectness | very serious[6] | none | 5/191 (2.6%) | 2.2% | RR 0.60 (0.13 to 2.86) | 9 fewer per 1000 (from 19 fewer to 41 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ED visit (follow-up mean 6 months)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[7] | serious[8] | no serious indirectness | very serious[6] | none | 5/183 (2.7%) | 13% | RR 0.89 (0.02 to 33.53) | 14 fewer per 1000 (from 127 fewer to 1000 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations requiring oral steroids (follow-up mean 6 months)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | very serious[6] | none | 28/140 (20%) | 21.3% | RR 0.94 (0.59 to 1.49) | 13 fewer per 1000 (from 87 fewer to 104 more) | ⊕⊕OO LOW | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Asthma control (follow-up 6-12 months; measured with: Asthma Control Questionnaire; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | very serious[9] | no serious indirectness | serious[3] | none | 240 | 238 | - | MD 0.24 lower (0.72 lower to 0.24 higher) | ⊕OOO VERY LOW | CRITICAL |
| **UHU GP visits (follow-up mean 6 months)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[3] | none | 51/140 (36.4%) | 29.1% | RR 1.25 (0.89 to 1.76) | 73 more per 1000 (from 32 fewer to 221 more) | ⊕⊕⊕O MODERATE | CRITICAL |
| **Change in FEV1 (mL) (follow-up mean 12 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[10] | no serious inconsistency | no serious indirectness | serious[3] | none | 101 | 99 | - | MD 250 higher (33.36 to 466.64 higher) | ⊕⊕OO LOW | IMPORTANT |
| **PEF (L/min) (follow-up mean 6 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[7] | no serious inconsistency | no serious indirectness | serious[3] | none | 43 | 46 | - | MD 39.2 higher (16.58 to 61.82 higher) | ⊕⊕OO LOW | IMPORTANT |
| **Withdrawal (follow-up 4-12 months)** | | | | | | | | | | | | |
| 4 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | very serious[6] | none | 58/312 (18.6%) | 15.2% | RR 1.01 (0.73 to 1.39) | 2 more per 1000 (from 41 fewer to 59 more) | ⊕⊕OO LOW | IMPORTANT |

[1] One study analysed complete cases and did not blind participants, investigators or outcome assessors, which carried the majority of the analysis weight.
[2] Heterogeneity was high (I squared = 53%)
[3] 95% CI crosses one of the MIDs
[4] Only one study used any blinding procedures (outcome assessors), and there were uncertainties regarding allocation concealment
[5] Heterogeneity was not statistically significant (I squared = 42%), but point estimates are very different
[6] 95% CIs cross both MIDs
[7] Study carrying the most weight did not blind outcome assessors (and could not blind participants and investigators), and dropout was high in both groups
[8] Heterogeneity was high (I squared = 80%)
[9] Heterogeneity was very high (I squared = 91%)
[10] No blinding of outcome assessors (and unable to blind participants and investigators). Only complete cases were analysed.

## Table 197: Adult comparison 3: tele-healthcare package vs nothing (usual care)

| Quality assessment | No of patients | Effect | Quality | Importance |
|---|---|---|---|---|

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Tele-health packages** | **Nothing (usual care)** | **Relative (95% CI)** | **Absolute** | | |
| **Quality of life (follow-up 10-12 months; measured with: Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 3 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision | none | 806 | 827 | - | MD 0.08 higher (0.03 lower to 0.20 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU hospitalisation (follow-up 6-12 months)** | | | | | | | | | | | | |
| 4 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision[2] | none | 1/205 (0.49%) | 5.6% | OR 0.16 (0.05 to 0.56)[4] | 47 fewer per 1000 (from 24 fewer to 53 fewer) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU ED visit (follow-up 6-12 months)** | | | | | | | | | | | | |
| 4 | randomised trials | serious[1] | no serious inconsistency[4] | no serious indirectness | very serious[5] | none | 10/210 (4.8%) | 6.5% | RR 0.82 (0.38 to 1.8) | 12 fewer per 1000 (from 40 fewer to 52 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations requiring oral steroids (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[5] | none | 21/31 (67.7%) | 72.4% | RR 0.94 (0.67 to 1.3) | 43 fewer per 1000 (from 239 fewer to 217 more) | ⊕OOO VERY LOW | CRITICAL |
| **Asthma control (follow-up mean 12 months; measured with: Asthma Control Questionnaire; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | no serious imprecision | none | 270 | 286 | - | MD 0.04 lower (0.2 lower to 0.12 higher) | ⊕⊕⊕⊕ HIGH | CRITICAL |
| **UHU GP visits (follow-up 6-12 months)** | | | | | | | | | | | | |
| 3 | randomised trials | serious[1] | Serious[6] | no serious indirectness[7] | very serious[5] | none | 31/150 (20.7%) | 38.9% | RR 0.96 (0.39 to 2.37) | 16 fewer per 1000 (from 237 fewer to 533 more) | ⊕OOO VERY LOW | CRITICAL |
| **Change in FEV1 (mL) (follow-up mean 6 months; Better indicated by higher values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[8] | none | 85 | 80 | - | MD 183 higher (85 to 281 higher) | ⊕⊕OO LOW | IMPORTANT |
| **Symptom days per month (range of scores: 0-30; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[8] | none | 311 | 297 | - | MD 0.6 higher (0.82 lower to 2.02 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **Symptom nights per month (range of scores: 0-30; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[8] | none | 311 | 297 | - | MD 0.1 lower (1.21 lower to 1.01 higher) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **Withdrawal (follow-up 6-12 months)** | | | | | | | | | | | | |
| 5 | randomised trials | serious[1] | no serious inconsistency[(4)] | no serious indirectness | serious[5] | none | 28/255 (11%) | 11.1% | RR 0.81 (0.51 to 1.29) | 21 fewer per 1000 (from 54 fewer to 32 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] Issues across studies with blinding, completeness of outcome data, and allocation concealment
[2] Confidence intervals were wide but did not cross an MID
[3] Very rare events - Peto odds ratio used
[4] Point estimates were varied but statistical heterogeneity was low - random effects sensitivity did not change imprecision
[5] 95% CI crossed both MIDs
[6] Heterogeneity was high (I squared = 66%)
[7] One study was only recruited older adults (53% of analysis weight)
[8] 95% CIs crossed an MID

**Table 198: Child comparison 1: tele-health services vs face-to-face equivalents**

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Tele-health services** | **face-to-face equivalents** | **Relative (95% CI)** | **Absolute** | | |
| **Quality of life - child (follow-up mean 12 months; measured with: Paediatric Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 60 | 60 | - | MD 0.3 higher (0.11 lower to 0.71 higher) | ⊕⊕OO LOW | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **Quality of life - caregiver (follow-up mean 12 months; measured with: Paediatric Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 60 | 60 | - | MD 0.2 higher (0.12 lower to 0.52 higher) | ⊕⊕OO LOW | CRITICAL |
| **UHU hospitalisation (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 1/60 (1.7%) | 1.7% | RR 1 (0.06 to 15.62) | 0 fewer per 1000 (from 16 fewer to 249 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ED visit (follow-up mean 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 4/60 (6.7%) | 3.3% | RR 2 (0.38 to 10.51) | 33 more per 1000 (from 20 fewer to 314 more) | ⊕OOO VERY LOW | CRITICAL |
| **FEV1 % predicted (follow-up mean 12 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 60 | 60 | - | MD 5.2 higher (1.48 lower to 11.88 higher) | ⊕⊕OO LOW | IMPORTANT |

[1] No blinding and unbalanced attrition
[2] 95% CI crosses an MID
[3] 95% CI crosses both MIDs

## Table 199: Child comparison 2: tele-monitoring vs paper-based monitoring

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Tele-monitoring** | **Paper-based monitoring** | **Relative (95% CI)** | **Absolute** | | |
| **Change in morning PEF (L/min) (follow-up mean 3 months; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 82 | 71 | - | MD 7.80 higher (6.37 lower to 21.97 higher) | ⊕⊕OO LOW | IMPORTANT |
| **Change in evening PEF (L/min) (follow-up mean 3 months; Better indicated by higher values)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 82 | 71 | - | MD 12 higher (3.59 lower to 27.59 higher) | ⊕⊕OO LOW | IMPORTANT |
| **Withdrawal (follow-up mean 3 months)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 6/88 (6.8%) | 6.6% | RR 1.04 (0.33 to 3.26) | 3 more per 1000 (from 44 fewer to 149 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] Participants and investigators could not be blind (outcome assessors were blinded)
[2] 95% CI crosses an MID
[3] 95% CI crosses both MIDs

## Table 200: Child comparison 3: tele-healthcare package vs nothing (usual care)

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **No of studies** | **Design** | **Risk of bias** | **Inconsistency** | **Indirectness** | **Imprecision** | **Other considerations** | **Tele-health packages** | **Nothing (usual care)** | **Relative (95% CI)** | **Absolute** | | |
| **Quality of life - child (follow-up 6-12 months; measured with: Paediatric Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | No serious inconsistency | no serious indirectness | serious[3] | none | 41 | 41 | - | MD 0.70 higher (0.29 to 1.11 higher) | ⊕⊕OO LOW | CRITICAL |
| **Quality of life - caregiver (follow-up 6-12 months; measured with: Paediatric Asthma Quality of Life Questionnaire; range of scores: 1-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | no serious imprecision[2] | none | 89 | 92 | - | MD 0.18 higher (0.10 lower to 0.46 higher) | ⊕⊕⊕O MODERATE | CRITICAL |
| **UHU hospitalisation (follow-up 3-12 months)** | | | | | | | | | | | | |
| 5 | randomised trials | serious[4] | no serious inconsistency[5] | no serious indirectness | very serious[6] | none | 11/305 (3.6%) | 2% | RR 1.43 (0.59 to 3.46) | 9 more per 1000 (from 8 fewer to 49 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU ED visit (follow-up 3-12 months)** | | | | | | | | | | | | |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4 | randomised trials | serious[4] | no serious inconsistency[5] | no serious indirectness | very serious[6] | none | 19/285 (6.7%) | 9.2% | RR 1 (0.56 to 1.8) | 0 fewer per 1000 (from 40 fewer to 74 more) | ⊕OOO VERY LOW | CRITICAL |
| **Exacerbations requiring oral steroids (follow-up 6-12 months)** | | | | | | | | | | | | |
| 2 | randomised trials | serious[4] | no serious inconsistency | no serious indirectness | very serious[6] | none | 41/62 (66.1%) | 71.9% | RR 1.01 (0.8 to 1.27) | 7 more per 1000 (from 144 fewer to 194 more) | ⊕OOO VERY LOW | CRITICAL |
| **Asthma control (follow-up mean 12 months; measured with: Asthma Control Questionnaire; range of scores: 0-6; Better indicated by lower values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[3] | none | 148 | 153 | - | MD 0.31 lower (0.56 to 0.06 lower) | ⊕⊕OO LOW | CRITICAL |
| **UHU GP visits (follow-up mean 8 months)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | very serious[6] | none | 6/48 (12.5%) | 15.7% | RR 0.80 (0.30 to 2.13) | 31 fewer per 1000 (from 110 fewer to 177 more) | ⊕⊕OO LOW | CRITICAL |
| **Withdrawal (follow-up 3-12 months)** | | | | | | | | | | | | |
| 5 | randomised trials | serious[4] | serious[7] | no serious indirectness | serious[6] | none | 51/408 (12.5%) | 16.1% | RR 0.86 (0.53 to 1.41) | 23 fewer per 1000 (from 76 fewer to 66 more) | ⊕OOO VERY LOW | IMPORTANT |

[1] One or more study did not blind outcome assessors
[2] MID is close to, but does not cross, the 0.5 MID
[3] 95% CI crosses one MID
[4] Issues across studies with blinding, completeness of outcome data, and allocation concealment
[5] Point estimates were varied but statistical heterogeneity was low - random effects sensitivity did not change imprecision
[6] 95% CI crosses both MIDs
[7] Some inconsistency (I squared = 38%), random effects used

**Table 201: Adult comparison 4: Telehealthcare without healthcare professional involvement vs usual care**

| Quality assessment | No of patients | Effect | Quality | Importance |
|---|---|---|---|---|

| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Interactive voice response telephone calls | no calls | Relative (95% CI) | Absolute | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| **QOL <6 months (follow-up 10 weeks; measured with: AQLQ; range of scores: 0-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | serious[2] | none | 25 | 25 | - | MD 0.23 higher (0.32 lower to 0.78 higher) | ⊕⊕OO LOW | CRITICAL |
| **Asthma Control Questionnaire <6 months (follow-up 10 weeks; measured with: ACT; range of scores: 5-25; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | serious[1] | no serious inconsistency | no serious indirectness | very serious[3] | none | 25 | 25 | - | MD 0.72 higher (1.51 lower to 2.95 higher) | ⊕OOO VERY LOW | CRITICAL |

[1] Method of randomisation and allocation concealment unclear
[2] Crosses one MID
[3] Crosses two MIDs

## Table 202: Child comparison 4: Telehealthcare without healthcare professional involvement vs usual care

| Quality assessment | | | | | | | No of patients | | Effect | | Quality | Importance |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Telephone calls | No calls | Relative (95% CI) | Absolute | | |
| **Exacerbations ≥6 months (follow-up 6 months; assessed with: Self report OCS (assumed to be for exacerbation))** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | serious[4] | none | 16/39 (41%) | 52.5% | RR 0.78 (0.48 to 1.26) | 116 fewer per 1000 (from 273 fewer to 136 more) | ⊕OOO VERY LOW | CRITICAL |
| **QOL ≥6 months (follow-up 6 months; measured with: Pediatric Asthma Quality of Life Questionnaire (carer); range of scores: 0-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | serious[4] | none | 39 | 41 | - | MD 0.2 higher (0.48 lower to 0.88 higher) | ⊕OOO VERY LOW | CRITICAL |
| **QOL ≥6 months (follow-up 6 months; measured with: Pediatric Asthma Quality of Life Questionnaire (child); range of scores: 0-7; Better indicated by higher values)** | | | | | | | | | | | | |
| 1 | randomised | very | no serious | no serious | no serious | none | 39 | 41 | - | MD 0.6 higher (0.16 to | ⊕⊕OO | CRITICAL |

| | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | trials | serious[1,2,3] | inconsistency | indirectness | imprecision | | | | | 1.04 higher) | LOW | |
| **UHU ED visit ≥6 months (follow-up 6 months; assessed with: ED visit self report)** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | very serious[5] | none | 6/39 (15.4%) | 12.5% | RR 1.23 (0.41 to 3.7) | 29 more per 1000 (from 74 fewer to 338 more) | ⊕OOO VERY LOW | CRITICAL |
| **UHU hospitalisation ≥6 months (follow-up 6 months; assessed with: Hospital admission self report )** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | very serious[5] | none | 4/39 (10.3%) | 10% | RR 1.03 (0.28 to 3.82) | 3 more per 1000 (from 72 fewer to 282 more) | ⊕OOO VERY LOW | CRITICAL |
| **School days lost ≥6 months (follow-up 6 months; assessed with: Self report (yes/no to any time off school))** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | very serious[5] | none | 20/38 (52.6%) | 56.4% | RR 0.93 (0.62 to 1.4) | 39 fewer per 1000 (from 214 fewer to 226 more) | ⊕OOO VERY LOW | IMPORTANT |
| **Parents' work days lost ≥6 months (follow-up 6 months; assessed with: Self report (yes/no to any work days lost))** | | | | | | | | | | | | |
| 1 | randomised trials | very serious[1,2,3] | no serious inconsistency | no serious indirectness | very serious[5] | none | 13/39 (33.3%) | 33.3% | RR 1 (0.53 to 1.87) | 0 fewer per 1000 (from 157 fewer to 290 more) | ⊕OOO VERY LOW | IMPORTANT |
| **Controller medication use in patients who should have been on controller medications at baseline ≥6 months (follow-up 12 months; assessed with: i.e. persistent asthma )** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[4] | none | 7/19 (36.8%) | 16.7% | RR 2.21 (0.82 to 5.97) | 202 more per 1000 (from 30 fewer to 830 more) | ⊕⊕⊕O MODERATE | IMPORTANT |
| **Persistent asthma on controllers at baseline but discontinued at 6 months (follow-up 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | very serious[5] | none | 6/42 (14.3%) | 5.2% | RR 2.76 (0.73 to 10.42) | 92 more per 1000 (from 14 fewer to 490 more) | ⊕⊕OO LOW | IMPORTANT |
| **Of those who met severity criteria for controllers at baseline, number on them at 12 months (follow-up 12 months)** | | | | | | | | | | | | |
| 1 | randomised trials | no serious risk of bias | no serious inconsistency | no serious indirectness | serious[4] | none | 34/53 (64.2%) | 61% | RR 1.05 (0.81 to 1.37) | 30 more per 1000 (from 116 fewer to 226 more) | ⊕⊕⊕O MODERATE | IMPORTANT |

[1] *Method of randomisation and allocation concealment unclear*
[2] *Groups not comparable at baseline*

[3] *Underpowered*
[4] *Crosses one MID*
[5] *Crosses two MIDs*

# Appendix J: Forest plots

## J.1 Diagnosis: Signs and symptoms

### J.1.1 Coupled sensitivity / specificity forest plots and ROC curves

#### J.1.1.1 Adults: symptoms vs. physician Dx and an objective test

**Figure 47: Paroxsymal coughing**




**Figure 48: Dyspnoea without wheeze**




**Figure 49: Wheeze without dyspnoea**




**Figure 50: Diurnal cough**




**Figure 51: Nocturnal cough**




**Figure 52: Diurnal wheeze**



**Figure 53: Nocturnal wheeze**




**Figure 54: Dyspnoea**




**Figure 55: Wheeze**




**Figure 56: Cough**




**Figure 57: Nocturnal dyspnoea**




**Figure 58: Diurnal symptoms**




**Figure 59: Total symptom score ≥5**

CHOI 2007: numbers for 2x2 table not reported. Sensitivity 74.3%, Specificity 47.8%

**Figure 60: Dyspnoea attacks**

SCHNEIDER 2012: numbers for 2x2 table not reported. Sensitivity 40%, Specificity 78.4%

**Figure 61: Dyspnoea going upstairs**

SCHNEIDER 2012: numbers for 2x2 table not reported. Sensitivity 47.1%, Specificity 49.6%

**Figure 62: Dyspnoea when walking**

SCHNEIDER 2012: numbers for 2x2 table not reported. Sensitivity 4.8%, Specificity 93.2%

**Figure 63: Dyspnoea on minimal exercise**

SCHNEIDER 2012: numbers for 2x2 table not reported. Sensitivity 2.5%, Specificity 94.1%

**Children <5 years: symptoms vs. physician Dx**

**Figure 64: Cough and wheeze**




**Figure 65: Dyspnoea**




**Figure 66: Wheeze**




**Figure 67: Cough**



# J.2 Diagnosis: History of atopic disorders

## J.2.1 Coupled sensitivity / specificity forest plots and ROC curves

### Figure 68: Adults: Personal history of atopic disorders




### Figure 69: Adults: Family history of atopic disorders




### Figure 70: Children 5-16 years: Family history of asthma




### Figure 71: Children <5 years: Family history of atopic disorders




### Figure 72: Children <5 years: Personal history of rhinitis




### Figure 73: Children <5 years: Personal history of eczema



# J.3 Diagnosis: Symptoms after exercise

## J.3.1 Coupled sensitivity / specificity forest plots and ROC curves

**Figure 74: Clinical history of symptoms in response to exercise vs Reference Standard (adults)**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| CHOI 2007 | 84 | 20 | 126 | 72 | 0.40 [0.33, 0.47] | 0.78 [0.68, 0.86] |




# J.4 Diagnosis: Occupational asthma

## J.4.1 Question whether symptoms are better away from work vs. reference standard

**Figure 75: Asking whether their symptoms are better away from work (all causative agents)**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Baur 1998 (flour/enzymes) | 7 | 8 | 0 | 13 | 1.00 [0.59, 1.00] | 0.62 [0.38, 0.82] |
| Baur 1998 (isocyanates) | 14 | 32 | 7 | 61 | 0.67 [0.43, 0.85] | 0.66 [0.55, 0.75] |
| Baur 1998 (latex) | 11 | 34 | 1 | 16 | 0.92 [0.62, 1.00] | 0.32 [0.20, 0.47] |
| Malo 1991 (many) | 65 | 39 | 10 | 48 | 0.87 [0.77, 0.93] | 0.55 [0.44, 0.66] |
| Vandenplas 2001 (latex) | 15 | 4 | 16 | 10 | 0.48 [0.30, 0.67] | 0.71 [0.42, 0.92] |
| Vandenplas 2005 (many) | 53 | 60 | 19 | 80 | 0.74 [0.62, 0.83] | 0.57 [0.49, 0.65] |




**Figure 76: Improvement or disappearance of symptoms at weekend.**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Vandenplas 2005 (many) | 55 | 64 | 17 | 76 | 0.76 [0.65, 0.86] | 0.54 [0.46, 0.63] |




**Figure 77: Improvement of disappearance of symptoms during vacation.**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Vandenplas 2005 (many) | 53 | 60 | 19 | 80 | 0.74 [0.62, 0.83] | 0.57 [0.49, 0.65] |




**Figure 78: Symptoms better away from work (flour).**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Baur 1998 (flour/enzymes) | 7 | 8 | 0 | 13 | 1.00 [0.59, 1.00] | 0.62 [0.38, 0.82] |




**Figure 79: Symptoms better away from work (isocyanate).**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Baur 1998 (isocyanates) | 14 | 32 | 7 | 61 | 0.67 [0.43, 0.85] | 0.66 [0.55, 0.75] |




**Figure 80: Symptoms better away from work (latex).**

| Study | TP | FP | FN | TN | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|---|---|
| Baur 1998 (latex) | 11 | 34 | 1 | 16 | 0.92 [0.62, 1.00] | 0.32 [0.20, 0.47] |
| Vandenplas 2001 (latex) | 15 | 4 | 16 | 10 | 0.48 [0.30, 0.67] | 0.71 [0.42, 0.92] |



**Figure 81: Symptoms better away from work (many causal agents).**



# J.5 Diagnosis: Spirometry

## J.5.1.1 Coupled sensitivity / specificity forest plots and ROC curves

### Adults: FEV1/FVC ratio measures

**Figure 82: FEV1/FVC <70%**




**Figure 83: FEV1/FVC <70% and/or FEV1<80%**




### Adults: FEV1 only measures

**Figure 84: FEV1 <80%**




### Children: FEV1 measures

**Figure 85: FEV1 <80%**



# J.6 Diagnosis: Bronchodilator reversibility

## J.6.1.1 Adults: Bronchodilator reversibility vs. Physician Dx

### Figure 86: ΔFEV1%init ≥12% and ΔFEV1[L] ≥0.2L




### Figure 87: ΔFEV1%init >15% and ΔFEV1[L] >0.2L



# J.7 Diagnosis: PEF variability

## J.7.1.1 Adults > 16 years

**Figure 88: Amp%mean (mean over 3 weeks >5%)**




**Figure 89: Amp%mean (mean over 3 weeks >10%)**




**Figure 90: Amp%mean (mean over 3 weeks >15%)**




**Figure 91: Amp%highest (>15% on 4 days or more)**




**Figure 92: Amp%highest (>20% on 3 days or more)**




**Figure 93: Amp%highest (mean over 2 weeks >10%)**



**Figure 94: Amp%highest (mean over 2 weeks >10%)**




1

2 **J.7.1.2 Children 5-16 years**

3

**Figure 95: Amp%mean >12.3%**




4

**Figure 96: Amp%mean >20% versus PC20 histamine >16mg/mL.**




5

**Figure 97: Amp%mean >20% versus bronchodilator reversibility change in FEV1 >10%.**




6

7

# J.8 Diagnosis: Skin prick tests

## J.8.1.1 Skin prick tests vs. Physician Dx with objective test: ADULTS

**Figure 98: D. pteronyssinus (Der P) +/- D. farinae (house dust mite)**




**Figure 99: Alternaria temius (mould)**




**Figure 100: ≥1 positive from mixed allergens (mite and grass, plus ≥1 more of weed, tree, dust, cat, dog, feathers, mould, egg, milk)**




**Figure 101: Grasses mixed or timothy only**




**Figure 102: Cat**




**Figure 103: Cladosporium**




## J.8.1.2 Skin prick tests vs. Physician Dx with objective test: CHILDREN 5-16 years

**Figure 104: D. pteronyssinus (Der P) +/- D. farinae (house dust mite)**



**Figure 105: Phleum pratense (Phl P) timothy grass from Gramineae family**




1

**Figure 106: Ambrosia artemisifoliae (Amb A) common ragweed**




2

**Figure 107: ≥1 positive from mixed allergens (mite and grass, plus ≥1 more of weed, tree, dust, cat, dog, feathers, mould, egg, milk)**




3

**Figure 108: Grasses mixed or timothy only**




4

5 **J.8.1.3 Skin prick tests vs. Physician Dx *without* objective test: ADULTS**

**Figure 109: Gramineae (grasses) both wild and cultivated**




6

**Figure 110: Artemisia vulgaris (mugwort )**




7

**Figure 111: Grasses mixed or timothy only .**




8

### J.8.1.4 Skin prick tests vs. Physician Dx *without* objective test: CHILDREN 5-16 years

**Figure 112: D. pteronyssinus (Der P) +/- D. farinae (house dust mite)**




**Figure 113: ≥1 positive from mixed allergens (mite and grass, plus ≥1 more of weed, tree, dust, cat, dog, feathers, mould, egg, milk ).**




# J.9 Diagnosis: IgE

### J.9.1.1 Adults: IgE vs. Physician Dx

**Figure 114: DUST MITE specific IgE**

**Dust mite IgE vs Physician (≥0.35 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Abraham 2007 | 187 | 27 | 306 | 97 | 0.38 [0.34, 0.42] | 0.78 [0.70, 0.85] |
| Linneberg 2006 | 27 | 260 | 5 | 417 | 0.84 [0.67, 0.95] | 0.62 [0.58, 0.65] |
| Soriano 1999 | 53 | 336 | 83 | 1344 | 0.39 [0.31, 0.48] | 0.80 [0.78, 0.82] |




**Dust mite vs. Physician Dx (≥0.70 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Plaschke 1999 | 16 | 86 | 68 | 1402 | 0.19 [0.11, 0.29] | 0.94 [0.93, 0.95] |




**Dust mite vs. Physician Dx (≥100 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|




**Dust mite IgE vs. Physician Dx (unclear cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|



## Figure 115: BIRCH specific IgE

**Birch IgE vs. Physician Dx (≥0.35 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|

**Birch IgE vs. Physician Dx (≥0.70 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Plaschke 1999 | 25 | 155 | 59 | 1333 | 0.30 [0.20, 0.41] | 0.90 [0.88, 0.91] |

**Birch IgE vs. Physician Dx (≥100 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|

**Birch IgE vs. Physician Dx (unclear cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|




## Figure 116: GRASSspecific IgE

**Grass IgE vs. Physician Dx (≥0.35 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Abraham 2007 | 164 | 24 | 329 | 100 | 0.33 [0.29, 0.38] | 0.81 [0.73, 0.87] |
| Soriano 1999 | 93 | 223 | 43 | 1457 | 0.68 [0.60, 0.76] | 0.87 [0.85, 0.88] |

**Grass IgE vs. Physician Dx (≥0.70 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Plaschke 1999 | 30 | 187 | 54 | 1301 | 0.36 [0.26, 0.47] | 0.87 [0.86, 0.89] |

**Grass IgE vs. Physician Dx (≥100 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|

**Grass IgE vs. Physician Dx (unclear cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|




## Figure 117: *ALTERNARIA*specific IgE

**Alternaria IgE vs. Physician Dx (≥0.35 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| Abraham 2007 | 167 | 18 | 326 | 106 | 0.34 [0.30, 0.38] | 0.85 [0.78, 0.91] |

**Alternaria IgE vs. Physician Dx (≥0.70 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|

**Alternaria IgE vs. Physician Dx (≥100 cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|

**Alternaria IgE vs. Physician Dx (unclear cut-off)**

| Study | TP | FP | FN | TN | Sensitivity | Specificity |
|---|---|---|---|---|---|---|



**Figure 118: *CLADOSPORIUM* specific IgE**




**Figure 119: POLLEN specific IgE**




1

## Figure 120: TOTAL IgE




## Figure 121: Cat IgE




## Figure 122: Dog IgE



# J.10 Diagnosis: FeNO

### J.10.1.1 Coupled sensitivity / specificity forest plots and ROC curves

**Forest plots: FeNO vs. Physician Dx with objective test**

Adults

**Figure 123: FeNO >27ppb**




**ADULTS: FeNO >30ppb**

Voutilainen 2013. Number of TP, FP, FN and TN not provided.

Sensitivity: 43.0%; Specificity: 89.0%

**Figure 124: FeNO >36ppb**




**Figure 125: FeNO >38.8ppb**




**Figure 126: ADULTS: FeNO >40ppb**




Children

**Figure 127: CHILDREN: FeNO >22ppb**



**Summary ROC Curve (fitted at a variety of test thresholds, selecting one threshold per study): Adults only**




**Forest plots: FeNO vs. other tests**

ADULTS:

**Figure 128: Adults: FeNO >30ppb versus methacholine ≤8mg/mL**



## FeNO levels

**Table 203: FeNO levels – medians and means presented**

| Reference | Population and mean or median FeNO levels (ppb) | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | Asthma (bronchial, allergic or non-allergic) | Chronic cough | Bronchitis | Eosinophilic bronchitis | Rhinitis | GERD | Mixed non-asthma Dx | Healthy | Cough variant asthma |
| BERLYNE 2000 | 39 | - | - | 65.0 | - | - | - | 10 | - |
| CARDINALE 2005 | 22.7 (children) | - | - | - | 15.3 (children) | - | - | 5.9 (children) | - |
| CHATKIN 1999**(also c-c study) | 75.0 | 16.7 | - | - | - | - | - | 28.3 | - |
| CIPRANDI 2013^ | 34 (children) | - | - | - | 27 children | - | - | - | - |
| CORDEIRO 2011**$ | 44 | - | - | - | 21 | - | 17 | - | - |
| DEYKIN 2002 | 57.9 | - | - | - | - | - | - | 26.3 | - |
| FUKHARA 2011** | 90.1 | - | - | - | - | - | 40.1 | - | - |
| HEFFLER 2006**$ (also c-c study) | 59.7 | - | - | - | - | - | 30.4 | 12.2 | - |
| KOSTIKAS 2008**£(also c-c study) | 24.0 | - | - | - | 17.5 | - | 11.0 | 11.0 | - |
| KOWAL 2008**(also c-c study) | 86 | - | - | - | 37 | 14.8 | - | 13 | - |
| LOUHELAINEN 2008A | 35.5 (children)<br>81.8 (adult) | -<br>- | -<br>- | - | -<br>- | -<br>- | -<br>- | 11.9 (children)<br>16.6 (adult) | - |
| SATO 2008** | 93.5 | - | 16.4 | - | - | - | 21.2 | - | - |
| SHIMODA 2013 | 92.6 | - | - | - | - | - | - | 18.0 | 35.6 |
| SHOME 2006 | 24.8 | - | - | - | - | - | - | 5.9 | - |
| WOO 2012** | 23.4 (children) | - | - | - | - | - | 12.6 (children) | - | - |
| VOUTILAINEN 2013**$ | 29.7 | - | - | - | - | - | 14.6 | - | - |
| ZIETKOWSKI 2006A | 64.9 | - | - | - | - | - | - | 12.9 | - |

| Reference | Population and mean or median FeNO levels (ppb) | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|
| | Asthma (bronchial, allergic or non-allergic) | Chronic cough | Bronchitis | Eosinophilic bronchitis | Rhinitis | GERD | Mixed non-asthma Dx | Healthy | Cough variant asthma |
| **MEDIAN (range) ALL** | 50.95 (22.7-93.5) | 16.7 | 16.4 | 65.0 | 21.0 (15.3-37.0) | 14.8 | 17.0 (11.0-40.1) | 12.6 (5.9-28.3) | 35.6 |
| **MEDIAN (range) Adults/mixed** | 62.3 (24.0-93.5) | 16.7 | 16.4 | 65.0 | 27 (17.5-37) | 14.8 | 19.1 (11.0-40.1) | 13.0 (5.9-28.3) | 35.6 |
| **MEDIAN (range) Children only** | 28.7 (22.7-35.5) | - | - | - | 21.2 (15.3-27) | - | 12.6 | 8.9 (5.9-11.9) | - |

***(a)*** *** is a sens/spec study*
***(b)*** *^all patients have allergy (positive skin prick test)*
***(c)*** *$ mixed population of adults and children*
***(d)*** *£ excluding smokers*

# J.11 Diagnosis: Eosinophils

## J.11.1.1 ADULTS: PBE vs. Physician Dx

**Figure 129: PBE ≥4.15%**
TILEMANN 2011: 2x2 table not reported. Sensitivity 36%, specificity 83%

**Figure 130: PBE cut-off not reported**




## J.11.1.2 Children 5-16 years: PBE vs. Physician Dx

**Figure 131: PBE >4%**
SHIELDS 1999: 2x2 table not reported. Sensitivity 62%, specificity 67%

**Figure 132: PBE >8%**
SHIELDS 1999: 2x2 table not reported. Sensitivity 38%, specificity 93%

**Figure 133: PBE ≥0.45 x $10^9$/l**




## J.11.1.3 PBE counts

**Table 204: Adults: PBE counts**

| Study | N | Counts | Units |
|---|---|---|---|
| **PBE counts only** | | | |
| BACKER 2002 | 624 (N=103 asthma) | Non-asthma: **0.19**<br>Asthma: **0.26** | x$10^9$/L |
| HALVANI 2012 | 98 (N=61 asthma) | Healthy: **0.21**<br>Asthma ICS: **0.40**<br>Asthma no ICS: **0.52** | x$10^9$/L |
| HUNTER 2002 | 110 (N=89 asthma) | Healthy: **1.9**<br>Pseudoasthma: **2.0**<br>Asthma: **4.3** | % |
| KHAKZAD 2009 | 62 (N=50 asthma) | Healthy: **1.2**<br>All asthma: **1.0**<br>Mild intermittent: **2.0**<br>Mild persistent: **3.6**<br>Moderate persistent: **3.2**<br>Severe: **3.2** | % |
| KROEGEL 1998 | 56 (N=14 asthma) | Healthy: **0.10**<br>Bronchiectasis: **0.10** | x$10^9$/L median |

| Study | N | Counts | Units |
|---|---|---|---|
| | | COPD: **0.12**<br>Allergic asthma: **0.31** | |
| METSO 2000 | 190 (N=160 asthma) | Healthy: **0.13**<br>Pre-Tx 1: **0.11**<br>Pre-Tx 2: **0.14**<br>Pre-Tx 3: **0.12** | $x10^9$/L |
| RYTILA 2000 | 68 (N=25 asthma) | Healthy: **0.11**<br>Symptomatic: **0.17**<br>All asthma: **0.41**<br>Atopic asthma: **0.51**<br>Non-atopic asthma: **0.27** | $x10^9$/L |
| TOMASIAKLOZOWSKA 2012 | 110 (N=91 asthma) | Healthy: **32.0**<br>A stable – no ICS: **29.5**<br>A stable - ICS: **42.4**<br>A unstable – ICS: **49.8** | cells/$mm^3$ |
| ZIETKOWSKI 2006A | 140 (N=101 asthma) | Healthy: **119**<br>A allergic: **247**<br>A non-allergic: **211** | cells/$mm^3$ |
| **Median (range)** | **Asthma**<br><br>**Non-asthma**** | **0.29 (0.10 - 0.52)**<br>**3.2 (2.0 – 4.3)**<br>**0.13 (0.10 – 0.21)**<br>**1.9 (1.2 – 2.0)** | **$x10^9$/L**<br>**%**<br>**$x10^9$/L**<br>**%** |
| **Median (range)** | **A – allergic**<br>**A – non allergic** | **0.41 (0.31 – 0.51)**<br>**0.27 (0.27)** | **$x10^9$/L**<br>**$x10^9$/L** |
| **Other results:** | • 1 study showed that >50% of pts had PBE count >0.45 $x10^9$/L.<br>• 2 studies showed that patients with asthma had higher PBE counts (cells/$mm^3$) than healthy controls (although stable asthma without ICS Tx was similar to healthy controls in 1 study).<br>• 1 study showed that patients with allergic asthma had higher PBE counts (cells/$mm^3$) than patients with non-allergic asthma.<br>• 1 study showed that patients with asthma treated with ICS had higher PBE counts (cells/$mm^3$) than patients with asthma not treated with ICS (regardless of whether the asthma was stable or unstable). | | |

*ICS = inhaled corticosteroid; A = allergic; Tx = treatment. *where applicable, all units have been converted into $x10^9$/L as these are the standard units used in current UK clinical practice. **this includes healthy controls*

**Table 205: Children 5-16 years: PBE counts**

| Study | N | Counts | Units* | |
|---|---|---|---|---|
| **PBE counts only** | | | | |
| LABBE 2001 | 143 (N=88 asthma) | Healthy: **0.25**<br>Chronic cough: **0.21**<br>Asthma: **0.40** | $x10^9$/L | Children (mean 7 yrs) |

| Study | N | Counts | Units* | |
|---|---|---|---|---|
| NORDLUND 2012 | 39 | Asthma (mild/mod): **0.25** | x$10^9$/L | Children (mean 14 yrs) |
| SILVESTRI 2001A | 112 | Allergic: **500, 7.5%**<br>Non-allergic: **125, 2.5%** | Cells/$mm^3$ and % | Children (mean 11 yrs) |
| SILVESTRI 2003 | 92 | All: **5.5%**<br>Atopic: **6.7%**<br>Non-atopic: **3.0%** | % | Children (mean 11 yrs) |
| TUCHINDA 1987 | 1000 | 0 – 500 = **40%**<br>501-1000 = **29%**<br>1001-1500 = **16%**<br>1501-2000 = **9%**<br>>2000 = **7%** | Cells/$mm^3$ | Children <13 years (mean not reported) |
| VILA-INDURAIN 1999 | 57 (N=36 asthma) | • Healthy: **161**<br>• Asthma (norm $FEV_1$): **509**<br>• Asthma (< norm $FEV_1$ , norm with SABA): **397**<br>• Asthma (< norm $FEV_1$ , not norm with SABA): **319** | Cells/$mm^3$ | Children (8-18 yrs, mean not reported) |
| **Mean (range)** | **Asthma**<br><br>**Non-asthma****| **0.33 (0.25 – 0.40)**<br>**5.5 (5.5)**<br>**0.23 (0.21 – 0.25)**<br>- | **x$10^9$/L**<br>**%**<br>**x$10^9$/L**<br>**%** | |
| | **A – allergic**<br><br>**A - nonallergic** | -<br>**7.1 (6.7 – 7.5)**<br>-<br>**2.8 (2.5 – 3.0)** | **x$10^9$/L**<br>**%**<br>**x$10^9$/L**<br>**%** | |
| **Other results:** | • 1 study showed that the % of pts decreased with increasing PBE cell counts (0-500 cells/$mm^3$ had the most pts, with >2000 cells/$mm^3$ having the least).<br>• 1 study showed that patients with asthma had higher PBE counts (cells/$mm^3$) than healthy controls<br>• 1 study showed that patients with allergic asthma had higher PBE counts (cells/$mm^3$) than patients with non-allergic asthma<br>• 1 study showed that patients with asthma with a normal $FEV_1$ had higher PBE counts (cells/$mm^3$) than patients with asthma with <normal $FEV_1$ (regardless of whether the $FEV_1$ normalised with SABA). | | | |

*SABA = short-acting beta-agonists; *where applicable, all units have been converted into x$10^9$/L as these are the standard units used in current UK clinical practice. **this includes healthy controls*

**Table 206: Children <5 years: PBE counts**

| Study | N | Counts | Units | |
|---|---|---|---|---|
| **PBE counts only** | | | | |
| PIIPPOSAVOLAINEN 2007 | 83 | Asthma: 0.1 | $10^9$/L | Children (<2 yrs, mean not reported) |

| Study | N | Counts | | Units | |
|---|---|---|---|---|---|
| Median | | Asthma | 0.1 | $10^9$/L | |
| Range of means | | Asthma | 0.1 | $10^9$/L | |

# J.12 Diagnosis: Histamine and methacholine challenge tests

### J.12.1.1 Coupled sensitivity / specificity forest plots and ROC curves

**Adults: Methacholine/Histamine Challenge Tests vs Reference Standard**

**Figure 134: PC20 ≤8mg/ml**




**Figure 135: PD20 ≤6900µg**




**Figure 136: PD20 ≤2600µg**




**Children: Methacholine/Histamine Challenge Tests vs Reference Standard**

**Figure 137: Age <18 yrs- PC20 ≤16mg/ml**

Data unsuitable for RevMan:

ANDERSON 2009 (n=115; MCT cut-off 16mg/ml): Sensitivity 66.2%; Specificity = 62.9%

**Methacholine/Histamine Challenge Tests vs Other Tests**

**Figure 138: Histamine Challenge Test vs Mannitol (adults)- PD15≤1mg**




**Figure 139: Histamine Challenge Test vs Mannitol (adults) - PD15≤0.4mg**



**Figure 140: Histamine Challenge Test vs Mannitol (<18 yrs)**

No data found on sensitivity or specificity

# J.13 Diagnosis: Mannitol challenge test

### 3.13.1.1 Coupled sensitivity / specificity forest plots

**Mannitol Challenge Test vs Reference Standard**

**Figure 141: Mannitol Challenge Test vs Reference Standard (all age groups)≥15% fall in FEV1 ≤635mg or 10% fall between consecutive doses**




**Figure 142: Mannitol Challenge Test vs Reference Standard (<18 yrs) ≥15% fall in FEV1 ≤635mg or 10% fall between consecutive doses**

Data unsuitable for RevMan:

1. ANDERSON 2009: Sensitivity 63.2%; Specificity = 81.4%

# J.14 Diagnosis: Exercise challenge test

### 3.14.1.1 Exercise test vs. Physician Dx: ADULTS

**Figure 143: Exercise test ΔFEV1≥10%**




### 5.14.1.2 Exercise test vs. other tests: ADULTS

**Figure 144: Exercise test ΔFEV1 ≥18% vs. methacholine**




**Figure 145: Exercise test ΔFEV1 ≥20% vs. methacholine**




### 8.14.1.3 Exercise test vs. other tests: CHILDREN 5-16 years

**Figure 146: Cold air exercise test ΔFEV1 % init >15% vs. mannitol ΔFEV1 % init >15%.**




**Figure 147: Exercise ΔFEV1 ≥8.2% vs. methacholine PC20 ≤8mg/mL**



# 1 J.15 Monitoring: Questionnaires

## 2.15.1.1 3 Children (5-16 years) with uncontrolled asthma: Monitoring questionnaires + treatment vs UC + treatment.

**Figure 148: QOL <6 months (PAQLQ; scale 1-7)**




**Figure 149: QOL ≥6 months (PAQLQ; range 1-7)**




**Figure 150: Exacerbations (OCS) ≥6 months**




**Figure 151: Asthma control <6 months (ACQ, range 0-6)**




**Figure 152: Asthma control ≥6 months (ACQ, range 0-6)**




**Figure 153: Lung Function <6 months (FEV1 L)**



**Figure 154: Lung Function ≥6 months (FEV1 L)**




**Figure 155: Symptom free days <6 months (% over 2 weeks)**




**Figure 156: Symptom free days ≥6 months (% over 2 weeks)**




**Figure 157: ICS use <6 months (mean daily dose)**




**Figure 158: ICS use ≥6 months (mean daily dose)**




1

### 2.15.1.2 Adults and young people (>16 years) overall: Monitoring questionnaires + treatment vs UC + treatment.

**Figure 159: QOL ≥6 months (PAQLQ; range 1-7)**



**Figure 160: Exacerbations (OCS) ≥6 months**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Fixed, 95% CI |
|---|---|---|---|---|
| MEER 2009 | 0.1655 | 0.428 | 100.0% | 1.18 [0.51, 2.73] |
| **Total (95% CI)** | | | **100.0%** | **1.18 [0.51, 2.73]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.39 (P = 0.70)




**Figure 161: Exacerbations (OCS, ER or hospitalisation) ≥6 months**

| Study or Subgroup | Monitoring control Events | Total | Usual care Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| MEER 2009 | 11 | 91 | 10 | 92 | 53.8% | 1.11 [0.50, 2.49] |
| MEHUYS 2008 | 10 | 80 | 8 | 70 | 46.2% | 1.09 [0.46, 2.62] |
| **Total (95% CI)** | | **171** | | **162** | **100.0%** | **1.10 [0.61, 1.99]** |
| Total events | 21 | | 18 | | | |

Heterogeneity: Chi² = 0.00, df = 1 (P = 0.98); I² = 0%
Test for overall effect: Z = 0.33 (P = 0.74)




**Figure 162: UHU (ER or hospitalisation) ≥6 months**

| Study or Subgroup | Monitoring control Events | Total | Usual care Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| MEHUYS 2008 | 1 | 80 | 5 | 70 | 100.0% | 0.17 [0.02, 1.46] |
| **Total (95% CI)** | | **80** | | **70** | **100.0%** | **0.17 [0.02, 1.46]** |
| Total events | 1 | | 5 | | | |

Heterogeneity: Not applicable
Test for overall effect: Z = 1.61 (P = 0.11)




**Figure 163: Asthma control <6 months (ACT, range 5-25)**

| Study or Subgroup | Monitoring control Mean | SD | Total | Usual care Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| MEHUYS 2008 | 20.3 | 3.2 | 99 | 20 | 3.8 | 84 | 100.0% | 0.30 [-0.73, 1.33] |
| **Total (95% CI)** | | | **99** | | | **84** | **100.0%** | **0.30 [-0.73, 1.33]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.57 (P = 0.57)




**Figure 164: Asthma control ≥6 months (ACT, range 5-25)**

| Study or Subgroup | Monitoring control Mean | SD | Total | Usual care Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| MEHUYS 2008 | 20.2 | 3.5 | 80 | 19.7 | 4.8 | 70 | 100.0% | 0.50 [-0.86, 1.86] |
| **Total (95% CI)** | | | **80** | | | **70** | **100.0%** | **0.50 [-0.86, 1.86]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.72 (P = 0.47)




**Figure 165: Asthma control ≥6 months (ACQ, range 0-6)**

| Study or Subgroup | Mean Difference | SE | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|
| MEER 2009 | -0.47 | 0.0867 | 100.0% | -0.47 [-0.64, -0.30] |
| **Total (95% CI)** | | | **100.0%** | **-0.47 [-0.64, -0.30]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 5.42 (P < 0.00001)



**Figure 166: Lung Function ≥6 months (FEV1 L)**




**Figure 167: Symptom free days ≥6 months (% over 2 weeks)**




1

**Figure 168: ICS use ≥6 months (mean daily dose)**




**Figure 169: Rescue medication <6 months (mean puffs/day)**




**Figure 170: Rescue medication ≥6 months (mean puffs/day)**




2
3

# J.16 Monitoring: Lung function test

## J.16.1.1 Adults: Monitoring PEF versus symptom monitoring

### Figure 171: QOL ≥6 months (AQLQ increase more than 0.5 points)

| Study or Subgroup | PEF monitoring Events | Total | Symptom monitoring Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Buist 2006 | 52 | 134 | 50 | 128 | 100.0% | 0.99 [0.73, 1.35] |
| **Total (95% CI)** | | **134** | | **128** | **100.0%** | **0.99 [0.73, 1.35]** |
| Total events | 52 | | 50 | | | |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.04 (P = 0.97)




### Figure 172: QOL ≥6 months (AQLQ decrease more than 0.5 points)

| Study or Subgroup | PEF monitoring Events | Total | Symptom monitoring Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Buist 2006 | 16 | 134 | 11 | 128 | 100.0% | 1.39 [0.67, 2.88] |
| **Total (95% CI)** | | **134** | | **128** | **100.0%** | **1.39 [0.67, 2.88]** |
| Total events | 16 | | 11 | | | |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.88 (P = 0.38)




### Figure 173: Exacerbations ≥6 months (OCS)

| Study or Subgroup | PEF monitoring Events | Total | Symptom monitoring Events | Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| Charlton 1990 | 14 | 27 | 7 | 33 | 56.7% | 2.44 [1.15, 5.18] |
| Turner 1998 | 3 | 44 | 6 | 48 | 43.3% | 0.55 [0.15, 2.05] |
| **Total (95% CI)** | | **71** | | **81** | **100.0%** | **1.28 [0.29, 5.57]** |
| Total events | 17 | | 13 | | | |

Heterogeneity: Tau² = 0.85; Chi² = 3.81, df = 1 (P = 0.05); I² = 74%
Test for overall effect: Z = 0.33 (P = 0.74)




### Figure 174: Exacerbations ≥6 months (no. of OCS courses)

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Cote 1997 | 0.7 | 1.4 | 50 | 0.9 | 1.3 | 45 | 100.0% | -0.20 [-0.74, 0.34] |
| **Total (95% CI)** | | | **50** | | | **45** | **100.0%** | **-0.20 [-0.74, 0.34]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.72 (P = 0.47)




### Figure 175: UHU ≥6 months (total asthma-related health care utilisation)

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Buist 2006 | 1.39 | 1.98 | 148 | 1.5 | 2.23 | 146 | 100.0% | -0.11 [-0.59, 0.37] |
| **Total (95% CI)** | | | **148** | | | **146** | **100.0%** | **-0.11 [-0.59, 0.37]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.45 (P = 0.65)



## Figure 176: UHU ≥6 months (Hospitalisation)

| Study or Subgroup | PEF monitoring Events | PEF monitoring Total | Symptom monitoring Events | Symptom monitoring Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Cowie 1997 | 2 | 46 | 2 | 45 | 50.3% | 0.98 [0.14, 6.65] |
| Lopez-Vina 2000 | 2 | 56 | 0 | 44 | 13.9% | 3.95 [0.19, 80.17] |
| Turner 1998 | 0 | 44 | 1 | 48 | 35.8% | 0.36 [0.02, 8.68] |
| **Total (95% CI)** | | **146** | | **137** | **100.0%** | **1.17 [0.31, 4.43]** |
| Total events | 4 | | 3 | | | |

Heterogeneity: Chi² = 1.18, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.23 (P = 0.82)




## Figure 177: UHU ≥6 months (mean number of hospital admissions)

| Study or Subgroup | PEF monitoring Mean | PEF monitoring SD | PEF monitoring Total | Symptom monitoring Mean | Symptom monitoring SD | Symptom monitoring Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Cote 1997 | 0.04 | 0.28 | 50 | 0.09 | 0.27 | 45 | 100.0% | -0.05 [-0.16, 0.06] |
| **Total (95% CI)** | | | **50** | | | **45** | **100.0%** | **-0.05 [-0.16, 0.06]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.89 (P = 0.38)




## Figure 178: UHU ≥6 months (mean number of days of hospitalisation)

| Study or Subgroup | PEF monitoring Mean | PEF monitoring SD | PEF monitoring Total | Symptom monitoring Mean | Symptom monitoring SD | Symptom monitoring Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Adams 2001 | 0.07 | 0.3 | 48 | 0.1 | 0.5 | 40 | 100.0% | -0.03 [-0.21, 0.15] |
| **Total (95% CI)** | | | **48** | | | **40** | **100.0%** | **-0.03 [-0.21, 0.15]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.33 (P = 0.74)




## Figure 179: UHU ≥6 months (ED visits)

| Study or Subgroup | PEF monitoring Events | PEF monitoring Total | Symptom monitoring Events | Symptom monitoring Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Lopez-Vina 2000 | 3 | 56 | 0 | 44 | 22.6% | 5.53 [0.29, 104.25] |
| Turner 1998 | 6 | 44 | 2 | 48 | 77.4% | 3.27 [0.70, 15.38] |
| **Total (95% CI)** | | **100** | | **92** | **100.0%** | **3.78 [0.96, 14.93]** |
| Total events | 9 | | 2 | | | |

Heterogeneity: Chi² = 0.10, df = 1 (P = 0.75); I² = 0%
Test for overall effect: Z = 1.90 (P = 0.06)




## Figure 180: UHU ≥6 months (mean number of ED visits)

| Study or Subgroup | PEF monitoring Mean | PEF monitoring SD | PEF monitoring Total | Symptom monitoring Mean | Symptom monitoring SD | Symptom monitoring Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Adams 2001 | 0.11 | 0.4 | 48 | 0.15 | 0.4 | 40 | 91.3% | -0.04 [-0.21, 0.13] |
| Cote 1997 | 0.7 | 1.4 | 50 | 0.7 | 1.3 | 45 | 8.7% | 0.00 [-0.54, 0.54] |
| **Total (95% CI)** | | | **98** | | | **85** | **100.0%** | **-0.04 [-0.20, 0.12]** |

Heterogeneity: Chi² = 0.02, df = 1 (P = 0.89); I² = 0%
Test for overall effect: Z = 0.45 (P = 0.66)




## Figure 181: UHU ≥6 months (unscheduled doctors visits)

| Study or Subgroup | PEF monitoring Events | PEF monitoring Total | Symptom monitoring Events | Symptom monitoring Total | Weight | Risk Ratio M-H, Random, 95% CI |
|---|---|---|---|---|---|---|
| Cowie 1997 | 5 | 46 | 14 | 45 | 47.2% | 0.35 [0.14, 0.89] |
| Turner 1998 | 17 | 44 | 12 | 48 | 52.8% | 1.55 [0.84, 2.86] |
| **Total (95% CI)** | | **90** | | **93** | **100.0%** | **0.77 [0.18, 3.34]** |
| Total events | 22 | | 26 | | | |

Heterogeneity: Tau² = 0.97; Chi² = 6.95, df = 1 (P = 0.008); I² = 86%
Test for overall effect: Z = 0.35 (P = 0.72)



**Figure 182: Rescue medications ≥6 months (no. of patients requiring nebulised salbutamol)**

| Study or Subgroup | PEF monitoring Events | Total | Symptom monitoring Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Charlton 1990 | 3 | 28 | 2 | 37 | 100.0% | 1.98 [0.35, 11.08] |
| **Total (95% CI)** | | **28** | | **37** | **100.0%** | **1.98 [0.35, 11.08]** |
| Total events | 3 | | 2 | | | |

Heterogeneity: Not applicable
Test for overall effect: Z = 0.78 (P = 0.44)




**Figure 183: FEV1 L ≥6 months**

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Adams 2001 | 2.45 | 0.82 | 48 | 2.71 | 0.86 | 40 | 100.0% | -0.26 [-0.61, 0.09] |
| **Total (95% CI)** | | | **48** | | | **40** | **100.0%** | **-0.26 [-0.61, 0.09]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 1.44 (P = 0.15)




**Figure 184: FEV1 % ≥6 months**

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Kaya 2009 | 87.74 | 19.02 | 31 | 87.35 | 21.25 | 32 | 1.0% | 0.39 [-9.56, 10.34] |
| Lopez-Vina 2000 | 80.9 | 2.3 | 56 | 80.8 | 2.8 | 44 | 99.0% | 0.10 [-0.92, 1.12] |
| **Total (95% CI)** | | | **87** | | | **76** | **100.0%** | **0.10 [-0.92, 1.12]** |

Heterogeneity: Chi² = 0.00, df = 1 (P = 0.95); I² = 0%
Test for overall effect: Z = 0.20 (P = 0.84)




**Figure 185: PEF % ≥6 months**

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Kaya 2009 | 84.93 | 14.32 | 31 | 79.62 | 14.92 | 32 | 100.0% | 5.31 [-1.91, 12.53] |
| **Total (95% CI)** | | | **31** | | | **32** | **100.0%** | **5.31 [-1.91, 12.53]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 1.44 (P = 0.15)




**Figure 186: Time off work ≥6 months (number of patients)**

| Study or Subgroup | PEF monitoring Events | Total | Symptom monitoring Events | Total | Weight | Risk Ratio M-H, Fixed, 95% CI |
|---|---|---|---|---|---|---|
| Lopez-Vina 2000 | 2 | 56 | 0 | 44 | 6.8% | 3.95 [0.19, 80.17] |
| Turner 1998 | 9 | 44 | 8 | 48 | 93.2% | 1.23 [0.52, 2.90] |
| **Total (95% CI)** | | **100** | | **92** | **100.0%** | **1.41 [0.62, 3.21]** |
| Total events | 11 | | 8 | | | |

Heterogeneity: Chi² = 0.55, df = 1 (P = 0.46); I² = 0%
Test for overall effect: Z = 0.82 (P = 0.41)




**Figure 187: Time off work ≥6 months (mean number of days)**

| Study or Subgroup | PEF monitoring Mean | SD | Total | Symptom monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| Adams 2001 | 5 | 1 | 48 | 2.3 | 4 | 40 | 94.2% | 2.70 [1.43, 3.97] |
| Cote 1997 | 2.2 | 12.7 | 50 | 2.9 | 12.7 | 45 | 5.8% | -0.70 [-5.81, 4.41] |
| **Total (95% CI)** | | | **98** | | | **85** | **100.0%** | **2.50 [1.27, 3.74]** |

Heterogeneity: Chi² = 1.60, df = 1 (P = 0.21); I² = 37%
Test for overall effect: Z = 3.97 (P < 0.0001)




1

## 1.16.1.2 Children: Monitoring PEF versus symptom monitoring

**Figure 188: Exacerbations <6 months (OCS)**




**Figure 189: Exacerbations ≥6 months (OCS)**




**Figure 190: UHU <6 months (hospitalisation)**




**Figure 191: UHU <6 months (attendance at A&E)**




**Figure 192: UHU <6 months (emergency GP visits)**



**Figure 193: Rescue medications ≥6 months (no. of patients requiring nebulised salbutamol)**




**Figure 194: FEV1 % <6 months**




**Figure 195: PEF % L/min <6 months**




**Figure 196: Time off school <6months (number of patients)**




1
2

# J.17 Monitoring: FeNO

## J.17.1.1 Adults – Unscheduled healthcare utilisation

**Figure 197: FeNO versus Conventional Monitoring in Adults, UHU – ED visit [≥6 months]**




**Figure 198: FeNO versus Conventional Monitoring in Adults, UHU - hospitalisation [≥6 months]**




## J.17.1.2 Adults - Exacerbation

**Figure 199: FeNO versus Conventional Monitoring in Adults, exacerbation [≥6 months]**




**Figure 200: FeNO versus Conventional Monitoring in Adults, exacerbation [≥6 months]**



**Figure 201: FeNO versus Conventional Monitoring in Adults, exacerbation [≥6 months]**




1

### 2.17.1.3 Adults - Quality of Life

**Figure 202: FeNO versus Conventional Monitoring in Adults, quality of life (AQLQ) [≥6 months]**




3

### 4.17.1.4 Adults - Asthma Control Questionnaire

**Figure 203: FeNO versus Conventional Monitoring in Adults, asthma control questionnaire (ACQ) [≥6 months]**




5 **Figure 204: FeNO versus Conventional Monitoring in Adults, asthma control questionnaire (ACQ,**
6 **clinically important improvement, ≥0.5) [≥6 months]**




7

### 8.17.1.5 Adults - Lung Function

9 **Figure 205: FeNO versus Conventional Monitoring in Adults, lung function (FEV1, litres) [≥6**
10 **months]**




1

2

3 **Figure 206: FeNO versus Conventional Monitoring in Adults, lung function (FEV1, %) [≥6 months]**




4

5

6 **Figure 207: FeNO versus Conventional Monitoring in Adults, lung function (PEF am, L/min) [≥6**
7 **months]**




8

9

10 **Figure 208: FeNO versus Conventional Monitoring in Adults, lung function (PEF pm, L/min) [<6**
11 **months]**




12

13 **3.17.1.6 Adults - Symptoms**

**Figure 209: FeNO versus Conventional Monitoring in Adults, % symptom free days [ ≥6 months]**




14

### 1.17.1.7 Adults - Dose of Regular Therapy

**Figure 210: FeNO versus Conventional Monitoring in Adults, dose of regular therapy (ICS use, fluticasone dose) [≥6 months]**




2

### 3.17.1.8 Adults - Rescue Medication

**Figure 211: FeNO versus Conventional Monitoring in Adults, rescue medication (puffs/day) [≥6 months]**




4

### 5.17.1.9 Adults - Time off school or work

**Figure 212: FeNO versus Conventional Monitoring in Adults, time off (missing days off school or work, number of participants) [≥6 months]**




6

### 7.17.1.10 Children – Unscheduled Healthcare Utilisation

**Figure 213: FeNO versus Conventional Monitoring in Children, unscheduled healthcare utilisation (unscheduled visits) [≥6 months]**




8

**Figure 214: FeNO versus Conventional Monitoring in Children, unscheduled healthcare utilisation (hospitalisation) [≥6 months]**




**Figure 215: FeNO versus Conventional Monitoring in Children, unscheduled healthcare utilisation (number of children ≥1 emergency room admission) [≥6 months]**




### J8 17.1.11 Children – Exacerbation

**Figure 216: FeNO versus Conventional Monitoring in Children, exacerbation (OCS) [≥6 months]**




### 10 17.1.12 Children – Quality of Life

**Figure 217: FeNO versus Conventional Monitoring in Children, quality of life (ACT score) [≥6 months]**



**Figure 218: FeNO versus Conventional Monitoring in Children, quality of life (Paediatric Asthma Caregiver Quality of Life Questionnaire) [≥6 months]**




## J4 17.1.13 Children – Lung Function

**Figure 219: FeNO versus Conventional Monitoring in Children, lung function (FEV1 % pred) [≥6 months]**




## J5 17.1.14 Children – Symptoms

**Figure 220: FeNO versus Conventional Monitoring in Children, symptoms (% symptom free days) [≥6 months]**




**Figure 221: FeNO versus Conventional Monitoring in Children, symptoms (number of symptom days in last 2 weeks) [≥6 months]**



## J117.1.15 Children – Dose of Regular Therapy

**Figure 222: FeNO versus Conventional Monitoring in Children, dose of regular therapy (ICS use, daily dose) [≥6 months]**




**Figure 223: FeNO versus Conventional Monitoring in Children, dose of regular therapy (number of patients not using inhaled corticosteroids or anti-leukotrienes) [≥6 months]**



### J17.1.16 Children – Rescue Medication

**Figure 224: FeNO versus Conventional Monitoring in Children, rescue medication (number of patients needed beta-agonist due to symptoms) [≥6 months]**




### J17.1.17 Children – Time Off school

**Figure 225: FeNO versus Conventional Monitoring in Children, time off (number of days missed in last 2 weeks) [≥6 months]**




**Figure 226: FeNO versus Conventional Monitoring in Children, time off (number of children missed school) [≥6 months]**


# 3 J.18 Monitoring: Challenge tests

### 4.18.1.1 ADULTS Methacholine challenge test versus no challenge test for asthma monitoring

**Figure 227: Mortality ≥6 months**



## Figure 228: Exacerbations (undefined) ≥6 months




## Figure 229: Rescue medications (puffs/day) ≥6 months




## Figure 230: ICS mean daily dose ≥6 months




1

## Figure 231: FEV1 (L or L/year) ≥6 months




## Figure 232: % symptom free days ≥6 months



**Figure 233: PEF am (L/min) ≥6 months**




**Figure 234: PEF pm (L/min) ≥6 months**




## 1.18.1.2 ADULTS Mannitol challenge test versus no challenge test for asthma monitoring

**Figure 235: QOL (miniAQLQ) ≥6 months**




**Figure 236: Exacerbations (OCS) ≥6 months**




**Figure 237: Rescue medications (puffs/day) ≥6 months**




2

**Figure 238: ICS mean daily dose ≥6 months**



### Figure 239: FEV1 (%) ≥6 months




### Figure 240: PEF (%) ≥6 months




### Figure 241: PEF am (L/min) ≥6 months




## 1.18.1.3 CHILDREN Methacholine challenge test versus no challenge test for asthma monitoring

### Figure 242: Exacerbations (OCS) ≥6 months




### Figure 243: ICS mean daily dose for treatment period ≥6 months




### Figure 244: FEV1 (%)≥6 months



**Figure 245: % symptom free days ≥6 months**



# J.19 Monitoring adherence to treatment

## J.19.1.1 Children (5-16 years) with uncontrolled asthma: Monitoring adherence + feedback vs no monitoring

**Figure 246: Adherence <6 months (% of prescribed doses measured by the electronic inhaler)**




**Figure 247: Adherence ≥6 months (number of canister refills, 100% adherence = 3.0)**




**Figure 248: Self-reported adherence ≥6 months**




**Figure 249: Exacerbation (OCS) <6 months**




**Figure 250: Exacerbation (OCS) ≥6 months (no. of OCS courses in 6 months)**




**Figure 251: UHU (hospitalisation) ≥6 months (no. of hospitalisations in 6 months)**



**Figure 252: Rescue medication < 6months (reliever medication 3 or more times a week)**




1

### 2.19.1.2 Adults (>16 years) overall: Monitoring adherence + feedback vs no monitoring

**Figure 253: Adherence ≥6 months (% adherence to prescription refills in previous 3 months)**




**Figure 254: QOL <6 months (AQLQ, range 1-7)**




**Figure 255: Exacerbation (OCS) ≥6months**




**Figure 256: UHU (hospitalisation) ≥6months**




**Figure 257: UHU (ED visit) ≥6months**



**Figure 258: Lung function <6months (FEV1 L)**



# J.20 Monitoring inhaler technique

## 3.20.1.1 ADULTS: Monitoring inhaler technique vs no monitoring

### Figure 259: Lung function <6 months (PEF Min%Max, higher is less variability)

| Study or Subgroup | Monitoring Mean [%] | SD [%] | Total | No monitoring Mean [%] | SD [%] | Total | Weight | Mean Difference IV, Fixed, 95% CI [%] |
|---|---|---|---|---|---|---|---|---|
| BASHETI 2007 | 83.8 | 8.3 | 53 | 77.6 | 9.2 | 44 | 100.0% | 6.20 [2.68, 9.72] |
| **Total (95% CI)** | | | **53** | | | **44** | **100.0%** | **6.20 [2.68, 9.72]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 3.45 (P = 0.0006)




### Figure 260: Lung function ≥6 months (PEF Min%Max, higher is less variability)

| Study or Subgroup | Monitoring Mean [%] | SD [%] | Total | No monitoring Mean [%] | SD [%] | Total | Weight | Mean Difference IV, Fixed, 95% CI [%] |
|---|---|---|---|---|---|---|---|---|
| BASHETI 2007 | 78.9 | 9.7 | 53 | 74.4 | 8.9 | 44 | 100.0% | 4.50 [0.79, 8.21] |
| **Total (95% CI)** | | | **53** | | | **44** | **100.0%** | **4.50 [0.79, 8.21]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 2.38 (P = 0.02)




### Figure 261: QOL <6 months (Marks AQLQ, 0-10, better indicated by lower values)

| Study or Subgroup | Monitoring Mean | SD | Total | No monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| BASHETI 2007 | 0.8 | 0.5 | 53 | 1.35 | 0.6 | 44 | 100.0% | -0.55 [-0.77, -0.33] |
| **Total (95% CI)** | | | **53** | | | **44** | **100.0%** | **-0.55 [-0.77, -0.33]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 4.84 (P < 0.00001)




### Figure 262: QOL ≥6 months (Marks AQLQ, 0-10, better indicated by lower values)

| Study or Subgroup | Monitoring Mean | SD | Total | No monitoring Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| BASHETI 2007 | 0.8 | 0.6 | 53 | 1.3 | 0.6 | 44 | 100.0% | -0.50 [-0.74, -0.26] |
| **Total (95% CI)** | | | **53** | | | **44** | **100.0%** | **-0.50 [-0.74, -0.26]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 4.09 (P < 0.0001)


## 3.20.1.2 ADULTS: Monitoring (verbal and electronic) vs verbal monitoring only

### Figure 263: QOL <6 months (mini AQLQ, 1-7, better indicated by higher values)

| Study or Subgroup | Verbal and electronic Mean | SD | Total | Verbal only Mean | SD | Total | Weight | Mean Difference IV, Fixed, 95% CI |
|---|---|---|---|---|---|---|---|---|
| ALSHOWAIR 2007 | 4.6 | 1 | 36 | 4.2 | 1 | 35 | 74.6% | 0.40 [-0.07, 0.87] |
| AMMARI 2013 | -0.409 | 1.05 | 17 | -0.748 | 1.31 | 17 | 25.4% | 0.34 [-0.46, 1.14] |
| **Total (95% CI)** | | | **53** | | | **52** | **100.0%** | **0.38 [-0.02, 0.79]** |

Heterogeneity: Chi² = 0.02, df = 1 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.88 (P = 0.06)




### Figure 264: Lung function <6 months (FEV1 L)

| Study or Subgroup | Verbal and electronic Mean [L] | SD [L] | Total | Verbal only Mean [L] | SD [L] | Total | Weight | Mean Difference IV, Fixed, 95% CI [L] |
|---|---|---|---|---|---|---|---|---|
| ALSHOWAIR 2007 | 1.93 | 0.63 | 36 | 2.16 | 0.74 | 35 | 100.0% | -0.23 [-0.55, 0.09] |
| **Total (95% CI)** | | | **36** | | | **35** | **100.0%** | **-0.23 [-0.55, 0.09]** |

Heterogeneity: Not applicable
Test for overall effect: Z = 1.41 (P = 0.16)



**Figure 265: Lung function <6 months (FEV1 % pred)**




1

### 2.20.1.3 CHILDREN: Monitoring (verbal and electronic) vs verbal monitoring only

**Figure 266: Lung function <6 months (FEV1 % pred)**




**Figure 267: QOL <6 months (PAQLQ, 1-7, better indicated by higher values)**




## 3 J.21 Monitoring: Tele-healthcare

### 4.21.1.1 Tele-healthcare for adults >17

**Figure 268: Quality of life – Asthma Quality of Life Questionnaire (AQLQ)**

5




**Figure 269: UHU hospitalisation**




1

**Figure 270: UHU ED visit**




1

**Figure 271: Exacerbations requiring oral steroids**




2

**Figure 272: Asthma Control Questionnaire (ACQ)**




1

**Figure 273: UHU GP visits**




2

**Figure 274: Change in forced expiratory volume in 1 second ($FEV_1$, mL)**




1

**Figure 275: Percentage predicted forced expiratory volume in 1 second ($FEV_1$)**




2

**Figure 276: Peak expiratory flow (PEF, litres per minute)**




3

4

**Figure 277: Withdrawal**




1

### 2.21.1.2 Tele-healthcare for children aged 5 to 17

**Figure 278: Paediatric Asthma Quality of Life Questionnaire (PAQLQ) – child subscale**




3

**Figure 279: Paediatric Asthma Quality of Life Questionnaire (PAQLQ) – caregiver subscale**




1

**Figure 280: UHU hospitalisation**




2

**Figure 281: UHU ED visit**




3

**Figure 282: Exacerbations requiring oral steroids**




1

**Figure 283: Asthma Control Questionnaire (ACQ)**




2

**Figure 284: UHU GP visits**




3

**Figure 285: Percentage predicted forced expiratory volume in 1 second ($FEV_1$)**




4

**Figure 286: Change in morning peak expiratory flow (PEF, litres per minute)**




5

**Figure 287: Change in evening peak expiratory flow (PEF, litres per minute)**




1

**Figure 288: Withdrawal**




(1) Random effects used due to heterogeneity in this comparison. Point estimate for 2.11.1 not affected.

2

### 3.21.1.3 Adults and young people (>16 years): Telehealthcare without healthcare professional involvement vs usual care

4

**Figure 289: QOL <6 months (AQLQ, range 0-7)**




**Figure 290: Asthma control questionnaires <6 months (ACT, range 5-25)**




5

## 1.21.1.4 Children (5-16 years): Telehealthcare without healthcare professional involvement vs usual care

**Figure 291: Exacerbations ≥6 months (OCS rescue use)**


**Figure 292: QOL ≥6 months (pAQLQ carer).**




**Figure 293: QOL ≥6 months (pAQLQ child).**




**Figure 294: UHU ≥6 months (self-report ED presentation)**




**Figure 295: UHU ≥6 months (self-report hospitalisation)**




2

**Figure 296: School days lost ≥6 months (self-report yes/no)**

**Figure 297: Parent work days lost ≥6 months (self-report yes/no)**




**Figure 298: Patients who should have been on controllers at baseline (i.e. persistent asthma) but were not, who were on controllers at 6 months**




**Figure 299: Persistent asthma on controllers at baseline but discontinued at 6 months.**




**Figure 300: Of those who met severity criteria for controllers at baseline, number on them at 12 months**




1
2

# Appendix K: Excluded clinical studies

## K.1 Diagnosis: Signs and symptoms

**Table 207: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ABRAMSON 1992[9] | General population and no subgroup analysis |
| ABRAMSON 1996A[10] | General population and no subgroup analysis |
| ABRAMSON 2002[12] | Wrong definition of Phys Dx – no objective test. |
| AMAT 2011[41] | Wrong definition of Phys Dx – no objective test. |
| ANDERSON 1986[44] | Wrong definition of Phys Dx – no objective test. |
| ANDERSON 1987[45] | Wrong definition of Phys Dx – no objective test. |
| ANTOLINAMERIGO 2012[54] | Conference abstract |
| ARIF 2003[67] | General population and no subgroup analysis |
| ARIF 2004[66] | Older children: wrong definition of Phys Dx – no objective test. Younger children: looks at wrong risk factors (not those specified in our protocol). |
| ARIF 2007[69] | Wrong definition of Phys Dx – no objective test. |
| ARIF 2008[68] | General population and no subgroup analysis; QoL only given in asthma subgroup. |
| ARNEDOPENA 2009[73] | General population and no subgroup analysis |
| ARSHAD 2005[74] | Wrong definition of Phys Dx – no objective test. |
| ASHER 2008[76] | Wrong definition of Phys Dx – no objective test. |
| ATHERTON 1996[77] | Wrong definition of Phys Dx – no objective test. |
| AUSTIN 1997[79] | RFs for wheeze, not asthma. |
| BACHARIER 2012BACHARIER2012} | Asthma (wheeze in children) and no comparison group. |
| BACKER 2009[88] | No comparison group – asthma only. |
| BAI 1998[92] | Wrong definition of Phys Dx – no objective test. |
| BALL 2000[98] | Gives prevalence of asthma but not symptoms. |

| Reference | Reason for exclusion |
|---|---|
| BARRY 2012[116] | General population and no subgroup analysis, and looks at the wrong risk factors (not those specified in our protocol), |
| BAUMAN 1992[127] | Wrong definition of Phys Dx – no objective test. |
| BAUMANN 1986[128] | Wrong comparison group: asthma vs. healthy controls. |
| BEACH 1995[133] | Diurnal variation in methacholine results, not in symptoms. |
| BEEH 2003[136] | Wrong population: only patients without asthma. |
| BELAMARICH 2000[142] | Wrong definition of Phys Dx – no objective test. |
| BELLIA 2000[147] | Wrong definition of Phys Dx – no objective test. |
| BENTUR 2004[153] | Wrong definition of Phys Dx – no objective test. |
| BERG 2004[157] | General population and no subgroup analysis |
| BERG 2011[154] | Wrong definition of Phys Dx – no objective test. |
| BERZ 2007[165] | Correct Phys Dx, but Looks at the wrong risk factors (not those specified in our protocol), and gives prevalence in people with asthma with no comparison group. |
| BISGAARD 2011[175] | Wrong population for sens/spec: general population. Wrong populatin for prevalence data: asthma or general population, nt asthma vs. other respiratory diseases. Predictors of asthma development are not given in useable categories. |
| BOLLAG 2000[182] | Wrong outcomes: asthma attack rates. |
| BONER 2010[185] | Wrong definition of Phys Dx – no objective test. |
| BORREGO 2009 A [192] | Does not give the % of people with asthma. |
| BORREGO 2010[193] | Looks at the wrong risk factors (not those specified in our protocol). |
| BOUDREAU 1995[199] | Wrong results: presence of |

| Reference | Reason for exclusion |
|---|---|
| | symptoms during histamine challenge. |
| BOULET 1991[201] | Asthma pts only and no comparison group. |
| BOUSQUET 2004[203] | Wrong definition of Phys Dx of asthma only group – no objective test. |
| BRAUNFAHRLANDER 1998[218] | Wrong definition of Phys Dx – no objective test. |
| BRAUNFAHRLANDER 2004[219] | General population and no subgroup analysis |
| BRENNER 2001[221] | Wrong definition of Phys Dx – no objective test. |
| BRESCIANINI 2009[222] | Wrong definition of Phys Dx – no objective test. |
| BROEKHUIZEN 2010[227] | Cannot calculate sensitivity and specificity |
| BROOKE 1998[230] | Wrong definition of Phys Dx – no objective test. |
| BRUTSCHE 2006[239] | Wrong outcomes/population: prevalence of symptoms in previously asymptomatic pts. |
| BURNEY 1989[248] | Wrong outcomes: sens/spec for wheeze, asthma attack, or bronchial irritability, not asthma Dx. |
| BURROWS 1991[250] | Wrong definition of Phys Dx – no objective test. |
| BUSINCO 1979[253] | Gives prevalence of people with asthma (wheezers) only, no comparison group. |
| CAREY 1996[272] | Wrong definition of Phys Dx – no objective test. |
| CARTER 2006[287] | Wrong definition of Phys Dx – no objective test. |
| CAUDRI 2007[293] | Wrong definition of Phys Dx – no objective test. |
| CAUDRI 2009[294] | Wrong definition of Phys Dx – no objective test. |
| CAUDRI 2010[295] | Wrong outcomes: risk factors for future asthma symptoms not asthma Dx. Prevalence of symptoms in suspected asthma but not in asthma vs. other respiratory diseases. |
| CHANG 2013[301] | Population does not match protocol – family history of respiratory allergy |
| CHINN 2004[316] | General population and no |

| Reference | Reason for exclusion |
|---|---|
| | subgroup analysis |
| CHRISTOFF 2013[326] | Conference abstract |
| COLEMAN 2001[359] | Wrong definition of Phys Dx – no objective test. |
| CORDEIRO 2011[365,365] | Population does not match protocol – general allergic symptoms not respiratory symptoms only. |
| CORTESALVAREZ 2007[368] | Reference standard does not match protocol – history of atopic disorders in ≤ 3 yrs with wheezing, but no Dx of asthma made |
| COURT 2002[372] | Wrong definition of Phys Dx – no objective test. |
| CSONKA 2000A[382] | Wrong definition of Phys Dx – no objective test. |
| CUIJPERS 1994[383] | Wrong definition of Phys Dx – no objective test. |
| DALES 1987[391] | Wrong outcomes: sens/spec and predictors of AHR not asthma. |
| DALES 1988[392] | Wrong outcomes: predictors of AHR not asthma. |
| DAS 2003[393] | Levels of IgE in wheezers v. controls. Not signs and symptoms. |
| DEBENEDICTIS 1986[396] | Not known who had asthma, but only people with chronic cough who were MCT positive. |
| DEMARCO 2005[404] | Wrong definition of Phys Dx – no objective test. |
| DEMARCO 2006[405] | Prognostic factors for asthma severity, rather than for developing asthma. |
| DEN OTTER 1998[423] | Wrong outcomes; symptoms in people who consulted the GP vs. those who did not, rather than people with asthma. |
| DODGE 1994[444] | Wrong definition of Phys Dx – no objective test. |
| DODGE 1996[445] | Wrong definition of Phys Dx – no objective test. |
| FANIRAN 1999[490] | General population and no subgroup analysis |
| FLEMING 2000[504] | Prevalence of asthma over |

| Reference | Reason for exclusion |
|---|---|
| | time rather than symptoms. |
| FOUCARD 1984[513] | Reference standard does not match protocol (children who reported asthma symptoms during the last year were regarded as having asthma) |
| FRANK 1996[516] | Wrong definition of Phys Dx – no objective test. |
| FRANK 2001[517] | Wrong definition of Phys Dx – no objective test. |
| FRANK 2008[518] | Predictors of wheeze, not asthma. |
| FRISCHER 1993[524] | Wrong definition of Phys Dx – no objective test. |
| FUJIMURA 2005[533] | Looks at the wrong risk factors (not those specified in our protocol). |
| GARCINUNO 2013[550] | Wrong definition of Phys Dx – no objective test. |
| GERALD 2009[556] | Cannot calculate sensitivity and specificity |
| GLASGOW 2001[574] | General population and no subgroup analysis; and sens/spec not in suspected asthma. |
| GODDEN 1994[575] | Meets all inclusion criteria for prevalence study, except wrong sample size, N<200. |
| GOKSOR 2006[582] | Wrong definition of Phys Dx – no objective test. |
| GOKSOR 2008[583] | Wrong definition of Phys Dx – no objective test. |
| GUERRA 2004[612] | Wrong definition of Phys Dx – no objective test. |
| GUILBERT 2004A[614] | Wrong definition of Phys Dx – no objective test. |
| GUILBERT 2004B[613] | Risk factors for wheeze in adults, not asthma. |
| GUILBERT 2011A [615] | Wrong definition of Phys Dx – no objective test. |
| HABBICK 1999[620] | Wrong definition of Phys Dx – no objective test. |
| HABY 2001[621] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence in general population. |
| HAFKAMP 2012[625] | Looks at the wrong risk factors (not those specified in our protocol). |

| Reference | Reason for exclusion |
|---|---|
| HAFKAMP 2013[624] | Wrong definition of Phys Dx – no objective test. |
| HAFKAMP 2013A [623] | Prevalence in general population. |
| HAHN 1994[626] | Wrong definition of Phys Dx – no objective test. |
| HALL 2006[628] | Wrong definition of Phys Dx – no objective test. |
| HALLIDAY 1993[630] | Wrong definition of Phys Dx – no objective test. |
| HALONEN 1999[631] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence in general population. |
| HALONEN 2013[632] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence in general population. |
| HANCOX 2004[635] | Wrong definition of Phys Dx – no objective test. |
| HANCOX 2005[636] | Looks at the wrong risk factors (not those specified in our protocol). |
| HANCOX 2006[637] | Wrong definition of Phys Dx – no objective test. |
| HANSEL 2011[639] | Cannot calculate sensitivity and specificity |
| HEINRICH 1998[661] | Prevalence in general population. |
| HEINRICH 1999[660] | Prevalence in general population. Looks at the wrong risk factors (not those specified in our protocol). |
| HEINRICH 2002[659] | Wrong definition of Phys Dx – no objective test. |
| HENDERSON 1995[664] | Predictor of wheeze, not asthma. |
| HENDERSON 2005[666] | Prevalence in wrong population: RSV pts vs. controls, not asthma vs. other respiratory diseases. |
| HENDERSON 2008[665] | Wrong definition of Phys Dx – no objective test. |
| HENDERSON 2008A[667] | Wrong definition of Phys Dx – no objective test. |
| HENSLEY 2003[671] | Prevalence in wrong population: not asthma vs. other respiratory diseases. |

| Reference | Reason for exclusion |
|---|---|
| HERR 2012[673] | Age 18 months, but assessment of symptoms made in the previous 12 months. |
| HERR 2012A[672] | Age 18 months, but assessment of symptoms made in the previous 12 months. |
| HICKSON 2009[677] | Prevalence in general population. |
| HIRSCH 1999[683] | Wrong definition of Phys Dx – no objective test. |
| HIRSCH 2004[682] | Looks at a new score for Dx of asthma. However the score contains other aspects as well as symptoms, and results are not given separately for the symptoms. |
| HODGE 1996[684] | Looks at the wrong risk factors (not those specified in our protocol). |
| HOEK 2012[685] | Prevalence in general population. |
| HOLSTER 2012[691] | Wrong definition of Phys Dx – no objective test. Looks at the wrong risk factors (not those specified in our protocol). |
| HOLT 2010[693] | Prevalence in general population. Looks at the wrong risk factors (not those specified in our protocol). |
| HOMNICK 2007[697] | Wrong definition of Phys Dx – no objective test. |
| HOPP 1995[703] | Dx ability of questionnaire but looks at asthma a vs. controls in general population, not suspected asthma pts. |
| HOPPER 1995[704] | Prevalence in general population. |
| HOPPER 2012[705] | Wrong definition of Phys Dx – no objective test. |
| HORAK 2003[706] | Wrong definition of Phys Dx – no objective test. |
| HORAK 2006[708] | Prevalence in general population. |
| HORAK 2007[707] | Prevalence in general population. Looks at the wrong risk factors (not those specified in our protocol). |

| Reference | Reason for exclusion |
|---|---|
| HORWOOD 1985[711] | Meets all inclusion criteria for prognostic study in children, except wrong follow-up time: 6 years. |
| HU 1997[715] | Prevalence in general population. Looks at the wrong risk factors (not those specified in our protocol). |
| HU 1997A[714] | Wrong definition of Phys Dx – no objective test. |
| HUBLET 2006[718] | Prevalence in general population. |
| HUNGER 2010[720] | Wrong definition of Phys Dx – no objective test. |
| ILLI 2001[733] | Wrong definition of Phys Dx – no objective test. |
| ILLI 2001A[732] | Prevalence in general population. |
| ILLI 2004[734] | Wrong definition of Phys Dx – no objective test. |
| ILLI 2006[735] | Wrong definition of Phys Dx – no objective test. |
| INKLEY 1967[738] | Prevalence in general population. |
| IRWIN 1990[739] | Gives the prevalence of asthma in people with cough, not the prevalence of cough in people who do not have asthma. |
| ISLAM 2007[742] | Wrong definition of Phys Dx – no objective test. |
| IVERSEN 2005[743] | Wrong definition of Phys Dx – no objective test. |
| JACKSON 2008[747] | Wrong definition of Phys Dx – no objective test. |
| JACOBS 2012[748] | Wrong definition of Phys Dx – no objective test. |
| JAMES 2010[753] | Wrong definition of Phys Dx – no objective test. |
| JAMES 2013[754] | Prevalence in general population. |
| JAMROZIK 2009[756] | Wrong definition of Phys Dx – no objective test. |
| JANSON 2001[760] | Wrong definition of Phys Dx – no objective test. |
| JANSON 2001A [761] | Wrong definition of Phys Dx – no objective test. |
| JARTTI 2008[766] | Wrong definition of Phys Dx – |

| Reference | Reason for exclusion |
|---|---|
| | no objective test. |
| JARVIS 1994[769] | Prevalence in general population. |
| JARVIS 1996[767] | Wrong definition of Phys Dx – no objective test. |
| JARVIS 2002[768] | Wrong definition of Phys Dx – no objective test. |
| JEFFS 2000[771] | Unclear Phsy Dx – but seems like ISAAC questionnaire. |
| JENKINS 1994A[774] | Wrong definition of Phys Dx – no objective test. |
| JENKINS 2006[773] | Wrong definition of Phys Dx – no objective test. |
| JOHNSON 2013[780] | General population and no subgroup analysis |
| JOHNSTON 1998[781] | Risk factors for other respiratory problems, not asthma. Prevalence of people with asthma with no comparison group. |
| JONES 2008[785] | Results separated for different ethnic groups. Mixed ages of children (<5 and >5 years with no subgroup analysis). Wrong definition of Phys Dx – no objective test. |
| JOSEPH 1996[788] | Wrong definition of Phys Dx – no objective test. |
| JOSEPH 1999[789] | Reference standard does not match protocol (self-reported physician Dx of asthma – no objective test). |
| JOSEPH-BOWEN 2004[791] | Reference standard does not match protocol; physician diagnosis + symptoms of wheeze in last 12 months + asthma meds in last 12 months (no objective test) |
| JUHN 2005[792] | Looks at the wrong risk factors (not those specified in our protocol). Unclear percentage who had objective test with the Phys Dx. |
| JUNG 2012[795] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence in general population. |
| JUNG 2012A[794] | Predictors of wheeze, not asthma. |
| JUST 2010[809] | Predictors of wheeze, not |

| Reference | Reason for exclusion |
|---|---|
| | asthma. |
| JUST 2013[810] | Wrong outcome: predictors of different types of wheeze. |
| KABESCH 2004[811] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence in general population. |
| KABIR 2009[812] | Wrong definition of Phys Dx – no objective test. |
| KABLE 2001[813] | Prevalence and sens/spec in general population. |
| KAGEN 2014[814] | Conference abstract |
| KAPPELLE 2012[820] | Wrong definition of Phys Dx – no objective test. |
| KARAKOC 2002[825] | Prevalence in general population, and looks at wrong risk factors (not those specified in our protocol). |
| KAUFFMANN 1997[830] | Wrong definition of Phys Dx – no objective test. |
| KAUFFMANN 2011[831] | Epidemiology. |
| KAUGARS 2008[833] | Looks at wrong risk factors (not those specified in our protocol). |
| KEALL 2012[837] | Prevalence in general population. |
| KEARNEY 1998[838] | Wrong definition of Phys Dx – no objective test. |
| KEIL 1996[841] | General population and no subgroup analysis |
| KEIL 2006[840] | Review – used as a source of references |
| KELLY 1987[842] | Unclear Phys Dx. Case-control study. |
| KELLY 1995[843] | Wrong definition of Phys Dx – no objective test. |
| KELLY 1996[844] | Wrong definition of Phys Dx – no objective test. |
| KERCSMAR 2008[849] | Conference summary. |
| KERKHOF 2009[851] | Wrong definition of Phys Dx – no objective test. |
| KHARITONOV 1996[860] | Asthma only – no comparison group. Correct Phys Dx with objective test. |
| KHOSHOO 2009[863] | Meets all inclusion criteria for prevalence study, except |

| Reference | Reason for exclusion |
|---|---|
| | sample size N<200. |
| KIEFTEDE 2012[864] | Looks at wrong risk factors. Prevalence in general population. |
| KING 2004[877] | Predictors of lung function, not asthma. Does not give prevalence in asthma pts. |
| KISS 2003[878] | Symptoms as predictors of angina, not asthma! Unclear asthma Dx. |
| KLAASSEN 2012[884] | Does not give prevalence of symptoms, or predictors, or ability to diagnose. |
| KLINNERT 2001[889] | Wrong definition of Phys Dx – no objective test. |
| KLINNERT 2008[890] | General population and no subgroup analysis, and looks at wrong risk factors (not those specified in out protocol). |
| KLJAKOVIC 1991[891] | General population and no subgroup analysis |
| KNEYBER 2000[892] | Does not give symptoms in asthma, but bronchiolitis and control group. |
| KOLLER 1997[903] | Age < 1 year |
| KOLNAAR 1995[904] | Reference standard does not match protocol - comparison of histamine test to presence of asthma symptoms (not to physician Dx) |
| KOPONEN 2012[911] | Wrong definition of Phys Dx – no objective test. |
| KOSHY 2010[913] | General population and no subgroup analysis |
| KOZYRSKYJ 2003[926] | Wrong definition of Phys Dx – no details given or mention of objective test. |
| KOZYRSKYJ 2004[927] | Wrong definition of Phys Dx – no objective test. |
| KOZYRSKYJ 2009[925] | Wrong definition of Phys Dx – no objective test. |
| KUEHNI 2000[931] | Wrong definition of Phys Dx – no objective test. |
| KUEHNI 2001[932] | Prevalence of symptoms in people with asthma only, no comparison group. |
| KUEHR 1995[934] | Wrong comparison group: |

| Reference | Reason for exclusion |
|---|---|
| | asthma vs. non-asthma (not other respiratory symptoms). |
| KUHNI 1995[936] | Does not mention asthma definition of Dx. |
| KUMAR 2008[941] | General population and no subgroup analysis |
| KURUKULAARATCHY 2002[946] | Gives prevalence data in people with asthma but no other respiratory comparison group. Prognostic data not used as wrong follow-up time: baseline (birth) to 10 years later (does not match our protocol criteria). |
| KURUKULAARATCHY 2003[948] | Risk of wheeze not asthma (older children). |
| KURUKULAARATCHY 2003A[950] | Asthma only - no comparison group. |
| KURUKULAARATCHY 2004[945] | Wrong population: wheeze not asthma (older children). |
| KURUKULAARATCHY 2004A[949] | General population and no subgroup analysis |
| KURUKULAARATCHY 2005[951] | General population and no subgroup analysis; looks at wrong risk factors (not those in our protocol). |
| KURUKULAARATCHY 2005A[947] | Prevalence and risk factors for atopy, not asthma. |
| LABRUZZO 2007[956] | Review. |
| LAI 2009[960] | General population and no subgroup analysis |
| LANGE 2010[964] | General population and no subgroup analysis |
| LAU 2000[972] | General population and no subgroup analysis |
| LAU 2002[974] | Prevalence in wheezers (young children) but no comparison group. |
| LAU 2003[973] | Predictors of impaired lung function not asthma. |
| LAU 2005[971] | Wrong definition of Phys Dx – no objective test. |
| LAUBEREAU 2002[975] | General population and no subgroup analysis |
| LEERMAKERS 2013[986] | General population and no subgroup analysis |
| LEONARDI 2011[993] | Wrong definition of Phys Dx – |

| Reference | Reason for exclusion |
|---|---|
| | no objective test. |
| LEONE 2012[994] | Wrong definition of Phys Dx – no objective test. |
| LESOUEF 1995[980] | General population and no subgroup analysis |
| LEUNG 1994[997] | Wrong definition of Phys Dx – no objective test. |
| LEVESQUE 2004[1000] | Wrong definition of Phys Dx – no objective test. |
| LEWIS 1995[1004] | Predictors of wheeze not asthma (in young people). |
| LEWIS 1996[1003] | General population and no subgroup analysis |
| LI 2006B[1010] | Wrong definition of Phys Dx – no objective test. |
| LIEM 2007[1013] | RFs for transient tachypnea and wheeze, not asthma. |
| LINEHAN 2007[1022] | General population and no subgroup analysis. |
| LINEHAN 2009[1021] | Prevalence in people with respiratory symptoms, not asthma. |
| LINEHAN 2012[1020] | General population and no subgroup analysis. |
| LOERBROKS 2012[1036] | Prevalence in general population but not in asthma subgroup. |
| LUYT 1993[1053] | General population or asthma subgroup (no comparison group). |
| LUYT 1994[1052] | Wrong definition of Phys Dx for children up to 5 years old: no objective test, just symptoms ascertained by questionnaire. |
| LUYT 1995[1051] | General population or asthma subgroup (no comparison group). Looks at wrong risk factors (not those specified in our protocol). |
| MAAS 2009[1054] | Does not answerthe question. Effect of allergen-reduction interventions on the prevention of asthma. |
| MAGDALIJNS 2011[1059] | General population and no subgroup analysis |
| MAHER 2004[1063] | Cannot calculate sensitivity and specificity |
| MAITRA 2004[1066] | General population and no |

| Reference | Reason for exclusion |
|---|---|
| | subgroup analysis |
| MALLOL 2010[1074] | Percentage of wheezers who had asthma, rather than % of asthma who had wheeze. |
| MANDHANE 2005[1082] | RFs for wheeze, not asthma. |
| MANFREDA 2001[1083] | Wrong definition of Phys Dx – no objective test. |
| MANNING 2007[1084] | Conference abstract. |
| MARBURY 1996[1088] | General population and no subgroup analysis |
| MAROSSY 2007[1091] | Wrong definition of Phys Dx – no objective test. |
| MARTINDALE 2005[1092] | General population and no subgroup analysis |
| MARTINEZ 1995[1093] | General population and no subgroup analysis |
| MARTINEZ 2006[1094] | General population and no subgroup analysis |
| MATHESON 2006[1099] | Looks at the wrong risk factors (not those specified in our protocol). |
| MATRICARDI 2008[1101] | Predictors of wheeze not asthma (in young people). |
| MAZIAK 2002[1109] | Wrong definition of Phys Dx – no objective test. |
| MAZIAK 2004[1110] | Wrong definition of Phys Dx – no objective test. |
| MCCONNELL 1999[1113] | Wrong definition of Phys Dx – no objective test. |
| MCCONNELL 2002[1114] | Wrong definition of Phys Dx – no objective test. |
| MCHEDLISHVILI 2013[1120] | Conference abstract |
| MCKEEVER 2002[1121] | Unclear age of children and follow-up time. |
| MICHEL 2006[1141] | Dx of wheeze in older children (not asthma). |
| MIDODZI 2010[1143] | Wrong definition of Phys Dx for children up to 5 years old: no objective test, just symptoms ascertained by questionnaire. |
| MIEDINGER 2007[1146] | Good definition of Phys Dx, but gives sens/spec in general population (not suspected asthma), and prevalence in |

| Reference | Reason for exclusion |
|---|---|
| | asthma pts only (no comparison group). |
| MILAM 2008[1148] | No comparison group: wheeze only. |
| MILLSTEIN 2004[1154] | Wrong definition of Phys Dx – no objective test. Wrong definition of Phys Dx – no objective test. |
| MITCHELL 1989[1162] | General population and no subgroup analysis. |
| MITCHELL 1994[1160] | Wrong definition of Phys Dx – no objective test. |
| MITCHELL 1997[1164] | Methods paper – not study results. |
| MITCHELL 2009[1163] | Predictors of wheeze, not asthma (older children) |
| MOHANGOO 2010[1171] | Good definition of Phys Dx, but gives sensitivity/specificity in general population (not suspected asthma), and prevalence in general population (not people with asthma). |
| MOMAS 1998[1172] | Wrong definition of Phys Dx – no objective test. |
| MOMMERS 2005[1173] | Wrong comparison group - - prevalence in asthma vs. controls (not vs. other respiratory diseases), and looks at the wrong risk factors (not those specified in our protocol). |
| MORASS 2008[1178] | General population and no subgroup analysis; looks at the wrong risk factors (not those specified in our protocol). |
| MORGAN 2005[1179] | Literature review. |
| MUSK 2011[1197] | Wrong definition of Phys Dx – no objective test. |
| MVULA 2005[1201] | General population and no subgroup analysis |
| NAGEL 2009A[1205] | Looks at the wrong risk factors (not those specified in our protocol). |
| NAGEL 2010[1207] | Looks at the wrong risk factors (not those specified in our protocol). Prevalence of asthma in general population |

| Reference | Reason for exclusion |
|---|---|
| NAGEL 2012[1206] | Wrong definition of Phys Dx – no objective test. |
| NANKANI 1990[1208] | Wrong definition of Phys Dx – no objective test. |
| NEJJARI 1994[1220] | Case-control study: asthma vs. healthy controls (not other respiratory diseases). |
| NEUMAN 2012[1222] | Wrong definition of Phys Dx – no objective test. |
| NEVILLE 1992[1224] | Wrong definition of Phys Dx – no objective test. |
| NEVILLE 2001[1225] | Prevalence in asthma pts only (no comparison group). |
| NGMANKWONG 2001[1227] | General population and no subgroup analysis |
| NGMANKWONG 2002[1226] | Wrong definition of Phys Dx – no objective test. |
| NICOLAI 2003[1234] | General population and no subgroup analysis |
| NINAN 1993[1248] | Prevalence data only given in the symptomatic group who are BHR+ (ie people with asthma), not in any comparison group. |
| NINAN 1995[1247] | Reference standard does not match protocol – Dx made on the basis of symptoms |
| NWARU 2013[1263] | General population and no subgroup analysis; wrong risk factors (not those specified in the protocol). |
| OBERLE 2003[1266] | Wrong definition of Phys Dx – no objective test. |
| ODDY 1999[1269] | Wrong definition of Phys Dx – no objective test. |
| ODDY 2000[1267] | Wrong definition of Phys Dx – no objective test. |
| ODDY 2002[1268] | Wrong definition of Phys Dx – no objective test. |
| ODDY 2002A[1270] | General population and no subgroup analysis |
| ODDY 2004[1271] | Wrong definition of Phys Dx – no objective test. |
| OSMAN 2007[1288] | Wrong definition of Phys Dx – no objective test. |
| PALMER 2004[1299] | Wrong definition of Phys Dx – no objective test. |
| PANICO 2007[1302] | General population and no |

| Reference | Reason for exclusion |
|---|---|
| | subgroup analysis |
| PARARAJASINGAM 1992[1308] | General population and no subgroup analysis |
| PARK 1986[1311] | Wrong definition of Phys Dx – no objective test. |
| PATERSON 1997[1318] | General population and no subgroup analysis |
| PATTEMORE 1990[1320] | Reference standard does not match protocol (asthma diagnosis by previous report of a diagnosis but no objective test) |
| PEARLMAN 2005[1322] | Wrong comparison group: people with asthma on Tx vs. Tx-naiive people with asthma. |
| PEAT 1991A[1323] | Predictors of wheeze, not asthma (older children). |
| PEAT 1993[1326] | Good Phys Dx definition, but looks at wrong risk factors for asthma (not in our protocol). |
| PEAT 1994[1327] | Good Phys Dx definition, but only gives prevalence in General population and no subgroup analysis. |
| PERSKY 1998[1340] | Asthma and no comparison group. |
| PERZANOWSKI 2008A[1342] | General population and no subgroup analysis |
| PETERS 1999[1347] | Wrong definition of Phys Dx – no objective test. |
| PINTO 2010[1366] | General population and no subgroup analysis |
| PIZZICHINI 2000[1367] | Wrong definition of Phys Dx – no objective test. |
| PLESSMULLOLI 2000[1371] | General population and no subgroup analysis |
| PLESSMULLOLI 2001[1372] | General population and no subgroup analysis |
| PONSONBY 2000[1376] | General population - gives prevalence of symptoms in asthma vs. no asthma (not other respiratory diseases). |
| PONSONBY 2004[1378] | General population and no subgroup analysis |
| PONSONBY 2008[1379] | General population and no subgroup analysis |
| POWELL 1995[1387] | Wrong definition of Phys Dx – no objective test. |

| Reference | Reason for exclusion |
|---|---|
| POWELL 1996[1388] | Wrong definition of Phys Dx – no objective test. |
| POWELL 1999[1386] | General population and no subgroup analysis |
| POWER 1995[1391] | Wrong definition of Phys Dx – no objective test. |
| PRABHU 2010[1394] | Prevalence in general population and asthma, but no comparison group. |
| PUJADESRODRIGUEZ 2009[1413] | General population and no subgroup analysis |
| PUJADESRODRIGUEZ 2009A[1414] | Wrong definition of Phys Dx – no objective test. |
| RADON 2002[1421] | Wrong definition of Phys Dx – no objective test. |
| RAHERISON 2006[1424] | Prevalence in asthma, but no comparison group. |
| RASMUSSEN 2002[1435] | Wrong definition of Phys Dx – no objective test. |
| RAZA 2012[1438] | Wrong definition of Phys Dx – no objective test. |
| REDLINE 2003[1442] | Cannot calculate sensitivity and specificity |
| REGNIER 2013[1444] | Looks at the wrong risk factors (not those specified in our protocol). |
| REMES 2001[1447] | General population and no subgroup analysis; and looks at the wrong risk factors (not those specified in our protocol). |
| RENNIE 2004[1449] | Prevalence in asthma subgroup, but no comparison group. |
| RIETVELD 1996[1460] | Wrong population for Dx accuracy – asthma vs. controls rather than suspected asthma. |
| RIETVELD 1998[1461] | Wrong definition of Phys Dx – no objective test. |
| RIZWAN 2004[1465] | General population and no subgroup analysis |
| ROBINSON 2012A[1467] | Correct definition of Phys Dx, but looks at the wrong risk factors (not those specified in our protocol). |
| RODRIGO 2013[1469] | Treatment study |
| RODUIT 2009[1471] | General population and no |

| Reference | Reason for exclusion |
|---|---|
| | subgroup analysis |
| RONA 1995[1476] | General population and no subgroup analysis |
| ROORDA 2001[1477] | Prevalence of symptoms in suspected asthma, but not asthma vs. other respiratory diseases. |
| ROSIER 1994[1483] | Does not answer the question. Gives data on prevalence of symptoms in patients with asthma vs. patients without asthma. Divides data into severity categories and measurs of function within each category. |
| SALAM 2004[1501] | Looks at the wrong risk factors (not those specified in our protocol). |
| SALOME 1987[1503] | Wrong definition of Phys Dx – no objective test. |
| SAVENIJE 2011[1519] | Wrong definition of Phys Dx – no objective test. |
| SCARLETT 1995[1520] | General population and no subgroup analysis |
| SCHACHTER 2001[1523] | Looks at the wrong risk factors (not those specified in our protocol). |
| SCHACHTER 2003[1522] | General population and no subgroup analysis |
| SCHACHTER 1984[1521] | Wrong definition of Phys Dx – no objective test. |
| SCHAPER 2010[1524] | Wrong definition of Phys Dx – no objective test. |
| SCHERNHAMMER 2008[1528] | Wrong definition of Phys Dx – no objective test. |
| SCHOLTENS 2009[1539] | General population and no subgroup analysis |
| SCHOLTENS 2009A[1541] | General population and no subgroup analysis |
| SCHOLTENS 2010[1540] | General population and no subgroup analysis |
| SCHONBERGER 2004[1542] | Meets all inclusion criteria for prognostic study, but wrong follow-up time: >5 years. Children with wheeze followed for development of asthma in adolescence. |
| SCHUMPERT 2006[1544] | Wrong definition of Phys Dx – no objective test. |

| Reference | Reason for exclusion |
|---|---|
| SCOTT 2010[1550] | Wrong definition of Phys Dx – no objective test. |
| SEARS 1996[1554] | Prevalence in General population and no subgroup analysis. Looks at the wrong risk factors (not those specified in our protocol). |
| SENNHAUSER 1995[1560] | Wrong definition of Phys Dx – no objective test. |
| SENTHILSELVAN 1993[1561] | Wrong definition of Phys Dx – no objective test. |
| SHAHEEN 1998[1567] | General population and no subgroup analysis |
| SHAHEEN 1999[1565] | General population and no subgroup analysis |
| SHAHEEN 2005[1563] | General population and no subgroup analysis |
| SHAHEEN 2000[1566] | General population and no subgroup analysis |
| SHAHEEN 2002[1564] | Prevalence of wheeze in future wheezers vs. non-wheezers (wrong comparison group). |
| SHANKARDASS 2009[1569] | General population and no subgroup analysis |
| SHAVIT 2007[1573] | Wrong definition of Phys Dx – no objective test. |
| SHERRIFF 2009[1575] | General population and no subgroup analysis |
| SHIN 2010[1581] | Good definition of Phys Dx – uses objective test. BUT wrong comparison group: asthma vs. healthy controls, not other respiratory symptoms. |
| SHREWSBURY 2000[1588] | Meta-analysis of Tx studies – shows symptoms in asthma only (no comparison group). |
| SIBBALD 1992[1589] | General population and no subgroup analysis |
| SILVER 1998[1593] | Wrong definition of Phys Dx – no objective test. |
| SILVERS 2009[1594] | General population and no subgroup analysis; and looks at the wrong risk factors (not those specified in our protocol). |
| SILVERS 2012[1595] | Looks at the wrong risk factors (not those specified in |

| Reference | Reason for exclusion |
|---|---|
| | our protocol). |
| SIMPSON 2010[1607] | Prevalence in General population and no subgroup analysis. Looks at the wrong risk factors (not those specified in our protocol). |
| SIN 2002[1611] | Wrong definition of Phys Dx – no objective test. |
| SISTEK 2001A[1617] | Wrong definition of Phys Dx – no objective test. |
| SISTEK 2006[1618] | Reference standard does not match protocol – asthma Dx based on questionnaire responses to doctor diagnosed asthma and attack in the last 12 months (no mention of objective test) |
| SMIT 2009[1626] | Does not give prevalence of symptoms. |
| SNIJDERS 2007[1634] | Looks at the wrong risk factors (not those specified in our protocol). |
| SOCKRIDER 2001[1636] | Wrong definition of Phys Dx – no objective test. |
| SOLOMON 2003[1637] | General population and no subgroup analysis |
| SONNENSCHEIN 2012[1641] | Looks at the wrong risk factors (not those specified in our protocol). |
| SONNENSCHEIN VAN DER VOORT 2012[1640] | General population and no subgroup analysis |
| SORIANO 2003[1647] | All asthma pts – no comparison group; does not give prevalence of symptoms. |
| SOTIR 2006[1648] | Prevalence of asthma and wheeze in RTI pts, not symptoms in asthma. |
| SOTORAMIREZ 2013[1649] | Wrong definition of Phys Dx – no objective test. |
| SPEEVANDERWEKKE 1998[1656] | General population and no subgroup analysis |
| SPYCHER 2008[1664] | General population and no subgroup analysis |
| SPYCHER 2009[1666] | General population and no subgroup analysis |
| SPYCHER 2012[1665] | Wrong definition of Phys Dx – no objective test. |
| STERN 2008[1677] | Wrong definition of Phys Dx – no objective test. |

| Reference | Reason for exclusion |
|---|---|
| STINGONE 2008[1681] | Asthma and no comparison group. |
| STINGONE 2011[1682] | Asthma and no comparison group. |
| STODDARD 1995[1683] | General population and no subgroup analysis |
| STRACHAN 1985[1687] | General population and no subgroup analysis |
| STRACHAN 1988A[1688] | Wrong definition of Phys Dx – no objective test. |
| STRACHAN 1994[1689] | Wrong definition of Phys Dx – no objective test. |
| STRACHAN 1996[1691] | Unclear definition of diagnosis – seems like self-reported. |
| STRACHAN 1996B[1690] | Wrong definition of Phys Dx – no objective test. |
| STRUNK 2002[1693] | RFs for night-awakening due to asthma, not for asthma. Prevalence of symptoms in people with asthma but no comparison group. |
| SUN 2011[1700] | General population and no subgroup analysis. Looks at the wrong risk factors (not those specified in our protocol). |
| SUN 2013[1699] | General population and no subgroup analysis. Looks at the wrong risk factors (not those specified in our protocol). |
| SUNYER 2004[1702] | Wrong outcomes: fraction of asthma caused by atopy. |
| SUTHERLAND 2007[1704] | Wrong definition of Phys Dx – no objective test. |
| TAGIYEVA 2010[1714] | General population and no subgroup analysis |
| TAI 2009[1715] | General population and no subgroup analysis |
| TAKENOUE 2012[1719] | Meta-analysis of the influence of NO in the Dx of asthma. |
| TAN 2013[1724] | Wrong population: prevalence in obstructive airways combined, not asthma separated. |
| TAUSSIG 2003[1734] | Review of a study (TUSCON study). |
| TAVERAS 2006[1735] | Correct definition of Phys Dx, but looks at the wrong risk |

| Reference | Reason for exclusion |
|---|---|
| | factors (not those specified in our protocol). |
| TAYLOR 1983[1736] | General population and no subgroup analysis |
| TAYLOR 2005[1737] | Wrong definition of Phys Dx – no objective test. |
| THOMAS 2010[1749] | Wrong definition of Phys Dx – no objective test. |
| THOMSON 2012[1751] | General population and no subgroup analysis |
| THORNE 2005[1753] | Looks at the wrong risk factors (not those specified in our protocol). Does not give prevalence in asthma vs. other respiratory diseases. |
| TIMONEN 2002[1758] | Wrong definition of Phys Dx – no objective test (older children). |
| TO 2004[1762] | Wrong definition of Phys Dx – no objective test. |
| TO 2009[1760] | Looks at the wrong risk factors (not those specified in our protocol). Does not give prevalence in asthma vs. other respiratory diseases, only in general population. |
| TO 2012A[1761] | Wrong definition of Phys Dx – no objective test. |
| TOLLERUD 1991[1769] | Wrong definition of Phys Dx – no objective test. |
| TOLPPANEN 2013[1770] | General population and no subgroup analysis |
| TOOP 1985[1774] | Wrong definition of Phys Dx – no objective test. |
| TOREN 1993[1775] | Literature review. |
| TORRENT 2007[1777] | Wrong definition of Phys Dx – no objective test. |
| TROMP 2012[1787] | Looks at the wrong risk factors (not those specified in our protocol). |
| TSE 1993[1789] | Wrong definition of Phys Dx – no objective test. |
| TURBYVILLE 2011[1799] | Wrong definition of Phys Dx – no objective test. |
| TURCOTTE 2003[1800] | Prevalence and sens/spec in general population of athletes vs. controls (not suspected asthma, or asthma vs. other |

| Reference | Reason for exclusion |
|---|---|
| | respiratory diseases). |
| TURNER 2008[1805] | Wrong symptoms: rattles, purrs, and whistles. |
| TURNER 2010A[1806] | General population and no subgroup analysis |
| TURNERWARWICK 1988[1807] | Prevalence in people with asthma, but no comparison group. |
| VALERY 2001[1815] | Not UK-relevant population. |
| VALERY 2004[1816] | Older children: looks at the wrong risk factors (not those specified in our protocol). Younger children: no comparison group (just prevalence in asthma) |
| VANBEVER 1999[1820] | Wrong population: croup and not compared with people without asthma. |
| VANDERGUGTEN 2012[1822] | General population and no subgroup analysis |
| VANDERMARK 2014[1823] | Longitunial study – symptoms occurring aged 1-5 years as a predictor for asthma at 6 years |
| VANDERVALK 2012B[1830] | General population and no subgroup analysis |
| VANDERVALK 2013[1831] | General population and no subgroup analysis |
| VANDEVEN 2006[1821] | General population and no subgroup analysis |
| VANGENT 2007[1834] | Wrong definition of Phys Dx – no objective test (older children). |
| VANGYSEL 2007[1835] | General population and no subgroup analysis |
| VANMAANEN 2013[1836] | Wrong definition of Phys Dx – no objective test. |
| VANNIMWEGEN 2011[1837] | General population and no subgroup analysis |
| VANSCHAYCK 1991[1840] | Meets all inclusion criteria for prevalence study except sample size is N<200. |
| VANSCHAYCK 2000[1839] | Does not give the specific symptoms in the asthma subgroup. |
| VANZAANE 2007[1841] | Validation of a questionnaire; but does not give prevalence of symptoms in subgroup with |

| Reference | Reason for exclusion |
|---|---|
| | asthma. |
| VARGAS 2007[1846] | Only gives data for the asthma group (no comparison group). |
| VEDAL 1998[1850] | Wrong definition of Phys Dx – no objective test. |
| VELLINGA 2005[1851] | Wrong definition of Phys Dx – no objective test. |
| VENABLES 1993[1853] | Sens/spec in general population; symptoms in asthma vs. control (wrong comparison group). |
| VENN 2000[1854] | General population and no subgroup analysis; Looks at the wrong risk factors: (not those specified in our protocol). |
| VENN 2001[1855] | Risk factors for wheeze, not asthma (in mostly older children). |
| VIALDUPUY 2011[1861] | Wrong definition of Phys Dx – no objective test. |
| VOGELMEIER 2011[1870] | Post-Tx symptoms. |
| VOLKMER 1995[1872] | General population and no subgroup analysis |
| VONEHRENSTEIN 2000[1875] | General population and no subgroup analysis |
| VONMUTIUS 1999[1876] | Looks at the wrong risk factors: (not those specified in our protocol). |
| VUGT 2012[1881] | Gives prevalence in people with obstruction, but does not subgroup into asthma or COPD etc. |
| WAKE 2013[1883] | General population and no subgroup analysis |
| WANG 2008[1890] | Wrong definition of Phys Dx – no objective test. |
| WANG 2008A[1888] | General population and no subgroup analysis |
| WANG 2010[1889] | Wrong definition of Phys Dx – no objective test. |
| WASSALL 2005[1897] | Wrong definition of Phys Dx – no objective test. |
| WATELET 2010[1898] | Looks at the wrong risk factors: chronic cough (for the development of concomitant asthma). |

| Reference | Reason for exclusion |
|---|---|
| WEINMAYR 2007[1903] | Wrong definition of Phys Dx – no objective test. |
| WEINMAYR 2013[1902] | Prevalence in General population and no subgroup analysis. |
| WHITROW 2010[1910] | Wrong definition of Phys Dx – no objective test. |
| WICKENS 2005[1911] | Wrong definition of Phys Dx – no objective test. |
| WICKENS 2008[1912] | Prevalence in General population and no subgroup analysis. |
| WIJGA 2003[1916] | Prevalence in general population and no subgroup analysis. Prevalence of asthma in wheezers, not prevalence of wheeze in people with asthma. |
| WILLERS 2007[1920] | General population and no subgroup analysis; and looks at the wrong risk factors: (not those specified in our protocol). |
| WILLERS 2008[1921] | Wrong definition of Phys Dx – no objective test. |
| WITHERS 1998[1926] | Wrong definition of Phys Dx – no objective test. |
| WJST 1994[1929] | Wrong definition of Phys Dx – no objective test. |
| WJST 1998[1931] | Wrong definition of Phys Dx – no objective test. |
| WJST 2001[1930] | General population and no subgroup analysis; and looks at the wrong risk factors: (not those specified in our protocol). |
| WOLF 2003A[1933] | Wrong definition of Phys Dx – no objective test. |
| WOODS 2000[1940] | General population and no subgroup analysis; and looks at the wrong risk factors: (not those specified in our protocol). |
| WOODS 2001[1941] | General population and no subgroup analysis |
| WOODS 2001A[1939] | Wrong outcomes: predictors of breathlessness or food allergy intolerance in adults, not asthma. |
| WOODS 2002[1942] | General population and food |

| Reference | Reason for exclusion |
|---|---|
| | allergies, no asthma subgroup analysis |
| WRIGHT 2001[1944] | General population and no subgroup analysis |
| WRIGHT 2006[1945] | Wrong definition of Phys Dx – no objective test. |
| WUTHRICH 1995[1947] | General population and no subgroup analysis |
| YEATTS 2000[1957] | Wrong definition of Phys Dx – no objective test. |
| YEATTS 2000A[1956] | Prevalence in subgroup with asthma, but no comparison group. |
| YEATTS 2003[1958] | General population and no subgroup analysis and looks at the wrong risk factors: (not those specified in our protocol). |
| YUNGINGER 1992[1967] | Dx sens/sepc data: wrong population – general population.<br>Prevalence data: wrong compariuson group – asthma vs. probable asthma or single episode wheezers. |
| ZHOU 2013[1978] | General population and no subgroup analysis |
| ZOLLNER 2005[1990] | General population and no subgroup analysis |
| ZUIDGEEST 2008[1991] | Wrong definition of Phys Dx – use of asthma medication to indicate asthma. |
| ZUIDGEEST 2009[1992] | Looks at the wrong risk factors: (not those specified in our protocol). Prevalence in asthma but no comparison group. |
| ZWAR 2011[1994] | Correct Phys Dx but does not give prevalence of symptoms in the asthma vs. COPD groups and does not look at the correct RFs (not those specified in our protocol). |

# K.2 Diagnosis: History of atopic disorders

**Table 208: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALBUQUERQUE2013[34] | Conference abstract |
| ALVAREZPUEBLA 2002[39] | Index test does not match protocol – total |

| Reference | Reason for exclusion |
|---|---|
| | asthma symptoms questionnaire, not history of atopic disorders |
| ANDERSON 2009[48] | Index test does not match protocol – history of atopic disorders not reported |
| BACKER 1991[87] | Reference standard does not match protocol – Dx made on the basis of questionnaire |
| BACKER 2014[91] | Index test and reference standard do not match protocol – sn/sp of FeNO to predict positive mannitol in suspected asthma (not physician diagnosis and objective test) |
| BEAUSOLEIL 2007[134] | Review article |
| BEEH 2000[137] | No relevant outcomes – prevalence in allergic vs non-allergic patients |
| BEEH 2001[138] | Index test does not match protocol – atopy defined as family history or positive SPT (cannot calculate the sn/sp of family history alone) |
| BEEH 2004[139] | Index test does not match protocol – total symptom score with no breakdown of atopy history alone |
| BENGASHIR 2004[148] | Population does not match protocol – all patients positive for atopic dermatitis (all positive for index test) |
| BOCCACCINO 2007[181] | Population does not match protocol - patients with respiratory symptoms picked up using a screening questionnaire |
| BONNER 1984[188] | Review article |
| BREGAS 2000[220] | Not in English |
| BURR 1975[249] | No relevant outcomes and does not match review question – cannot calculate sn/sp of family history |
| CAFFARELLI 2005[260] | Population does not match protocol – all patients positive atopic eczema (all positive for index test) |
| CANTANI 2003[268] | Reference standard does not match protocol – no objective test |
| CARTER 2000[286] | No relevant outcomes and does not match review question - sn/sp of patients report of allergy for positive SPT in people with confirmed asthma |
| CHEN 2014[310] | Population does not match protocol – general population |
| CHRISTOFF 2013[327] | Conference abstract |
| CIRILLO 2003[341] | Population does not match protocol – general population |
| CORTESALVAREZ 2007[368] | Reference standard does not match protocol – history of atopic disorders in ≤ 3 yrs with wheezing, but no Dx of asthma made |

| Reference | Reason for exclusion |
|---|---|
| CVITANOVIC 2007[388] | Population does not match protocol – all SPT positive. |
| DEBLEY 2012[409] | Population does not match protocol – children aged 4-36 months with ≥3 episodes of physician Dx wheezing (all people with asthma according to protocol criteria) |
| DELRIO 2004[415] | Case-control study – asymptomatic and symptomatic patients. |
| DELIU 2013[419] | Conference abstract |
| DENG 2010[424] | Population does not match protocol - patients with respiratory symptoms picked up using a screening questionnaire, not presenting to GP |
| DING 2012[443] | Population does not match protocol - patients with respiratory symptoms picked up using a screening questionnaire |
| ELIZUR 2007[474] | No relevant outcomes and does not match review question – prevalence study in general population |
| ERIKSSON 1978[480] | Population does not match protocol – all asthma and/or rhinitis |
| ERIKSSON 1990[481] | Population does not match protocol – all asthma and/or rhinitis |
| EYSINK 2005[487] | Case-control study – IgE positive and IgE negative |
| FANIRAN 1998[489] | Index test does not match protocol – sn/sp of first Dx by a physician in primary healthcare |
| FARHOUDI 2005[492] | Population does not match protocol – allergic patients with asthma and/or rhinitis |
| FONSECA 2004[506] | Population does not match protocol – not suspected asthma only, population consisted of people with confirmed asthma |
| FRANK 1998[519] | Population does not match protocol – general population |
| GALVEZ 1987[543] | Reference standard objective test does not match protocol – methacholine challenge test positive defined as PC20 <25mg/ml. |
| GUILBERT 2004[614] | Population does not match protocol – all had a personal or family history of atopic disorders |
| GULSVIK 1979[616] | No relevant outcomes – prevalence of symptoms in the general population |
| GUSTAFSSON 2000[618] | Population does not match protocol – children with atopic dermatitis |
| HAFKAMPDEGROEN 2013[622] | Longitudinal prognostic study |
| HEDMAN 1998[656] | Index test does not match protocol – history of atopic disorders not reported |
| JENKINS 1996[772] | Index test does not match protocol – sn/sp of symptoms questionnaire. Reference |

| Reference | Reason for exclusion |
|---|---|
| | standard does not match protocol – Dx based on a history of wheeze in the past 12 months |
| KARAKAYA 2012[824] | No relevant outcomes – sn/sp of physician Dx of atopy with SPT as the gold standard |
| KILPELAINEN 2001B[866] | Index test does not match protocol – sn/sp of symptoms questionnaire |
| KUMAR 2010[940] | No relevant outcomes – allergy Dx in patients with asthma or allergic rhinitis |
| KUMARI 2006[942] | Case-control study – atopic and non-atopic patients |
| LOMBARDI 2008[1038] | No relevant outcomes – prevalence of asthma and allergy in general population |
| LOMBARDI 2011[1037] | No relevant outcomes – prevalence of asthma and allergy in general population |
| MILLER 2007[1153] | Population does not match protocol – general population |
| MONTNEMERY 2002[1174] | Index test does not match protocol – sn/sp of first Dx of asthma in primary healthcare |
| NANTANDA 2013[1209] | Popultation does not match protocol – includes severe asthma and >50% <12 months old. |
| NJA 2001[1252] | Case-control study. Reference standard does not match protocol – Dx made on the basis of symptoms, no objective test |
| NINAN 1995[1247] | Case-control study – asymptomatic and symptomatic patients. Reference standard does not match protocol – Dx made on the basis of symptoms |
| PEDROSA 2009[1329] | No relevant outcomes – cannot calculate sn/sp of family history |
| RIEDLER 1994[1459] | Case control study |
| RUGINA 2002[1490] | No relevant outcomes - prevalence of symptoms in nasal polyposis |
| SCHLEICH 2012[1530] | Index test does not match protocol – FeNO and symptoms |
| SMITH 2009[1632] | Population does not match protocol – all currently Dx with rhinitis or asthma |
| SNIDER 1985[1633] | Review article |
| STAIKUNIENE 2008[1672] | Case-control study - chronic rhinosinusitis vs controls |
| TIMONEN 1997[1757] | Population does not match protocol - patients with chronic respiratory symptoms picked up using a screening questionnaire |
| VALERY 2003[1817] | Case-control study. Index test does not match protocol – sn/sp of symptoms |

| Reference | Reason for exclusion |
|---|---|
| | questionnaire |
| WOO 2012[1937] | Index test does not match protocol - FeNO |
| ZARAGOZA 2014[1972] | Conference abstract |

# K.3 Diagnosis: Symptoms after exercise

**Table 209: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ANDERSON 2009[44,48] | Index test does not match protocol. |
| ANDERSON 2010A[44,46] | Conference abstract |
| ANTOLINAMERIGO 2012[54] | Conference abstract |
| BRANNAN 1998[216,216] | No relevant outcomes and does not match review question (sensitivity and specificity of mannitol challenge test to predict EIA in participants with a positive response to exercise challenge test or eucapnic hyperventilation). |
| BROZEK 2009[234,234] | Conference abstract. Index test does not match protocol (exercise challenge test) |
| CARLSEN 2000[273,274] | No relevant outcomes and does not match review question (comparing methods of exercise challenge test in people with confirmed asthma with exercise-induced bronchoconstriction) |
| CHEW 1999[312,312] | Reference standard does not match protocol (asthma Dx made on the basis of the question 'have you (your child) ever had asthma?') |
| CHINELLATO 2012[315,315] | Population does not match protocol – all people with asthma on treatment |
| DEMISSIE 1998[421,421] | Population does not match protocol (general population, not suspected asthma); index test does not match protocol (general symptom questions, not symptoms after exercise); reference standard does not match protocol (Dx by questionnaire) |
| DRYDEN 2010[457,457] | Review including 2 studies with exercise symptoms as the index test (population does not match protocol for both studies – general population of athletes, not suspected asthma) |
| FOUCARD 1984[512,513] | Reference standard does not match protocol (children who reported asthma symptoms during the last year were regarded as having asthma) |
| FUENTES 2011[531,531] | Case control study. Reference standard for Dx in the group with asthma does not match protocol (no mention of objective test) so cannot use index test vs exercise challenge test. |

| Reference | Reason for exclusion |
|---|---|
| GREEN 1997[595,595] | No relevant outcomes and does not match review question (cannot calculate sensitivity and specificity of 'symptoms in response to exercise' in the Dx of asthma). |
| HETLEVIK 2000[675,675] | Reference standard does not match protocol (current asthma Dx if affirmative response to the question 'has your child ever had asthma?' and 'does your child still have asthma?') |
| HILDEBRAND 2011[680,680] | Not in English |
| JONES 1994[782,782] | Reference standard does not match protocol (not all had objective test) |
| JOSEPH 1999[788,789] | Reference standard does not match protocol (self-reported physician Dx of asthma – no objective test). |
| KERSTEN 2009[852,852] | Index test does not match protocol – exercise challenge test not history of symptoms with exercise |
| KIVILOOG 1975[881,881] | Reference standard does not match protocol - all people with confirmed asthma and possible to calculate test vs test (sn/sp of IT in detecting positive exercise challenge) but no mention of how asthma Dx was made (no mention of objective test). |
| LAI 1997[959,959] | Reference standard does not match protocol |
| LEX 2007[1006,1007] | Index test does not match protocol – sn/sp of symptoms to detect EIB in people with asthma but includes symptoms induced by exercise and other factors such as allergy, no breakdown of those who only had symptoms to exercise |
| LOWHAGEN 1999[1042,1042] | Review article checked for references |
| LUKRAFKA 2010[1046,1046] | Reference standard does not match protocol, no objective test (asthma Dx based on affirmative answer to 'Have you ever been told by a physician that you have asthma or bronchitis?') |
| MAJAK 2013[1067,1067] | Population does not match protocol (groups with and without a history of exercise symptoms, but group without symptoms in response to exercise included patients whose asthma was in remission). |
| MANSOURNIA 2007[1087,1087] | Target condition does not match protocol - sn/sp of exercise symptoms to Dx EIB in the general population |
| NEVILLE 1992[1224,1224] | No relevant outcomes and does not match review question (prevalence of symptoms in general population) |
| PEDROSA 2009[1329,1329] | Index test does not match protocol – cannot calcultate sn/sp of index test in Dx of asthma. |

| Reference | Reason for exclusion |
|---|---|
| PONSONBY 1996[1377,1377] | Population does not match protocol – general population (including healthy asymptomatic children) not suspected asthma alone |
| RANDOLPH 1997[1431,1431] | Population does not match protocol – general population (including healthy asymptomatic children) not suspected asthma alone |
| RANDOLPH 2011A[1431,1432] | Conference abstract |
| RANDOLPH 2012[1431,1434] | Conference abstract |
| RANDOLPH 2013[1431,1433] | Conference abstract |
| REMES 2002 [1447,1448] | Population does not match protocol – general population (including healthy asymptomatic children) not suspected asthma alone |
| SEEAR 2005[1556,1556] | No relevant outcomes and does not match review question (exercise challenge test to determine the accuracy of EIA Dx) |
| SIERSTED 1996[1590,1591] | Index test does not match protocol |
| SINCLAIR 1995[1612,1612] | Index test does not match protocol – exercise challenge test not history of symptoms with exercise |
| SMEETON 2006[1625,1625] | No relevant outcomes and does not match review question (prevalence of symptoms in general population) |
| STORMS 2000[1685,1685] | Review article |
| TERBLANCHE 1990[1741,1741] | Index test does not match protocol – exercise challenge test not history of symptoms with exercise |
| TERNESTENHASSEUS 2008[1743] | No relevant outcomes and does not match review question (gives levels and changes after exercise test, cannot calculate sn/sp) |
| TSYBULKINA 2009[1794,1795] | Conference abstract |
| WEST 1996[1907,1907] | Index test and reference standard do not match protocol |
| ZIAEE 2009[1979,1979] | Conference abstract |

# K.4 Diagnosis: Symptoms after drugs

**Table 210: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| AHMETAJ 2009[25] | Not addressing review question (prevalence of aspirin-sensitive asthma using challenge test in people with confirmed asthma) |
| ALONSO 2002[38] | Not addressing review question (diagnostic accuracy of challenge test vs. physician Dx of aspirin-induced asthma) |
| AMEISEN 1985[42] | Wrong population (asthma vs. healthy |

| Reference | Reason for exclusion |
|---|---|
| | controls). Wrong study type (case control) |
| BARLES 1988[108] | Wrong population (all aspirin-sensitive asthma patients). Not Dx of asthma |
| BARRANCO 2009[113] | Not addressing review question (aspirin challenge test to diagnose aspirin-sensitive asthma in people with confirmed asthma) |
| BAVBEK 2010[131] | Conference abstract. Not addressing review question (prevalence of aspirin-sensitive asthma in people with confirmed asthma) |
| BAVBEK 2012[130] | Not addressing review question (index test as a predictor of aspirin-sensitive asthma in people with confirmed asthma, not for asthma Dx) |
| BERGES 2002[158] | Wrong population (all aspirin-sensitive asthma patients). Not Dx of asthma |
| BOTEY 1988[197] | Wrong population (all people with asthma) |
| CALADO 2011[262] | Conference abstract. Full paper (CALADO 2012) obtained |
| CALADO 2012[263] | Non-English language publication (Portuguese) |
| CARNIMEO 1981[279] | Not addressing review question (index test as a predictor of positive aspirin challenge test not for asthma Dx) |
| CASADEVALL 2000[289] | Wrong population (asthma vs. healthy controls). Wrong study type (case control) |
| CASTILLO 1986[291] | Wrong population (all asthma patients) |
| CHANG 2011[300] | Not addressing review question (diagnostic accuracy of index test as a predictor of AERD in people with confirmed asthma, not for asthma Dx) |
| CROCE 1992[379] | Wrong population (asthma vs. healthy controls). Wrong study type (case control) |
| DAHLEN 1990[390] | Not addressing review question (aspirin challenge test to diagnose aspirin-sensitive asthma in people with confirmed asthma) |
| DELANEY 1976[417] | Not addressing review question (index test as a predictor of positive aspirin challenge test not for asthma Dx) |
| GENTON 1985[555] | Wrong population (asthma or urticarial) |
| GONZALEZ 2011[587] | Wrong population (all asthma patients) |
| GRZELEWSKA 1981[604] | Not addressing review question (index test as a predictor of aspirin-sensitive asthma) |
| HONG 1989[698] | Wrong population (all asthma patients) |
| HUSSEIN 1989[725] | Not addressing review question (index test as a predictor of positive aspirin |

| Reference | Reason for exclusion |
|---|---|
| | challenge test not for asthma Dx) |
| KARAKAYA 2000[822] | No comparison with reference standard |
| MAKOWSKA 2008[1068] | Not addressing review question (aspirin challenge test to diagnose aspirin-sensitive asthma in people with confirmed asthma) |
| MASCIA 2005[1096] | Index test vs. objective test but does not give the number of patients +ve/-ve for objective test so sensitivity and specificity of IT cannot be calculated |
| MELILLO 1991[1131] | Not addressing review question (index test as a predictor of positive aspirin challenge test not for asthma Dx) |
| MILEWSKI 1998[1150] | Wrong population (asthma vs. healthy controls). Wrong study type (case control) |
| MILLER 2013[1152] | Not addressing review question (challenge test to diagnose AERD in people with asthma) |
| MIRAKIAN 2012[1157] | Wrong population (all aspirin-sensitive asthma patients). Not Dx of asthma |
| MUNOZ 2013[1192] | Wrong population (patients with aspirin-sensitive asthma) |
| NIKLAS 1973[1233] | Wrong population (all asthma patients with no history of symptoms to aspirin) |
| NIZANKOWSKA 2000[1251] | Not addressing review question (aspirin challenge test to diagnose aspirin-sensitive asthma in people with confirmed asthma) |
| RACHELEFSKY 1975[1420] | Not addressing review question (prevalence of aspirin-sensitive asthma using challenge test in people with confirmed asthma) |
| RAM 2013[1425] | Wrong outcomes (not Dx of asthma) |
| RAMIREZ 2011[1427] | Not addressing review question (reliability study of provocation test – not Dx of asthma) |
| STENIUS 1976[1675] | Not addressing review question (prevalence of aspirin-sensitive asthma using challenge test in people with confirmed asthma) |
| SUETSUGU 1981[1697] | Wrong population (all aspirin-sensitive asthma patients) |
| VAIDYANATHAN 2012[1813] | Conference abstract. Not addressing review question (index test as a predictor of positive aspirin challenge test not for asthma Dx) |
| WEBER 1979[1899] | Wrong population (all asthma patients) |

| Reference | Reason for exclusion |
|---|---|
| WISMOL 2012[1925] | Wrong population (all aspirin-sensitive asthma patients). Not Dx of asthma |
| ZAMBONINO 2013[1971] | Conference abstract. Not addressing review question (index test not used for asthma Dx) |

# K.5 Diagnosis: Occupational asthma

**Table 211: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ANEES2003[51] | Not asking if symptoms better away from work |
| ARCHAMBAULT 2001[62] | Not all patients had gold standard test |
| BALDWIN 2002[96] | Not asking if symptoms better away from work |
| BARBER 2007[107] | Survey of diagnostic approach to single case scenario, not diagnostic value of asking if symptoms better away from work |
| BERNSTEIN 1993[161] | Not all patients had gold standard test |
| BLANC 1996[179] | Not asking if symptoms better away from work |
| CAMPBELL 2007[266] | Not asking if symptoms better away from work |
| CARTIER 2003[288] | No usable data |
| COTE 1990[370] | Only includes people with positive history so cannot calculate specificity |
| COTE 1993[371] | Not asking if symptoms better away from work |
| CRESPO 2001[378] | Not asking if symptoms better away from work |
| CRUZ 2010[380] | Not asking if symptoms better away from work |
| DELLABIANCA 1996[420] | Not asking if symptoms better away from work |
| DESCATHA 2005[430] | Not asking if symptoms better away from work |
| DOSTALER 2011[449] | No gold standard for occupational asthma, only questionnaire development |
| DUCE 1988[460] | Not asking if symptoms better away from work |
| ELSHABRAWI 2011[477] | Not asking if symptoms better away from work |
| ENARSON 1988[478] | Not asking if symptoms better |

| Reference | Reason for exclusion |
|---|---|
| | away from work |
| GAUTRIN 2010[553] | Not asking if symptoms better away from work |
| GIRARD 2004[572] | Not asking if symptoms better away from work |
| GORDON 1997[588] | Not asking if symptoms better away from work |
| GRAMMER 1992[593] | Not asking if symptoms better away from work |
| GRAMMER 1998[592] | Not asking if symptoms better away from work |
| HANNU 2013[638] | Not asking if symptoms better away from work |
| HAYATI 2008[651] | Not asking if symptoms better away from work |
| HAYATI 2006[650] | Not asking if symptoms better away from work |
| HUR 2008[723] | Reference standard is for diagnosis of occupational asthma or occupational eosinophilic bronchitis |
| JARES 2012[765] | No usable data |
| KARVALA 2010[827] | Not asking if symptoms better away from work |
| KIM 1998[868] | Not occupational asthma |
| KONGERUD 1992A[909] | All participants positive for history and bronchial challenge test |
| KRAW 1999[928] | Not asking if symptoms better away from work |
| LABRECQUE 2011[955] | Not asking if symptoms better away from work |
| LEMIERE 1999[992] | Not asking if symptoms better away from work |
| LEMIERE 2011[990] | Not asking if symptoms better away from work |
| LEMIERE 2011A[991] | Not asking if symptoms better away from work |
| LIPINSKA 2011[1029] | Not asking if symptoms better away from work |
| MALO 1993[1078] | Not asking if symptoms better away from work |
| MALO 1995[1081] | Not asking if symptoms better away from work |
| MERGET 1991[1136] | Not asking if symptoms better away from work |
| MIEDINGER 2013[1144] | Not asking if symptoms better away from work |
| MIRMOHAMMADI 2010[1159] | Assesses a questionnaire but |

| Reference | Reason for exclusion |
|---|---|
| | asking if symptoms better away from work was not part of the definition of questionnaire-positive responses |
| MOORE 2009[1177] | Not asking if symptoms better away from work |
| MOORE 2010[1176] | Not asking if symptoms better away from work |
| MOSCATO 1993[1181] | Not asking if symptoms better away from work |
| MURPHY 2002[1194] | Not asking if symptoms better away from work |
| NASIR 2011[1211] | Not asking if symptoms better away from work |
| OLAGUIBEL 1989[1279] | Not asking if symptoms better away from work |
| PERRIN 1992[1337] | Not asking if symptoms better away from work |
| PHAKTHONGSUK 2007[1355] | Not assessing asking if symptoms better away from work versus gold standard |
| QUIRCE 1995[1419] | Not asking if symptoms better away from work |
| SCHLUNSSEN 2011[1531] | Not asking if symptoms better away from work |
| SCHWAIBLMAIR 1997[1545] | Not asking if symptoms better away from work |
| SHOFER 2006[1584] | Not asking if symptoms better away from work |
| SKOVSTED 2003[1621] | Not asking if symptoms better away from work |
| SMITH 1987[1627] | Not asking if symptoms better away from work |
| STENTON 1993[1676] | Not asking if symptoms better away from work |
| SUARTHANA 2010[1695] | Outcome is wheat sensitisation not asthma |
| SURANGE 2011[1703] | Single case report not diagnostic test value |
| TALINI 2002[1721] | Not asking if symptoms better away from work |
| TARLO 1991[1728] | Not asking if symptoms better away from work |
| TARLO 2000[1729] | not all participants had gold standard test |
| TARLO 2008[1730] | Not assessing asking if symptoms better away from |

| Reference | Reason for exclusion |
|---|---|
| | work versus gold standard |
| TARLO 2009[1731] | Not assessing asking if symptoms better away from work versus gold standard |
| TEE 1998[1738] | Not asking if symptoms better away from work |
| TORRESDA 2002[1778] | non-English |
| TURNER 2010[1804] | Not asking if symptoms better away from work |
| VOGELMEIER 1991[1869] | Not asking if symptoms better away from work |
| WIESLANDER 1994[1915] | Not asking if symptoms better away from work |
| WITTCZAK 2012[1927] | Not asking if symptoms better away from work |
| WHITE 2013[1909] | General population |
| HATHAWAY 2014[649] | General population |
| WALTERS 2012A[1887] | General population |
| KAYHAN 2013[836] | General population |

# K.6 Diagnosis: Spirometry

**Table 212: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| AHFMR 2002[30] | Full article not available |
| ALBERTS 1994[32,32] | Index test does not match protocol – sn/sp of FEF25-75% |
| BROUWER 2010[232,233] | Index test does not match protocol – sn/sp of PEFv and FEV1 variation for Dx of asthma |
| BUFFELS 2012[242,242] | Reference standard does not match review protocol – Dx with spirometry taken as reference. |
| CERVERI 2009[296,296] | No relevant outcomes - sn/sp of FEV1/FVC in predicting airflow obstruction with lower limit of normality as gold standard in people with confirmed asthma |
| CIPRANDI 2010[331,337] | Population does not match protocol – all people with asthma or rhinitis. Index test does not match protocol – FeNO |
| CIPRANDI 2011B[331,336] | Population does not match protocol – all Dx with allergic rhinitis and excluded if a history of asthma or referred with asthma symptoms |
| CIPRANDI 2011C[331,333] | Population does not match protocol – patients with allergic rhinitis; exclusion criteria was previous asthma Dx or presence of asthma symptoms. |
| CIPRANDI 2012[331,334] | No relevant outcomes - sn/sp of FEV1 or FVC in predicting airways obstruction with |

| Reference | Reason for exclusion |
|---|---|
| | FEF25-75% as gold standard in people with confirmed asthma |
| CIRILLO 2006[339,341] | No relevant outcomes – association between positive MCT and the ratio between FEV1 and FEF25-75% |
| CORDEIRO 2011[365,365] | No relevant outcomes – cannot calculate the sn/sp of FEV1/FVC for asthma Dx. Only gives ROC AUC for FEV1/FVC |
| COUTO 1997[373,373] | Index test does not match protocol - MCT |
| DI LORENZO 2007[436] | Case control study – study gives sn/sp values for FEV1/FVC, but this includes asymptomatic healthy control group |
| DUNDAS 2006[462,463] | Review article |
| DUPONT 2003[464,464] | Index test does not match protocol - FeNO |
| DWYER 2012[466,466] | Review article |
| EID 2000[470,470] | No relevant outcomes – sn/sp of PEF to predict abnormal FEV1 |
| FOWLER 2000[514,514] | Index test does not match protocol – MCT and correlation of FEV1 with MCT |
| FRANKLIN 2003[520,520] | Population does not match protocol – general population |
| FUKUHARA 2011[535,535] | Index test does not match protocol - FeNO |
| GALVEZ 1987A[542,543] | No relevant outcomes – correlation between FEV1 and PC20 in people with confirmed asthma |
| GERALD 2004[557,558] | Population does not match protocol – general population. Index test does not match protocol – sn/sp of procedures including symptoms questionnaire, spirometry and exercise test. |
| GILBERT 1985[569,569] | Target condition does not match protocol – sn/sp of FEV1/FVC to Dx obstruction (asthma and COPD) with reference standard of clinical and body plethysmographic data |
| GILBERT 1986[568,569] | Target condition and reference standard do not match protocol – Dx of obstuction based on history, physical examination, chest radiographs, biopsy and body plethysmographic data |
| GOEDHART 2006[578,578] | Case control type study – confirmed asthma and COPD. Reference standard does not match protocol – without objective test. |
| GRZELEWSKI 2014[606,607] | Study does not report results in such a way that it is possible to calculate sensitivity and specificity. |
| HARGREAVE 2009[641,643] | Review article |
| HEDENSTROM 1987[655,655] | Case control study – sn/sp of FEV1 in people with asthma vs healthy controls |
| HOLT 2006[692,692] | No relevant outcomes – comparing treatment plans made by physicians using |

| Reference | Reason for exclusion |
|---|---|
| | symptoms alone or with spirometry |
| HUNTER 2002[721,721] | Case control study – calculation of sn/sp in people with confirmed asthma, healthy controls and pseudoasthma, with no breakdown. |
| JERZYNSKA 2014[776,776] | Study does not report results in such a way that it is possible to calculate sensitivity and specificity. |
| KING 1998[875,876] | Case report |
| KOMAROW 2012[906,906] | Index test does not match protocol – impulse oscillometry or BDR |
| LAMBERT 2013[963,963] | Meeting abstract |
| LEBECQUE 1993[981,981] | No relevant outcomes – comparing different spirometry measures in people with confirmed asthma |
| LEHMANN 2008[988,988] | Population does not match protocol – general population |
| LIAM 2001[1011,1011] | No relevant outcomes - association between FEV1 and symptoms or BDR in people with confirmed asthma |
| LIM 2005[1016,1017] | Review article |
| LINNA 1996[1024,1026] | Population does not match protocol – all people with asthma and cannot calculate sn/sp of test vs test. |
| LIOU 2009[1028,1028] | Review article |
| LUTFI 2011[1050,1050] | Case-control study – people with confirmed asthma and healthy controls |
| MAGYAR 1998[1062,1062] | Review article |
| MELBYE 2011[1129,1129] | Population and reference standard does not match protocol – confirmed asthma, COPD and asthma+COPD. Reference standard for Dx not reported. |
| MELTZER 1989[1132,1132] | No relevant outcomes- comparison of PEF and FEV1 in people with confirmed asthma |
| MENDONCA 2011[1133,1133] | Case-control study. Asthma Dx with clinical Dx, no mention of objective test |
| MILLER 1990[1151,1151] | No relevant outcomes – comparing different spirometry measures in people with confirmed asthma with normal FEV1/FVC |
| MINAKATA 2008[1155,1155] | Population does not match protocol – presenting with diseases other than respiratory diseases |
| MIRAVITLLES 2012[1158,1158] | No relevant outcomes – cannot calculate the sn/sp of spirometry for asthma |
| MODRYKAMIEN 2009[1167,1167] | Target condition does not match protocol – sn/sp of spirometry to detect upper airway obstruction with reference standard of bronchoscopy, laryngoscopy and tomogram |
| NEVE 2012[1223,1223] | Population does not match protocol – |

| Reference | Reason for exclusion |
|---|---|
| | preschool children aged 3-5 years old with wheezing disorders |
| NICOLAI 1993[1235,1235] | Population does not match protocol – general populations. Index test does not match protocol – cold air challenge |
| NIKKHAH 2011[1245,1245] | Case control study |
| OTTER 1997[422] | Index test does not match protocol |
| OZAREKHANC 2012[1293] | Article not in English |
| PEDROSA 2009[1329,1329] | Population and index test do not match protocol – all patients normal spirometry and index test is challenge test |
| SATO 2008[1514,1515] | Index test does not match protocol - FeNO |
| SAURO 2005[1517,1517] | Populations does not match protocol – general population |
| SCHERMER 2000[1526,1526] | Review article |
| SIMON 2010[1604,1604] | All people with asthma (test vs test) – can calculate sn/sp of FEV1/FVC for detecting BDR. FEV1/FVC at 95% cut-off (best cut-off determined from ROC curve) for detecting BDR 20% increase in FEV1 |
| SLIEKER 2003A[1624,1624] | No relevant outcomes – sn/sp of PEF to predict abnormal FEV1 pre- and post-bronchodilator |
| STENTON 1993[1676,1676] | Population does not match protocol – screening shipyard workers and job applicants |
| TEETER 1999[1739,1739] | Review article |
| THIADENS 1999[1746,1747] | No relevant outcomes – comparison of ΔPEF and ΔFEV1 for BDR |
| TINKELMAN 2006[1759,1759] | Target condition does not match protocol – sn/sp of questionnaire in the Dx of COPD |
| TODA 2009[1763,1763] | Index test does not match protocol – FEV1/FVC used as reference standard for obstruction |
| WALAMIES 1998A[1884,1884] | Case control study. Index test vs comparator test in people with asthma – cut-off values do not match protocol (FEV1/FVC 89% and BDR ΔFEV1pred ≥15% |
| YARTSEV 2006A[1953,1953] | Case- control study |
| YU 2004[1965,1965] | Population does not match protocol – general populations. Reference standard does not match protocol – parental report of doctor Dx asthma. |
| YURDAKUL 2005[1968,1968] | Case-control study. Index test does not match protocol |

# K.7 Diagnosis: Bronchodilator reversibility

**Table 213: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ADAMS 2003[17] | No data on bronchodilator response in diagnosed asthma group |
| BIBI 1991[171] | Wrong cut-off for FEV1: change >6%. |
| BIRING 2001[173] | Asthma and COPD together |
| BONINI 2007[186] | Not all participants had reference standard tests |
| BORREGO 2012[191] | Not in English |
| BORREGO 2013[194] | Not bronchodilator response over/under threshold versus asthma status |
| BOSSLEY 2009[196] | Number with bronchodilator response reported but not comparison/gold standard test |
| BUSSAMRA 2005[254] | Reference standard is the same test (bronchodilator response) with American Thoracic Society specified cut-off rather than 95$^{th}$ percentile cut off |
| CARLSEN 1995[273] | Case control study |
| CHOI 2007[318] | Bronchodilator response is part of gold standard (index test = questionnaire) |
| CIPRANDI 2011[336] | Allergic rhinitis patients not asthma |
| CIPRANDI 2011A[332] | Unavailable |
| CIPRANDI 2013[338] | Bronchial reversibility as gold standard (index test = FeNO) |
| CORDEIRO 2011[365] | Bronchial reversibility as part of gold standard (index test = FeNO) |
| CORSICO 2007[367] | Bronchial reversibility as part of asthma diagnosis (not all participants had this test) |
| COTE 1990[370] | Occupational asthma |
| DELRIO 2004[415] | Not bronchial reversibility versus doctor diagnosis (all had asthma) or versus other tests for diagnosis of asthma (symptomatic versus asymptomatic on ISAAC questionnaire) |
| DIAS 2010[437] | Not in English |
| DUMAS 2010[461] | Bronchodilator test was gold standard as well as index test |
| DUNDAS 2005[462] | Case control study |
| ELLIOTT 2013 | Population does not match protocol – children less than 1 year old |
| FABBRI 2003[488] | Variability to inhaled albuterol part of gold standard as well as index test |
| FISH 1978[500] | Workshop not primary study |
| FRUCHTER 2009[530] | Not all participants had bronchodilator reversibility test; longitudinal follow up |

| | |
|---|---|
| | for later diagnosis of asthma |
| FRUCHTER 2009[529] | Correlation between PC20 and ΔFEV1 not reversibility over/under threshold versus postivie/negative methacholine challenge test |
| GALANT 2007[541] | Population does not match protocol – general population |
| GHARAGOZLOU 2004[561] | Not all participants had bronchodilator test |
| GIBSON 1995[564] | Not bronchodilator response |
| GINGO 2012[571] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| GJEVRE 2006[573] | Subjects selected for meeting ATS bronchodilator response criteria |
| GOLDSTEIN 2001[586] | Longitudinal follow up for later diagnosis of asthma |
| GRIFFITHS 1999[599] | Bronchodilator reversibility = definition of asthma (gold standard not index test) |
| HELLINCKX 1998[662] | Not PEF, PEFR or $FEV_1$ |
| HUNTER 2002[721] | Case-control study. Mixed population of cases, controls and pseudoathma in the results. Not separated out the data. |
| HYVARINEN 2006[727] | Not PEF, PEFR or $FEV_1$ |
| IRWIN 1997[740] | Not PEF, PEFR or $FEV_1$ |
| JAIN 2013[750] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| JOSEPH 2011A[790] | Not bronchodilator reversibility versus doctor diagnosis or eligible comparator test for asthma |
| KESTEN 1994[853] | Lung function tests part of gold standard as well as index test |
| KJAER 2008A[882] | Case control study; bronchodilator test part of gold standard as well as index test |
| KONSTANTINOU 2010[910] | Longitudinal study: bronchodilator response during exacerbation compared with no exacerbation |
| KOWAL 2009[924] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| LEHMANN 2008[988] | Bronchodilator reversibility = gold standard not index test; not shown versus doctor diagnosis of asthma or other comparator tests (only questionnaire symptoms or other measures of FEV1 or FVC) |
| LERDLUEDEEPORN 1999[995] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |

| | |
|---|---|
| LINNA 1999[1024] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| LORBER 1978[1040] | Wrong population – general population |
| MALMBERY 2003[1076] | Case control study |
| MEHRPARVAR 2013[1127] | Occupational asthma |
| MELE 2010[1130] | Not PEF, PEFR or $FEV_1$ |
| MESLIER1989[1137,1137] | Only reports change in FEV1 as % initial or absolute volume alone |
| MIRAVITLLES 2010[1158] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test |
| MUNNIK 2010[1191] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test |
| MUSK 2011[1197] | Not all participants had bronchodilator test |
| NOWAK 1996[1259] | Not all participants had bronchodilator test |
| OHKURA 2013[1274] | Conference abstract – have enough fully published data already |
| OOSTVEEN 2010[1283] | Age <5 years; not PEF, PEFR or $FEV_1$ |
| PATON 2010[1319] | Not primary study |
| PEDROSA 2010[1330] | All participants selected for negative bronchodilator test |
| PETANJEK 2007[1346] | All participants selected for positive bronchodilator test |
| PINO 1996[1365] | Wrong outcome measure of FEV1 (Change in FEV1% >15% - not clinically relevant) |
| POSTMA 1995 [1385] | Longitudinal study – bronchodilator test and diagnosis not at the same time |
| PRUITT 2012 [1412] | Not primary study |
| REED 2010[1443] | Not primary study |
| RENWICK 1996 [1451] | Not all participants had bronchodilator test |
| RHEE 2013[1453] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test |
| RICHTER2008[1456,1456] | Only reports change in FEV1 as % initial or absolute volume alone |
| ROBINSON 2010[1466] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma (same study as Robinson 2012 below) |
| ROBINSON 2012[1467] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| RUPPEL 2012[1492] | Not a primary study |
| SALLAWAY 2011[1502] | Not all participants had bronchodilator |

| | |
|---|---|
| | test |
| SALOME 1999[1504] | Not all participants had bronchodilator test |
| SANCHEZ 2012[1505] | Participants selected for negative bronchodilator test |
| SANCHEZ 2013[1506] | Bronchodilator test part of gold standard not index test |
| SCHNEIDER 2013[1536] | Not all participants had bronchodilator test |
| SCOTT 2012[1551] | Not all participants had bronchodilator test |
| SILVESTRI 2008[1596] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test(from guidelines cited references 13 and 14: asthma info page 6 of asthma guideline and COPD info on p 11 of COPD guideline; both pdfs accessed from: http://www.jornaldepneumologia.com.br/detalhe_suplemento.asp?id=40 (in Portuguese) |
| SIN 2006[1609] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test |
| SINGH 2012[1614] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| SLIEKER 2003[1624] | Not all participants had bronchodilator test |
| SMITH 2004[1630] | Bronchodilator test part of gold standard (doctor diagnosis) as well as index test |
| SOBOL 1985[1635] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| SPOSATO 2008[1661] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| THIADENS 1998A[1745] | Bronchodilator test as gold standard (doctor diagnosis) not index test |
| THIADENS 1999[1747] | Bronchodilator test as gold standard (doctor diagnosis) as well as index test |
| TOMITA 2013[1773] | Bronchodilator test part of gold standard (doctor diagnosis) not index test. Scoring system of signs and symptoms, algorithm based on BDR or reversibility. |
| TSE 2013[1790] | Case control study |
| ULRIK 2005[1810] | Wrong outcome measure of FEV1 (Change in FEV1% >10% - not clinically relevant) |
| VUGT 2012[1881] | Bronchodilator test used as gold |

| | |
|---|---|
| | standard as well as index test |
| WALAMIES 1998[1884] | Wrong cut-off value for FEV1: change ≥5% |
| WALRAVEN 2001[1886] | Not all participants had bronchodilator test |
| WARDMAN 1986[1895] | Not all participants had bronchodilator test |
| WOLFF 2012[1935] | Not all participants had bronchodilator test |
| YANG 2011A[1950] | Case control study; bronchodilator test part of gold standard (doctor diagnosis) not index test |
| YAO 2011[1952] | FeNO not bronchodilator response |
| YOO 2007[1960] | Not doctor diagnosed asthma; not bronchodilator reversibility versus doctor diagnosis or other test for asthma |
| ZWAR 2011[1994] | Not bronchodilator reversibility versus doctor diagnosis or other test for asthma |

# K.8 Diagnosis: PEF variability

**Table 214: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| AGGARWAL2002[21,21] | Case control study |
| AITKHALED2006[26] | Not PEF over/under a certain threshold versus asthma status |
| ALBERTINI1989[31,31] | Case control study |
| ANEES2011[50,51] | Not PEF over/under a certain threshold versus asthma status |
| BARUA2005[117,117] | Not a primary study |
| BASER2007[118,118] | Not PEF versus another test for asthma (PEF included in the definition of asthma) |
| BECKETT2006[135,135] | Not PEF over/under a certain threshold versus asthma status |
| BELLIA1985[146,146] | Not PEF for diagnosis (prognosis of morning dip) |
| BERNSTEIN1993[161,161] | Occupational asthma |
| BERRY1985[164,164] | Not PEF over/under a certain threshold versus asthma status |
| BOULET1994[201,202] | Not PEF over/under a certain threshold versus asthma status |
| BRAND1991[210,210] | Not PEF over/under a certain threshold |

| Reference | Reason for exclusion |
|---|---|
| | versus asthma status |
| BRAND1997B[210,212] | Not PEF over/under a certain threshold versus asthma status |
| BRITTON1997[224,225] | Not PEF over/under a certain threshold versus asthma status |
| BROUWER2006[232,232] | Not PEF over/under a certain threshold versus asthma status |
| CHU2008[328,328] | Not primary study; not PEF over/under a certain threshold versus asthma status |
| COTE1990[370,370] | Occupational asthma |
| CURRIE2005[385,385] | Not PEF over/under a certain threshold versus asthma status |
| DESALU2009[429,429] | Wrong population. Reference standard – no objective test. |
| DICKINSON1999[440,440] | Not PEF versus another test for asthma (PEF included in the definition of asthma) |
| DOW2001[451,451] | Not PEF versus another test for asthma (PEF included in the definition of asthma) |
| ENRIGHT1997[479,479] | Not PEF over/under a certain threshold versus asthma status or other test |
| FERDOUSI1997[494,494] | Not PEF over/under a certain threshold versus asthma status |
| FERDOUSI2005[494,495] | Not doctor-diagnosed asthma |
| FIELDER1999[498,498] | Not PEF over/under a certain threshold versus asthma status |
| FRISCHER 1995[524,526] | Wrong population: general population, not suspected asthma. |
| FRISCHER1993B[524,525] | Not PEF over/under a certain threshold versus asthma status |
| GIBSON1995[564,564] | Case control study |
| GOLDSTEIN 2001[585,586] | PEFv calculation includes post-BD values |
| HANSEN1994[640,640] | Not PEF over/under a certain threshold versus asthma status |
| HARGREAVE1982[643,643] | Not PEF over/under a certain threshold versus asthma status |
| HARGREAVE1986[642,643] | Not PEF over/under a certain threshold versus asthma status |
| HART2002[646,646] | Not primary study |
| HEDMAN1998[656,656] | PEF included in the definition of asthma (i.e. in reference standard not index |

| Reference | Reason for exclusion |
|---|---|
| | test) |
| HENDERSON1989[663,663] | Case control study |
| HETZEL1980[676,676] | Not PEF over/under a certain threshold versus asthma status |
| HIGGINS 1992[678,679] | Wrong reference standard: Physician Dx but no objective test. |
| HIGGINS1989[679,679] | Not PEF over/under a certain threshold versus asthma status or sensitivity/specificity |
| HSU1997[713,713] | Not PEF over/under a certain threshold versus asthma status or sensitivity/specificity |
| JAIN1998[749,749] | No numerical data for sensitivity/specificity; not a primary study |
| JAMISON1993[755,755] | Case control study |
| JINDAL2002[778,778] | Not a primary study |
| KERCSMAR1996[848,848] | Not a primary study |
| KHOO1984[862,862] | Not PEF over/under a certain threshold versus asthma status |
| KOH2005[897,898] | Not PEF over/under a certain threshold versus asthma status |
| KOLBE1996[902,902] | Not PEF over/under a certain threshold versus asthma status |
| KUNZLI 1999[943,943] | Wrong population: general population, not suspected asthma. |
| LAPRISE1997[966,966] | Not PEF over/under a certain threshold versus asthma status |
| LARSSON1994[969,969] | Not PEF over/under a certain threshold versus asthma status (PEF included in diagnosis) |
| LARSSON1995[968,969] | Not PEF over/under a certain threshold versus asthma status (PEF included in diagnosis) |
| LAWSON2011[978,978] | Not PEF over/under a certain threshold versus asthma status |
| LEBOWITZ1997[982,982] | Not PEF over/under a certain threshold versus asthma status |
| LEWIS 2001[1002,1005] | Wrong population: general population, not suspected asthma.<br>Wrong reference standard: Physician Dx but no objective test. |
| LINDENSMITH2004[1019,1019] | Not PEF over/under a certain threshold versus asthma status |
| LINNA1993[1026,1026] | Not PEF over/under a certain threshold versus asthma status |
| MAGYAR1998[1062,1062] | Not primary study |
| MATSUNAGA2008[1106,1106] | Not PEF over/under a certain threshold versus asthma status |

| Reference | Reason for exclusion |
|---|---|
| MICHOUD1982[1142,1142] | Not PEF over/under a certain threshold versus asthma status |
| MOORE2009[1177,1177] | Function of different monitoring devices not PEF over/under a certain threshold versus asthma status or other test |
| MOSCATO1993[1181,1181] | Occupational asthma |
| MOSFELDTLAURSEN1993[1182] | Not PEF over/under a certain threshold versus asthma status |
| MUERS1984[1187,1187] | Not PEF over/under a certain threshold versus asthma status |
| PAGGIARO1993[1295,1295] | Not PEF over/under a certain threshold versus asthma status or sensitivity/specificity |
| PARAMESWARAN1999[1306,1306] | Not PEF over/under a certain threshold versus asthma status |
| PINO1996[1365,1365] | Not PEF variability over/under a certain threshold versus asthma status; PEF during bronchodilator test versus FEV1 during bronchodilator test – included in bronchodilator response review |
| PODER1987[1373,1373] | Not PEF over/under a certain threshold versus asthma status |
| POGSON2009[1374,1374] | Not PEF over/under a certain threshold versus asthma status |
| PRIETO1998[1406,1406] | Not PEF over/under a certain threshold versus asthma status |
| PRIETO2000[1406,1407] | Not PEF over/under a certain threshold versus asthma status |
| SANO2004[1509,1509] | Not all patients had reference standard test |
| SEKEREL1997[1558,1558] | Not PEF over/under a certain threshold versus asthma status |
| SHAKERI2012[1568,1568] | Mixed population of patients with asthma and COPD |
| SHIRAHATA2005[1583,1583] | Not PEF over/under a certain threshold versus asthma status |
| SIERSTED 1994[1590,1590] | Wrong reference standard: Physician Dx but no objective test. |
| SIERSTED 1996[1590,1591] | Wrong reference standard: Physician Dx but no objective test.<br>Wrong population: general population, not suspected asthma. |
| SINGH2012[1613,1614] | Case control study |
| SLIEKER 2003A[1624,1624] | Wrong outcome measure: PEF not PEF variability. |
| STEIN1997[1673,1673] | Not PEF over/under a certain threshold versus asthma status |
| TAJI2013[1717,1717] | Not PEF over/under a certain threshold versus asthma status |

| Reference | Reason for exclusion |
|---|---|
| THIADENS 1999[1746,1747] | Index test is BDR |
| TIMONEN1997[1757,1757] | Not PEF over/under a certain threshold versus asthma status |
| TOKUYAMA1998[1767,1768] | Not PEF over/under a certain threshold versus asthma status |
| TOUNGOUSSOVA2007[1780,1780] | Not PEF over/under a certain threshold versus asthma status |
| VANSCHAYCK1996[1838] | Not PEF over/under a certain threshold versus asthma status |
| VARGAS2005[1845,1845] | Not PEF over/under a certain threshold versus asthma status |
| VASAR1996[1847,1847] | Not PEF over/under a certain threshold versus asthma status |
| VENABLES1984[1852,1852] | Not PEF over/under a certain threshold versus asthma status |
| YOO2007[1959,1959] | Not PEF over/under a certain threshold versus asthma status |
| YURDAKUL2005[1968,1968] | PEF variability included as part of reference standard as well as index test |
| ZILMER2011[1988,1988] | Not PEF over/under a certain threshold versus asthma status |
| ZUREIK1995[1993,1993] | Not PEF over/under a certain threshold versus asthma status with a reference standard (comparing 2, 3 or 4 measurements of PEF versus 5) |

# K.9 Diagnosis: Skin prick tests

**Table 215: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALENIZI2013[35] | Conference abstract – have enough fully published data already |
| ALMEIDA 1999[394] | Results for SPT not given thus cannot calculate sens/spec. |
| ANTOLIN2013[55] | Conference abstract – have enough fully published data already |
| ANTOLINAMERIGO 2012[54] | Conference abstract – have enough fully published data already |
| ARDUSSO 2009[63] | Conference abstract – have enough fully published data already |
| ARMENTIA2007[71] | no data on SPT by/within asthma status |
| BARNIG 2013[112] | Correlation study – cannot |

| Reference | Reason for exclusion |
|---|---|
| | calculate sens/spec. |
| BONINI 2010[187] | Conference abstract – have enough fully published data already |
| BRAND 1993[213] | Results in mixed population of asthma/COPD (no asthma subgroup analysis). |
| BUSINCO1988[252] | not SPT by asthma status |
| CAIMMI2013A[261] | Conference abstract – have enough fully published data already |
| COMERT2014[361] | No reference standard |
| CONNOLLY1981[362] | not SPT by asthma status |
| DEANE2005[408] | not SPT by asthma status |
| DELACOURT1994[416] | control group too young (<1 year) |
| DERVADERICS2002[428] | no data on SPT by/within asthma status |
| DHARMAGE1998[434] | not SPT by asthma status |
| DIBEK 2007[439] | All asthma pts – no comparative test group thus unable to calculate sens/spec. |
| ESCUDERO 1993[483] | Wrong reference standard: allergen challenge was part of the reference standard test. |
| FOUCARD1973[512] | longitudinal not cross-sectional data |
| FUIANO2013[532] | Conference abstract – have enough fully published data already |
| GARCIA1997[547] | patients selected for previous negative SPT |
| GARCIAGONZALEZ1999[548] | castor bean pollen not relevant to UK |
| GOETZ2007[580] | Asian ladybug not relevant to UK, no other SPT by asthma reported |
| GRADMAN2006[589] | Some children had both asthma and rhinitis; table of SPT by diagnosis double counts these children so sensitivity/specificity not calculable |
| GRAIF 2002[590] | Wrong comparison: data in this study are given for suspected asthma pts or control pts only and are for test vs. test rather than test vs physician Dx (which is the comparison we look for in suspected asthma pts) |

| Reference | Reason for exclusion |
|---|---|
| GUDELJ 2012[608] | Wrong reference standard: physician Dx includes the objective test |
| GUERRA1995[611] | Percentages given for SPT positive and negative and number with asthma but unable to calculate raw data or sensitivity/specificity etc due to rounding |
| HAYES2013[654] | All patients had positive SPT |
| HILL1994[681] | not SPT by asthma status |
| HUERTAS2011[719] | All pollen-allergic; no data on SPT by asthma status |
| IMBEAU1978[737] | not SPT by asthma status |
| JULIA1995[793] | Population is rhinitis and/or asthma (not suspected asthma) |
| KARAKAYA 2006[823] | Asthma/rhinitis pts – does not split results for asthma or rhinitis groups separately, thus cannot calc sens/spec for asthma. |
| KAUFMAN1984[832] | not SPT by asthma status |
| KIM 2002[872] | Wrong reference standard definition: Physician Dx = patient-reported in a questionnaire. |
| KIM2013A[867] | General population |
| KOUTSOUPIAS2013A[920] | Conference abstract – have enough fully published data already |
| KOWAL 2009[924] | Unable to calculate sens/spec as the number of +ve and –ve SPTs are bnit given for SPT with asthma. |
| KUMAR2011A[939] | Conference abstract – have enough fully published data already |
| KUMARI 2006[942] | Wrong allergens / country for allergen: food allergies and pollen in India. |
| LAURENT1994[977] | SPT to diagnose winter pollinosis not asthma |
| LEWIS1989[1002] | Case-control study including asthma and suspected asthma groups in the sensitivity/specificity analysis |
| LUISI 2012[1045] | All asthma pts, but unable to calculate sens/pec of SPT vs. other tests (BDR or spirometry). |
| MARINOVIC2013[1089] | Conference abstract – have enough fully published data |

| Reference | Reason for exclusion |
|---|---|
| | already |
| MASULLO1996[1098] | All SPT positive |
| MIGUERES2011[1147] | selected for positive skin prick tests |
| MOSBECH 1987A[1180] | All asthma pts but wrong comparative test: bronchial, conjunctival challenge wit the same allergen as the index (SPT) test. |
| MURRAY1985[1196] | not SPT by asthma status |
| MUSKEN2002[1198] | not SPT by asthma status |
| NEGRINI1992[1218] | not SPT by asthma status |
| NIEDOSZYTKO2007[1238] | not symptomatic controls |
| NIEMEIJER 1992A[1240] | All asthma pts – SPT but no comparison test, thus cannot calculate sens/spec. |
| NOGUEIRA1994[1254] | Non-English |
| NOLTE 1990[1256] | Suspected asthma pts recruited, but no final Physician Dx of asthma was done and the wrong comparison tests also used. |
| OSTERGAARD 1990[1290] | All asthma pts: wrong comparison test - IgE or BPT with the allergens. |
| PALMACARLOS2005[1296] | not SPT by asthma status |
| PANASZEK 2007[1300] | Does not give SPT results for Dx of asthma – cannot calc sens/spec. |
| PANICHWATTANA2013[1301] | Conference abstract – have enough fully published data already |
| PAPA2001[1304] | selected for SPT positivity |
| PEARLMAN 2009[1321] | Correlation study and cannot calculate sens/spec for asthma pts.. |
| QUIRALTE2005[1418] | all SPT positive |
| RESANO1998[1452] | Intradermal not skin prick test |
| RODRIGUEZ2013[1470] | Not in English |
| ROTTOLI1989[1485] | not SPT by asthma status |
| SASTRE 1996[1513] | Duplicate study – already excluded |
| SASTRE1996[1513] | not SPT by asthma status |
| SCHWARTZ1995[1546] | not SPT by asthma status |
| SILVESTRI1996[1599] | not SPT by asthma status |
| SILVESTRI1997[1598] | not SPT by asthma status |
| SMITH2005[1629] | not SPT by asthma status |
| SRITIPSUKHO 2004[1667] | All asthma pts – no comparative |

| Reference | Reason for exclusion |
|---|---|
| | test group thus unable to calculate sens/spec. |
| STAFANGER 1986[1668] | Wrong comparison test: BPT (contains the same allergens as the index SPT) |
| STELMACH 2002A[1674] | Results for SPT allergens divided by cockroach allergen – ve and +ve pts; cannot calc sens/spec of true asthma pts. |
| STOKES2000[1684] | not SPT by asthma status |
| TASKINEN 1997[1732] | Wrong allergen results: results for >10 moulds all pooled together. Unable to get specific results for C*ladosporium* or *Alternaria* |
| TAUBER 2000[1733] | Correlation study – cannot calculate sens/spec. |
| TOMASSEN2013[1772] | General population/no objective test |
| TORRESRODRIGUEZ2012[1779] | All skin prick positive |
| TROISE1992[1786] | not SPT by asthma status |
| TSCHOPP 1998[1788] | Wrong reference standard definition: Physician Dx = patient-reported in a questionnaire. |
| VARELA2003[1844] | SPT given for asthma group but not for control group |
| VENTURA2007[1856] | Some participants had both asthma and rhinitis so sensitivity/specificity not calculable |
| VERVLOET1999[1860] | All skin prick positive |
| VIEIRA 2009[1863] | Conference abstract – have enough fully published data already |
| VIEIRA 2011[1864] | Wrong reference standard definition: Physician Dx = patient-reported in a questionnaire. Validation study. |
| WEINTRAUB 2001[1904] | Wrong definition of physician Dx: physician Dx was patient-reported via a questionnaire |
| WOODMANSEE 2009[1938] | Conference abstract – have enough fully published data already |
| YURDAKUL 2005[1968] | Case-control study including asthma and suspected asthma groups in the sensitivity/specificity analysis |
| ZETTERSTROM 1972[1976] | Wrong country for allergen: pollen in Sweden. |

# 1K.10 Diagnosis: IgE

2 **Table 216: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ABDULAMIR 2009[7,7] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| ABUT 2007[14,14] | Wrong outcomes: correlations of IgE not no. of positive/negative. |
| ADLER 1985[19,19] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| AGATA 1993[20,20] | Wrong comparisons: different IgE methods compared. |
| AHLSTEDT 1974[22,22] | Mixed population (asthma and/or allergic rhinitis), with no separate analysis for Dx of asthma. |
| AHMAD 2008[23,23] | Incorrect study design: case-control study |
| AKCAKAYA 2005[27,27] | Wrong outcomes: only gives SPT results, not IgE. |
| ALMQVIST 2007[37,37] | Wrong outcomes: predictors of subsequent development of sensitisation. |
| BACKER 1992[87,90] | Mixed population (asthma, rhinitis and dermatitis), with no separate analysis for Dx of asthma. |
| BARNES 2014[111] | Conference abstract |
| BEEH 2000[137,137] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| BJORNSSON 1994[176,176] | Wrong outcomes: correlations of IgE not no. of positive/negative. |
| BRANCATO 1995[208,208] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| BRAND 1993[210,213] | Mixed population (asthma and COPD), with no separate analysis for Dx of asthma |
| BRUCE 1976[235,235] | Wrong outcomes: levels of IgE and split by HLA antuigen groups, not no. of positive/negative. |
| BRYANT 1975[240,240] | Wrong reference standard: allergen-specific BPT. |
| BURROWS 1991[250,250] | Wrong outcomes: predictors of subsequent development of asthma. |
| BUTERLEVICIUTE 2013[257,257] | Conference abstract |
| CANTANI 1990[267,267] | Mixed population (asthma and/or rhinitis with others), with no separate analysis for Dx of asthma. Wrong outcomes: Dx of atopy, not asthma. |
| CANTANI 2005A[267,269] | Wrong outcomes: levels of IgE not no. of positive/negative. |

| | |
|---|---|
| CANTONI 2003[267,268] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| CARSIN 2013[285,285] | Wrong outcomes: predictors of subsequent development of asthma. |
| CASSIMOS 2008[290,290] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| CHAKRABARTI 1993[297,297] | Wrong outcomes: Dx of Aspergillus lung disease not asthma. |
| CHAO 2001[302,302] | Incorrect study design: case-control study. |
| CHEN 2014[308,310] | General population |
| CHOI 2005[319,320] | Wrong outcome (Dx): Dx of early or late airway reaction, not asthma Dx. |
| CHOI 2005A[319,322] | Incorrect study design: case-control study |
| CHOU 2002[323,323] | Cannot calculate sens/spec as only gives numbers who were positive for asthma only. |
| COCKCROFT 1979[356,356] | Wrong outcomes: correlations/relationships of IgE not no. of positive/negative. |
| COOKSON 1976[363,364] | Wrong outcomes: correlations of IgE not no. of positive/negative. |
| CRAMERI 1998[375,375] | Wrong outcomes:levels of IgE not no. of positive/negative. |
| CULLINAN 2004[384,384] | Wrong outcomes: not Dx of asthma. |
| CUSTOVIC 1996[387,387] | Does not mention IgE. |
| DECLERK 1986[398] | Wrong comparison: methods/assay development. |
| DELOVIN 1994[403] | Wrong comparison: sens/spec of RAST vs. mite-levels in mattress. |
| DOEKES 1996[446,446] | Wrong comparison: two different methods of IgE measurement. |
| DUC 1988[459,459] | Mixed population (asthma and/or rhinitis with others), with no separate analysis for Dx of asthma. |
| EWAN 1990[485,485] | Mixed population (asthma and/or rhinitis with others), with no separate analysis for Dx of asthma. |
| EYSINK 2001[486,486] | Wrong outcomes: predictors of subsequent development of asthma. |
| EYSINK 2005[486,487] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| FERNANDEZ 2007[497,497] | Wrong reference standard: allergen-specific BPT. |
| FERNANDEZ 2011[496,497] | Wrong reference standard: allergen-specific BPT. |
| FLAHERTY 1980[502,502] | Wrong study design: case-control study. |

| | |
|---|---|
| | Wrong outcomes: levels of IgE not no. of positive/negative. |
| FREIDHOFF 1993[522,522] | Cannot calculate sens/spec as only gives numbers who were positive or negative for each test individually. |
| FRITH 2011[527,527] | Wrong comparison: SPT |
| GERGEN 2009[559,559] | Cannot calculate sens/spec as only gives numbers of positives for each test individually. |
| GODFREY 1975[576,576] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| GOLDSTEIN 2005[584,585] | Wrong population: not asthma but allergy |
| HAATELA 1981[619,619] | Mixed population (wheeze or asthma), with no separate analysis for Dx of asthma. |
| HEIDEN 2010[658] | Incorrect study design: case-control study. Wrong outcomes: levels and relationships of IgE, not no. of positive/negative. |
| HOFFMANN 2013[686] | Wrong comparison (SPT) |
| HOGARTH 1973[687] | Wrong comparison: SPT |
| IWAMOTO 1990[744,744] | Incorrect study design: case-control study |
| JAAKKOLA 2006[745,745] | Incorrect study design: case-control study |
| JACKOLA 2004[746,746] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| JANG 2007[758,759] | Incorrect study design: case-control study |
| KALYONCU 1995[815,815] | Incorrect study design: case-control study. Wrong outcomes: levels of IgE not no. of positive/negative. |
| KARADAG 2007[821,821] | Wrong outcomes: not Dx of asthma but of atopic eczema (in general population). |
| KARTASAMITA 1994[826,826] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| KEIL 2006[840,841] | Review – used as a source of references. |
| KELSO 1991[846,846] | Mixed population (asthma and/or rhinitis), with no separate analysis for Dx of asthma. |
| KERKHOF 2003[850,850] | Mixed population (asthma and/or allergy symptoms), with no separate analysis for Dx of asthma. |
| KHADADAH 2000A[854,855] | Wrong comparison: SPT |
| KING 2004[876,877] | Wrong outcomes: levels of IgE and Odds, not no. of positive/negative. |
| KITANI 1993[879,879] | Does not answer the question: |

| | |
|---|---|
| | compares drug-induced asthma vs. non-drug induced asthma, and only gives numbers who were positive for each test individually. |
| KJAER 2008[883,883] | Wrong outcomes: results for SPT and IgE are combined. |
| KLINKANOVA 1995[888,888] | Abstract not fully published paper. |
| KOIVIKKO 1991[899,899] | Cannot calculate sens/spec. |
| KONDERAK 2013[907,907] | Conference abstract |
| KOROL 2006[912,912] | Wrong study design: case-control. Wrong outcomes: levels of IgE, not no. of positive/negative. |
| KOVAC 2007[921,921] | Wrong outcomes: asthma severity. |
| KURIMOTO 1978[944,944] | Wrong outcomes: agreement with IgE, not no. of positive/negative. |
| LAI 2002[959,961] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| LASKE 2003[970,970] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| LODRUPCARLSEN 2010A[1035,1035] | Wrong outcomes: predictors of subsequent development of asthma. |
| MASUKO 2011[1097,1097] | Wrong population: healthy people only. Wrong outcomes: levels of IgE. |
| MATRICARDI 1990[1102,1102] | Mixed population (asthma and/or oculorhinitis with others), with no separate analysis for Dx of asthma. |
| MATRICARDI 2009[1100,1102] | Wrong outcomes: levels of IgE over time, not no. of positive/negative. |
| MATSUI 2010[1103,1103] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| MOGI 1977[1168,1168] | Incorrect study design: case-control study. Wrong outcomes: levels of IgE not no. of positive/negative. |
| MOGI 1977A[1168,1169] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| MOUTHUY 2011[1185,1185] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| MOVERARE 2002[1186,1186] | Mixed population (asthma and/or rhinoconjunctivitis), with no separate analysis for Dx of asthma. |
| MUSTONEN 2013[1200,1200] | Wrong outcomes: predictors of asthma over time linked to CRP.levels of IgE not no. of positive/negative. |
| MYGIND 1978[1202,1202] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| NAVRATIL 2009[1217,1217] | Wrong outcomes: levels and relationships of IgE, not no. of positive/negative. |
| NIELSEN 1992[1239,1239] | Results for all allergens pooled together. |

| | |
|---|---|
| NIGGEMAN 2008[1242,1243] | Wrong outcomes: Dx of allergy made with symptoms and IgE,not Dx of asthma. |
| NOLLES 2001[1255,1255] | Wrong outcomes: not Dx of asthma. |
| NUSSLEIN 1987[1262,1262] | Wrong comparison: old RAST vs. new RAST |
| OKUDAIRA 1983[1277,1277] | Cannot calculate sens/spec as only gives numbers for each test individually. |
| ORYSZCZYN 2009[1285,1286] | Not IgE versus SPT status; cannot calculate sensitivity etc of test. |
| OSTERBALLE 1979[1289,1289] | Cannot calculate sens/spec as only shows data as graphs. |
| PANZANI 1993[1303,1303] | Not physician diagnosed asthma and no objective tests. |
| PARK 1997[1311,1312] | Wrong outcomes: not Dx of asthma. |
| PASTORELLO 1995[1317,1317] | Wrong outcomes; Dx of symptomatic and non-symptomatic allergy, not asthma. |
| PEAT 1996[1324,1325] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| PECOUD 1982[1328,1328] | Wrong comparison: newer RAST test vs. older RAST test. |
| PEKKARINEN 2007[1332,1332] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| PELIKAN 1982[1333,1333] | Results for all allergens pooled together. |
| PEPYS 1975[1334,1334] | Mixed population (asthma and/or allergic rhinitis), with no separate analysis for Dx of asthma. |
| PEREIRA 2005[1335,1335] | Mixed population (asthma and/or allergic rhinitis), with no separate analysis for Dx of asthma. |
| PERRIN 1983[1338,1338] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| PERZANOWSKI 1998[1344,1344] | Report of data from several other studies. |
| PLASCHKE 1996[1369,1369] | Wrong outcomes: not Dx of asthma but of atopy (in general population). |
| PLEBANI 1995[1370,1370] | Not asthma versus no asthma (mixed population of asthma and rhinitis patients) |
| PRICE 1989[1403,1403] | Wrong outcomes: % agreement of SPT and RAST, not no. of positive/negative. |
| PRICHARD 1985[1404,1404] | Occupational asthma. |
| RAHERISON 2004[1423,1423] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| REIJULA 2003[1446,1446] | Mixed population (asthma with others), with no separate analysis for Dx of asthma. Incorrect study design: case-control study. |
| ROGERS 2002[1472,1472] | Not asthma versus no asthma (not Dx of |

| | |
|---|---|
| | asthma); no reference standard or other test for allergy |
| ROSARIO 1997[1481,1481] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| RUDZKI 1990[1489,1489] | Wrong population: atopic dermatitis pts. |
| RYDJORD 2008[1494,1494] | Wrong outcomes: not used for Dx of asthma. |
| SANTOSO 1998[1511,1511] | Wrong comparison: SPT |
| SCHOEFER 2008[1538,1538] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| SCORDAMAGLIA 1992[1549,1549] | Mixed population (asthma, rhinitis and conjunctivitis), with no separate analysis for Dx of asthma. |
| SELASSIE 2000[1559,1559] | Incorrect study design: case-control study |
| SHARMA 2006A[1572,1572] | Incorrect study design: case-control study. |
| SHERRILLI 1999[1576,1577] | Wrong outcomes: wheezing, not Dx of asthma. |
| SHIBASAKI 1997[1578,1578] | Incorrect study design: case-control study |
| SIMONI 2001[1605,1605] | Wrong test: PRIST test (modified RAST test) – not commonly used in current practice. |
| SIMPSON 2005[1606,1606] | Wrong outcomes: Dx of wheeze not asthma. |
| SIROUX 2003[1616,1616] | Correlation study in people with asthma |
| STAFANGER 1986[1668,1668] | Cannot calculate sens/spec as only gives data in graphs. |
| STEVENS 1983[1679,1679] | Mixed population (asthma and/or rhinitis), with no separate analysis for Dx of asthma. |
| STEVENS 2011[1678,1679] | Incorrect study design: case-control study |
| SUBIRA 1976[1696,1696] | Wrong outcomes: levels and correlations of IgE not no. of positive/negative. |
| SUMAN 2005[1698,1698] | Incorrect study design: case-control study. Wrong test: for indian-specific pollen. |
| SUNYER 1996[1701,1701] | Cannot calculate sens/spec as only gives numbers who were positive for each test individually. |
| SUNYER 2004[316,316] | Not asthma versus no asthma (not Dx of asthma); no reference standard or other test for allergy |
| TAMURA 1991[1723,1723] | Wrong outcomes: predicted true positives and negatives, not actual numbers. |
| TANG 1989[1726,1726] | Wrong comparison: SPT |

| | |
|---|---|
| TANG 2010[1725,1726] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| TERZIOGLU 1998[1744,1744] | IgE vs. SPT (measures of the same thing); no comparison with Physician Dx. |
| TOMASSEN 2013[1772,1772] | General population / wrong comparison (SPT). |
| TORRENT 2006[1776,1776] | Wrong outcomes: risk of sensitisation, not Dx of asthma. |
| TU 2013[1796,1796] | Conference abstract |
| VAGIC 2008[1812,1812] | Incorrect study design: case-control study. Wrong outcomes: levels of IgE not no. of positive/negative. |
| VALENCIA 1993[1814,1814] | Mixed population (asthma or rhinitis), with no separate analysis for Dx of asthma. |
| VANTO 1982[1843,1843] | Wrong reference standard: allergen-specific BPT. |
| VIANDER 1983[1862,1862] | Wrong comparison: conjunctival provocation test. |
| VOOREN 1983[1877,1877] | Wrong reference standard: allergen-specific BPT. |
| WAKAMORI 2009[1882,1882] | Wrong population: dermatitis not asthma. |
| WANG 1992[1892,1892] | Wrong test: MAST test – not commonly used in current practice. RAST test also used in study but results not reported. |
| WANG 2009[1891,1892] | Wrong outcomes: levels of IgE and predictors of mortality. |
| WEDNER 1987[1900,1900] | Wrong allergen: rare plant |
| WEINMAYR 2007[1903,1903] | Wrong outcomes: not used for Dx of asthma. |
| WICKMAN 2005[1913,1914] | Mixed population (asthma and/or allergic rhinitis), with no separate analysis for Dx of asthma. |
| WITTEMAN 1996[1928,1928] | Wrong outcomes: levels of IgE not no. of positive/negative. |
| WOODMANSEE 2009[1938,1938] | Abstract only (conference abstract, not a full paper) |
| YANG 2010[1951,1951] | Abstract only (conference abstract, not a full paper) |
| YAZICIOGLU 1994[1955,1955] | Incorrect study design: case-control study. Results for all allergens pooled together. |
| ZIMMERMAN 1988A[1989,1989] | Mixed population (asthma and/or rhinitis and others), with no separate analysis for Dx of asthma. |

# 1K.11 Diagnosis: FeNO

2 **Table 217: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| *ANSARIN2001*[52] | Not treatment naïve (>50% on CS treatment) |
| ANTUS2010[56] | Not treatment naïve (>50% on CS treatment) |
| *ARTLICH1996*[75] | N<50 for case-control study |
| AVITAL2001[84] | Reference standard objective test not widely used |
| BACKER 2014[91] | Reference standard does not match protocol – sn/sp of FeNO to predict positive mannitol in suspected asthma (not physician diagnosis and objective test) |
| *BAKKEHEIM2011*[94] | Not treatment naïve (>50% on CS treatment) |
| BALINOTTI2013[97] | No objective test for asthma, only Asthma Predictive Index |
| *BARALDI2003*[104] | Case-control study for FeNO levels but <50 people |
| BARALDI2003A[101] | Not treatment naïve (>50% on CS treatment) |
| BARALDI2005[103] | N<50 for case-control study |
| *BARALDI2006*[102] | Case-control study for FeNO levels but <50 people |
| *BARRETO2001*[114] | Not treatment naïve (unclear % of patients on CS treatment) |
| *BARRETO2006*[115] | N<50 for case-control study |
| BEG2009[140] | Index test does not match protocol – flow rate of 200ml/s |
| *BEIGELMAN2008*[141] | Not treatment naïve and no objective test |
| BERKMAN2005[159] | Index test does not match protocol – flow rate of 250ml/s |
| *BERNSTEIN2009*[162] | Not treatment naïve (no restrictions on treatment) |
| *BERRY2005A*[163] | Not treatment naïve (>50% on CS treatment) |
| BEVER2003[166] | Non-English |
| BOBOLEA2012 | Not full paper (letter) |
| *BOMMARITO2008*[183] | Not treatment naïve; no objective test |
| BRINDICCI2007[223] | N<50 for case-control study |
| *BRODLIE2010*[226] | Review not primary study |
| *BRUSSEE2005*[237] | Population does not match protocol – general population. |
| *BYRNES1997*[259] | Not treatment naïve (>50% on CS treatment) |

| Reference | Reason for exclusion |
|---|---|
| *CARRARO2005*[281] | N<50 for case-control study |
| *CARRARO2007A*[283] | Not treatment naïve (>50% on CS treatment) |
| *CARRARO2010*[282] | N<50 for case-control study |
| *CASTRORODRIGUEZ2013*[292] | All people with asthma for FeNO levels but <50 people |
| CHEROTKORNOBIS2011[311] | Case-control study for FeNO levels but <50 people |
| CHO2013[317] | Index test does not match protocol – incorrect flow rate |
| CHOW2009[324] | Results split into obese vs. non-obese pts; if use the non-obese people with asthma it means N<50 for case-control study. Otherwise meets all inclusion criteria. |
| *CIPRANDI2010*[337] | Reference standard does not match protocol – unclear if objective test used |
| *COLONSEMIDEY2000*[360] | All people with asthma for FeNO levels but <50 people |
| *CORRADI2001*[366] | N<50 for case-control study (if exclude the subgroup on CS Tx) |
| *CRANE2012*[376] | Not treatment naïve; no objective test |
| DEBLEY2010[410] | Asthma only pts, but N<50. |
| *DEBOT2013*[397] | No objective test |
| *DECIMO2011*[411] | Meets all inclusion criteria, but does not report the FeNO levels. |
| *DEDIEGO2005*[399] | FeNO levels but <50 people; not sensitivity/ specificity vs. other test |
| DEGOUW2001[400] | N<50 for case-control study |
| *DEGROOT2012*[401] | Not treatment naïve (all on CS treatment) |
| DELABARRA2011 | Cannot calculate sn/sp |
| *DELEN2000*[418] | Not treatment naïve (unclear % of patients on CS treatment) |
| *DELGIUDICE2004*[414] | All people with asthma for FeNO levels but <50 people |
| *DEMEER2005*[406] | No relevant outcomes – cannot calculate sn/sp of FeNO for Dx of asthma |
| *DOTSCH1996*[450] | Unclear physician Dx. |
| *DRESSEL2008*[452] | Method of asthma Dx not reported. |
| DRESSEL2010[453] | Unclear physician Dx. |
| EKROOS2009[471] | Index test does not match protocol – flow rate of 80-150ml/s |
| ELHALAWANI2003[472] | Suspected EIB and exercise challenge test. |
| ELLIOTT 2013[475,476] | Population does not match protocol – children less than 1 year old |
| *FABBRI2003*[488] | Case-control study for FeNO levels but |

| Reference | Reason for exclusion |
|---|---|
| | <50 people |
| *FITZPATRICK2006*[501] | Severe asthma and moderate asthma. If exclude the sever asthma subgroup then N<50 for case-control study. |
| *FORMANEK2002*[509] | Index test does not match protocol – nitrite levels not FeNO |
| FORTUNA2007[511] | Reference standard objective test does not match protocol – methacholine challenge test cut-off at 16mg/ml |
| FOWLER2009[515] | Not treatment naïve (>50% on CS treatment) |
| *FRANK1998*[519] | Not treatment naïve (unclear % of patients on CS treatment) |
| *FRANKLIN2003*[520] | Population does not match protocol – general population, asymptomatic children |
| *FRANKLIN2004*[521] | Population does not match protocol – general population |
| *FUJIMURA2008*[534] | FeNO levels but <50 patients |
| *GABRIELE2005*[536] | All people with asthma for FeNO levels but <50 people |
| *GADE2009*[537] | Asthma only pts but N<50. |
| *GAGLIARDO2009*[538] | Not treatment naïve (>50% on CS treatment) |
| *GEVORGYAN2013*[560] | Review not primary study |
| GRONKE2002[600] | Population does not match protocol – all atopic and comparing FeNO levels in groups with different durations of asthma |
| *GRZELEWSKI 2014*[606,607] | Study does not report results in such a way that it is possible to calculate sensitivity and specificity. |
| HAHN 2007 | Sn/sp of FeNO for predicting response to ICS treatment, not asthma |
| *HENRIKSEN2001*[668] | Not treatment naïve (unclear % of patients on CS treatment) |
| *HENRIKSEN2002*[670] | No relevant outcomes – cannot calculate sn/sp of FeNO for Dx of asthma |
| *HENRIKSEN2003*[669] | Not treatment naïve (unclear % of patients on CS treatment) |
| *HERVAS2008*[674] | Not treatment naïve (unclear % of patients on CS treatment) |
| HOGMAN2001[689] | Not treatment naïve (>50% on CS treatment) |
| *HOGMAN2002*[688] | Not treatment naïve (>50% on CS treatment) |
| HOLGUIN2011[690] | Not treatment naïve (>50% on CS treatment) |
| *HORVATH2004*[710] | Physician Dx with no objective tests (just |

| Reference | Reason for exclusion |
|---|---|
| | does SPT). |
| HOVI2010[712] | Non-English |
| HSU2013 | Sn/sp of FeNO for predicting response to ICS treatment, not asthma |
| HUSZAR2002[726] | Index test does not match protocol – flow rate of 5-6L/min |
| ISHIZUKA2011[741] | No objective test |
| JATAKANON1998A[770] | All asthma pts but N<50 |
| JENTZSCH2006[775] | Not treatment naïve (>50% on CS treatment) |
| *JERZYNSKA 2014*[776,776] | Study does not report results in such a way that it is possible to calculate sensitivity and specificity. |
| KANAZAWA2004[817] | Case-control study. Phys Dx with objective test but wrong cut-off for objective test (BDR >20% - should be 12%) |
| KATSOULIS2013[828] | Reference standard does not match protocol – sn/sp of FeNO to predict positive methacholine challenge test not physician diagnosis of asthma with objective test. |
| KEEN2011[839] | Not treatment naïve (>50% on CS treatment) |
| *KHARITONOV2003*[859] | Unclear physician Dx. |
| *KIELBASA2008*[865] | Not treatment naïve (>50% on CS treatment) |
| *KIM2013*[874] | Wrong-cut off for the MCT objective test as part of Phys Dx. MCT <16mg/ml or FEV1 12% (doesn't give the % Dx by MCT or FEV1). |
| KLEIS2007[886] | Wrong-cut off for the MCT objective test as part of Phys Dx. MCT <16mg/ml – should be 8mg/ml. |
| *KO2009*[894] | Not treatment naïve (>50% on CS treatment) |
| *KOMAKULA2007*[905] | Not treatment naïve (>50% on CS treatment) |
| *KONDO2003*[908] | FeNO levels but <50 people |
| *KOSKELA2008*[914] | Not treatment naïve (>50% on CS treatment) |
| *KOVESI2008*[923] | Not treatment naïve (unclear % on CS treatment) |
| KOVESI2009[922] | No objective test |
| *LAGRUTTA2003*[953] | Not treatment naïve (>50% on CS treatment) |
| *LANGLEY2003*[965] | Not treatment naïve (>50% on CS treatment) |
| *LARA2008*[967] | Not treatment naïve (>50% on CS |

| Reference | Reason for exclusion |
|---|---|
| | treatment) |
| *LEHTIMAKI2002*[989] | FeNO levels measured but not reported in paper (only alveolar NO concentration and bronchial NO flux) |
| *LEUPPI2002*[999] | Population does not match protocol – FeNO levels in patients with atopy, not asthma |
| LI2006[1008] | All people with asthma for FeNO levels but <50 people |
| *LI2006A*[1009] | Not treatment naïve (>50% on CS treatment) |
| LIM2000A[1017] | Not treatment naïve (>50% on CS treatment) |
| LINKOSALA2012 | Sn/sp of FeNO to predict positive exercise challenge test. |
| *LINN2009B*[1023] | Population does not match protocol – general population |
| *LUDVIKSDOTTIR2012*[1044] | Review not primary study |
| MACLEOD2009[1055] | Not treatment naïve (>50% on CS treatment) |
| *MALBYSCHOOS2012*[1069] | All on CS Tx. |
| *MALINOVSCHI2009*[1072] | No objective test |
| MALINOVSCHI2012[1071] | Reference standard does not match protocol – not all patients had objective test (response to treatment only) |
| *MALMBERG2003*[1076] | Sens/spec is calculated for the wrong population: suspected asthma vs. healthy controls. |
| MALMBERG2009[1077] | Comparator test does not match protocol – outdoor running test with non-standard cut-off |
| *MANSO2011*[1086] | Only reports FeNO levels but is not a case-control study or case-series. Pts are suspected asthma. |
| *MARTINS2008*[1095] | Population does not match protocol – FeNO levels in symptomatic patients, not asthma |
| *MATSUNAGA2011*[1105] | Unclear cut-off for objective test part of the Phys Dx. |
| *MCELDOWNEY2008*[1116] | FeNO levels but <50 people |
| *MENZIES2007A*[1134] | Not treatment naïve (>50% on CS treatment) |
| MITSUFUJI2001[1165] | FeNO levels after bronchoprovocation |
| *MONTUSCHI2010*[1175] | Unclear cut-offs for objective tests as part of the Phys Dx. |
| *MUSK2011*[1197] | Not asthma vs. no asthma |
| *NADIF2010*[1204] | Reference standard does not match protocol – no objective test |
| *NARANG2002*[1210] | Not treatment naïve (>50% on CS |

| Reference | Reason for exclusion |
|---|---|
| | treatment) |
| *NELSON1997*[1221] | Not treatment naïve (>50% on CS treatment) |
| NICKELS2014[1231] | Conference abstract |
| NICKELS2014A[1232] | Conference abstract |
| *NICOLAOU2006*[1236] | Population does not match protocol – FeNO levels in general population and patients with wheeze |
| *NOGAMI2003*[1253] | No relevant outcomes – correlation of FeNO and FEV1 |
| *NORDVALL2005*[1258] | Population does not match protocol – general population |
| OH2008[1273] | Population does not match protocol – only chronic cough and unclear treatment |
| *OHKURA2009*[1275] | Not treatment naïve (>50% on CS treatment) |
| OHKURA2013[1274] | Conference abstract |
| OJOO2005[1276] | Case-control study for FeNO levels but <50 people |
| *OLIN2006*[1280] | Population does not match protocol – general population |
| *ONUR2011*[1281] | FeNO levels but <50 people |
| OZAREKHANC2012[1293] | Non-English |
| *PARAMESWARAN2001*[1305] | Case-control study for FeNO levels but <50 people |
| *PAREDI2002*[1309] | Case-control study for FeNO levels but <50 people |
| PAREDI2005[1310] | People with asthma only for FeNO levels but <50 people |
| PEDROSA2010[1330] | Reference standard objective test does not match protocol – methacholine challenge test cut-off at 16mg/ml |
| PEIRSMAN 2013[1331,1331] | Study included in FeNO monitoring review |
| PERZANOWSKI2010[1345] | No objective test (only questionnaire report of wheeze) |
| *PERZANOWSKI2010A*[1343] | Population does not match protocol – general population |
| *PETSKY 2010*[1350,1353] | Abstract |
| *PETSKY 2014*[1353,1354] | Study included in FeNO monitoring review |
| PIACENTINI1999[1357] | People with asthma only for FeNO levels but <50 people |
| *PIACENTINI2000*[1356] | Not treatment naïve (>50% on CS treatment) |
| *PRADO2011*[1395] | Non-English |
| *PRASAD2006*[1396] | Population does not match protocol – general population |

| Reference | Reason for exclusion |
|---|---|
| PRIETO2009[1408] | Not treatment naïve (>50% on CS treatment). Reference standard does not match protocol - ICS responsiveness. |
| *PROFITA2010*[1409] | Not treatment naïve (>50% on CS treatment) |
| *RADULOVIC2010*[1422] | FeNO levels but <50 people |
| *RAMIREZ2010*[1426] | FeNO versus C-reactive protein (not in protocol) |
| *RAMSER2008*[1428] | Sn/sp of FeNO to predict BHR or positive exercise challenge test. |
| *RATNAWATI2006*[1437] | Not treatment naïve (>50% on CS treatment) |
| *REID2003*[1445] | N<50 pts who are ICS naiive, for a study which can only calculate FeNO levels. |
| *RICCIONI2012*[1455] | Not treatment naïve (unclear % on CS treatment) |
| *ROBINSON2012A*[1467] | Population does not match protocol – general population |
| *ROBROEKS2007*[1468] | Not treatment naïve (>50% on CS treatment) |
| *ROLLA2007*[1473] | Not asthma vs. non-asthma |
| ROSA2011[1480] | No objective test (only questionnaire report of wheeze) |
| *ROSIAS2004*[1482] | Not treatment naïve (>50% on CS treatment) |
| *ROUHOS2008*[1487] | Not asthma |
| *SACHSOLSEN2010*[1497] | Population does not match protocol – general population |
| *SAITO2004*[1499] | Population does not match protocol – FeNO levels in patients with and without wheeze, no Dx of asthma |
| *SAKAI2010*[1500] | Reference standard does not match protocol – no objective test |
| *SALOME1999*[1504] | Population does not match protocol – general population |
| *SANDRINI2010*[1507] | Review not primary study |
| *SARAIVA2009*[1512] | FeNO levels but <50 people; not treatment naive |
| *SATOUCHI1996*[1516] | Case-control study for FeNO levels but <50 people |
| SCHLEICH2012[1530] | Reference standard objective test does not match protocol - methacholine challenge test cut-off at 16mg/ml |
| *SCHNEIDER2009*[1537] | Wrong reference standard: Physician Dx with objective test, but objective test uses the wrong cut-off: methacholine at 16ug/ml (should be 8ug/ml). |
| *SCHNEIDER2013*[1536] | Wrong reference standard: Physician Dx with objective test, but objective test |

| Reference | Reason for exclusion |
|---|---|
| | uses the wrong cut-off: methacholine at 16ug/ml (should be 8ug/ml). |
| SCHNEIDER2014[1534] | Wrong reference standard: no objective test |
| *SCHULZE2013*[1543] | Reference standard does not match protocol – no objective test |
| *SCOLLO2000*[1548] | All people with asthma for FeNO levels but <50 people |
| SCOTT2010[1550] | Population does not match protocol – general population |
| *SEE2013*[1555] | Population does not match protocol – general population |
| *SETHI2010*[1562] | All people with asthma for FeNO levels but <50 people |
| SHIN2006[1582] | Case-control study for FeNO levels but <50 people |
| *SHORT2011*[1587] | Not treatment naïve (>50% on CS treatment) |
| SILKOFF2000[1592] | FeNO levels but < 50 people |
| SILVESTRI2000[1601] | Index test does not match protocol – incorrect flow rate |
| SILVESTRI2001[1602] | Index test does not match protocol – incorrect flow rate |
| *SILVESTRI2003*[1603] | Population does not match protocol – FeNO levels in people with atopic and non-atopic asthma |
| *SILVESTRI2006*[1597] | Case-control study for FeNO levels but <50 people |
| SIMON2010[1604] | No relevant outcomes – correlation analysis |
| *SIMPSON2008*[1608] | Review not primary study |
| SINGH2007[1613] | Treatment study; not FeNO for diagnosis or levels in asthma/non-asthma |
| SIPPEL2000[1615] | No relevant outcomes – correlation analysis |
| SIVAN2009[1619] | Index test does not match protocol – no flow rate reported |
| SMITH2004[1630] | Reference standard objective test does not match protocol - hypertonic saline challenge test |
| SMITH2005[1629] | Reference standard objective test does not match protocol - ICS response only used for Dx in a proportion of patients. |
| SONNAPPA2010[1639] | Not treatment naïve (>50% on CS treatment) |
| SONNAPPA2011[1638] | Population does not match protocol – FeNO levels in general population and patients with wheeze |
| *SORDILLO2011*[1643] | Population does not match protocol – |

| Reference | Reason for exclusion |
|---|---|
| | general population |
| SPALLAROSSA2003[1654] | Wrong phys Dx – does not mention objective test. |
| SPITALE2012[1660] | Review not primary study |
| STRUNK2003[1694] | No relevant outcomes – correlation analysis |
| SUTHERLAND2007[1704] | Not treatment naïve; no objective test |
| SVERRILD2009[1708] | Population does not match protocol – general population |
| SVERRILD2010[1707] | Population does not match protocol – general population |
| TAMASI2009[1722] | Population does not match protocol – pregnancy |
| TERADA2001[1740] | All people with asthma for FeNO levels but <50 people |
| THOMAS2005[1750] | Population does not match protocol – general population |
| TILEMANN2011[1756] | Wrong reference standard: Physician Dx with objective test, but objective test uses the wrong cut-off: methacholine at 16ug/ml (should be 8ug/ml). |
| TOMASIAKLOZOWSKA2012[1771] | Case-control study for FeNO levels but <50 people (excluding those on CS treatment) |
| TRAVERS2007[1784] | Population does not match protocol – general population |
| TSUJINO2000[1791] | Unclear / insufficient Dx criteria. National heart and lung institute criteria. |
| TUFVESSON2007[1798] | Case-control (rhinitis vs healthy controls: 26 of the rhinitis patients also had asthma but with the n=12 healthy controls this only makes n=38 |
| TURKTAS2003[1802] | All people with asthma for FeNO levels but <50 people |
| UASUF1999[1808] | Reference standard does not match protocol – no objective test |
| VANAMSTERDAM2003[1818] | Population does not match protocol – general population |
| VANASCH2008[1819] | Population does not match protocol – general population |
| VANDERVALK2012[1829] | Population does not match protocol – general population |
| VANDERVALK2012A[1828] | No relevant outcomes – FeNO for monitoring |
| VERLEDEN1999[1858] | Population does not match protocol – smokers and non-smokers |
| VIEIRA2011[1864] | Population does not match protocol – general population |
| VISSER2000[1868] | Case-control study for FeNO levels but <50 people (excluding those on CS |

| Reference | Reason for exclusion |
|---|---|
| | treatment) |
| VOORENDVAN2013[1878] | Conference abstract |
| WANG2012[1893] | Reference standard does not match protocol – not all patients had objective test |
| WARKE2002[1896] | No relevant outcomes – sn/sp is not for Dx of asthma |
| WELSH2007[1905] | Population does not match protocol – general population |
| WILLIAMSON2010[1923] | Not treatment naïve (>50% of asthma patients on CS treatment) |
| XU2011[1948] | No objective test |
| YAO2011[1952] | Population does not match protocol – general population |
| YAVUZ2012[1954] | No relevant outcomes – FeNO for monitoring |
| YOON2012[1961] | Not treatment naïve; not FeNO levels in asthma vs. non-asthma or diagnostic accuracy |
| ZETTERQUIST2008[1975] | Case-control study for FeNO levels but <50 people |
| ZHAO2013[1977] | No objective test |
| ZIETKOWSKI2007[1986] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2008[1982] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2008A[1981] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2008B[1984] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2009[1987] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2010[1983] | Case-control study for FeNO levels but <50 people |
| ZIETKOWSKI2010B[1985] | Exclude: correlations not sensitivity/ specificity for FeNO; <50 treatment naïve patients + healthy controls |

# 1K.12 Diagnosis: Eosinophils

2 **Table 218: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ADJAMI 2011[18] | Conference abstract. Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative |
| ALVAREZPUEBLA 2003[40] | Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative |

| Reference | Reason for exclusion |
|---|---|
| ATTAPATTU 1991[78] | General population. Wrong comparative test: blood eosinophils vs. SPT. |
| BARNES 1999[110] | Combinations of tests. Does not report eosinophil counts. |
| BJORNSSON 1994[176] | Incorrect population |
| BOUZIGON 2012[204] | Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative |
| BRAND 1993[213] | Not addressing specified population: mixed population (no asthma subgroup analysis) |
| BURNETT 2011[247] | Conference abstract. Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative. |
| BURROWS 1991[250] | Not addressing specified outcomes: predictors of future disease of asthma |
| CRATER 1999[377] | NOT addressing specified outcomes |
| DIFRANCO 2003[435] | Not addressing review question: sputum eosinophil not blood; eosinophil blood levels given at baseline but N<50. |
| DILORENZO 2007[436] | Incorrect study design |
| FRANKLIN 2003[520] | Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative. |
| FRETTE 1991[523] | Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative |
| FUJIMURA 2005[533] | Predictors of future asthma development and eosinophil levels, but N<50. |
| HALLDEN 1999[629] | Case-control study which reports levels of eosinophils, but N<50. |
| HASTIE 2013[648] | Incorrect population |
| HYVARINEN 2010[728] | Predictors of future asthma development |
| IMAI 1999[736] | Case-control study which reports levels of eosinophils, but N<50. |
| JANG 2003[759] | Case control: but N<50 and does not report eosinophil counts at baseline, only correlations. |

| Reference | Reason for exclusion |
|---|---|
| JUNG 2011[796] | NOT addressing review question: excluded asthma patients |
| KARTASAMITA 1994[826] | Not addressing specified outcomes |
| KOWAL 2009[924] | Not addressing specified outcomes/population |
| KUEHR 1994[933] | Mixed population of asthma and non-asthma but data not separated. |
| LECKIE 2000[983] | Wrong study: looks at effects of treatment |
| LIANG 2012[1012] | Not addressing review question |
| LIM 2010[1015] | Conference abstract. Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative. |
| MAGNAN 1998[1061] | Not addressing review question. Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative. |
| MAHMOUD 2011[1065] | Incorrect study design |
| MAHMOUD 2013[1064] | Meeting abstract |
| MALINOVSCHI 2013[1073] | Incorrect population & reference standard |
| MATSUNAGA 2011[1105] | Incorrect study design. Not addressing specified outcomes |
| MATSUNAGA 2012[1104] | NOT addressing specified outcomes |
| MEYER 2014[1140] | Incorrect population |
| MOHAMMADIEN 2009[1170] | Wrong study/Incorrect study design: case-control study and relationships + levels |
| NOGAMI 2003[1253] | Not addressing specified outcomes: values not given |
| PALMER 2001[1298] | Not addressing clinical/review question |
| PARK 2013[1314] | Conference abstract |
| POHUNEK 2005[1375] | Wrong outcomes: predictors of subsequent development of asthma. |
| POSTMA 1995[1385] | Incorrect population |
| PRONK 2001[1410] | Case control study, but does not report levels of blood eosinophils. |

| Reference | Reason for exclusion |
|---|---|
| RAZI 2010[1439] | Wrong outcomes: eosinophil count as predictor of response to treatment |
| ROQUET 1996[1479] | Levels: hyperactive versus hyperactive patients; N,50. |
| SOUMA 2011[1651] | Conference abstract. Wrong outcomes: associations of eosinophil levels. |
| SPALLAROSSA 1995[1653] | Case-control study which reports levels of eosinophils, but N<50. |
| SPECTOR 2012[1655] | Case-control study which reports levels of eosinophils, but N<50. |
| TSYBULKINA 2012[1793] | Conference abstract. Wrong outcomes: levels and correlations of eosinophils, not no. of positive/negative. |
| ULRIK 2005[1810] | General population. Does not give +ve and –ve for eosinophils or eosinophil levels. |
| VOLBEDA 2013[1871] | Not disease but markers of control (i.e. monitoring) |
| YURDAKUL 2005[1968] | Incorrect study design |
| ZEDAN 2010[1973] | Incorrect study design |

# 1K.13 Diagnosis: Histamine and methacholine challenge tests

2 **Table 219: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALBERTS 1994[32,32] | Index test and reference standard do not match protocol – sn/sp of FEF25-75% in predicting positive methacholine test |
| ALBORNOZ 1995[33,33] | All people with confirmed asthma and no comparator test |
| ALVAREZPUEBLA 2003[40] | Reference standard does not match protocol (Dx based on symptoms without objective test) |
| ANDERSON 2010A[44,46] | Conference abstract |
| ANDERSON 2011[44,47] | Review article |
| ANDREGNETTE 2011[49,49] | Conference abstract |
| ANTOLINAMERIGO 2012[54] | Conference abstract |
| ANTOLINAMERIGO 2013[55] | Conference abstract |
| AVITAL 1995[82,82] | Population does not match protocol – mean age < 5years |
| AVITAL 1995A[82,83] | Comparator tests do not match protocol |

| Reference | Reason for exclusion |
|---|---|
| | (methacholine vs AMP and exercise) and sn/sp of methacholine not compared to reference standard of physician Dx with objective test (American Thoracic Soc diagnostic criteria for asthma) |
| BACKER 1991[87,87] | Reference standard does not match protocol – questionnaire based on symptoms and physician Dx without report of objective test |
| BACKER 1992[87,90] | No relevant outcomes and does not match review question - relationship between bronchial responsiveness and IgE |
| BACKER 1992B[87,89] | Index test does not match protocol (sn and sp of physician Dx and symptoms in relation to exercise challenge) |
| BACKER 1995[86,87] | Population does not match protocol - prevelence of positive HCT in general population and correlation with asthma and atopy |
| BACKER 2014[87,91] | Index test and reference standard do not match protocol – sn/sp of FeNO to predict positive mannitol in suspected asthma (not physician diagnosis and objective test) |
| BAILLY 2011[93,93] | No relevant outcomes and does not match review question (different methods of measuring methacholine response, Pc20 used as part of reference standard for Dx) |
| BALLWEG 2012[99,99] | Review article |
| BARBEN 2011[106,106] | Index test does not match protocol – mannitol and exercise challenge test |
| BASIR 1995[123,123] | Index test does not match protocol – methacholine challenge test. No reference standard of physician diagnosis with objective test |
| BENNETT 1987[152,152] | No relevant outcomes and does not match review question (different methods of measuring methacholine and histamine response; all people with confirmed asthma and comparator does not match protocol) |
| BERKMAN 2005[159,159] | Reference standard does not match protocol – physician Dx without objective test in a proportion of patients and no data on the percentage of patients who were Dx with an objective test. |
| BEYDON 2008[167,167] | No relevant outcomes and does not match review question – correlation between BDR and methacholine response |
| BIBI 1991[171,171] | Reference standard does not match protocol – physician Dx without objective test. Cannot compare index test vs comparator test as people with suspected asthma and no suitable reference standard |

| Reference | Reason for exclusion |
|---|---|
| BIRNBAUM 2007[174,174] | Review article |
| BONAVIA 1996[184,184] | Comparator tests and reference standard do not match protocol (asthma group defined by symptom score not physician Dx) |
| BOONSAWAT 1992[189,189] | Reference standard does not match protocol (physician Dx without objective test) |
| BOUAZIZ 1996[198,198] | Comparing different methods of measuring methacholine test (all patients with asthma and no comparator test) |
| BRAND 1993[210,213] | Index test does not match protocol – no challenge test performed |
| BRUSCHI 1989[236,236] | Population does not match protocol - general population not suspected asthma |
| BUSSE 2005[255,255] | Review / report from workshop |
| CARLSEN 1998[273,275] | case-control study |
| CARLSTEN 2011[277,278] | Reference standard does not match protocol – Dx was clinical decision made by the paediatric allergist based on symptoms of wheeze and cough, use of medications and physical findings |
| CHATHAM 1982[305,305] | Sn/sp of histamine and methacholine vs exercise in people with asthma and controls (does not match this protocol comparator). No reference standard of physician Dx with objective test. |
| CHOI 2003[319,319] | Index test does not match protocol (incorrect cut-off for positive test) |
| CHOI 2007A[319,321] | Population does not match protocol (all patients had positive methacholine challenge test) |
| CHUNG 2010[329,329] | Conference abstract – sn/sp of mannitol and methacholine but reference standard not mentioned |
| CIPRANDI 2010[331,337] | No relevant outcomes and does not match review question – correlation between FeNO and methacholine PC20 and sn/sp of FeNO to predict positive methacholine test |
| CIPRANDI 2011[331,335] | Population does not match protocol – all Dx with allergic rhinitis and excluded if a history of asthma or referred with asthma symptoms |
| CIRILLO 2009[340,341] | Population does not match protocol – all Dx with allergic rhinitis and excluded if a history of asthma or referred with asthma symptoms |
| COCKCROFT 1979[356,356] | No relevant outcomes and does not match review question (correlation between allergen PC20 and histamine PC20 in people with confirmed asthma) |
| COCKCROFT 1992[355,356] | Reference standard does not match |

| Reference | Reason for exclusion |
|---|---|
| | protocol – Dx based on questionnaire (previous doctor diagnosis or wheeze symptoms) |
| COCKCROFT 2005[354,356] | No relevant outcomes and does not match review question (correlation between allergen, histamine and methacholine PC20 in people with confirmed asthma) |
| COCKCROFT 2009[356,357] | Review article |
| COCKCROFT 2010[356,358] | Review article |
| CORDEIRO 2011[365,365] | Index test and reference standard do not match protocol – histamine test used as part of reference standard to Dx (index test = FeNO) |
| DEHAUT 1983[412,412] | No relevant outcomes and does not match review question (different methods of measuring histamine response) |
| DELGIUDICE 2004[414] | No relevant outcomes and does not match review question – correlation between FeNO and PC20 (all patients with asthma but Dx made by physician with no objective test) |
| DEN OTTER 1997[422] | Reference standard for asthma diagnosis included methacholine/histamine challenge test |
| DI LORENZO 2007[436] | Case control type study with 3 groups (asthma Dx by symptoms and objective test; gastro-oesophageal reflux group with asthma symptoms; healthy controls) – study gives sn/sp values for MCT but this is based on 52% of patients having asthma (includes asymptomatic healthy control group) |
| DREWEK 2009[454,454] | Index test does not match protocol (sn and sp of FEF25-75 to measure methacholine response; diagnosis of asthma based on symptoms during challenge test) |
| DURAND 2011[458] | Conference abstract – reference standard not mentioned |
| DURZO 2012[389] | Conference abstract |
| FORASTIERE 1991[507,507] | Reference standard does not match protocol (asthma defined as affirmative answer to 'has a doctor ever said this child has asthma' or 3 out of 4 wheezing symptoms on questionnaire) |
| FORTUNA 2007[510,511] | Methacholine used as reference standard - sn/sp of FeNO, eos, spirometry and BDR with positive methacholine test used to diagnose asthma |
| FRANKLIN 2003[520,520] | Population does not match protocol (all asymptomatic at time of the study) |
| FRUCHTER 2009[530,530] | Reference standard does not match protocol - not physician diagnosis and |

| Reference | Reason for exclusion |
|---|---|
| | objective test |
| GADE 2009[537,537] | Does not match review question (influence of mannitol and methacholine tests on each other) |
| GARCIA-RIO 2004[549] | Population does not match protocol – all had positive histamine challenge |
| GHODRATI 2011[562,562] | Not in English |
| GILBERT 1990[569,570] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test) |
| GODFREY 1999[576,577] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test) |
| GOLDSTEIN 1994[585,585] | Reference standard does not match protocol – based on symptoms and response to therapy (no objective test) |
| GOLDSTEIN 2001[585,586] | Does not match review question – longitudinal follow-up to asthma diagnosis and methacholine test used as part of reference standard to Dx asthma |
| GRAIF 2002[590,590] | Sn/sp of SPT with positive methacholine test used to diagnose asthma (no reference standard of physician Dx to calculate sn/sp of methacholine test) |
| GREENSPON 1992[598,598] | Reference standard does not match protocol – Dx asthma group gave a history typical of asthma and had histories of acute exacerbation that were relieved by bronchodilator therapy |
| GRUCHALLA 2003[601,601] | Reference standard does not match protocol – methacholine used as part of Dx of asthma for calculation of sn/sp of symptoms questionnaire in the Dx of asthma |
| HIGGINS 1992[678,679] | Reference standard does not match protocol – Dx based on symptoms questionnaire or 'ever had asthma attack' (no mention of objective test) |
| HOPP 1984[702,702] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). |
| HUNTER 2002[721,721] | Methacholine challenge tests used as one of the objective tests to Dx asthma in the group with asthma |
| HUR 2009[723,724] | Conference abstract |
| HUR 2010[722,723] | Conference abstract – duplicate of Hur 2010 |
| IRWIN 1997[739,740] | Population does not match protocol – all symptomatic and methacholine challenge positive |

| Reference | Reason for exclusion |
|---|---|
| JAMES 1992[751,751] | Reference standard does not match protocol (physician Dx without objective test and/or wheeze in the last 12 months) |
| JAMES 1997[751,752] | Review article – summarises studies sn/sp of challenge tests but ref standard does not match protocol (use symptom questionnaire and diagnosis based on wheeze in last 12 months or asthma Dx by doctor) |
| JOHNSON 1987[779,779] | Reference standard does not match protocol – association of methacholine response with symptoms not physician Dx |
| JOSEPH 2004[791] | Reference standard does not match protocol; physician diagnosis + symptoms of wheeze in last 12 months + asthma meds in last 12 months (no objective test) |
| KANG 2005[818,818] | No relevant outcomes and does not match review question (people with confirmed asthma with no comparator test) |
| KHALID 2009[857,857] | Sn/sp of different measure for methacholine challenge (with PC20 positive/negative used for asthma Dx) |
| KIM 2002[872,873] | Reference standard does not match protocol (correlation of BHR with risk factors and symptoms from questionnaire – no physician Dx) |
| KIM 2014A[871,873] | Conference abstract |
| KIM 2014B[869,873] | Case control study |
| KING 1989[876,876] | Index test and reference standard do not match protocol – sn/sp of wheezing on max forced exhalation as predictor of positive methacholine test |
| KIVASTIK 2007[880,880] | Population does not match protocol (age range 3-6 years) |
| KNOX 1989[893,893] | No relevant outcomes and does not match review question (different methods of measuring methacholine response) |
| KOLNAAR 1995[904,904] | Reference standard does not match protocol - comparison of histamine test to presence of asthma symptoms (not to physician Dx) |
| LAU 2002[972,974] | Population does not match protocol – general population |
| LEE 2011[984,985] | Conference abstract |
| LEVIN 2011[1001,1001] | Reference standard does not match protocol - self-reported symptoms of asthma in the last 12 months |
| LEWIS 2001[1002,1005] | Reference standard does not match protocol - self reported doctor-Dx asthma and no mention of objective test |
| LIEM 2008[1013,1014] | No relevant outcomes and does not match |

| Reference | Reason for exclusion |
|---|---|
| | review question (healthy controls and people with confirmed asthma with no comparator test) |
| LINNA 1998[1025,1026] | All patients with asthma and no comparator test (comparing different methods of measuring methacholine challenge) |
| LUMELLI 2010[1047,1047] | Conference abstract |
| MADSEN 1985[1057,1057] | Reference standard does not match protocol – some patients were Dx without objective test on basis of answer to 2 questions on attacks of shortness of breath |
| MADSEN 1986[1056,1057] | Reference standard does not match protocol – some patients were Dx without objective test on basis of answer to 2 questions on attacks of shortness of breath |
| MALMBERG 2001[1075,1075] | No relevant outcomes and does not match review question (people with confirmed asthma with no comparator test) |
| MANNINO 1996[1085,1085] | Methacholine challenge test but no comparator or reference standard test |
| MANSO 2011[1086,1086] | Reference standard does not match protocol – methacholine test used as reference standard to Dx asthma in some patients |
| MCCLEAN 2010[1111,1111] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). Physician diagnosis without objective test |
| MCGARVEY 1998[1118,1118] | No relevant outcomes and does not match review question - histamine challenge in comparison to treatment response for various respiratory diseases |
| METSO 1996[1138,1138] | Reference standard does not match protocol |
| MIEDINGER 2010[1145,1146] | Reference standard does not match protocol – not all patients Dx with asthma had an objective test (some physician Dx only) |
| MULLER 1993[1188,1188] | Case control study |
| NADASKIC 2010[1203,1203] | Conference abstract |
| NICKELS 2014[1231,1231] | Conference abstract |
| NIGGEMANN 2001[1242,1242] | Reference standard does not match protocol - sn/sp if histamine challenge to predict asthma symptoms (not diagnosis of asthma) |
| NISH 1992[1249,1249] | Reference standard does not match protocol – physician Dx with objective test not reported and histamine challenge used as part of reference standard to Dx |
| OCONNOR 1994[1264] | Reference standard does not match |

| Reference | Reason for exclusion |
|---|---|
| | protocol - affirmative response to 'have you ever had asthma?' |
| OHKURA 2013[1274,1275] | Conference abstract |
| OKUPA 2012[1278,1278] | Conference abstract |
| PALMEIRO 1992[1297,1297] | Reference standard does not match protocol – asthma Dx based on questionnaire reponses |
| PARAMESWARAN 1999[1306,1306] | Reference standard does not match protocol - physian Dx without objective test |
| PARK 2009[1311,1313] | Conference abstract |
| PARKER 2004[1315,1315] | Population does not match protocol (all patients had positive methacholine challenge test and looking at factors which influence the PC20) |
| PARKERSON 2011[1316,1316] | Review article |
| PATTEMORE 1990[1320,1320] | Reference standard does not match protocol (asthma diagnosis by previous report of a diagnosis but no objective test) |
| PEDROSA 2009[1329,1329] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of AMP challenge |
| PEDROSA 2010[1329,1330] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of FeNO |
| PERPINA 1993[1336,1336] | Case control type study with 4 groups (asthma; rhinitis; chronic bronchitis; healthy controls) – study gives sn/sp values for MCT but this is basedall patients (includes asymptomatic healthy control group) |
| POPA 1988[1380,1380] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). |
| PORSBJERG 2007[1382,1383] | Population does not match protocol – relationship between the response to methacholine and mannitol in asymptomatic subjects who do not have asthma |
| PORSBJERG 2009[1383,1384] | Review article |
| PRATTER 1983[1398,1398] | Index test and reference standard do not match protocol – sn/sp of wheeze symptoms vs reference standard of physician Dx with methacholine test |
| PRIETO 1998[1406,1406] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of PEFV |
| PRIETO 1998A[1405,1406] | No relevant outcomes and does not match review question (differences in dose- |

| Reference | Reason for exclusion |
|---|---|
| | response curve to methacholine in asthma, rhinitis and controls) |
| PUOLIJOKI 1992[1415,1415] | Population does not match protocol – all methacholine challenge test negative patients |
| PUROKIVI 2007[1416,1416] | Index test does not match protocol – hypertonic histamine challenge |
| REMES 2002[1447,1448] | Methacholine challenge tests used as one of the objective tests to Dx asthma |
| RENWICK 1996[1451,1451] | Chronic airway obstruction prevelence and BDR |
| RIJCKEN 1989[1462,1462] | Reference standard does not match protocol (sensitivity and specificity of histamine challenge test to detect self-reported symptoms (symptomatic or asymptomatic) |
| ROQUET 1996[1479,1479] | No relevant outcomes and does not match review question –sn/sp of Eos to predict positive challenge test |
| SACHOLSEN 2010[1497] | Population does not match protocol - general population not all people with asthma or suspected asthma |
| SCHLEICH 2012[1530,1530] | Methacholine challenge test used as part of the reference standard to Dx asthma in suspected asthma patients without airway obstruction or BDR |
| SCHMIDT 1992[1532,1532] | All patients with asthma and no comparator test (comparing different methods of histamine challenge). Physician Dx only, no objective test |
| SCHNEIDER 2009A[1535,1537] | Methacholine challenge test used as part of the reference standard to Dx asthma and assess the sn/sp of spirometry in GP |
| SCHULZE 2013[1543,1543] | No relevant outcomes and does not match review question – sn/sp of methacholine challenge to detect a positive allergen response |
| SHAPIRO 1982[1571,1571] | Reference standard does not match protocol – methacholine test used as reference standard to Dx asthma |
| SIERSTED 1994[1590,1590] | Reference standard does not match protocol – asthma Dx based on questionnaire responses to doctor diagnosed asthma and symptoms (no mention of objective test) |
| SIERSTED 1994[1590,1590] | Duplicate – ordered twice, already excluded for this review |
| SIERSTED 1996[1590,1591] | Reference standard does not match protocol – methacholine test used as part of reference standard to Dx asthma |
| SISTEK 2006[1617,1618] | Reference standard does not match protocol – asthma Dx based on |

| Reference | Reason for exclusion |
|---|---|
| | questionnaire responses to doctor diagnosed asthma and attack in the last 12 months (no mention of objective test) |
| SORIANO 1999[1644,1646] | Reference standard does not match protocol - positive methacholine test used to Dx asthma |
| SOVIJARVI 1986[1652,1652] | No relevant outcomes and does not match review question – different methods of measuring methacholine test |
| SPIROPOULOS 1986[1659,1659] | No relevant outcomes and does not match review question – sn/sp of methacholine test in predicting hyper-reative airway symptoms not physician Dx of asthma |
| SPOSATO 2014[1661,1662] | Index test and reference standard do not match protocol |
| SPRINGER 2000[1663,1663] | Population does not match protocol (aged 2-8 years). All people with confirmed asthma and no comparator test |
| STAHL 2009[1669,1670] | Conference abstract |
| SUN 2007[319,321] | Duplicate of CHOI 2007A – already excluded in this review |
| SVERRILD 2009 [1708,1708] | Same data used for Sverrild 2010 paper already excluded from this review. |
| SVERRILD 2010[1707,1708] | Reference standard does not match protocol - physician Dx without objective test (physician Dx made on the basis of symptoms in the last 12 months in combination with either a eNO level of greater than 30 ppb, a history of allergic rhinoconjunctivitis, dermatitis, a positive skin prick test response, a familial predisposition to atopic disease, nonallergic rhinoconjunctivitis, or an FEV1/forced vital capacity ratio of less than 75%). |
| SVERRILD 2012[1706,1708] | Review article |
| SVERRILD 2013[1705,1708] | Sn/sp of FeNO in predicting positive mannitol response. Reference standard does not match protocol - physian Dx with no mention of objective test |
| TAKAMI 2013[1718,1718] | No relevant outcomes and does not match review question (correlation study) |
| TERNESTEN 2002[1742] | Methacholine challenge test used as part of the reference standard to Dx asthma |
| TIE 2012[1755,1755] | Reference standard does not match protocol |
| TODD 2004[1764,1764] | Not relevant outcomes and does not answer review question - all people with asthma with positive methacholine challange (comparing methods of performing methacholine test) |
| TOELLE 1992[1765,1765] | Methacholine challenge test used as part of the reference standard to Dx asthma |

| Reference | Reason for exclusion |
|---|---|
| TOWNLEY 1975[1782,1782] | Reference standard does not match protocol – no objective test |
| TOWNLEY 1990[1781,1782] | Can only calculate sensitivity (methacholine challenge in suspected asthma and asymptomatic controls – all suspected group were Dx based on reference standard and no Dx of control group reported) |
| VILOZNI 2009[1866,1867] | Population does not match protocol (aged 3-6 years) |
| WONGTIM 1997[1936,1936] | Methacholine challenge test used as part of the reference standard to Dx asthma |
| WOO 2012[1937,1937] | Methacholine challenge test used as part of the reference standard to Dx asthma – Dx based on symptoms and BDR and/or positive methacholine challenge |
| WOOLCOCK 1984[1943,1943] | Histamine challenge test but no comparator or reference standard test (looking at dose-response curve to histamine in people with asthma and controls) |
| WU 2011[1946,1946] | Conference abstract |
| XU 2001[1949,1949] | Reference standard does not match protocol - asthma was defined as a history of physician-diagnosed asthma at any time in the past (no mention of objective test) |
| YURDAKUL 2005[1968,1968] | Reference standard does not match protocol – methacholine test used as part of reference standard to Dx asthma |
| ZAGHLOUL 2009[1970,1970] | Conference abstract |

# 1K.14 Diagnosis: Mannitol challenge test

2 **Table 220: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALBERTS 1994[32,32] | Index test and reference standard do not match protocol – sn/sp of FEF25-75% in predicting positive methacholine test |
| ALBORNOZ 1995[33,33] | All people with confirmed asthma and no comparator test |
| ALVAREZPUEBLA 2003[40] | Reference standard does not match protocol (Dx based on symptoms without objective test) |
| ANDERSON 2010A[44,46] | Conference abstract |
| ANDERSON 2011[44,47] | Review article |
| ANDREGNETTE 2011[49,49] | Conference abstract |
| ANTOLINAMERIGO 2012[54] | Conference abstract |
| ANTOLINAMERIGO 2013[55] | Conference abstract |
| AVITAL 1995[82,82] | Population does not match protocol – mean age < 5years |

| Reference | Reason for exclusion |
|---|---|
| AVITAL 1995A[82,83] | Comparator tests do not match protocol (methacholine vs AMP and exercise) and sn/sp of methacholine not compared to reference standard of physician Dx with objective test (American Thoracic Soc diagnostic criteria for asthma) |
| BACKER 1991[87,87] | Reference standard does not match protocol – questionnaire based on symptoms and physician Dx without report of objective test |
| BACKER 1992[87,90] | No relevant outcomes and does not match review question - relationship between bronchial responsiveness and IgE |
| BACKER 1992B[87,89] | Index test does not match protocol (sn and sp of physician Dx and symptoms in relation to exercise challenge) |
| BACKER 1995[86,87] | Population does not match protocol - prevelence of positive HCT in general population and correlation with asthma and atopy |
| BACKER 2014[87,91] | Index test and reference standard do not match protocol – sn/sp of FeNO to predict positive mannitol in suspected asthma (not physician diagnosis and objective test) |
| BAILLY 2011[93,93] | No relevant outcomes and does not match review question (different methods of measuring methacholine response, Pc20 used as part of reference standard for Dx) |
| BALLWEG 2012[99,99] | Review article |
| BARBEN 2011[106,106] | Reference standard does not match protocol – sn/sp for Mannitol test only calculated taking into account index test result. Can calculated sn/sp of mannitol vs exercise test in children but this is only in suspected asthma (cannot do calculation for those children Dx according to the RS) |
| BASIR 1995[123,123] | No reference standard of physician diagnosis with objective test |
| BENNETT 1987[152,152] | No relevant outcomes and does not match review question (different methods of measuring methacholine and histamine response; all people with confirmed asthma and comparator does not match protocol) |
| BERKMAN 2005[159,159] | Reference standard does not match protocol – physician Dx without objective test in a proportion of patients and no data on the percentage of patients who were Dx with an objective test. |
| BEYDON 2008[167,167] | No relevant outcomes and does not match review question – correlation between BDR and methacholine response |
| BIBI 1991[171,171] | Index test does not match protocol – |

| Reference | Reason for exclusion |
|---|---|
| | methacholine challenge test |
| BIRNBAUM 2007[174,174] | Review article |
| BONAVIA 1996[184,184] | Comparator tests and reference standard do not match protocol (asthma group defined by symptom score not physician Dx) |
| BOONSAWAT 1992[189,189] | Reference standard does not match protocol (physician Dx without objective test) |
| BOUAZIZ 1996[198,198] | Comparing different methods of measuring methacholine test (all patients with asthma and no comparator test) |
| BRAND 1993[210,213] | Index test does not match protocol – no challenge test performed |
| BRUSCHI 1989[236,236] | Population does not match protocol - general population not suspected asthma |
| BUSSE 2005[255,255] | Review / report from workshop |
| CARLSEN 1998[273,275] | case-control study |
| CARLSTEN 2011[277,278] | Reference standard does not match protocol – Dx was clinical decision made by the paediatric allergist based on symptoms of wheeze and cough, use of medications and physical findings |
| CHATHAM 1982[305,305] | Sn/sp of histamine and methacholine vs exercise in people with asthma and controls (does not match this protocol comparator). No reference standard of physician Dx with objective test. |
| CHOI 2003[319,319] | Index test does not match protocol – methacholine challenge test |
| CHOI 2007A[319,321] | Population does not match protocol (all patients had positive methacholine challenge test) |
| CHUNG 2010[329,329] | Conference abstract – sn/sp of mannitol and methacholine but reference standard not mentioned |
| CIPRANDI 2010[331,337] | No relevant outcomes and does not match review question – correlation between FeNO and methacholine PC20 and sn/sp of FeNO to predict positive methacholine test |
| CIPRANDI 2011[331,335] | Population does not match protocol – all Dx with allergic rhinitis and excluded if a history of asthma or referred with asthma symptoms |
| CIRILLO 2009[340,341] | Population does not match protocol – all Dx with allergic rhinitis and excluded if a history of asthma or referred with asthma symptoms |
| COCKCROFT 1979[356,356] | No relevant outcomes and does not match review question (correlation between allergen PC20 and histamine PC20 in people with confirmed asthma) |

| Reference | Reason for exclusion |
|---|---|
| COCKCROFT 1992[355,356] | Reference standard does not match protocol – Dx based on questionnaire (previous doctor diagnosis or wheeze symptoms) |
| COCKCROFT 2005[354,356] | No relevant outcomes and does not match review question (correlation between allergen, histamine and methacholine PC20 in people with confirmed asthma) |
| COCKCROFT 2009[356,357] | Review article |
| COCKCROFT 2010[356,358] | Review article check for refs |
| CORDEIRO 2011[365,365] | Index test and reference standard do not match protocol – histamine test used as part of reference standard to Dx (index test = FeNO) |
| DEHAUT 1983[412,412] | No relevant outcomes and does not match review question (different methods of measuring histamine response) |
| DELGIUDICE 2004[414] | No relevant outcomes and does not match review question – correlation between FeNO and PC20 (all patients with asthma but Dx made by physician with no objective test) |
| DI LORENZO 2007[436] | Case control type study with 3 groups (asthma Dx by symptoms and objective test; gastro-oesophageal reflux group with asthma symptoms; healthy controls) – study gives sn/sp values for MCT but this is based on 52% of patients having asthma (includes asymptomatic healthy control group) |
| DREWEK 2009[454,454] | Index test does not match protocol (sn and sp of FEF25-75 to measure methacholine response; diagnosis of asthma based on symptoms during challenge test) |
| DURAND 2011[458] | Conference abstract – reference standard not mentioned |
| DURZO 2012[389] | Conference abstract |
| FORASTIERE 1991[507,507] | Reference standard does not match protocol (asthma defined as affirmative answer to 'has a doctor ever said this child has asthma' or 3 out of 4 wheezing symptoms on questionnaire) |
| FORTUNA 2007[510,511] | Methacholine used as reference standard - sn/sp of FeNO, eos, spirometry and BDR with positive methacholine test used to diagnose asthma |
| FRANKLIN 2003[520,520] | Population does not match protocol (all asymptomatic at time of the study) |
| FRUCHTER 2009[530,530] | Index test and reference standard do not match protocol – sn/sp of BDR to predict positive methacholine in suspected asthma (not physician diagnosis and objective test) |
| GADE 2009[537,537] | Does not match review question (influence |

| Reference | Reason for exclusion |
|---|---|
| | of mannitol and methacholine tests on each other) |
| GARCIA-RIO 2004[549] | Population does not match protocol – all had positive histamine challenge |
| GHODRATI 2011[562,562] | Not in English |
| GILBERT 1990[569,570] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test) |
| GODFREY 1999[576,577] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test) |
| GOLDSTEIN 1994[585,585] | Index test does not match protocol – methacholine challenge test |
| GOLDSTEIN 2001[585,586] | Does not match review question – longitudinal follow-up to asthma diagnosis and methacholine test used as part of reference standard to Dx asthma |
| GRAIF 2002[590,590] | Sn/sp of SPT with positive methacholine test used to diagnose asthma (no reference standard of physician Dx to calculate sn/sp of methacholine test) |
| GREENSPON 1992[598,598] | Reference standard does not match protocol – Dx asthma group gave a history typical of asthma and had histories of acute exacerbation that were relieved by bronchodilator therapy |
| GRUCHALLA 2003[601,601] | Reference standard does not match protocol – methacholine used as part of Dx of asthma for calculation of sn/sp of symptoms questionnaire in the Dx of asthma |
| HEDMAN 1998[656,656] | Index test does not match protocol – methacholine challenge test |
| HIGGINS 1992[678,679] | Reference standard does not match protocol – Dx based on symptoms questionnaire or 'ever had asthma attack' (no mention of objective test) |
| HOPP 1984[702,702] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). |
| HUNTER 2002[721,721] | Methacholine challenge tests used as one of the objective tests to Dx asthma in the group with asthma |
| HUR 2009[723,724] | Conference abstract |
| HUR 2010[722,723] | Conference abstract – duplicate of Hur 2010 |
| IRWIN 1997[739,740] | Population does not match protocol – all symptomatic and methacholine challenge positive |

| Reference | Reason for exclusion |
|---|---|
| JAMES 1992[751,751] | Reference standard does not match protocol (physician Dx without objective test and/or wheeze in the last 12 months) |
| JAMES 1997[751,752] | Review article – summarises studies sn/sp of challenge tests but ref standard does not match protocol (use symptom questionnaire and diagnosis based on wheeze in last 12 months or asthma Dx by doctor) |
| JOHNSON 1987[779,779] | Reference standard does not match protocol – association of methacholine response with symptoms not physician Dx |
| JOSEPH 2004[791] | Reference standard does not match protocol; physician diagnosis + symptoms of wheeze in last 12 months + asthma meds in last 12 months (no objective test) |
| KANG 2005[818,818] | No relevant outcomes and does not match review question (people with confirmed asthma with no comparator test) |
| KHALID 2009[857,857] | Sn/sp of different measure for methacholine challenge (with PC20 positive/negative used for asthma Dx) |
| KIM 2002[872,873] | Reference standard does not match protocol (correlation of BHR with risk factors and symptoms from questionnaire – no physician Dx) |
| KIM 2014[869,873] | Case control study |
| KIM 2014A[871,873] | Conference abstract |
| KING 1989[876,876] | Index test and reference standard do not match protocol – sn/sp of wheezing on max forced exhalation as predictor of positive methacholine test |
| KIVASTIK 2007[880,880] | Population does not match protocol (age range 3-6 years) |
| KNOX 1989[893,893] | No relevant outcomes and does not match review question (different methods of measuring methacholine response) |
| KOLNAAR 1995[904,904] | Reference standard does not match protocol - comparison of histamine test to presence of asthma symptoms (not to physician Dx) |
| KOSKELA 2003[915,915] | All patients with asthma and comparator test does not match protocol (comparators histamine and cold air challenge tests) |
| KOWAL 2009[924,924] | Index test does not match protocol – histamine challenge test |
| LEE 2011[984,985] | Conference abstract |
| LEVIN 2011[1001,1001] | Reference standard does not match protocol - self-reported symptoms of asthma in the last 12 months |
| LEWIS 2001[1002,1005] | Reference standard does not match |

| Reference | Reason for exclusion |
|---|---|
| | protocol - self reported doctor-Dx asthma and no mention of objective test |
| LIEM 2008[1013,1014] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test) |
| LINNA 1998[1025,1026] | All patients with asthma and no comparator test (comparing different methods of measuring methacholine challenge) |
| LUMELLI 2010[1047,1047] | Conference abstract |
| MADSEN 1985[1057,1057] | Reference standard does not match protocol – some patients were Dx without objective test on basis of answer to 2 questions on attacks of shortness of breath |
| MADSEN 1986[1056,1057] | Reference standard does not match protocol – some patients were Dx without objective test on basis of answer to 2 questions on attacks of shortness of breath |
| MALMBERG 2001[1075,1075] | No relevant outcomes and does not match review question (people with confirmed asthma with no comparator test) |
| MANNINO 1996[1085,1085] | Methacholine challenge test but no comparator or reference standard test |
| MANSO 2011[1086,1086] | Reference standard does not match protocol – methacholine test used as reference standard to Dx asthma in some patients |
| MCCLEAN 2010[1111,1111] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). Physician diagnosis without objective test |
| MCGARVEY 1998[1118,1118] | No relevant outcomes and does not match review question - histamine challenge in comparison to treatment response for various respiratory diseases |
| METSO 1996[1138,1138] | Reference standard does not match protocol |
| MIEDINGER 2010[1145,1146] | Reference standard does not match protocol – not all patients Dx with asthma had an objective test (some physician Dx only) |
| MULLER 1993[1188,1188] | Case control study |
| NADASKIC 2010[1203,1203] | Conference abstract |
| NICKELS 2014[1231,1231] | Conference abstract |
| NIEMINEN 1992[1241,1241] | Index test does not match protocol – methacholine challenge test |
| NIGGEMANN 2001[1242,1242] | Reference standard does not match protocol - sn/sp if histamine challenge to predict asthma symptoms (not diagnosis of asthma) |

| Reference | Reason for exclusion |
|---|---|
| NISH 1992[1249,1249] | Reference standard does not match protocol – physician Dx with objective test not reported and histamine challenge used as part of reference standard to Dx |
| OCONNOR 1994[1264] | Reference standard does not match protocol - affirmative response to 'have you ever had asthma?' |
| OHKURA 2013[1274,1275] | Conference abstract |
| OKUPA 2012[1278,1278] | Conference abstract |
| OTTER 1997[422] | Index test does not match protocol – histamine challenge test |
| PALMEIRO 1992[1297,1297] | Reference standard does not match protocol – asthma Dx based on questionnaire reponses |
| PARAMESWARAN 1999[1306,1306] | Reference standard does not match protocol - physian Dx without objective test |
| PARK 2009[1311,1313] | Conference abstract |
| PARKER 2004[1315,1315] | Population does not match protocol (all patients had positive methacholine challenge test and looking at factors which influence the PC20) |
| PARKERSON 2011[1316,1316] | Review article |
| PATTEMORE 1990[1320,1320] | Reference standard does not match protocol (asthma diagnosis by previous report of a diagnosis but no objective test) |
| PEDROSA 2009[1329,1329] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of AMP challenge |
| PEDROSA 2010[1329,1330] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of FeNO |
| PERPINA 1993[1336,1336] | Case control type study with 4 groups (asthma; rhinitis; chronic bronchitis; healthy controls) – study gives sn/sp values for MCT but this is basedall patients (includes asymptomatic healthy control group) |
| POPA 1988[1380,1380] | No relevant outcomes and does not match review question (healthy controls and people with confirmed asthma with no comparator test). |
| PORSBJERG 2007[1382,1383] | Population does not match protocol – relationship between the response to methacholine and mannitol in asymptomatic subjects who do not have asthma |
| PORSBJERG 2009[1383,1384] | Review article |
| PRATTER 1983[1398,1398] | Index test and reference standard do not match protocol – sn/sp of wheeze symptoms vs reference standard of |

| Reference | Reason for exclusion |
|---|---|
| | physician Dx with methacholine test |
| PRIETO 1998[1406,1406] | Index test and reference standard do not match protocol – methacholine test used as reference standard to Dx asthma and assess sn/sp of PEFV |
| PRIETO 1998A[1405,1406] | No relevant outcomes and does not match review question (differences in dose-response curve to methacholine in asthma, rhinitis and controls) |
| PUOLIJOKI 1992[1415,1415] | Population does not match protocol – all methacholine challenge test negative patients |
| PUROKIVI 2007[1416,1416] | Index test does not match protocol – histamine challenge test |
| REMES 2002[1447,1448] | Methacholine challenge tests used as one of the objective tests to Dx asthma |
| RENWICK 1996[1451,1451] | Chronic airway obstruction prevelence and BDR |
| RIJCKEN 1989[1462,1462] | Reference standard does not match protocol (sensitivity and specificity of histamine challenge test to detect self-reported symptoms (symptomatic or asymptomatic) |
| ROQUET 1996[1479,1479] | No relevant outcomes and does not match review question –sn/sp of Eos to predict positive challenge test |
| SACHOLSEN 2010[1497] | Population does not match protocol - general population not all with asthma or suspected asthma |
| SCHLEICH 2012[1530,1530] | Methacholine challenge test used as part of the reference standard to Dx asthma in suspected asthma patients without airway obstruction or BDR |
| SCHMIDT 1992[1532,1532] | All patients with asthma and no comparator test (comparing different methods of histamine challenge). Physician Dx only, no objective test |
| SCHNEIDER 2009A[1535,1537] | Methacholine challenge test used as part of the reference standard to Dx asthma and assess the sn/sp of spirometry in GP |
| SCHULZE 2013[1543,1543] | No relevant outcomes and does not match review question – sn/sp of methacholine challenge to detect a positive allergen response |
| SHAPIRO 1982[1571,1571] | Reference standard does not match protocol – methacholine test used as reference standard to Dx asthma |
| SIERSTED 1994[1590,1590] | Reference standard does not match protocol – asthma Dx based on questionnaire responses to doctor diagnosed asthma and symptoms (no mention of objective test) |

| Reference | Reason for exclusion |
|---|---|
| SIERSTED 1994[1590,1590] | Duplicate – ordered twice, already excluded for this review |
| SIERSTED 1996[1590,1591] | Reference standard does not match protocol – methacholine test used as part of reference standard to Dx asthma |
| SISTEK 2006[1617,1618] | Reference standard does not match protocol – asthma Dx based on questionnaire responses to doctor diagnosed asthma and attack in the last 12 months (no mention of objective test) |
| SORIANO 1999[1644,1646] | Reference standard does not match protocol - positive methacholine test used to Dx asthma |
| SOVIJARVI 1986[1652,1652] | No relevant outcomes and does not match review question – different methods of measuring methacholine test |
| SPIROPOULOS 1986[1659,1659] | No relevant outcomes and does not match review question – sn/sp of methacholine test in predicting hyper-reative airway symptoms not physician Dx of asthma |
| SPOSATO 2014[1661,1662] | Index test and reference standard do not match protocol |
| SPRINGER 2000[1663,1663] | Population does not match protocol (aged 2-8 years). All people with confirmed asthma and no comparator test |
| STAHL 2009[1669,1670] | Conference abstract |
| SUN 2007[319,321] | Duplicate of CHOI 2007A – already excluded in this review |
| SVERRILD 2009 [1708,1708] | Same data used for Sverrild 2010 paper already excluded from this review. |
| SVERRILD 2010[1707,1708] | Reference standard does not match protocol - physician Dx without objective test (physician Dx made on the basis of symptoms in the last 12 months in combination with either a eNO level of greater than 30 ppb, a history of allergic rhinoconjunctivitis, dermatitis, a positive skin prick test response, a familial predisposition to atopic disease, nonallergic rhinoconjunctivitis, or an FEV1/forced vital capacity ratio of less than 75%). |
| SVERRILD 2012[1706,1708] | Review article |
| SVERRILD 2013[1705,1708] | sn/sp of FeNO in predicting positive mannitol response. Reference standard does not match protocol - physian Dx with no mention of objective test |
| TAKAMI 2013[1718,1718] | No relevant outcomes and does not match review question (correlation study) |
| TERNESTEN 2002[1742] | Methacholine challenge test used as part of the reference standard to Dx asthma |
| TIE 2012[1755,1755] | Reference standard does not match |

| Reference | Reason for exclusion |
|---|---|
| | protocol |
| TODD 2004[1764,1764] | Not relevant outcomes and does not answer review question - all people with asthma with positive methacholine challange (comparing methods of performing methacholine test) |
| TOELLE 1992[1765,1765] | Methacholine challenge test used as part of the reference standard to Dx asthma |
| TOWNLEY 1975[1782,1782] | Reference standard does not match protocol – no objective test |
| TOWNLEY 1990[1781,1782] | Can only calculate sensitivity (methacholine challenge in suspected asthma and asymptomatic controls – all suspected group were Dx based on reference standard and no Dx of control group reported) |
| VILOZNI 2009[1866,1867] | Population does not match protocol (aged 3-6 years) |
| WONGTIM 1997[1936,1936] | Methacholine challenge test used as part of the reference standard to Dx asthma |
| WOO 2012[1937,1937] | Methacholine challenge test used as part of the reference standard to Dx asthma – Dx based on symptoms and BDR and/or positive methacholine challenge |
| WOOLCOCK 1984[1943,1943] | Histamine challenge test but no comparator or reference standard test (looking at dose-response curve to histamine in people with asthma and controls) |
| WU 2011[1946,1946] | Conference abstract |
| XU 2001[1949,1949] | Reference standard does not match protocol - asthma was defined as a history of physician-diagnosed asthma at any time in the past (no mention of objective test) |
| YURDAKUL 2005[1968,1968] | Reference standard does not match protocol – methacholine test used as part of reference standard to Dx asthma |
| ZAGHLOUL 2009[1970,1970] | Conference abstract |

# 1K.15 Diagnosis: Exercise challenge test

2 **Table 221: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALBERTS1994[32,32] | Not exercise test |
| ANDERSON2009[44,48] | Exercise test as gold standard not index test |
| ANDERSON2010A[44,46] | Exercise test as gold standard not index test |
| ANDERSON2011[44,47] | Not primary study |
| ANSLEY2012 | Not exercise test |

| Reference | Reason for exclusion |
|---|---|
| [53,53] | |
| ARIASIRIGOYEN1999[65,65] | Case control study |
| AVITAL 1995A[82,83] | Wrong cut-off value: Change in FEV1 of 5% is very low. |
| AVITAL1995[82,82] | Mean age <5 years |
| BACKER 1992[87,89] | Wrong population: general population, not suspected asthma. |
| BACKER1991[87,87] | Not exercise test +/- versus histamine challenge +/- or diagnosis of asthma |
| BAILLY2011[93,93] | Not exercise |
| BARBEN2011[106,106] | Exercise test as gold standard not index test |
| BELCHER1987[143,143] | Not exercise test to diagnose asthma (refractoriness to second test) |
| BENARB 2011[149] | Wrong reference standard: ISAAC questionnaire but no objective test. |
| BENNETT1987[152,152] | Not exercise |
| BERKMAN 2005[159,159] | Wrong reference standard: physician Dx but no objective test. |
| BEYDON2008[167,167] | Not exercise |
| BHAGAT1984[168,168] | Not exercise test over/under threshold versus comparator |
| BLACKIE1990[178,178] | Review not primary study |
| BOCCACCINO2007[181,181] | No comparator test of diagnosis of asthma/no asthma |
| BORGES2011[190,190] | Review not primary study |
| BOUGAULT2010[200,200] | Not exercise test |
| BRANNAN2012[216,217] | Review not primary study |
| BROZEK2009[234,234] | Case control study |
| BUCHVALD2005[241,241] | Exercise test as gold standard not index test |
| CALVERT2005[265,265] | Case control study |
| CAREY2010[271,272] | Not diagnosis of asthma (healthy subjects) |
| CARLSEN 1998[273,275] | Wrong reference standard: physician Dx but no objective test. |
| CARLSEN2002[273,276] | Not primary study |
| CARLSTEN2011[277,278] | Not exercise test |
| CHATHAM1982[305,305] | Unclear cut-offs. Case-control study |
| CHEN2014[308,310] | Population does not match protocol – general population |
| CHOI2005 [319,320] | EIB as outcome not index test |
| CLEARIE2010[343,343] | Elite athletes |
| COCKCROFT1992[355,356] | Not exercise test |
| COCKCROFT2009[356,357] | SR not primary study - no data presented |

| Reference | Reason for exclusion |
|---|---|
| COCKCROFT2009A[353,356] | Review not primary study |
| COCKCROFT2010[356,358] | Not a primary study – no data presented |
| DEMISSIE 1998[421,421] | Wrong reference standard: physician Dx but no objective test. |
| DICKINSON2006[440,442] | Elite athletes |
| DICKINSON2006A[440,441] | Elite athletes |
| DOR1999[448,448] | Non-English |
| DRYDEN2010[457,457] | Exercise test as gold standard not index test |
| ELHALAWANI2003[472,472] | Exercise test as gold standard not index test |
| ELIASSON1992[473,473] | Case control study |
| FEITOSA2012[493,493] | Exercise test as gold standard not index test |
| FUENTES2011[531,531] | Case control study |
| GARCIADELARUBIA1998[546] | Case control study |
| GARCIARIO2004[549] | Not exercise test |
| GERALD2002[557,557] | Information on subjects with positive exercise test only, not those with negative test |
| GIFT1994[567,567] | Commentary not primary study |
| GODFREY1999[576,577] | Compares outcome of exercise test in subjects with asthma against previously published studies in normal populations; data for test results comparing exercise with methacholine challenge within asthma group not shown |
| GRUCHALLA2003[601,601] | Case control study and not all participants had exercise test |
| GRUCHALLA2009[601,602] | Not exercise test |
| GRZELEWSKI2012[605,606] | Exercise test as gold standard not index test |
| HOLZER2002[696,696] | Not exercise test as index test |
| HOLZER2003[695,696] | Not exercise test as index test |
| HOPP1984[702,702] | Not exercise test |
| HORIE1983[709,709] | Not exercise positive/negative versus asthma diagnosis or other test positive/ negative |
| JOHNSON1987[779,779] | Not exercise test |
| JONES1994[782,782] | Case control study with longitudinal follow up |
| JONES1994A[782,783] | Case control study |
| JOOS2003[786,786] | Review not primary study |
| KANAZAWA2002[816,816] | Not exercise test +/- versus asthma diagnosis or other test |
| KANNISTO2000[819,819] | No data on exercise +/- versus comparator |

| Reference | Reason for exclusion |
|---|---|
| KING1989[876,876] | Not exercise test |
| KIVILOOG 1975[881,881] | Wrong outcome measure: not a standard measure (change in PEFR ≥15%) |
| KNOX1989[893,893] | Not exercise test |
| KOH1996[897,897] | Not exercise +/- versus comparator +/-` |
| KOH1998[896,897] | Not exercise +/- versus comparator +/-` |
| KOTANIEMISYRJANEN2002[917] | Exercise test part of gold standard not index test |
| LAZOVELASQUEZ2005[979] | Case control study |
| LEX2007[1006,1007] | Exercise test as gold standard not index test |
| LIEM2008[1013,1014] | Not exercise test |
| LUNTSOV2012[1048,1048] | Not exercise +/- versus comparator +/-` |
| MADSEN1985[1057,1057] | Not exercise test |
| MADSEN1986[1056,1057] | Not exercise test |
| MALMBERG2009[1075,1077] | Exercise test as gold standard not index test |
| MANSO2011[1086,1086] | Not exercise test |
| MIEDINGER2010[1145,1146] | Case control study |
| MODL 1995[1166,1166] | Wrong population: symptom-free and medication-free people with asthma |
| MULLER 1993[1188,1188] | Not exercise test |
| MUSSAFFI1986[1199,1199] | Not exercise +/- versus comparator +/-` |
| NEIJENS1983[1219,1219] | Review not primary study |
| NISH1992[1249,1249] | Exercise test as part of gold standard not index test |
| NISHIO2007[1250,1250] | Exercise test as gold standard not index test |
| OBATA1994[1265,1265] | Case control study |
| PEDROSA2009[1329,1329] | Not exercise test |
| PONSONBY 1996[1377,1377] | Wrong reference standard: ISAAC questionnaire but no objective test. |
| PORSBJERG2009[1383,1384] | Not primary study |
| PRATTER1989[1397,1398] | Not all patients had exercise test and exercise test part of gold standard not index |
| PUOLIJOKI1992[1415,1415] | Not exercise test |
| RAMSER2008[1428,1428] | Exercise test as gold standard not index test |
| RANDOLPH2011[1430,1431] | Review not primary study |
| RANDOLPH2011A[1431,1432] | Unclear what is the gold standard |
| REMES 2002[1447,1448] | Wrong reference standard: physician Dx but no objective test. |
| RIEDLER1992A[1458,1458] | Non-English |
| RIEDLER1994[1458,1459] | Case control study |

| Reference | Reason for exclusion |
|---|---|
| RIEDLER1997[1457,1458] | Review, not primary study. |
| ROMBERG2011[1474,1474] | Elite athletes |
| ROMBERG2012[1474,1475] | Elite athletes |
| ROUHOS2010[1486,1487] | Exercise test mentioned but results not reported |
| RUNDELL2004[1491,1491] | Exercise = index test but also part of gold standard |
| SACHSOLSEN2010[1497] | Exercise test as part of gold standard not index test |
| SACHSOLSEN2013[1498] | Case control study |
| SCOLLO2000[1548,1548] | Exercise test as gold standard not index test |
| SHAPIRO1982[1571,1571] | Not exercise test |
| SIERSTED 1996[1590,1591] | Wrong population: general population, not suspected asthma. |
| SIN2009[1610,1611] | Data versus methacholine test was not all in asthma patients; data versus diagnosis not calculable |
| SINCLAIR1995[1612,1612] | Exercise test as both index and comparison test |
| SMITH1990[1627,1631] | Exercise test as gold standard not index test |
| SOTORAMOS2013[1650] | Comparator test is FeNO – not on list in protocol |
| SOVIJARVI1986 1652,1652 | Not exercise test |
| SPIERING2004 1658,1658 | Exercise test as gold standard not index test |
| SPIROPOULOS1986[1659,1659] | Not exercise test |
| STICKLAND2011[1680,1680] | Review, not primary study. Exercise test as gold standard not index test |
| TAL1984[1720,1720] | Cold air and exercise tests are both index tests – no comparator from protocol list |
| TERBLANCHE 1990[1741,1741] | Wrong population: general population, not suspected asthma. |
| TOWNLEY1975[1782,1782] | Not exercise test |
| TSYBULKINA2008[1794,1794] | No comparator |
| TSYBULKINA2011[1792,1794] | Not exercise +/- versus comparator +/-` |
| VILOZNI2007[1866,1866] | Children aged 3 to 6 years (mean <5 years); not exercise test positive/ negative versus diagnosis or other test |
| VILOZNI2009[1866,1867] | Not exercise test |
| WEST1996[1907,1907] | Case control study |
| WOJNAROWSKI1996[1932,1932] | Not exercise test |

# 1K.16 Monitoring: Questionnaires

2 **Table 222: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ADAMS 2000[16] | Validation of AQLQ-M. |
| APFELBACHER 2011[57] | Review article |
| APFELBACHER 2012[58] | Validation study of mini AQLQ-J and AQLQ-S and correlation with symptoms, control and patient characteristics. |
| ALMOAMARY 2012[28] | Intervention does not match protocol – asthma control questionnaire score to guide initial therapy not ongoing management. |
| BARLEY 1999[109] | Correlation of diary cards with questionnaires and lung function. |
| BATEMAN 2001[125] | Review article |
| BATEMAN 2006[126] | Intervention does not match protocol – step down of treatment according to monitoring using GINA guidelines. |
| BAYLISS 2000[132] | Validation of ITG-ASF QOL questionnaire. |
| BHOGAL 2006[170] | Systematic review - intervention and comparison do not match protocol – monitoring symptoms vs PEF |
| BIME 2012[172] | Validation study of ASUI |
| BRAIDO 2012[206] | Validation of RhinAsthma Patient Perspective QOL questionnaire. |
| BUIST 2006[243] | Intervention does not match protocol – monitoring using a peak flow monitor. |
| CARRANZAROSENZWEIG 2007[280] | Conference abstract |
| CARROLL 2013[284] | Review article |
| DESOUZA 2011[407] | Not in English |
| EHRS 2006[469] | Validation of mini AQLQ |
| ERKOCOGLU 2012[482] | Comparison of control determined by C-ACT or GINA |
| EVERHART 2009[484] | Validation of a pictorial version of the AQLQ |
| GALANT 1999 [540] | Conference abstract |
| GARRATT 2000[552] | Validation of AQLQ |
| GRAINGER-ROUSSEAU 1996[591] | Article not available |
| GREEN 2007[594] | No relevant outcomes - results of phase 2 (ACT completed for physician visits) not reported in this paper. |
| GREEN 2013[596] | Comparison of level of control between measures (FeNO, spirometry, cACT and clinical assessment). |
| GUENDELMAN 2002[609] | Intervention does not match protocol – interactive self-management and education programme, includes questions about symptoms, PEF, use of medications and health services and functional status (not symptoms alone) |

| Reference | Reason for exclusion |
|---|---|
| GUENDELMAN 2004[610] | Intervention does not match protocol – interactive self-management and education programme, includes questions about symptoms, PEF, use of medications and health services and functional status (not symptoms alone) |
| HALBERT 2009[627] | Systematic review of validation studies. |
| HOLT 2010A[694] | Review of ACT |
| JAN 2007[757] | Intervention does not match protocol – monitoring of symptoms and PEF (comparison of diaries and electronic diaries) |
| JIA 2013[777] | Systematic review of validation studies of ACT and ACQ |
| JUNIPER 1993[802] | Validation of AQLQ. |
| JUNIPER 1996[800] | Validation of PAQLQ |
| JUNIPER 1997[801] | Validation of the PAQLQ |
| JUNIPER 1999[799] | Validation of the mini AQLQ |
| JUNIPER 1999A[797] | Validation of the AQLQ-S |
| JUNIPER 1999C[805] | Validation of the ACQ |
| JUNIPER 2000[804] | No relevant outcomes. Comparison of daily control diary and clinician assessment of control. |
| JUNIPER 2001[803] | Validation of 4 QOL instruments |
| JUNIPER 2001A[806] | Validation of the ACQ |
| JUNIPER 2005[808] | Validation of the AQLQ 12+ |
| JUNIPER 2005A[807] | Validation of 3 shortened versions of the ACQ |
| JUNIPER 2010[798] | Validation of ACQ in children. |
| KATZ 1999[829] | Validation of AQLQ-M |
| KAVUT 2010[834] | Intervention does not match protocol – asthma awareness session, ACT is an outcome. |
| KHEIR 2008[861] | Intervention does not match protocol – pharmaceutical care service including assessment of adherence and PEF monitoring to guide care plan. |
| KWON 2008A[952] | Conference abstract |
| LEUNG 2013[998] | Review article |
| LIU 2007[1031] | Development and validation of cACT |
| LOBO 2007[1034] | Conference abstract. Validation of PAQLQ in severe asthma. |
| MAGNAN 2004[1060] | Review article |
| MARKS 1993[1090] | Validation study of AQLQ-M and correlation with symptoms, lung function and BHR. |
| MCDONALD 2009[1115] | Conference abstract. Validation of ACQ in children. |

| Reference | Reason for exclusion |
|---|---|
| NATHAN 2004[1212] | Validation of the ACT |
| NGUYEN 2014[1228] | Validation of ACQ in children. |
| PINNOCK 2012[1364] | Validation of the RCP-3 |
| PRABHAKARAN 2010A[1393] | Intervention does not match protocol - monitoring using SMS service based on symptoms and medication use. |
| THOMAS 2009[1748] | Validation of the RCP-3 and cross-sectional correlation analysis with control, QOL, BD use, lung function and FeNO. |
| TURNER 1998[1803] | Intervention does not match protocol – PEF monitoring vs symptom monitoring (symptoms monitoring does not focus on symptom scores or diaries to monitor control) |
| VANGAALEN 2013[1833] | Same study as MEER 2009 (included in this review). Long term follow-up at 30 months but monitoring intervention ended at 12 months. Already using outcomes at 12 months (use of 30 months would be double counting for >6months). |
| WING 2012[1924] | Validation of PAQLQ and mini PAQLQ. |
| YOOS 2002[1963] | Intervention and comparison do not match protocol – monitoring symptoms vs symptoms + PEF |
| ZEMEK 2008[1974] | Systematic review - intervention and comparison do not match protocol – monitoring symptoms vs PEF |

1

2

# 1K.17 Monitoring: Lung function tests

2 **Table 223: Studies excluded from the clinical review**

| Study | Exclusion reason |
|---|---|
| Abramson 2010[13] | Not guideline condition. Asthma or COPD patients are included and the results are not shown separately |
| Abramson 2012[11] | Incorrect interventions. Spirometry intervention versus usual care (abstract only) |
| Anon 2004[4] | Commentary not primary study |
| Armour 2007[72] | Incorrect interventions. Intervention is not monitoring with spirometry or PEF |
| Ayres 1996[85] | Both groups monitored PEF |
| Berg 1997[155] | Incorrect interventions. No self-management in control group |
| Bheekie 2001[169] | Alternate allocation (not randomized). Inadequate allocation concealment. No relevant outcomes. |
| Boath 1998[180] | Conference abstract not freely available |
| Bramson 1996[207] | Not full paper. Commentary on a study already excluded from this review (LAHDESUO 1996) |
| Brouwer 2008[231] | Not SR or RCT |
| Charlton 1994[303] | Incorrect interventions. Both groups monitored PEF |
| De asis 2004[395] | No clinical outcomes. Cost-effectiveness paper based on clinical data from a paper already included in this review (COWIE 1997) |
| Deschildre 2012[431] | Severe asthma. Severe allergic asthma according to the Third Paediatric Asthma Consensus (i. e. frequent acute episodes requiring oral corticosteroid therapy, associated with moderate episodes (exercise-induced asthma, chronic cough, sleep disturbances, treatment with short-acting beta 2-agonists >3 times per week) and airflow limitation). Incorrect intervention. Incorrect interventions |
| Drummond 1994[456] | Incorrect interventions. No self-management in control group |
| Gibson 2002[566] | SR: self-management (PEF or symptoms) versus usual care |
| Gibson 2004[565] | SR: all RCTs checked |
| Huang 2009[717] | Not self-management in the control group |
| Ignacio 1993[729] | Not in English |
| Ignacio-garcia 1995[730] | Incorrect interventions. Intervention group received education and self-management plan. Control group were monitored by their physician according to symptoms but did not receive education or a self-mangement plan. |
| Jan 2007[757] | Incorrect interventions. Both groups used PEF monitoring |
| Janson 2010[763] | Not self-monitoring peak flow. Not self-monitoring peak flow . Not self-monitoring peak flow versus not (intervention = monthly trend PEF data given to GPs; control allowed to use PEF) |
| Janson-bjerklie 1988[764] | Not self-management |
| Jones 1995[784] | Incorrect interventions. Control group did not have self-management |
| Kelso 2005[845] | Commentary not primary study |
| Kemple 2003[847] | Action plans but not PEF monitoring versus not (not all intervention group had a peak flow monitor) |

| | |
|---|---|
| Klein 2001[885] | Control group also given peak flow meter. Incorrect interventions |
| Kotses 1996[918] | 2 groups both self-managed with PEF, the third group did not self-manage. Incorrect interventions |
| Kotses 2007[919] | Conference abstract not freely available |
| Lahdensuo 1996[958] | Incorrect interventions. No self-management in control group |
| Lahdensuo 1998[957] | Incorrect interventions. Control group did not have self-management |
| Lefevre 2002[987] | SR: RCTs checked, all already in separately |
| Löwhagen 2002[1043] | Incorrect interventions. Wrong comparator (ECP) |
| Magar 2005[1058] | No self-management in control group |
| Malo 1993[1080] | Crossover study |
| Mcgrath 2001[1119] | SR: RCTs checked |
| Mcmullen 2002[1124] | Not our outcomes (qualitative data from Yoos 2002 trial) |
| Milenkovic 2007[1149] | Incorrect interventions. No self-management in control group |
| Nhlbi 2005[1229] | Protocol only, no results |
| Osman 2002[1287] | Incorrect interventions. No self-monitoring in control group |
| Persaud 1996[1339] | No self-management in control group |
| Powell 2002[1390] | SR: RCTs checked |
| Reddel 2006[1441] | Review article |
| Ross 2012[1484] | No self-management in control group (abstract only) |
| Sangha 2004[1508] | Not review population. Not persistent asthma (seasonal symptoms) |
| Schermer 2002[1527] | Incorrect interventions. Control group did not self-manage |
| Slader 2006[1622] | Incorrect interventions. Not randomised comparison of PEF monitoring versus other self-monitoring |
| Slader 2007[1623] | Incorrect interventions. Not randomised comparison of PEF versus symptoms monitoring |
| Stahlman 2006[1671] | Crossover study. Crossover |
| Tagaya 2005[1713] | Incorrect interventions. No self management in control group |
| Tapp 2007[1727] | Incorrect interventions. Education (could be self-management with PEF or symptoms or both) versus no education, not self-management with PEF versus no PEF |
| Thoonen 2003[1752] | Incorrect interventions. No self management in control group |
| Thurber 2006[1754] | Conference abstract not freely available |
| Toelle 2011[1766] | Withdrawn by Cochrane Library |
| Van der palen 1998[1826] | SR: RCTs checked |
| Van der palen 2001[1827] | Control group did not self-treat exacerbations |
| Vazquez 1993[1849] | Not PEF self-management versus other self-management. Incorrect interventions |
| Walders 2006[1885] | Incorrect interventions. All participants had self-management based on PEF and symptoms |
| Weinberger 2002[1901] | Incorrect interventions. No self-monitoring in control group |
| Yoon 1993[1962] | Incorrect interventions. All participants had peak flow meter; randomised comparison was of an education session |
| Zemek 2008[1974] | SR: all included studies already on our list individually |

# 1K.18 Monitoring: FeNO

2 **Table 224: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| [91]BACKER 2014 | Population does not match protocol. Not monitoring FeNO. |
| HASHIMOTO 2011[647,647] | Population does not match protocol – severe asthma |
| HONKOOP 2011[701,701] | Published trial protocol |
| HONKOOP 2013[699,701] | Conference abstract |
| KATSOULIS 2013[828,828] | Population does not match protocol. Not monitoring FeNO |
| LURA 2010[1049,1049] | Conference abstract |
| MALERBA 2008[1070,1070] | Intervention does not match protocol – monitoring FeNO and sputum eosinophils combined. |
| NICKELS 2014[1231,1231] | Conference abstract |
| NICKELS 2014A[1231,1232] | Conference abstract |
| OHKURA 2013[1274,1275] | Conference abstract |
| PETSKY 2010[1351,1353] | Conference abstract |
| PETSKY 2010[1350,1353] | Conference abstract (duplicate) |
| PETSKY 2010[1350,1353] | Conference abstract (duplicate) |
| POWELL 2011[1387,1389] | Population does not match protocol – pregnant women. |
| SCHNEIDER 2014[1534,1537] | Population does not match protocol. Not FeNO monitoring. |
| SYK 2012[1709,1709] | Conference abstract |
| SYK 2012A[1709,1710] | Conference abstract |
| VOORENDVAN 2013 [1878] | Conference abstract |
| VOUTILAINEN 2013[1879,1879] | Population does not match protocol. Not FeNO monitoring. |
| WANICH 2009[1894,1894] | Commentary |

# 3K.19 Monitoring: Peripheral blood eosinophils

4 **Table 225: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ALMOSAWI 2008[36,36] | Study design does not match protocol – observational case control study comparing eosinophil levels. |
| BASYIGIT 2004A[124,124] | Intervention does not match protocol – not monitoring blood eosinophils. |
| BELDA 2001[144,144] | Study design does not match protocol – observational prognostic study of eosinophil levels as a risk factor for exacerbation. |
| BRUSSELLE 2013[238,238] | Review article |
| BUSH 2005[251,251] | Clinical trial protocol only. Population does not match protocol – severe asthma. |

| Reference | Reason for exclusion |
|---|---|
| | Intervention does not match protocol – monitoring using sputum not blood eosinophils. |
| BUSSE 2013[255,256] | Intervention does not match protocol – not monitoring. |
| DEYKIN 2005[432,433] | Intervention does not match protocol – not monitoring. |
| GREEN 2002A[595,597] | Intervention does not match protocol (monitoring sputum eosinophils). |
| LOWHAGEN 2002[1043,1043] | Intervention and comparison do not match protocol – monitoring serum eosinophil cationic protein vs monitoring PEF (as % best, not PEFv). |
| MALERBA 2008[1070,1070] | Study design does not match protocol – observational case series (all patients monitored, no control group). Intervention does not match protocol (monitoring sputum eosinophils). |
| NIIMI 1999[1244,1244] | Review article |
| PARAMESWARAN2000A[1306,1307] | Conference abstract |
| PETSKY 2007[1353,1353] | Systematic review - intervention does not match protocol (monitoring sputum eosinophils). |
| PETSKY 2012[1352,1353] | Systematic review - intervention does not match protocol (monitoring sputum eosinophils). |
| PREHN 2000[1399,1399] | Pilot study. Study design does not match protocol – observational case series (all patients monitored using serum eosinophil protein levels, no control group). |
| ZACHARASIEWICZ 2006[1969,1969] | Review article |

# 1K.20 Monitoring: Challenge tests

2 **Table 226: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ARKINS 1968[70,70] | Not relevant to review question |
| BELDA 2006[144,145] | Intervention does not match protocol – Step-down treatment strategy, BHR as an outcome. |
| BRAND 1992A[209,210] | Population and intervention do not match protocol |
| FORESI 2005[508,508] | Intervention does not match protocol – RCT of 2 step-down treatment strategies, BHR as an outcome. |
| HAYES 2012[652,653] | Intervention does not match protocol - Health Technology assessment of Mannitol challenge test for diagnosis not monitoring. |
| JOOS 2003A[786,787] | Review article |

| Reference | Reason for exclusion |
|---|---|
| MCKINLAY 2011[1122,1122] | Conference abstract. Relevant for mannitol |
| NUIJSINK 2013[1260,1261] | Same study as NUIJSINK 2007 – long term follow up after intervention had finished. |
| PADOVANO 2000[1294,1294] | Conference abstract |
| PROSPERINI 2002[1411,1411] | Intervention does not match protocol – Step-down treatment strategy, BHR as an outcome. |
| RENSEN 1998[1450,1450] | Conference abstract |
| SCHERR 2012[1529,1529] | Conference abstract – intervention does not match protocol |
| SHORT 2011A[1586,1587] | Conference abstract. Relevant for mannitol |
| THOONEN 2003[1752,1752] | Intervention does not match protocol |

1

2

# 1K.21 Monitoring: Adherence to treatment

2 **Table 227: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| APTER 2005[59,60] | Not full paper (clinical trial protocol only). Intervention does not match protocol. |
| ARMOUR 2007[72,72] | Intervention does not match protocol – asthma management plan including counselling/education, review of inhaler technique, review of adherence and referral to GP. |
| BALDWIN 1991[95,95] | Intervention and comparison do not match protocol – new portable system vs conventional system for monitoring theophylline levels. |
| BENDER 2014[150,151] | Conference abstract |
| BLACK 2008[177,177] | Not full paper (conference abstract only). |
| BOZEK 2010[205,205] | No relevant outcomes and does not match review question. Correlation between cognitive status and compliance in elderly people with asthma. |
| BRANDT 1994[215,215] | Intervention does not match protocol - intervention included monitoring of inhaler technique, monitoring theophylline levels and counselling. Population does not match protocol – moderate to severe asthma. |
| BROERS 2002[228,229] | Not full paper (conference abstract only). |
| BURGESS 2009[245,245] | Not full paper (conference abstract only) – full text assessed BURGESS 2010 |
| CHIA 2008[314,314] | Intervention does not match protocol – education on asthma and inhaler technique. |
| GIBSON 2009[563,564] | Intervention and comparison does not match protocol – systematic review of FeNO vs symptom monitoring. |
| JANSON 2005[762,764] | Not full paper (clinical trial protocol only). Intervention does not match protocol. |
| KRISHNAN 2012[929,929] | No relevant outcomes and does not match review question – comparison between subjective and objective measures of adherence. |
| LAUFENBERGHORSTMANN 2006[976] | Intervention does not match protocol - community pharmacist initiated intervention included monitoring of inhaler technique and adherence. |
| MATUI 2014[1107,1107] | Systematic review. Intervention does not match protocol. |
| MCCLURE 2008[1112,1112] | Intervention does not match protocol - supervision of medication administration in children to improve adherence (not based on feedback as a result of monitoring adherence). |

| Reference | Reason for exclusion |
|---|---|
| MEHUYS 2008[1128,1128] | No relevant outcomes and does not match review question. Monitoring level of asthma control to guide therapy |
| MITCHELL 2005[1161,1162] | Intervention does not match protocol – asthma clinical pathway. |
| MOULLEC 2012[1184,1184] | Intervention does not match protocol – systematic review of interventions to improve adherence (eg self-management and decision support). |
| MUNDY 2007[1190,1190] | Review article |
| NIDES 1993[1237,1237] | Population does not match protocol – not people with asthma. |
| PERTSEVA 2004[1341,1341] | Not full paper (conference abstract only). |
| PETITTO 2012[1348,1348] | Not full paper – full text assessed KRISHNAN 2012. No relevant outcomes and does not match review question – comparison between subjective and objective measures of adherence. |
| RAND 1994[1429,1429] | Review article |
| SANTOS 2010[1510,1510] | Intervention does not match protocol – counselling intervention to improve adherence. |
| STRANDBYGAARD 2010[1692,1692] | Intervention does not match protocol – daily SMS reminder to take medication (adherence is an outcome, intervention is not monitoring adherence). |
| TRAN 2014[1783,1783] | Systematic review. Intervention does not match protocol. |
| VASBINDER 2013[1848,1848] | Intervention does not match protocol – text reminder 15 minutes following missed dose to improve adherence (not based on monitoring the individual patient's adherence) |
| VRIES 2010[1880,1880] | Not in English. |
| VOLLMER 2011[1873,1874] | Intervention does not match protocol – refill reminder call to improve adherence both before and after missed prescription fill (not based on monitoring the individual patient's adherence) |

# 1K.22 Monitoring: Inhaler technique

2 **Table 228: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| BASHETI 2005[121,121] | No relevant outcomes – primary outcome is inhaler technique score. |
| BASHETI 2006[120,121] | Conference abstract |
| BOSNIC 2010[195] | No relevant outcomes – primary outcome is inhaler |

| Reference | Reason for exclusion |
|---|---|
| | technique score. |
| BRAND 2005[210,214] | Review article. |
| BYNUM 2001[258,258] | No relevant outcomes – primary outcome is inhaler technique score. |
| CICUTTO 2013[330,330] | Intervention does not match protocol – asthma education. |
| FARBER 2009[491,491] | Review article |
| GOEMAN 2013[579,579] | Intervention does not match protocol – asthma education. |
| KUETHE 2013[935,935] | Systematic review. Intervention does not match protocol – nurse led care vs physician led care. |
| KUMAR 2009[937,938] | Intervention does not match protocol – asthma education. |
| LAUFENBERGHORSTMANN 2006[976] | Study design does not match protocol – observational study. |
| MCELNAY 1989[1117,1117] | Study design does not match protocol – observational study. |
| MULLOY 1996[1189,1189] | Intervention does not match protocol – asthma education. |
| NIDES 1993[1237,1237] | Population does not match protocol – not people with asthma. |
| NIMMO 1993[1246,1246] | Population does not match protocol – asthma and COPD. Crossover study of 2 types of inhaler. |
| PRESS 2012[1400,1400] | Population does not match protocol – mixed asthma and COPD (33% asthma) |
| ROOTMENSEN 2008[1478,1478] | Intervention does not match protocol – asthma education. |
| RYDMAN 1999[1495,1495] | No relevant outcomes – primary outcome is inhaler technique score. |
| SAVAGE 2003[1518,1518] | No relevant outcomes – inhaler technique score. Immediately before and after intervention, not long-term follow-up of patient outcomes. |
| SKAER 1996[1620,1620] | Study design does not |

| Reference | Reason for exclusion |
|---|---|
| | match protocol – observational study. |
| TURGEON 1996[1801,1801] | No relevant outcomes – inhaler technique score. UHU and missed school days assessed but not reported. |
| VAN DER PALAN 1997[1825] | Population does not match protocol – COPD. |
| VERVER 1996[1859,1859] | No relevant outcomes – inhaler technique score and self-reported symptoms. |

# 1K.23 Monitoring: Tele-healthcare

2 **Table 229: Studies excluded from the clinical review**

| Reference | Reason for exclusion |
|---|---|
| ACTRN12606000400561 [80] | Abstract only (protocol or conference abstract, not a full paper) |
| Ahmed 2011[24] | Study protocol |
| Apter 2000[59] | Intervention does not match the protocol (not tele-healthcare) |
| Araujo 2012[61] | Study design does not match protocol (crossover design) |
| Arguel 2013[64] | Ongoing study |
| Bendeer NCT00958932[151] | Abstract only (protocol or conference abstract, not a full paper) |
| Burbank 2012[244] | Abstract only (protocol or conference abstract, not a full paper) |
| Bynum 2001[258] | Intervention does not match the protocol (not monitoring) |
| Chen 2013[309] | Intervention does not match the protocol (not tele-healthcare) |
| Clark 2007[342] | Intervention does not match the protocol (not monitoring) |
| Clover N0702196597 [5] | Abstract only (protocol or conference abstract, not a full paper) |
| Cruz-Correia 2007[381] | Study design does not match protocol (crossover design) |
| De Jongste 2009[402] | Intervention does not match the protocol (FeNO monitoring) |
| DRKS00000584[465] | Population does not match protocol (mixed diagnoses) |
| Eakin 2012[467] | Intervention does not match the protocol (not tele-healthcare) |

| Reference | Reason for exclusion |
|---|---|
| eMATIC NTR2583[1848] | Ongoing study |
| Finkelstein CRISP[499] | Abstract only (protocol or conference abstract, not a full paper) |
| Fonseca 2006[505] | Not outcome of RCT. |
| Friedman CRISP[2] | Abstract only (protocol or conference abstract, not a full paper) |
| Garbutt 2010[544] | Intervention does not match the protocol (not monitoring) |
| Garbutt 2012[545] | Ongoing study |
| Gustafson NCT00993590 [351] | Study terminated |
| Hashimoto 2011[647] | Population (severe asthma and monitoring to taper OCS dose) |
| Huang 2013[716] | Abstract only (protocol or conference abstract, not a full paper) |
| Ilo 2014[731] | Non-English language publication (Japanese). Education not monitoring. |
| Kokubu 1999[901] | Non-English language publication (Japanese) |
| Kokubu 2000[900] | Non-English language publication (Japanese) |
| Lam 2011[962] | Abstract only (protocol or conference abstract, not a full paper) |
| Mayers NCT00562081 [347] | Abstract only (protocol or conference abstract, not a full paper) |
| Merchant 2013[1135] | Abstract only (protocol or conference abstract, not a full paper) |
| Moldrup NCT00917410 [349] | Study design does not match protocol (no control group) |
| Murphy 2001[1195] | Abstract only (protocol or conference abstract, not a full paper) |
| NCT00149474 [344] | Abstract only (protocol or conference abstract, not a full paper) |
| NCT00964301 [350] | Ongoing study |
| NCT01117805 [352] | Ongoing study |
| Osman N0411013273 [1] | Abstract only (protocol or conference abstract, not a full paper) |
| Partridge N0016132017 [3] | Abstract only (protocol or conference abstract, not a full paper) |

| Reference | Reason for exclusion |
|---|---|
| Petrie 2012[1349] | No relevant outcomes (primary outcome – adherence). |
| Razi 2012[1439,1440] | No relevant outcomes |
| Ricci 2001[1454] | Unclear methodology (could not locate any information) |
| Rikkers 2012[1464] | Included in monitoring questionnaires review: self-management based on monitoring online ACQ scores (no monitoring of ACQ scores in the control group) |
| Rikkers-Mutsaert 2010[1463] | Abstract only (protocol or conference abstract, not a full paper) |
| Schatz 2010[1525] | Study design does not match protocol (letter) |
| Sciamanna 2013[1547] | Abstract only (protocol or conference abstract, not a full paper) |
| Searing 2012[1553] | Abstract only (protocol or conference abstract, not a full paper) |
| Shanovich 2009[1570] | Abstract only (protocol or conference abstract, not a full paper) |
| Sparrow NCT00232557 [345] | Abstract only (protocol or conference abstract, not a full paper) |
| Stout 2012[1686] | Study design does not match protocol (cluster randomised feasibility trial) |
| Strandbygeerd 2010[1692] | No uploading of patient information. |
| Strunk NCT00910585[348] | Abstract only (protocol or conference abstract, not a full paper) |
| Taitel 2014[1716] | Not monitoring (only one telephone call) |
| Uysal 2013[1811] | Experimental study looking at the feasibility of using the ACT via text |
| van Gaalen 2012[1832] | Abstract only (protocol or conference abstract, not a full paper). |
| VANGAALEN 2013[1833] | Included in monitoring questionnaires review: self-management based on monitoring online ACQ scores (no monitoring of ACQ scores in the control group). |
| Vollmer 2011[1874] | No relevant outcomes (primary outcome – adherence). |

| Reference | Reason for exclusion |
|---|---|
| VOOREND-VAN 2013[1878] | Abstract only (protocol or conference abstract, not a full paper) |
| Wouters NCT00411346 [346] | Abstract only (protocol or conference abstract, not a full paper) |
| Yun 2013[1966] | No relevant outcomes (QOL reported incompletely, cannot combine in meta-analysis). |

1

# Appendix L: Excluded economic studies

## L.1 Diagnosis: FeNO

**Table 230: Studies excluded from the economic review**

| Reference | Reason for exclusion |
|---|---|
| BERG2008[156] | Price 2009[1402] is an update of this analysis |
| Harnan 2013[644] | This study only assessed diagnostic tests in isolation rather than as part of a diagnostic pathway. |
| PRICE2009[1402] | This study only assessed diagnostic tests in isolation rather than as part of a diagnostic pathway. |

## L.2 Monitoring: Lung function tests

**Table 231: Studies excluded from the economic review**

| Reference | Reason for exclusion |
|---|---|
| De Asis[395] | This study was assessed as partially applicable with very serious limitations. |

## L.3 Monitoring: FeNO

**Table 232: Studies excluded from the economic review**

| Reference | Reason for exclusion |
|---|---|
| Price 2009[1402] | This study was assessed as partially applicable with very serious limitations. Harnan et al. 2013[644] is more recent and more applicable. |
| Berg 2008[156] | This study was assessed as partially applicable with very serious limitations. Price et al. 2009[1402] updated this analysis using a UK NHS perspective and is hence more applicable. |

## L.4 Monitoring: Tele-healthcare

**Table 233: Studies excluded from the economic review**

| Reference | Reason for exclusion |
|---|---|
| Pinnock 2007[1361,1362] | Only includes cost to the service rather than cost to the NHS. Including these additional costs could change the results of the study as cost differences are very small. |
| Pinnock 2005[1362,1363] | Only uses proportion of patients reviewed as an outcome. Excluding quality of life from the analysis could change the results as face to face reviews may improve health outcomes. |

# Appendix M: Cost-effectiveness analysis: Diagnosis of asthma in adults and young people aged over 16

## M.1 Introduction

There are a variety of tests that can be used to diagnose asthma, and no clear gold standard. Available tests have different costs and different levels of accuracy, therefore it is important to identify which combination of tests represents a cost-effective use of NHS resources. Currently it is believed that asthma is over-diagnosed with a large portion of individuals with asthma currently being in-correctly diagnosed. This concern has been confirmed in a recent study by Aaron et al[6,6] which found that nearly a third of individuals with an asthma diagnosis did not have asthma. Misdiagnosis of asthma represents a large waste of NHS resources as a significant portion of patients will be receiving treatment that does not improve their condition. For these reasons the GDG prioritised original economic analysis to be conducted to compare different combinations of diagnostic tests for the diagnosis of asthma. This analysis will weigh up the cost of providing additional tests against the cost savings from reducing unnecessary asthma treatment and improved health outcomes from providing the correct treatment.

The economic review found no studies that assessed the cost-effectiveness of diagnostic pathways. However two studies were found which assessed the cost-effectiveness of asthma diagnostic tests as standalone tests. Although the results from these studies give little indication of how cost-effective a test will be as part of a pathway they do give insight into the methods used to build an economic model for asthma diagnosis. These methods are compared to the following analysis in M.4.4.

## M.2 Methods

### M.2.1 Model overview

#### M.2.1.1 Comparators

Six diagnostic strategies were created using combinations of the following tests:

- spirometry
- bronchodilator reversibility
- FeNO
- peak expiratory flow variability
- challenge tests.

The GDG agreed that only one challenge test would ever be conducted per patient meaning that challenge testing would only appear once in a diagnostic strategy. Therefore once the diagnostic strategies were developed it was proposed to duplicate each strategy which used challenge testing using the diagnostic accuracies and costs of histamine/methacholine, mannitol or exercise challenge test. However once the costs of an exercise challenge test and a methacholine challenge test had been established it was apparent that the exercise challenge test was the more expensive test (see M.2.3.7). The clinical review also found that exercise challenge tests had a lower sensitivity and specificity when compared to a methacholine challenge test. Therefore exercise challenge tests were not modelled as they would always be dominated (more costly and provide lower health outcomes) when compared to methacholine challenge tests. Mannitol was also not modelled as the clinical

review found it had a low sensitivity and specificity. Adding mannitol to the diagnostic pathway would in fact decrease the overall diagnostic accuracy of the pathway making it dominated by strategies that did not use challenge tests.

All the pathways were constructed using clinical judgement and taking into account the evidence produced in the clinical review.

**Strategy 1**

Strategy 1 involves the fewest number of tests. The exact point that each test appears in the diagnostic pathway and at which point patients are diagnosed with asthma is shown in Figure 301. For example in Figure 301 spirometry (S) is used as the initial test, followed by bronchodilator reversibility (BDR) if S detects obstruction (Obs) or FeNO (F) if S does not detect obstruction (No obs). BDR is not performed after a non-obstructive spirometry as there is no obstructive airway to reverse. If BDR is negative this is followed by F. A diagnosis of asthma is made with either a positive BDR or F, while asthma is excluded only with a negative F.

**Figure 301: Strategy 1**




*(-ve): negative; (+ve): positive; BDR: bronchodilator reversibility test; F: FeNO; S: spirometry; (Obs): obstruction*

**Strategy 2**

The second strategy involves spirometry, bronchodilator reversibility, FeNO and PEF variability (PEF). The diagnostic pathway is shown in Figure 302. As more tests can be conducted after a FeNO test, if a patient receives a negative FeNO test, the FeNO level that was measured in the patient is also taken into account when deciding what to do next. This test is considered negative when the FeNO level is below 40 parts per billion (ppb), however the confidence in excluding a diagnosis of asthma depends on how close to this cut off the result is. If the FeNO level is below 25 parts per billion (ppb), along with an obstructive spirometry and a negative BDR, asthma is ruled out. If the FeNO level is between 25 – 40ppb then the diagnosis of asthma still cannot be ruled out and further tests are conducted. In strategy 2 below the patient goes on to have a PEFv test.

**Figure 302: Strategy 2**




*(-ve): negative; (+ve): positive; BDR: bronchodilator reversibility test; F: FeNO; S: spirometry; (Obs): obstruction; PEF: peak expiratory flow variability*

**Strategy 3**

The third strategy uses spirometry, bronchodilator reversibility, FeNO, PEF variability and a methacholine challenge test (CT). The diagnostic pathway is shown in Figure 303. Note in this pathway challenge tests are only used on patients who have a non-obstructive spirometry.

**Figure 303: Strategy 3**




*(-ve): negative; (+ve): positive; BDR: bronchodilator reversibility test; CT: challenge test; F: FeNO; S: spirometry; (Obs): obstruction; PEF: peak expiratory flow variability*

**Strategy 4**

The forth strategy shown in Figure 304 expands the use of challenge tests as seen in strategy 3. Now a CT is also conducted on patients with a positive BDR, negative FeNO and a negative PEFv result. The use of FeNO levels is also taken into account, whereby a CT is only conducted in this arm when FeNO levels are between 25-40ppb.

**Figure 304: Strategy 4**




*(-ve): negative; (+ve): positive; BDR: bronchodilator reversibility test; CT: challenge test; F: FeNO; S: spirometry; (Obs): obstruction; PEF: peak expiratory flow variability*

**Strategy 5**

The fifth strategy, shown below in Figure **305**, also expands the use of challenge tests, as seen in strategy 3, however places the additional CT at a different point in the pathway. Now a CT is also conducted on patients with a negative BDR, negative FeNO (between 25-40ppb) and a negative PEFv test result.

**Figure** 305**: Strategy 5**



**Strategy 6**

The sixth strategy, shown below in Figure 306, is the most comprehensive and uses the maximum number of challenge tests.

**Figure 306: Strategy 6**



**Strategy 7**

A final strategy considered involves not giving the patient any tests and diagnosing without the use of objective tests. To make this strategy more reflective of current practice it is assumed that some of the non-asthmatics will be correctly diagnosed as not having asthma. One prevailing thought is that one third of people currently diagnosed with asthma are misdiagnosed, ie they do not have asthma (False positive) according to a study by Aaron et al[6,6]. Therefore the proportion of false positives calculated in this strategy will be a third of the total number of positive diagnoses made:

$$\frac{False\ positives}{False\ positives + True\ positives} = \frac{1}{3}$$

As no tests are conducted the only costs that are incurred in this strategy are those that occur after the diagnosis is made (e.g. the cost of asthma treatment). An assumption was made that all people with asthma are correctly diagnosed giving this strategy a sensitivity of 100%.

#### M.2.1.2 Population

The model considers patients over 16 years of age who present symptoms of asthma to their GP. Patients who present symptoms in a secondary care setting are not considered.

A separate analysis was considered for children between 5 – 16 years of age. However there were no included studies in the clinical review which identified the diagnostic accuracy of bronchodilator reversibility in this age group. As this test would appear in all diagnostic pathways its diagnostic accuracy would highly influence which pathway is cost-effective. On top of this, the evidence found for the diagnostic accuracies of other tests on children was weak.

#### M.2.1.3 Time horizon, perspective, discount rates used

The analysis follows the standard assumptions of the reference case including discounting at 3.5% for costs and health effects, and incremental analysis is conducted. A sensitivity analysis using a discount rate of 1.5% for costs and 1.5% for health benefits is conducted. A lifetime horizon has been chosen to fully capture the long-term adverse outcome derived from incorrect diagnosis.

### M.2.2 Approach to modelling

The model is based on two parts:

- **Decision tree** - Using the sensitivity and specificity, combined with data on the prevalence of asthma in the defined population, the model identifies the proportion of patients that receive a true positive (TP), true negative (TN), false positive (FP) or false negative (FN) diagnosis.
- **Markov model** - Once the diagnosis is made the patient moves on to the second part of the model which involves a Markov model to fully evaluate the patients' health and cost outcomes.

Further information and technical details are provided below.

#### M.2.2.1 Model structure

**Diagnostic pathways (decision tree)**

First of all patients go through a decision tree to calculate the proportion that will receive either a FN, FP, TN or TP diagnosis. The way this is calculated is shown below in Figure 304. Here strategy 1 is used as an example (detailed in **Figure 301** above).

In Figure 304 below the circles represent chance nodes. This means that the outcome is determined by a probability, rather than a decision. When the patient enters the model, they have a probability

of having asthma or not, depending on the asthma prevalence in the defined population. If the patient has asthma then the probability of a test result being positive is determined by the sensitivity of that test. If the patient does not have asthma then the probability of the test result being negative is determined by the specificity of that test. Using these probabilities the decision tree can calculate the proportion of patients that will end up at each arm. For example the probability of an asthmatic patient having an obstructive spirometry and a positive result from a bronchodilator reversibility test is:

$$Probability\big(Asthma \cap S(Obs) \cap BDR(+ve)\big) = (Probability\ of\ having\ asthma) * (Sensitivity\ of\ spirometry) * (Sensitivity\ of\ bronchodilator\ reversibility)$$

In this case the patient will receive a true positive diagnosis. Likewise the probability of a non-asthmatic having an obstructive spirometry and a positive BDR result is:

$$Probability\big(No\ Asthma \cap S(Obs) \cap BDR(+ve)\big) = (Probability\ of\ not\ having\ asthma) * (1 - Specificity\ of\ spirometry) * (1 - specificity\ of\ bronchodilator\ reversibility)$$

In this case the patient will receive a false positive diagnosis.

Once the proportion of patients that will receive either a TP, TN, FP or FN diagnosis is calculated, final health and cost outcomes are determined by a Markov model which is discussed below.

**Figure 307: Calculating patient movement through the model**




*(-ve): negative; (+ve): positive; BDR: bronchodilator reversibility test;; F: FeNO; S: spirometry; (Obs): obstruction; Sen: sensitivity; Sp: specificity; TP: True positive; FP: false positive; FN: False negative; TN: True negative.*

**Calculating health and cost outcomes after diagnosis for patients who have asthma (Markov model)**

The decision tree will determine the proportion of people with asthma that receive a correct diagnosis (true positive) and that receive an incorrect diagnosis (false negative).

*False negatives*

After a false negative diagnosis is made the patient enters the Markov model depicted in Figure 308.

**Figure 308: Markov model for false negative diagnoses**




The patient starts in the state 'un-treated asthma'. After a cycle length of six months there is a probability that the false negative diagnosis will be rectified and the patient will be treated for asthma. This probability is determined by whether or not the patient has an exacerbation. It is assumed that after an exacerbation the patient will be correctly re-diagnosed as having asthma. In this case the patient is treated and moves from 'un-treated asthma' to 'treated asthma'. After one year has passed the patient will move to treated asthma, regardless of whether they have had an exacerbation, and a re-diagnosis cost is added. This is to reflect that a patient with un-treated asthma will have persisting symptoms and an assumption was imposed that a methacholine challenge test along with a respiratory outpatient visit and persisting asthmatic symptoms would guarantee a correct diagnosis at this point. The probability of the patient entering the dead state is contingent on an all-cause mortality rate plus an added mortality risk associated with an exacerbation. As the patient is more likely to exacerbate if they are untreated, the mortality risk is slightly higher for un-treated asthmatics.

The costs associated with each state are discussed in section M.2.3.7. The quality of life (QoL) associated with each state is discussed in section M.2.3.6.

*True positives*

After a true positive diagnosis is made the patient enters the Markov model depicted in Figure 309.

**Figure 309: Markov model for true positive**




The patient starts in the 'treated asthma' state and remains there until they die. The QoL, exacerbations, and costs associated with this state are the same as those in the 'treated asthma' state in Figure 308.

**Calculating health and cost outcomes after diagnosis for patients that do not have asthma (Markov model)**

The decision tree will determine the proportion of non-asthmatic patients that receive a correct diagnosis (true negative) and the proportion that receive an incorrect diagnosis (false positive).

An important aspect of the model was to consider the condition the individual is likely to have if they present asthma symptoms but don't have asthma. The true underlying condition the patient has will determine the length and severity of misdiagnosis. The GDG identified four sub-groups of patients that would have asthmatic symptoms but not have asthma:

The first two subgroups of patients would have an illness that would go un-treated if an asthma diagnosis were made, as the physician would believe the patient was being correctly treated. As these patients would forego correct treatment then during this period of incorrect diagnosis they would receive a lower quality of life, relative to what they could achieve with optimal treatment. The NHS would also incur unnecessary asthma treatment costs. The GDG felt the two main groups this would affect are patients with COPD or chronic heart failure. As these patients will remain symptomatic after asthma treatment the probability of re-diagnosis will be high and increase over time as it becomes clearer that asthma treatment is not helping the patients. It is worth noting that once these patients are being correctly treated the NHS will now incur the cost of the respective treatment meaning that re-diagnosis is not necessarily cost-saving.

The third and fourth subgroups of patients would not forego any treatment because they are labelled as having asthma. Therefore for these patients there is no disutility from being labelled as asthmatic; instead the only disadvantage of incorrect diagnosis is that the NHS has to incur unnecessary asthma treatment costs. The GDG felt the two main groups this would affect are patients with physical de-conditioning or short-lived acute symptoms. Patients with short-lived acute symptoms, such as those recovering from an infection, would not be on asthma medication long as they would quickly become asymptomatic, naturally rather than due to medication, and stop taking asthma medication. Individuals with physical de-conditioning however could remain on asthma medication for a long time as they remain symptomatic but symptoms would rise and fall over time.

The GDG recognised that there would be other conditions that the patient could have however the four outlined above would cover the majority and those not covered would produce similar outcomes to those outlined above. As there is no data in the literature on the distribution of diseases amongst the misdiagnosed asthmatics an assumption was made that the probability of a patient having one of the above conditions was equal. This assumption, along with all data inputs used for these patients, are extensively tested in the sensitivity analysis, detailed in section M.2.5.

**False positives**

After a false positive diagnosis is made the patient enters the Markov model depicted below in Figure 310.

**Figure 310: Markov model for false positives**




The individual starts in the state 'treated for asthma', as the individual does not have asthma this can be classed as 'incorrect treatment'. After a cycle length of six months there is a probability that the individual will be correctly diagnosed as not having asthma. This probability is contingent on the under-lying condition the individual has. After each cycle the probability of correct diagnosis increases, the extent to which also depends on the patient's underlying condition. This is to reflect the fact that the longer un-treated symptoms reside the more likely the physician is to make a re-diagnosis. If the individual is correctly re-diagnosed then they move to the state 'correctly treated', which means they are receiving the treatment for the condition they actually have (if a treatment is required), where they remain until they die. The model assumes that once asthma is excluded, the real condition is diagnosed correctly. To enter the state 'correctly treated' it is assumed that a patient has a respiratory outpatient visit and under-goes a methacholine challenge test to rule-out the diagnosis of asthma, as this test was identified as having the highest sensitivity and specificity in the clinical review. A sensitivity analysis was conducted around re-diagnosis costs as detailed in section M.2.5.

The costs associated with each state are discussed in section M.2.3.7. The quality of life (QoL) associated with each state is discussed in section M.2.3.6.

**True negatives**

After a true negative diagnosis is made the patient enters the Markov model in Figure 311.

**Figure 311: Markov model for true negative**




It is assumed that by ruling out asthma as a potential cause of symptoms the individual will start in the state 'correctly treated', which means they are receiving the treatment for the condition they actually have (if a treatment is required) and remain there until they die. The QoL and costs associated with this state are the same as those in Figure 310.

### M.2.2.2 Key assumptions

The key assumptions of the model are summarised in **Table 234** below:

**Table 234: Summary of key assumptions**

| Assumption | Comment |
|---|---|
| A patient with a false negative diagnosis will always be correctly re-diagnosed after an exacerbation. | |
| A patient with a false negative diagnosis will remain misdiagnosed for a maximum of one year, even if an exacerbation does not occur. | |
| Adults correctly identified as not having asthma will either have, with equal probability: acute symptoms, physical de-conditioning, chronic heart failure or COPD. | This assumption was built into the model to address the concern that those identified as not having asthma are likely to have something else. This ensures the model gives a better reflection of the true costs and health losses incurred through misdiagnosis. |
| After a true negative diagnosis patients are assumed to be correctly treated for their true underlying condition. | This assumption is built on the fact that ruling out asthma as a potential cause of symptoms will help rule in the true diagnosis after further tests. The costs of these tests (such as an echocardiogram) have been excluded from the model as they will be incurred for both true negatives and false positives and therefore there will be no incremental cost. |
| Uncontrolled asthma was used as a proxy for untreated asthma when calculating QoL | |
| FeNO is conditionally independent with other tests | As FeNO is the only test in the model that measures inflammation of the airways a patient's FeNO count is unlikely to be dependent on the results of other tests. Likewise other lung function test results are unlikely to be dependent on a patient's FeNO count. Therefore this test was considered to be conditionally independent with all other tests. Further details regarding conditional independence are provided in section M.2.2.3 below. |

### M.2.2.3 Conditional dependence

In the clinical review, the sensitivity and specificity of each test was calculated across the whole population of interest. However, if a test is only conducted after a certain test result (for example if test 2 is only conducted following a positive result from test 1 then ideally we would use accuracy data for the second test on this sub-group of the original population. The sensitivity and specificity of a test will be different in this sub-group if the two tests (T1 and T2 in example below) are conditionally dependent. **Table 235** below shows how conditional dependence affects the probability of obtaining two test results.

**Table 235: Probability of obtaining two test results**

| Event | Probability |
|---|---|
| **Patients who have the disease** | |
| T1(+ve) AND T2(-ve) | $Se(T1) \times (1 - Se(T2)) - \gamma_{se}$ |
| T1(+ve) AND T2(+ve) | $Se(T1) \times Se(T2) + \gamma_{se}$ |
| T1(-ve) AND T2(+ve) | $(1 - Se(T1)) \times Se(T2) - \gamma_{se}$ |
| T1(-ve) AND T2(-ve) | $(1 - Se(T1)) \times (1 - Se(T2)) + \gamma_{se}$ |
| **Patients who do not have the disease** | |
| T1(+ve) AND T2(-ve) | $(1 - Sp(T1)) \times Sp(T2) - \gamma_{sp}$ |
| T1(+ve) AND T2(+ve) | $(1 - Sp(T1)) \times (1 - Sp(T2)) + \gamma_{sp}$ |
| T1(-ve) AND T2(+ve) | $Sp(T1) \times (1 - Sp(T2)) - \gamma_{sp}$ |
| T1(-ve) AND T2(-ve) | $Sp(T1) \times Sp(T2) + \gamma_{sp}$ |

*Abbreviations: Se = sensitivity; Sp = specificity; T1 = test 1; T2 = test 2; $\gamma_{se}$ = sensitivity covariance; $\gamma_{sp}$= specificity covariance*

From **Table 235** shows that the probability of obtaining any one result is dependent on the covariance between the two sensitivities $\gamma_{se}$ or specificities $\gamma_{sp}$. Assuming that tests 1 and 2 are positively correlated, the upper-limit of these co-variances can be calculated as follows:

$$\gamma_{se} = MIN(Se_1(1 - Se_2);\ Se_2(1 - Se_1))$$

$$\gamma_{sp} = MIN(Sp_1(1 - Sp_2);\ Sp_2(1 - Sp_1))$$

where MIN is a function which selects the minimum value between those listed.

This limit ensures the probability of obtaining two test results is bounded between zero and one. Therefore the covariance must fall between zero and this upper limit. If a test result is highly dependent on a previous test result then the covariance is likely to fall closer to the upper limit. If the result of the second test is fairly independent from the result of the first test then the covariance will be closer to zero. This method is outlined in full in Gardener et al[551,551].

For the model the GDG were asked to give their opinion on how strongly they believed the conditional dependence between two tests were. Tests that were weakly dependent were given a covariance value closer to zero; tests that were moderately dependent were given a value midway between zero and the upper limit. The results are shown in **Table 236**. Some points to note:

- FeNO does not appear as it was assumed to be conditionally independent with the other tests.
- The diagnostic review on bronchodilator reversibility was assessed in patients that had an obstructive spirometry therefore conditional dependence will have already been taken into account between those two tests.
- The conditional dependence between spirometry and other tests has not been considered as the GDG agreed that other test results are unlikely to be dependent on the results from a single spirometry.

- Finally it is assumed that the dependence between tests will be the same for individuals with and without asthma. Therefore the strength of dependence applies equally to specificities and sensitivities.

**Table 236: Strength of dependence between tests**

| Test 1 | Test 2 | Strength of dependence (value given between 0 and 1) | Source |
|---|---|---|---|
| Bronchodilator reversibility | PEFv | Weak (0.1) | GDG opinion |
| PEFv | Histamine/Methacholine | Moderate (0.5) | GDG opinion |
| Bronchodilator reversibility | Histamine/Methacholine | Moderate (0.5) | GDG opinion |

*Abbreviations: PEFv= Peak expiratory flow variability*

Using this information and the formulas in **Table 235** the sensitivity and specificity of tests which occur further down the pathway can be re-calculated to account for conditional dependence. For example the specificity of test 2 for patients without asthma who test positive for test 1 is:

$$Sp_2 = \frac{\text{Probability}(T1_{+ve} \cap T2_{-ve})}{Sp_1}$$

Using the formula for $\text{Probability}(T1_{+ve} \cap T2_{-ve})$ from **Table 235** and results from **Table 236** we know:

$$\text{Probability}(T1_{+ve} \cap T2_{-ve}) = (1 - Sp_1)(Sp_2) - \{(\gamma_{sp}) * (Strength\ of\ dependence)\}$$

Here 'strength of dependence' lies between zero and one.

Although conditional dependence has been incorporated into the model not every dependency has been accounted for. As challenge tests are incorporated last in the diagnostic pathway they will have the most dependencies between tests. In the model conditional dependence has not been fully incorporated for challenge test results that are dependent on more than one test result. In some circumstances a challenge test will be dependent on the results from a PEFv test and a BDR test. An assumption was made that if a challenge test proceeds a BDR and PEFv test then the conditional dependence will only be taken into account between the BDR test and the challenge test. Rather than formally model three way dependencies, this issue has been examined in a sensitivity analysis detailed in section M.2.5.

### M.2.2.4 Uncertainty

The model was built probabilistically to take account of the uncertainty around input parameter point estimates. A probability distribution was defined for each model input parameter. When the model was run, a value for each input was randomly selected simultaneously from its respective probability distribution; mean costs and mean QALYs were calculated using these values. The model was run 5,000 times for the base case.

**Table 237: Description of the type and properties of distributions used in the probabilistic sensitivity analysis**

| Parameter | Type of distribution | Properties of distribution |
|---|---|---|
| Specificity | Beta | Bounded between 0 and 1. As the sample size and the number of events were specified r and n values were calculated as follows: |

| Parameter | Type of distribution | Properties of distribution |
|---|---|---|
| | | r=(True negatives)<br>n=(Number of patients)-(True negatives) |
| Diagnostic Odds ratio (DOR)[a] | Normal | Derived from:<br>Mean = ln(DOR)<br>Standard error = Se(ln(DOR)) |
| Exacerbation rate | Log-normal | Derived from the mean and standard deviation |
| Utility , asthma prevalence, transition probabilities, covariance strength | Beta | Bounded between 0 and 1. Derived from mean of a domain and its standard error, using the method of moments.<br>Alpha and beta values were calculated as follows:<br>$Alpha = mean^2 *[(1-mean)/SE^2]-mean$<br>$Beta = Alpha*[(1-mean)/mean]$ |
| NHS Reference Costs, test costs | Gamma | Bounded at 0, positively skewed. Derived from mean and its standard error.<br>Alpha and lambda values were calculated as follows:<br>$Alpha = (mean/SE)^2$<br>$Lambda = SE^2/Mean$ |

*Note: When the standard error (SE) is not given an assumption was imposed that the SE is 20% of the mean.*
*a) The use of the diagnostic odds ratio is discussed in section M.2.3.3*

In addition, various deterministic sensitivity analyses were undertaken to test the robustness of model assumptions. In these, one or more inputs were changed and the analysis rerun to evaluate the impact on results and whether conclusions on which intervention should be recommended would change.

As sensitivities were estimated as functions of other variables, no distributions were attached to these parameters.

## M.2.3 Model inputs

### M.2.3.1 Summary table of model inputs

Model inputs were based on clinical evidence identified in the systematic review undertaken for the guideline, supplemented by additional data sources as required. Model inputs were validated with clinical members of the GDG. A summary of the model inputs used in the base-case (primary) analysis is provided in Table 238 below. More details about sources, calculations and rationale for selection can be found in the sections following this summary table.

**Table 238: Summary of base-case model inputs**

| Input | Input | Source |
|---|---|---|
| Probability patient is male (adult) | 0.40 | Weighted average from the diagnostic studies identified in the clinical review |
| Patient age at diagnosis (adult) | 43 | Weighted average from the diagnostic studies identified in the clinical review |
| Time horizon | Lifetime | |
| Discount rate | Costs = 3.5%;<br>effects = 3.5% | |

**Table 239: Overview of parameters and parameter distributions used in the model**

| Parameter description | Point estimate | Probability distribution | Distribution parameters | Source |
|---|---|---|---|---|
| **Decision tree probabilities** | | | | |
| Prevalence of asthma | 0.406 | Beta | α = 606, β = 887 | *Taken from a meta-analysis of the diagnostic studies identified in the clinical review, see section (A.2.3.2)* |
| Sensitivity of spirometry | 0.465 | - | - | Pino 1996[1365,1365] |
| Specificity of spirometry | 0.415 | Beta | r = 17, n =41 | Pino 1996[1365,1365] |
| Ln(Diagnostic odds ratio for spirometry) | -0.485 | Normal | μ = -0.485, σ = 0.44 | *Derived from sensitivity and specificity, see section M.2.3.3* |
| Sensitivity of BDR used in model | 0.409 | *Distributions were fitted directly on the parameters derived from each of the two studies and in each iteration the pooled average was calculated from the individual parameters.* | - | Pooled average from Kim 2012[870,873] and Chhabra 2012[313,313] below |
| Specificity of BDR used in model | 0.713 | | - | Pooled average from Kim 2012 and Chhabra 2012[313,313] - see below |
| Sensitivity of BDR (Chabbra 2012) | 0.65 | - | - | Chhabra 2012[313,313] |
| Specificity of BDR (Chabbra 2012) | 0.811 | Beta | r = 125, n =154 | Chhabra 2012[313,313] |
| Ln(Diagnostic odds ratio for BDR) (Chabbra 2012) | 2.08 | Normal | μ = 2.08, σ = 0.25 | Derived from sensitivity and specificity, *section M.2.3.3* |
| Sensitivity of BDR (Kim 2012) | 0.168 | - | - | Kim 2012[870,873] |
| Specificity of BDR (Kim 2012) | 0.614 | Beta | r = 89, n =145 | Kim 2012[870,873] |
| Ln(Diagnostic odds ratio for BDR) (Kim 2012) | -1.14 | Normal | μ = -1.14, σ = 0.22 | *Derived from sensitivity and specificity, section M.2.3.3* |
| Sensitivity of FeNO | 0.88 | - | - | Kowal 2009[924,924] |
| Specificity of FeNO | 0.83 | Beta | R = 299, n =362 | Kowal 2009[924,924] |
| Ln(Diagnostic odds ratio for FeNO) | 3.57 | Normal | μ =3.57 , σ = 0.27 | *Derived from sensitivity and specificity, section M.2.3.3* |
| Sensitivity of PEFv | 0.116 | - | - | Thiadens 1998[1746,1746] |
| Specificity of PEFv | 0.99 | Beta | R = 100, n = 101 | Thiadens 1998[1746,1746] |
| Ln(Diagnostic odds ratio for PEFv) | 2.57 | Normal | μ = 2.57, σ = 1.07 | *Derived from sensitivity and specificity, section M.2.3.3* |
| Sensitivity of histamine challenge test | 0.933 | - | - | Kowal 2009[924,924] |

| Parameter description | Point estimate | Probability distribution | Distribution parameters | Source |
|---|---|---|---|---|
| Specificity of histamine challenge test | 0.99[(a)] | Beta[(a)] | R = 358, n =362 | Kowal 2009[924,924] |
| Ln(Diagnostic odds ratio for histamine challenge test) | 8.52 | Normal | μ =8.52 , σ = 1.05 | *Derived from sensitivity and specificity, section M.2.3.3* |
| Mean FeNO level for an asthmatic | 96 | Lognormal | μ = 4.32, σ = 0.52 | *See section M.2.3.3 for derivation* |
| Probability that FeNO level < 25ppb for a patient with asthma and a FeNO below 40ppb | 0.142 | - | - | *Derived from the distribution around the mean FeNO level for patients with asthma* |
| Mean FeNO level for a non-asthmatic | 25 | Lognormal | μ = 2.77, σ = 0.94 | *See section M.2.3.3 for derivation* |
| Probability that FeNO level < 25ppb for a patient without asthma and a FeNO level below 40ppb | 0.823 | - | - | *Derived from the distribution around the mean FeNO level for patients without asthma* |
| Strength of dependence between BDR and PEFv | 0.1 | Beta | α = 6.11, β = 54.96 | GDG opinion |
| Strength of dependence between PEFv and histamine/methacholine | 0.5 | Beta | α = 85.7, β = 85.7 | GDG opinion |
| Strength of dependence between BDR and histamine/methacholine | 0.5 | Beta | α = 85.7, β = 85.7 | GDG opinion |
| Proportion of non-asthmatic patients that have acute symptoms | 0.25 | Beta[(c)] | α = 78.16, β = 233.8 | GDG opinion |
| Proportion of non-asthmatic patients that have physical de-conditioning | 0.25 | Beta[(c)] | α = 78.16, β = 233.8 | GDG opinion |
| Proportion of non-asthmatic patients that have heart failure | 0.25 | Beta[(c)] | α = 78.16, β = 233.8 | GDG opinion |
| Proportion of non-asthmatic patients that have COPD | 0.25 | Beta[(c)] | α = 78.16, β = 233.8 | GDG opinion |
| **Utility weights** | | | | |
| QoL increase from asthma treatment | 0.0443 | Beta | α = 23.86, β = 518.33 | McTaggart et al[1125] |
| Disutility from severe exacerbation | 0.56 | Beta | α = 0.91 β = 71 | Lloyd et al[1033,1033] |
| Duration of severe exacerbation (in years) | 0.08 | Gamma | α = 19.26, λ = 246.34 | Harnan 2014[644] |
| Disutility from non-severe exacerbation | 0.32 | Beta | α = 0.537, β = 1.14 | Lloyd et al[1033,1033] |
| Duration of non-severe exacerbation (years) | 0.01 | Gamma | α = 82.9, λ = 8259 | Harnan 2014[644] |
| QoL increase for a mild severity COPD patient being correctly treated for COPD as | 0.045 | Beta | α = 23.83, β = 505.73 | Spencer et al[1657,1657] |

| Parameter description | Point estimate | Probability distribution | Distribution parameters | Source |
|---|---|---|---|---|
| opposed to asthma. | | | | |
| QoL increase for a moderate severity COPD patient being correctly treated for COPD as opposed to asthma. | 0.025 | Beta | α = 24.35, β = 949.65 | Spencer et al[1657,1657] |
| QoL increase for a heart failure patient being correctly treated for heart failure as opposed to asthma. | 0.098 | Beta | α = 22.45, β = 206.65 | Gohler et al[581,581] |
| **Cost (£)[(b)]** | | | | |
| Cost of hospitalised exacerbation | £873.75 | Gamma | α = 25, λ = 0.028 | NHS reference costs[425] (weighted average of HRG codes DZ15H, DZ15J, DZ15K, DZ15L) |
| Cost of non-hospitalised exacerbation | £38.33 | Gamma | α = 25, λ = 0.65 | PSSRU[386,386], NHS drug tariff[1230] |
| Cost of spirometry | £16.86 | Gamma | α = 100, λ = 5.93 | GDG opinion, PSSRU[386,386], NHS supply catalogue[426] |
| Cost of BDR | £26.16 | Gamma | α = 100, λ = 3.82 | GDG opinion, PSSRU[386,386], NHS supply catalogue[426] |
| Cost of FeNO | £13.66 | Gamma | α = 100, λ = 4.23 | GDG opinion, PSSRU[386,386], NHS supply catalogue[426] |
| Cost of PEF | £21.08 | Gamma | α = 100, λ = 4.74 | GDG opinion, PSSRU[386,386], NHS supply catalogue[426] |
| Cost of histamine/methacholine challenge test | £162.50 | - | - | GDG opinion, NHS reference costs[425] |
| Cost of Bronchial Challenge Studies, HRG code: DZ36Z | £102 | Lognormal | α = 25, λ = 0.2451 | NHS reference costs[425] |
| Cost of respiratory outpatient visit | £150.22 | Gamma | α = 100, λ = 0.6657 | NHS reference costs[425] |
| Cost of GP appointment | £37 | - | - | PSSRU[386,386] |
| Cost of annual asthma management | £290.00 | Gamma | See **Table 253** | Price et al[1401,1403] |
| Cost of annual asthma management for patients without asthma but who have acute symptoms | £180.00 | Gamma | See **Table 253** | Price et al[1401,1403] |
| Cost of annual asthma management for patients without asthma but who have chronic symptoms | £248.91 | Gamma | See **Table 253** | Price et al[1401,1403] |
| Annual cost of COPD management for moderate severity | £307.74 | Gamma | α = 25, λ = 0.08 | NICE 2010 COPD guideline[1213] |
| Annual cost of COPD | £149.68 | Gamma | α = 25, λ = 0.17 | NICE 2010 COPD |

| Parameter description | Point estimate | Probability distribution | Distribution parameters | Source |
|---|---|---|---|---|
| management for mild severity | | | | guideline (CG101)[1213] |
| Cost of heart failure treatment | £135 | Gamma | α = 25, λ = 0.19 | NICE 2014 Acute heart failure guideline (CG187)[1214] |
| **Transition probabilities for Markov model and mortality adjustments** | | | | |
| Annual exacerbation rate for un-treated asthmatics | 1.02 | Lognormal | μ =0.02 , σ = 0.1 | Harnan 2014[644] |
| Annual exacerbation rate for treated asthmatics | 0.42 | Lognormal | μ =-0.87 , σ = 0.2 | Shaw et al[1574,1574] |
| Probability of exacerbation for un-treated asthmatic per cycle | 40% | - | - | *Derived from the exacerbation rate for un-treated asthmatics. See section (M.2.4)* |
| Probability of exacerbation for un-treated asthmatic per cycle | 19% | - | - | *Derived from the exacerbation rate for un-treated asthmatics. See section (M.2.4)* |
| Proportion of exacerbations that are hospitalised | 2.7% | Beta | R =40,243, n = 1474698 | See section (M.2.3.6) for derivation and source input |
| Probability of death after hospitalisation | 0.41% | Beta | R = 165, n =40,243 | National review of asthma deaths 2014[1488] |
| Probability of correct re-diagnosis for patients with acute symptoms in 6 months | 20% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for further details. |
| Probability of correct re-diagnosis for patients with physical de-conditioning in 6 months | 1% | Beta | α = 0.06, β = 5.77 | GDG opinion, see section M.2.3.5 for further details. |
| Probability of correct re-diagnosis for patients with moderate COPD in 6 months | 20% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for further details. |
| Probability of correct re-diagnosis for patients with mild COPD in 6 months | 10% | Beta | α = 6.11, β = 55 | GDG opinion, see section M.2.3.5 for further details. |
| Probability of correct re-diagnosis for patients with heart failure in 6 months | 30% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for further details. |
| Absolute probability increase of correct re-diagnosis after each 6-month cycle for patients with acute symptoms | 20% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for further details. |
| Absolute probability increase of correct re-diagnosis after each 6-month cycle for patients with physical de-conditioning | 0.5% | Beta | α = 0.01, β = 2.42 | GDG opinion, see section M.2.3.5 for further details. |
| Absolute probability increase of correct re-diagnosis after | 20% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for |

| Parameter description | Point estimate | Probability distribution | Distribution parameters | Source |
|---|---|---|---|---|
| each 6-month cycle for patients with moderate COPD | | | | further details. |
| Absolute probability increase of correct re-diagnosis after each 6-month cycle for patients with mild COPD | 5% | Beta | α = 1.59, β = 30.17 | GDG opinion, see section M.2.3.5 for further details. |
| Absolute probability increase of correct re-diagnosis after each 6-month cycle for patients with heart failure | 20% | Beta | α = 21.87, β = 87.47 | GDG opinion, see section M.2.3.5 for further details. |
| Hazard ratio of mortality for COPD patient | 1.28 | Lognormal | μ =0.247 , σ = 0.064 | Diaz-Guzman et al[438] |
| Hazard ratio of mortality for patient with physical de-conditioning | 1.18 | Lognormal | μ =0.166 , σ = 0.028 | Flegal 2013[503,503] |
| Hazard ratio of mortality for patient with chronic heart failure | 2.1 | Lognormal | μ =0.742 , σ = 0.103 | Mosterd 2001[1183,1183] |

*Abbreviations:* BDR: bronchodilator reversibility; FeNO: fractional exhaled nitric oxide; PEF: peak expiratory flow variability

*(a) This study found that the specificity of histamine and methacholine challenge tests were 100%. However the GDG agreed that there is no perfect test so this value was reduced to 99% to reflect the high specificity but allowing some scope for error. This assumption was also incorporated into the beta distribution by changing the number of true negatives to achieve a specificity of 99%.*

*(b) These are costs of the tests as they appear in the pathway rather than the cost of conducting the test independently*

*(c) To ensure these values sum to one once a value has been chosen from each distribution the probability of having a particular disease becomes:* $Prob(disease\ A) = Prob(disease\ A) / \sum Prob(disease_n)$ *where each probability is taken from its respective beta distribution.*

### M.2.3.2 Initial cohort settings

The initial cohort settings were derived from information given in the studies included in our clinical review of diagnostic accuracy studies. The prevalence of asthma was obtained from a meta-analysis of all the included diagnostic studies which looked at the model's defined population. Ideally prevalence would be based only on UK studies, however no UK studies were included in the clinical reviews. To obtain a prevalence estimate applicable to the population in the model a few exclusion criteria were imposed. Firstly studies were excluded which only looked at children or looked at both adults and children and did not separate out the results. The prevalence of asthma is likely to deviate significantly between adults and children and therefore including child studies could bias the prevalence, most likely upwards. Secondly studies were included only if the inclusion criteria for patient entry into the study were patients presenting symptoms of asthma. For example if only patients with a normal spirometry were allowed to enter the study then the prevalence of asthma would fall as a significant portion of asthmatics have an obstructive spirometry. Finally as no study was conducted in the UK the GDG felt that studies which were conducted in Northern Europe, North America, Australia and New Zealand would give a better indication of asthma prevalence in the UK. Therefore studies outside of these areas were excluded when calculating asthma prevalence. The resulting meta-analysis is shown below in Figure 312 was based on four studies[422,1535,1747].

**Figure 312: Meta-analysis for asthma prevalence**




The majority of excluded studies had a lower prevalence rate ranging from 20% to 37%. Three studies had a prevalence of approximately 70% however they were all in Asian countries (Japan and S. Korea). It is worth noting a paper by Morice et al found asthma prevalence to be on average 25% across 13 studies in patients with chronic cough. This paper was not used in the base case as it is not clear what the exact recruitment methods were for patients into the studies, secondly patients entering the model are likely to exhibit other asthma symptoms rather than just a chronic cough. However this study suggests that the 41% estimate produced above is unlikely to be an underestimate of asthma prevalence in the defined population.

This value was also tested in the sensitivity analysis detailed in section M.2.5.

### M.2.3.3 Diagnostic accuracies

*Using diagnostic odds ratios to conduct probabilistic sensitivity analysis*

The clinical review did not identify enough diagnostic studies to conduct meaningful diagnostic meta-analyses. Therefore, for each test included in the model the most relevant study used for the base case was identified as that which had: the correct cut-off, most relevant population and best reference standard. As there is no universally agreed reference standard for the diagnosis of asthma, the GDG agreed that an appropriate reference standard would be an objective test alongside a physician diagnosis. The bronchodilator reversibility test was the only exception where an average was taken from the two studies identified in the clinical review. The reason was that the GDG could not identify one study being more appropriate than the other, therefore an average was used in the base case and each separate set of diagnostic accuracies was used in a sensitivity analysis.

To account for uncertainty around diagnostic accuracies and correlation between sensitivity and specificity a joint distribution was used when making diagnostic accuracies probabilistic. The following method is outlined in Genders et al.[554,554] First of all the diagnostic odds ratio (DOR) was calculated for the diagnostic test:

$$DOR = \frac{sensitivity}{1 - sensitivity} * \frac{specificity}{1 - specificity}$$

The standard error of the log DOR was calculated using the absolute values for the number of TP, TN, FP and FN:

$$SE(\ln(DOR)) = \sqrt{\frac{1}{TP} + \frac{1}{FN} + \frac{1}{TN} + \frac{1}{FP}}$$

Using these equations a normal distribution was fitted using the log of the DOR and the standard error of ln(DOR). Once the DOR is calculated, the sensitivity can become a function of the DOR and the specificity:

$$sensitivity = 1 - \frac{specificity}{specificity + (1 - specificity) * DOR}$$

Finally a beta distribution was fitted around the specificity of the test, therefore when probabilistic sensitivity analysis is conducted the specificity will change in accordance to the overall diagnostic uncertainty and its relationship with the test sensitivity.

*Using additional cut-offs for negative FeNO results*

In some diagnostic strategies we had to take into account the probability of a FeNO level below 25ppb together with the probability of receiving a negative FeNO result (FeNO level < 40 ppb). The GDG recognised that the lower an individual's FeNO level was the lower the probability the individual has asthma. Current guidelines[1552] recommend that an individual with a FeNO level below 25ppb is highly unlikely to have asthma. None of the studies identified in the clinical review gave a sensitivity and specificity at 25ppb cut-off. Therefore to calculate the probability of a patient with asthma producing a FeNO level below 25ppb two pieces of information were used:

- The mean FeNO level for an asthmatic.
- The sensitivity of FeNO at a 40ppb cut-off.

**Figure 313: Probability distribution of FeNO levels in individuals with asthma**




As shown in Figure 313 above, using these two pieces of information a distribution was fitted around what FeNO level would be achieved by asthmatics. At 40ppb the sensitivity used for FeNO in the model was 89%. This means that the area under the curve highlighted in blue should equate to 89%. The mean FeNO level calculated for asthmatics in that study was 96ppb. As FeNO levels cannot go below zero a gamma and lognormal distribution were fitted to see which was more appropriate. A lognormal distribution was chosen as the gamma distribution gave a much higher probability to values close to zero whereas the lognormal gave a more even distribution amongst lower values.

After this distribution was fitted, the final step was to calculate the proportion of patients with asthma that would produce a FeNO level below 25ppb.

**Figure 314: Probability distribution of FeNO levels in individuals with asthma**




As shown in Figure 314 above this was done by calculating the area under the distribution that fell to the left of 25ppb.

The same process was then completed for patients without asthma except this time the mean FeNO level for non-asthmatics and the specificity at a 40ppb cut-off (instead of the sensitivity) were used.

### M.2.3.4 Mortality

For all patients at any point in the model the probability of death is determined by an age specific all-cause mortality rate. For patients with asthma the probability of death is also dependent on the probability of having a hospitalised exacerbation and the probability of death after hospitalisation. As exacerbation rates are higher in un-treated asthmatics, the overall probability of death calculated by the model is slightly higher for un-treated asthmatics compared to treated asthmatics. For non-asthmatics correct or incorrect treatment has no differential impact on mortality. Age-specific all-cause mortality, weighted for the gender split of the cohort population, was based on the most recent available life tables for England and Wales (2012-2013)[1272]. For non-asthmatic conditions hazard ratios were identified in the literature for patients with: COPD, chronic heart failure and de-conditioning. In the model the hazard ratio in people with obesity is used as a proxy for physical de-conditioning.

### M.2.3.5 Re-diagnosis and exacerbation rates

The transition probability of re-diagnosis was determined through GDG opinion. The transition probability for correct re-diagnosis for false negatives was calculated using an assumption whereby the probability of re-diagnosis is contingent on whether the patient has an exacerbation.

Exacerbation rates were taken from the clinical review conducted on monitoring asthma control. For individuals with asthma who remain untreated, due to a false negative diagnosis, the exacerbation rate was taken from Harnan et al.[644] As the exacerbation rate for untreated asthma was derived mostly from assumption, due to the lack of clinical data, this value was extensively tested in a sensitivity analysis. A study by Shaw et al[1574,1574] was chosen to reflect the exacerbation rates of a treated asthma patient as it was the most current study conducted in a UK setting. Once the exacerbation rates had been derived these were converted into transition probabilities for the respective cycle length (6 months) before inputting into the Markov model. The above conversion was done using the following formulae:

| | |
|---|---|
| $Selected\ rate\ (r) = \frac{-\ln(1-P)}{t}$ | Where<br>*P*=probability of event over time *t*<br>*t*=time over which probability occurs (1 year) |
| $Transition\ Probability\ (P) = 1 - e^{-rt}$ | Where<br>*r*=selected rate<br>*t*=cycle length (6 months) |

For false positives there was no clinical evidence to derive the length of time an individual would retain the incorrect asthma diagnosis for. The GDG agreed this value would vary considerably, with some individuals being re-diagnosed within the year whereas others would retain the diagnosis for the rest of their life. The GDG felt the probability of re-diagnosis would be contingent on the underlying condition causing the asthma symptoms to occur. As outlined in section M.2.2.1 four conditions were used in this model:

*Heart failure*

The GDG felt that most individuals with heart failure would be re-diagnosed within a year and a few individuals may retain an asthma diagnosis beyond two years. To achieve this, an assumption was imposed that 30% of individuals would be re-diagnosed in the first 6 months and every 6 months the probability of re-diagnosis would increase by 20 percentage points. Therefore after two and a half years no individuals with heart failure would retain an asthma diagnosis in the model.

*COPD*

Individuals with mild COPD could remain misdiagnosed with asthma for a considerable length of time and the GDG therefore gave a low probability of re-diagnosis every 6 months of 10%. Every 6 months the probability of re-diagnosis would increase by 5 percentage points as the GDG felt that eventually a re-diagnosis would occur. Individuals with moderate COPD however would be re-diagnosed much sooner as their symptoms would appear far less well managed. Therefore the probability of re-diagnosis was set to 20% each 6 months and this increased by 10 percentage points for every 6 months after that.

*Physical deconditioning*

Individuals with physical deconditioning were the one group the GDG agreed that re-diagnosis may never occur. Therefore the probability of re-diagnosis was set to a low 1% each 6 months and this only increased by 0.5 percentage points for every occurring 6 months.

*Acute symptoms*

Finally the GDG felt that individuals with acute symptoms would receive a re-diagnosis very quick as symptoms would completely subside over short period of time. Therefore the probability of re-diagnosis was set to 20% each 6 months and this increased by 20 percentage points for every occurring 6 months.

These values were extensively tested in a sensitivity analysis detailed in section M.2.5.

### M.2.3.6 Utilities

*Utility in people with asthma*

The QoL for patients with asthma was derived from a systematic search of the literature. Only one study[1125] measured asthma utility in a UK population using EQ-5D with UK weights, as per the NICE reference case. The study details asthma utility for four levels of self-reported asthma control: uncontrolled, moderately controlled, well controlled and fully controlled as shown in **Table 240**.

**Table 240: Quality of life and level of asthma control**

| Self-reported asthma control | Utility measured using EQ-5D |
|---|---|
| Very well controlled | 0.9 |
| Well controlled | 0.84 |
| Adequately controlled | 0.81 |
| Not controlled | 0.8 |

*Source: McTaggart et al (2008)[1125]*

It was assumed that un-treated individuals with asthma will receive a QoL equal to a person with 'not controlled' asthma. Individuals that are treated for asthma will achieve a higher level of control. A study by Price et al details the proportion of patients being treated for asthma in the UK that are experiencing either: full control, partial control or uncontrolled asthma as shown in **Table 241:** .

**Table 241: Levels of asthma control for treated patients with asthma**

| Asthma control | Proportion |
|---|---|
| Controlled | 18.2% |
| Partially controlled | 60% |
| Uncontrolled | 21.8% |

*Source: Price et a[1401,1403]l*

The study shows that while some patients achieve full control the majority achieve either partial control or remain uncontrolled. It was assumed that well controlled, detailed in **Table 240**, represents the QoL for partial control, and adequate control represents the QoL for uncontrolled, treated asthma. Therefore the health related quality of life (HRQoL) for treated asthmatics is:

$$HRQoL_{Treated} = Proportion(uncontrolled) * HRQoL(adequately\ controlled) + Proportion(partial\ control) * HRQoL(well\ controlled) + Proportion(controlled) * HRQoL(very\ well\ controlled)$$

Using the information detailed above the average HRQoL for treated asthma is 0.8443. Therefore the HRQoL increase for treating asthma is:

$$HRQoL_{Treated} - HRQoL(not\ controlled) = 0.8443 - 0.8 = 0.0443$$

*Utility of exacerbation*

One limitation with the EQ-5D questionnaire is that the individual is asked how their health is on that specific day when the questionnaire is administered. Therefore the EQ5D score does not take into account the HRQoL impact from exacerbations (if the patient had no exacerbation on that day). A study by Lloyd et al[1033,1033] derives an EQ-5D measure for exacerbations. Therefore in the model a patient receives a disutility if they experience an exacerbation. The size of this disutility is determined

by whether the exacerbation is severe and therefore requiring hospitalisation and is weighted by the duration. The disutility is shown in **Table 242**.

**Table 242: Disutility a patient experiences with an exacerbation**

| Severity of exacerbation | Quality of life decrease during exacerbation | Duration of exacerbation (years) | Disutility (QALYs) |
|---|---|---|---|
| Severe | 0.56 | 0.08 | 0.0448 |
| Non-severe | 0.32 | 0.01 | 0.0032 |

*Source: Lloyd et al*[1033,1033]

To calculate the proportion of adults that would have a hospitalised (severe) exacerbation, the proportion of hospitalised exacerbations was divided by the total number of exacerbations. The total number of exacerbations that occur each year was calculated by taking the annual probability of having an exacerbation and multiplying this by the number of adults with asthma in the UK (4.1 million taken from asthma UK). The annual probability of having an exacerbation was extracted from Shaw et al.[1574] The total number of annual hospitalisations in adults (40,243) was taken from the National review of Asthma deaths.[1488]

*Utility of correctly treating non-asthmatics with asthma symptoms*

For patients with COPD it is assumed that they will have either moderate or mild severity of COPD. In the model if the spirometry shows an obstruction an assumption was made that the patient would have moderate COPD whereas a spirometry showing no obstruction would indicate mild COPD. The quality of life associated with COPD severity is shown in Table 243.

**Table 243: Quality of life for COPD patients by severity**

| COPD severity | Quality of life (SE) | Quality of life if treated for asthma |
|---|---|---|
| Mild | 0.81 (0.02) | 0.765 |
| Moderate | 0.72 (0.03) | 0.695 |
| Severe | 0.67 (0.05) | NA |

*Source: Spencer et al*[1657,1657]

In the model if the patient has COPD but is treated for asthma then they will receive a QoL in between two severity levels, depending on how severe their COPD is. Therefore if a patient has mild COPD and is being treated for asthma they will receive a quality of life of 0.765, which is a quality of life half way between mild and moderate COPD. The GDG decided to use the value half way between these points as asthma medication will slightly help treat COPD. Once the patient has been correctly re-diagnosed as having COPD their QoL will increase to the mean QoL for their severity level.

For patients with heart failure it was assumed that the majority would be classified under the New York Heart Association (NYHA) as class 2. Patients classified under NYHA class 1 are less likely to present any asthma related symptoms whereas patients with NYHA class 3 and 4 are likely to present non-asthma related symptoms that will indicate heart failure. The GDG made an assumption that 80% of patients would be class II, 10% would be class I and 10% would be class III. The quality of life for each class is shown in Table 244.

**Table 244: Quality of life by NYHA class**

| NYHA class | Quality of life (95% CI) | Quality of life if treated for asthma |
|---|---|---|
| I | 0.855 (0.845 – 0.864) | 0.771 |
| II | 0.771 (0.761 – 0.781) | 0.673 |
| III | 0.673 (0.665 – 0.690) | 0.532 |
| IV | 0.532 (0.480 – 0.584) | NA |

*Source: Gholer et al*[581,581]

As the NYHA class the patient falls into is determined by the severity of their symptoms an assumption was used that patients who would fall under NYHA class II would have the quality of life of a patient with class III. Therefore a patient with class II heart failure being treated for asthma will have a QoL of 0.673. This QoL will increase to 0.770 once the patient has been correctly re-diagnosed and is treated accordingly.

These quality of life increases are extensively tested in the sensitivity analyses detailed in M.2.5.

Individuals with either acute symptoms or physical de-conditioning will receive no quality of life benefit from being correctly re-diagnosed as not having asthma. This is because any other management would not be mutually exclusive with asthma medication and therefore these costs and HRQoL benefits would occur in both true negatives and false positives leading to no incremental benefit. Individuals with 'acute symptoms' will therefore receive a quality of life equal to the general population 0.96. Individuals with physical deconditioning will receive a quality of life equal to the general population minus a disutility of 0.05. Both these values were taken from Harnan et al.[644,645] This disutility takes into account their symptoms and is thus equal to the disutility of having asthma. These values will not influence the cost-effectiveness of any strategy as they are not influenced by whether the individual is falsely diagnosed.

### M.2.3.7 Resource use and costs

**Diagnostic tests – primary care**

For diagnostic tests conducted in primary care, resource use was elicited from the GDG. This included information on: the health care professional who conducts the test, the time taken to administer the test, and the equipment used. Costs were then applied using data from the NHS supply chain catalogue[426] and the PSSRU[386,386]. Costs of individual tests conducted in primary care are reported below (Table 245 to Table 248).

**Table 245: Cost of spirometry**

| Item | Quantity | Unit cost | Total Cost (quantity*unit cost) | Source |
|---|---|---|---|---|
| Time of GP practice nurse to conduct the test | 20 minutes | £0.73 per minute | £14.66 | GDG opinion, PSSRU[386,386] |
| Micro-lab spirometer [(a)] | 1/1500 | £1498.90 per spirometer | £1.00 | GDG opinion, NHS supply catalogue[426] |
| Bacterial filter, 3-litre syringe for calibration[(a)] | 1/1500 | £295.77 per syringe | £0.20 | GDG opinion, NHS supply catalogue[426] |
| Bacterial filter | 1 | £0.99 per filter | £0.99 | NHS supply catalogue[426] |
| **Total** | | | **£16.86** | |

*(a) To calculate the marginal cost it was assumed that the equipment lasts for 5 years and is used on average 1500 times in this period.*

**Table 246: Cost of bronchodilator reversibility**

| Item | Quantity | Unit cost | Total Cost (quantity*unit cost) | Source |
|---|---|---|---|---|

| Item | Quantity | Unit cost | Total Cost (quantity*unit cost) | Source |
|---|---|---|---|---|
| Time taken to administer bronchodilator and check for reversibility | 20 minutes | £0.73 per minute | £14.66 | GDG opinion, PSSRU[386,386] |
| Volumatic spacer | 1 | £3.81 per spacer | £3.81 | NHS supply catalogue[426] |
| MDI | 1 | £5.50 per MDI | £5.50 | NHS supply catalogue[426] |
| Spirometry equipment to check for reversibility[(a)] | 1 | £2.19 (see **Table 245** above) | £2.19 | NHS supply catalogue[426] |
| **Total** | | | **£26.16** | |

*(a) When a bronchodilator reversibility test is being performed in the model the first spirometry reading will have already been taken.*

**Table 247: Cost of FeNO**

| Item | Quantity | Unit cost | Total Cost (quantity*unit cost) | Source |
|---|---|---|---|---|
| Time taken to conduct test with GP practice nurse | 10 minutes | £0.73 per minute | £7.30 | GDG opinion, PSSRU[386,386] |
| Marginal cost of using equipment (NIOX VERO[(a)]) | 1 | £6.36 per use | £6.36 | Harnan et al[644] |
| **Total** | | | **£13.66** | |

*(a) It was assumed that NIOX VERO is the most commonly used FeNO test*

**Table 248: Cost of peak expiratory flow variability**

| Item | Quantity | Unit cost | Total Cost (quantity*unit cost) | Source |
|---|---|---|---|---|
| Time taken to instruct patient how to use test with GP practice nurse | 10 minutes | £0.73 per minute | £7.30 | GDG opinion, PSSRU[386,386] |
| Time taken to interpret results by GP practice nurse | 10 minutes | £0.73 per minute | £7.30 | GDG opinion, PSSRU[386,386] |
| Mini wright peak flow meter | 1 | £6.48 per meter | £6.48 | NHS supply catalogue[426] |
| **Total** | | | **£21.08** | |

**Diagnostic tests – secondary care**

The following tests are conducted in a secondary care setting. The costs of exercise and histamine/methacholine challenge tests are detailed in **Table 249** and **Table 250** respectively. It is

assumed that a GP will refer a patient to have a challenge test and the patient will complete the test in a secondary care setting. The results of the test will be interpreted by a respiratory physician and sent back to the GP for analysis.

**Table 249: Cost of exercise challenge test**

| Item | Quantity | Unit cost | Total cost | Source |
|---|---|---|---|---|
| Cost of interpreting result – 15 minutes of associate specialist time | 1 | £23.50 | £23.50 | GDG opinion, PSSRU[386,386] |
| Investigation costs | 1 | £167 | £167 | NHS reference costs[425] - (Complex lung function exercise testing[(a)] HRG code: DZ31Z) |
| Cost of GP referral | 1 | £37 | £37 | GDG opinion, PSSRU[386,386] |
| **Total** | | | **£227.50** | |

*(a) The HRG cost was weighted assuming that the test would only be conducted in outpatient and direct access*

**Table 250: Cost of histamine/methacholine**

| Item | Quantity | Unit cost | Total cost | Source |
|---|---|---|---|---|
| Cost of interpreting result – 15 minutes of associate specialist time | 1 | £23.50 | £23.50 | GDG opinion, PSSRU[386,386] |
| Investigation costs | 1 | £102.00 | £102.00 | NHS reference costs[425] - (Bronchial challenge studies[(a)] HRG code: DZ36Z) |
| Cost of GP referral | 1 | £37 | £37 | GDG opinion, PSSRU[386,386] |
| **Total** | | | **£162.50** | |

*(a) The HRG cost was chosen assuming that the test would only be conducted in directly accessed diagnostic services*

To parameterise the reference costs probabilistically, the distribution of best fit was found by fitting a gamma and lognormal distribution. To fit each distribution, the standard deviation of the trust cost was estimated matching the reported interquartile ran ge to that calculated using the reported mean, and where appropriate the distribution's alpha and beta values. The distribution of best fit was that which provided the interquartile range of closest value to that reported by the NHS reference cost.

**Cost of asthma treatment**

The annual cost of asthma management was taken from a study by Price et al[1401,1403]. A large driver of the cost of asthma management is the level of asthma control the individual achieves. Individuals achieving poor asthma control will have higher drug costs as they will be on a higher step of asthma medication receiving more expensive treatments. Likewise, individuals achieving good asthma control will have lower drug costs as they will be on a much less intensive form of treatment. The study by Price et al differentiates annual asthma costs by level of control and number of exacerbations. This annual cost incorporates: drug costs, GP consultations and hospitalisations and is

shown in **Table 251**. N (%) represents the number and percentage of patients that fall in a particular cohort, mean (SD) represents the mean cost and its associated standard deviation.

**Table 251: Annual asthma costs**

| | | Number of exacerbations | | | |
|---|---|---|---|---|---|
| **Level of GINA control** | | **0** | **1** | **2-3** | **4+** |
| **Controlled** | **N (%)**<br>**Mean annual cost (SD)** | 2583 (16.2%)<br>£180 (£225) | 196 (1.2%)<br>£284 (£287) | 38 (0.24%)<br>£471 (£408) | 13 (0.08%)<br>£573 (£481) |
| **Partially controlled** | **N (%)**<br>**Mean annual cost (SD)** | 7079 (44.5%)<br>£238 (279) | 814 (5.1%)<br>£397 (£358) | 307 (1.9%)<br>£557 (£427) | 67 (0.42%)<br>£645 (£549) |
| **Uncontrolled** | **N (%)**<br>**Mean annual cost (SD)** | 3642 (22.8%)<br>£319 (£366) | 745 (4.7%)<br>£491 (£416) | 399 (2.1%)<br>£672 (£493) | 102 (0.64%)<br>£928 (£755) |
| **Annual weighted asthma cost** | £290 | | | | |

*Source: Price et al*[1401,1403]

Using this information the annual cost of asthma management can be calculated for the average asthma patient by taking a weighted average. This is done by weighting the cost of asthma management by the proportion of patients experiencing a certain number of exacerbations at a certain level of control. This average cost is equal to £290.

*Annual cost of asthma treatment for non-asthmatics*

Individuals who do not have asthma but are prescribed asthma medication (false positive) are likely to have a different annual cost compared to individuals with asthma. This has been incorporated into the model by extrapolating from the data presented in **Table 251**.

For individuals with acute symptoms they are likely to appear to be achieving full asthma control as their symptoms will pass with time. As they don't have asthma they will not experience any exacerbations. Therefore the cost given to these individuals in the model is the cost associated with controlled asthma and zero exacerbations which in **Table 251** is £180.

For individuals with either heart failure or physical de-conditioning their symptoms will be worse and it will appear that their asthma may be uncontrolled, however they won't experience any exacerbations. Therefore for these individuals a weighted cost of asthma management was calculated based on the number of individuals experiencing zero exacerbations but achieving differing levels of asthma control. As there is no data on the perceived level of asthma control achieved by non-asthmatics an assumption was made that the proportions achieving a certain level for control will be the same as asthmatics. This information is displayed in **Table 252** and has been extrapolated from the data presented in Table 251. The GDG also noted that once the individual has been diagnosed with heart failure some individuals will retain their incorrect asthma diagnosis and remain on asthma treatment for the rest of their life. Therefore in the model 25% of the cost of asthma management will be retained after the individual has been diagnosed as having heart failure. This value was removed in a sensitivity analysis detailed in section M.2.5.

**Table 252: Annual asthma costs for people with an incorrect diagnosis of asthma who have either heart failure or physical deconditioning**

| | Number of exacerbations |
|---|---|
| **Level of GINA control** | **0** |

| | | Number of exacerbations |
|---|---|---|
| **Controlled** | (%)<br>Mean (SD) | (19.4%)<br>£180 (£225) |
| **Partially controlled** | (%)<br>Mean (SD) | (53.2%)<br>£238 (279) |
| **Uncontrolled** | (%)<br>Mean (SD) | (27.4%)<br>£319 (£366) |
| **Annual average asthma cost** | £248.91 | |

Finally for COPD patients it was assumed that if they were treated for asthma then they would incur the same costs as an asthma patient. This is likely to be an underestimate as COPD patients exacerbate more than asthma patients especially if they are being treated for asthma as opposed to COPD. This will make the results more conservative for strategies with higher specificities.

These costs are tested in the sensitivity analysis in section M.2.5.

*Adding uncertainty around asthma costs*

As shown by the large standard deviations in **Table 251**, there is a great deal of uncertainty around the annual cost of asthma. This uncertainty was captured by attaching gamma distributions to each combination of control and exacerbation. The distribution parameters attached are shown in **Table 253**. Alpha and lambda parameters were calculated using the mean and standard deviation detailed in **Table 251**.

**Table 253: Gamma distribution parameters for annual asthma costs[(a)]**

| Level of control/no. of exacerbations | Point estimate | Alpha | Lambda |
|---|---|---|---|
| Controlled / 0 | £180 | 0.64 | 0.004 |
| Partially controlled / 0 | £238 | 0.72 | 0.003 |
| Uncontrolled / 0 | £319 | 0.76 | 0.002 |
| Controlled / 1 | £284 | 0.98 | 0.003 |
| Partially controlled / 1 | £397 | 1.23 | 0.003 |
| Uncontrolled / 1 | £491 | 1.39 | 0.003 |
| Controlled / 2-3 | £472 | 1.34 | 0.003 |
| Partially controlled / 2-3 | £557 | 1.7 | 0.003 |
| Uncontrolled / 2-3 | £672 | 1.86 | 0.003 |
| Controlled / 4+ | £573 | 1.4 | 0.002 |
| Partially controlled / 4+ | £645 | 1.38 | 0.002 |
| Uncontrolled / 4+ | £928 | 1.51 | 0.002 |

*(a) Numbers are rounded to 2 decimal places or nearest integer*

*Annual cost of non-asthmatic treatment*

For patients with COPD and heart failure once they are correctly re-diagnosed the NHS will incur the costs of their respective treatment rather than asthma medication.

The costs for COPD management were taken from the NICE COPD guideline.[1213] In the guideline the annual incremental costs of a patient with mild COPD, relative to the general population, were £149.68. For patients with moderate COPD this incremental cost increases to £307.74. Therefore in

the model once a patient with COPD is correctly re-diagnosed and treated for COPD, the NHS will incur these costs rather than asthma management costs.

For heart failure patients the NHS will incur the cost of heart failure medication once the patient is correctly re-diagnosed. This cost was estimated to be £135 per year in the recent acute heart failure guideline[1214].

*Cost of exacerbations*

In the model exacerbation costs are calculated for patients who have an exacerbation whilst they are not being treated for asthma. This cost is dependent on whether the exacerbation is severe. If the exacerbation is not severe then the cost includes one GP appointment (£37 from PSSRU[386,386]) and a course of oral steroids with Prednisolone (cost=£1.33 from NHS drug tariff[1230]). If the exacerbation is severe then the patient will be hospitalised and the cost of asthma hospitalisation will be added (cost = £873.74 from NHS reference cost[425]).

Therefore the average cost of an exacerbation is:

$$Average\ cost\ of\ exacerbation = Prob(hospitalisation) * cost(hospitalisation - \big(1 - Prob(Hospitalisation)\big) * cost(non - severe\ exacerbation)$$

Once the patient is being treated for asthma the exacerbation costs have already been taken into account as reported in Table 251 and therefore these costs as calculated above are excluded in these patients to avoid double counting.

### M.2.4 Computations

The model was constructed in TreeAge Pro 2009[1785,1785] and was evaluated by cohort simulation. Time dependency was built in by cross referencing the cohorts age as a respective risk factor for mortality.

QALYs for the cohort were computed each cycle. To calculate QALYs for each cycle, Q(t), the time spent in the alive state of the model was weighted by a utility value that is dependent on the time spent in the model and the health state. QALYs were then discounted to reflect time preference (discount rate = 3.5%) using the following formula:

| | |
|---|---|
| $\text{Discounted total} = \frac{\text{Total}}{(1+r)^n}$ | Where:<br>*r*=discount rate per annum<br>*n*=time (years) |

QALYs during the first cycle were not discounted. The total discounted QALYs were the sum of the discounted QALYs per cycle. The total discounted QALYs were the sum of the discounted QALYs per cycle.

Costs per cycle, C(t), were calculated in the same way as QALYs. Costs were discounted to reflect time preference (discount rate = 3.5%) in the same way as QALYs using the formula above.

*Estimating cost-effectiveness*

The widely used cost-effectiveness metric is the incremental cost-effectiveness ratio (ICER). This is calculated by dividing the difference in costs associated with two alternatives by the difference in QALYs. The decision rule then applied is that if the ICER falls below a given cost per QALY threshold

the result is considered to be cost-effective. If both costs are lower and QALYs are higher the option is said to dominate and an ICER is not calculated.

$$ICER = \frac{Costs\ (B) - Costs\ (A)}{QALYs\ (B) - QALYs\ (A)}$$

Where: Costs(A) = total costs for option A; QALYs(A) = total QALYs for option A

Cost-effective if:
- ICER < Threshold

When there are more than two comparators, as in this analysis, options must be ranked in order of increasing cost then options ruled out by dominance or extended dominance before calculating ICERs excluding these options. An option is said to be dominated, and ruled out, if another intervention is less costly and more effective. An option is said to be extendedly dominated if a combination of two other options would prove to be less costly and more effective.

It is also possible, for a particular cost-effectiveness threshold, to re-express cost-effectiveness results in term of net monetary benefit (NMB). This is calculated by multiplying the total QALYs for a comparator by the threshold cost per QALY value (for example, £20,000) and then subtracting the total costs (formula below). The decision rule then applied is that the comparator with the highest NMB is the most cost-effective option at the specified threshold. That is the option that provides the highest number of QALYs at an acceptable cost.

$$Net\ \ Monetary\ \ \ Benefit\ \ (X) = (QALYs\ \ (X) \times \lambda) - Costs\ \ (X)$$

*Where: λ = threshold (£20,000 per QALY gained)*

Cost-effective if:
- Highest net benefit

Both methods of determining cost-effectiveness will identify exactly the same optimal strategy. For ease of computation NMB is used in this analysis to identify the optimal strategy.

Results are also presented graphically where total costs and total QALYs for each diagnostic strategy are shown. Comparisons not ruled out by dominance or extended dominance are joined by a line on the graph where the slope represents the incremental cost-effectiveness ratio.

### M.2.5 Sensitivity analyses

The sensitivity analyses conducted below were undertaken to test some of the key assumptions employed in the model.

**Table 254: Sensitivity analyses conducted**

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| S1 | Probability of COPD, physical deconditioning, heart failure or acute symptoms being cause of asthmatic symptoms | As the exact distribution of these underlying conditions is unknown this sensitivity analysis addresses different distributions between the four conditions. The model was run eight times with each condition being given a higher proportion (35%) once and a lower proportion (15%) once. The distribution between the remaining three | a) Probability of COPD being cause of symptoms: 15%, 35%<br><br>b) Probability of obesity being cause of symptoms: 15%, 35%<br><br>c) Probability of heart failure being cause | As there is no indication of what this distribution might be extreme values were run to cover a large range. |

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| | | conditions was set to be equal. | of symptoms: 15%, 35%<br><br>d)<br>Probability of symptoms being acute: 15%, 35% | |
| S2 | Sensitivity and specificity of bronchodilator reversibility | In the clinical review two papers were identified for bronchodilator reversibility that used the correct cut-off and had the right population. In the base case an average was taken of the two studies. This sensitivity analysis re-runs the model using both sources separately. | a)<br>Sensitivity: 61%<br>Specificity: 80%<br><br>b)<br>Sensitivity: 17%<br>Specificity: 61% | Diagnostic accuracy taken from Chhabra et al[313,313] and Kim et al[870,873] |
| S3 | Sensitivity and specificity of FeNO | In the clinical review one other paper was identified for FeNO that used the 40ppb cut-off and had the right population. The model was re-run using these values. | Sensitivity: 79%<br>Specificity: 89% | Diagnostic accuracy taken from Fukuhara 2012[535,535] |
| S4 | Sensitivity and specificity of MCT | In the clinical review one other study was identified for MCT that used the correct cut-off and had the right population. The model was re-run using these values. | Sensitivity: 97%<br>Specificity: 83% | Diagnostic accuracy taken from Niemen 1992[1241,1241] |
| S5 | Sensitivity and specificity of spirometry | In the clinical review one other study was identified for spirometry that used the correct cut-off and had the right population. The model was re-run using these values. | Sensitivity: 29%<br>Specificity: 59% | Diagnostic accuracy taken from Schneider 2009[1535,1537] |
| S6 | Probability of re-diagnosis for false positives. | This parameter was derived from clinical judgement as no data exists on what the real value is likely to be. Two scenarios were considered, one where re-diagnosis occurs much faster (probability | Probability of re-diagnosis is twice as likely, all relevant probabilities doubled.<br><br>Probability of re- | As there is no indication of what this value might be extreme values were run to cover a wide range. |

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| | | of re-diagnosis is higher) and one where re-diagnosis occurs much slower (probability of re-diagnosis is lower). | diagnosis is more unlikely, all relevant probabilities halved. | |
| S7 | Probability of re-diagnosis for false negatives | This parameter was derived from clinical judgement as no data exists on what the real value is likely to be. An assumption was made that a patient with asthma would always be diagnosed within a year. This assumption was tested by running the model twice, once where this value is halved and once where this value is doubled. | Maximum length of time for an asthmatic to remain undiagnosed:<br><br>6 months, 2 years | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S8 | Cost of asthma medication for false positives | This parameter was derived by extrapolating from robust data on annual asthma costs. Two scenarios were considered: one where asthma treatment costs were 25% higher and one where asthma treatment costs were 25% lower. | Asthma treatment costs for patients with COPD: £218, £363<br><br>Asthma treatment costs for patients with acute symptoms: £135, £225<br><br>Asthma treatment costs for patients with obesity: £186, £311<br><br>Asthma treatment costs for patients with heart failure: £186, £311 | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S9 | Strength of dependence between PEFv and BDR | This parameter was derived from clinical judgement as no data could be found on its exact value. This value was increased to reflect the possibility of PEFv results being more conditionally dependent on the result from BDR. | Strength of dependence between BDR and PEFv: 0.5 | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S10 | Strength of dependence between challenge tests | This parameter was derived from clinical | Strength of dependence | As there is no indication of what |

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| | and BDR | judgement as no data could be found on its exact value. This value was increased to reflect the possibility of challenge test results being more conditionally dependent on the result from a BDR test. | between histamine challenge test and BDR: 0.75 | this value might be extreme values were run to cover a wide range. |
| S11 | Strength of dependence between challenge tests and PEFv | This parameter was derived from clinical judgement as no data could be found on its exact value. This value was increased to reflect the possibility of challenge test results being more conditionally dependent on the result from PEFv. | Strength of dependence between histamine challenge test and PEFv: 0.75 | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S12 | Quality of life improvement for COPD patients being correctly treated for COPD as opposed to asthma. | This parameter was extrapolated from the literature using GDG opinion. Two sensitivities were run, one where QoL improvements for COPD patients are 50% higher and one were they are 50% lower. | QoL increase for a mild severity COPD patient being correctly treated: 0.01 – 0.06<br>QoL increase for a moderate COPD patient being correctly treated: 0.02 – 0.09 | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S13 | Quality of life improvement for heart failure patients being correctly treated for heart failure as opposed to asthma. | This parameter was extrapolated from the literature using GDG opinion. Two sensitivities were run, one where QoL improvements for heart failure patients are 50% higher and one were they are 50% lower. | QoL increase for a heart failure patient being correctly treated: 0.04 – 0.15 | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S14 | Re-diagnosis costs | This parameter was extrapolated using GDG opinion. Sensitivity was run where re-diagnosis costs only included one GP appointment. This can be seen as the minimum cost it could be. | Cost of re-diagnosis: £37 | As there is no indication of what this value might be the lowest plausible estimate was used as an extreme value. |
| S15 | Asthma prevalence | This parameter was derived from a meta-analysis. The model was re-run using the lower | Asthma prevalence: 0.37, 0.43 | |

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| | | and upper limits of the 95% confidence interval. | | |
| S16 | Cost of methacholine challenge tests | A threshold analysis was run around the cost of methacholine challenge tests to see when treatment decisions would change. | Threshold analysis: Value run from £50 - £600 | |
| S17 | Conducting all primary care tests in one appointment | In the base case it was assumed that all primary care tests would be performed in one sitting. This sensitivity analysis adds the cost of one GP appointment to each primary care test | Cost of BDR, FeNO and PEFv increased by one GP appointment (£37) | |
| S18 | Exacerbation rate for a untreated asthmatic | In the base case this value was based on weak data. For ethical reasons the exacerbation rate of an untreated asthmatic is unlikely to be known. The exacerbation rate for an untreated asthmatic will have an ambiguous effect on the model results as a high exacerbation rate is associated with disutility and a slightly higher mortality rate; however a high exacerbation rate means patients are re-diagnosed quicker which means a higher quality of life. | Threshold analysis: Exacerbation rate of untreated asthmatic run from 0.5 – 1.5. | As there is no indication of what this value might be extreme values were run to cover a wide range. |
| S19 | Discount rate | Discount rate was changed from 3% for costs and QALYs to 1.5%. This is to reflect uncertainty around the true discount rate. | Discount rate: 1.5% | |
| S20 | Probability that a heart failure patient retains an incorrect asthma diagnosis permenantly | The GDG noted that even after the true cause of symptoms has been identified, some heart failure patients will retain a diagnosis of asthma as the two diseases are not | Probability of heart failure patient retaining asthma diagnosis: 0% | |

| Analysis | Parameter | Description | Values | Comment |
|---|---|---|---|---|
| | | necessarily mutually exclusive. In the base case this value was set as 25%. This assumption was removed in this sensitivity analysis. | | |
| S21 | Sensitivity and specificity of MCT | A two way sensitivity analysis was conducted on these two values running the diagnostic sensitivity from 90 – 98% and the specificity from 80 – 99%. This range covers the uncertainty surrounding what the diagnostic accuracy is of these tests in light of the clinical evidence and conditional dependence. | Sensitivity of MCT: 90-98%<br><br>Specificity of MCT: 80-99% | |

### M.2.6 Interpreting Results

NICE's report 'Social value judgements: principles for the development of NICE guidance'[1215] sets out the principles that GDGs should consider when judging whether an intervention offers good value for money. In general, an intervention was considered to be cost-effective if either of the following criteria applied (given that the estimate was considered plausible):

- The intervention dominated other relevant strategies (that is, it was both less costly in terms of resource use and more clinically effective compared with all the other relevant alternative strategies), or
- The intervention costs less than £20,000 per quality-adjusted life-year (QALY) gained compared with the next best strategy.

As we have several interventions, we use the NMB to rank the strategies on the basis of their relative cost-effectiveness. The highest NMB identifies the optimal strategy at a willingness to pay of £20,000 per QALY gained.

### M.2.7 Model validation

The model was developed in consultation with the GDG; model structure, inputs and results were presented to and discussed with the GDG for clinical validation and interpretation.

The model was systematically checked by the health economist undertaking the analysis; this included inputting null and extreme values and checking that results were plausible given inputs. The model was peer reviewed by a second experienced health economist from the NCGC; this included systematic checking all of the model calculations.

# M.3 Results

## M.3.1 Base case

The results below in **Table 255** show that diagnostic strategy 3 has the highest net monetary benefit and is therefore the most cost-effective way of diagnosing asthma. Strategy 6 produces the highest number of QALYs however is not deemed cost-effective at a £20,000 per QALY threshold. Strategy 1 produces the least QALYs and the highest cost.

**Table 255: Base case results (probabilistic)**

| Strategy | Mean per patient | | NMB at £20,000 threshold | Rank at £20,000 threshold | Probability of being CE at £20,000 threshold |
|---|---|---|---|---|---|
| | QALYs | Cost | | | |
| Current practice | 16.7766 | £3,730 | £331,802 | 6 | 6% |
| Strategy 1 | 16.7760 | £3,753 | £331,768 | 7 | 0% |
| Strategy 2 | 16.7776 | £3,686 | £331,866 | 5 | 19% |
| Strategy 3 | 16.7783 | £3,683 | £331,882 | 1 | 44% |
| Strategy 4 | 16.7785 | £3,691 | £331,878 | 4 | 0% |
| Strategy 5 | 16.7784 | £3,686 | £331,881 | 2 | 23% |
| Strategy 6 | 16.7787 | £3,695 | £331,879 | 3 | 8% |

*(a) Full details on each strategy is covered in section M.2.1.1*

**Figure 315** below shows the results from **Table 255** above on a cost-effectiveness plane. As you can see current practice and strategy 1 are dominated options, producing lower health gains at a higher cost relative to other strategies. Strategies 4 and 5 are extendedly dominated.

**Figure 315: Cost-effectiveness plane showing incremental costs and QALYs of each individual strategy**



**Table 256** below shows the overall sensitivity and specificity of each diagnostic pathway, that is the percentage of patients with asthma that receive a true positive diagnosis and the percentage of patients without asthma that receive a true negative diagnosis.

**Table 256: Diagnostic accuracies of each strategy**

| | Current practice | Strategy 1 | Strategy 2 | Strategy 3 | Strategy 4 | Strategy 5 | Strategy 6 |
|---|---|---|---|---|---|---|---|
| Sensitivity | 100% | 90.3% | 89.3% | 86.3% | 88.7% | 87.7% | 90.3% |
| Specificity | 65.8% | 69.1% | 82.4% | 89.5% | 89.4% | 89.4% | 89.4% |

*Note: Accuracies rounded to one decimal place*

**Table 256** shows that no strategy has a single highest value for sensitivity and specificity though strategy 6 has the highest diagnostic odds ratio. Finally Table 257 details the cost of diagnostic tests associated with each strategy.

**Table 257: Cost of testing in each strategy**

| | Current practice | Strategy 1 | Strategy 2 | Strategy 3 | Strategy 4 | Strategy 5 | Strategy 6 |
|---|---|---|---|---|---|---|---|
| Cost associated with diagnostic tests | £0 | £42 | £52 | £92 | £100 | £95 | £103 |

Table 257 shows that although the strategies that include challenge tests cost more the increase in cost is far less than the cost of a single challenge tests as the majority of individuals will not go on to receive one.

### M.3.2 Sensitivity analyses

The following sensitivity analyses were run deterministically. Of the 21 sensitivity analyses conducted, as detailed in section M.2.5, the following resulted in a change in conclusions of the model :

*S2a: Changing the sensitivity and specificity of BDR to 61% and 80% respectively.*

Table 258 below shows the results of just the non-dominated strategies. As you can see strategy 5 is now the most cost-effective strategy at a £20,000 per QALY threshold. This is because a higher sensitivity of BDR means that more patients with asthma will receive a positive BDR result. As the pathway continues after a positive BDR it becomes more cost-effective to continue testing after negative test results to ensure false negatives are kept to a minimum. Likewise now the specificity is higher, more non-asthmatics receive a negative BDR result; therefore it becomes less cost-effective to continue testing after negative BDR results as the number of false negatives is already quite low.

**Table 258: Results of sensitivity analysis S2a**

| Strategy | Mean per patient | | ICER (per QALY gained) |
|---|---|---|---|
| | QALYs | Cost | |
| Strategy 3 (CT only after no obs) | 16.8355 | £3,550 | - |
| Strategy 5 (additional CT after -ve BDR) | 16.8357 | £3,552 | £10,667 |
| Strategy 6 (largest amount of CT) | 16.8358 | £3,561 | £56,755 |

*S2b: Changing the sensitivity and specificity of BDR to 17% and 61% respectively.*

Table 259 below shows the results of just the non-dominated strategies. Now strategy 5 is extendedly dominated . As the sensitivity of BDR is much lower very few asthmatics receive a positive BDR result. Likewise the low specificity means that lots of non-asthmatics will receive a positive BDR result. After a positive BDR test the individual will receive a FeNO test. If the FeNO comes out negative then, with these BDR diagnostic accuracies, it is highly likely that the individual does not have asthma thus making challenge testing beyond this point less cost-effective. Likewise as the majority of asthmatics will receive a negative BDR result it will be more cost-effective to keep testing beyond this point to ensure these false negatives are rectified.

**Table 259: Results of sensitivity analysis S2b**

| | Mean per patient | | |
|---|---|---|---|
| **Strategy** | **QALYs** | **Cost** | **ICER (per QALY gained)** |
| Strategy 3 (CT only after no obs) | 16.7838 | £3,692 | - |
| Strategy 4 (additional CT after -ve BDR) | 16.7841 | £3,699 | £24,281 |
| Strategy 6 (largest amount of CT) | 16.7842 | £3,703 | £60,422 |

*S3: Changing the sensitivity and specificity of FeNO to 79% and 89% respectively.*

The results in Table 260 show that the only non-dominated strategies are strategy 2, 5 and 6. As the FeNO specificity is much higher it becomes less cost-effective to continue testing after a positive result. Therefore if the individual has a non-obstructive spirometry and a positive FeNO then it becomes less cost-effective to continue testing after that point. Likewise a lower sensitivity means it is more cost-effective to keep testing after a negative FeNO result to ensure false negative results are reversed. Taking these two points into account strategy 3 becomes less cost-effective and strategies 5 and 6 become more cost-effective causing strategy 3 to become extendedly dominated.

**Table 260: Results of sensitivity analysis S3**

| | Mean per patient | | |
|---|---|---|---|
| **Strategy** | **QALYs** | **Cost** | **ICER (per QALY gained)** |
| Strategy 2 (No CT) | 16.7832 | £3,659 | - |
| Strategy 5 (additional CT after +ve BDR) | 16.7838 | £3,670 | £19,307 |
| Strategy 6 (largest amount of CT) | 16.7843 | £3,684 | £28,691 |

*S4: Changing the sensitivity and specificity of MCT to 97% and 83% respectively*

The results in Table 261 show that the results from the base case are sensitive to changes in the diagnostic accuracy of a methahcholine challenge test. In this sensitivity analysis the specificity is drastically decreased to 83%, from 99%. The sensitivity is increased however from 93% to 97%. As challenge tests are leading to fewer true negatives strategy 3 no longer dominates. It is worth noting that additional challenge tests after a bronchodilator reversibility test are no longer cost-effective. This is because although these additional challenge tests increase the sensitivity of the diagnostic pathway they now significantly reduce the specificity.

**Table 261: Results of sensitivity analysis S4**

| | Mean per patient | | |
|---|---|---|---|
| **Strategy** | **QALYs** | **Cost** | **ICER (per QALY gained)** |

| Strategy | Mean per patient | | ICER (per QALY gained) |
|---|---|---|---|
| | QALYs | Cost | |
| Strategy 2 (No CT) | 16.7832 | £3,692 | - |
| Strategy 3 (CT only after no obs) | 16.7838 | £3,698 | £8,530 |
| Strategy 5 (additional CT after +ve BDR) | 16.7840 | £3,708 | £62,477 |
| Strategy 6 (largest amount of CT) | 16.7840 | £3,717 | £170,957 |

*S15: Threshold analysis on the cost of methacholine challenge test.*

The sensitivity analysis showed that if the cost of a methacholine challenge test was £88 lower at £75 then strategy 6 (maximum number of challenge tests) becomes the new most cost-effective strategy. Likewise if the cost of the test was £87 higher at £240 then strategy 2 (no challenge tests) becomes the most cost-effective option. In reality as the methacholine challenge test is an infrequently used test; if this test was to be used more frequently then the costs could fall due to economies of scale. Therefore the likelihood of the test cost exceeding £240 is unlikely.

*S20: Two way sensitivity analysis on the sensitivity and specificity of MCT*

Figure 316 below shows the most cost-effective strategy for a range of different values used for the sensitivity and specificity of a MCT. The shaded colour indicates which strategy is most cost-effective at particular co-ordinates on the graph, with sensitivity being on the x-axis and specificity being on the y-axis. The graph shows that challenge tests stil cost-effective if the sensitivity and specificity are far lower than the values used in the base case (93% sensitivity and 99% specificity). There is no clinical evidence to suggest the values are this low and conditional depdence would not cause the overall sensitivity AND specificity to decrease.

**Figure 316: Two way sensitivity analysis on sensitivity and specificity of a MCT**



# M.4 Discussion

## M.4.1 Summary of results

This analysis showed that providing challenge tests as part of a diagnostic pathway for individuals who present with asthma symptoms, have a non-obstructive spirometry and conflicting PEFv and FeNO results (strategy 3) is the most cost-effective strategy at a £20,000 per QALY threshold. Further challenge testing on patients with an obstructive spirometry provided higher health outcomes however was not cost-effective at a £20,000 per QALY threshold. All other strategies were either dominated or extendedly dominated.

The sensitivity analyses show that there is an element of uncertainty regarding the use of challenge tests for individuals who have an obstructive spirometry. The value of these additional challenge tests (those detailed in strategies 4, 5 and 6) is contingent on the diagnostic accuracy of bronchodilator reversibility tests, FeNO and methacholine challenge tests. This level of uncertainty has been captured in the recommendations whereby these tests are considered but not routinely offered.

In all sensitivity analysis a diagnostic pathway that incorparted challenge testing was always a cost-effective strategy. This is despite the fact there there are many aspects of the model that reduce the cost-effectiveness of challenge testing. For example it is assumed there is no mortality impact from falsely diagnosing individuals who have COPD and heart failure with asthma. Secondly the model does not cover all illnesses that could receive a false diagnosis of asthma. Conditions such as lung cancer and tuberculosis could have profound health consequences if misdiagnosed as asthma.

With regards to the routine use of challenge tests in asthma diagnosis for individuals with unobstructive spirometry (strategy 3) the model results are highly robust to changes in all key assumptions made within the model. Therefore although there is uncertainty regarding conditional dependence and the health and cost consequences of false diagnoses, solving this uncertainty will not change the conclusions of the model.

## M.4.2 Limitations and interpretation

The main limitation with the model is the lack of clinical data available to inform some of the key parameters; mainly those surrounding misdiagnosis for non-asthmatics. To compensate for this, all the assumptions made have been conservative towards strategies that produce higher specificities. Firstly the model assumes that 50% of patients without asthma forego no quality of life from being diagnosed with asthma. In reality this number is likely to be an overestimate and there are likely to be some adverse effects of asthma medication as well that have not been captured. Secondly severe illnesses such as lung cancer have not been captured in this model which would have drastic quality of life impact if misdiagnosed as asthma. Finally no mortality effects have been captured for heart failure patients from foregoing correct treatment. All of this means that challenge testing for patients with non-obstructive spirometry is likely to be more cost-effective than is depicted in the model. It is worth noting that these limitations were extensively tested in the sensitivity analyses and challenge testing remained cost-effective at a £20,000 per QALY threshold in all of them.

Another limitation is that the evidence collected for the diagnostic accuracy of each test was not conducted in the appropriate subgroup of patients. For example in the diagnostic pathway ideally we would want to know the diagnostic accuracy of PEFv in a subgroup of patients who present symptoms of asthma and have no obstruction and a negative FeNO. Instead the diagnostic accuracy was taken from a review on all patients who present asthma symptoms. This issue was tackled for the majority of tests, as detailed in section M.2.2.3, however conditional dependence was not fully incorporated for challenge tests in the model. A sensitivity analysis showed that both the sensitivity

and specificity of a methacholine challenge test would have to decrease significantly to make them no longer cost-effective at a £20,000 per QALY threshold therefore indicating that conditional dependence is unlikely to have an impact of the model results.

### M.4.3 Generalisability to other populations or settings

The results produced in this analysis are specific to a UK setting. To generalise the results to other countries the costs used and asthma prevalence parameter would need to be re-evaluated as these are likely to be country specific. Consideration also needs to be made as to how challenge tests are conducted. In this analysis it is assumed the GP refers the patient for the challenge test where it is performed and analysed in a secondary care setting. The results are then referred back to the GP where they discuss treatment options with the patient. Other methods of conducting the challenge test will have different cost implications and therefore make the results less generalizable to other settings.

It is worth noting that these results are not generalisable for children aged 16 or younger. The main reason for this is that the asthma prevalence in this population is very different. In a child population asthma is likely to be a much more common cause of a chronic cough. As asthma prevalence is higher this will increase the cost-effectiveness of more sensitive diagnostic strategies. Secondly children will not have other common conditions such COPD or heart failure for example. This will affect the final cost and health outcomes of each diagnostic strategy.

### M.4.4 Comparisons with published studies

This is the first economic evaluation that addresses the cost-effectiveness of diagnostic pathways for diagnosing asthma. However other studies have attempted to assess the cost-effectiveness of asthma diagnostic tests on their own rather than as part of a pathway. To do this these studies have to make similar assumptions outlined in the methods above. Only one study attempts to do this and that is a study by Harnan et al.[644] The approach taken by Harnan et al was to assume that non-asthmatics had a disutility that remained until the correct diagnosis was made. This disutility was equal to the difference in quality of life between an asthmatic and a non-asthmatic. This approach attaches a much higher quality of life loss to incorrect diagnosis than the methods used in our model as it assumes all non-asthmatics will forego treatment that will cure them of their asthmatic symptoms. The approach by Harnan also overestimates the cost-savings to the NHS. If an individual is being treated for asthma then they forego correct medication, therefore the unnecessary asthma medication is a cost but there are savings being made by not prescribing the correct medication. The overall cost to the NHS from incorrectly prescribing asthma medication is therefore lower as money is not spent on the correct medication. Therefore relative to other methods the results produced in this analysis are much more conservative for strategies with higher specificities. As the results from Harnan et al are for singular diagnostic tests, their results are not comparable to the analysis presented above.

### M.4.5 Conclusions

The main conclusion to be drawn from this model is that there is a place for routine challenge testing in a diagnostic pathway, despite its initial high cost. This is because its initial high costs are then offset by reduced unnecessary asthma management and a gain in QALYs. This conclusion was robust to a wide range of sensitivity analyses. A second important conclusion is that there is scope for further challenge tests, conducted on patients further down the pathway after an obstructive spirometry, to be cost-effective at a £20,000 per QALY threshold. In the base case the ICER for providing these extra challenge tests was £32,565 per QALY. However the sensitivity analyses showed there were some scenarios where it was cost-effective to do extra challenge tests,

particularly for individuals who receive a positive bronchodilator result. The GDG believed further challenge tests would be cost-effective in some situations. For example if another diagnosis, such as COPD, is considered likely then further challenge testing should not be considered. Therefore these additional challenge tests should not be routinely carried out, unlike those placed in strategy 3.

### M.4.6 Implications for future research

Areas in the model that were most uncertain are difficult to resolve with further research due to ethical implications. For example the difference in quality of life between treated and untreated patients with asthma, or the quality of life lost by treating a heart failure patient with asthma medication. Although there was considerable uncertainty surrounding some diagnostic accuracies and conditional dependence the model results were robust to large changes in these parameters. Therefore additional research in these areas will not lead to any changes in management. One key area of uncertainty revolved around the diagnostic accuracy of mannitol. There was limited evidence on the diagnostic accuracy of mannitol and it is a cheaper test to perform relative to other challenge tests. There is also scope for mannitol to be conducted in primary care. If mannitol was proven to have a higher sensitivity and specificity then it could be a more cost-effective replacement for methacholine in the diagnostic pathway.

# Appendix N: Research recommendations

## N.1 High-priority research recommendations

**N.1.1.1** **Research question 1:** What is the acceptability and diagnostic accuracy of objective tests that could be used to comprise a diagnostic pathway for asthma in children aged 5-16 years old (for example, exercise challenge, direct bronchial challenge with histamine or methacholine, indirect bronchial challenge with mannitol and peripheral blood eosinophil count)?

**Why this is important:** Asthma is a common condition, diagnosed in nearly 1 in 10 children. There are no validated and reliable objective criteria for diagnosing asthma, so the vast majority of asthma diagnoses are currently based on symptoms and signs. However, symptoms and signs consistent with a diagnosis of asthma are not specific to the condition and can be present in other illnesses. This diagnostic uncertainty results in many children being incorrectly diagnosed with asthma, and many children with asthma in whom the diagnosis is delayed or missed. A single objective measure, or set of objective measures, that can be performed easily in non-specialist clinical settings (although it is noted that challenge tests need to be performed in specialist settings) will help improve diagnostic certainty and reduce the proportion of children treated inappropriately for asthma. This would ensure that children with the condition are identified and treated early.

**Criteria for selecting high-priority research recommendations:**

| | |
|---|---|
| PICO question | **Population:** Children aged 5-16 years with respiratory symptoms.<br>**Index test:** Exercise challenge, direct bronchial challenge with histamine or methacholine, indirect bronchial challenge with mannitol and peripheral blood eosinophil count.<br>**Reference standard:** Physician diagnosis of asthma with an objective test (e.g. spirometry +/- BDR and FeNO test).<br>**Outcome:** Diagnostic accuracy (sensitivity and specificity); serious adverse events; adverse events. |
| Importance to patients or the population | Correct and timely diagnosis of asthma in children will lead to appropriate treatment and improve patient outcomes. |
| Relevance to NICE guidance | Data from this research question will improve the sensitivity and specificity of the diagnostic algorithm in a future update of the NICE guideline. |
| Relevance to the NHS | Appropriate identification of children with asthma will reduce over-diagnosis and result in a reduction of inappropriate treatment. This will result in cost savings to the NHS. |
| National priorities | This is appropriate for the priority areas of improved management of long term conditions and reduction in respiratory morbidity and mortality. |
| Current evidence base | There is very little high quality data available on objective tests for the diagnosis of asthma in children aged 5-16 years. The current data available are inconsistent and are of limited utility in setting clear objective measurements in this age group. |
| Equality | n/a |
| Study design | This requires primary research in children who have clinical respiratory illnesses. Cross-sectional studies would be used for the assessment of the diagnostic accuracy of one (or a combination) of objective tests in the diagnosis of asthma or non-asthma, as determined by the reference standard. Randomised controlled trials could also be used to compare the downstream effects of test accuracy on patient outcomes. |
| Feasibility | Most secondary and tertiary clinical facilities will be able to participate in a multicentre study which would allow the rapid recruitment of the required number of children to give clear answers to the research question. |

| | |
|---|---|
| Other comments | Asthma is one of the most common clinical diagnoses made in children and leads to the prescription and consumption of preventive drugs that have known side-effects. Reduction in incorrect diagnosis of asthma could be viewed as a public health measure and the studies suggested would reduce the drug-load and cost-burden of unnecessary drugs. |
| Importance | • High: the research is essential to inform future updates of key recommendations in the guideline. |

1**N.1.1.2** **Research question 2:** What is the clinical and cost effectiveness of using an indirect bronchial
2 challenge test with mannitol to diagnose asthma in adults and young people older than 16?

3 **Why this is important:** Chronic airway inflammation is associated with bronchial hyper-
4 responsiveness, which is integral to defining asthma. Bronchial challenge testing can help diagnose
5 asthma and assess response to inhaled corticosteroid therapy. It can also be used to monitor asthma
6 control, alongside assessing symptoms and lung function. It is increasingly used in asthma
7 management, although currently most tests are performed only in specialised centres or research
8 settings.

9 Indirect challenge tests with inhaled mannitol act via active inflammatory cells and mediators,
10 whereas direct challenge tests with inhaled histamine or methacholine act directly on bronchial
11 smooth muscle. Indirect challenge testing is more specific but less sensitive than direct challenges.

12 Direct challenge testing may not identify a person who will respond to inhaled steroids. A positive
13 result to an indirect challenge may reflect active airway inflammation that is likely to respond to
14 inhaled corticosteroid therapy. Because a response to mannitol indicates active airway inflammation,
15 identifying non-responsiveness in treated patients may help demonstrate good asthma control with
16 inhaled corticosteroid therapy and identify people less likely to deteriorate after a dose reduction.

17 Mannitol bronchial challenge testing is quicker and simpler than current direct tests (which are
18 generally confined to specialist respiratory centres), and uses a standardised inhaler device, so is
19 potentially more useful in primary care.

20 **Criteria for selecting high-priority research recommendations:**

| | |
|---|---|
| PICO question | **Population:** Adults and young people aged over 16 years with respiratory symptoms.<br>**Index test:** Indirect BCT with mannitol.<br>**Comparison:** Direct BCT with histamine or methacholine.<br>**Reference standard:** Physician diagnosis of asthma with an objective test.<br>**Outcome:** Diagnostic accuracy (sensitivity and specificity); adverse events. |
| Importance to patients or the population | Asthma is a treatable, but as yet incurable, chronic inflammatory condition of the lungs. A number of recent studies and reports highlight significant variations in the standard of care across the country with evidence that poor quality care is associated with worse outcomes, poorer quality of life and increased healthcare utilisation.<br>Asthma is one of the most prevalent long-term conditions in the UK. It affects 5.4 million people, is a leading cause of avoidable hospital admissions, and is responsible for more than £1 billion of NHS spending every year. Premature mortality rates from asthma are over 1.5 times higher in the UK than in the rest of Europe, but there is no reason why the standard of care in the UK should be any lower than that of other European countries.[427,1934] |
| Relevance to NICE guidance | Clarification of the role of mannitol BCT both in terms of diagnostic accuracy compared to direct BCTs and as a potential tool in the monitoring of asthma would allow the NICE guideline on the diagnosis and monitoring of asthma to make firm recommendations regarding its use in clinical practice. |

| | |
|---|---|
| Relevance to the NHS | Asthma continues to result in a significant number of avoidable deaths, admissions and quality of life impairment, all with associated costs. Better diagnosis and monitoring of asthma will reduce healthcare utilisation, reduce the economic burden to the NHS and improve quality of life to people with asthma. |
| National priorities | The NHS Atlas of Variation in Healthcare demonstrates that there is significant variation in health outcomes for asthma across the NHS in England.<br>The National Review of Asthma Deaths (NRAD)[1488] identified a number of quality and safety concerns related to the provision of asthma care in the UK. It raised particular concern around standards in primary care concluding that there was an urgent need to tackle 'complacency' about asthma. |
| Current evidence base | Indirect BCTs (such as mannitol) are more specific, though less sensitive, than direct BCT (such as methacholine, histamine) for identifying patients with active asthma. The potential for monitoring asthma with airway hyper-responsiveness is of particular interest to clinicians. Sont el al. demonstrated that management of asthma therapy based on reducing BHR in conjunction with symptoms and lung function leads to more effective control of asthma than management based on symptom control alone.<br>The current evidence base suggests bronchial challenge testing is useful in the diagnosis of asthma. Mannitol BCT has high specificity for the diagnosis of asthma, although the sensitivity is only moderate when compared to direct BCTs (e.g. methacholine, histamine). The clinical efficacy and cost-effectiveness of mannitol BCT within a diagnostic algorithm for suspected asthma requires more research particularly in patients not receiving inhaled corticosteroids (ICS).<br>The potential use of the mannitol challenge to assist monitoring of asthma in clinical practice is also of particular interest with respect to facilitating down titration of ICS and worthy of further research.<br>The mannitol BCT provides a standardised, reproducible, rapid and simple test that does not require specialised equipment and may have some practical advantages, particularly for use in primary care. |
| Equality | Asthma affects all ages and ethnic groups, and the design of the research needs to encompass this. |
| Study design | Appropriately designed and powered real world randomised controlled trials:<br>a) comparing mannitol BCT to direct BCT in the diagnosis of asthma in adults.<br>b) comparing mannitol BCT to current recommended guideline based approach in the monitoring of asthma in adults.<br>Particularly important outcome measures will include healthcare utilisation, exacerbation frequency, cumulative steroid burden (oral and inhaled) and cost-effectiveness. |
| Feasibility | Asthma is very common and uncontrolled in over half of all patients.<br>Mannitol BCT was developed to solve some of the practical issues associated with other BCTs and to make BCTs more widely available to clinicians. It is feasible and practical to recommend future research in this area. |
| Other comments | None. |
| Importance | • High: the research is essential to inform future updates of key recommendations in the guideline. |

**1N.1.1.3** **Research question 3:** What is the clinical and cost effectiveness of using electronic alert systems designed to monitor and improve adherence with regular inhaled maintenance therapy in people with asthma?

**Why this is important:** Adherence with regular maintenance inhaled corticosteroids, on their own or in combination with long-acting beta agonists, is of paramount importance to achieve control of asthma and prevent asthma attacks. Published evidence in patients with severe asthma suggests that

at least 30% of patients are partially or non-adherent with their prescribed medications[1193], and the Royal College of Physicians' National Review of Asthma Deaths(NRAD)[1488] demonstrated that poor adherence was associated with 38% of asthma deaths.

**Criteria for selecting high-priority research recommendations:**

| | |
|---|---|
| PICO question | **Population:** Adults, children and young people with mild to moderate asthma.<br>**Intervention:** Monitoring adherence using different technologies/devices (eg prescription and refill monitoring systems; electronic monitoring inhalers).<br>**Comparison:** Usual care; different frequencies of monitoring adherence using different technologies/devices.<br>**Outcomes:** Mortality; QoL; exacerbations; unscheduled healthcare utilisation; adherence; asthma control. |
| Importance to patients or the population | Adherence with regular inhaled asthma therapies is suboptimal in a significant proportion of patients with asthma. Targetted intervention studies, that have improved adherence, have demonstrated a significant improvement in asthma control and reduced healthcare utilisation.<br>Asthma outcomes have not improved in the last 15 years and the personal and economic costs of poor control are high. The efficient use of systems to monitor adherence and improve patient adherence and outcomes via feedback mechanisms, and the integration of these new technologies into healthcare are important for patients and for healthcare systems in terms of convenience, costs and outcomes. |
| Relevance to NICE guidance | Identification of clinically and cost-effective methods of monitoring adherence will allow the NICE guideline on Asthma: Diagnosis and Monitoring to make recommendations on the appropriate use of adherence monitoring strategies in NHS care. |
| Relevance to the NHS | Asthma continues to lead to avoidable deaths and considerable unscheduled health care utilization. Improved adherence with prescribed therapies will have a significant impact on health care utilization and improve asthma related quality of life. |
| National priorities | Reducing mortality considered amenable to healthcare is the overarching indicator of Domain 1 of the NHS Outcomes Framework, and poor adherence has been identified in the national review of Asthma deaths as a potentially avoidable factor in asthma deaths. Improving outcomes in asthma are highlighted in the National Strategy in COPD and Asthma as a national priority. |
| Current evidence base | There is a very limited current evidence base on the best monitoring method to monitor and feedback on a person's adherence to asthma maintenance therapy, in order to improve patient outcomes of QOL, morbidity and mortality. The majority of published studies have been conducted in patients with severe asthma, which comprise less than 5% of the asthma population.<br>Further research is required to determine the optimal method of monitoring adherence for improving adherence and patient outcomes, particularly in people with mild to moderate asthma. |
| Equality | Asthma affects all ages and ethnic groups, and the design of the research needs to encompass this. In particular, the study of adherence monitoring interventions needs to ensure that the programmes are accessible to those with learning and physical disabilities, non-English speakers, different age groups and those with health literacy problems. |
| Study design | Cluster randomised controlled trials comparing monitoring adherence using different technologies/devices. Implicit in the investigation of the best monitoring method or device, is that poor adherers will be detected and feedback will improve adherence to controller medication and therefore improve patient outcomes and asthma control. A range of studies may be needed, including 'efficacy' trials and more pragmatic 'real-world' effectiveness and implementation trials. Studies will need to compare the different |

| | |
|---|---|
| | devices/strategies that are currently available to monitor adherence and feedback this information to patients with the aim of improving adherence and patient outcomes. Studies need to include health economic evaluation and be of sufficient duration to confirm persistence of benefit (minimum of 12 months). Studies should be adequately powered to detect sub-groups who are likely to respond or not respond to this strategy. |
| Feasibility | Asthma is common and uncontrolled in over half of all patients. Multiple different technologies to monitor adherence are already available. |
| Other comments | There are commercial implications to technologies designed to monitor adherence and commercial partnership is possible. Intellectual property rights issues will need to be considered. |
| Importance | • High: the research is essential to inform future updates of key recommendations in the guideline. |

**1N.1.1.4** **Research question 4:** What is the current frequency and the current method being used to check the inhaler technique of people with asthma? What is the optimal frequency and the best method of checking inhaler technique to improve clinical outcomes for people with asthma?

**Why this is important:** The knowledge and understanding of how to use an inhaler properly is the cornerstone of asthma management and symptom control. There has been an increase in the types of inhaler devices and the types of delivery system available. The various types of drugs for asthma control are also available in different inhaler devices on their own and in combination of two drugs. It is therefore vital for patients to learn the proper inhaler technique for their device to ensure optimum drug delivery to the lungs for asthma control.

**Criteria for selecting high-priority research recommendations:**

| | |
|---|---|
| PICO question | **Population:** Adults, children and young people aged 5-16 years with a confirmed diagnosis of asthma; children 0-5 years with recurrent wheeze.<br>**Intervention:** Electronic devices to monitor inhaler technique; visual assessment by doctor, nurse or pharmacist.<br>**Comparison:** Different frequencies of monitoring inhaler technique; monitoring using electronic devices vs. monitoring by visual assessment.<br>**Outcomes:** Mortality; QoL; exacerbations; unscheduled healthcare utilisation; adherence; asthma control. |
| Importance to patients or the population | Proper inhaler technique for optimum drug delivery to the lungs of people with asthma is vital for asthma control. Asthma exacerbations can occur frequently if not properly controlled. This has a significant impact on the quality of life and constitutes a considerable healthcare burden with pressures on secondary care emergency departments. There is a lack of objective evidence that regular review of inhaler technique improves asthma control and reduces exacerbations. This is important because checking inhaler technique is a simple intervention that if effective could result in lower doses of inhaled steroids to control the asthma and in a reduction of acute exacerbations. |
| Relevance to NICE guidance | The answer to this question will allow NICE to make a definitive statement on the optimal frequency and the best method of checking inhaler technique to improve clinical outcome for people with asthma. |
| Relevance to the NHS | Acute asthma attacks are one of the commonest reasons for visits to hospital emergency departments. The most expensive expenditure for the NHS is on prescribing the inhaled drugs used for respiratory conditions. It is estimated that the top three most expensive drugs in the NHS are inhalers. It is important to teach patients with asthma the correct technique for using their inhalers. It is equally important to review their inhaler technique regularly. Current guidance is to check the patient's inhaler technique annually. The inhalers should only be prescribed after patient has received training in the use of the device and have |

| | |
|---|---|
| | demonstrated satisfactory technique.<br>Satisfactory understanding of individual inhaler techniques and regular checking by the clinicians and pharmacists is vital to improving clinical outcomes for control of asthma. |
| National priorities | The intervention is simple and could result in better asthma control without increasing medication use. The 'prescribing and medicine uses' recommendation from NRAD (National Review of Asthma Deaths)[1488] is to assess inhaler technique routinely and formally document at every annual review. It should also be checked by the pharmacist when a new device is dispensed. |
| Current evidence base | There is a lack of good quality data available. Different studies used non-standardised scores making comparisons difficult. Teaching inhaler technique has been shown to improve correct usage but it is less clear if that leads to improved asthma control.<br>For 'monitoring inhaler technique vs no monitoring' evidence was only available in adults from one small RCT and evidence was of low and very low quality for all outcomes.<br>For 'Monitoring using an electronic training device and physician feedback compared to physician feedback only', evidence in adults was available from 2 studies, and in children from 1 study. Evidence for all outcomes was of low and very low quality.<br>Based on the NRAD report, people with asthma who are unable to use their inhaler correctly are at risk of poor asthma control, potentially resulting in an asthma attack. It is recorded in the report that only 96 out of 135 (71%) patients had an assessment of inhaler technique. |
| Equality | Asthma affects all ages and ethnic groups, and the design of the research needs to encompass this. In particular, the study needs to ensure that the programmes are accessible to those with learning and physical disabilities, non-English speakers, different age groups and those with health literacy problems. |
| Study design | A systematic review is needed first to elucidate the current frequency and the current method being used to check inhaler technique. This will inform randomised control trials to investigate the optimal frequency and best method of checking inhaler technique. |
| Feasibility | Due to the multiple different types of inhaler currently available it will be difficult to develop a single study to answer this critical research question. However, it will be possible to look at dry powder and metered dose inhalers separately to address the issues of how best to teach inhaler technique and the optimal frequency for monitoring it.<br>All primary and secondary care facilities will be able to participate in a multicentre study which would allow the rapid recruitment of the required number of participants to give a clear answer to the research question. |
| Other comments | It is important to study simple techniques that improve control without increases in steroid medication.<br>Trials to check inhaler technique for monitoring asthma control will attract commercial sponsors. However given the size of the problem, the potential impact to the patients and the NHS and the favourable policy context, a high quality study addressing this question would be an appropriate target for NIHR funding. |
| Importance | • High: the research is essential to inform future updates of key recommendations in the guideline. |

**N.1.1.5** **Research question 5:** What is the long-term (more than 12 months) clinical and cost effectiveness of using tele-healthcare as a means to monitor asthma control in children, young people and adults? Modalities of tele-healthcare can include telephone interview (healthcare professional involvement) and internet or smartphone-based monitoring support (no healthcare professional involvement).

**Why this is important:** Asthma outcomes have not improved in the past 15 years, and the personal and economic costs of poor control are high. Computers and smartphones play an ever-greater role in modern life, with a growing proportion of the population using them regularly for work, leisure, communication and information. The efficient use of distance monitoring systems and the integration of new technologies into healthcare are important for patients and for healthcare systems in terms of convenience, costs and outcomes.

**Criteria for selecting high-priority research recommendations:**

| | |
|---|---|
| PICO question | **Population:** Adults, children and young people with a confirmed diagnosis of asthma.<br>**Intervention:** Monitoring asthma control using telephone interview with a healthcare professional and internet/smartphone-based monitoring support.<br>**Comparison:** Usual care; monitoring asthma control with healthcare professional involvement e.g. telephone interview vs. monitoring asthma control with no healthcare professional involvement e.g. internet/smartphone-based monitoring support.<br>**Outcome:** Mortality; QoL; exacerbations; unscheduled healthcare utilisation; adherence; asthma control. |
| Importance to patients or the population | Asthma is a long-term and incurable condition, and outcomes remain sub-optimal. Regular monitoring and self-management are recommended in guidelines to improve outcomes, but can be difficult to achieve in practice. New technologies can be used to improve communication between patient and clinician and to provide individualised education and self-management support. |
| Relevance to NICE guidance | Clarification of the role of tele-healthcare in asthma will allow the NICE guidelines relating to the diagnosis and monitoring of asthma to make recommendations on the appropriate use of tele-healthcare strategies in NHS care. |
| Relevance to the NHS | Asthma continues to result in avoidable deaths, admissions and quality of life impairment, all with associated costs. More efficient monitoring can allow proactive care to prevent adverse outcomes and so potentially reduces health resource use and costs by more efficient care. |
| National priorities | Reducing mortality considered amenable to healthcare is the overarching indicator of Domain 1 of the NHS Outcomes Framework, and inadequate monitoring has been identified in the national review of Asthma deaths as a potentially avoidable factor in asthma deaths. Improving outcomes in asthma are highlighted in the National Strategy in COPD and Asthma as a national priority. |
| Current evidence base | The current evidence base of tele-healthcare in asthma is inadequate and contradictory; some studies have indicated potential benefits, but some have not. Further research is required to identify the modality of tele-healthcare that is most effective (e.g. telephone support, internet/smartphone based monitoring and self-management support), qualifying the acceptability, benefits, risks and costs associated with different programmes in different patient groups. |
| Equality | Asthma affects all ages and ethnic groups, and the design of the research needs to encompass this. In particular, the study of digital technology interventions needs to ensure that the programmes are accessible to those with learning and physical disabilities, non-English speakers, different age groups and those with health literacy problems. |
| Study design | Appropriately designed and powered randomised controlled trials comparing tele-healthcare interventions with usual care and with other monitoring |

| | |
|---|---|
| | strategies. A range of studies may be needed, including 'efficacy' trials and more pragmatic 'real-world' effectiveness and implementation trials. Cluster randomisation is likely to be needed to prevent 'contamination' of control groups. Studies need to include health economic evaluation and be of sufficient length to confirm persistence of benefit (minimum of 12 months). Studies should be adequately powered to detect sub-groups who are likely to respond or not respond to this strategy. |
| Feasibility | Asthma is very common and uncontrolled in over half of all patients. With technological advances, access to tele-healthcare and digital technologies is common and relatively inexpensive. |
| Other comments | There are potential commercial implications to tele-healthcare monitoring systems, and commercial partnership is possible. IPR issues will need to be carefully considered. |
| Importance | • High: the research is essential to inform future updates of key recommendations in the guideline. |

## N.2 Other research recommendations

6. What is the clinical and cost effectiveness of using validated quality of life questionnaires and the RCP 3 Questions as tools to monitor asthma control in adults and young people aged over 16 years?
7. What is the clinical and cost effectiveness of using validated paediatric questionnaires to monitor asthma control in children aged 5-16 years old with asthma?
8. What is the clinical and cost effectiveness of using blood eosinophils as a tool to monitor asthma control?
9. Which patient groups are likely to benefit from FeNO monitoring to guide asthma management, for example, individuals with atopy, frequent asthma attacks, poor adherence?
10. What is the clinical and cost effectiveness of FeNO-guided monitoring of asthma in real-world settings?

# Appendix O: Contributors to the guideline

**NICE project team**

- Sarah Willett – Guideline Lead
- Martin Allaby – Clinical Adviser
- Caroline Keir – Guidelines Commissioning Manager
- Margaret Ghlaimi – Guideline Coordinator
- Judith Thornton – Technical Lead
- David Glynn – Health Economist
- Gareth Haman – Editor

**Stakeholders**

- TBC

# Appendix P: References

1 N0411013273 - A randomised controlled trial of benefits of specialist review or telephone follow up after an Accident and Emergency attendance for asthma. [Clinical trial]. 1997

2 Impact of a telecommunication system in childhood asthma. [Clinical trial]. 1999. Available from: http://projectreporter.nih.gov/project_info_details.cfm?aid=6185659&icde=0 [Last accessed: 10 November 2014]

3 N0016132017 - Proposal to study whether we can reduce hospital attendance by those with respiratory conditions without compromising care by the use of telephone consultation. [Clinical trial]. 2003

4 Peak expiratory flow rate does not predict asthma exacerbations. Journal of Family Practice. 2004; 53(8):608

5 N0702196597 - Self-management of chronic conditions using telemedicine. [Clinical trial]. 2006

6 Aaron SD, Vandemheen KL, Boulet LP, McIvor RA, Fitzgerald JM, Hernandez P et al. Overdiagnosis of asthma in obese and nonobese adults. Canadian Medical Association Journal. 2008; 179(11):1121-1131

7 Abdulamir AS, Hafidh RR, Abubakar F. Different inflammatory mechanisms in lungs of severe and mild asthma: Crosstalk of NF-kappa-B, TGFbeta1, Bax, Bcl-2, IL-4 and IgE. Scandinavian Journal of Clinical and Laboratory Investigation. 2009; 69(4):487-495

8 Abraham CM, Ownby DR, Peterson EL, Wegienka G, Zoratti EM, Williams LK et al. The relationship between seroatopy and symptoms of either allergic rhinitis or asthma. Journal of Allergy and Clinical Immunology. 2007; 119(5):1099-1104

9 Abramson M, Kutin J, Bowes G. The prevalence of asthma in Victorian adults. Australian and New Zealand Journal of Medicine. 1992; 22(4):358-363

10 Abramson M, Kutin J, Czarny D, Walters EH. The prevalence of asthma and respiratory symptoms among young adults: is it increasing in Australia? Journal of Asthma. 1996; 33(3):189-196

11 Abramson MJ, Schattner RL, Holton C, Simpson P, Briggs N, Beilby J et al. Spirometry and regular follow-up do not improve outcomes in children or adolescents with asthma. Respirology. 2012; 17:50

12 Abramson M, Matheson M, Wharton C, Sim M, Walters EH. Prevalence of respiratory symptoms related to chronic obstructive pulmonary disease and asthma among middle aged and older adults. Respirology. 2002; 7(4):325-331

13 Abramson MJ, Schattner RL, Sulaiman ND, Birch KE, Simpson PP, Del Colle EA et al. Do spirometry and regular follow-up improve health outcomes in general practice patients with asthma or COPD? A cluster randomised controlled trial. Medical Journal of Australia. 2010; 193(2):104-109

14 Abut L, Ozerol I, Apan T. Total and specific IgE in the sera of patients with asthma, urticaria, or allergic rhinitis from the Southeast Anatolia region of Turkey. Laboratory Medicine. 2007; 38(10):621-623

15 Adams RJ, Boath K, Homan S, Campbell DA, Ruffin RE. A randomized trial of peak-flow and symptom-based action plans in adults with moderate-to-severe asthma. Respirology. 2001; 6(4):297-304

16 Adams RJ, Ruffin RE, Smith BJ. Validity of a modified version of the Marks Asthma Quality of Life Questionnaire. Journal of Asthma. 2000; 37(2):131-143

17 Adams RJ, Wilson DH, Appleton S, Taylor A, Dal Grande E, Chittleborough CR et al. Underdiagnosed asthma in South Australia. Thorax. 2003; 58(10):846-850

18 Adjami M, Hooshiar B, Rafiee A, Ghafari J, Ajami A. Serum level of IL-6 and IL-8 in severe and mild asthma. Allergy. 2011; 66:518

19 Adler TR, Beall GN, Heiner DC. Immunologic and clinical correlates of bronchial challenge responses to Bermuda grass pollen extracts. Journal of Allergy and Clinical Immunology. 1985; 75(1 Pt.1):31-36

20 Agata H, Yomo A, Hanashiro Y, Muraki T, Kondo N, Orii T. Comparison of the MAST chemiluminescent assay system with RAST and skin tests in allergic children. Annals of Allergy. 1993; 70(2):153-157

21 Aggarwal AN, Gupta D, Kumar V, Jindal SK. Assessment of diurnal variability of peak expiratory flow in stable asthmatics. Journal of Asthma. 2002; 39(6):487-491

22 Ahlstedt S, Eriksson N, Lindgren S, Roth A. Specific IgE determination by RAST compared with skin and provocation tests in allergy diagnosis with birch pollen, timothy pollen and dog epithelium allergens. Clinical Allergy. 1974; 4(2):131-140

23 Ahmad Al Obaidi AH, Mohamed Al Samarai AG, Yahya Al Samarai AK, Al Janabi JM. The predictive value of IgE as biomarker in asthma. Journal of Asthma. 2008; 45(8):654-663

24 Ahmed S, Bartlett SJ, Ernst P, Pare G, Kanter M, Perreault R. Effect of a web-based chronic disease management system on asthma control and health-related quality of life: Study protocol for a randomized controlled trial. Trials. 2011; 12(1):260

25 Ahmetaj LN, Kokollari F, Lokaj V. Prevalence of aspirin-induced asthma in certain group of kosovo population and its presentation. Macedonian Journal of Medical Sciences. 2009; 2(1):42-48

26 Ait-Khaled N, Enarson DA. How to diagnose asthma and determine the degree of severity of the disease. International Journal of Tuberculosis and Lung Disease. 2006; 10(3):252-255

27 Akcakaya N, Cokugras H, Camcioglu Y, Ozdemir M. Skin test hypersensitivity for childhood asthma in Istanbul during a period of 16 years. Allergologia Et Immunopathologia. 2005; 33(1):15-19

28 Al Moamary MS, Al-Kordi AG, Al Ghobain MO, Tamim HM. Utilization and responsiveness of the asthma control test (ACT) at the initiation of therapy for patients with asthma: a randomized controlled trial. BMC Pulmonary Medicine. 2012; 12:14

29 Al-Showair RAM, Pearson SB, Chrystyn H. The potential of a 2Tone Trainer to help patients use their metered-dose inhalers. Chest. 2007; 131(6):1776-1782

30 Alberta Heritage Foundation for Medical Research. Efficacy and/or effectiveness of spirometry and forced oscillation technique in the diagnosis of childhood asthma. Alberta Heritage Foundation for Medical Research (AHFMR), 2002

31 Albertini M, Politano S, Berard E, Boutte P, Mariani R. Variation in peak expiratory flow of normal and asymptomatic asthmatic children. Pediatric Pulmonology. 1989; 7(3):140-144

32 Alberts WM, Ferris MC, Brooks SM, Goldman AL. The FEF25-75% and the clinical diagnosis of asthma. Annals of Allergy. 1994; 73(3):221-225

33 Albornoz C, Calvo M, Marin F. Correlation between the clinical classification of bronchial asthma severity and the methacholine test in children. Journal of Investigational Allergology and Clinical Immunology. 1995; 5(6):322-324

34 Albuquerque LA, Silva JM, Camara A, Arruda LK, Ferriani VP. Wheezing in young children and development of asthma in school age: Use of the Asthma Predictive Index in a subtropical environment. Allergy: European Journal of Allergy and Clinical Immunology. 2013; 68:277-278

35 Alenizi AA, Arifhodzic N, Alenezi AA, Alanezi AT. The high prevalence of sensitisation to pollen allergens in adult patients with respiratory allergy in Kuwait. Allergy. 2013; 68:457-458

36 Almosawi TA, Al-Zubaidy TS, Howorth PH. Sputum eosinophil markers in monitoring asthmatic patients in United Arab Emirates. Saudi Medical Journal. 2008; 29(7):1061-1064

37 Almqvist C, Li Q, Britton WJ, Kemp AS, Xuan W, Tovey ER et al. Early predictors for developing allergic disease and asthma: examining separate steps in the 'allergic march'. Clinical and Experimental Allergy. 2007; 37(9):1296-1302

38 Alonso-Llamazares A, Martinez-Cocera C, Dominguez-Ortega J, Robledo-Echarren T, Cimarra-Alvarez M, Mesa del Castillo M. Nasal provocation test (NPT) with aspirin: a sensitive and safe method to diagnose aspirin-induced asthma (AIA). Allergy. 2002; 57(7):632-635

39 Alvarez Puebla MJ, Castillo R, Rey A, Ortega N, Blanco C, Carrillo T. Sputum eosinophilia and maximal airway narrowing in Dermatophagoides pteronyssinus allergic rhinitis patients: only rhinitis or rhinitis plus mild asthma? Chest. 2002; 122(5):1560-1565

40 Alvarez-Puebla MJ, Garcia-Figueroa BE, Tabar-Purroy AI, Olaguibel-Rivera JM. Discriminant analysis in allergic rhinitis and asthma: methacholine dose-response slope allows a good differentiation between mild asthma and rhinitis. Respiratory Medicine. 2003; 97(1):30-36

41 Amat F, Vial A, Pereira B, Petit I, Labbe A, Just J. Predicting the long-term course of asthma in wheezing infants is still a challenge. ISRN Allergy. 2011; 2011:493624

42 Ameisen JC, Capron A, Joseph M, Maclouf J, Vorng H, Pancre V et al. Aspirin-sensitive asthma: abnormal platelet response to drugs inducing asthmatic attacks. Diagnostic and physiopathological implications. International Archives of Allergy and Applied Immunology. 1985; 78(4):438-448

43 Ammari WG, Chrystyn H. Optimizing the inhalation flow and technique through metered dose inhalers of asthmatic adults and children attending a community pharmacy. Journal of Asthma. 2013; 50(5):505-513

44 Anderson HR, Bland JM, Patel S, Peckham C. The natural history of asthma in childhood. Journal of Epidemiology and Community Health. 1986; 40(2):121-129

45 Anderson HR, Bland JM, Peckham CS. Risk factors for asthma up to 16 years of age. Evidence from a national cohort study. Chest. 1987; 91(6 Suppl):127S-130S

46 Anderson SD, Pearlman DS, Weiler JM, Perry CP, Charlton B. Mannitol and methacholine tests to identify EIB and asthma in children with symptoms but no definite diagnosis: A phase 3 study. Journal of Allergy and Clinical Immunology. 2010; 125(2 Suppl.1):AB3

47 Anderson SD, Brannan JD. Bronchial provocation testing: the future. Current Opinion in Allergy and Clinical Immunology. 2011; 11(1):46-52

48 Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS et al. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respiratory Research. 2009; 10:4

49 Andregnette M, Fernandez-Nieto M, Sanchez S, Garcia M, Aguado E, Ibanez M et al. Comparison of bronchial hyperresponsiveness to methacholine and mannitol in asthmatic children. Journal of Allergy and Clinical Immunology. 2011; 127(2 Suppl.1):AB134

50 Anees W, Blainey D, Moore VC, Robertson K, Burge PS. Differentiating occupational asthmatics from non-occupational asthmatics and irritant-exposed workers. Occupational Medicine. 2011; 61(3):190-195

51 Anees W. Use of pulmonary function tests in the diagnosis of occupational asthma. Annals of Allergy, Asthma and Immunology. 2003; 90(5 Suppl.2):47-51

52 Ansarin K, Chatkin JM, Ferreira IM, Gutierrez CA, Zamel N, Chapman KR. Exhaled nitric oxide in chronic obstructive pulmonary disease: Relationship to pulmonary function. European Respiratory Journal. 2001; 17(5):934-938

53 Ansley L, Kippelen P, Dickinson J, Hull JHK. Misdiagnosis of exercise-induced bronchoconstriction in professional soccer players. Allergy. 2012; 67(3):390-395

54 Antolin-Amerigo D, Rodriguez-Rodriguez M, Barbarroja EJ, Sanchez-Gonzalez M, Alvarez-Mon SM. The utility of mannitol challenge in the assessment of asthma. Allergy. 2012; 67:460

55 Antolin-Amerigo D, Sanchez-Gonzalez MJ, Rodriguez-Rodriguez M, Barbarroja-Escudero J, Alvarez-Mon M. Asthma diagnosis and treatment-1004. The utility of mannitol challenge in the assessment of asthma. World Allergy Organization Journal. 2013; 6

56 Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I et al. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. American Journal of Respiratory and Critical Care Medicine. 2010; 182(12):1492-1497

57 Apfelbacher CJ, Hankins M, Stenner P, Frew AJ, Smith HE. Measuring asthma-specific quality of life: structured review. Allergy. 2011; 66(4):439-457

58 Apfelbacher CJ, Jones C, Hankins M, Smith H. Validity of two common asthma-specific quality of life questionnaires: Juniper mini asthma quality of life questionnaire and Sydney asthma quality of life questionnaire. Health and Quality of Life Outcomes. 2012; 10:97

59 Apter A. Inhaled steroid adherence in moderate or severe asthma. [Clinical trial], 2000

60 Apter A. Comparison of two medication adherence strategies to improve asthma treatment adherence. ClinicalTrials Gov. 2005;

61 Araujo L, Jacinto T, Moreira A, Castel-Branco MG, Delgado L, Costa-Pereira A et al. Clinical efficacy of web-based versus standard asthma self-management. Journal of Investigational Allergology and Clinical Immunology. 2012; 22(1):28-34

62 Archambault S, Malo J-L, Infante-Rivard C, Ghezzo H, Gautrin D. Incidence of sensitization, symptoms, and probable occupational rhinoconjunctivitis and asthma in apprentices starting exposure to latex. Journal of Allergy and Clinical Immunology. 2001; 107(5 Suppl.):921-923

63 Ardusso LRF, Molinas J, Crisci CD, Jares EJ, Molinas S. Prevalence of sensitization to soybean hull in patients with asthma and/or allergic rhinitis in Argentina. Journal of Allergy and Clinical Immunology. 2009; 123(2 Suppl.1):S231

64 Arguel A, Lau AY, Dennis S, Liaw ST, Coiera E. An internet intervention to improve asthma management: rationale and protocol of a randomized controlled trial. JMIR Research Protocols. 2013; 2(2):e28

65 Arias Irigoyen J. Mild to moderate asthmatics and free running. Journal of Investigational Allergology and Clinical Immunology. 1999; 9(1):50-54

66 Arif AA, Borders TF, Patterson PJ, Rohrer JE, Xu KT. Prevalence and correlates of paediatric asthma and wheezing in a largely rural USA population. Journal of Paediatrics and Child Health. 2004; 40(4):189-194

67 Arif AA, Delclos GL, Lee ES, Tortolero SR, Whitehead LW. Prevalence and risk factors of asthma and wheezing among US adults: an analysis of the NHANES III data. European Respiratory Journal. 2003; 21(5):827-833

68 Arif AA. Presence of asthma with night-time asthma symptoms is associated with impaired health-related quality of life in children. Journal of Asthma. 2008; 45(10):908-910

69 Arif AA, Delclos GL, Colmer-Hamood J. Association between asthma, asthma symptoms and C-reactive protein in US adults: data from the National Health and Nutrition Examination Survey, 1999-2002. Respirology. 2007; 12(5):675-682

70 Arkins JA, Schleuter DP, Fink JN. The effect of corticosteroids on methacholine inhalation in symptomatic bronchial asthma. Journal of Allergy. 1968; 41(4):209-216

71 Armentia A, Bartolome B, Puyo M, Paredes C, Calderon S, Asensio T et al. Tobacco as an allergen in bronchial disease. Annals of Allergy, Asthma and Immunology. 2007; 98(4):329-336

72 Armour C, Bosnic-Anticevich S, Brillant M, Burton D, Emmerton L, Krass I et al. Pharmacy Asthma Care Program (PACP) improves outcomes for patients in the community. Thorax. 2007; 62(6):496-502

73 Arnedo-Pena A, Puig-Barbera J, Bellido-Blasco JB, Pac-Sa MR, Campos-Cruanes JB, Artero-Sivera A et al. Risk factors and prevalence of asthma in schoolchildren in Castellon (Spain): a cross-sectional study. Allergologia Et Immunopathologia. 2009; 37(3):135-142

74 Arshad SH, Kurukulaaratchy RJ, Fenn M, Matthews S. Early life risk factors for current wheeze, asthma, and bronchial hyperresponsiveness at 10 years of age. Chest. 2005; 127(2):502-508

75 Artlich A, Hagenah JU, Jonas S, Ahrens P, Gortner L. Exhaled nitric oxide in childhood asthma. European Journal of Pediatrics. 1996; 155(8):698-701

76 Asher MI, Stewart AW, Clayton T, Crane J, Ellwood PI, Mackay R et al. Has the prevalence and severity of symptoms of asthma changed among children in New Zealand? ISAAC Phase Three. New Zealand Medical Journal. 2008; 121(1284):52-63

77 Atherton HA, White PT, Hewett G, Howells K. Relationship of daytime asthma symptom frequency to morning peak expiratory flow. European Respiratory Journal. 1996; 9(2):232-236

78 Attapattu MC. Allergic bronchopulmonary aspergillosis among asthmatics. Ceylon Medical Journal. 1991; 36(2):45-51

79 Austin JB, Russell G. Wheeze, cough, atopy, and indoor environment in the Scottish Highlands. Archives of Disease in Childhood. 1997; 76(1):22-26

80 Australian New Zealand Clinical Trials Registry. ACTRN12606000400561 - Improving childhood asthma management through a telemedicine monitoring network. 2006. Available from: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12606000400561 [Last accessed: 10 November 2014]

81 Avital A, Godfrey S, Springer C. Exercise, methacholine, and adenosine 5'-monophosphate challenges in children with asthma: relation to severity of the disease. Pediatric Pulmonology. 2000; 30(3):207-214

82 Avital A, Picard E, Uwyyed K, Springer C. Comparison of adenosine 5'-monophosphate and methacholine for the differentiation of asthma from chronic airway diseases with the use of the auscultative method in very young children. Journal of Pediatrics. 1995; 127(3):438-440

83 Avital A, Springer C, Bar-Yishay E, Godfrey S. Adenosine, methacholine, and exercise challenges in children with asthma or paediatric chronic obstructive pulmonary disease. Thorax. 1995; 50(5):511-516

84 Avital A, Uwyyed K, Berkman N, Godfrey S, Bar-Yishay E, Springer C. Exhaled nitric oxide and asthma in young children. Pediatric Pulmonology. 2001; 32(4):308-313

85 Ayres JG, Campbell LM. A controlled assessment of an asthma self-management plan involving a budesonide dose regimen. OPTIONS Research Group. European Respiratory Journal. 1996; 9(5):886-892

86 Backer V. Bronchial hyperresponsiveness in children and adolescents. Danish Medical Bulletin. 1995; 42(5):397-409

87 Backer V, Groth S, Dirksen A, Bach-Mortensen N, Hansen KK, Laursen EM et al. Sensitivity and specificity of the histamine challenge test for the diagnosis of asthma in an unselected sample of children and adolescents. European Respiratory Journal. 1991; 4(9):1093-1100

88 Backer V, Rasmussen LM. Exercise-Induced Asthma Symptoms and Nighttime Asthma: Are They Similar to AHR? Journal of Allergy. 2009; 2009:378245

89 Backer V, Ulrik CS. Bronchial responsiveness to exercise in a random sample of 494 children and adolescents from Copenhagen. Clinical and Experimental Allergy. 1992; 22(8):741-747

90 Backer V, Ulrik CS, Wendelboe D, Bach-Mortensen D, Hansen KK, Laursen EM et al. Distribution of serum IgE in children and adolescents aged 7 to 16 years in Copenhagen, in relation to factors of importance. Allergy. 1992; 47(5):484-489

91 Backer V, Sverrild A, Porsbjerg C. FENO and AHR mannitol in patients referred to an out-of-hospital asthma clinic: a real-life study. Journal of Asthma. 2014; 51(4):411-416

92 Bai J, Peat JK, Berry G, Marks GB, Woolcock AJ. Questionnaire items that predict asthma and other respiratory conditions in adults. Chest. 1998; 114(5):1343-1348

93 Bailly C, Crenesse D, Albertini M. Evaluation of impulse oscillometry during bronchial challenge testing in children. Pediatric Pulmonology. 2011; 46(12):1209-1214

94 Bakkeheim E, Mowinckel P, Carlsen KH, Burney P, Carlsen KCL. Altered oxidative state in schoolchildren with asthma and allergic rhinitis. Pediatric Allergy and Immunology. 2011; 22(2):178-185

95 Baldwin DR, Berg JD, Buckley BM, Mackay AD. Theophylline analysis at the chest clinic--comparison of a portable versus conventional system. Respiratory Medicine. 1991; 85(1):21-25

96 Baldwin DR, Gannon P, Bright P, Newton DT, Robertson A, Venables K et al. Interpretation of occupational peak flow records: level of agreement between expert clinicians and Oasys-2. Thorax. 2002; 57(10):860-864

97 Balinotti JE, Colom A, Kofman C, Teper A. Association between the asthma predictive index and levels of exhaled nitric oxide in infants and toddlers with recurrent wheezing. Archivos Argentinos De Pediatria. 2013; 111(3):191-195

98 Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. New England Journal of Medicine. 2000; 343(8):538-543

99 Ballweg T. Mannitol Bronchial Challenge Test. Journal of Asthma and Allergy Educators. 2012; 3(2):82

100 Baptist AP, Ross JA, Yang Y, Song PX, Clark NM. A randomized controlled trial of a self-regulation intervention for older adults with asthma. Journal of the American Geriatrics Society. 2013; 61(5):747-753

101 Baraldi E, Ghiro L, Piovan V, Carraro S, Zacchello F, Zanconato S. Safety and success of exhaled breath condensate collection in asthma. Archives of Disease in Childhood. 2003; 88(4):358-360

102 Baraldi E, Giordano G, Pasquale MF, Carraro S, Mardegan A, Bonetto G et al. 3-Nitrotyrosine, a marker of nitrosative stress, is increased in breath condensate of allergic asthmatic children. Allergy. 2006; 61(1):90-96

103 Baraldi E, Bonetto G, Zacchello F, Filippone M. Low exhaled nitric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. American Journal of Respiratory and Critical Care Medicine. 2005; 171(1):68-72

104 Baraldi E, Ghiro L, Piovan V, Carraro S, Ciabattoni G, Barnes PJ et al. Increased exhaled 8-isoprostane in childhood asthma. Chest. 2003; 124(1):25-31

105 Barbanel D, Eldridge S, Griffiths C. Can a self-management programme delivered by a community pharmacist improve asthma control? A randomised trial. Thorax. 2003; 58(10):851-854

106 Barben J, Kuehni CE, Strippoli MP, Schiller B, Hammer J, Trachsel D et al. Mannitol dry powder challenge in comparison with exercise testing in children. Pediatric Pulmonology. 2011; 46(9):842-848

107 Barber CM, Naylor S, Bradshaw LM, Francis M, Harris-Roberts J, Rawbone R et al. Approaches to the diagnosis and management of occupational asthma amongst UK respiratory physicians. Respiratory Medicine. 2007; 101(9):1903-1908

108 Barles PG, Duce Garcia F, Portillo Olmo JR, Perez Aznar J, Escuer Alarma JL. Adverse reaction of acetaminophen as an alternative analgesic in A.A.S. Triad. Allergologia Et Immunopathologia. 1988; 16(5):321-325

109 Barley EA, Jones PW. A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma. European Respiratory Journal. 1999; 14(3):591-596

110 Barnes KC, Freidhoff LR, Horowitz EM, Mathias RA, Mulkern DM, Bonacum JT et al. Physician-derived asthma diagnoses made on the basis of questionnaire data are in good agreement with interview-based diagnoses and are not affected by objective tests. Journal of Allergy and Clinical Immunology. 1999; 104(4 Pt 1):791-796

111 Barnes-Mercado S, Velazquez V, Pietri-Ramirez A. Are total serum IgE levels good predictors of allergies in children? Journal of Allergy and Clinical Immunology. 2014; 133(2 Suppl.1):AB125

112 Barnig C, Purohit A, Casset A, Sohy C, Lieutier-Colas F, Sauleau E et al. Nonallergic airway hyperresponsiveness and allergen-specific IgE levels are the main determinants of the early and late asthmatic response to allergen. Journal of Investigational Allergology and Clinical Immunology. 2013; 23(4):267-274

113 Barranco P, Bobolea I, Larco JI, Prior N, Lopez-Serrano MC, Quirce S. Diagnosis of aspirin-induced asthma combining the bronchial and the oral challenge tests: a pilot study. Journal of Investigational Allergology and Clinical Immunology. 2009; 19(6):446-452

114 Barreto M, Villa MP, Martella S, Falasca C, Guglielmi F, Pagani J et al. Off-line exhaled nitric oxide measurements in children. Pediatric Pulmonology. 2001; 32(2):159-167

115 Barreto M, Villa MP, Montesano M, Rennerova Z, Monti F, Darder MT et al. Reduced exhaled nitric oxide in children after testing of maximal expiratory pressures. Pediatric Pulmonology. 2006; 41(2):141-145

116 Barry RJ, Pickett W, Rennie DC, Senthilselvan A, Cockcroft DW, Lawson JA. Factors contributing to risks for pediatric asthma in rural Saskatchewan. Annals of Allergy, Asthma and Immunology. 2012; 109(4):255-259

117 Barua P, O'Mahony MS. Overcoming gaps in the management of asthma in older patients: new insights. Drugs and Aging. 2005; 22(12):1029-1059

118 Baser S, Ozkurt S, Topuz B, Kiter G, Karabulut H, Akdag B et al. Peak expiratory flow monitoring to screen for asthma in patients with allergic rhinitis. Journal of Investigational Allergology and Clinical Immunology. 2007; 17(4):211-215

119 Basheti IA, Armour CL, Bosnic-Anticevich SZ, Reddel HK. Evaluation of a novel educational strategy, including inhaler-based reminder labels, to improve asthma inhaler technique 1503. Patient Education and Counseling. 2008; 72(1):26-33

120 Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Impact of inhaler technique: improved asthma outcomes with a simple intervention by community pharmacists. Respirology. 2006; 11(Suppl 2):Abstract

121 Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Counseling about turbuhaler technique: needs assessment and effective strategies for community pharmacists. Respiratory Care. 2005; 50(5):617-623

122 Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. Journal of Allergy and Clinical Immunology. 2007; 119(6):1537-1538

123 Basir R, Lehrman SG, De Lorenzo LJ, Kalenderian R, Maguire GP. Lack of significant bronchial reactivity to inhaled normal saline in subjects with a positive methacholine challenge test. Journal of Asthma. 1995; 32(1):63-67

124 Basyigit I, Yildiz F, Ozkara SK, Boyaci H, Ilgazli A, Ozkarakas O. Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology. 2004; 9(4):514-520

125 Bateman ED. Measuring asthma control. Current Opinion in Allergy and Clinical Immunology. 2001; 1(3):211-216

126 Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M. Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. Journal of Allergy and Clinical Immunology. 2006; 117(3):563-570

127 Bauman A, Mitchell CA, Henry RL, Robertson CF, Abramson MJ, Comino EJ et al. Asthma morbidity in Australia: an epidemiological study. Medical Journal of Australia. 1992; 156(12):827-831

128 Baumann UA, Haerdi E, Keller R. Relations between clinical signs and lung function in bronchial asthma: how is acute bronchial obstruction reflected in dyspnoea and wheezing? Respiration. 1986; 50(4):294-300

129 Baur X, Huber H, Degens PO, Allmers H, Ammon J. Relation between occupational asthma case history, bronchial methacholine challenge, and specific challenge test in patients with suspected occupational asthma. American Journal of Industrial Medicine. 1998; 33(2):114-122

130 Bavbek S, Yilmaz I, Celik G, Aydin O, Erkekol FO, Orman A et al. Prevalence of aspirin-exacerbated respiratory disease in patients with asthma in Turkey: a cross-sectional survey. Allergologia Et Immunopathologia. 2012; 40(4):225-230

131 Bavbek S, Ylmaz I, Celik G, Aydin O, Erkekol FO, Aktas A et al. Prevalence of aspirin intolerance in patients with asthma in Turkey:A cross-sectional survey. European Annals of Allergy and Clinical Immunology. 2010; 42(2):42

132 Bayliss MS, Espindle DM, Buchner D, Blaiss MS, Ware JE. A new tool for monitoring asthma outcomes: the ITG Asthma Short Form. Quality of Life Research. 2000; 9(4):451-466

133 Beach JR, Stenton SC, Connolly MJ, Walters EH, Hendrick DJ. Effects of diurnal variation and prolonged refractoriness on repeated measurements of airways responsiveness to methacholine. Thorax. 1995; 50(3):235-239

134 Beausoleil JL, Fiedler J, Spergel JM. Food Intolerance and childhood asthma: what is the link? Paediatric Drugs. 2007; 9(3):157-163

135 Beckett WS, Gent JF, Naeher LP, Belanger K, Triche EW, Bracken MB et al. Peak expiratory flow rate variability is not affected by home combustion sources in a group of nonsmoking women. Archives of Environmental and Occupational Health. 2006; 61(4):176-182

136 Beeh KM, Beier J, Kornmann O, Meier C, Taeumer T, Buhl R. A single nasal allergen challenge increases induced sputum inflammatory markers in non-asthmatic subjects with seasonal allergic rhinitis: correlation with plasma interleukin-5. Clinical and Experimental Allergy. 2003; 33(4):475-482

137 Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. European Respiratory Journal. 2000; 16(4):609-614

138 Beeh KM, Micke P, Ksoll M, Buhl R. Cigarette smoking, but not sensitization to Alternaria, is associated with severe asthma in urban patients. Journal of Asthma. 2001; 38(1):41-49

139 Beeh KM, Kornmann O, Beier J, Ksoll M, Buhl R. Clinical application of a simple questionnaire for the differentiation of asthma and chronic obstructive pulmonary disease. Respiratory Medicine. 2004; 98(7):591-597

140 Beg MFS, Alzoghaibi MA, Abba AA, Habib SS. Exhaled nitric oxide in stable chronic obstructive pulmonary disease. Annals of Thoracic Medicine. 2009; 4(2):65-70

141 Beigelman A, Mauger D, Mao J, Bacharier LB. Association between fractional concentration of exhaled nitric oxide (FeNO) levels and risk of respiratory tract illness in preschool children with moderate to severe intermittent wheezing [Abstract]. Journal of Allergy and Clinical Immunology. 2008; 21(2 Suppl 1):S76

142 Belamarich PF, Luder E, Kattan M, Mitchell H, Islam S, Lynn H et al. Do obese inner-city children with asthma have more symptoms than nonobese children with asthma? Pediatrics. 2000; 106(6):1436-1441

143 Belcher NG, Rees PJ, Clark TJ, Lee TH. A comparison of the refractory periods induced by hypertonic airway challenge and exercise in bronchial asthma. American Review of Respiratory Disease. 1987; 135(4):822-825

144 Belda J, Giner J, Casan P, Sanchis J. Mild exacerbations and eosinophilic inflammation in patients with stable, well-controlled asthma after 1 year of follow-up. Chest. 2001; 119(4):1011-1017

145 Belda J, Parameswaran K, Lemiere C, Kamada D, O'Byrne PM, Hargreave FE. Predictors of loss of asthma control induced by corticosteroid withdrawal. Canadian Respiratory Journal. 2006; 13(3):129-133

146 Bellia V, Cibella F, Migliara G. Characteristics and prognostic value of morning dipping of peak expiratory flow rate in stable asthmatic subjects. Chest. 1985; 88(1):89-93

147 Bellia V, Pistelli R, Filippazzo G, Cibella F, Scichilone N, Catalano F et al. Prevalence of nocturnal asthma in a general population sample: determinants and effect of aging. Journal of Asthma. 2000; 37(7):595-602

148 Ben-Gashir MA, Seed PT, Hay RJ. Predictors of atopic dermatitis severity over time. Journal of the American Academy of Dermatology. 2004; 50(3):349-356

149 Benarab-Boucherit Y, Mehdioui H, Nedjar F, Delpierre S, Bouchair N, Aberkane A. Prevalence rate of exercise-induced bronchoconstriction in Annaba (Algeria) schoolchildren. Journal of Asthma. 2011; 48(5):511-516

150 Bender BG, Apter A, Bogen DK, Dickinson P, Fisher L, Wamboldt FS et al. Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma. Journal of the American Board of Family Medicine. 2010; 23(2):159-165

151 Bender BG, Cvietusa P, Goodrich G, Lowe CR, Nuanes H, Shetterly S et al. A 24-month randomized, controlled trial of an automated speech recognition program to improve adherence in pediatric asthma. Journal of Allergy and Clinical Immunology. 2014; 133(2 Suppl.1):AB166

152 Bennett JB, Davies RJ. A comparison of histamine and methacholine bronchial challenges using the DeVilbiss 646 nebulizer and the Rosenthal-French dosimeter. British Journal of Diseases of the Chest. 1987; 81(3):252-259

153 Bentur L, Beck R, Irving CS, Godfrey S. Nocturnal wheeze measurement in young asthmatics. Pediatric Asthma, Allergy and Immunology. 2004; 17(3):191-197

154 Berg CM, Thelle DS, Rosengren A, Lissner L, Toren K, Olin AC. Decreased fraction of exhaled nitric oxide in obese subjects with asthma symptoms: data from the population study INTERGENE/ADONIX. Chest. 2011; 139(5):1109-1116

155 Berg J, Dunbar-Jacob J, Sereika SM. An evaluation of a self-management program for adults with asthma. Clinical Nursing Research. 1997; 6(3):225-238

156 Berg J, Lindgren P. Economic evaluation of FE(NO) measurement in diagnosis and 1-year management of asthma in Germany. Respiratory Medicine. 2008; 102(2):219-231

157 Berg J, Rachelefsky G, Jones CA, Tichacek MJ, Morphew T. Identification of preschool children with asthma from low-income families in Los Angeles, CA. Annals of Allergy, Asthma and Immunology. 2004; 93(5):465-471

158 Berges-Gimeno MP, Simon RA, Stevenson DD. The natural history and clinical characteristics of aspirin-exacerbated respiratory disease. Annals of Allergy, Asthma and Immunology. 2002; 89(5):474-478

159 Berkman N, Avital A, Breuer R, Bardach E, Springer C, Godfrey S. Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests. Thorax. 2005; 60(5):383-388

160 Berlyne GS, Parameswaran K, Kamada D, Efthimiadis A, Hargreave FE. A comparison of exhaled nitric oxide and induced sputum as markers of airway inflammation. Journal of Allergy and Clinical Immunology. 2000; 106(4):638-644

161 Bernstein DI, Korbee L, Stauder T, Bernstein JA, Scinto J, Herd ZL et al. The low prevalence of occupational asthma and antibody-dependent sensitization to diphenylmethane diisocyanate in a plant engineered for minimal exposure to diisocyanates. Journal of Allergy and Clinical Immunology. 1993; 92(3):387-396

162 Bernstein JA, Davis B, Alvarez-Puebla MJ, Nguyen D, Levin L, Olaguibel JM. Is exhaled nitric oxide a useful adjunctive test for assessing asthma? Journal of Asthma. 2009; 46(9):955-960

163 Berry MA, Shaw DE, Green RH, Brightling CE, Wardlaw AJ, Pavord ID. The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma. Clinical and Experimental Allergy. 2005; 35(9):1175-1179

164 Berry RB, Fairshter RD. Partial and maximal expiratory flow-volume curves in normal and asthmatic subjects before and after inhalation of metaproterenol. Chest. 1985; 88(5):697-702

165 Berz JB, Carter AS, Wagmiller RL, Horwitz SM, Murdock KK, Briggs-Gowan M. Prevalence and correlates of early onset asthma and wheezing in a healthy birth cohort of 2- to 3-year olds. Journal of Pediatric Psychology. 2007; 32(2):154-166

166 Bever HP, Chng SY, Dahlia S, Goh DYT. The influence of spirometry on the level of exhaled nitric oxide in asthmatic children [abstract]. European Respiratory Journal. 2003; 22(Suppl 45):569s

167 Beydon N, M'Buila C, Peiffer C, Bernard A, Zaccaria I, Denjean A. Can bronchodilator response predict bronchial response to methacholine in preschool coughers? Pediatric Pulmonology. 2008; 43(8):815-821

168 Bhagat RG, Grunstein MM. Comparison of responsiveness to methacholine, histamine, and exercise in subgroups of asthmatic children. American Review of Respiratory Disease. 1984; 129(2):221-224

169 Bheekie A, Syce JA, Weinberg EG. Peak expiratory flow rate and symptom self-monitoring of asthma initiated from community pharmacies. Journal of Clinical Pharmacy and Therapeutics. 2001; 26(4):287-296

170 Bhogal SK, Zemek RL, Ducharme F. Written action plans for asthma in children. Cochrane Database of Systematic Reviews. 2006; Issue 3:CD005306. DOI:10.1002/14651858.CD005306.pub2

171 Bibi H, Montgomery M, Pasterkamp H, Chernick V. Relationship between response to inhaled salbutamol and methacholine bronchial provocation in children with suspected asthma. Pediatric Pulmonology. 1991; 10(4):244-248

172 Bime C, Wei CY, Holbrook JT, Sockrider MM, Revicki DA, Wise RA. Asthma symptom utility index: reliability, validity, responsiveness, and the minimal important difference in adult asthmatic patients. Journal of Allergy and Clinical Immunology. 2012; 130(5):1078-1084

173 Biring MS, Madison S, Mohsenifar Z. Use of forced inspiratory vital capacity to identify bronchodilator reversibility in obstructive lung disease. Journal of Asthma. 2001; 38(6):495-500

174 Birnbaum S, Barreiro TJ. Methacholine challenge testing: identifying its diagnostic role, testing, coding, and reimbursement. Chest. 2007; 131(6):1932-1935

175 Bisgaard H, Pipper CB, Bonnelykke K. Endotyping early childhood asthma by quantitative symptom assessment. Journal of Allergy and Clinical Immunology. 2011; 127(5):1155-1164

176 Bjornsson E, Janson C, Hakansson L, Enander I, Venge P, Boman G. Serum eosinophil cationic protein in relation to bronchial asthma in a young Swedish population. Allergy. 1994; 49(9):730-736

177 Black PN, Garratt E, Arandjus C, Salmon BT, Sutherland G. An inhaler with ring tones improves compliance with inhaled steroids in childhood asthma. American Thoracic Society International Conference, May 16-21, 2008, Toronto. 2008;Poster

178 Blackie SP, Pardy RL. Exercise testing in the assessment of pulmonary disease. Clinical Reviews in Allergy. 1990; 8(2-3):215-227

179 Blanc PD, Cisternas M, Smith S, Yelin E. Occupational asthma in a community-based survey of adult asthma. Chest. 1996; 109(3 Suppl.):56S-57S

180 Boath K, Homan S, Adams R, Campbell D. Written action plans for asthma; symptoms or peak flow based? Australian and New Zealand Journal of Medicine. 1998; 28:256

181 Boccaccino A, Peroni DG, Pietrobelli A, Piacentini GL, Aversano MP, Spinosa E et al. Forced oscillometry is applicable to epidemiological settings to detect asthmatic children. Allergy and Asthma Proceedings. 2007; 28(2):170-173

182 Bollag U, Paget WJ, Oberreich J, Cloetta J. Asthma in the community: Observations by the Swiss Sentinel Surveillance Network over a ten year period (1988-1997). European Journal of General Practice. 2000; 6(4):122-129

183 Bommarito L, Migliore E, Bugiani M, Heffler E, Guida G, Bucca C et al. Exhaled nitric oxide in a population sample of adults. Respiration. 2008; 75(4):386-392

184 Bonavia M, Crimi E, Quaglia A, Brusasco V. Comparison of early and late asthmatic responses between patients with allergic rhinitis and mild asthma. European Respiratory Journal. 1996; 9(5):905-909

185 Boner AL, Piacentini GL, Peroni DG, Irving CS, Goldstein D, Gavriely N et al. Children with nocturnal asthma wheeze intermittently during sleep. Journal of Asthma. 2010; 47(3):290-294

186 Bonini M, Lapucci G, Petrelli G, Todaro A, Pamich T, Rasi G et al. Predictive value of allergy and pulmonary function tests for the diagnosis of asthma in elite athletes. Allergy. 2007; 62(10):1166-1170

187 Bonini S, Bonifazi F, Maggi E, Mascialino B, Melioli G, Mus-sap M et al. Allergen component resolved diagnostics in multi-sensitized patients with respiratory symptoms. Journal of Allergy and Clinical Immunology. 2010; 125(2 Suppl.1):AB136

188 Bonner JR. The epidemiology and natural history of asthma. Clinics in Chest Medicine. 1984; 5(4):557-565

189 Boonsawat W, Salome CM, Woolcock AJ. Effect of allergen inhalation on the maximal response plateau of the dose-response curve to methacholine. American Review of Respiratory Disease. 1992; 146(3):565-569

190 Borges MC, Ferraz E, Vianna EO. Bronchial provocation tests in clinical practice. Sao Paulo Medical Journal. 2011; 129(4):243-249

191 Borrego LM, Couto M, Almeida I, Morais-Almeida M. Pre-school spirometry in clinical practice. Revista Portuguesa De Imunoalergologia. 2012; 20(1):23-31

192 Borrego LM, Stocks J, Leiria-Pinto P, Peralta I, Romeira AM, Neuparth N et al. Lung function and clinical risk factors for asthma in infants and young children with recurrent wheeze. Thorax. 2009; 64(3):203-209

193 Borrego LM, Stocks J, Leiria-Pinto P, Peralta I, Romeira AM, Rosado-Pinto J et al. Lung function and clinical risk factors for asthma in infants and young children with recurrent wheeze. Revista Portuguesa De Imunoalergologia. 2010; 18(2):117-135

194 Borrego LM, Stocks J, Almeida I, Stanojevic S, Antunes J, Leiria-Pinto P et al. Bronchodilator responsiveness using spirometry in healthy and asthmatic preschool children. Archives of Disease in Childhood. 2013; 98(2):112-117

195 Bosnic-Anticevich SZ, Sinha H, So S, Reddel HK. Metered-dose inhaler technique: The effect of two educational interventions delivered in community pharmacy over time. Journal of Asthma. 2010; 47(3):251-256

196 Bossley CJ, Saglani S, Kavanagh C, Payne DNR, Wilson N, Tsartsali L et al. Corticosteroid responsiveness and clinical characteristics in childhood difficult asthma. European Respiratory Journal. 2009; 34(5):1052-1059

197 Botey J, Navarro C, Marin A, Eseverri JL. Aspirin-induced asthma in children. Allergologia Et Immunopathologia. 1988; 16(3):145-149

198 Bouaziz N, Beyaert C, Gauthier R, Monin P, Peslin R, Marchal F. Respiratory system reactance as an indicator of the intrathoracic airway response to methacholine in children. Pediatric Pulmonology. 1996; 22(1):7-13

199 Boudreau D, Styhler A, Gray-Donald K, Martin JG. A comparison of breathlessness during spontaneous asthma and histamine-induced bronchoconstriction. Clinical and Investigative Medicine. 1995; 18(1):25-32

200 Bougault V, Turmel J, Boulet LP. Bronchial challenges and respiratory symptoms in elite swimmers and winter sport athletes: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2 Suppl.):31S-37S

201 Boulet LP, Milot J, Turcotte H. Relationship between changes in diurnal variation of expiratory flows, lung volumes and respiratory symptoms after acute asthma. Respiratory Medicine. 1991; 85(6):487-493

202 Boulet LP, Turcotte H, Brochu A. Persistence of airway obstruction and hyperresponsiveness in subjects with asthma remission. Chest. 1994; 105(4):1024-1031

203 Bousquet J, Boushey HA, Busse WW, Canonica GW, Durham SR, Irvin CG et al. Characteristics of patients with seasonal allergic rhinitis and concomitant asthma. Clinical and Experimental Allergy. 2004; 34(6):897-903

204 Bouzigon E, Monier F, Boussaha M, Le Moual N, Huyvaert H, Matran R et al. Associations between nitric oxide synthase genes and exhaled NO-related phenotypes according to asthma status. PloS One. 2012; 7(5):e36672

205 Bozek A, Jarzab J. Adherence to asthma therapy in elderly patients. Journal of Asthma. 2010; 47(2):162-165

206 Braido F, Baiardini I, Stagi E, Scichilone N, Rossi O, Lombardi C et al. RhinAsthma patient perspective: a short daily asthma and rhinitis QoL assessment. Allergy. 2012; 67(11):1443-1450

207 Bramson R. Self-management of asthma. Journal of Family Practice. 1996; 43(1):21-22

208 Brancato I, Signoriello G, de Angelis CP, Verde R, Cioffi D, Maselli R. Asthma and bronchial reactivity: a contribution from multivariate analysis. Monaldi Archives for Chest Disease. 1995; 50(2):81-85

209 Brand PL, Kerstjens HA, Postma DS, Sterk PJ, Quanjer PH, Sluiter HJ et al. Long-term multicentre trial in chronic nonspecific lung disease: methodology and baseline assessment in adult patients. Dutch CNSLD Study Group. European Respiratory Journal. 1992; 5(1):21-31

210 Brand PL, Postma DS, Kerstjens HA, Koeter GH. Relationship of airway hyperresponsiveness to respiratory symptoms and diurnal peak flow variation in patients with obstructive lung disease. American Review of Respiratory Disease. 1991; 143(5 Pt.1):916-921

211 Brand PL, Quanjer PH, Postma DS, Kerstjens HA, Koeter GH, Dekhuijzen PN et al. Interpretation of bronchodilator response in patients with obstructive airways disease. The Dutch Chronic Non-Specific Lung Disease (CNSLD) Study Group. Thorax. 1992; 47(6):429-436

212 Brand PLP, De Gooijer A, Postma DS. Changes in peak expiratory flow in healthy subjects and in patients with obstructive lung disease. European Respiratory Journal, Supplement. 1997; 10(24):69S-71S

213 Brand PLP, Kerstjens HAM, Jansen HM, Kauffman HF, De Monchy JGR, Kerrebijn KF et al. Interpretation of skin tests to house dust mite and relationship to other allergy parameters in patients with asthma and chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology. 1993; 91(2):560-570

214 Brand PLP. Key issues in inhalation therapy in children. Current Medical Research and Opinion. 2005; 21(Suppl.4):S27-S32

215 Brandt HD, Muntingh GL. Decreasing asthma morbidity. South African Medical Journal. 1994; 84(12):842-844

216 Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise- and hyperventilation-induced asthma. American Journal of Respiratory and Critical Care Medicine. 1998; 158(4):1120-1126

217 Brannan JD, Lougheed MD. Airway hyperresponsiveness in asthma: mechanisms, clinical significance, and treatment. Frontiers in Physiology. 2012; 3:460

218 Braun-Fahrlander C, Gassner M, Grize L, Minder CE, Varonier HS, Vuille JC et al. Comparison of responses to an asthma symptom questionnaire (ISAAC core questions) completed by adolescents and their parents. SCARPOL-Team. Swiss Study on Childhood Allergy and Respiratory Symptoms with respect to Air Pollution. Pediatric Pulmonology. 1998; 25(3):159-166

219 Braun-Fahrlander C, Gassner M, Grize L, Takken-Sahli K, Neu U, Stricker T et al. No further increase in asthma, hay fever and atopic sensitisation in adolescents living in Switzerland. European Respiratory Journal. 2004; 23(3):407-413

220 Bregas M, Diego DA, Perpi TM. Usefulness of the IUATLD respiratory symptoms questionnaire for the differential diagnosis of bronchial asthma and chronic bronchitis. Archivos De Bronconeumologia. 2000; 36(8):441-449

221 Brenner BE, Chavda KK, Karakurum MB, Karras DJ, Camargo CAJ, Investigators MARC. Circadian differences among 4,096 emergency department patients with acute asthma. Critical Care Medicine. 2001; 29(6):1124-1129

222 Brescianini S, Brunetto B, Iacovacci P, D'Ippolito C, Alberti G, Schirru MA et al. Prevalence of self-perceived allergic diseases and risk factors in Italian adolescents. Pediatric Allergy and Immunology. 2009; 20(6):578-584

223 Brindicci C, Ito K, Barnes PJ, Kharitonov SA. Effect of an inducible nitric oxide synthase inhibitor on differential flow-exhaled nitric oxide in asthmatic patients and healthy volunteers. Chest. 2007; 132(2):581-588

224 Britton J. Measurement of peak flow variability in community populations: methodology. European Respiratory Journal, Supplement. 1997; 24:42S-44S

225 Britton J, Pavord I, Richards K, Knox A, Wisniewski A, Weiss Tattersfield SA. Dietary sodium intake and the risk of airway hyperreactivity in a random adult population. Thorax. 1994; 49(9):875-880

226 Brodlie M, McKean MC. Exhaled nitric oxide in the diagnosis of childhood asthma. BMJ. 2010; 340(7738):113-114

227 Broekhuizen BDL, Sachs APE, Hoes AW, Moons KGM, van den Berg JWK, Dalinghaus WH et al. Undetected chronic obstructive pulmonary disease and asthma in people over 50 years with persistent cough. British Journal of General Practice. 2010; 60(576):489-494

228 Broers S, Smets EM, Bindels PJ, Haes JC. Design of the IMPACT intervention study: patient-GP communication and adherence to asthma medication [Abstract]. International Primary Care Respiratory Group Congress: Amsterdam, June 2002. 2002;36

229 Broers S, Smets EM, Bindels PJ, Haes JC. Design of the IMPACT intervention study: patient-GP communication and adherence to asthma medication [Abstract]. International Primary Care Respiratory Group Congress: Amsterdam, June 2002. 2002;36

230 Brooke AM, Lambert PC, Burton PR, Clarke C, Luyt DK, Simpson H. Recurrent cough: natural history and significance in infancy and early childhood. Pediatric Pulmonology. 1998; 26(4):256-261

231 Brouwer AFJ, Brand PLP. Asthma education and monitoring: what has been shown to work. Paediatric Respiratory Reviews. 2008; 9(3):193-200

232 Brouwer AFJ, Roorda RJ, Brand PLP. Home spirometry and asthma severity in children. European Respiratory Journal. 2006; 28(6):1131-1137

233 Brouwer AFJ, Visser CAN, Duiverman EJ, Roorda RJ, Brand PLP. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatric Pulmonology. 2010; 45(4):326-332

234 Brozek G, Zejda J, Farnik M. Practical usefulness of submaximal exercise challenge test in a population asthma screening test in children. Allergy. 2009; 64:562-563

235 Bruce CA, Bias WB, Norman PS, Lightenstein LM, Marsh DG. Studies of HLA antigen frequencies, IgE levels, and specific allergic sensitivities in patients having ragweed hayfever, with and without asthma. Clinical and Experimental Immunology. 1976; 25(1):67-72

236 Bruschi C, Cerveri I, Zoia MC, Maccarini L, Grassi M, Rampulla C. Bronchial responsiveness to inhaled methacholine in epidemiological studies: comparison of different indices. European Respiratory Journal. 1989; 2(7):630-636

237 Brussee JE, Smit HA, Kerkhof M, Koopman LP, Wijga AH, Postma DS et al. Exhaled nitric oxide in 4-year-old children: relationship with asthma and atopy. European Respiratory Journal. 2005; 25(3):455-461

238 Brusselle GG, Maes T, Bracke KR. Eosinophils in the spotlight: Eosinophilic airway inflammation in nonallergic asthma. Nature Medicine. 2013; 19(8):977-979

239 Brutsche MH, Downs SH, Schindler C, Gerbase MW, Schwartz J, Frey M et al. Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study. Thorax. 2006; 61(8):671-677

240 Bryant DH, Burns MW, Lazarus L. The correlation between skin tests, bronchial provocation tests and the serum level of IgE specific for common allergens in patients with asthma. Clinical Allergy. 1975; 5(2):145-157

241 Buchvald F, Hermansen MN, Nielsen KG, Bisgaard H. Exhaled nitric oxide predicts exercise-induced bronchoconstriction in asthmatic school children. Chest. 2005; 128(4):1964-1967

242 Buffels J, Degryse J, Liistro G, Decramer M. Differential diagnosis in a primary care population with presumed airway obstruction: A real-life study. Respiration. 2012; 84(1):44-54

243 Buist AS, Vollmer WM, Wilson SR, Frazier EA, Hayward AD. A randomized clinical trial of peak flow versus symptom monitoring in older adults with asthma. American Journal of Respiratory and Critical Care Medicine. 2006; 174(10):1077-1087

244 Burbank A, Rettiganti M, Brown RH, Jones S, Perry TT. Asthma education via telemedicine: Effects on asthma knowledge and self-efficacy. Journal of Investigative Medicine. 2012; 2012(60):1-401

245 Burgess S, Sly P, Devadason S. Monitoring and providing feedback on adherence improves adherence with preventive medication in childhood asthma [Abstract]. Respirology. 2009; 14(Suppl.1):A76

246 Burgess SW, Sly PD, Devadason SG. Providing feedback on adherence increases use of preventive medication by asthmatic children. Journal of Asthma. 2010; 47(2):198-201

247 Burnett M, Wegienka G, Havstad S, Ownby D, Cole JC, Zoratti E. The relationship of fractional exhaled nitric oxide levels to allergy and asthma biomarkers in young adults. Journal of Allergy and Clinical Immunology. 2011; 127(2 Suppl.1):AB58

248 Burney PG, Chinn S, Britton JR, Tattersfield AE, Papacosta AO. What symptoms predict the bronchial response to histamine? Evaluation in a community survey of the bronchial symptoms questionnaire (1984) of the International Union Against Tuberculosis and Lung Disease. International Journal of Epidemiology. 1989; 18(1):165-173

249 Burr ML, St Leger AS, Bevan C, Merrett TG. A community survey of asthmatic characteristics. Thorax. 1975; 30(6):663-668

250 Burrows B, Lebowitz MD, Barbee RA, Cline MG. Findings before diagnoses of asthma among the elderly in a longitudinal study of a general population sample. Journal of Allergy and Clinical Immunology. 1991; 88(6):870-877

251 Bush A. The use of inflammatory markers to guide therapy in children with severe asthma. 2005. Available from: http://www.clinicaltrials.gov/ct/show/NCT00262340 [Last accessed: 11 July 2013]

252 Businco L, Cantani A, Farinella F, Businco E. Month of birth and grass pollen or mite sensitization in children with respiratory allergy: A significant relationship. Clinical Allergy. 1988; 18(3):269-274

253 Businco L, Frediani T, Lucarelli S, Finocchi M, Puddu M, Businco E. A prospective study of wheezing infants: clinical and immunological results. Annals of Allergy. 1979; 43(2):120-122

254 Bussamra MH, Cukier A, Stelmach R, Rodrigues JC. Evaluation of the magnitude of the bronchodilator response in children and adolescents with asthma. Chest. 2005; 127(2):530-535

255 Busse WW, Wanner A, Adams K, Reynolds HY, Castro M, Chowdhury B et al. Investigative bronchoprovocation and bronchoscopy in airway diseases. American Journal of Respiratory and Critical Care Medicine. 2005; 172(7):807-816

256 Busse W, Spector S, Rosen K, Wang Y, Alpan O. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. Journal of Allergy and Clinical Immunology. 2013; 132(2):485-486

257 Buterleviciute N, Paltarackiene V, Rudzeviciene O. Frequency of normal serum total IgE in allergic diseases in children. Allergy. 2013; 68:280-281

258 Bynum A, Hopkins D, Thomas A, Copeland N, Irwin C. The effect of telepharmacy counseling on metered-dose inhaler technique among adolescents with asthma in rural Arkansas. Telemedicine Journal and E-Health. 2001; 7(3):207-217

259 Byrnes CA, Dinarevic S, Shinebourne EA, Barnes PJ, Bush A. Exhaled nitric oxide measurements in normal and asthmatic children. Pediatric Pulmonology. 1997; 24(5):312-318

260 Caffarelli C, Bacchini PL, Gruppi L, Bernasconi S. Exercise-induced bronchoconstriction in children with atopic eczema. Pediatric Allergy and Immunology. 2005; 16(8):655-661

261 Caimmi S, De Amici M, Trovamala V, Caimmi D, Testa G, Marseglia A et al. Usefulness of molecular diagnosis. Allergy. 2013; 68:311-312

262 Calado G, Gaspar MJ, Chambel M, Martins P, Leiria PP. Nonsteroidal antiinflammatory drugs hypersensitivity in pediatric patients with asthma. Allergy. 2011; 66:162

263 Calado G, Gaspar MJ, Chambel M, Martins P, Leiria PP. Nonsteroidal anti-inflammatory drugs hypersensitivity in pediatric patients with asthma. Revista Portuguesa De Imunoalergologia. 2012; 20(4):273-280

264 Calhoun WJ, Ameredes BT, King TS, Icitovic N, Bleecker ER, Castro M et al. Comparison of physician-, biomarker-, and symptom-based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial. JAMA. 2012; 308(10):987-997

265 Calvert J, Burney P. Effect of body mass on exercise-induced bronchospasm and atopy in African children. Journal of Allergy and Clinical Immunology. 2005; 116(4):773-779

266 Campbell CP, Jackson AS, Johnson AR, Thomas PS, Yates DH. Occupational sensitization to lupin in the workplace: occupational asthma, rhinitis, and work-aggravated asthma. Journal of Allergy and Clinical Immunology. 2007; 119(5):1133-1139

267 Cantani A, Ferrara M, Barbieri C, Monteleone A, Businco L. Evaluation of new test (Phadiatop(TM)) for the screening of respiratory allergic disorders in children. Annals of Allergy. 1990; 64(2 I):158-161

268 Cantani A, Micera M. Epidemiology of atopy in 220 children: Diagnostic reliability of skin prick tests and total and specific IgE levels. Minerva Pediatrica. 2003; 55(2):129-142

269 Cantani A, Micera M. A prospective study of asthma desensitization in 1182 children, 592 asthmatic children and 590 nonatopic controls. European Review for Medical and Pharmacological Sciences. 2005; 9(6):325-329

270 Cardinale F, De Benedictis FM, Muggeo V, Giordano P, Loffredo MS, Iacoviello G et al. Exhaled nitric oxide, total serum IgE and allergic sensitization in childhood asthma and allergic rhinitis. Pediatric Allergy and Immunology. 2005; 16(3):236-242

271 Carey DG, Aase KA, Pliego GJ. The acute effect of cold air exercise in determination of exercise-induced bronchospasm in apparently healthy athletes. Journal of Strength and Conditioning Research. 2010; 24(8):2172-2178

272 Carey VJ, Weiss ST, Tager IB, Leeder SR, Speizer FE. Airways responsiveness, wheeze onset, and recurrent asthma episodes in young adolescents. The East Boston Childhood Respiratory Disease Cohort. American Journal of Respiratory and Critical Care Medicine. 1996; 153(1):356-361

273 Carlsen KH, Carlson KC, Halvorsen R. Tidal flow volume loops and inflammatory indicators in small children. International Archives of Allergy and Immunology. 1995; 107(1-3):163-165

274 Carlsen KH, Engh G, Mork M. Exercise-induced bronchoconstriction depends on exercise load. Respiratory Medicine. 2000; 94(8):750-755

275 Carlsen KH, Engh G, Mork M, Schroder E. Cold air inhalation and exercise-induced bronchoconstriction in relationship to metacholine bronchial responsiveness: different patterns in asthmatic children and children with other chronic lung diseases. Respiratory Medicine. 1998; 92(2):308-315

276 Carlsen KH, Carlsen KCL. Exercise-induced asthma. Paediatric Respiratory Reviews. 2002; 3(2):154-160

277 Carlsten C, Dimich-Ward H, Becker AB, Ferguson A, Chan HW, DyBuncio A et al. Indoor allergen exposure, sensitization, and development of asthma in a high-risk birth cohort. Pediatric Allergy and Immunology. 2010; 21(4 Pt 2):e740-e746

278 Carlsten C, Dimich-Ward H, Ferguson A, Becker A, DyBuncio A, Chan-Yeung M. Airway hyperresponsiveness to methacholine in 7-year-old children: sensitivity and specificity for pediatric allergist-diagnosed asthma. Pediatric Pulmonology. 2011; 46(2):175-178

279 Carnimeo N, Resta O, Foschino-Barbaro MP. Functional assessment of airways bronchoconstriction with nebulized acetil salicilic acid. Allergologia Et Immunopathologia. 1981; 9(1):1-8

280 Carranza Rosenzweig JR, Jhingran PM, Dalal AA. Impact and use of asthma control test (ACT) on healthcare resource use (HCRU) in a managed care (MC) setting [Abstract]. Journal of Allergy and Clinical Immunology. 2007; 119(1 Suppl):S72

281 Carraro S, Folesani G, Corradi M, Zanconato S, Gaston B, Baraldi E. Acid-base equilibrium in exhaled breath condensate of allergic asthmatic children. Allergy. 2005; 60(4):476-481

282 Carraro S, Piacentini G, Lusiani M, Uyan ZS, Filippone M, Schiavon M et al. Exhaled air temperature in children with bronchopulmonary dysplasia. Pediatric Pulmonology. 2010; 45(12):1240-1245

283 Carraro S, Rezzi S, Reniero F, Heberger K, Giordano G, Zanconato S et al. Metabolomics applied to exhaled breath condensate in childhood asthma. American Journal of Respiratory and Critical Care Medicine. 2007; 175(10):986-990

284 Carroll W. Limitations of asthma control questionnaires in the management and follow up of childhood asthma. Paediatric Respiratory Reviews. 2013; 14(4):229-231

285 Carsin AE, Zock JP, Jarvis D, Basagana X, Heinrich J, Toren K et al. Serum total immunoglobulin E is a surrogate of atopy in adult-onset asthma: a longitudinal study. International Archives of Allergy and Immunology. 2013; 160(4):387-392

286 Carter ER, Pulos E, Delaney J, Matheson EJ, Moffitt DR. Allergy history does not predict skin test reactivity in asthmatic children. Journal of Asthma. 2000; 37(8):685-690

287 Carter ER, Debley JS, Redding GR. Chronic productive cough in school children: prevalence and associations with asthma and environmental tobacco smoke exposure. Cough. 2006; 2:11

288 Cartier A. Diagnosing occupational asthma. Allergy and Clinical Immunology International. 2003; 15(5):197-202

289 Casadevall J, Ventura PJ, Mullol J, Picado C. Intranasal challenge with aspirin in the diagnosis of aspirin intolerant asthma: evaluation of nasal response by acoustic rhinometry. Thorax. 2000; 55(11):921-924

290 Cassimos DC, Tsalkidis A, Tripsianis GA, Stogiannidou A, Anthracopoulos M, Ktenidou-Kartali S et al. Asthma, lung function and sensitization in school children with a history of bronchiolitis. Pediatrics International. 2008; 50(1):51-56

291 Castillo JA, Picado C. Prevalence of aspirin intolerance in asthmatics treated in a hospital. Respiration. 1986; 50(3):153-157

292 Castro-Rodriguez JA, Sardon O, Perez-Yarza EG, Korta J, Aldasoro A, Corcuera P et al. Young infants with recurrent wheezing and positive asthma predictive index have higher levels of exhaled nitric oxide. Journal of Asthma. 2013; 50(2):162-165

293 Caudri D, Wijga A, Gehring U, Smit HA, Brunekreef B, Kerkhof M et al. Respiratory symptoms in the first 7 years of life and birth weight at term: the PIAMA Birth Cohort. American Journal of Respiratory and Critical Care Medicine. 2007; 175(10):1078-1085

294 Caudri D, Wijga A, Schipper A, Hoekstra M, Postma DS, Koppelman GH et al. Predicting the long-term prognosis of children with symptoms suggestive of asthma at preschool age. Journal of Allergy and Clinical Immunology. 2009; 124(5):903-907

295 Caudri D, Wijga AH, Hoekstra MO, Kerkhof M, Koppelman GH, Brunekreef B et al. Prediction of asthma in symptomatic preschool children using exhaled nitric oxide, Rint and specific IgE. Thorax. 2010; 65(9):801-807

296 Cerveri I, Corsico AG, Accordini S, Cervio G, Ansaldo E, Grosso A et al. What defines airflow obstruction in asthma? European Respiratory Journal. 2009; 34(3):568-573

297 Chakrabarti A, Roy P, Jindal SK. Evaluation of serological methods for determination of specific IgE in diagnosis of aspergillus lung disease. Indian Journal of Medical Research. 1993; 97:118-121

298 Chan DS, Callahan CW, Hatch-Pigott VB, Lawless A, Proffitt HL, Manning NE et al. Internet-based home monitoring and education of children with asthma is comparable to ideal office-based care: results of a 1-year asthma in-home monitoring trial. Pediatrics. 2007; 119(3):569-578

299 Chan EY, Dundas I, Bridge PD, Healy MJ, McKenzie SA. Skin-prick testing as a diagnostic aid for childhood asthma. Pediatric Pulmonology. 2005; 39(6):558-562

300 Chang HS, Park JS, Jang AS, Park SW, Uh St, Kim YH et al. Diagnostic value of clinical parameters in the prediction of aspirin-exacerbated respiratory disease in asthma. Allergy, Asthma and Immunology Research. 2011; 3(4):256-264

301 Chang TS, Lemanske RFJ, Guilbert TW, Gern JE, Coen MH, Evans MD et al. Evaluation of the modified asthma predictive index in high-risk preschool children. Journal of Allergy and Clinical Immunology In Practice. 2013; 68(2):152-156

302 Chao PL, Peng HJ, Tang RB, Hung MW, Tsai LC. Serum specific IgE reactivity to recombinant Der f 11 in asthmatic children. Journal of Asthma. 2001; 38(5):391-398

303 Charlton I, Antoniou AG, Atkinson J, Campbell MJ, Chapman E, Mackintosh T et al. Asthma at the interface: bridging the gap between general practice and a district general hospital. Archives of Disease in Childhood. 1994; 70(4):313-318

304 Charlton I, Charlton G, Broomfield J, Mullee MA. Evaluation of peak flow and symptoms only self management plans for control of asthma in general practice. BMJ. 1990; 301(6765):1355-1359

305 Chatham M, Bleecker ER, Smith PL. A comparison of histamine, methacholine, and exercise airway reactivity in normal and asthmatic subjects. American Review of Respiratory Disease. 1982; 126(2):235-240

306 Chatkin JM, Ansarin K, Silkoff PE, McClean P, Gutierrez C, Zamel N et al. Exhaled nitric oxide as a noninvasive assessment of chronic cough. American Journal of Respiratory and Critical Care Medicine. 1999; 159(6):1810-1813

307 Chatkin JM, Blanco DC, Scaglia N, Wagner MB, Fritscher CC. Impact of a low-cost and simple intervention in enhancing treatment adherence in a Brazilian asthma sample. Journal of Asthma. 2006; 43(4):263-266

308 Chen H, Gould MK, Blanc PD, Miller DP, Kamath TV, Lee JH et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. Journal of Allergy and Clinical Immunology. 2007; 120(2):396-402

309 Chen SH, Huang JL, Yeh KW, Tsai YF. Interactive support interventions for caregivers of asthmatic children. Journal of Asthma : Official Journal of the Association for the Care of Asthma. 2013; 50(6):649-657

310 Chen X, Li Y, Zeng M. Diagnostic values of combination of free running asthma screening test and total serum allergen IgE level in children with asthma. Chinese Medical Journal. 2014; 127(5):873-877

311 Cherot-Kornobis N, Hulo S, Edme JL, de Broucker V, Matran R, Sobaszek A. Analysis of nitrogen oxides (NOx) in the exhaled breath condensate (EBC) of subjects with asthma as a complement to exhaled nitric oxide (FeNO) measurements: a cross-sectional study. BMC Research Notes. 2011; 4:202

312 Chew FT, Goh DYT, Lee BW. Under-recognition of childhood asthma in Singapore: Evidence from a questionnaire survey. Annals of Tropical Paediatrics. 1999; 19(1):83-91

313 Chhabra SK. Acute bronchodilator response has limited value in differentiating bronchial asthma from COPD. Journal of Asthma. 2005; 42(5):367-372

314 Chia YC, Vinothini A, Liew SM. Impact of nurse educators on medication adherence in patients with asthma; a randomised controlled trial [Abstract]. Primary Care Respiratory Journal. 2008; 17(2):130

315 Chinellato I, Piazza M, Sandri M, Cardinale F, Peroni DG, Boner AL et al. Evaluation of association between exercise-induced bronchoconstriction and childhood asthma control test questionnaire scores in children. Pediatric Pulmonology. 2012; 47(3):226-232

316 Chinn S, Jarvis D, Burney P, Luczynska C, Ackermann-Liebrich U, Anto JM et al. Increase in diagnosed asthma but not in symptoms in the European Community Respiratory Health Survey. Thorax. 2004; 59(8):646-651

317 Cho YJ, Lim HJ, Park JS, Lee JH, Lee CT, Yoon HI. Measurement of fractional exhaled nitric oxide in stable bronchiectasis. Tuberculosis and Respiratory Diseases. 2013; 74(1):7-14

318 Choi BW, Yoo KH, Jeong JW, Yoon HJ, Kim SH, Park YM et al. Easy diagnosis of asthma: computer-assisted, symptom-based diagnosis. Journal of Korean Medical Science. 2007; 22(5):832-838

319 Choi IS, Hong SN, Lee YK, Koh YI, Jang AS, Lee HC. Asthmatic airway inflammation is more closely related to airway hyperresponsiveness to hypertonic saline than to methacholine. Korean Journal of Internal Medicine. 2003; 18(2):83-88

320 Choi IS, Koh YI, Koh JS, Lee MG. Sensitivity of the skin prick test and specificity of the serum-specific IgE test for airway responsiveness to house dust mites in asthma. Journal of Asthma. 2005; 42(3):197-202

321 Choi SH, Kim DK, Yoo Y, Yu J, Koh YY. Comparison of deltaFVC between patients with allergic rhinitis with airway hypersensitivity and patients with mild asthma. Annals of Allergy, Asthma and Immunology. 2007; 98(2):128-133

322 Choi SY, Sohn MH, Yum HY, Kwon BC, Kim KE. Correlation between inhalant allergen-specific IgE and pulmonary function in children with asthma. Pediatric Pulmonology. 2005; 39(2):150-155

323 Chou T-Y, Wu K-Y, Shieh C-C, Wang J-Y. The clinical efficacy of in vitro allergen-specific IgE antibody test in the diagnosis of allergic children with asthma. Acta Paediatrica Taiwanica. 2002; 43(1):35-39

324 Chow JSW, Leung ASM, Li WWS, Tse TPK, Sy HY, Leung TF. Airway inflammatory and spirometric measurements in obese children. Hong Kong Medical Journal. 2009; 15(5):346-352

325 Christakis DA, Garrison MM, Lozano P, Meischke H, Zhou C, Zimmerman FJ. Improving parental adherence with asthma treatment guidelines: a randomized controlled trial of an interactive website. Academic Pediatrics. United States 2012; 12(4):302-311

326 Christoff GC, Karova EG. Clinical relevance of inhalant and food allergens sensitisation in a crosssectional epidemiological study of atopic diseases. Allergy: European Journal of Allergy and Clinical Immunology. 2013; 68:540

327 Christoff GC, Karova EG, Stoeva IL. Association between asthma and rhinitis prevalence, use of health resources, quality of life, and number of atopic sensitisations. Allergy: European Journal of Allergy and Clinical Immunology. 2013; 68:243-244

328 Chu MW, Han JK. Introduction to pulmonary function. Otolaryngologic Clinics of North America. 2008; 41(2):387-viii

329 Chung C, Choi Y, Kim S, Park S, Min K, Moon H et al. Feasibility of mannitol provocation test to identify bronchial asthma in Korean population: Comparative analysis with methacholine challenge test. Allergy. 2010; 65:554

330 Cicutto L, To T, Murphy S. A randomized controlled trial of a public health nurse-delivered asthma program to elementary schools. Journal of School Health. 2013; 83(12):876-884

331 Ciprandi G, Alesina R, Ariano R, Aurnia P, Borrelli P, Cadario G et al. Characteristics of patients with allergic polysensitization: the POLISMAIL study. European Annals of Allergy and Clinical Immunology. 2008; 40(3):77-83

332 Ciprandi G, Brambilla I, Tosca MA, Arrigo T, Salpietro A, Leonardi S et al. Body mass index is related with bronchial function and reversibility in children with allergic rhinitis and asthma. International Journal of Immunopathology and Pharmacology. 2011; 24(4 Suppl):21-24

333 Ciprandi G, Capasso M, Tosca MA. Early bronchial involvement in children with allergic rhinitis. American Journal of Rhinology and Allergy. 2011; 25(1):e30-e33

334 Ciprandi G, Capasso M, Tosca M, Salpietro C, Salpietro A, Marseglia G et al. A forced expiratory flow at 25-75% value <65% of predicted should be considered abnormal: a real-world, cross-sectional study. Allergy and Asthma Proceedings. 2012; 33(1):e5-e8

335 Ciprandi G, Cirillo I, Signori A. Impact of allergic rhinitis on bronchi: an 8-year follow-up study. American Journal of Rhinology and Allergy. 2011; 25(2):e72-e76

336 Ciprandi G, Signori A, Cirillo I. Relationship between bronchial hyperreactivity and bronchodilation in patients with allergic rhinitis. Annals of Allergy, Asthma and Immunology. 2011; 106(6):460-466

337 Ciprandi G, Tosca MA, Capasso M. Exhaled nitric oxide in children with allergic rhinitis and/or asthma: a relationship with bronchial hyperreactivity. Journal of Asthma. 2010; 47(10):1142-1147

338 Ciprandi G, Tosca MA, Capasso M. High exhaled nitric oxide levels may predict bronchial reversibility in allergic children with asthma or rhinitis. Journal of Asthma. 2013; 50(1):33-38

339 Cirillo I, Klersy C, Marseglia GL, Vizzaccaro A, Pallestrini E, Tosca M et al. Role of FEF25%-75% as a predictor of bronchial hyperreactivity in allergic patients. Annals of Allergy, Asthma and Immunology. 2006; 96(5):692-700

340 Cirillo I, Pistorio A, Tosca M, Ciprandi G. Impact of allergic rhinitis on asthma: effects on bronchial hyperreactivity. Allergy. 2009; 64(3):439-444

341 Cirillo I, Vizzaccaro A, Tosca MA, Milanese M, Ciprandi G. Prevalence and treatment of allergic rhinitis in Italian conscripts. European Annals of Allergy and Clinical Immunology. 2003; 35(6):204-207

342 Clark NM, Gong ZM, Si JW, Lin X, Bria WF, Johnson TR. A randomized trial of a self-regulation intervention for women with asthma. Chest. 2007; 132(1):88-97

343 Clearie KL, Williamson PA, Vaidyanathan S, Short P, Goudie A, Burns P et al. Disconnect between standardized field-based testing and mannitol challenge in Scottish elite swimmers. Clinical and Experimental Allergy. 2010; 40(5):731-737

344 ClinicalTrials.gov. NCT00149474 - Peak Flow Monitoring in Older Adults With Asthma. 2005. Available from: http://clinicaltrials.gov/ct2/show/NCT00149474 [Last accessed: 10 November 2014]

345 ClinicalTrials.gov. NCT00232557 - Telecommunications System in Asthma. 2005. Available from: http://clinicaltrials.gov/ct2/show/NCT00232557 [Last accessed: 10 November 2014]

346 ClinicalTrials.gov. NCT00411346 - Patient Research In Self-Management of Asthma (PRISMA). 2006. Available from: http://clinicaltrials.gov/ct2/show/NCT00411346 [Last accessed: 10 November 2014]

347 ClinicalTrials.gov. NCT00562081 - The Virtual Asthma Clinic (VAC). 2007. Available from: http://clinicaltrials.gov/ct2/show/NCT00562081 [Last accessed: 10 November 2014]

348 ClinicalTrials.gov. NCT00910585 - Coaching in Childhood Asthma. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00910585 [Last accessed: 10 November 2014]

349 ClinicalTrials.gov. NCT00917410 - Mobile Phone Text for Optimizing Asthma Treatment. 2009. Available from: http://clinicaltrials.gov/ct2/show/NCT00917410 [Last accessed: 10 November 2014]

350 ClinicalTrials.gov. NCT00964301 - Telemedicine Education for Rural Children With Asthma. 2009. [Last accessed: 10 November 2014]

351 ClinicalTrials.gov. NCT00993590 - Mobile CHESS Research on Emergency Medical Services for Children. 2009. Available from: http://clinicaltrials.gov/show/NCT00993590 [Last accessed: 10 November 2014]

352 ClinicalTrials.gov. NCT01117805 - Women of Color and Asthma Control. 2010. Available from: http://clinicaltrials.gov/ct2/show/NCT01117805 [Last accessed: 10 November 2014]

353 Cockcroft DW, Davis BE. Diagnostic and therapeutic value of airway challenges in asthma. Current Allergy and Asthma Reports. 2009; 9(3):247-253

354 Cockcroft DW, Davis BE, Boulet LP, Deschesnes F, Gauvreau GM, O'Byrne PM et al. The links between allergen skin test sensitivity, airway responsiveness and airway response to allergen. Allergy. 2005; 60(1):56-59

355 Cockcroft DW, Murdock KY, Berscheid BA, Gore BP. Sensitivity and specificity of histamine PC20 determination in a random selection of young college students. Journal of Allergy and Clinical Immunology. 1992; 89(1 Pt 1):23-30

356 Cockcroft DW, Ruffin RE, Frith PA. Determinants of allergen-induced asthma: Dose of allergen, circulating IgE antibody concentration, and bronchial responsiveness to inhaled histamine. American Review of Respiratory Disease. 1979; 120(5):1053-1058

357 Cockcroft D, Davis B. Direct and indirect challenges in the clinical assessment of asthma. Annals of Allergy, Asthma and Immunology. 2009; 103(5):363-400

358 Cockcroft DW. Direct challenge tests: Airway hyperresponsiveness in asthma: its measurement and clinical significance. Chest. 2010; 138(2 Suppl):18S-24S

359 Coleman H, McCann DC, McWhirter J, Calvert M, Warner JO. Asthma, wheeze and cough in 7- to 9-year-old British schoolchildren. Ambulatory Child Health. 2001; 7(3-4):313-321

360 Colon-Semidey AJ, Marshik P, Crowley M, Katz R, Kelly HW. Correlation between reversibility of airway obstruction and exhaled nitric oxide levels in children with stable bronchial asthma. Pediatric Pulmonology. 2000; 30(5):385-392

361 Comert S, Demir AU, Karakaya G, Kalyoncu AF. Minimum prick test panel for adult patients with asthma and rhinitis in Ankara, Turkey. Journal of Asthma. 2014; 51(4):417-422

362 Connolly CK. House dust mite hypersensitivity: Morning dipping and severity of wheeze. Respiration. 1981; 42(4):258-262

363 Cookson JB, Makoni G. Seasonal asthma and the house-dust mite in tropical Africa. Clinical Allergy. 1975; 5(4):375-380

364 Cookson JB, Merrett J, Merrett TG. Identification of allergen-specific IgE antibodies in the sera of African asthmatics. Clinical Allergy. 1976; 6(4):395-398

365 Cordeiro D, Rudolphus A, Snoey E, Braunstahl GJ. Utility of nitric oxide for the diagnosis of asthma in an allergy clinic population. Allergy and Asthma Proceedings. 2011; 32(2):119-126

366 Corradi M, Montuschi P, Donnelly LE, Pesci A, Kharitonov SA, Barnes PJ. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. American Journal of Respiratory and Critical Care Medicine. 2001; 163(4):854-858

367 Corsico AG, Villani S, Zoia MC, Niniano R, Ansaldo E, Cervio G et al. Chronic productive cough in young adults is very often due to chronic rhino-sinusitis. Monaldi Archives for Chest Disease. 2007; 67(2):90-94

368 Cortes Alvarez N, Martin Mateos MA, Plaza Martin AM, Giner Munoz MT, Piquer M, Sierra Martinez JI. Risk factors of developing asthma in children with recurrent wheezing in the first three years of life. Allergologia Et Immunopathologia. 2007; 35(6):228-231

369 Cote J, Cartier A, Robichaud P, Boutin H, Malo JL, Rouleau M et al. Influence on asthma morbidity of asthma education programs based on self-management plans following treatment optimization. American Journal of Respiratory and Critical Care Medicine. 1997; 155(5):1509-1514

370 Cote J, Kennedy S, Chan-Yeung M. Sensitivity and specificity of PC20 and peak expiratory flow rate in cedar asthma. Journal of Allergy and Clinical Immunology. 1990; 85(3):592-598

371 Cote J, Kennedy S, Chan-Yeung M. Quantitative versus qualitative analysis of peak expiratory flow in occupational asthma. Thorax. 1993; 48(1):48-51

372 Court CS, Cook DG, Strachan DP. Comparative epidemiology of atopic and non-atopic wheeze and diagnosed asthma in a national sample of English adults. Thorax. 2002; 57(11):951-957

373 Couto A, Goncalves L, Reis Ferreira JM. Diagnostic value of FEV1 in inhalatory challenge test. Atemwegs- Und Lungenkrankheiten. 1997; 23(7):421-422

374 Cowie RL, Revitt SG, Underwood MF, Field SK. The effect of a peak flow-based action plan in the prevention of exacerbations of asthma. Chest. 1997; 112(6):1534-1538

375 Crameri R, Hemmann S, Ismail C, Menz G, Blaser K. Disease-specific recombinant allergens for the diagnosis of allergic bronchopulmonary aspergillosis. International Immunology. 1998; 10(8):1211-1216

376 Crane J, Lampshire P, Wickens K, Epton M, Siebers R, Ingham T et al. Asthma, atopy and exhaled nitric oxide in a cohort of 6-yr-old New Zealand children. Pediatric Allergy and Immunology. 2012; 23(1):59-64

377 Crater SE, Peters EJ, Martin ML, Murphy AW, Platts-Mills TA. Expired nitric oxide and airway obstruction in asthma patients with an acute exacerbation. American Journal of Respiratory and Critical Care Medicine. 1999; 159(3):806-811

378 Crespo JF, Rodriguez J, Vives R, James JM, Reano M, Daroca P et al. Occupational IgE-mediated allergy after exposure to lupine seed flour. Journal of Allergy and Clinical Immunology. 2001; 108(2):295-297

379 Croce M, Costa Manso E, Croce J, Gato JJ, Vargas F. Bronchial challenge with aspirin lysine in the diagnosis of asthmatics with sensitization to aspirin and its inhibition by aerosolized furosemide. Journal of Investigational Allergology and Clinical Immunology. 1992; 2(4):196-204

380 Cruz M, Velasco M, Roca O, Culebras M, Morell F, Munoz X. Addition of exhaled breath condensate Ph to pef monitoring to improve the diagnosis of occupational asthma. American Journal of Respiratory and Critical Care Medicine. 2010; 181(1 MeetingAbstracts)

381 Cruz-Correia R, Fonseca J, Lima L, Araujo L, Delgado L, Castel-Branco MG et al. Web-based or paper-based self-management tools for asthma--patients' opinions and quality of data in a randomized crossover study. Studies in Health Technology and Informatics. 2007; 127:178-189

382 Csonka P, Kaila M, Laippala P, Kuusela AL, Ashorn P. Wheezing in early life and asthma at school age: predictors of symptom persistence. Pediatric Allergy and Immunology. 2000; 11(4):225-229

383 Cuijpers CE, Wesseling GJ, Swaen GM, Sturmans F, Wouters EF. Asthma-related symptoms and lung function in primary school children. Journal of Asthma. 1994; 31(4):301-312

384 Cullinan P, MacNeill SJ, Harris JM, Moffat S, White C, Mills P et al. Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: A cohort study. Thorax. 2004; 59(10):855-861

385 Currie GP, Fardon TC, Lee DK. The role of measuring airway hyperresponsiveness and inflammatory biomarkers in asthma. Therapeutics and Clinical Risk Management. 2005; 1(2):83-92

386 Curtis L. Unit costs of health and social care 2013. Canterbury: Personal Social Services Research Unit, University of Kent; 2013. Available from: http://www.pssru.ac.uk/project-pages/unit-costs/2013/index.php

387 Custovic A, Taggart SCO, Francis HC, Chapman MD, Woodcock A. Exposure to house dust mite allergens and the clinical activity of asthma. Journal of Allergy and Clinical Immunology. 1996; 98(1):64-72

388 Cvitanovic S, Znaor L, Kanceljak-Macan B, Macan J, Gudelj I, Grbic D. Allergic rhinitis and asthma in southern Croatia: impact of sensitization to Ambrosia elatior. Croatian Medical Journal. 2007; 48(1):68-75

389 D'urzo A. Simple spirometry as a first line test for asthma diagnosis in primary care. Canadian Respiratory Journal. 2012; 19(3):e36

390 Dahlen B, Zetterstrom O. Comparison of bronchial and per oral provocation with aspirin in aspirin-sensitive asthmatics. European Respiratory Journal. 1990; 3(5):527-534

391 Dales RE, Ernst P, Hanley JA, Battista RN, Becklake MR. Prediction of airway reactivity from responses to a standardized respiratory symptom questionnaire. American Review of Respiratory Disease. 1987; 135(4):817-821

392 Dales RE, Nunes F, Partyka D, Ernst P. Clinical prediction of airways hyperresponsiveness. Chest. 1988; 93(5):984-986

393 Das BK, Kumar S, Panda BK, Mishra OP. Serum immunoglobulin E in early childhood wheezing. Indian Journal of Pediatrics. 2003; 70(3):213-215

394 de Almeida MM, Pinto JR. Bronchial asthma in children: clinical and epidemiologic approach in different Portuguese speaking countries. Pediatric Pulmonology Supplement. 1999; 27(S18):49-53

395 de Asis ML, Greene R. A cost-effectiveness analysis of a peak flow-based asthma education and self-management plan in a high-cost population. Journal of Asthma. United States 2004; 41(5):559-565

396 De Benedictis FM, Canny GJ, Levison H. Methacholine inhalational challenge in the evaluation of chronic cough in children. Journal of Asthma. 1986; 23(6):303-308

397 de Bot CMA, Moed H, Bindels PJE, van Wijk RG, Berger MY, de Groot H et al. Exhaled nitric oxide measures allergy not symptoms in children with allergic rhinitis in primary care: a prospective cross-sectional and longitudinal cohort study. Primary Care Respiratory Journal. 2013; 22(1):44-50

398 De Clerck LS, Verhelst JA, Bleys W, Blockx P, Stevens WJ. Comparative evaluation of the multiple RAST and discrete RAST for inhalant allergy. Allergy. 1986; 41(5):327-330

399 De Diego A, Martinez E, Perpina M, Nieto L, Compte L, Macian V et al. Airway inflammation and cough sensitivity in cough-variant asthma. Allergy. 2005; 60(11):1407-1411

400 De Gouw HW, Marshall-Partridge SJ, Van Der Veen H, Van Den Aardweg JG, Hiemstra PS, Sterk PJ. Role of nitric oxide in the airway response to exercise in healthy and asthmatic subjects. Journal of Applied Physiology. 2001; 90(2):586-592

401 de Groot EP, Nijkamp A, Duiverman EJ, Brand PLP. Allergic rhinitis is associated with poor asthma control in children with asthma. Thorax. 2012; 67(7):582-587

402 de Jongste JC, Carraro S, Hop WC, CHARISM Study Group, Baraldi E. Daily telemonitoring of exhaled nitric oxide and symptoms in the treatment of childhood asthma. American Journal of Respiratory and Critical Care Medicine. 2009; 179(2):93-97

403 De Lovinfosse S, Charpin D, Dornelas A, Birnbaum J, Vervloet D. Can mite-specific IgE be used as a surrogate for mite exposure? Allergy. 1994; 49(1):64-66

404 de Marco R, Locatelli F, Cazzoletti L, Bugianio M, Carosso A, Marinoni A. Incidence of asthma and mortality in a cohort of young adults: a 7-year prospective study. Respiratory Research. 2005; 6:95

405 de Marco R, Marcon A, Jarvis D, Accordini S, Almar E, Bugiani M et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. Journal of Allergy and Clinical Immunology. 2006; 117(6):1249-1256

406 de Meer G, van Amsterdam JGC, Janssen NAH, Meijer E, Steerenberg PA, Brunekreef B. Exhaled nitric oxide predicts airway hyper-responsiveness to hypertonic saline in children that wheeze. Allergy. 2005; 60(12):1499-1504

407 de Souza PG, Sant'Anna CC, March MFBP. Quality of life in asthmatic children: A literature review. Revista Paulista De Pediatria. 2011; 29(4):640-644

408 Deane PMG. Conifer pollen sensitivity in western New York: cedar pollens. Allergy and Asthma Proceedings. 2005; 26(5):352-355

409 Debley J, Stanojevic S, Filbrun AG, Subbarao P. Bronchodilator responsiveness in wheezy infants and toddlers is not associated with asthma risk factors. Pediatric Pulmonology. 2012; 47(5):421-428

410 Debley JS, Stamey DC, Cochrane ES, Gama KL, Redding GJ. Exhaled nitric oxide, lung function, and exacerbations in wheezy infants and toddlers. Journal of Allergy and Clinical Immunology. 2010; 125(6):1228-1234

411 Decimo F, Capristo C, Amelio R, Maiello N, Capristo AF, Miraglia Del Giudice M. Evaluation of bronchial hyperreactivity with mannitol dry powder challenge test in a paediatric population with intermittent allergic asthma or allergic rhinitis. International Journal of Immunopathology and Pharmacology. 2011; 24(4):1069-1074

412 Dehaut P, Rachiele A, Martin RR, Malo JL. Histamine dose-response curves in asthma: reproducibility and sensitivity of different indices to assess response. Thorax. 1983; 38(7):516-522

413 Deilami GD, Khandashpour M, Paknejad O, Pazooki M. Evaluation of methacholine challenge test results in chronic cough patients referring to clinic of pulmonary disease. Acta Medica Iranica. 2009; 47(3):175-179

414 del Giudice MM, Brunese FP, Piacentini GL, Pedulla M, Capristo C, Decimo F et al. Fractional exhaled nitric oxide (FENO), lung function and airway hyperresponsiveness in naive atopic asthmatic children. Journal of Asthma. 2004; 41(7):759-765

415 Del Rio-Navarro BE, Hernandez-Roman MP, Espinola Reyna G, Berber A, Escalante-Dominguez AJ, Gonzalez-Reyes M et al. A comparative study of bronchodilator reversibility with albuterol, between asthma symptomatic and asymptomatic children according to ISAAC questionnaire in Mexico City. Allergologia Et Immunopathologia. 2004; 32(6):334-339

416 Delacourt C, Labbe D, Vassault A, Brunet-Langot D, de Blic J, Scheinmann P. Sensitization to inhalant allergens in wheezing infants is predictive of the development of infantile asthma. Allergy. 1994; 49(10):843-847

417 Delaney JC. The diagnosis of aspirin idiosyncrasy by analgesic challenge. Clinical Allergy. 1976; 6(2):177-181

418 Delen FM, Sippel JM, Osborne ML, Law S, Thukkani N, Holden WE. Increased exhaled nitric oxide in chronic bronchitis: comparison with asthma and COPD. Chest. 2000; 117(3):695-701

419 Deliu M, Belgrave D, Semic-Jusufagic A, Lowe L, Simpson A, Custovic A. Longitudinal analysis of the impact of rhinitis on asthma severity during childhood: A population-based birth cohort study. Allergy: European Journal of Allergy and Clinical Immunology. 2013; 68:108-109

420 Dellabianca A, Omodeo P, Colli MC, Bianchi P, Scibilia J, Moscato G. Bronchial responsiveness to ultrasonic "fog" in occupational asthma due to low molecular weight chemicals. Annals of Allergy, Asthma and Immunology. 1996; 77(5):378-384

421 Demissie K, White N, Joseph L, Ernst P. Bayesian estimation of asthma prevalence, and comparison of exercise and questionnaire diagnostics in the absence of a gold standard. Annals of Epidemiology. 1998; 8(3):201-208

422 den Otter JJ, Reijnen GM, van den Bosch WJ, van Schayck CP, Molema J, Van Weel C. Testing bronchial hyper-responsiveness: provocation or peak expiratory flow variability? British Journal of General Practice. 1997; 47(421):487-492

423 den Otter JJ, van Dijk B, van Schayck CP, Molema J, Van Weel C. How to avoid underdiagnosed asthma/chronic obstructive pulmonary disease? Journal of Asthma. 1998; 35(4):381-387

424 Deng X, Gebretsadik T, Jin M, Gao YT, Bai C, Christman JW et al. Development of a nomogram for identification of asthma among adults in epidemiologic studies. Annals of Allergy, Asthma and Immunology. 2010; 105(3):203-210

425 Department of Health. NHS reference costs 2012-13. 2012. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/261154/nhs_reference_costs_2012-13_acc.pdf [Last accessed: 17 March 2014]

426 Department of Health. NHS Supply Chain Catalogue. 2014. Available from: http://www.supplychain.nhs.uk/ [Last accessed: 21 November 2014]

427 Department of Health Medical Directorate RespiratoryTeam. An outcomes strategy for chronic obstructive pulmonary disease (COPD) and asthma. London. Department of Health, 2011. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/216139/dh_128428.pdf

428 Dervaderics M, Fust G, Otos M, Barok J, Pataky G. Differences in the sensitisation to ragweed pollen and occurrence of late summer allergic symptoms between native and immigrant workers of the nuclear power plant of Hungary. Immunological Investigations. 2002; 31(1):29-40

429 Desalu OO, Oluboyo PO, Salami AK. The prevalence of bronchial asthma among adults in Ilorin, Nigeria. African Journal of Medicine and Medical Sciences. 2009; 38(2):149-154

430 Descatha A, Fromageot C, Ameille J, Lejaille M, Falaize L, Louis A et al. Is forced oscillation technique useful in the diagnosis of occupational asthma? Journal of Occupational and Environmental Medicine. 2005; 47(8):847-853

431 Deschildre A, Beghin L, Salleron J, Iliescu C, Thumerelle C, Santos C et al. Home telemonitoring (forced expiratory volume in 1 s) in children with severe asthma does not reduce exacerbations. European Respiratory Journal. 2012; 39(2):290-296

432 Deykin A, Lazarus SC, Fahy JV, Wechsler ME, Boushey HA, Chinchilli VM et al. Sputum eosinophil counts predict asthma control after discontinuation of inhaled corticosteroids. Journal of Allergy and Clinical Immunology. 2005; 115(4):720-727

433 Deykin A, Massaro AF, Drazen JM, Israel E. Exhaled nitric oxide as a diagnostic test for asthma: online versus offline techniques and effect of flow rate. American Journal of Respiratory and Critical Care Medicine. 2002; 165(12):1597-1601

434 Dharmage SC, Abramson M, Raven J, Thien FC, Walters EH. Why do only some of the young adults with bronchial hyperreactivity wheeze? Journal of Asthma. 1998; 35(5):391-399

435 Di Franco A, Bartoli ML, Carnevali S, Cianchetti S, Bacci E, Dente FL et al. Analysis of sputum cell counts during spontaneous moderate exacerbations of asthma in comparison to the stable phase. Journal of Asthma. 2003; 40(2):155-162

436 Di Lorenzo G, Mansueto P, Esposito-Pellitteri M, Ditta V, Castello F, Lo Bianco C et al. The characteristics of different diagnostic tests in adult mild asthmatic patients: comparison with patients with asthma-like symptoms by gastro-oesophageal reflux. Respiratory Medicine. 2007; 101(7):1455-1461

437 Dias RM, Chacur FH, Carvalho SRdS, Neves DD. Which functional parameters can help differentiate severe asthma from COPD? Revista Portuguesa De Pneumologia. 2010; 16(2):253-272

438 Diaz-Guzman E, Khosravi M, Mannino DM. Asthma, chronic obstructive pulmonary disease, and mortality in the U.S. population. COPD. 2011; 8(6):400-407

439 Dibek ME, Reha CM. Skin prick test results of child patients diagnosed as bronchial asthma. Allergologia Et Immunopathologia. 2007; 35(1):21-24

440 Dickinson JA, Meaker M, Searle M, Ratcliffe G. Screening older patients for obstructive airways disease in a semi-rural practice. Thorax. 1999; 54(6):501-505

441 Dickinson JW, Whyte GP, McConnell AK, Harries MG. Screening elite winter athletes for exercise induced asthma: a comparison of three challenge methods. British Journal of Sports Medicine. 2006; 40(2):179-182

442 Dickinson JW, Whyte GP, McConnell AK, Nevill AM, Harries MG. Mid-expiratory flow versus FEV1 measurements in the diagnosis of exercise induced asthma in elite athletes. Thorax. 2006; 61(2):111-114

443 Ding YP, Yao HX, Tang XL, He HW, Shi HF, Lin L et al. An epidemiology study of bronchial asthma in the Li ethnic group in China. Asian Pacific Journal of Tropical Medicine. 2012; 5(2):157-161

444 Dodge R, Cline MG, Lebowitz MD, Burrows B. Findings before the diagnosis of asthma in young adults. Journal of Allergy and Clinical Immunology. 1994; 94(5):831-835

445 Dodge R, Martinez FD, Cline MG, Lebowitz MD, Burrows B. Early childhood respiratory symptoms and the subsequent diagnosis of asthma. Journal of Allergy and Clinical Immunology. 1996; 98(1):48-54

446 Doekes G. Enzyme immunoassays for total and allergen specific IgE in population studies. Occupational and Environmental Medicine. 1996; 53(1):63-70

447 Donald KJ, McBurney H, Teichtahl H, Irving L. A pilot study of telephone based asthma management. Australian Family Physician. 2008; 37(3):170-173

448 Dor A, Liebhart J, Malolepszy J. Comparison of exercise and histamine provocation tests in patients with bronchial asthma. Pneumonologia i Alergologia Polska. 1999; 67(1-2):22-27

449 Dostaler M, Olajos-Clow J, Turcotte SE, Minard JP, Holness D, Haines T et al. Development and validation of a work-related asthma screening questionnaire. American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

450 Dotsch J, Demirakca S, Terbrack HG, Huls G, Rascher W, Kuhl PG. Airway nitric oxide in asthmatic children and patients with cystic fibrosis. European Respiratory Journal. 1996; 9(12):2537-2540

451 Dow L, Fowler L, Phelps L, Waters K, Coggon D, Kinmonth AL et al. Prevalence of untreated asthma in a population sample of 6000 older adults in Bristol, UK. Thorax. 2001; 56(6):472-476

452 Dressel H, de la Motte D, Reichert J, Ochmann U, Petru R, Angerer P et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respiratory Medicine. 2008; 102(7):962-969

453 Dressel H, Muller F, Fischer R, Rommelt H, Hohlfeld JM, Behr J et al. Independent information of nonspecific biomarkers in exhaled breath condensate. Respiration. 2010; 80(5):401-409

454 Drewek R, Garber E, Stanclik S, Simpson P, Nugent M, Gershan W. The FEF25-75 and its decline as a predictor of methacholine responsiveness in children. Journal of Asthma. 2009; 46(4):375-381

455 Drkulec V, Nogalo B, Perica M, Plavec D, Pezer M, Turkalj M. Sensitization profile in differential diagnosis: allergic asthma vs. chronic (nonspecific) cough syndrome. Medical Science Monitor. 2013; 19:409-415

456 Drummond N, Abdalla M, Beattie JAG, Buckingham JK, Lindsay T, Osman LM et al. Effectiveness of routine self monitoring of peak flow in patients with asthma. BMJ. 1994; 308(6928):564-567

457 Dryden DM, Spooner CH, Stickland MK, Vandermeer B, Tjosvold L, Bialy L et al. Exercise-induced bronchoconstriction and asthma. Rockville, MD. Agency for Healthcare Research and Quality, 2010. Available from: http://www.ahrq.gov/research/findings/evidence-based-reports/eibeia-evidence-report.pdf

458 Du Rand IA, O'Reilly L, Wilson D. Impact study of 243 indirect bronchial provocation tests with mannitol in the diagnosis and management of asthma. Thorax. 2011; 66:A149

459 Duc J, Peitrequin R, Pecoud A. Value of a new screening test for respiratory allergy. Allergy. 1988; 43(5):332-337

460 Duce F, de Gregorio MA, Perez J, Portillo JR, Pascual G, Alfonso ER. A prospective and immunologic study of factory workers exposed to TDI (toluene diisocyanate). Allergologia Et Immunopathologia. 1988; 16(3):139-144

461 Dumas ME, Praud JP, Joseph MC, Geoffroy M, Vlachos-Mayer H. Assessment of the bronchodilator response in preschool asthmatics. Paediatric Respiratory Reviews. 2010; 11:S79

462 Dundas I, Chan EY, Bridge PD, McKenzie SA. Diagnostic accuracy of bronchodilator responsiveness in wheezy children. Thorax. 2005; 60(1):13-16

463 Dundas I, Mckenzie S. Spirometry in the diagnosis of asthma in children. Current Opinion in Pulmonary Medicine. 2006; 12(1):28-33

464 Dupont LJ, Demedts MG, Verleden GM. Prospective evaluation of the validity of exhaled nitric oxide for the diagnosis of asthma. Chest. 2003; 123(3):751-756

465 Dwinger S, Dirmaier J, Herbarth L, Konig HH, Eckardt M, Kriston L et al. Telephone-based health coaching for chronically ill patients: study protocol for a randomized controlled trial. Trials. 2013; 14:337

466 Dwyer TM, Abraham GE. Spirometry: How should we order this bedrock of diagnosis and management for asthma and COPD? Respiratory Care. 2012; 57(10):1692-1695

467 Eakin MN, Rand CS, Bilderback A, Bollinger ME, Butz A, Kandasamy V et al. Asthma in Head Start children: effects of the Breathmobile program and family communication on asthma outcomes. Journal of Allergy and Clinical Immunology. 2012; 129(3):664-670

468 Eggleston PA. A comparison of the asthmatic response to methacholine and exercise. Journal of Allergy and Clinical Immunology. 1979; 63(2):104-110

469 Ehrs PO, Nokela M, Stallberg B, Hjemdahl P, Wikstrom Jonsson E. Brief questionnaires for patient-reported outcomes in asthma: validation and usefulness in a primary care setting. Chest. 2006; 129(4):925-932

470 Eid N, Yandell B, Howell L, Eddy M, Sheikh S. Can peak expiratory flow predict airflow obstruction in children with asthma? Pediatrics. 2000; 105(2):354-358

471 Ekroos H, Rouhos A, Pallasaho P, Karjalainen J, Sarna S, Sovijarvi ARA. Equally elevated concentrations of exhaled nitric oxide in nonatopic and low-sensitized atopic asthmatics. Respiratory Medicine. 2009; 103(1):152-158

472 ElHalawani SM, Ly NT, Mahon RT, Amundson DE. Exhaled nitric oxide as a predictor of exercise-induced bronchoconstriction. Chest. 2003; 124(2):639-643

473 Eliasson AH, Phillips YY, Rajagopal KR, Howard RS. Sensitivity and specificity of bronchial provocation testing. An evaluation of four techniques in exercise-induced bronchospasm. Chest. 1992; 102(2):347-355

474 Elizur A, Pollack N, Boslaugh SE, Kannai Y, Katz Y. Maternal positive skin prick test results and asthma prediction after early childhood wheezing. Annals of Allergy, Asthma and Immunology. 2007; 98(6):540-545

475 Elliott M, Heltshe SL, Stamey DC, Cochrane ES, Redding GJ, Debley JS. Exhaled nitric oxide predicts persistence of wheezing, exacerbations, and decline in lung function in wheezy infants and toddlers. Clinical and Experimental Allergy. 2013; 43(12):1351-1361

476 Elliott RA, Barber N, Clifford S, Horne R, Hartley E. The cost effectiveness of a telephone-based pharmacy advisory service to improve adherence to newly prescribed medicines. Pharmacy World and Science. United Kingdom 2008; 30(1):17-23

477 Elshabrawi IA, Abu NA, Sedky M, Elnawawy A, Montaser M. Work related asthma in the Damietta governorate. Allergy. 2011; 66:590

478 Enarson DA, Vedal S, Chan-Yeung M. Fate of grainhandlers with bronchial hyperreactivity. Clinical and Investigative Medicine. 1988; 11(3):193-197

479 Enright PL, Burchette RJ, Peters JA, Lebowitz MD, McDonnell WF, Abbey DE. Peak flow lability: Association with asthma and spirometry in an older cohort. Chest. 1997; 112(4):895-901

480 Eriksson NE. Food sensitivity reported by patients with asthma and hay fever. A relationship between food sensitivity and birch pollen-allergy and between food sensitivity and acetylsalicylic acid intolerance. Allergy. 1978; 33(4):189-196

481 Eriksson NE. Allergy screening with Phadiatop and CAP Phadiatop in combination with a questionnaire in adults with asthma and rhinitis. Allergy. 1990; 45(4):285-292

482 Erkocoglu M, Akan A, Civelek E, Kan R, Azkur D, Kocabas CN. Consistency of GINA criteria and childhood asthma control test on the determination of asthma control. Pediatric Allergy and Immunology. 2012; 23(1):34-39

483 Escudero AI, Sanchez-Guerrero IM, Mora AM, Soriano V, Lopez JD, Garcia FJ et al. Cost-effectiveness of various methods of diagnosing hypersensitivity to Alternaria. Allergologia Et Immunopathologia. 1993; 21(4):153-157

484 Everhart RS, Fiese BH. Development and initial validation of a pictorial quality of life measure for young children with asthma. Journal of Pediatric Psychology. 2009; 34(9):966-976

485 Ewan PW, Coote D. Evaluation of a capsulated hydrophilic carrier polymer (the ImmunoCAP) for measurement of specific IgE antibodies. Allergy. 1990; 45(1):22-29

486 Eysink P, Bindels P, Huisman J, Bottema B, Aalberse R, Schade B. Development of specific immunoglobulin E in coughing toddlers: a medical records review of symptoms in general practice. Pediatric Allergy and Immunology. 2001; 12(3):133-141

487 Eysink PED, Ter Riet G, Aalberse RC, van Aalderen WMC, Roos CM, van der Zee JS et al. Accuracy of specific IgE in the prediction of asthma: development of a scoring formula for general practice. British Journal of General Practice. 2005; 55(511):125-131

488 Fabbri LM, Romagnoli M, Corbetta L, Casoni G, Busljetic K, Turato G et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2003; 167(3):418-424

489 Faniran AO, Peat JK, Woolcock AJ. Persistent cough: is it asthma? Archives of Disease in Childhood. 1998; 79(5):411-414

490 Faniran AO, Peat JK, Woolcock AJ. Prevalence of atopy, asthma symptoms and diagnosis, and the management of asthma: comparison of an affluent and a non-affluent country. Thorax. 1999; 54(7):606-610

491 Farber HJ. Care management for childhood asthma: What works? Pediatric Asthma, Allergy and Immunology. 2009; 22(3):105-110

492 Farhoudi A, Razavi A, Chavoshzadeh Z, Heidarzadeh M, Bemanian MH, Nabavi M. Descriptive study of 226 patients with allergic rhinitis and asthma in karaj city. Iranian Journal of Allergy, Asthma, and Immunology. 2005; 4(2):99-101

493 Feitosa LAS, Dornelas de Andrade A, Reinaux CMA, Britto MCA. Diagnostic accuracy of exhaled nitric oxide in exercise-induced bronchospasm: Systematic review. Revista Portuguesa De Pneumologia. 2012; 18(4):198-204

494 Ferdousi HA, Dreborg S. Asthma, bronchial hyperreactivity and mediator release in children with birch pollinosis. ECP and EPX levels are not related to bronchial hyperreactivity. Clinical and Experimental Allergy. 1997; 27(5):530-539

495 Ferdousi HA, Zetterstrom O, Dreborg S. Bronchial hyper-responsiveness predicts the development of mild clinical asthma within 2 yr in school children with hay-fever. Pediatric Allergy and Immunology. 2005; 16(6):478-486

496 Fernandez C, Bevilacqua E, Fernandez N, Gajate P, de la Camara AG, Garcimartin M et al. Asthma related to Alternaria sensitization: an analysis of skin-test and serum-specific IgE efficiency based on the bronchial provocation test. Clinical and Experimental Allergy. 2011; 41(5):649-656

497 Fernandez C, Cardenas R, Martin D, Garcimartin M, Romero S, de la Camara AG et al. Analysis of skin testing and serum-specific immunoglobulin E to predict airway reactivity to cat allergens. Clinical and Experimental Allergy. 2007; 37(3):391-399

498 Fielder HM, Lyons RA, Heaven M, Morgan H, Govier P, Hooper M. Effect of environmental tobacco smoke on peak flow variability. Archives of Disease in Childhood. 1999; 80(3):253-256

499 Finkelstein MM, Chapman KR, McIvor RA, Sears MR. Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in Ontario. Canadian Respiratory Journal. 2011; 18(6):327-332

500 Fish JE, Permutt S. Which test best measures a bronchodilator response? Chest. 1978; 73(6 Suppl):986-987

501 Fitzpatrick AM, Gaston BM, Erzurum SC, Teague WG, National Institutes of Health/National Heart LaBISARP. Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide. Journal of Allergy and Clinical Immunology. 2006; 118(6):1218-1225

502 Flaherty DK, Geller M, Surfus JE. HLA antigen frequencies and natural history in Alternaria-sensitive and perennial nonallergic asthmatics. Journal of Allergy and Clinical Immunology. 1980; 66(5):408-416

503 Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013; 309(1):71-82

504 Fleming DM, Cross KW, Sunderland R, Ross AM. Comparison of the seasonal patterns of asthma identified in general practitioner episodes, hospital admissions, and deaths. Thorax. 2000; 55(8):662-665

505 Fonseca JA, Costa-Pereira A, Delgado L, Fernandes L, Castel-Branco MG. Asthma patients are willing to use mobile and web technologies to support self-management. Allergy. 2006; 61(3):389-390

506 Fonseca JA, Delgado L, Costa-Pereira A, Tavares C, Moreira A, Morete A et al. Evaluation of the Asthma Life Quality test for the screening and severity assessment of asthma. Allergy. 2004; 59(11):1198-1204

507 Forastiere F, Pistelli R, Michelozzi P, Corbo GM, Agabiti N, Bertollini R et al. Indices of nonspecific bronchial responsiveness in a pediatric population. Chest. 1991; 100(4):927-934

508 Foresi A, Mastropasqua B, Chetta A, D'Ippolito R, Testi R, Olivieri D et al. Step-down compared to fixed-dose treatment with inhaled fluticasone propionate in asthma. Chest. 2005; 127(1):117-124

509 Formanek W, Inci D, Lauener RP, Wildhaber JH, Frey U, Hall GL. Elevated nitrite in breath condensates of children with respiratory disease. European Respiratory Journal. 2002; 19(3):487-491

510 Fortuna AM, Fexias T, Gonzalez M, Casan P. Determination of exhaled nitric oxide in healthy volunteers and asthmatic patients - comparison of two devices [Abstract]. European Respiratory Journal. 2006; 28(Suppl 50):791s

511 Fortuna AM, Feixas T, Gonzalez M, Casan P. Diagnostic utility of inflammatory biomarkers in asthma: exhaled nitric oxide and induced sputum eosinophil count. Respiratory Medicine. 2007; 101(11):2416-2421

512 Foucard T. A follow-up study of children with asthmatoid bronchitis. I. Skin test reactions and IgE antibodies to common allergens. Acta Paediatrica Scandinavica. 1973; 62(6):633-644

513 Foucard T, Sjoberg O. A prospective 12-year follow-up study of children with wheezy bronchitis. Acta Paediatrica Scandinavica. 1984; 73(5):577-583

514 Fowler SJ, Dempsey OJ, Sims EJ, Lipworth BJ. Screening for bronchial hyperresponsiveness using methacholine and adenosine monophosphate. Relationship to asthma severity and beta(2)-receptor genotype. American Journal of Respiratory and Critical Care Medicine. 2000; 162(4 Pt 1):1318-1322

515 Fowler SJ, Langley SJ, Truman NJ, Woodcock A, Simpson A, Custovic A. Long-term effects of allergen sensitization and exposure in adult asthma: a prospective study. World Allergy Organization Journal. 2009; 2(5):83-90

516 Frank P, Ferry S, Moorhead T, Hannaford P. Use of a postal questionnaire to estimate the likely under-diagnosis of asthma-like illness in adults. British Journal of General Practice. 1996; 46(406):295-297

517 Frank PI, Frank TL, Cropper J, Hirsch S, Niven RM, Hannaford P et al. The use of a screening questionnaire to identify children with likely asthma. British Journal of General Practice. 2001; 51(463):117-120

518 Frank PI, Morris JA, Hazell ML, Linehan MF, Frank TL. Long term prognosis in preschool children with wheeze: longitudinal postal questionnaire study 1993-2004. BMJ. 2008; 336(7658):1423-1426

519 Frank TL, Adisesh A, Pickering AC, Morrison JF, Wright T, Francis H et al. Relationship between exhaled nitric oxide and childhood asthma. American Journal of Respiratory and Critical Care Medicine. 1998; 158(4):1032-1036

520 Franklin PJ, Turner SW, Le Souef PN, Stick SM. Exhaled nitric oxide and asthma: complex interactions between atopy, airway responsiveness, and symptoms in a community population of children. Thorax. 2003; 58(12):1048-1052

521 Franklin PJ, Stick SM, Le Souef PN, Ayres JG, Turner SW. Measuring exhaled nitric oxide levels in adults: the importance of atopy and airway responsiveness. Chest. 2004; 126(5):1540-1545

522 Freidhoff LR, Marsh DG. Relationship among asthma, serum IgE levels and skin test sensitivity to inhaled allergens. International Archives of Allergy and Immunology. 1993; 100(4):355-361

523 Frette C, Annesi I, Korobaeff M, Neukirch F, Dore MF, Kauffmann F. Blood eosinophilia and FEV1. Cross-sectional and longitudinal analyses. American Review of Respiratory Disease. 1991; 143(5 Pt 1):987-992

524 Frischer T, Kuehr J, Meinert R, Karmaus W, Urbanek R. Risk factors for childhood asthma and recurrent wheezy bronchitis. European Journal of Pediatrics. 1993; 152(9):771-775

525 Frischer T, Kuhr J, Meinert R, Karmaus W, Urbanek R. Influence of maternal smoking on variability of peak expiratory flow rate in school children. Chest. 1993; 104(4):1133-1137

526 Frischer T, Meinert R, Urbanek R, Kuehr J. Variability of peak expiratory flow rate in children: short and long term reproducibility. Thorax. 1995; 50(1):35-39

527 Frith J, Fleming L, Bossley C, Ullmann N, Bush A. The complexities of defining atopy in severe childhood asthma. Clinical and Experimental Allergy. 2011; 41(7):948-953

528 Fritsch M, Uxa S, Horak F, Putschoegl B, Dehlink E, Szepfalusi Z et al. Exhaled nitric oxide in the management of childhood asthma: A prospective 6-months study. Pediatric Pulmonology. 2006; 41(9):855-862

529 Fruchter O, Hardak E, Yigla M. The response to bronchodilators in adults is not predictive of bronchial-hyperreactivity. Journal of Asthma. 2009; 46(5):455-459

530 Fruchter O, Yigla M. Bronchodilator response after negative methacholine challenge test predicts future diagnosis of asthma. Journal of Asthma. 2009; 46(7):722-725

531 Fuentes C, Contreras S, Padilla O, Castro-Rodriguez JA, Moya A, Caussade S. Exercise challenge test: is a 15% fall in FEV(1) sufficient for diagnosis? Journal of Asthma. 2011; 48(7):729-735

532 Fuiano N, Incorvaia C, Diddi G. Diagnostic performance of the atopy patch test with inhalant allergens. Allergy. 2013; 68:419

533 Fujimura M, Nishizawa Y, Nishitsuji M, Nomura S, Abo M, Ogawa H. Predictors for typical asthma onset from cough variant asthma. Journal of Asthma. 2005; 42(2):107-111

534 Fujimura M, Ohkura N, Abo M, Furusho S, Waseda Y, Ichikawa Y et al. Exhaled nitric oxide levels in patients with atopic cough and cough variant asthma. Respirology. 2008; 13(3):359-364

535 Fukuhara A, Saito J, Sato S, Sato Y, Nikaido T, Saito K et al. Validation study of asthma screening criteria based on subjective symptoms and fractional exhaled nitric oxide. Annals of Allergy, Asthma and Immunology. 2011; 107(6):480-486

536 Gabriele C, Pijnenburg MWH, Monti F, Hop W, Bakker ME, De Jongste JC. The effect of spirometry and exercise on exhaled nitric oxide in asthmatic children. Pediatric Allergy and Immunology. 2005; 16(3):243-247

537 Gade E, Thomsen SF, Porsbjerg C, Backer V. The bronchial response to mannitol is attenuated by a previous methacholine test: but not vice versa. Clinical and Experimental Allergy. 2009; 39(7):966-971

538 Gagliardo R, La Grutta S, Chanez P, Profita M, Paterno A, Cibella F et al. Non-invasive markers of airway inflammation and remodeling in childhood asthma. Pediatric Allergy and Immunology. 2009; 20(8):780-790

539 Gaig P, Enrique E, Garcia-Ortega P, Olona M, del Mar San Miguel M, Richart C. Asthma, mite sensitization, and sleeping in bunks. Annals of Allergy, Asthma and Immunology. 1999; 82(6):531-533

540 Galant DM. Effect of feedback to physicians on asthma patients' health-related quality of life. Dissertation Abstracts International: Section B: the Sciences & Engineering. 1999; 60(2B)

541 Galant SP, Morphew T, Amaro S, Liao O. Value of the bronchodilator response in assessing controller naive asthmatic children. Journal of Pediatrics. 2007; 151(5):457-462

542 Galvez RA, McLaughlin FJ, Levison H. The relationship between airway obstruction and bronchial hyperreactivity in childhood asthma. Annals of Allergy. 1987; 58(1):45-47

543 Galvez RA, McLaughlin FJ, Levison H. The role of the methacholine challenge in children with chronic cough. Journal of Allergy and Clinical Immunology. 1987; 79(2):331-335

544 Garbutt JM, Banister C, Highstein G, Sterkel R, Epstein J, Bruns J et al. Telephone coaching for parents of children with asthma: impact and lessons learned. Archives of Pediatrics and Adolescent Medicine. 2010; 164(7):625-630

545 Garbutt JM, Highstein G, Yan Y, Strunk RC. Partner randomized controlled trial: study protocol and coaching intervention. BMC Pediatrics. 2012; 12:42

546 Garcia de la Rubia S, Pajaron-Fernandez MJ, Sanchez-Solis M, Martinez-Gonzalez Moro I, Perez-Flores D, Pajaron-Ahumada M. Exercise-induced asthma in children: a comparative study of free and treadmill running. Annals of Allergy, Asthma and Immunology. 1998; 80(3):232-236

547 Garcia JJ, Trigo MM, Cabezudo B, Recio M, Vega JM, Barber D et al. Pollinosis due to Australian pine (Casuarina): An aerobiologic and clinical study in southern Spain. Allergy. 1997; 52(1):11-17

548 Garcia-Gonzalez JJ, Bartolome-Zavala B, Del Mar Trigo-Perez M, Barcelo-Munoz JM, Fernandez-Melendez S, Negro-Carrasco MA et al. Pollinosis to Ricinus communis (castor bean): an aerobiological, clinical and immunochemical study. Clinical and Experimental Allergy. 1999; 29(9):1265-1275

549 Garcia-Rio F, Mediano O, Ramirez M, Vinas A, Alonso A, Alvarez-Sala R et al. Usefulness of bronchial reactivity analysis in the diagnosis of bronchial asthma in patients with bronchial hyperresponsiveness. Respiratory Medicine. 2004; 98(3):199-204

550 Garcinuno AC, Gandarillas IM, Cobo RA, Perez CI, Diaz EE, Yanez MB et al. Early patterns of wheezing in asthmatic and nonasthmatic children. European Respiratory Journal. 2013; 42(4):1020-1028

551 Gardner IA, Stryhn H, Lind P, Collins MT. Conditional dependence between tests affects the diagnosis and surveillance of animal diseases. Preventive Veterinary Medicine. 2000; 45(1-2):107-122

552 Garratt AM, Hutchinson A, Russell I. Patient-assessed measures of health outcome in asthma: a comparison of four approaches. Respiratory Medicine. 2000; 94(6):597-606

553 Gautrin D, Malo JL. Risk factors, predictors, and markers for work-related asthma and rhinitis. Current Allergy and Asthma Reports. 2010; 10(5):365-372

554 Genders T, Hunink M. Modeling the Joint Distribution of Sensitivity nd Specificity. Society for Medical Decision Making. 2009; 31

555 Genton C, Frei PC, Pecoud A. Value of oral provocation tests to aspirin and food additives in the routine investigation of asthma and chronic urticaria. Journal of Allergy and Clinical Immunology. 1985; 76(1):40-45

556 Gerald JK, Sun Y, Grad R, Gerald LB. Asthma morbidity among children evaluated by asthma case detection. Pediatrics. 2009; 124(5):e927-e933

557 Gerald LB, Redden D, Turner-Henson A, Feinstein R, Hemstreet MP, Hains C et al. A multi-stage asthma screening procedure for elementary school children. Journal of Asthma. 2002; 39(1):29-36

558 Gerald LB, Grad R, Turner-Henson A, Hains C, Tang S, Feinstein R et al. Validation of a multistage asthma case-detection procedure for elementary school children. Pediatrics. 2004; 114(4):e459-e468

559 Gergen PJ, Arbes SJJ, Calatroni A, Mitchell HE, Zeldin DC. Total IgE levels and asthma prevalence in the US population: results from the National Health and Nutrition Examination Survey 2005-2006. Journal of Allergy and Clinical Immunology. 2009; 124(3):447-453

560 Gevorgyan A, Fokkens WJ. Fractional exhaled nitric oxide (FeNO) measurement in asthma and rhinitis. Primary Care Respiratory Journal. 2013; 22(1):10-11

561 Gharagozlou M, Kompani F, Movahedi M. Comparison between peak expiratory flow rate and forced expiratory volume in one second in the evaluation of children suspected to have asthma. Iranian Journal of Allergy, Asthma and Immunology. 2004; 3(1):21-24

562 Ghodrati S, Hormati A, Mousavi NN, Afifian M. Comparison of FEV1 and PEF values in cough variant asthma during methacholine challenge test. Journal of Zanjan University of Medical Sciences and Health Services. 2011; 19(77):3

563 Gibson PG. Using fractional exhaled nitric oxide to guide asthma therapy: design and methodological issues for ASthma TReatment ALgorithm studies. Clinical and Experimental Allergy. 2009; 39(4):478-490

564 Gibson PG, Mattoli S, Sears MR, Dolovich J, Hargreave FE. Increased peak flow variability in children with asymptomatic hyperresponsiveness. European Respiratory Journal. 1995; 8(10):1731-1735

565 Gibson PG, Powell H. Written action plans for asthma: an evidence-based review of the key components. Thorax. 2004; 59(2):94-99

566 Gibson PG, Powell H, Wilson A, Abramson MJ, Haywood P, Bauman A et al. Self-management education and regular practitioner review for adults with asthma. Cochrane Database of Systematic Reviews. 2002; Issue 3:CD001117. DOI:10.1002/14651858.CD001117

567 Gift AG. The effect of cold air on asthmatic patients. Perspectives in Respiratory Nursing. 1994; 5(4):6

568 Gilbert R, Auchincloss JH. What is a 'restrictive' defect? Archives of Internal Medicine. 1986; 146(9):1779-1781

569 Gilbert R, Auchincloss JHJ. The interpretation of the spirogram. How accurate is it for 'obstruction'? Archives of Internal Medicine. 1985; 145(9):1635-1639

570 Gilbert R, Auchincloss JHJ. Post-test probability of asthma following methacholine challenge. Chest. 1990; 97(3):562-565

571 Gingo MR, Wenzel SE, Steele C, Kessinger CJ, Lucht L, Lawther T et al. Asthma diagnosis and airway bronchodilator response in HIV-infected patients. Journal of Allergy and Clinical Immunology. 2012; 129(3):708-714

572 Girard F, Chaboillez S, Cartier A, Cote J, Hargreave FE, Labrecque M et al. An effective strategy for diagnosing occupational asthma: use of induced sputum. American Journal of Respiratory and Critical Care Medicine. 2004; 170(8):845-850

573 Gjevre JA, Hurst TS, Taylor-Gjevre RM, Cockcroft DW. The American Thoracic Society's spirometric criteria alone is inadequate in asthma diagnosis. Canadian Respiratory Journal. 2006; 13(8):433-437

574 Glasgow NJ, Ponsonby AL, Yates RE, McDonald T, Attewell R. Asthma screening as part of a routine school health assessment in the Australian Capital Territory. Medical Journal of Australia. 2001; 174(8):384-388

575 Godden DJ, Ross S, Abdalla M, McMurray D, Douglas A, Oldman D et al. Outcome of wheeze in childhood. Symptoms and pulmonary function 25 years later. American Journal of Respiratory and Critical Care Medicine. 1994; 149(1):106-112

576 Godfrey RC. Asthma and IgE levels in rural and urban communities of The Gambia. Clinical Allergy. 1975; 5(2):201-207

577 Godfrey S, Springer C, Bar-Yishay E, Avital A. Cut-off points defining normal and asthmatic bronchial reactivity to exercise and inhalation challenges in children and young adults. European Respiratory Journal. 1999; 14(3):659-668

578 Goedhart DM, Zanen P, Lammers JW. Relevant and redundant lung function parameters in discriminating asthma from COPD. COPD. 2006; 3(1):33-39

579 Goeman D, Jenkins C, Crane M, Paul E, Douglass J. Educational intervention for older people with asthma: a randomised controlled trial. Patient Education and Counseling. 2013; 93(3):586-595

580 Goetz DW. Harmonia axyridis ladybug hypersensitivity in clinical allergy practice. Allergy and Asthma Proceedings. 2007; 28(1):50-57

581 Gohler A, Geisler BP, Manne JM, Kosiborod M, Zhang Z, Weintraub WS et al. Utility estimates for decision-analytic modeling in chronic heart failure--health states based on New York Heart Association classes and number of rehospitalizations. Value in Health. 2009; 12(1):185-187

582 Goksor E, Amark M, Alm B, Gustafsson PM, Wennergren G. Asthma symptoms in early childhood--what happens then? Acta Paediatrica. 2006; 95(4):471-478

583 Goksor E, Gustafsson PM, Alm B, Amark M, Wennergren G. Reduced airway function in early adulthood among subjects with wheezing disorder before two years of age. Pediatric Pulmonology. 2008; 43(4):396-403

584 Goldstein IF, Perzanowski MS, Lendor C, Garfinkel RS, Hoepner LA, Chew GL et al. Prevalence of allergy symptoms and total IgE in a New York City cohort and their association with birth order. International Archives of Allergy and Immunology. 2005; 137(3):249-257

585 Goldstein MF, Pacana SM, Dvorin DJ, Dunsky EH. Retrospective analyses of methacholine inhalation challenges. Chest. 1994; 105(4):1082-1088

586 Goldstein MF, Veza BA, Dunsky EH, Dvorin DJ, Belecanech GA, Haralabatos IC. Comparisons of peak diurnal expiratory flow variation, postbronchodilator FEV(1) responses, and methacholine inhalation challenges in the evaluation of suspected asthma. Chest. 2001; 119(4):1001-1010

587 Gonzalez-Perez R, Poza-Guedes P, Vives-Conesa R. The nose as a target organ in the diagnosis of severe aspirin-exacerbated respiratory disease. American Journal of Rhinology and Allergy. 2011; 25(3):166-169

588 Gordon SB, Curran AD, Murphy J, Sillitoe C, Lee G, Wiley K et al. Screening questionnaires for bakers' asthma--are they worth the effort? Occupational Medicine. 1997; 47(6):361-366

589 Gradman J, Wolthers OD. Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic. Pediatric Allergy and Immunology. 2006; 17(7):524-526

590 Graif Y, Yigla M, Tov N, Kramer MR. Value of a negative aeroallergen skin-prick test result in the diagnosis of asthma in young adults: correlative study with methacholine challenge testing. Chest. 2002; 122(3):821-825

591 Grainger-Rousseau T-J, McElnay JC. A model for community pharmacist involvement with general practitioners in the management of asthma patients. Journal of Applied Therapeutics. 1996; 1(2):145-161

592 Grammer L, Shaughnessy M, Kenamore B. Utility of antibody in identifying individuals who have or will develop anhydride-induced respiratory disease. Chest. 1998; 114(4):1199-1202

593 Grammer LC, Harris KE, Sonenthal KR, Ley C, Roach DE. A cross-sectional survey of 46 employees exposed to trimellitic anhydride. Allergy Proceedings. 1992; 13(3):139-142

594 Green AW, Foels TJ. Improving asthma management: one health plan's experience. American Journal of Managed Care. 2007; 13(8):482-485

595 Green R, Luyt D. Clinical characteristics of childhood asthmatics in Johannesburg. South African Medical Journal. 1997; 87(7):878-882

596 Green RJ, Klein M, Becker P, Halkas A, Lewis H, Kitchin O et al. Disagreement among common measures of asthma control in children. Chest. 2013; 143(1):117-122

597 Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet. 2002; 360(9347):1715-1721

598 Greenspon LW, Gracely E. A discriminant analysis applied to methacholine bronchoprovocation testing improves classification of patients as normal, asthma, or COPD. Chest. 1992; 102(5):1419-1425

599 Griffiths C, Feder G, Wedzicha J, Foster G, Livingstone A, Marlowe GS. Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice. Respiratory Medicine. 1999; 93(12):903-908

600 Gronke L, Kanniess F, Holz O, Jorres RA, Magnussen H. The relationship between airway hyper-responsiveness, markers of inflammation and lung function depends on the duration of the asthmatic disease. Clinical and Experimental Allergy. 2002; 32(1):57-63

601 Gruchalla RS, Gan V, Roy L, Bokovoy J, McDermott S, Lawrence G et al. Results of an inner-city school-based asthma and allergy screening pilot study: a combined approach using written questionnaires and step testing. Annals of Allergy, Asthma and Immunology. 2003; 90(5):491-499

602 Gruchalla RS, Sampson HA, Matsui E, David G, Gergen PJ, Calatroni A et al. Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. Journal of Allergy and Clinical Immunology. 2009; 124(2):213-221

603 Gruffydd-Jones K, Hollinghurst S, Ward S, Taylor G. Targeted routine asthma care in general practice using telephone triage. British Journal of General Practice. 2005; 55:918-923

604 Grzelewska-Rzymowska I, Rozniecki J, Szmidt M, Kowalski ML. Asthma with aspirin intolerance. Clinical entity or coincidence of nonspecific bronchial hyperreactivity and aspirin intolerance. Allergologia Et Immunopathologia. 1981; 9(6):533-538

605 Grzelewski T, Grzelewska A, Majak P, Stelmach W, Kowalska A, Stelmach R et al. Fractional exhaled nitric oxide (FeNO) may predict exercise-induced bronchoconstriction (EIB) in schoolchildren with atopic asthma. Nitric Oxide. 2012; 27(2):82-87

606 Grzelewski T, Majak P, Jerzynska J, Cichalewski L, Krakowiak J, Stelmach W et al. The association between fractional exhaled nitric oxide (FeNO) and cat dander in asthmatic children. Nitric Oxide. 2011; 25(3):288-293

607 Grzelewski T, Witkowski K, Makandjou-Ola E, Grzelewska A, Majak P, Jerzynska J et al. Diagnostic value of lung function parameters and FeNO for asthma in schoolchildren in large, real-life population. Pediatric Pulmonology. 2014; 49(7):632-640

608 Gudelj I, Mrkic Kobal I, Munivrana Skvorc H, Mise K, Vrbica Z, Plavec D et al. Intraregional differences in asthma prevalence and risk factors for asthma among adolescents in Split-Dalmatia County, Croatia. Medical Science Monitor. 2012; 18(4):H43-H50

609 Guendelman S, Meade K, Benson M, Chen YQ, Samuels S. Improving asthma outcomes and self-management behaviors of inner-city children: a randomized trial of the Health Buddy interactive device and an asthma diary. Archives of Pediatrics and Adolescent Medicine. 2002; 156(2):114-120

610 Guendelman S, Meade K, Chen YQ, Benson M. Asthma control and hospitalizations among inner-city children: results of a randomized trial. Telemedicine Journal and E-Health. 2004; 10 Suppl 2:S-14

611 Guerra F, Galan Carmen C, Daza JC, Miguel R, Moreno C, Gonzalez J et al. Study of sensitivity to the pollen of Fraxinus spp. (Oleaceae) in Cordoba, Spain. Journal of Investigational Allergology and Clinical Immunology. 1995; 5(3):166-170

612 Guerra S, Wright AL, Morgan WJ, Sherrill DL, Holberg CJ, Martinez FD. Persistence of asthma symptoms during adolescence: role of obesity and age at the onset of puberty. American Journal of Respiratory and Critical Care Medicine. 2004; 170(1):78-85

613 Guilbert T. Persistent and relapsed wheezing is associated with sensitivity to domestic allergens, gender and smoking status. Evidence-Based Healthcare. 2004; 8(2):92-94

614 Guilbert TW, Morgan WJ, Zeiger RS, Bacharier LB, Boehmer SJ, Krawiec M et al. Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma. Journal of Allergy and Clinical Immunology. 2004; 114(6):1282-1287

615 Guilbert TW, Singh AM, Danov Z, Evans MD, Jackson DJ, Burton R et al. Decreased lung function after preschool wheezing rhinovirus illnesses in children at risk to develop asthma. Journal of Allergy and Clinical Immunology. 2011; 128(3):532-10

616 Gulsvik A. Prevalence and manifestations of obstructive lung disease in the city of Oslo. Scandinavian Journal of Respiratory Diseases. 1979; 60(5):286-296

617 Gustafson D, Wise M, Bhattacharya A, Pulvermacher A, Shanovich K, Phillips B et al. The effects of combining web-based eHealth with telephone nurse case management for pediatric asthma control: A randomized controlled trial. Journal of Medical Internet Research. 2012; 14(4):41-59

618 Gustafsson D, Sjoberg O, Foucard T. Development of allergies and asthma in infants and young children with atopic dermatitis--a prospective follow-up to 7 years of age. Allergy. 2000; 55(3):240-245

619 Haahtela T, Jaakonmaki I. Relationship of allergen-specific IgE antibodies, skin prick tests and allergic disorders in unselected adolescents. Allergy. 1981; 36(4):251-256

620 Habbick BF, Pizzichini MM, Taylor B, Rennie D, Senthilselvan A, Sears MR. Prevalence of asthma, rhinitis and eczema among children in 2 Canadian cities: the International Study of Asthma and Allergies in Childhood. CMAJ. 1999; 160(13):1824-1828

621 Haby MM, Peat JK, Marks GB, Woolcock AJ, Leeder SR. Asthma in preschool children: prevalence and risk factors. Thorax. 2001; 56(8):589-595

622 Hafkamp-de Groen E, Lingsma HF, Caudri D, Levie D, Wijga A, Koppelman GH et al. Predicting asthma in preschool children with asthma-like symptoms: validating and updating the PIAMA risk score. Journal of Allergy and Clinical Immunology. 2013; 132(6):1303-1310

623 Hafkamp-de Groen E, Mohangoo AD, Landgraf JM, de Jongste JC, Duijts L, Moll HA et al. The impact of preschool wheezing patterns on health-related quality of life at age 4 years. European Respiratory Journal. 2013; 41(4):952-959

624 Hafkamp-de Groen E, Sonnenschein-van der Voort A, Mackenbach JP, Duijts L, Jaddoe VWV, Moll HA et al. Socioeconomic and sociodemographic factors associated with asthma related outcomes in early childhood: the generation R study. PloS One. 2013; 8(11):e78266

625 Hafkamp-de Groen E, van Rossem L, de Jongste JC, Mohangoo AD, Moll HA, Jaddoe VWV et al. The role of prenatal, perinatal and postnatal factors in the explanation of socioeconomic inequalities in preschool asthma symptoms: the Generation R Study. Journal of Epidemiology and Community Health. 2012; 66(11):1017-1024

626 Hahn DL, Beasley JW, Andres J, Will I, Angoncillo J, Jackson J et al. Diagnosed and possible undiagnosed asthma: A Wisconsin Research Network (WReN) study. Journal of Family Practice. 1994; 38(4):373-379

627 Halbert RJ, Tinkelman DG, Globe DR, Lin SL. Measuring asthma control is the first step to patient management: a literature review. Journal of Asthma. 2009; 46(7):659-664

628 Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet. 2006; 368(9537):771-779

629 Hallden G, Hellman C, Gronneberg R, Lundahl J. Increased levels of IL-5 positive peripheral blood eosinophils and lymphocytes in mild asthmatics after allergen inhalation provocation. Clinical and Experimental Allergy. 1999; 29(5):595-603

630 Halliday JA, Henry RL, Hankin RG, Hensley MJ. Increased wheeze but not bronchial hyperreactivity near power stations. Journal of Epidemiology and Community Health. 1993; 47(4):282-286

631 Halonen M, Stern DA, Lohman C, Wright AL, Brown MA, Martinez FD. Two subphenotypes of childhood asthma that differ in maternal and paternal infuences on asthma risk. American Journal of Respiratory and Critical Care Medicine. 1999; 160(2):564-570

632 Halonen M, Lohman IC, Stern DA, Ellis WL, Rothers J, Wright AL. Perinatal tumor necrosis factor-alpha production, influenced by maternal pregnancy weight gain, predicts childhood asthma. American Journal of Respiratory and Critical Care Medicine. 2013; 188(1):35-41

633 Halterman JS, Sauer J, Fagnano M, Montes G, Fisher S, Tremblay P et al. Working toward a sustainable system of asthma care: Development of the School-Based Preventive Asthma Care Technology (SB-PACT) trial. Journal of Asthma. 2012; 49(4):395-400

634 Halvani A, Tahghighi F, Nadooshan HH. Evaluation of correlation between airway and serum inflammatory markers in asthmatic patients. Lung India. 2012; 29(2):143-146

635 Hancox RJ, Milne BJ, Taylor DR, Greene JM, Cowan JO, Flannery EM et al. Relationship between socioeconomic status and asthma: a longitudinal cohort study. Thorax. 2004; 59(5):376-380

636 Hancox RJ, Milne BJ, Poulton R, Taylor DR, Greene JM, McLachlan CR et al. Sex differences in the relation between body mass index and asthma and atopy in a birth cohort. American Journal of Respiratory and Critical Care Medicine. 2005; 171(5):440-445

637 Hancox RJ, Poulton R, Taylor DR, Greene JM, McLachlan CR, Cowan JO et al. Associations between respiratory symptoms, lung function and gastro-oesophageal reflux symptoms in a population-based birth cohort. Respiratory Research. 2006; 7:142

638 Hannu T, Lindstrom I, Palmroos P, Kuuliala O, Sauni R. Prediction of obeche wood-induced asthma by specific skin prick testing. Occupational Medicine. 2013; 63(6):429-431

639 Hansel NN, Matsui EC, Rusher R, McCormack MC, Curtin-Brosnan J, Peng RD et al. Predicting future asthma morbidity in preschool inner-city children. Journal of Asthma. 2011; 48(8):797-803

640 Hansen KK, Mosfeldt LE, Backer V, Bach-Mortensen N, Prahl P, Koch C. Bronchial responsiveness in children and adolescents: A comparison between previously asthmatic, currently asthmatic, and normal subjects. Journal of Asthma. 1994; 31(2):99-107

641 Hargreave FE, Nair P. The definition and diagnosis of Asthma. Clinical and Experimental Allergy. 2009; 39(11):1652-1658

642 Hargreave FE, Ramsdale EH, Kirby JG, O'Byrne PM. Asthma and the role of inflammation. European Journal of Respiratory Diseases Supplement. 1986; 147:16-21

643 Hargreave FE, Ryan G, Thomson NC, O'Byrne PM, Latimer K, Juniper EF. Bronchial responsiveness to histamine or methacholine in asthma: measurement and clinical significance. European Journal of Respiratory Diseases Supplement. 1982; 121:79-88

644 Harnan S, Tappenden P, Essat M, Gomersall T, Minton J, Wong R et al. Measurement of exhaled nitric oxide concentration in asthma - NIOX MINO and NObreath, 2013. Available from: http://guidance.nice.org.uk/DT/13

645 Harnan S, Tappenden P, Essat M, Gomersall T, Minton J, Wong R et al. Measurement of exhaled nitric oxide concentration in asthma - NIOX MINO and NObreath, 2013. Available from: http://guidance.nice.org.uk/DT/13

646 Hart MA, Kercsmar CM. Is it asthma, postnasal drip, or reflux? Chronic cough in children: Pursuing specific causes. Journal of Respiratory Diseases. 2002; 4(1):22-27

647 Hashimoto S, Ten BA, Roldaan AC, Van Veen IH, Möller GM, Sont JK et al. Internet-based tapering of oral corticosteroids in severe asthma: A pragmatic randomised controlled trial. Thorax. 2011; 66(6):514-520

648 Hastie AT, Moore WC, Li H, Rector BM, Ortega VE, Pascual RM et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. Journal of Allergy and Clinical Immunology. 2013; 132(1):72-80

649 Hathaway JA, Molenaar DM, Cassidy LD, Feeley TM, Cummings BJ. Cross-sectional survey of workers exposed to aliphatic diisocyanates using detailed respiratory medical history and questions regarding accidental skin and respiratory exposures. Journal of Occupational and Environmental Medicine. 2014; 56(1):52-57

650 Hayati F, Maghsoodloo S, DeVivo MJ, Carnahan BJ. Control chart for monitoring occupational asthma. Journal of Safety Research. 2006; 37(1):17-26

651 Hayati F, Maghsoodloo S, DeVivo MJ, Thomas RE, Lemiere C. Quality control chart method for analyzing PEF variability in occupational asthma. American Journal of Industrial Medicine. 2008; 51(3):223-228

652 HAYES. Nitric oxide breath analysis for the diagnosis and management of asthma. HAYES, Inc, 2007

653 HAYES. Mannitol bronchial provocation challenge for asthma. HAYES, Inc, 2012

654 Hayes J, Jhaveri MA, Mannino DM, Strawbridge H, Temprano J. The effect of mold sensitization and humidity upon allergic asthma. Clinical Respiratory Journal. 2013; 7(2):135-144

655 Hedenstrom H, Malmberg P. Optimal combinations of lung function tests in the detection of various types of early lung disease. European Journal of Respiratory Diseases. 1987; 71(4):273-285

656 Hedman J, Poussa T, Nieminen MM. A rapid dosimetric methacholine challenge in asthma diagnostics: a clinical study of 230 patients with dyspnoea, wheezing or a cough of unknown cause. Respiratory Medicine. 1998; 92(1):32-39

657 Heffler E, Guida G, Marsico P, Bergia R, Bommarito L, Ferrero N et al. Exhaled nitric oxide as a diagnostic test for asthma in rhinitic patients with asthmatic symptoms. Respiratory Medicine. 2006; 100(11):1981-1987

658 Heidenfelder B, Johnson M, Hudgens E, Inmon J, Hamilton RG, Neas L et al. Increased plasma reactive oxidant levels and their relationship to blood cells, total IgE, and allergen-specific IgE levels in asthmatic children. Journal of Asthma. 2010; 47(1):106-111

659 Heinrich J, Hoelscher B, Frye C, Meyer I, Wjst M, Wichmann HE. Trends in prevalence of atopic diseases and allergic sensitization in children in Eastern Germany. European Respiratory Journal. 2002; 19(6):1040-1046

660 Heinrich J, Hoelscher B, Wjst M, Ritz B, Cyrys J, Wichmann H. Respiratory diseases and allergies in two polluted areas in East Germany. Environmental Health Perspectives. 1999; 107(1):53-62

661 Heinrich J, Richter K, Magnussen H, Wichmann HE. Is the prevalence of atopic diseases in East and West Germany already converging? European Journal of Epidemiology. 1998; 14(3):239-245

662 Hellinckx J, De Boeck K, Bande-Knops J, van der Poel M, Demedts M. Bronchodilator response in 3-6.5 years old healthy and stable asthmatic children. European Respiratory Journal. 1998; 12(2):438-443

663 Henderson AJ, Carswell F. Circadian rhythm of peak expiratory flow in asthmatic and normal children. Thorax. 1989; 44(5):410-414

664 Henderson FW, Henry MM, Ivins SS, Morris R, Neebe EC, Leu SY et al. Correlates of recurrent wheezing in school-age children. The Physicians of Raleigh Pediatric Associates. American Journal of Respiratory and Critical Care Medicine. 1995; 151(6):1786-1793

665 Henderson J, Granell R, Heron J, Sherriff A, Simpson A, Woodcock A et al. Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood. Thorax. 2008; 63(11):974-980

666 Henderson J, Hilliard TN, Sherriff A, Stalker D, Al Shammari N, Thomas HM. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatric Allergy and Immunology. 2005; 16(5):386-392

667 Henderson J, Northstone K, Lee SP, Liao H, Zhao Y, Pembrey M et al. The burden of disease associated with filaggrin mutations: a population-based, longitudinal birth cohort study. Journal of Allergy and Clinical Immunology. 2008; 121(4):872-877

668 Henriksen AH, Holmen TL, Bjermer L. Sensitization and exposure to pet allergens in asthmatics versus non-asthmatics with allergic rhinitis. Respiratory Medicine. 2001; 95(2):122-129

669 Henriksen AH, Holmen TL, Bjermer L. Gender differences in asthma prevalence may depend on how asthma is defined. Respiratory Medicine. 2003; 97(5):491-497

670 Henriksen AH, Tveit KH, Holmen TL, Sue-Chu M, Bjermer L. A study of the association between exercise-induced wheeze and exercise versus methacholine-induced bronchoconstriction in adolescents. Pediatric Allergy and Immunology. 2002; 13(3):203-208

671 Hensley MJ, Chalmers A, Clover K, Gibson PG, Toneguzzi R, Lewis PR. Symptoms of asthma: comparison of a parent-completed retrospective questionnaire with a prospective daily symptom diary. Pediatric Pulmonology. 2003; 36(6):509-513

672 Herr M, Just J, Nikasinovic L, Foucault C, Le Marec AM, Giordanella JP et al. Influence of host and environmental factors on wheezing severity in infants: findings from the PARIS birth cohort. Clinical and Experimental Allergy. 2012; 42(2):275-283

673 Herr M, Just J, Nikasinovic L, Foucault C, Le Marec AM, Giordanella JP et al. Risk factors and characteristics of respiratory and allergic phenotypes in early childhood. Journal of Allergy and Clinical Immunology. 2012; 130(2):389-396

674 Hervas D, Milan JM, Garde J. Differences in exhaled nitric oxide in atopic children. Allergologia Et Immunopathologia. 2008; 36(6):331-335

675 Hetlevik O, Ploen O, Nystad W, Magnus P. The wheezing schoolchild--an undiagnosed asthmatic. A follow-up of children with parentally reported episodes of wheeze without diagnosed asthma. Scandinavian Journal of Primary Health Care. 2000; 18(2):122-126

676 Hetzel MR, Clark TJH. Comparison of normal and asthmatic circadian rhythms in peak expiratory flow rate. Thorax. 1980; 35(10):732-738

677 Hickson DA, Wilhite RL, Petrini MF, White WB, Burchfiel C. Asthma and asthma severity among African American adults in the Jackson Heart Study. Journal of Asthma. 2009; 46(4):421-428

678 Higgins BG, Britton JR, Chinn S, Cooper S, Burney PG, Tattersfield AE. Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies. American Review of Respiratory Disease. 1992; 145(3):588-593

679 Higgins BG, Britton JR, Chinn S, Jones TD, Jenkinson D, Burney PG et al. The distribution of peak expiratory flow variability in a population sample. American Review of Respiratory Disease. 1989; 140(5):1368-1372

680 Hildebrand K, Przybylowski T, Maskey-Warzechowska M, Chazan R. Usefulness of selected tests in the diagnosis of exercise induced bronchoconstriction. Pneumonologia i Alergologia Polska. 2011; 79(6):397-406

681 Hill DJ, Bannister DG, Hosking CS, Kemp AS. Cow milk allergy within the spectrum of atopic disorders. Clinical and Experimental Allergy. 1994; 24(12):1137-1143

682 Hirsch S, Frank TL, Shapiro JL, Hazell ML, Frank PI. Development of a questionnaire weighted scoring system to target diagnostic examinations for asthma in adults: a modelling study. BMC Family Practice. 2004; 5(1):30

683 Hirsch T, Weiland SK, von Mutius E, Safeca AF, Grafe H, Csaplovics E et al. Inner city air pollution and respiratory health and atopy in children. European Respiratory Journal. 1999; 14(3):669-677

684 Hodge L, Salome CM, Peat JK, Haby MM, Xuan W, Woolcock AJ. Consumption of oily fish and childhood asthma risk. Medical Journal of Australia. 1996; 164(3):137-140

685 Hoek G, Pattenden S, Willers S, Antova T, Fabianova E, Braun-Fahrlander C et al. PM10, and children's respiratory symptoms and lung function in the PATY study. European Respiratory Journal. 2012; 40(3):538-547

686 Hoffmann-Petersen B, Host A, Larsen KT, Bergstein KR, Thomsen ML, Braendholt V et al. Prevalence of IgE sensitization in Danish children with suspected asthma. Pediatric Allergy and Immunology. 2013; 24(8):727-733

687 Hogarth-Scott RS, McNicol RN, Williams HE. Diagnosis of allergy in vitro. A comparison between skin sensitivity testing and serum levels of specific IgE antibody in children. Medical Journal of Australia. 1973; 1(26):1293-1297

688 Hogman M, Holmkvist T, Wegener T, Emtner M, Andersson M, Hedenstrom H et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respiratory Medicine. 2002; 96(1):24-30

689 Hogman M, Ludviksdottir D, Anderson SD, George S, Hakansson L, Chan HK et al. Inhaled mannitol shifts exhaled nitric oxide in opposite directions in asthmatics and healthy subjects. Respiration Physiology. 2001; 124(2):141-150

690 Holguin F, Rojas M, Brown LA, Fitzpatrick AM. Airway and plasma leptin and adiponectin in lean and obese asthmatics and controls. Journal of Asthma. 2011; 48(3):217-223

691 Holster IL, Vila AM, Caudri D, den Hoed CM, Perez-Perez GI, Blaser MJ et al. The impact of Helicobacter pylori on atopic disorders in childhood. Helicobacter. 2012; 17(3):232-237

692 Holt EW, Tan J, Hosgood III HD. The impact of spirometry on pediatric asthma diagnosis and treatment. Journal of Asthma. 2006; 43(7):489-493

693 Holt PG, Rowe J, Kusel M, Parsons F, Hollams EM, Bosco A et al. Toward improved prediction of risk for atopy and asthma among preschoolers: a prospective cohort study. Journal of Allergy and Clinical Immunology. 2010; 125(3):653-659

694 Holt S, Perrin K. Using the asthma control test to improve asthma outcomes. New Zealand Medical Journal. 2010; 123(1323):43-47

695 Holzer K, Anderson SD, Chan HK, Douglass J. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. American Journal of Respiratory and Critical Care Medicine. 2003; 167(4):534-537

696 Holzer K, Anderson SD, Douglass J. Exercise in elite summer athletes: Challenges for diagnosis. Journal of Allergy and Clinical Immunology. 2002; 110(3):374-380

697 Homnick DN, DeJong SR. Parent-reported physician diagnosis is an important factor in asthma management: an elementary school survey. Clinical Pediatrics. 2007; 46(5):431-436

698 Hong SP, Park HS, Lee MK, Hong CS. Oral provocation tests with aspirin and food additives in asthmatic patients. Yonsei Medical Journal. 1989; 30(4):339-345

699 Honkoop P, Loijmans R, Termeer E, Snoeck-Stroband J, Assendelft P, Sterk P et al. A cluster randomized trial comparing strict, partial, and FeNO-guided asthma control strategies in primary care [Abstract]. European Respiratory Society Annual Congress, 2013 Sept 7-11, Barcelona, Spain. 2013; 42(Suppl 57):397s

700 Honkoop PJ, Loijmans RJ, Termeer EH, Snoeck-Stroband JB, van den Hout WB, Bakker MJ et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. Journal of Allergy and Clinical Immunology. 2014; Epublication

701 Honkoop PJ, Loymans RJ, Termeer EH, Snoeck-Stroband JB, Bakker MJ, Assendelft WJ et al. Asthma control cost-utility randomized trial evaluation (ACCURATE): the goals of asthma treatment. BMC Pulmonary Medicine. England 2011; 11:53

702 Hopp RJ, Bewtra AK, Nair NM, Townley RG. Specificity and sensitivity of methacholine inhalation challenge in normal and asthmatic children. Journal of Allergy and Clinical Immunology. 1984; 74(2):154-158

703 Hopp RJ, Biven RE, Degan JA, Bewtra AK, Townley RG. The usefulness of questionnaire-derived information to predict the degree of nonspecific bronchial hyperresponsiveness. Allergy Proceedings. 1995; 16(3):129-134

704 Hopper JL, Jenkins MA, Carlin JB, Giles GG. Increase in the self-reported prevalence of asthma and hay fever in adults over the last generation: a matched parent-offspring study. Australian Journal of Public Health. 1995; 19(2):120-124

705 Hopper JL, Bui QM, Erbas B, Matheson MC, Gurrin LC, Burgess JA et al. Does eczema in infancy cause hay fever, asthma, or both in childhood? Insights from a novel regression model of sibling data. Journal of Allergy and Clinical Immunology. 2012; 130(5):1117-1122

706 Horak E, Lanigan A, Roberts M, Welsh L, Wilson J, Carlin JB et al. Longitudinal study of childhood wheezy bronchitis and asthma: outcome at age 42. BMJ. 2003; 326(7386):422-423

707 Horak E, Morass B, Ulmer H. Association between environmental tobacco smoke exposure and wheezing disorders in Austrian preschool children. Swiss Medical Weekly. 2007; 137(43-44):608-613

708 Horak E, Murr C, Streif W, Schroecksnadel K, Schennach H, Fuchs D. Association between neopterin in cord blood, urinary neopterin in early childhood and the development of atopic dermatitis, asthma and hay fever. Pediatric Allergy and Immunology. 2006; 17(1):11-16

709 Horie T, Enomoto S, Inazawa T, Okuma A, Hosokawa Y, Okayasu M. Comparison of airway responsiveness to exercise and histamine inhalation in asthmatics. Japanese Journal of Medicine. 1983; 22(1):26-30

710 Horvath I, Donnelly LE, Kiss A, Balint B, Kharitonov SA, Barnes PJ. Exhaled nitric oxide and hydrogen peroxide concentrations in asthmatic smokers. Respiration. 2004; 71(5):463-468

711 Horwood LJ, Fergusson DM, Shannon FT. Social and familial factors in the development of early childhood asthma. Pediatrics. 1985; 75(5):859-868

712 Hovi S. Exhaled nitric oxide in asthma diagnosis and treatment monitoring. Helsinki. Finnish Office for Health Care Technology Assessment (FinOHTA), 2010

713 Hsu JY, Huang CM, King SL, Chiang CD. Importance of sputum differential cell counting in the diagnosis of airway diseases. Journal of the Formosan Medical Association. 1997; 96(5):330-335

714 Hu FB, Persky V, Flay BR, Richardson J. An epidemiological study of asthma prevalence and related factors among young adults. Journal of Asthma. 1997; 34(1):67-76

715 Hu FB, Persky V, Flay BR, Zelli A, Cooksey J, Richardson J. Prevalence of asthma and wheezing in public schoolchildren: association with maternal smoking during pregnancy. Annals of Allergy, Asthma and Immunology. 1997; 79(1):80-84

716 Huang J-L, Chen S-H, Yeh K-W. Health outcomes, education, healthcare delivery and quality-3056. Constructed supporting program improves asthma treatment outcomes in children. World Allergy Organization Journal.: Lippincott Williams and Wilkins. 2013; 6(Suppl 1):224

717 Huang TT, Li YT, Wang CH. Individualized programme to promote self-care among older adults with asthma: randomized controlled trial. Journal of Advanced Nursing. 2009; 65(2):348-358

718 Hublet A, Andersen A, Godeau E, Vereecken C, Valimaa R, Tynjala J et al. Asthma and wheezing symptoms in young people in six Western countries. Revue D'Epidemiologie Et De Sante Publique. 2006; 54(4):305-312

719 Huertas AJ, Lopez-Saez MP, Carnes J. Clinical profile of a Mediterranean population sensitised to date palm pollen (Phoenix dactylifera). A retrospective study. Allergologia Et Immunopathologia. 2011; 39(3):145-149

720 Hunger T, Rzehak P, Wichmann HE, Heinrich J. Prognostic values of specific respiratory sounds for asthma in adolescents. European Journal of Pediatrics. 2010; 169(1):39-46

721 Hunter CJ, Brightling CE, Woltmann G, Wardlaw AJ, Pavord ID. A comparison of the validity of different diagnostic tests in adults with asthma. Chest. 2002; 121(4):1051-1057

722 Hur G, Moon J, Kim H, Ha E, Lee K, Jung K et al. The effectiveness of mannitol challenge test for diagnosis of bronchial asthma. American Journal of Respiratory and Critical Care Medicine. 2010; 181(1 MeetingAbstracts)

723 Hur GY, Koh DH, Choi GS, Park HJ, Choi SJ, Ye YM et al. Clinical and immunologic findings of methylene diphenyl diisocyanate-induced occupational asthma in a car upholstery factory. Clinical and Experimental Allergy. 2008; 38(4):586-593

724 Hur G-Y, Moon J-Y, Kim H-O, Lee K-J, Lee S-Y, Shim J-J et al. Comparison of methacholine and mannitol challenge test for diagnosis of bronchial asthma. Respirology. 2009; 14:A137

725 Hussein A. The incidence of analgesics intolerance in asthmatic children detected by history and inhalation challenge with lysine acetylsalicylate. Klinische Padiatrie. 1989; 201(1):1-5

726 Huszar E, Vass G, Vizi E, Csoma Z, Barat E, Molnar Vilagos G et al. Adenosine in exhaled breath condensate in healthy volunteers and in patients with asthma. European Respiratory Journal. 2002; 20(6):1393-1398

727 Hyvarinen MK, Kotaniemi-Syrjanen A, Reijonen TM, Korhonen K, Kiviniemi V, Korppi M. Responses to inhaled bronchodilators in infancy are not linked with asthma in later childhood. Pediatric Pulmonology. 2006; 41(5):420-427

728 Hyvarinen MK, Kotaniemi-Syrjanen A, Reijonen TM, Piippo-Savolainen E, Korppi M. Eosinophil activity in infants hospitalized for wheezing and risk of persistent childhood asthma. Pediatric Allergy and Immunology. 2010; 21(1 Pt 1):96-103

729 Ignacio JM, González P. Educational program on medication auto-control in asthmatic patients withpeak flow [PEF] home-monitoring. Neumosur. 1993; 5(2):33-43

730 Ignacio-Garcia JM, Gonzalez-Santos P. Asthma self-management education program by home monitoring of peak expiratory flow. American Journal of Respiratory and Critical Care Medicine. 1995; 151(2 Pt 1):353-359

731 Iio M, Takenaka K, Narita M, Futamura M, Hamaguchi M, Fukushima K et al. [Development and effectiveness of a tailored education program for caregivers of asthmatic children]. Arerugi. Japan 2014; 63(2):187-203

732 Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C et al. The role of early childhood infectious diseases in the development of asthma up to school age. Allergy and Clinical Immunology International. 2001; 13(3):99-106

733 Illi S, von Mutius E, Lau S, Bergmann R, Niggemann B, Sommerfeld C et al. Early childhood infectious diseases and the development of asthma up to school age: a birth cohort study. BMJ. 2001; 322(7283):390-395

734 Illi S, von Mutius E, Lau S, Nickel R, Gruber C, Niggemann B et al. The natural course of atopic dermatitis from birth to age 7 years and the association with asthma. Journal of Allergy and Clinical Immunology. 2004; 113(5):925-931

735 Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006; 368(9537):763-770

736 Imai C, Yamazaki H, Tanaka Y, Matsunaga M, Numata O, Torigoe K. Ratio of eosinophil cationic protein/eosinophil count as a new marker in children with acute asthma. Pediatrics International. 1999; 41(2):142-146

737 Imbeau SA, Geller M. Dermatophagoides farinae antigen skin test sensitivity in Wisconsin. Annals of Allergy. 1978; 41(5):283-284

738 Inkley SR, Oseasohn RO. A study of illness in a group of Cleveland families. 23. Ventilatory function in young adults a decade after repeated wheezing in childhood. American Review of Respiratory Disease. 1967; 96(3):408-410

739 Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. American Review of Respiratory Disease. 1990; 141(3):640-647

740 Irwin RS, French CT, Smyrnios NA, Curley FJ. Interpretation of positive results of a methacholine inhalation challenge and 1 week of inhaled bronchodilator use in diagnosing and treating cough-variant asthma. Archives of Internal Medicine. 1997; 157(17):1981-1987

741 Ishizuka T, Matsuzaki S, Aoki H, Yatomi M, Kamide Y, Hisada T et al. Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FENO in university students: gender differences in symptoms and FENO. Allergy, Asthma, and Clinical Immunology. 2011; 7(1):15

742 Islam T, Gauderman WJ, Berhane K, McConnell R, Avol E, Peters JM et al. Relationship between air pollution, lung function and asthma in adolescents. Thorax. 2007; 62(11):957-963

743 Iversen L, Hannaford PC, Price DB, Godden DJ. Is living in a rural area good for your respiratory health? Results from a cross-sectional study in Scotland. Chest. 2005; 128(4):2059-2067

744 Iwamoto I, Yamazaki H, Kimura A, Ochiai K, Tomioka H, Yoshida S. Comparison of a multi-allergen dipstick IgE assay to skin-prick test and RAST. Clinical and Experimental Allergy. 1990; 20(2):175-179

745 Jaakkola MS, Ieromnimon A, Jaakkola JJK. Are atopy and specific IgE to mites and molds important for adult asthma? Journal of Allergy and Clinical Immunology. 2006; 117(3):642-648

746 Jackola DR, Blumenthal MN, Rosenberg A. Evidence for two independent distributions of serum immunoglobulin E in atopic families: cognate and non-cognate IgE. Human Immunology. 2004; 65(1):20-30

747 Jackson DJ, Gangnon RE, Evans MD, Roberg KA, Anderson EL, Pappas TE et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. American Journal of Respiratory and Critical Care Medicine. 2008; 178(7):667-672

748 Jacobs JH, Fuertes E, Krop EJM, Spithoven J, Tromp P, Heederik DJJ. Swimming pool attendance and respiratory symptoms and allergies among Dutch children. Occupational and Environmental Medicine. 2012; 69(11):823-830

749 Jain P, Kavuru MS, Emerman CL, Ahmad M. Utility of peak expiratory flow monitoring. Chest. 1998; 114(3):861-876

750 Jain VV, Abejie B, Bashir MH, Tyner T, Vempilly J. Lung volume abnormalities and its correlation to spirometric and demographic variables in adult asthma. Journal of Asthma. 2013; 50(6):600-605

751 James A, Lougheed D, Pearce-Pinto G, Ryan G, Musk B. Maximal airway narrowing in a general population. American Review of Respiratory Disease. 1992; 146(4):895-899

752 James A, Ryan G. Testing airway responsiveness using inhaled methacholine or histamine. Respirology. 1997; 2(2):97-105

753 James AL, Knuiman MW, Divitini ML, Hui J, Hunter M, Palmer LJ et al. Changes in the prevalence of asthma in adults since 1966: the Busselton health study. European Respiratory Journal. 2010; 35(2):273-278

754 James AL, Knuiman MW, Divitini ML, Hui J, Hunter ML, Mulrennan SA et al. Risk factors for respiratory symptoms in adults: The Busselton Health Study. Respirology. 2013; 18(8):1256-1260

755 Jamison JP, McKinley RK. Validity of peak expiratory flow rate variability for the diagnosis of asthma. Clinical Science. 1993; 85(3):367-371

756 Jamrozik E, Knuiman MW, James A, Divitini M, Musk AWB. Risk factors for adult-onset asthma: a 14-year longitudinal study. Respirology. 2009; 14(6):814-821

757 Jan RL, Wang JY, Huang MC, Tseng SM, Su HJ, Liu LF. An internet-based interactive telemonitoring system for improving childhood asthma outcomes in Taiwan. Telemedicine Journal and E-Health. 2007; 13(3):257-268

758 Jang AS, Park JS, Lee JH, Park SW, Kim DJ, Park CS. Autologous serum skin test for autoantibodies is associated with airway hyperresponsiveness in patients with asthma. Respiration. 2007; 74(3):293-296

759 Jang AS, Yeum CH, Choi IS. Nitric oxide metabolites, eosinophils, and eosinophilic cationic protein in patients with asthma: sputum versus blood. Journal of Korean Medical Science. 2003; 18(4):489-493

760 Janson C, Chinn S, Jarvis D, Burney P. Determinants of cough in young adults participating in the European Community Respiratory Health Survey. European Respiratory Journal. 2001; 18(4):647-654

761 Janson C, Chinn S, Jarvis D, Zock JP, Toren K, Burney P et al. Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study. Lancet. 2001; 358(9299):2103-2109

762 Janson SL. Encouraging communication between doctors and patients to improve adherence to asthma medication. ClinicalTrials Gov. 2005;

763 Janson SL, McGrath KW, Covington JK, Baron RB, Lazarus SC. Objective airway monitoring improves asthma control in the cold and flu season: a cluster randomized trial. Chest. 2010; 138(5):1148-1155

764 Janson-Bjerklie S, Shnell S. Effect of peak flow informatioin on patterns of self-care in adult asthma. Heart and Lung: Journal of Critical Care. 1988; 17(5):543-549

765 Jares EJ, Baena-Cagnani CE, Gomez RM. Diagnosis of occupational asthma: an update. Current Allergy and Asthma Reports. 2012; 12(3):221-231

766 Jartti T, Lee WM, Pappas T, Evans M, Lemanske RFJ, Gern JE. Serial viral infections in infants with recurrent respiratory illnesses. European Respiratory Journal. 2008; 32(2):314-320

767 Jarvis D, Chinn S, Luczynska C, Burney P. Association of respiratory symptoms and lung function in young adults with use of domestic gas appliances. Lancet. 1996; 347(8999):426-431

768 Jarvis D, Chinn S, Potts J, Burney P, European Community. Association of body mass index with respiratory symptoms and atopy: results from the European Community Respiratory Health Survey. Clinical and Experimental Allergy. 2002; 32(6):831-837

769 Jarvis D, Lai E, Luczynska C, Chinn S, Burney P. Prevalence of asthma and asthma-like symptoms in young adults living in three east Anglian towns. British Journal of General Practice. 1994; 44(388):493-497

770 Jatakanon A, Lim S, Kharitonov SA, Chung KF, Barnes PJ. Correlation between exhaled nitric oxide, sputum eosinophils, and methacholine responsiveness in patients with mild asthma. Thorax. 1998; 53(2):91-95

771 Jeffs D, Grainger R, Powell P. Is childhood allergy more common amongst an island population? Journal of the Royal Society for the Promotion of Health. 2000; 120(4):236-241

772 Jenkins MA, Clarke JR, Carlin JB, Robertson CF, Hopper JL, Dalton MF et al. Validation of questionnaire and bronchial hyperresponsiveness against respiratory physician assessment in the diagnosis of asthma. International Journal of Epidemiology. 1996; 25(3):609-616

773 Jenkins MA, Dharmage SC, Flander LB, Douglass JA, Ugoni AM, Carlin JB et al. Parity and decreased use of oral contraceptives as predictors of asthma in young women. Clinical and Experimental Allergy. 2006; 36(5):609-613

774 Jenkins MA, Hopper JL, Bowes G, Carlin JB, Flander LB, Giles GG. Factors in childhood as predictors of asthma in adult life. BMJ. 1994; 309(6947):90-93

775 Jentzsch NS, le Bourgeois M, de Blic J, Scheinmann P, Waernessyckle S, Camargos PAM. Nitric oxide in children with persistent asthma. Jornal De Pediatria. 2006; 82(3):193-196

776 Jerzynska J, Majak P, Janas A, Stelmach R, Stelmach W, Smejda K et al. Predictive value of fractional nitric oxide in asthma diagnosis-subgroup analyses. Nitric Oxide. 2014; 40:87-91

777 Jia CE, Zhang HP, Lv Y, Liang R, Jiang YQ, Powell H et al. The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysis. Journal of Allergy and Clinical Immunology. 2013; 131(3):695-703

778 Jindal SK, Aggarwal AN, Gupta D. Diurnal variability of peak expiratory flow. Journal of Asthma. 2002; 39(5):363-373

779 Johnson KT, Funahashi A. Clinical characteristics and methacholine sensitivity in patients with suspected bronchial asthma. Wisconsin Medical Journal. 1987; 86(4):17-19

780 Johnson L, Shah I, Loh AX, Vinall LE, Teixeira AS, Rousseau K et al. MUC5AC and inflammatory mediators associated with respiratory outcomes in the British 1946 birth cohort. Respirology. 2013; 18(6):1003-1010

781 Johnston ID, Strachan DP, Anderson HR. Effect of pneumonia and whooping cough in childhood on adult lung function. New England Journal of Medicine. 1998; 338(9):581-587

782 Jones A. Asymptomatic bronchial hyperreactivity and the development of asthma and other respiratory tract illnesses in children. Thorax. 1994; 49(8):757-761

783 Jones A, Bowen M. Screening for childhood asthma using an exercise test. British Journal of General Practice. 1994; 44(380):127-131

784 Jones KP, Mullee MA, Middleton M, Chapman E, Holgate ST. Peak flow based asthma self-management: a randomised controlled study in general practice. Thorax. 1995; 50(8):851-857

785 Jones R, Lin S, Munsie JP, Radigan M, Hwang SA. Racial/ethnic differences in asthma-related emergency department visits and hospitalizations among children with wheeze in Buffalo, New York. Journal of Asthma. 2008; 45(10):916-922

786 Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B et al. Indirect airway challenges. European Respiratory Journal. 2003; 21(6):1050-1068

787 Joos GF. Bronchial hyperresponsiveness: too complex to be useful? Current Opinion in Pharmacology. 2003; 3(3):233-238

788 Joseph CL, Foxman B, Leickly FE, Peterson E, Ownby D. Prevalence of possible undiagnosed asthma and associated morbidity among urban schoolchildren. Journal of Pediatrics. 1996; 129(5):735-742

789 Joseph CL, Foxman B, Leickly FE, Peterson E, Ownby D. Sensitivity and specificity of asthma definitions and symptoms used in a survey of childhood asthma. Journal of Asthma. 1999; 36(7):565-573

790 Joseph J, Escobar A, Bashir M, Claes D. Abnormal RV/TLC ratio is a better criterion to diagnose obstruction in patients with asthma. Chest. 2011; 140(4 Meeting Abstracts):226A

791 Joseph-Bowen J, de Klerk NH, Firth MJ, Kendall GE, Holt PG, Sly PD. Lung function, bronchial responsiveness, and asthma in a community cohort of 6-year-old children. American Journal of Respiratory and Critical Care Medicine. 2004; 169(7):850-854

792 Juhn YJ, Weaver A, Katusic S, Yunginger J. Mode of delivery at birth and development of asthma: a population-based cohort study. Journal of Allergy and Clinical Immunology. 2005; 116(3):510-516

793 Julia JC, Martorell A, Ventas P, Cerda JC, Torro I, Carreira J et al. Lepidoglyphus destructor acarus in the urban house environment. Journal of Investigational Allergology and Clinical Immunology. 1995; 5(6):318-321

794 Jung KH, Hsu SI, Yan B, Moors K, Chillrud SN, Ross J et al. Childhood exposure to fine particulate matter and black carbon and the development of new wheeze between ages 5 and 7 in an urban prospective cohort. Environment International. 2012; 45:44-50

795 Jung KH, Yan B, Moors K, Chillrud SN, Perzanowski MS, Whyatt RM et al. Repeated exposure to polycyclic aromatic hydrocarbons and asthma: effect of seroatopy. Annals of Allergy, Asthma and Immunology. 2012; 109(4):249-254

796 Jung YG, Kim KH, Kim HY, Dhong HJ, Chung SK. Predictive capabilities of serum eosinophil cationic protein, percentage of eosinophils and total immunoglobulin E in allergic rhinitis without bronchial asthma. Journal of International Medical Research. 2011; 39(6):2209-2216

797 Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest. 1999; 115(5):1265-1270

798 Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. European Respiratory Journal. 2010; 36(6):1410-1416

799 Juniper EF, Guyatt GH, Cox FM, Ferrie PJ, King DR. Development and validation of the Mini Asthma Quality of Life Questionnaire. European Respiratory Journal. 1999; 14(1):32-38

800 Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Quality of Life Research. 1996; 5(1):35-46

801 Juniper EF, Guyatt GH, Feeny DH, Griffith LE, Ferrie PJ. Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties. European Respiratory Journal. 1997; 10(10):2285-2294

802 Juniper EF, Guyatt GH, Ferrie PJ, Griffith LE. Measuring quality of life in asthma. American Review of Respiratory Disease. 1993; 147(4):832-838

803 Juniper EF, Norman GR, Cox FM, Roberts JN. Comparison of the standard gamble, rating scale, AQLQ and SF-36 for measuring quality of life in asthma. European Respiratory Journal. 2001; 18(1):38-44

804 Juniper EF, O'Byrne PM, Ferrie PJ, King DR, Roberts JN. Measuring asthma control. Clinic questionnaire or daily diary? American Journal of Respiratory and Critical Care Medicine. 2000; 162(4 Pt 1):1330-1334

805 Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. European Respiratory Journal. 1999; 14(4):902-907

806 Juniper EF, O'Byrne PM, Roberts JN. Measuring asthma control in group studies: do we need airway calibre and rescue beta2-agonist use? Respiratory Medicine. 2001; 95(5):319-323

807 Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respiratory Medicine. 2005; 99(5):553-558

808 Juniper EF, Svensson K, Mork AC, Stahl E. Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health and Quality of Life Outcomes. 2005; 3:58

809 Just J, Belfar S, Wanin S, Pribil C, Grimfeld A, Duru G. Impact of innate and environmental factors on wheezing persistence during childhood. Journal of Asthma. 2010; 47(4):412-416

810 Just J, Saint-Pierre P, Gouvis-Echraghi R, Boutin B, Panayotopoulos V, Chebahi N et al. Wheeze phenotypes in young children have different courses during the preschool period. Annals of Allergy, Asthma and Immunology. 2013; 111(4):256-261

811 Kabesch M, Hoefler C, Carr D, Leupold W, Weiland SK, von Mutius E. Glutathione S transferase deficiency and passive smoking increase childhood asthma. Thorax. 2004; 59(7):569-573

812 Kabir Z, Manning PJ, Holohan J, Keogan S, Goodman PG, Clancy L. Second-hand smoke exposure in cars and respiratory health effects in children. European Respiratory Journal. 2009; 34(3):629-633

813 Kable S, Henry R, Sanson-Fisher R, Ireland M, Corkrey R, Cockburn J. Childhood asthma: can computers aid detection in general practice? British Journal of General Practice. 2001; 51(463):112-116

814 Kagen Z, Ledbetter J, Hamm J, Wilson E. The pediatric diagnostic conundrum of chronic respiratory symptoms. Journal of Allergy and Clinical Immunology. 2014; 68(2 Suppl.1):AB179

815 Kalyoncu AF, Coplu L, Selcuk ZT, Emri AS, Kolacan B, Kocabas A et al. Survey of the allergic status of patients with bronchial asthma in Turkey: A multicenter study. Allergy. 1995; 50(5):451-455

816 Kanazawa H, Asai K, Hirata K, Yoshikawa J. Vascular involvement in exercise-induced airway narrowing in patients with bronchial asthma. Chest. 2002; 122(1):166-170

817 Kanazawa H, Nomura S, Yoshikawa J. Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. American Journal of Respiratory and Critical Care Medicine. 2004; 169(10):1125-1130

818 Kang H, Koh YY, Yoo Y, Yu J, Kim DK, Kim CK. Maximal airway response to methacholine in cough-variant asthma: comparison with classic asthma and its relationship to peak expiratory flow variability. Chest. 2005; 128(6):3881-3887

819 Kannisto S, Vanninen E, Korppi M. Evaluation of the interrupter technique in measuring post-exercise bronchodilator responses in children. Clinical Physiology. 2000; 20(1):62-68

820 Kappelle L, Brand PLP. Severe episodic viral wheeze in preschool children: High risk of asthma at age 5-10years. European Journal of Pediatrics. 2012; 171(6):947-954

821 Karadag B, Ege MJ, Scheynius A, Waser M, Van Hage M, Pershagen G et al. Environmental determinants of atopic eczema phenotypes in relation to asthma and atopic sensitization. Allergy. 2007; 62(12):1387-1393

822 Karakaya G, Demir AU, Kalyoncu AF. From analgesic intolerance to analgesic induced asthma: are there some determinants? Allergologia Et Immunopathologia. 2000; 28(4):229-237

823 Karakaya G, Kalyoncu AF. The natural course of atopy determined by skin prick tests in patients with bronchial asthma and/or rhinitis. Allergologia Et Immunopathologia. 2006; 34(6):257-262

824 Karakaya G, Ozturk AB, Kalyoncu AF. Prediction of atopy by skin prick tests in patients with asthma and/or persistent rhinitis. Allergologia Et Immunopathologia. 2012; 40(1):37-40

825 Karakoc F, Remes ST, Martinez FD, Wright AL. The association between persistent eosinophilia and asthma in childhood is independent of atopic status. Clinical and Experimental Allergy. 2002; 32(1):51-56

826 Kartasamita CB, Rosmayudi O, Demedts M. Total serum IgE and eosinophil count in children with and without a history of asthma, wheezing, or atopy in an urban community in Indonesia. The Respiratory Disease Working Group. Journal of Allergy and Clinical Immunology. 1994; 94(6 Pt 1):981-988

827 Karvala K, Toskala E, Luukkonen R, Lappalainen S, Uitti J, Nordman H. New-onset adult asthma in relation to damp and moldy workplaces. International Archives of Occupational and Environmental Health. 2010; 83(8):855-865

828 Katsoulis K, Ganavias L, Michailopoulos P, Bikas C, Dinapogias E, Kontakiotis T et al. Exhaled nitric oxide as screening tool in subjects with suspected asthma without reversibility. International Archives of Allergy and Immunology. 2013; 162(1):58-64

829 Katz PP, Eisner MD, Henke J, Shiboski S, Yelin EH, Blanc PD. The Marks Asthma Quality of Life Questionnaire: further validation and examination of responsiveness to change. Journal of Clinical Epidemiology. 1999; 52(7):667-675

830 Kauffmann F, Annesi I, Chwalow J. Validity of subjective assessment of changes in respiratory health status: A 30 year epidemiological study of workers in Paris. European Respiratory Journal. 1997; 10(11):2508-2514

831 Kauffmann F, Varraso R. The epidemiology of cough. Pulmonary Pharmacology and Therapeutics. 2011; 24(3):289-294

832 Kaufman HS, Kelly PT, Modin GW. Antigen recognition in Chinese and Caucasians. Annals of Allergy. 1984; 53(2):135-137

833 Kaugars AS, Klinnert MD, Robinson J, Ho M. Reciprocal influences in children's and families' adaptation to early childhood wheezing. Health Psychology. 2008; 27(2):258-267

834 Kavut AB, Kalpakloglu AF. Impact of asthma education meeting on asthma control level assessed by asthma control test. World Allergy Organization Journal. 2010; 3(1):6-8

835 Kaya Z, Erkan F, Ozkan M, Ozkan S, Kocaman N, Ertekin BA et al. Self-management plans for asthma control and predictors of patient compliance. Journal of Asthma. 2009; 46(3):270-275

836 Kayhan S, Tutar U, Cinarka H, Gumus A, Koksal N. Prevalence of occupational asthma and respiratory symptoms in foundry workers. Pulmonary Medicine. 2013; 2013:370138

837 Keall MD, Crane J, Baker MG, Wickens K, Howden-Chapman P, Cunningham M. A measure for quantifying the impact of housing quality on respiratory health: a cross-sectional study. Environmental Health. 2012; 11:33

838 Kearney PM, Kearney PJ. The prevalence of asthma in schoolboys of travellers' families. Irish Medical Journal. 1998; 91(6):203-206

839 Keen C, Olin AC, Wennergren G, Gustafsson P. Small airway function, exhaled NO and airway hyper-responsiveness in paediatric asthma. Respiratory Medicine. 2011; 105(10):1476-1484

840 Keil T, Kulig M, Simpson A, Custovic A, Wickman M, Kull I et al. European birth cohort studies on asthma and atopic diseases: II. Comparison of outcomes and exposures - A GA2LEN initiative. Allergy. 2006; 61(9):1104-1111

841 Keil U, Weiland SK, Duhme H, Chambless L. The International Study of Asthma and Allergies in Childhood (ISAAC): objectives and methods; results from German ISAAC centres concerning traffic density and wheezing and allergic rhinitis. Toxicology Letters. 1996; 86(2-3):99-103

842 Kelly WJ, Hudson I, Phelan PD, Pain MC, Olinsky A. Childhood asthma in adult life: a further study at 28 years of age. BMJ. 1987; 294(6579):1059-1062

843 Kelly YJ, Brabin BJ, Milligan P, Heaf DP, Reid J, Pearson MG. Maternal asthma, premature birth, and the risk of respiratory morbidity in schoolchildren in Merseyside. Thorax. 1995; 50(5):525-530

844 Kelly YJ, Brabin BJ, Milligan PJ, Reid JA, Heaf D, Pearson MG. Clinical significance of cough and wheeze in the diagnosis of asthma. Archives of Disease in Childhood. 1996; 75(6):489-493

845 Kelso JM. Peak flow monitoring for guided self-management in childhood asthma: A randomized controlled trial. Pediatrics. 2005; 116(2):558-559

846 Kelso JM, Sodhi N, Gosselin VA, Yunginger JW. Diagnostic performance characteristics of the standard Phadebas RAST, modified RAST, and pharmacia CAP system versus skin testing. Annals of Allergy. 1991; 67(5):511-514

847 Kemple T, Rogers C. A mailed personalised self-management plan improves attendance and increases patients' understanding of asthma. Primary Care Respiratory Journal. 2003; 12(4):110-114

848 Kercsmar CM. Chronic cough in children: Pursuing specific causes. Journal of Respiratory Diseases. 1996; 17(6):484-493

849 Kercsmar CM. Meeting the challenges of asthma: Conference summary. Respiratory Care. 2008; 53(6):787-795

850 Kerkhof M, Dubois AEJ, Postma DS, Schouten JP, De Monchy JGR. Role and interpretation of total serum IgE measurements in the diagnosis of allergic airway disease in adults. Allergy. 2003; 58(9):905-911

851 Kerkhof M, Wijga AH, Brunekreef B, Smit HA, De Jongste JC, Aalberse RC et al. Effects of pets on asthma development up to 8 years of age: the PIAMA study. Allergy. 2009; 64(8):1202-1208

852 Kersten ETG, Driessen JMM, van der Berg JD, Thio BJ. Mannitol and exercise challenge tests in asthmatic children. Pediatric Pulmonology. 2009; 44(7):655-661

853 Kesten S, Rebuck AS. Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD? Chest. 1994; 105(4):1042-1045

854 Khadadah M, Onadeko BO, Ezeamuzie CI, Mustafa HT, Marouf R, Sugathan TN. The association of skin test reactivity, total serum IgE levels, and peripheral blood eosinophilia with asthma in Kuwait. Journal of Asthma. 2000; 37(6):481-488

855 Khadadah ME, Onadeko BO, Ezeamuzie CI, Maroof R, Mustafa HS, Sugathan TN. Studies of the relationship between allergen-specific IgE antibodies and skin test reactivity in patients with asthma in Kuwait. Medical Principles and Practice. 2000; 9(4):260-267

856 Khakzad MR, Mirsadraee M, Sankian M, Varasteh A, Meshkat M. Is serum or sputum eosinophil cationic protein level adequate for diagnosis of mild asthma? Iranian Journal of Allergy, Asthma and Immunology. 2009; 8(3):155-160

857 Khalid I, Morris ZQ, Digiovine B. Specific conductance criteria for a positive methacholine challenge test: are the American Thoracic Society guidelines rather generous? Respiratory Care. 2009; 54(9):1168-1174

858 Khan MSR, O'Meara M, Stevermuer TL, Henry RL. Randomized controlled trial of asthma education after discharge from an emergency department. Journal of Paediatrics and Child Health. 2004; 40(12):674-677

859 Kharitonov SA, Gonio F, Kelly C, Meah S, Barnes PJ. Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children. European Respiratory Journal. 2003; 21(3):433-438

860 Kharitonov SA, Yates DH, Chung KF, Barnes PJ. Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. European Respiratory Journal. 1996; 9(2):196-201

861 Kheir NM, Emmerton L, Shaw JP. Assessing the responsiveness of the Asthma Quality of Life Questionnaire with pharmaceutical care. Pharmacy World and Science. 2008; 30(4):322-328

862 Khoo KT, Connolly CK. A comparison of three methods of measuring broncholability in asthmatics, bronchitic cigarette smokers and normal subjects. Respiration. 1984; 45(3):219-224

863 Khoshoo V, Edell D, Mohnot S, Haydel RJ, Saturno E, Kobernick A. Associated factors in children with chronic cough. Chest. 2009; 136(3):811-815

864 Kiefte-de Jong JC, de Vries JH, Franco OH, Jaddoe VWV, Hofman A, Raat H et al. Fish consumption in infancy and asthma-like symptoms at preschool age. Pediatrics. 2012; 130(6):1060-1068

865 Kielbasa B, Moeller A, Sanak M, Hamacher J, Hutterli M, Cmiel A et al. Eicosanoids in exhaled breath condensates in the assessment of childhood asthma. Pediatric Allergy and Immunology. 2008; 19(7):660-669

866 Kilpelainen M, Terho EO, Helenius H, Koskenvuo M. Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. Allergy. 2001; 56(5):377-384

867 Kim HY, Shin YH, Yum HY, Jee HM, Jang SJ, Yoon JW et al. Patterns of sensitisation to common food and inhalant allergens and allergic symptoms in pre-school children. Journal of Paediatrics and Child Health. 2013; 49(4):272-277

868 Kim KT, Safadi GS, Sheikh KM. Diagnostic evaluation of type I latex allergy. Annals of Allergy, Asthma and Immunology. 1998; 80(1):66-70

869 Kim M-H, Song W-J, Kim T-W, Jin H-J, Sin Y-S, Ye Y-M et al. Diagnostic properties of the methacholine and mannitol bronchial challenge tests: A comparison study. Respirology. 2014; 19(6):852-856

870 Kim TB, Oh YM, Chang YS, Cho YS, Jang AS, Cho SH et al. The reality of an intermediate type between asthma and COPD in practice. Respiratory Care. 2012; 57(8):1248-1253

871 Kim YH, Kim MJ, Lee HS, Han YK, Park YA, Kim K-E et al. Extended nitric oxide analysis and bronchial hyperresponsiveness in children with asthma according to atopy. Journal of Allergy and Clinical Immunology. 2014; 133(2 SUPPL. 1):AB84

872 Kim YK, Kim SH, Tak YJ, Jee YK, Lee BJ, Kim SH et al. High prevalence of current asthma and active smoking effect among the elderly. Clinical and Experimental Allergy. 2002; 32(12):1706-1712

873 Kim YY, Cho SH, Kim WK, Park JK, Song SH, Kim YK et al. Prevalence of childhood asthma based on questionnaires and methacholine bronchial provocation test in Korea. Clinical and Experimental Allergy. 1997; 27(7):761-768

874 Kim YH, Kim KW, Baek J, Park HB, Kim H, Song KJ et al. Usefulness of impulse oscillometry and fractional exhaled nitric oxide in children with Eosinophilic bronchitis. Pediatric Pulmonology. 2013; 48(3):221-228

875 King D. Asthma diagnosis by spirometry. Sensitive or specific? Australian Family Physician. 1998; 27(3):183-185

876 King DK, Thompson BT, Johnson DC. Wheezing on maximal forced exhalation in the diagnosis of atypical asthma. Lack of sensitivity and specificity. Annals of Internal Medicine. 1989; 110(6):451-455

877 King MJ, Bukantz SC, Phillips S, Mohapatra SS, Tamulis T, Lockey RF. Serum total IgE and specific IgE to Dermatophagoides pteronyssinus, but not eosinophil cationic protein, are more likely to be elevated in elderly asthmatic patients. Allergy and Asthma Proceedings. 2004; 25(5):321-325

878 Kiss D, Veegh W, Schragel D, Bachl C, Stollberger C, Sertl K. Bronchial asthma causing symptoms suggestive of angina pectoris. European Respiratory Journal. 2003; 21(3):473-477

879 Kitani H, Kajimoto K, Sugimoto K, Mifune T, Mitsunobu F, Yokota S et al. IgE-mediated allergic reaction in drug-induced asthma. Acta Medica Okayama. 1993; 47(5):317-321

880 Kivastik J, Gibson AM, Primhak RA. Methacholine challenge in pre-school children--which outcome measure? Respiratory Medicine. 2007; 101(12):2555-2560

881 Kiviloog J. The correlation between exercise-induced bronchoconstriction and bronchial methacholine sensitivity in asthma. Pediatrics. 1975; 56(5 pt-2 suppl):908-909

882 Kjaer HF, Eller E, Bindslev-Jensen C, Host A. Spirometry in an unselected group of 6-year-old children: the DARC birth cohort study. Pediatric Pulmonology. 2008; 43(8):806-814

883 Kjaer HF, Eller E, Host A, Andersen KE, Bindslev-Jensen C. The prevalence of allergic diseases in an unselected group of 6-year-old children. The DARC birth cohort study. Pediatric Allergy and Immunology. 2008; 19(8):737-745

884 Klaassen EMM, van de Kant KDG, Jobsis Q, Hovig STP, van Schayck CP, Rijkers GT et al. Symptoms, but not a biomarker response to inhaled corticosteroids, predict asthma in preschool children with recurrent wheeze. Mediators of Inflammation. 2012; 2012:162571

885 Klein JJ, van der Palen J, Uil SM, Zielhuis GA, Seydel ER, van Herwaarden CL. Benefit from the inclusion of self-treatment guidelines to a self-management programme for adults with asthma. European Respiratory Journal. 2001; 17(3):386-394

886 Kleis S, Chanez P, Delvaux M, Louis R. Perception of dyspnea in mild smoking asthmatics. Respiratory Medicine. 2007; 101(7):1426-1430

887 Klepac-Pulanic T, Macan J, Plavec D, Kanceljak-Macan B. Exercise and allergic diseases. Archives of Industrial Hygiene and Toxicology. 2004; 55(2-3):197-204

888 Klinkanova M, Lyutskanova T, Ivancheva D, Genkova N, Lyutakova E. Increased IgE--diagnostic value of the index in children with bronchial obstruction. Folia Medica. 1995; 37(4A Suppl):54

889 Klinnert MD, Nelson HS, Price MR, Adinoff AD, Leung DY, Mrazek DA. Onset and persistence of childhood asthma: predictors from infancy. Pediatrics. 2001; 108(4):E69

890 Klinnert MD, Kaugars AS, Strand M, Silveira L. Family psychological factors in relation to children's asthma status and behavioral adjustment at age 4. Family Process. 2008; 47(1):41-61

891 Kljakovic M. The change in prevalence of wheeze in seven year old children over 19 years. New Zealand Medical Journal. 1991; 104(919):378-380

892 Kneyber MCJ, Steyerberg EW, de Groot R, Moll HA. Long-term effects of respiratory syncytial virus (RSV) bronchiolitis in infants and young children: a quantitative review. Acta Paediatrica. 2000; 89(6):654-660

893 Knox AJ, Coleman HE, Britton JR, Tattersfield AE. A comparison of three measures of the response to inhaled methacholine. European Respiratory Journal. 1989; 2(8):736-740

894 Ko FWS, Leung TF, Hui DSC, Chu HY, Wong GWK, Wong E et al. Asthma Control Test correlates well with the treatment decisions made by asthma specialists. Respirology. 2009; 14(4):559-566

895 Koenig SM, Murray JJ, Wolfe J, Andersen L, Yancey S, Prillaman B et al. Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma? Respiratory Medicine. 2008; 102(5):665-673

896 Koh YY, Jeong JH, Jin SM, Kim CK, Min KU. The occurrence of late asthmatic response to exercise after allergen challenge. Annals of Allergy, Asthma and Immunology. 1998; 81(4):366-372

897 Koh YY, Lim HS, Min KU, Kim YY. Maximal airway narrowing on the dose-response curve to methacholine is increased after exercise-induced bronchoconstriction. Journal of Asthma. 1996; 33(1):55-65

898 Koh YY, Kang H, Yoo Y, Yu J, Nah KM, Kim CK. Peak expiratory flow variability and exercise responsiveness in methacholine-hyperresponsive adolescents with asthma remission. Journal of Asthma. 2005; 42(1):17-23

899 Koivikko A, Viander M, Lanner A. Use of the extended Phadebas RAST panel in the diagnosis of mould allergy in asthmatic children. Allergy. 1991; 46(2):85-91

900 Kokubu F, Nakajima S, Ito K, Makino S, Kitamura S, Fukuchi Y et al. [Hospitalization reduction by an asthma tele-medicine system]. Arerugi. 2000; 49(1):19-31

901 Kokubu F, Suzuki H, Sano Y, Kihara N, Adachi M. [Tele-medicine system for high-risk asthmatic patients]. Arerugi. 1999; 48(7):700-712

902 Kolbe J, Richards G, Mercer-Fenwick J, Rea H. Relationship of non-specific airway hyperresponsiveness (AHR) to measures of peak expiratory flow (PEF) variability. Australian and New Zealand Journal of Medicine. 1996; 26(1):59-65

903 Koller DY, Wojnarowski C, Herkner KR, Weinlander G, Raderer M, Eichler I et al. High levels of eosinophil cationic protein in wheezing infants predict the development of asthma. Journal of Allergy and Clinical Immunology. 1997; 99(6 Pt 1):752-756

904 Kolnaar BG, Janssen JL, Folgering H, van den Hoogen HJ, Van Weel C. The relationship between respiratory symptoms and bronchial hyperresponsiveness in a population-based sample of adolescents and young adults. Respiratory Medicine. 1995; 89(2):93-100

905 Komakula S, Khatri S, Mermis J, Savill S, Haque S, Rojas M et al. Body mass index is associated with reduced exhaled nitric oxide and higher exhaled 8-isoprostanes in asthmatics. Respiratory Research. 2007; 8:32

906 Komarow HD, Skinner J, Young M, Gaskins D, Nelson C, Gergen PJ et al. A study of the use of impulse oscillometry in the evaluation of children with asthma: analysis of lung parameters, order effect, and utility compared with spirometry. Pediatric Pulmonology. 2012; 47(1):18-26

907 Konderak J, Pinter E, Witos Y, Balo Banga JM. Large scale serum IgE determination from various patients with suspicion of allergy within one year covering Hungary. Allergy. 2013; 68:573-574

908 Kondo R, Haniuda M, Yamanda T, Sato E, Fujimoto K, Kubo K et al. Effects of expiratory pressure on nitric oxide in exhaled breath. Is exhaled nitric oxide really unaffected by pressure? Respiratory Physiology and Neurobiology. 2003; 139(1):33-40

909 Kongerud J, Soyseth V, Burge S. Serial measurements of peak expiratory flow and responsiveness to methacholine in the diagnosis of aluminium potroom asthma. Thorax. 1992; 47(4):292-297

910 Konstantinou G, Xepapadaki P, Manousakis E, Makrinioti C, Kouloufakou-Gratsia K, Kafetzis D et al. Episodic viral wheeze in preschool children: Is it asthma? Allergy. 2010; 65:16

911 Koponen P, Helminen M, Paassilta M, Luukkaala T, Korppi M. Preschool asthma after bronchiolitis in infancy. European Respiratory Journal. 2012; 39(1):76-80

912 Korol D, Tobolczyk J, Hofman J. Differentiation of IgE-dependent and IgE-independent reactions in children with bronchial asthma on the basis of TOP CAST Paediatric Allergen Mix test. Advances in Medical Sciences. 2006; 51:232-236

913 Koshy G, Delpisheh A, Brabin BJ. Trends in prevalence of childhood and parental asthma in Merseyside, 1991-2006. Journal of Public Health. 2010; 32(4):488-495

914 Koskela HO, Purokivi MK, Kontra KM, Taivainen AH, Tukiainen HO. Hypertonic saline cough provocation test with salbutamol pre-treatment: evidence for sensorineural dysfunction in asthma. Clinical and Experimental Allergy. 2008; 38(7):1100-1107

915 Koskela HO, Hyvarinen L, Brannan JD, Chan HK, Anderson SD. Responsiveness to three bronchial provocation tests in patients with asthma. Chest. 2003; 124(6):2171-2177

916 Kostikas K, Papaioannou AI, Tanou K, Koutsokera A, Papala M, Gourgoulianis KI. Portable exhaled nitric oxide as a screening tool for asthma in young adults during pollen season. Chest. 2008; 133(4):906-913

917 Kotaniemi-Syrjanen A, Reijonen TM, Korhonen K, Korppi M. Wheezing requiring hospitalization in early childhood: predictive factors for asthma in a six-year follow-up. Pediatric Allergy and Immunology. 2002; 13(6):418-425

918 Kotses H, Stout C, McConnaughy K, Winder JA, Creer TL. Evaluation of individualized asthma self-management programs. Journal of Asthma. 1996; 33(2):113-118

919 Kotses H, Thurber L, Mosby A, McLacklan A, Harver A. Effects of home monitoring on subjective and objective indicators of asthma in pediatric patients: caregivers' perceived symptoms and child peak flow. American Thoracic Society International Conference, May 18-23, 2007, San Francisco, California, USA. 2007;Poster

920 Koutsoupias P, Meng Q, Bielory L. Increased allergy skin test reactivity in asthmatics: Results from the second and third national health and nutrition examination survey (1976-1994). Annals of Allergy, Asthma and Immunology. 2013; 111(5 Suppl.1):A44-A45

921 Kovac K, Dodig S, Tjesic-Drinkovic D, Raos M. Correlation between asthma severity and serum IgE in asthmatic children sensitized to Dermatophagoides pteronyssinus. Archives of Medical Research. 2007; 38(1):99-105

922 Kovesi TA, Dales RE. Effects of the indoor environment on the fraction of exhaled nitric oxide in school-aged children. Canadian Respiratory Journal. 2009; 16(3):e18-e23

923 Kovesi T, Dales R. Exhaled nitric oxide and respiratory symptoms in a community sample of school aged children. Pediatric Pulmonology. 2008; 43(12):1198-1205

924 Kowal K, Bodzenta-Lukaszyk A, Zukowski S. Exhaled nitric oxide in evaluation of young adults with chronic cough. Journal of Asthma. 2009; 46(7):692-698

925 Kozyrskyj AL, Kendall GE, Zubrick SR, Newnham JP, Sly PD. Frequent nocturnal awakening in early life is associated with nonatopic asthma in children. European Respiratory Journal. 2009; 34(6):1288-1295

926 Kozyrskyj AL, Mustard CA, Becker AB. Childhood wheezing syndromes and healthcare data. Pediatric Pulmonology. 2003; 36(2):131-136

927 Kozyrskyj AL, Mustard CA, Becker AB. Identifying children with persistent asthma from health care administrative records. Canadian Respiratory Journal. 2004; 11(2):141-145

928 Kraw M, Tarlo SM. Isocyanate medical surveillance: respiratory referrals from a foam manufacturing plant over a five-year period. American Journal of Industrial Medicine. 1999; 35(1):87-91

929 Krishnan JA, Bender BG, Wamboldt FS, Szefler SJ, Adkinson NFJ, Zeiger RS et al. Adherence to inhaled corticosteroids: an ancillary study of the Childhood Asthma Management Program clinical trial. Journal of Allergy and Clinical Immunology. 2012; 129(1):112-118

930 Kroegel C, Schuler M, Forster M, Braun R, Grahmann PR. Evidence for eosinophil activation in bronchiectasis unrelated to cystic fibrosis and bronchopulmonary aspergillosis: discrepancy

between blood eosinophil counts and serum eosinophil cationic protein levels. Thorax. 1998; 53(6):498-500

931 Kuehni CE, Brooke AM, Silverman M. Prevalence of wheeze during childhood: retrospective and prospective assessment. European Respiratory Journal. 2000; 16(1):81-85

932 Kuehni CE, Davis A, Brooke AM, Silverman M. Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet. 2001; 357(9271):1821-1825

933 Kuehr J, Frischer T, Barth R, Karmaus W, Kruger S, Meinert R et al. Eosinophils and eosinophil cationic protein in children with and without sensitization to inhalant allergens. European Journal of Pediatrics. 1994; 153(10):739-744

934 Kuehr J, Frischer T, Meinert R, Barth R, Schraub S, Urbanek R et al. Sensitization to mite allergens is a risk factor for early and late onset of asthma and for persistence of asthmatic signs in children. Journal of Allergy and Clinical Immunology. 1995; 95(3):655-662

935 Kuethe MC, Vaessen-Verberne Anja APH, Elbers RG, Van Aalderen Wim MC. Nurse versus physician-led care for the management of asthma. Cochrane Database of Systematic Reviews. 2013; Issue 2:CD009296. DOI:10.1002/14651858.CD009296.pub2

936 Kuhni CE, Sennhauser FH. The Yentl syndrome in childhood asthma: risk factors for undertreatment in Swiss children. Pediatric Pulmonology. 1995; 19(3):156-160

937 Kumar DSA, Adepu R, Parthasarathi G, Mahesh PA. Impact of community pharmacist provided patient education in asthma patients on treatment outcomes - A study. Indian Journal of Pharmaceutical Education and Research. 2009; 43(2):125-133

938 Kumar L, Rajput N, Majumdar S. Nitric oxide metabolites in induced sputum: a noninvasive marker of airway inflammation in asthma. Indian Pediatrics. 2005; 42(4):329-337

939 Kumar R. Association of sensitization to food and inhalant allergens in patients of asthma and rhinitis. Clinical and Translational Allergy. 2011; 1

940 Kumar R, Kumari D, Srivastava P, Khare V, Fakhr H, Arora N et al. Identification of IgE-mediated food allergy and allergens in older children and adults with asthma and allergic rhinitis. Indian Journal of Chest Diseases and Allied Sciences. 2010; 52(4):217-224

941 Kumar R, Yu Y, Story RE, Pongracic JA, Gupta R, Pearson C et al. Prematurity, chorioamnionitis, and the development of recurrent wheezing: a prospective birth cohort study. Journal of Allergy and Clinical Immunology. 2008; 121(4):878-884

942 Kumari D, Kumar R, Sridhara S, Arora N, Gaur SN, Singh BP. Sensitization to blackgram in patients with bronchial asthma and rhinitis: clinical evaluation and characterization of allergens. Allergy. 2006; 61(1):104-110

943 Kunzli N, Stutz EZ, Perruchoud AP, Brandli O, Tschopp JM, Bolognini G et al. Peak flow variability in the SAPALDIA study and its validity in screening for asthma-related conditions. The SPALDIA Team. American Journal of Respiratory and Critical Care Medicine. 1999; 160(2):427-434

944 Kurimoto Y, Baba S. Specific IgE estimations by RAST in Japanese asthmatics compared with skin, passive transfer and bronchial provocation tests. Clinical Allergy. 1978; 8(2):175-185

945 Kurukulaaratchy RJ, Fenn M, Matthews S, Arshad SH. Characterisation of atopic and non-atopic wheeze in 10 year old children. Thorax. 2004; 59(7):563-568

946 Kurukulaaratchy RJ, Fenn M, Twiselton R, Matthews S, Arshad SH. The prevalence of asthma and wheezing illnesses amongst 10-year-old schoolchildren. Respiratory Medicine. 2002; 96(3):163-169

947 Kurukulaaratchy RJ, Matthews S, Arshad SH. Defining childhood atopic phenotypes to investigate the association of atopic sensitization with allergic disease. Allergy. 2005; 60(10):1280-1286

948 Kurukulaaratchy RJ, Matthews S, Holgate ST, Arshad SH. Predicting persistent disease among children who wheeze during early life. European Respiratory Journal. 2003; 22(5):767-771

949 Kurukulaaratchy RJ, Matthews S, Arshad SH. Does environment mediate earlier onset of the persistent childhood asthma phenotype? Pediatrics. 2004; 113(2):345-350

950 Kurukulaaratchy RJ, Matthews S, Waterhouse L, Arshad SH. Factors influencing symptom expression in children with bronchial hyperresponsiveness at 10 years of age. Journal of Allergy and Clinical Immunology. 2003; 112(2):311-316

951 Kurukulaaratchy RJ, Waterhouse L, Matthews SM, Arshad SH. Are influences during pregnancy associated with wheezing phenotypes during the first decade of life? Acta Paediatrica. 2005; 94(5):553-558

952 Kwon N, Shim J, Lee Y, Uh S, Jung K, Park S et al. Longitudinal validation of the asthma control test in moderate persistent asthma [Abstract]. Journal of Allergy and Clinical Immunology. 2008; 21(2 Suppl 1):S161

953 La Grutta S, Gagliardo R, Mirabella F, Pajno GB, Bonsignore G, Bousquet J et al. Clinical and biological heterogeneity in children with moderate asthma. American Journal of Respiratory and Critical Care Medicine. 2003; 167(11):1490-1495

954 Labbe A, Aublet-Cuvelier B, Jouaville L, Beaugeon G, Fiani L, Petit I et al. Prospective longitudinal study of urinary eosinophil protein X in children with asthma and chronic cough. Pediatric Pulmonology. 2001; 31(5):354-362

955 Labrecque M, Malo JL, Alaoui KM, Rabhi K. Medical surveillance programme for diisocyanate exposure. Occupational and Environmental Medicine. 2011; 68(4):302-307

956 Labruzzo BA, Edgerton L, Rideout S. What is the preferred treatment for a child with mild persistent asthma? Journal of Family Practice. 2007; 56(2):137-139

957 Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P et al. Randomised comparison of cost effectiveness of guided self management and traditional treatment of asthma in Finland. BMJ. 1998; 316(7138):1138-1139

958 Lahdensuo A, Haahtela T, Herrala J, Kava T, Kiviranta K, Kuusisto P et al. Randomised comparison of guided self management and traditional treatment of asthma over one year. BMJ. 1996; 312(7033):748-752

959 Lai CK, Chan JK, Chan A, Wong G, Ho A, Choy D et al. Comparison of the ISAAC video questionnaire (AVQ3.0) with the ISAAC written questionnaire for estimating asthma associated with bronchial hyperreactivity. Clinical and Experimental Allergy. 1997; 27(5):540-545

960 Lai CKW, Beasley R, Crane J, Foliaki S, Shah J, Weiland S et al. Global variation in the prevalence and severity of asthma symptoms: phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009; 64(6):476-483

961 Lai CL, Shyur SD, Wu CY, Chang CL, Chu SH. Specific IgE to 5 different major house dust mites among asthmatic children. Acta Paediatrica Taiwanica. 2002; 43(5):265-270

962 Lam A. Practice innovations: delivering medication therapy management services via Videoconference interviews. Consultant Pharmacist : the Journal of the American Society of Consultant Pharmacists. 2011; 26(10):764-774

963 Lambert A, Bradley DM, Wei C, McCormack M, Wise R. Accuracy of using FEV1/FVC Z-score thresholds to diagnose asthma. Chest. 2013; 144(4 Meeting Abstract)

964 Lange NE, Rifas-Shiman SL, Camargo CAJ, Gold DR, Gillman MW, Litonjua AA. Maternal dietary pattern during pregnancy is not associated with recurrent wheeze in children. Journal of Allergy and Clinical Immunology. 2010; 126(2):250-254

965 Langley SJ, Goldthorpe S, Custovic A, Woodcock A. Relationship among pulmonary function, bronchial reactivity, and exhaled nitric oxide in a large group of asthmatic patients. Annals of Allergy, Asthma and Immunology. 2003; 91(4):398-404

966 Laprise C, Boulet LP. Asymptomatic airway hyperresponsiveness: a three-year follow-up. American Journal of Respiratory and Critical Care Medicine. 1997; 156(2 Pt 1):403-409

967 Lara A, Khatri SB, Wang Z, Comhair SAA, Xu W, Dweik RA et al. Alterations of the arginine metabolome in asthma. American Journal of Respiratory and Critical Care Medicine. 2008; 178(7):673-681

968 Larsson L, Boethius G. Differences in utilization of asthma drugs between two neighbouring Swedish provinces: Relation to treatment in individuals with airway disease. Journal of Internal Medicine. 1995; 238(4):307-316

969 Larsson L, Boethius G, Uddenfeldt M. Differences in utilisation of asthma drugs between two neighbouring Swedish provinces: relation to prevalence of obstructive airway disease. Thorax. 1994; 49(1):41-49

970 Laske N, Bunikowski R, Niggemann B. Extraordinarily high serum IgE levels and consequences for atopic phenotypes. Annals of Allergy, Asthma and Immunology. 2003; 91(2):202-204

971 Lau S, Illi S, Platts-Mills TAE, Riposo D, Nickel R, Gruber C et al. Longitudinal study on the relationship between cat allergen and endotoxin exposure, sensitization, cat-specific IgG and development of asthma in childhood--report of the German Multicentre Allergy Study (MAS 90). Allergy. 2005; 60(6):766-773

972 Lau S, Illi S, Sommerfeld C, Niggemann B, Bergmann R, von Mutius E et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet. 2000; 356(9239):1392-1397

973 Lau S, Illi S, Sommerfeld C, Niggemann B, Volkel K, Madloch C et al. Transient early wheeze is not associated with impaired lung function in 7-yr-old children. European Respiratory Journal. 2003; 21(5):834-841

974 Lau S, Nickel R, Niggemann B, Gruber C, Sommerfeld C, Illi S et al. The development of childhood asthma: lessons from the German Multicentre Allergy Study (MAS). Paediatric Respiratory Reviews. 2002; 3(3):265-272

975 Laubereau B, Grote V, Holscher G, Holscher B, Frye C, Wichmann HE et al. Vaccination against Haemophilus influenzae type b and atopy in east German schoolchildren. European Journal of Medical Research. 2002; 7(9):387-392

976 Laufenberg-Horstmann E, DeVore E, Bassuener K. The Coulee Region Community Pharmacy Asthma Intervention study. Journal of the American Pharmacists Association. 2006; 46(6):738-7

977 Laurent J, Decoux L, Ickovic MR, Le Gall C, Gacouin JC, Sauvaget J et al. Winter pollinosis in Paris. Allergy. 1994; 49(9):696-701

978 Lawson JA, Dosman JA, Rennie DC, Beach J, Newman SC, Senthilselvan A. Relationship of endotoxin and tobacco smoke exposure to wheeze and diurnal peak expiratory flow variability in children and adolescents. Respirology. 2011; 16(2):332-339

979 Lazo-Velasquez JC, Lozada AR, Cruz HM. Evaluation of severity of bronchial asthma through an bronchial challenge. Pediatric Pulmonology. 2005; 40(5):457-463

980 Le Souef PN, Sears MR, Sherrill D. The effect of size and age of subject on airway responsiveness in children. American Journal of Respiratory and Critical Care Medicine. 1995; 152(2):576-579

981 Lebecque P, Kiakulanda P, Coates AL. Spirometry in the asthmatic child: is FEF25-75 a more sensitive test than FEV1/FVC? Pediatric Pulmonology. 1993; 16(1):19-22

982 Lebowitz MD, Krzyzanowski M, Quackenboss JJ, O'Rourke MK. Diurnal variation of PEF and its use in epidemiological studies. European Respiratory Journal, Supplement. 1997; 24:49S-56S

983 Leckie MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet. 2000; 356(9248):2144-2148

984 Lee J, Yun I, Park H, Cho J, Oh T, Park J et al. Clinical characteristics of airway hyperresponsiveness in allergic airway diseases. Journal of Allergy and Clinical Immunology. 2011; 127(2 Suppl. 1):AB8

985 Lee JH, Lee YW, Shin YS, Jung YH, Hong CS, Park JW. Exercise-induced airway obstruction in young asthmatics measured by impulse oscillometry. Journal of Investigational Allergology and Clinical Immunology. 2010; 20(7):575-581

986 Leermakers ETM, Sonnenschein-van der Voort AMM, Heppe DHM, De Jongste JC, Moll HA, Franco OH et al. Maternal fish consumption during pregnancy and risks of wheezing and eczema in childhood: the Generation R Study. European Journal of Clinical Nutrition. 2013; 67(4):353-359

987 Lefevre F, Piper M, Weiss K, Mark D, Clark N, Aronson N. Do written action plans improve patient outcomes in asthma? An evidence-based analysis. Journal of Family Practice. 2002; 51(10):842-848

988 Lehmann S, Bakke PS, Eide GE, Gulsvik A. Clinical data discriminating between adults with positive and negative results on bronchodilator testing. International Journal of Tuberculosis and Lung Disease. 2008; 12(2):205-213

989 Lehtimaki L, Kankaanranta H, Saarelainen S, Turjanmaa V, Moilanen E. Increased alveolar nitric oxide concentration in asthmatic patients with nocturnal symptoms. European Respiratory Journal. 2002; 20(4):841-845

990 Lemiere C, Begin D, Forget A, Boulet L-P, Camus M, Gerin M. Occupational exposures of workers with occupational asthma and work-exacerbated asthma. American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

991 Lemiere C, Boulet L-P, Blais L, Villeneuve H, Forget A, Chaboillez S. Do work-exacerbated asthma and occupational asthma differ? American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

992 Lemiere C, Pizzichini MM, Balkissoon R, Clelland L, Efthimiadis A, O'Shaughnessy D et al. Diagnosing occupational asthma: use of induced sputum. European Respiratory Journal. 1999; 13(3):482-488

993 Leonardi NA, Spycher BD, Strippoli MP, Frey U, Silverman M, Kuehni CE. Validation of the Asthma Predictive Index and comparison with simpler clinical prediction rules. Journal of Allergy and Clinical Immunology. 2011; 127(6):1466-1472

994 Leone N, Courbon D, Berr C, Barberger-Gateau P, Tzourio C, Alperovitch A et al. Abdominal obesity and late-onset asthma: cross-sectional and longitudinal results: the 3C study. Obesity. 2012; 20(3):628-635

995 Lerdluedeeporn P, Suwanjutha S, Preutthipan A. Pulmonary function and exercise challenge test in Thai children: 10 years post respiratory syncytial virus infection. Journal of the Medical Association of Thailand. 1999; 82 Suppl 1:S149-S153

996 Letz KL, Schlie AR, Smits WL. A randomized trial comparing peak expiratory flow versus symptom self-management plans for children with persistent asthma. Pediatric Asthma, Allergy and Immunology. 2004; 17(3):177-190

997 Leung RC, Carlin JB, Burdon JG, Czarny D. Asthma, allergy and atopy in Asian immigrants in Melbourne. Medical Journal of Australia. 1994; 161(7):418-425

998 Leung TF, Ko FWS, Wong GWK. Recent advances in asthma biomarker research. Therapeutic Advances in Respiratory Disease. 2013; 7(5):297-308

999 Leuppi JD, Downs SH, Downie SR, Marks GB, Salome CM. Exhaled nitric oxide levels in atopic children: relation to specific allergic sensitisation, AHR, and respiratory symptoms. Thorax. 2002; 57(6):518-523

1000 Levesque B, Rhainds M, Ernst P, Grenier AM, Kosatsky T, Audet N et al. Asthma and allergic rhinitis in Quebec children. Canadian Respiratory Journal. 2004; 11(5):343-348

1001 Levin ME, Muloiwa R, Motala C. Associations between asthma and bronchial hyper-responsiveness with allergy and atopy phenotypes in urban black South African teenagers. South African Medical Journal. 2011; 101(7):472-476

1002 Lewis HM, Haeney M, Jeacock J, Thomas H. Chronic cough in a hospital population; its relationship to atopy and defects in host defence. Archives of Disease in Childhood. 1989; 64(11):1593-1598

1003 Lewis S, Butland B, Strachan D, Bynner J, Richards D, Butler N et al. Study of the aetiology of wheezing illness at age 16 in two national British birth cohorts. Thorax. 1996; 51(7):670-676

1004 Lewis S, Richards D, Bynner J, Butler N, Britton J. Prospective study of risk factors for early and persistent wheezing in childhood. European Respiratory Journal. 1995; 8(3):349-356

1005 Lewis SA, Weiss ST, Britton JR. Airway responsiveness and peak flow variability in the diagnosis of asthma for epidemiological studies. European Respiratory Journal. 2001; 18(6):921-927

1006 Lex C, Dymek S, Heying R, Kovacevic A, Kramm CM, Schuster A. Value of surrogate tests to predict exercise-induced bronchoconstriction in atopic childhood asthma. Pediatric Pulmonology. 2007; 42(3):225-230

1007 Lex C, Ferreira F, Zacharasiewicz A, Nicholson AG, Haslam PL, Wilson NM et al. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. American Journal of Respiratory and Critical Care Medicine. 2006; 174(12):1286-1291

1008 Li AM, Tsang TWT, Chan DFY, Lam HS, So HK, Sung RYT et al. Cough frequency in children with mild asthma correlates with sputum neutrophil count. Thorax. 2006; 61(9):747-750

1009 Li AM, Tsang TWT, Chan DFY, Lam HS, So HK, Sung RYT et al. Sputum induction in children with asthma: a tertiary-center experience. Pediatric Pulmonology. 2006; 41(8):720-725

1010 Li Y-F, Gauderman WJ, Avol E, Dubeau L, Gilliland FD. Associations of tumor necrosis factor G-308A with childhood asthma and wheezing. American Journal of Respiratory and Critical Care Medicine. 2006; 173(9):970-976

1011 Liam CK, Goh CT, Isahak M, Lim KH, Wong CM. Relationship between symptoms and objective measures of airway obstruction in asthmatic patients. Asian Pacific Journal of Allergy and Immunology. 2001; 19(2):79-83

1012 Liang Z, Zhao H, Lv Y, Li R, Dong H, Liu L et al. Moderate accuracy of peripheral eosinophil count for predicting eosinophilic phenotype in steroid-naive non-atopic adult asthmatics. Internal Medicine. 2012; 51(7):717-722

1013 Liem JJ, Huq SI, Ekuma O, Becker AB, Kozyrskyj AL. Transient tachypnea of the newborn may be an early clinical manifestation of wheezing symptoms. Journal of Pediatrics. 2007; 151(1):29-33

1014 Liem JJ, Kozyrskyj AL, Cockroft DW, Becker AB. Diagnosing asthma in children: what is the role for methacholine bronchoprovocation testing? Pediatric Pulmonology. 2008; 43(5):481-489

1015 Lim D, Kim J, Son B. Atopic biomarkers for bronchial hyper-responsiveness in Korean child with asthma. Allergy. 2010; 65:666-667

1016 Lim KG, Morgenthaler TI. Pulmonary function tests, part 1: Applying the basics. Journal of Respiratory Diseases. 2005; 26(1):26-40

1017 Lim S, Jatakanon A, Meah S, Oates T, Chung KF, Barnes PJ. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax. 2000; 55(3):184-188

1018 Lin CC, Wu JL, Huang WC, Lin CY. A bronchial response comparison of exercise and methacholine in asthmatic subjects. Journal of Asthma. 1991; 28(1):31-40

1019 LindenSmith J, Morrison D, Deveau C, Hernandez P. Overdiagnosis of asthma in the community. Canadian Respiratory Journal. 2004; 11(2):111-116

1020 Linehan MF, Niven RM, Baxter DN, Morris JA, Frank TL. Prevalence of respiratory symptoms at two time points in a population of children in Manchester - A cohort study. BMJ Open. 2012; 2(5)

1021 Linehan MF, Frank PI, Niven R, Hazell ML, Morris JA, Francis H et al. Prevalence of respiratory symptoms, features of asthma, and characteristics associated with respiratory disease, in 6-11 year olds in Manchester. Primary Care Respiratory Journal. 2009; 18(1):21-26

1022 Linehan MF, Frank TL, Hazell ML, Francis HC, Morris JA, Baxter DN et al. Is the prevalence of wheeze in children altered by neonatal BCG vaccination? Journal of Allergy and Clinical Immunology. 2007; 119(5):1079-1085

1023 Linn WS, Rappaport EB, Berhane KT, Bastain TM, Avol EL, Gilliland FD. Exhaled nitric oxide in a population-based study of southern California schoolchildren. Respiratory Research. 2009; 10:28

1024 Linna O. Spirometry, bronchodilator test or symptom scoring for the assessment of childhood asthma. Acta Paediatrica. 1996; 85(5):564-569

1025 Linna O. Sensitivity of peak expiratory flow rate for diagnosing bronchial obstruction on methacholine inhalation challenge in school-aged asthmatic children. Acta Paediatrica. 1998; 87(6):635-637

1026 Linna OV. Twice-daily peak expiratory flow rate monitoring for the assessment of childhood asthma. Allergy Proceedings. 1993; 14(1):33-36

1027 Linneberg A, Husemoen LLN, Nielsen NH, Madsen F, Frolund L, Johansen N. Screening for allergic respiratory disease in the general population with the ADVIA Centaur Allergy Screen Assay. Allergy. 2006; 61(3):344-348

1028 Liou TG, Kanner RE. Spirometry. Clinical Reviews in Allergy and Immunology. 2009; 37(3):137-152

1029 Lipinska A, Wittczak T, Wiszniewska M, Palczynski C, Nieradka A, Walusiak-Skorupa J. Cleaners' asthma - Does it really exist? Allergy. 2011; 66:595-596

1030 Lipworth BJ, Short PM, Williamson PA, Clearie KL, Fardon TC, Jackson CM. A randomized primary care trial of steroid titration against mannitol in persistent asthma: STAMINA trial. Chest. 2012; 141(3):607-615

1031 Liu AH, Zeiger R, Sorkness C, Mahr T, Ostrom N, Burgess S et al. Development and cross-sectional validation of the Childhood Asthma Control Test. Journal of Allergy and Clinical Immunology. 2007; 119(4):817-825

1032 Liu WT, Huang CD, Wang CH, Lee KY, Lin SM, Kuo HP. A mobile telephone-based interactive self-care system improves asthma control. European Respiratory Journal. 2011; 37(2):310-317

1033 Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Primary Care Respiratory Journal. 2007; 16(1):22-27

1034 Lobo ES, Revicki D, Grant W, Turk F, Massanari M. Assessment of the psychometric properties of the paediatric asthma quality of life questionnaire (PAQLQ) in moderate to severe pediatric asthma patients [Abstract]. Journal of Allergy and Clinical Immunology. 2007; 119(1 Suppl):S151

1035 Lodrup Carlsen KC, Soderstrom L, Mowinckel P, Haland G, Pettersen M, Munthe Kaas MC et al. Asthma prediction in school children; The value of combined IgE-antibodies and obstructive airways disease severity score. Allergy. 2010; 65(9):1134-1140

1036 Loerbroks A, Herr RM, Subramanian S, Bosch JA. The association of asthma and wheezing with major depressive episodes: an analysis of 245 727 women and men from 57 countries. International Journal of Epidemiology. 2012; 41(5):1436-1444

1037 Lombardi C, Canonica GW, Passalacqua G, IGRAM Italian Group on Respiratory Allergy in Migrants. The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Annals of Allergy, Asthma and Immunology. 2011; 106(5):407-411

1038 Lombardi C, Penagos M, Senna G, Canonica GW, Passalacqua G. The clinical characteristics of respiratory allergy in immigrants in northern Italy. International Archives of Allergy and Immunology. 2008; 147(3):231-234

1039 Lopez-Vina A, del Castillo-Arevalo E. Influence of peak expiratory flow monitoring on an asthma self-management education programme. Respiratory Medicine. 2000; 94(8):760-766

1040 Lorber DB, Kaltenborn W, Burrows B. Responses to isoproterenol in a general population sample. American Review of Respiratory Disease. 1978; 118(5):855-861

1041 Louhelainen N, Rytila P, Obase Y, Makela M, Haahtela T, Kinnula VL et al. The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma. Journal of Asthma. 2008; 45(2):149-154

1042 Lowhagen O. Asthma and asthma-like disorders. Respiratory Medicine. 1999; 93(12):851-855

1043 Löwhagen O, Wever AM, Lusuardi M, Moscato G, Backer WA, Gandola L et al. The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respiratory Medicine. 2002; 96(2):95-101

1044 Ludviksdottir D, Diamant Z, Alving K, Bjermer L, Malinovschi A. Clinical aspects of using exhaled NO in asthma diagnosis and management. Clinical Respiratory Journal. 2012; 6(4):193-207

1045 Luisi F, Pinto LA, Marostica L, Jones MH, Stein RT, Pitrez PM. Persistent pulmonary function impairment in children and adolescents with asthma. Jornal Brasileiro De Pneumologia. 2012; 38(2):158-166

1046 Lukrafka JL, Fuchs SC, Moreira LB, Picon RV, Fischer GB, Fuchs FD. Performance of the ISAAC questionnaire to establish the prevalence of asthma in adolescents: a population-based study. Journal of Asthma. 2010; 47(2):166-169

1047 Lumelli D, Garcia Del PM, Manso L, Fernandez-Nieto M, Sastre J. Comparison of bronchial hyperresponsiveness to methacholine and adenosine in clinical practice. Journal of Allergy and Clinical Immunology. 2010; 125(2 Suppl.1):AB2

1048 Luntsov A, Skorokhodkina O. A diagnostic program for bronchial asthma including allergen challenge and exercise bronchoprovocation testing in young patients. Allergy. 2012; 67:454

1049 Lurà MP, Inci D, Staffelbach S, Wildhaber J, Möller A. Exhaled nitric oxide and its role in monitoring asthma control in atopic children [Abstract]. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22. 4/10 2010;4774

1050 Lutfi MF. Acceptable alternatives for forced vital capacity in the spirometric diagnosis of bronchial asthma. International Journal of Applied and Basic Medical Research. 2011; 1(1):20-23

1051 Luyt DK, Bourke AM, Lambert P, Burton P, Simpson H. Wheeze in preschool children: who is followed-up, who is treated and who is hospitalized? European Respiratory Journal. 1995; 8(10):1736-1741

1052 Luyt DK, Burton P, Brooke AM, Simpson H. Wheeze in preschool children and its relation with doctor diagnosed asthma. Archives of Disease in Childhood. 1994; 71(1):24-30

1053 Luyt DK, Burton PR, Simpson H. Epidemiological study of wheeze, doctor diagnosed asthma, and cough in preschool children in Leicestershire. BMJ. 1993; 306(6889):1386-1390

1054 Maas T, Kaper J, Sheikh A, Knottnerus JA, Wesseling G, Dompeling E et al. Mono and multifaceted inhalant and/or food allergen reduction interventions for preventing asthma in children at high risk of developing asthma. Cochrane Database of Systematic Reviews. 2009; Issue 3:CD006480. DOI:10.1002/14651858.CD006480.pub2

1055 Macleod KA, Horsley AR, Bell NJ, Greening AP, Innes JA, Cunningham S. Ventilation heterogeneity in children with well controlled asthma with normal spirometry indicates residual airways disease. Thorax. 2009; 64(1):33-37

1056 Madsen F, Holstein-Rathlou NH, Frolund L, Weeke B, Svendsen UG. Bronchial histamine challenge in the diagnosis of asthma. The predictive value of changes in airway resistance determined by the interrupter method. Allergy. 1986; 41(3):187-195

1057 Madsen F, Holstein-Rathlou NH, Mosbech H, Weeke B, Svendsen UG. The predictive value of bronchial histamine challenge in the diagnosis of bronchial asthma. Scandinavian Journal of Clinical and Laboratory Investigation. 1985; 45(5):453-460

1058 Magar Y, Vervloet D, Steenhouwer F, Smaga S, Mechin H, Rocca Serra JP et al. Assessment of a therapeutic education programme for asthma patients: "un souffle nouveau". Patient Education and Counseling. 2005; 58(1):41-46

1059 Magdelijns FJH, Mommers M, Penders J, Smits L, Thijs C. Folic acid use in pregnancy and the development of atopy, asthma, and lung function in childhood. Pediatrics. 2011; 128(1):e135-e144

1060 Magnan A. Tools to assess (and achieve?) long-term asthma control. Respiratory Medicine. 2004; 98(Suppl.2):S16-S21

1061 Magnan A, Fourre-Jullian C, Jullian H, Badier M, Lanteaume A, Vervloet D et al. Rhinitis alone or rhinitis plus asthma: what makes the difference? European Respiratory Journal. 1998; 12(5):1073-1078

1062 Magyar P. The significance of lung function tests in the differential diagnosis of bronchial asthma. Acta Microbiologica Et Immunologica Hungarica. 1998; 45(1):95-100

1063 Maher JE, Mullooly JP, Drew L, DeStefano F. Infant vaccinations and childhood asthma among full-term infants. Pharmacoepidemiology and Drug Safety. 2004; 13(1):1-9

1064 Mahmoud H, Elqady M. Relationship between skin prick test, peripheral eosinophilic count, serum total and specific ige, and severity of asthma in atopic asthma. Chest. 2013; 144(4 Meeting Abstracts):78A

1065 Mahmoud H, Elqady M, Mohamed H. Relationship between skin prick test, peripheral eosinophil counts, serum total & specific IgE and severity in atopic asthma. Allergy. 2011; 66:578

1066 Maitra A, Sherriff A, Strachan D, Henderson J, ALSPAC Study Team. Mode of delivery is not associated with asthma or atopy in childhood. Clinical and Experimental Allergy. 2004; 34(9):1349-1355

1067 Majak P, Cichalewski L, Ozarek-Hanc A, Stelmach W, Jerzynska J, Stelmach I. Airway response to exercise measured by area under the expiratory flow-volume curve in children with asthma. Annals of Allergy, Asthma and Immunology. 2013; 111(6):512-515

1068 Makowska JS, Grzegorczyk J, Bienkiewicz B, Wozniak M, Kowalski ML. Systemic responses after bronchial aspirin challenge in sensitive patients with asthma. Journal of Allergy and Clinical Immunology. 2008; 121(2):348-354

1069 Malby Schoos AM, Chawes BLK, Bonnelykke K, Bisgaard H. Fraction of exhaled nitric oxide and bronchial responsiveness are associated and continuous traits in young children independent of asthma. Chest. 2012; 142(6):1562-1568

1070 Malerba M, Ragnoli B, Radaeli A, Tantucci C. Usefulness of exhaled nitric oxide and sputum eosinophils in the long-term control of eosinophilic asthma. Chest. 2008; 134(4):733-739

1071 Malinovschi A, Backer V, Harving H, Porsbjerg C. The value of exhaled nitric oxide to identify asthma in smoking patients with asthma-like symptoms. Respiratory Medicine. 2012; 106(6):794-801

1072 Malinovschi A, Janson C, Hogman M, Rolla G, Toren K, Norback D et al. Both allergic and nonallergic asthma are associated with increased FE(NO) levels, but only in never-smokers. Allergy. 2009; 64(1):55-61

1073 Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. Journal of Allergy and Clinical Immunology. 2013; 132(4):821-825

1074 Mallol J, Garcia-Marcos L, Sole D, Brand P, EISL Study Group. International prevalence of recurrent wheezing during the first year of life: variability, treatment patterns and use of health resources. Thorax. 2010; 65(11):1004-1009

1075 Malmberg LP, Nikander K, Pelkonen AS, Syvanen P, Koljonen T, Haahtela T et al. Acceptability, reproducibility, and sensitivity of forced expiratory volumes and peak expiratory flow during bronchial challenge testing in asthmatic children. Chest. 2001; 120(6):1843-1849

1076 Malmberg LP, Pelkonen AS, Haahtela T, Turpeinen M. Exhaled nitric oxide rather than lung function distinguishes preschool children with probable asthma. Thorax. 2003; 58(6):494-499

1077 Malmberg LP, Pelkonen AS, Mattila PS, Hammaren-Malmi S, Makela MJ. Exhaled nitric oxide and exercise-induced bronchoconstriction in young wheezy children - interactions with atopy. Pediatric Allergy and Immunology. 2009; 20(7):673-678

1078 Malo JL, Cote J, Cartier A, Boulet LP, L'Archeveque J, Chan-Yeung M. How many times per day should peak expiratory flow rates be assessed when investigating occupational asthma? Thorax. 1993; 48(12):1211-1217

1079 Malo JL, Ghezzo H, L'Archeveque J, Lagier F, Perrin B, Cartier A. Is the clinical history a satisfactory means of diagnosing occupational asthma? American Review of Respiratory Disease. 1991; 143(3):528-532

1080 Malo JL, L'Archeveque J, Trudeau C, d'Aquino C, Cartier A. Should we monitor peak expiratory flow rates or record symptoms with a simple diary in the management of asthma? Journal of Allergy and Clinical Immunology. 1993; 91(3):702-709

1081 Malo JL, Trudeau C, Ghezzo H, L'Archeveque J, Cartier A. Do subjects investigated for occupational asthma through serial peak expiratory flow measurements falsify their results? Journal of Allergy and Clinical Immunology. 1995; 96(5 Pt 1):601-607

1082 Mandhane PJ, Greene JM, Cowan JO, Taylor DR, Sears MR. Sex differences in factors associated with childhood- and adolescent-onset wheeze. American Journal of Respiratory and Critical Care Medicine. 2005; 172(1):45-54

1083 Manfreda J, Becklake MR, Sears MR, Chan-Yeung M, Dimich-Ward H, Siersted HC et al. Prevalence of asthma symptoms among adults aged 20-44 years in Canada. CMAJ. 2001; 164(7):995-1001

1084 Manning PJ, Goodman P, O'Sullivan A, Clancy L. Rising prevalence of asthma but declining wheeze in teenagers (1995-2003): ISAAC protocol. Irish Medical Journal. 2007; 100(10):614-615

1085 Mannino F, Mariotta S, Anticoli S, Lambert-Gardini S, Terzano C. Sensitivity of FEV1 and indices of flow volume curve in the methacholine test. Allergologia Et Immunopathologia. 1996; 24(2):75-80

1086 Manso L, Madero MF, Ruiz-Garcia M, Fernandez-Nieto M, Sastre J. Comparison of bronchial hyperresponsiveness to methacholine and adenosine and airway inflammation markers in patients with suspected asthma. Journal of Asthma. 2011; 48(4):335-340

1087 Mansournia MA, Jamali M, Mansournia N, Yunesian M, Moghadam KG. Exercise-induced bronchospasm among students of Tehran University of Medical Sciences in 2004. Allergy and Asthma Proceedings. 2007; 28(3):348-352

1088 Marbury MC, Maldonado G, Waller L. The indoor air and children's health study: methods and incidence rates. Epidemiology. 1996; 7(2):166-174

1089 Marinovic MA, Duarte P, Tordecilla R, Zuniga MD. Usefulness of aeroallergen atopy patch test in the diagnosis of atopic respiratory and skin diseases. Allergy. 2013; 68:641-642

1090 Marks GB, Dunn SM, Woolcock AJ. An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma. Journal of Clinical Epidemiology. 1993; 46(10):1103-1111

1091 Marossy AE, Strachan DP, Rudnicka AR, Anderson HR. Childhood chest illness and the rate of decline of adult lung function between ages 35 and 45 years. American Journal of Respiratory and Critical Care Medicine. 2007; 175(4):355-359

1092 Martindale S, McNeill G, Devereux G, Campbell D, Russell G, Seaton A. Antioxidant intake in pregnancy in relation to wheeze and eczema in the first two years of life. American Journal of Respiratory and Critical Care Medicine. 2005; 171(2):121-128

1093 Martinez FD, Wright AL, Taussig LM, Holberg CJ, Halonen M, Morgan WJ. Asthma and wheezing in the first six years of life. The Group Health Medical Associates. New England Journal of Medicine. 1995; 332(3):133-138

1094 Martinez P, Weiss BD. Unchanged asthma prevalence during 1990-1999 in rural Alaska Natives. International Journal of Circumpolar Health. 2006; 65(4):341-346

1095 Martins P, Caires I, Rosado Pinto J, Lopes da Mata P, Torres S, Valente J et al. The clinical use of exhaled nitric oxide in wheezing children. Revista Portuguesa De Pneumologia. 2008; 14(2):195-218

1096 Mascia K, Haselkorn T, Deniz YM, Miller DP, Bleecker ER, Borish L et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. Journal of Allergy and Clinical Immunology. 2005; 116(5):970-975

1097 Masuko H, Sakamoto T, Kaneko Y, Iijima H, Naito T, Noguchi E et al. Lower FEV1 in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV1, total IgE levels, and TSLP genotypes. International Journal of Chronic Obstructive Pulmonary Disease. 2011; 6:181-189

1098 Masullo M, Mariotta S, Torrelli L, Graziani E, Anticoli S, Mannino F. Respiratory allergy to parietaria pollen in 348 subjects. Allergologia Et Immunopathologia. 1996; 24(1):3-6

1099 Matheson MC, Ellis JA, Raven J, Johns DP, Walters EH, Abramson MJ. Beta2-adrenergic receptor polymorphisms are associated with asthma and COPD in adults. Journal of Human Genetics. 2006; 51(11):943-951

1100 Matricardi PM, Bockelbrink A, Keil T, Gruber C, Niggemann B, Hamelmann E et al. Dynamic evolution of serum immunoglobulin e to airborne allergens throughout childhood: Results from the Multi-Centre Allergy Study birth cohort. Clinical and Experimental Allergy. 2009; 39(10):1551-1557

1101 Matricardi PM, Illi S, Gruber C, Keil T, Nickel R, Wahn U et al. Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence. European Respiratory Journal. 2008; 32(3):585-592

1102 Matricardi PM, Nisini R, Pizzolo JG, D'Amelio R. The use of Phadiatop in mass-screening programmes of inhalant allergies: Advantages and limitations. Clinical and Experimental Allergy. 1990; 20(2):151-155

1103 Matsui EC, Sampson HA, Bahnson HT, Gruchalla RS, Pongracic JA, Teach SJ et al. Allergen-specific IgE as a biomarker of exposure plus sensitization in inner-city adolescents with asthma. Allergy. 2010; 65(11):1414-1422

1104 Matsunaga K, Yanagisawa S, Hirano T, Ichikawa T, Koarai A, Akamatsu K et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. Clinical and Experimental Allergy. 2012; 42(5):775-781

1105 Matsunaga K, Hirano T, Akamatsu K, Koarai A, Sugiura H, Minakata Y et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergology International. 2011; 60(3):331-337

1106 Matsunaga K, Kanda M, Hayata A, Yanagisawa S, Ichikawa T, Akamatsu K et al. Peak expiratory flow variability adjusted by forced expiratory volume in one second is a good index for airway responsiveness in asthmatics. Internal Medicine. 2008; 47(12):1107-1112

1107 Matui P, Wyatt JC, Pinnock H, Sheikh A, McLean S. Computer decision support systems for asthma: a systematic review. NPJ Primary Care Respiratory Medicine. 2014; 24:14005

1108 May KL. Allergy to Artemisia vulgaris in the region of Warsaw. Allergologia Et Immunopathologia. 1990; 18(1):57-60

1109 Maziak W, von Mutius E, Beimfohr C, Hirsch T, Leupold W, Keil U et al. The management of childhood asthma in the community. European Respiratory Journal. 2002; 20(6):1476-1482

1110 Maziak W, von Mutius E, Keil U, Hirsch T, Leupold W, Rzehak P et al. Predictors of health care utilization of children with asthma in the community. Pediatric Allergy and Immunology. 2004; 15(2):166-171

1111 McClean MA, Htun C, King GG, Berend N, Salome CM. Cut-points for response to mannitol challenges using the forced oscillation technique. Respiratory Medicine. 2011; 105(4):533-540

1112 McClure LA, Harrington KF, Graham H, Gerald LB. Internet-based monitoring of asthma symptoms, peak flow meter readings, and absence data in a school-based clinical trial. Clinical Trials. 2008; 5(1):31-37

1113 McConnell R, Berhane K, Gilliland F, London SJ, Vora H, Avol E et al. Air pollution and bronchitic symptoms in Southern California children with asthma. Environmental Health Perspectives. 1999; 107(9):757-760

1114 McConnell R, Berhane K, Gilliland F, Islam T, Gauderman WJ, London SJ et al. Indoor risk factors for asthma in a prospective study of adolescents. Epidemiology. 2002; 13(3):288-295

1115 McDonald E, Clarke FJ, Zhou Q, Freitag A, Cox G, Whitehead L. Validation of the asthma control questionnaire in children. American Thoracic Society International Conference, May 15-20, 2009, San Diego. 2009;A4321

1116 McEldowney SJ, Bush RK. House dust mite specific IgA and exhaled nitric acid are elevated in allergic asthma and rhinitis patients with positive methacholine challenges [Abstract]. Journal of Allergy and Clinical Immunology. 2008; 21(2 Suppl 1):S198

1117 McElnay JC, Scott MG, Armstrong AP, Stanford CF. Audiovisual demonstration for patient counselling in the use of pressurised aerosol bronchodilator inhalers. Journal of Clinical Pharmacy and Therapeutics. 1989; 14(2):135-144

1118 McGarvey LP, Heaney LG, Lawson JT, Johnston BT, Scally CM, Ennis M et al. Evaluation and outcome of patients with chronic non-productive cough using a comprehensive diagnostic protocol. Thorax. 1998; 53(9):738-743

1119 McGrath AM, Gardner DM, McCormack J. Is home peak expiratory flow monitoring effective for controlling asthma symptoms? Journal of Clinical Pharmacy and Therapeutics. 2001; 26(5):311-317

1120 Mchedlishvili N, Siradze N, Tsertsvadze S, Giorgobiani A, Kiknadze N. Wheezing phenotypes and lung function in pre-school children. Allergy: European Journal of Allergy and Clinical Immunology. 2013; 68:535-536

1121 McKeever TM, Lewis SA, Smith C, Hubbard R. The importance of prenatal exposures on the development of allergic disease: a birth cohort study using the West Midlands General Practice Database. American Journal of Respiratory and Critical Care Medicine. 2002; 166(6):827-832

1122 McKinlay L, Jackson CM, Williamson PA, Fardon TC, Burns P, Clearie K et al. Steroid titration against mannitol in mild to moderate asthma: The stamina community study. Journal of Allergy and Clinical Immunology. 2011; 127(2 SUPPL. 1):AB5

1123 McLean S, Chandler D, Nurmatov U, Liu JLY, Pagliari C, Car J et al. Telehealthcare for asthma. Cochrane Database of Systematic Reviews. 2010; Issue 10:CD007717. DOI:10.1002/14651858.CD007717.pub2

1124 McMullen AH, Yoos HL, Kitzman H. Peak flow meters in childhood asthma: parent report of use and perceived usefulness. Journal of Pediatric Health Care. 2002; 16(2):67-72

1125 McTaggart-Cowan HM, Marra CA, Yang Y, Brazier JE, Kopec JA, Fitzgerald JM et al. The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. Quality of Life Research. 2008; 17(3):453-462

1126 Meer V, Stel HF, Bakker MJ, Roldaan AC, Assendelft WJ, Sterk PJ et al. Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma: an analysis of the SMASHING study. Respiratory Research. 2010; 11:74

1127 Mehrparvar AH, Hossein DM, Salmani NM, Hashemi SH, Mostaghaci M, Mirmohammadi SJ. Assessment of bronchodilator response in various spirometric patterns. Tanaffos. 2013; 12(2):28-33

1128 Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP et al. Effectiveness of pharmacist intervention for asthma control improvement. European Respiratory Journal. 2008; 31(4):790-799

1129 Melbye H, Drivenes E, Dalbak LG, Leinan T, Hoegh-Henrichsen S, Ostrem A. Asthma, chronic obstructive pulmonary disease, or both? Diagnostic labeling and spirometry in primary care patients aged 40 years or more. International Journal of Chronic Obstructive Pulmonary Disease. 2011; 6:597-603

1130 Mele L, Sly PD, Calogero C, Bernardini R, Novembre E, Azzari C et al. Assessment and validation of bronchodilation using the interrupter technique in preschool children. Pediatric Pulmonology. 2010; 45(7):633-638

1131 Melillo G, Padovano A, Masi C, Melillo E, Cocco G. Aspirin-induced asthma and bronchial hyperresponsiveness. Allergie Et Immunologie. 1991; 23(10):423-427

1132 Meltzer AA, Smolensky MH, D'Alonzo GE, Harrist RB, Scott PH. An assessment of peak expiratory flow as a surrogate measurement of FEV1 in stable asthmatic children. Chest. 1989; 96(2):329-333

1133 Mendonca NT, Kenyon J, LaPrad AS, Syeda SN, O'Connor GT, Lutchen KR. Airway resistance at maximum inhalation as a marker of asthma and airway hyperresponsiveness. Respiratory Research. 2011; 12:96

1134 Menzies D, Nair A, Lipworth BJ. Portable exhaled nitric oxide measurement: Comparison with the "gold standard" technique. Chest. 2007; 131(2):410-414

1135 Merchant R, Inamdar R, Quade R, Van SD, Maenner M, Patmas M. Interim results from a randomized, controlled trial of remote monitoring of inhaled bronchodilator use on asthma control and management [Abstract]. Chest: American College of Chest Physicians. 2013; 144(4 Meeting Abstracts):71A

1136 Merget R, Schultze-Werninghaus G, Bode F, Bergmann EM, Zachgo W, Meier-Sydow J. Quantitative skin prick and bronchial provocation tests with platinum salt. British Journal of Industrial Medicine. 1991; 48(12):830-837

1137 Meslier N, Racineux JL, Six P, Lockhart A. Diagnostic value of reversibility of chronic airway obstruction to separate asthma from chronic bronchitis: a statistical approach. European Respiratory Journal. 1989; 2(6):497-505

1138 Metso T, Kilpio K, Bjorksten F, Kiviranta K, Haahtela T. Can early asthma be confirmed by laboratory tests? Allergy. 1996; 51(4):226-231

1139 Metso T, Kilpio K, Bjorksten F, Kiviranta K, Haahtela T. Detection and treatment of early asthma. Allergy. 2000; 55(5):505-509

1140 Meyer N, Nuss SJ, Rothe T, Siebenhuner A, Akdis CA, Menz G. Differential serum protein markers and the clinical severity of asthma. Journal of Asthma and Allergy. 2014; 7:67-75

1141 Michel G, Silverman M, Strippoli M-PF, Zwahlen M, Brooke AM, Grigg J et al. Parental understanding of wheeze and its impact on asthma prevalence estimates. European Respiratory Journal. 2006; 28(6):1124-1130

1142 Michoud MC, Ghezzo H, Amyot R. A comparison of pulmonary function tests used for bronchial challenges. Clinical Respiratory Physiology. 1982; 18(4):609-621

1143 Midodzi WK, Rowe BH, Majaesic CM, Saunders LD, Senthilselvan A. Early life factors associated with incidence of physician-diagnosed asthma in preschool children: results from the Canadian Early Childhood Development cohort study. Journal of Asthma. 2010; 47(1):7-13

1144 Miedinger D, Burge C, Burge S, To B, Luthiger J, Yereaztian C. The pef-logger application for the diagnosis of work-related asthma (WRA). Respiration. 2013; 85(6):618

1145 Miedinger D, Mosimann N, Meier R, Karli C, Florek P, Frey F et al. Asthma tests in the assessment of military conscripts. Clinical and Experimental Allergy. 2010; 40(2):224-231

1146 Miedinger D, Chhajed PN, Tamm M, Stolz D, Surber C, Leuppi JD. Diagnostic tests for asthma in firefighters. Chest. 2007; 131(6):1760-1767

1147 Migueres M, Fontaine JF, Haddad T, Grosclaude M, Saint-Martin F, Bem David D et al. Characteristics of patients with respiratory allergy in France and factors influencing immunotherapy prescription: a prospective observational study (REALIS). International Journal of Immunopathology and Pharmacology. 2011; 24(2):387-400

1148 Milam J, McConnell R, Yao L, Berhane K, Jerrett M, Richardson J. Parental stress and childhood wheeze in a prospective cohort study. Journal of Asthma. 2008; 45(4):319-323

1149 Milenkovic BA, Stankovic IJ, Ilic AM, Petrovic VI. Peak expiratory flow-guided self-management treatment of asthma in Serbia. Journal of Asthma. 2007; 44(9):699-704

1150 Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test with lysine-aspirin for diagnosis of aspirin-sensitive asthma. Journal of Allergy and Clinical Immunology. 1998; 101(5):581-586

1151 Miller A. A simple spirometric clue to asthma: Airways obstruction suggested by negative or reduced forced expiratory reserve volume despite normal FEV1-FVC ratio. Mount Sinai Journal of Medicine. 1990; 57(2):85-92

1152 Miller B, Mirakian R, Gane S, Larco J, Sannah AA, Darby Y et al. Nasal lysine aspirin challenge in the diagnosis of aspirin - exacerbated respiratory disease. Clinical and Experimental Allergy. 2013; 43(8):874-880

1153 Miller CJ, Joseph J, Safa W, Flood PE, Dunn EV, Shaheen HM. Accuracy of Arabic versions of three asthma symptoms questionnaires against the clinical diagnosis of asthma. Journal of Asthma. 2007; 44(1):29-34

1154 Millstein J, Gilliland F, Berhane K, Gauderman WJ, McConnell R, Avol E et al. Effects of ambient air pollutants on asthma medication use and wheezing among fourth-grade school children from 12 Southern California communities enrolled in The Children's Health Study. Archives of Environmental Health. 2004; 59(10):505-514

1155 Minakata Y, Sugiura H, Yamagata T, Yanagisawa S, Ichikawa T, Koarai A et al. Prevalence of COPD in primary care clinics: Correlation with non-respiratory diseases. Internal Medicine. 2008; 47(2):77-82

1156 Miraglia Del Giudice M, Pedulla M, Piacentini GL, Capristo C, Brunese FP, Decimo F et al. Atopy and house dust mite sensitization as risk factors for asthma in children. Allergy. 2002; 57(2):169-172

1157 Mirakian R, Miller B, Gane S, Larco J, Al SA, Darby Y et al. Lysine aspirin nasal challenge in the diagnosis of aspirin exacerbated respiratory disease-suitable for outpatient practice? Clinical and Experimental Allergy. 2012; 42(12):1834

1158 Miravitlles M, Andreu I, Romero Y, Sitjar S, Altes A, Anton E. Difficulties in differential diagnosis of COPD and asthma in primary care. British Journal of General Practice. 2012; 62(595):e68-e75

1159 Mirmohammadi SJ, Mehrparvar AH, Gharavi M, Fathi F. A comparison between Venables standardized respiratory questionnaire and pre-shift spirometry in screening of occupational asthma in a steel industry. International Journal of Occupational and Environmental Medicine. 2010; 1(4):191-197

1160 Mitchell EA, Asher MI. Prevalence, severity and medical management of asthma in European school children in 1985 and 1991. Journal of Paediatrics and Child Health. 1994; 30(5):398-402

1161 Mitchell EA, Didsbury PB, Kruithof N, Robinson E, Milmine M, Barry M et al. A randomized controlled trial of an asthma clinical pathway for children in general practice. Acta Paediatrica. 2005; 94(2):226-233

1162 Mitchell EA, Stewart AW, Pattemore PK, Asher MI, Harrison AC, Rea HH. Socioeconomic status in childhood asthma. International Journal of Epidemiology. 1989; 18(4):888-890

1163 Mitchell EA, Stewart AW, Clayton T, Asher MI, Ellwood P, Mackay R et al. Cross-sectional survey of risk factors for asthma in 6-7-year-old children in New Zealand: International Study of Asthma and Allergy in Childhood Phase Three. Journal of Paediatrics and Child Health. 2009; 45(6):375-383

1164 Mitchell H, Senturia Y, Gergen P, Baker D, Joseph C, McNiff-Mortimer K et al. Design and methods of the National Cooperative Inner-City Asthma Study. Pediatric Pulmonology. 1997; 24(4):237-252

1165 Mitsufuji H, Kobayashi H, Imasaki T, Ichikawa T, Kawakami T, Tomita T. Acute changes in bronchoconstriction influences exhaled nitric oxide level. Japanese Journal of Physiology. 2001; 51(2):151-157

1166 Modl M, Eber E, Steinbrugger B, Weinhandl E, Zach MS. Comparing methods for assessing bronchial responsiveness in children: single step cold air challenge, multiple step cold air challenge, and histamine provocation. European Respiratory Journal. 1995; 8(10):1742-1747

1167 Modrykamien AM, Gudavalli R, McCarthy K, Liu X, Stoller JK. Detection of upper airway obstruction with spirometry results and the flow-volume loop: a comparison of quantitative and visual inspection criteria. Respiratory Care. 2009; 54(4):474-479

1168 Mogi G, Maeda S, Yoshida T, Watanabe N. IgE in respiratory tract allergies. Transactions Section on Otolaryngology American Academy of Ophthalmology and Otolaryngology. 1977; 84(2):272-284

1169 Mogi G, Maeda S, Yoshida T, Watanabe N. IgE studies on respiratory tract allergies. Archives of Otolaryngology. 1977; 103(5):251-257

1170 Mohammadien HA, Mohamed HA, Elqady MA. Relationship between skin prich test, peripheral eosinophilic count, serum total and specific IgE and severity of asthma in atopic asthma. Annals of Thoracic Medicine. 2009; 4(2):99

1171 Mohangoo AD, de Koning HJ, Hafkamp-de Groen E, van der Wouden JC, Jaddoe VWV, Moll HA et al. A comparison of parent-reported wheezing or shortness of breath among infants as assessed by questionnaire and physician-interview: The Generation R study. Pediatric Pulmonology. 2010; 45(5):500-507

1172 Momas I, Dartiguenave C, Fauroux B, Bourdais M, Poinsard R, Grimfeld A et al. Prevalence of asthma or respiratory symptoms among children attending primary schools in Paris. Pediatric Pulmonology. 1998; 26(2):106-112

1173 Mommers M, Jongmans-Liedekerken AW, Derkx R, Dott W, Mertens P, van Schayck CP et al. Indoor environment and respiratory symptoms in children living in the Dutch-German borderland. International Journal of Hygiene and Environmental Health. 2005; 208(5):373-381

1174 Montnemery P, Hansson L, Lanke J, Lindholm LH, Nyberg P, Lofdahl CG et al. Accuracy of a first diagnosis of asthma in primary health care. Family Practice. 2002; 19(4):365-368

1175 Montuschi P, Santonico M, Mondino C, Pennazza G, Mantini G, Martinelli E et al. Diagnostic performance of an electronic nose, fractional exhaled nitric oxide, and lung function testing in asthma. Chest. 2010; 137(4):790-796

1176 Moore VC, Jaakkola MS, Burge CBSG, Pantin CFA, Robertson AS, Burge PS. Do long periods off work in peak expiratory flow monitoring improve the sensitivity of occupational asthma diagnosis? Occupational and Environmental Medicine. 2010; 67(8):562-567

1177 Moore VC, Jaakkola MS, Burge CBSG, Robertson AS, Pantin CFA, Vellore AD et al. A new diagnostic score for occupational asthma: the area between the curves (ABC score) of peak expiratory flow on days at and away from work. Chest. 2009; 135(2):307-314

1178 Morass B, Kiechl-Kohlendorfer U, Horak E. The impact of early lifestyle factors on wheezing and asthma in Austrian preschool children. Acta Paediatrica. 2008; 97(3):337-341

1179 Morgan WJ. Factors predicting the persistence of asthma insights from the Tucson children's respiratory study. Revue Francaise D'Allergologie Et D'Immunologie Clinique. 2005; 45(7):542-546

1180 Mosbech H, Dirksen A, Madsen F. House dust mite asthma. Correlation between allergen sensitivity in various organs. Allergy. 1987; 42(6):456-463

1181 Moscato G, Dellabianca A, Corsico A, Biscaldi G, Gherson G, Vinci G. Bronchial responsiveness to ultrasonic fog in occupational asthma due to toluene diisocyanate. Chest. 1993; 104(4):1127-1132

1182 Mosfeldt Laursen E, Kaae Hansen K, Backer V, Bach-Mortensen N, Prahl P, Koch C. Pulmonary function in adolescents with childhood asthma. Allergy. 1993; 48(4):267-272

1183 Mosterd A, Cost B, Hoes AW, de Bruijne MC, Deckers JW, Hofman A et al. The prognosis of heart failure in the general population: The Rotterdam Study. European Heart Journal. 2001; 22(15):1318-1327

1184 Moullec G, Gour-Provencal G, Bacon SL, Campbell TS, Lavoie KL. Efficacy of interventions to improve adherence to inhaled corticosteroids in adult asthmatics: impact of using components of the chronic care model. Respiratory Medicine. 2012; 106(9):1211-1225

1185 Mouthuy J, Detry B, Sohy C, Pirson F, Pilette C. Presence in sputum of functional dust mite-specific IgE antibodies in intrinsic asthma. American Journal of Respiratory and Critical Care Medicine. 2011; 184(2):206-214

1186 Moverare R, Westritschnig K, Svensson M, Hayek B, Bende M, Pauli G et al. Different IgE reactivity profiles in birch pollen-sensitive patients from six European populations revealed by recombinant allergens: an imprint of local sensitization. International Archives of Allergy and Immunology. 2002; 128(4):325-335

1187 Muers MF. Diurnal variation in asthma. Archives of Disease in Childhood. 1984; 59(9):898-901

1188 Muller BA, Leick CA, Smith RM, Suelzer MT, Richerson HB. Comparisons of specific and nonspecific bronchoprovocation in subjects with asthma, rhinitis, and healthy subjects. Journal of Allergy and Clinical Immunology. 1993; 91(3):758-772

1189 Mulloy E, Donaghy D, Quigley C, McNicholas WT. A one-year prospective audit of an asthma education programme in an out-patient setting. Irish Medical Journal. 1996; 89(6):226-228

1190 Mundy L and Hiller JE. Smartinhaler? with audiovisual reminder for asthma medication. Adelaide Health Technology Assessment (AHTA), 2007. Available from: http://www.horizonscanning.gov.au/internet/horizon/publishing.nsf/Content/6B81AEB3E7EE0001CA2575AD0080F344/$File/Vol%2018%20-%20Smartinhaler.pdf

1191 Munnik P, van der Lee I, Fijn J, van Eijsden LJ, Lammers J-WJ, Zanen P. Comparison of eNO and histamine hyperresponsiveness in diagnosing asthma in new referrals. Respiratory Medicine. 2010; 104(6):801-807

1192 Munoz-Cano R, Bartra J, Sanchez-Lopez J, Picado C, Bissinger I, Valero A. Acoustic rhinometry and aspirin nasal challenge in the diagnosis of aspirin-intolerant asthma: clinical finding and safety aspects. International Archives of Allergy and Immunology. 2013; 160(3):307-312

1193 Murphy AC, Proeschal A, Brightling CE, Wardlaw AJ, Pavord I, Bradding P et al. The relationship between clinical outcomes and medication adherence in difficult-to-control asthma. Thorax. 2012; 67(8):751-753

1194 Murphy E, Harrison J, Beach J. Implementation of statutory occupational respiratory health surveillance. Occupational Medicine. 2002; 52(8):497-502

1195 Murphy JC. Telemedicine offers new way to manage asthma. American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists. 2001; 58(18):1693, 1696

1196 Murray AB, Ferguson AC, Morrison BJ. Sensitization to house dust mites in different climatic areas. Journal of Allergy and Clinical Immunology. 1985; 76(1):108-112

1197 Musk AW, Knuiman M, Hunter M, Hui J, Palmer LJ, Beilby J et al. Patterns of airway disease and the clinical diagnosis of asthma in the Busselton population. European Respiratory Journal. 2011; 38(5):1053-1059

1198 Musken H, Fernandez-Caldas E, Maranon F, Franz JT, Masuch G, Bergmann KC. In vivo and in vitro sensitization to domestic mites in German urban and rural allergic patients. Journal of Investigational Allergology and Clinical Immunology. 2002; 12(3):177-181

1199 Mussaffi H, Springer C, Godfrey S. Increased bronchial responsiveness to exercise and histamine after allergen challenge in children with asthma. Journal of Allergy and Clinical Immunology. 1986; 77(1 Pt 1):48-52

1200 Mustonen K, Orivuori L, Keski-Nisula L, Hyvarinen A, Pfefferle PI, Riedler J et al. Inflammatory response and IgE sensitization at early age. Pediatric Allergy and Immunology. 2013; 24(4):395-401

1201 Mvula M, Larzelere M, Kraus M, Moisiewicz K, Morgan C, Pierce S et al. Prevalence of asthma and asthma-like symptoms in inner-city schoolchildren. Journal of Asthma. 2005; 42(1):9-16

1202 Mygind N, Dirksen A, Johnsen NJ, Weeke B. Perennial rhinitis: an analysis of skin testing, serum IgE, and blood and smear eosinophilia in 201 patients. Clinical Otolaryngology and Allied Sciences. 1978; 3(2):189-196

1203 Nadaskic R, Celeketic D, Ivanovic A. Bronchial reactivity in patients with allergic rhinitis. Allergy. 2010; 65:537

1204 Nadif R, Matran R, Maccario J, Bechet M, Le Moual N, Scheinmann P et al. Passive and active smoking and exhaled nitric oxide levels according to asthma and atopy in adults. Annals of Allergy, Asthma and Immunology. 2010; 104(5):385-393

1205 Nagel G, Buchele G, Weinmayr G, Bjorksten B, Chen YZ, Wang H et al. Effect of breastfeeding on asthma, lung function and bronchial hyperreactivity in ISAAC Phase II. European Respiratory Journal. 2009; 33(5):993-1002

1206 Nagel G, Weinmayr G, Flohr C, Kleiner A, Strachan DP, ISAAC Phase Two Study Group. Association of pertussis and measles infections and immunizations with asthma and allergic sensitization in ISAAC Phase Two. Pediatric Allergy and Immunology. 2012; 23(8):737-746

1207 Nagel G, Weinmayr G, Kleiner A, Garcia-Marcos L, Strachan DP, ISAAC Phase Two Study Group. Effect of diet on asthma and allergic sensitisation in the International Study on Allergies and Asthma in Childhood (ISAAC) Phase Two. Thorax. 2010; 65(6):516-522

1208 Nankani JN, Northfield M, Beran YM, Richardson PD. Changes in asthmatic patients' symptoms and lifestyles on institution of inhaled budesonide therapy. Current Medical Research and Opinion. 1990; 12(3):198-206

1209 Nantanda R, Ostergaard MS, Ndeezi G, Tumwine JK. Factors associated with asthma among under-fives in Mulago hospital, Kampala Uganda: a cross sectional study. BMC Pediatrics. 2013; 13:141

1210 Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children: diagnostic use and pathophysiological significance. Thorax. 2002; 57(7):586-589

1211 Nasir S, Sanchez-Vazquez M, Dick F. Cross-sectional survey of respiratory symptoms and exposures in scottish health service cleaners. Occupational and Environmental Medicine. 2011; 68:A91

1212 Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P et al. Development of the asthma control test: a survey for assessing asthma control. Journal of Allergy and Clinical Immunology. 2004; 113(1):59-65

1213 National Clinical Guideline Centre. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care. London. National Institute for Health and Care Excellence, 2010. Available from: http://www.nice.org.uk/guidance/cg101/resources/guidance-chronic-obstructive-pulmonary-disease-pdf

1214 National Clinical Guideline Centre. Acute Heart Failure: Diagnosing and Managing Acute Heart Failure in Adults. London. National Institute for Health and Care Excellence, 2014. Available from: https://www.nice.org.uk/guidance/cg187/resources/guidance-acute-heart-failure-pdf

1215 National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf

1216 National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications.nice.org.uk/the-guidelines-manual-pmg6/

1217 Navratil M, Plavec D, Dodig S, Jelcic Z, Nogalo B, Erceg D et al. Markers of systemic and lung inflammation in childhood asthma. Journal of Asthma. 2009; 46(8):822-828

1218 Negrini AC, Arobba D. Allergenic pollens and pollinosis in Italy: Recent advances. Allergy. 1992; 47(4 II):371-379

1219 Neijens HJ, Duiverman EJ, Kerrebijn KF. Bronchial responsiveness in children. Pediatric Clinics of North America. 1983; 30(5):829-846

1220 Nejjari C, Tessier JF, Barberger-Gateau P, Jacqmin H, Dartigues JF, Salamon R. Functional status of elderly people treated for asthma-related symptoms: A population based case-control study. European Respiratory Journal. 1994; 7(6):1077-1083

1221 Nelson BV, Sears S, Woods J, Ling CY, Hunt J, Clapper LM et al. Expired nitric oxide as a marker for childhood asthma. Journal of Pediatrics. 1997; 130(3):423-427

1222 Neuman A, Hohmann C, Orsini N, Pershagen G, Eller E, Kjaer HF et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. American Journal of Respiratory and Critical Care Medicine. 2012; 186(10):1037-1043

1223 Neve V, Matran R, Baquet G, Methlin CM, Delille C, Boulenguez C et al. Quantification of shape of flow-volume loop of healthy preschool children and preschool children with wheezing disorders. Pediatric Pulmonology. 2012; 47(9):884-894

1224 Neville RG, Bryce FP, Robertson FM, Crombie IK, Clark RA. Diagnosis and treatment of asthma in children: Usefulness of a review of medical records. British Journal of General Practice. 1992; 42(365):501-503

1225 Neville RG, McCowan C, Hoskins G, Thomas G. Cross-sectional observations on the natural history of asthma. British Journal of General Practice. 2001; 51(466):361-365

1226 Ng Man Kwong G, Das C, Proctor AR, Whyte MKB, Primhak RA. Diagnostic and treatment behaviour in children with chronic respiratory symptoms: relationship with socioeconomic factors. Thorax. 2002; 57(8):701-704

1227 Ng Man Kwong G, Proctor A, Billings C, Duggan R, Das C, Whyte MK et al. Increasing prevalence of asthma diagnosis and symptoms in children is confined to mild symptoms. Thorax. 2001; 56(4):312-314

1228 Nguyen JM, Holbrook JT, Wei CY, Gerald LB, Teague WG, Wise RA et al. Validation and psychometric properties of the Asthma Control Questionnaire among children. Journal of Allergy and Clinical Immunology. 2014; 133(1):91-96

1229 NHLBI. Peak flow monitoring in older adults with asthma. 2005. Available from: http://www.clinicaltrials.gov/ct/show/NCT00149474 [Last accessed: 4 June 2014]

1230 NHS Business Services Authority. NHS electronic drug tariff. 2011. Available from: http://www.nhsbsa.nhs.uk/924.aspx [Last accessed: 24 November 2014]

1231 Nickels A, Lim KG, Scanlon P, Parker K. Exhaled nitric oxide performance compared to methacholine challenge in asthma. Journal of Allergy and Clinical Immunology. 2014; 133(2 Suppl.1):AB148

1232 Nickels A, Parker K, Scanlon P, Lim K. The role of a positive exhaled nitric oxide in evaluating the pulmonary patient: Exhaled nitric oxide versus methacholine challenge? Chest. 2014; 145(3 Meeting Abstracts):467A

1233 Nicklas RA. Detection of aspirin sensitivity by pulmonary function tests. Medical Annals of the District of Columbia. 1973; 42(2):59-61

1234 Nicolai T, Carr D, Weiland SK, Duhme H, von Ehrenstein O, Wagner C et al. Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children. European Respiratory Journal. 2003; 21(6):956-963

1235 Nicolai T, Mutius EV, Reitmeir P, Wjst M. Reactivity to cold-air hyperventilation in normal and in asthmatic children in a survey of 5,697 schoolchildren in southern Bavaria. American Review of Respiratory Disease. 1993; 147(3):565-572

1236 Nicolaou NC, Lowe LA, Murray CS, Woodcock A, Simpson A, Custovic A. Exhaled breath condensate pH and childhood asthma: unselected birth cohort study. American Journal of Respiratory and Critical Care Medicine. 2006; 174(3):254-259

1237 Nides MA, Tashkin DP, Simmons MS, Wise RA, Li VC, Rand CS. Improving inhaler adherence in a clinical trial through the use of the Nebulizer Chronolog. Chest. 1993; 104(2):501-507

1238 Niedoszytko M, Chelminska M, Jassem E, Czestochowska E. Association between sensitization to Aureobasidium pullulans (Pullularia sp) and severity of asthma. Annals of Allergy, Asthma and Immunology. 2007; 98(2):153-156

1239 Nielsen JP, Ostergaard PA, Harris RI, Gammelby P. Comparison of CLA with BPT, SPT, and RAST in children with asthma. Allergy. 1992; 47(1):30-34

1240 Niemeijer NR, De Monchy JGR. Age-dependency of sensitization to aero-allergens in asthmatics. Allergy. 1992; 47(4 II):431-435

1241 Nieminen MM. Unimodal distribution of bronchial hyperresponsiveness to methacholine in asthmatic patients. Chest. 1992; 102(5):1537-1543

1242 Niggemann B, Illi S, Madloch C, Volkel K, Lau S, Bergmann R et al. Histamine challenges discriminate between symptomatic and asymptomatic children. MAS-Study Group. Multicentre Allergy Study. European Respiratory Journal. 2001; 17(2):246-253

1243 Niggemann B, Nilsson M, Friedrichs F. Paediatric allergy diagnosis in primary care is improved by in vitro allergen-specific IgE testing. Pediatric Allergy and Immunology. 2008; 19(4):325-331

1244 Niimi A, Matsumoto H. Serum measurement of eosinophil cationic protein in the management of asthma. Current Opinion in Pulmonary Medicine. 1999; 5(2):111-117

1245 Nikkhah M, Amra B, Eshaghian A, Fardad S, Asadian A, Roshanzamir T et al. Comparison of impulse osillometry system and spirometry for diagnosis of obstructive lung disorders. Tanaffos. 2011; 10(1):19-25

1246 Nimmo CJ, Chen DN, Martinusen SM, Ustad TL, Ostrow DN. Assessment of patient acceptance and inhalation technique of a pressurized aerosol inhaler and two breath-actuated devices. Annals of Pharmacotherapy. 1993; 27(7-8):922-927

1247 Ninan TK, Macdonald L, Russell G. Persistent nocturnal cough in childhood: a population based study. Archives of Disease in Childhood. 1995; 73(5):403-407

1248 Ninan TK, Russell G. Is exercise testing useful in a community based asthma survey? Thorax. 1993; 48(12):1218-1221

1249 Nish WA, Schwietz LA. Underdiagnosis of asthma in young adults presenting for USAF basic training. Annals of Allergy. 1992; 69(3):239-242

1250 Nishio K, Odajima H, Motomura C, Nakao F, Nishima S. Exhaled nitric oxide and exercise-induced bronchospasm assessed by FEV1, FEF25-75% in childhood asthma. Journal of Asthma. 2007; 44(6):475-478

1251 Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A. Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. European Respiratory Journal. 2000; 15(5):863-869

1252 Nja F, Roksund OD, Carlsen KH. Eosinophil cationic protein (ECP) in school children living in a mountainous area of Norway: a population-based study of ECP as a tool for diagnosing asthma in children with reference values. Allergy. 2001; 56(2):138-144

1253 Nogami H, Shoji S, Nishima S. Exhaled nitric oxide as a simple assessment of airway hyperresponsiveness in bronchial asthma and chronic cough patients. Journal of Asthma. 2003; 40(6):653-659

1254 Nogueira JM, de Almeida MM, Santa Marta C, Pinto PL, Bastos G, Boavida MR et al. Quantitative skin prick tests and specific IgE (CAP System) for D. pteronissynus--correlation of results in a paediatric population. Allergie Et Immunologie. 1994; 26(3):102-106

1255 Nolles G, Hoekstra MO, Schouten JP, Gerritsen J, Kauffman HF. Prevalence of immunoglobulin E for fungi in atopic children. Clinical and Experimental Allergy. 2001; 31(10):1564-1570

1256 Nolte H, Storm K, Schiotz PO. Diagnostic value of a glass fibre-based histamine analysis for allergy testing in children. Allergy. 1990; 45(3):213-223

1257 Nordlund B, Konradsen JR, Kull I, Borres MP, Onell A, Hedlin G et al. IgE antibodies to animal-derived lipocalin, kallikrein and secretoglobin are markers of bronchial inflammation in severe childhood asthma. Allergy. 2012; 67(5):661-669

1258 Nordvall SL, Janson C, Kalm-Stephens P, Foucard T, Toren K, Alving K. Exhaled nitric oxide in a population-based study of asthma and allergy in schoolchildren. Allergy. 2005; 60(4):469-475

1259 Nowak D, Heinrich J, Jorres R, Wassmer G, Berger J, Beck E et al. Prevalence of respiratory symptoms, bronchial hyperresponsiveness and atopy among adults: West and East Germany. European Respiratory Journal. 1996; 9(12):2541-2552

1260 Nuijsink M, Hop WCJ, Sterk PJ, Duiverman EJ, De Jongste JC. Long-term asthma treatment guided by airway hyperresponsiveness in children: a randomised controlled trial. European Respiratory Journal. 2007; 30(3):457-466

1261 Nuijsink M, Vaessen-Verberne AAPH, Hop WCJ, Sterk PJ, Duiverman EJ, de Jongste JC et al. Long-term follow-up after two years of asthma treatment guided by airway responsiveness in children. Respiratory Medicine. 2013; 107(7):981-986

1262 Nusslein HG, Zimmermann T, Baum M, Fuchs C, Kolble K, Kalden JR. Improved in vitro diagnosis of allergy to Alternaria tenius and Cladosporium herbarum. Allergy. 1987; 42(6):414-422

1263 Nwaru BI, Craig LCA, Allan K, Prabhu N, Turner SW, McNeill G et al. Breastfeeding and introduction of complementary foods during infancy in relation to the risk of asthma and atopic diseases up to 10years. Clinical and Experimental Allergy. 2013; 43(11):1263-1273

1264 O'Connor GT, Sparrow D, Weiss ST. Normal range of methacholine responsiveness in relation to prechallenge pulmonary function. The Normative Aging Study. Chest. 1994; 105(3):661-666

1265 Obata T, Iikura Y. Comparison of bronchial reactivity to ultrasonically nebulized distilled water, exercise and methacholine challenge test in asthmatic children. Annals of Allergy. 1994; 72(2):167-172

1266 Oberle D, Von ME, Von KR. Childhood asthma and continuous exposure to cats since the first year of life with cats allowed in the child's bedroom. Allergy. 2003; 58(10):1033-1036

1267 Oddy WH. Breastfeeding and asthma in children: findings from a West Australian study. Breastfeeding Review. 2000; 8(1):5-11

1268 Oddy WH, de Klerk NH, Sly PD, Holt PG. The effects of respiratory infections, atopy, and breastfeeding on childhood asthma. European Respiratory Journal. 2002; 19(5):899-905

1269 Oddy WH, Holt PG, Sly PD, Read AW, Landau LI, Stanley FJ et al. Association between breast feeding and asthma in 6 year old children: findings of a prospective birth cohort study. BMJ. 1999; 319(7213):815-819

1270 Oddy WH, Peat JK, de Klerk NH. Maternal asthma, infant feeding, and the risk of asthma in childhood. Journal of Allergy and Clinical Immunology. 2002; 110(1):65-67

1271 Oddy WH, Sherriff JL, de Klerk NH, Kendall GE, Sly PD, Beilin LJ et al. The relation of breastfeeding and body mass index to asthma and atopy in children: a prospective cohort study to age 6 years. American Journal of Public Health. 2004; 94(9):1531-1537

1272 Office for National Statistics. Life tables 2011 - 2013. London. Office for National Statistics, 2014. Available from: http://www.ons.gov.uk/ons/dcp171778_377972.pdf

1273 Oh MJ, Lee JY, Lee BJ, Choi DC. Exhaled nitric oxide measurement is useful for the exclusion of nonasthmatic eosinophilic bronchitis in patients with chronic cough. Chest. 2008; 134(5):990-995

1274 Ohkura N, Fujimura M, Tani M, Okazaki A, Hara J, Nishitsuji M et al. The measurement of cough sensitivity to methacholine for discrimination of cough variant asthma. Respirology. 2013; 18:155

1275 Ohkura N, Fujimura M, Tokuda A, Furusho S, Abo M, Katayama N. Evaluation of airway hyperresponsiveness and exhaled nitric oxide as risk factors for airway remodeling in patients with stable asthma. Allergy and Asthma Proceedings. 2009; 30(4):419-423

1276 Ojoo JC, Mulrennan SA, Kastelik JA, Morice AH, Redington AE. Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax. 2005; 60(1):22-26

1277 Okudaira H, Hongo O, Ogita T, Haida M, Yamauchi N, Miyamoto T. Serum IgE and IgE antibody levels in patients with bronchial asthma, atopic dermatitis, eosinophilic granulomas of the soft tissue (Kimura's disease) and other diseases. Annals of Allergy. 1983; 50(1):51-54

1278 Okupa AY, Jackson DJ, Sorkness CA, Rajamanickam VP, Kang TJ, Awoyinka IA et al. Mannitol bronchoprovocation in the evaluation of airway reactivity in a high-risk pediatric cohort. Journal of Allergy and Clinical Immunology. 2012; 129(2 SUPPL. 1):AB2

1279 Olaguibel JM, Basomba A. Occupational asthma induced by chromium salts. Allergologia Et Immunopathologia. 1989; 17(3):133-136

1280 Olin AC, Rosengren A, Thelle DS, Lissner L, Bake B, Toren K. Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample. Chest. 2006; 130(5):1319-1325

1281 Onur E, Kabaroglu C, Gunay O, Var A, Yilmaz O, Dundar P et al. The beneficial effects of physical exercise on antioxidant status in asthmatic children. Allergologia Et Immunopathologia. 2011; 39(2):90-95

1282 Onyirimba F, Apter A, Reisine S, Litt M, McCusker C, Connors M et al. Direct clinician-to-patient feedback discussion of inhaled steroid use: its effect on adherence. Annals of Allergy, Asthma and Immunology. 2003; 90(4):411-415

1283 Oostveen E, Dom S, Desager K, Hagendorens M, De Backer W, Weyler J. Lung function and bronchodilator response in 4-year-old children with different wheezing phenotypes. European Respiratory Journal. 2010; 35(4):865-872

1284 Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2013. Available from: http://www.oecd.org/std/ppp [Last accessed: 27 November 2013]

1285 Oryszczyn MP, Annesi-Maesano I, Charpin D, Kauffmann F. Allergy markers in adults in relation to the timing of pet exposure: the EGEA study. Allergy. 2003; 58(11):1136-1143

1286 Oryszczyn MP, van Ree R, Maccario J, Nadif R, Kauffmann F, EGEA Cooperative Group. Cat sensitization according to cat window of exposure in adult asthmatics. Clinical and Experimental Allergy. 2009; 39(10):1515-1521

1287 Osman LM, Calder C, Godden DJ, Friend JAR, McKenzie L, Legge JS et al. A randomised trial of self-management planning for adult patients admitted to hospital with acute asthma. Thorax. 2002; 57(10):869-874

1288 Osman M, Tagiyeva N, Wassall HJ, Ninan TK, Devenny AM, McNeill G et al. Changing trends in sex specific prevalence rates for childhood asthma, eczema, and hay fever. Pediatric Pulmonology. 2007; 42(1):60-65

1289 Osterballe O, Malling HJ, Weeke B. Specific diagnosis of exogenous bronchial asthma in adults. Comparison between case history, intracutaneous test, RAST, histamine release from basophil leucocytes, and bronchial provocation. Allergy. 1979; 34(3):175-185

1290 Ostergaard PA, Ebbesen F, Nolte H, Skov PS. Basophil histamine release in the diagnosis of house dust mite and dander allergy of asthmatic children. Comparison between prick test, RAST, basophil histamine release and bronchial provocation. Allergy. 1990; 45(3):231-235

1291 Ostojic V, Cvoriscec B, Ostojic SB, Reznikoff D, Stipic-Markovic A, Tudjman Z. Improving asthma control through telemedicine: A study of short-message service. Telemedicine Journal and E-Health. 2005; 11(1):28-35

1292 Otsuki M, Eakin MN, Rand CS, Butz AM, Hsu VD, Zuckerman IH et al. Adherence feedback to improve asthma outcomes among inner-city children: a randomized trial. Pediatrics. 2009; 124(6):1513-1521

1293 Ozarek-Hanc A, Olczak S, Majak P, Jerzynska J, Smejda K, Stelmach I. Usefulness of bronchial reversibility test in asthma diagnosis in children. Alergia Astma Immunologia. 2012; 17(2):83-88

1294 Padovano A, D'Agostino F, Schiano MM, Martino P, Cocco G. Indentification of high risk asthma patients by methacholine bronchial provocation tests (MBPT). American Journal of Respiratory and Critical Care Medicine. 2000; 161(3 Suppl):A102

1295 Paggiaro PL, Moscato G, Giannini D, Di PF, Bertoletti R, Bacci E et al. The Italian Working Group on the use of peak expiratory flow rate (PEFR) in asthma. European Respiratory Review. 1993; 3(14):438-443

1296 Palma-Carlos AG, Palma-Carlos ML, Costa AC. "Minor" hemoglobinopathies: a risk factor for asthma. European Annals of Allergy and Clinical Immunology. 2005; 37(5):177-182

1297 Palmeiro EM, Hopp RJ, Biven RE, Bewtra AK, Nair NN, Townley RG. Probability of asthma based on methacholine challenge. Chest. 1992; 101(3):630-633

1298 Palmer LJ, Rye PJ, Gibson NA, Burton PR, Landau LI, Lesouef PN. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. American Journal of Respiratory and Critical Care Medicine. 2001; 163(1):37-42

1299 Palmer LJ, Valinsky L, Pikora T, Landau LI. Do regular check ups and preventive drug use reduce asthma severity in school children? Australian Family Physician. 2004; 33(7):573-576

1300 Panaszek B, Liebhart E, Liebhart J, Pawlowicz R, Fal AM. Serum concentration of C-reactive protein is not a good marker of bronchial hyperresponsiveness. Archivum Immunologiae Et Therapiae Experimentalis. 2007; 55(5):341-345

1301 Panichwattana W, Piboonpocanun O, Veskitkul J, Visitsunthorn N, Pacharn P, Vichyanond P. Cat sensitisation increases risk of asthma and allergic rhinitis among mite sensitive children. Allergy. 2013; 68:457

1302 Panico L, Bartley M, Marmot M, Nazroo JY, Sacker A, Kelly YJ. Ethnic variation in childhood asthma and wheezing illnesses: findings from the Millennium Cohort Study. International Journal of Epidemiology. 2007; 36(5):1093-1102

1303 Panzani RC, Mercier P, Delord Y, Riva G, Falagiani P, Reviron D et al. Prevalence of patent and latent atopy among a general normal adult population in the south east of France by RAST investigation and correlation with circulating total IgE levels. Allergologia Et Immunopathologia. 1993; 21(6):211-219

1304 Papa G, Romano A, Quaratino D, Di Fonso M, Viola M, Artesani MC et al. Prevalence of sensitization to Cupressus sempervirens: a 4-year retrospective study. Science of the Total Environment. 2001; 270(1-3):83-87

1305 Parameswaran K, Allen CJ, Kamada D, Efthimiadis A, Anvari M, Hargreave FE. Sputum cell counts and exhaled nitric oxide in patients with gastroesophageal reflux, and cough or asthma. Canadian Respiratory Journal. 2001; 8(4):239-244

1306 Parameswaran K, Belda J, Sears MR. Use of peak flow variability and methacholine responsiveness in predicting changes from pre-test diagnosis of asthma. European Respiratory Journal. 1999; 14(6):1358-1362

1307 Parameswaran K, Sasikumar P. Blood eosinophil count to assess compliance to inhaled corticosteroid therapy in asthma. American Journal of Respiratory and Critical Care Medicine. 2000; 161(3 Suppl):A711

1308 Pararajasingam CD, Sittampalam L, Damani P, Pattemore PK, Holgate ST. Comparison of the prevalence of asthma among Asian and European children in Southampton. Thorax. 1992; 47(7):529-532

1309 Paredi P, Kharitonov SA, Barnes PJ. Faster rise of exhaled breath temperature in asthma: A novel marker of airway inflammation? American Journal of Respiratory and Critical Care Medicine. 2002; 165(2):181-184

1310 Paredi P, Kharitonov SA, Barnes PJ. Correlation of exhaled breath temperature with bronchial blood flow in asthma. Respiratory Research. 2005; 6:15

1311 Park ES, Golding J, Carswell F, Stewart-Brown S. Preschool wheezing and prognosis at 10. Archives of Disease in Childhood. 1986; 61(7):642-646

1312 Park HS, Nahm DH, Suh CH, Lee SM, Choi SY, Jung KS et al. Evidence of Hop Japanese pollinosis in Korea: IgE sensitization and identification of allergenic components. Journal of Allergy and Clinical Immunology. 1997; 100(4):475-479

1313 Park S, Jee H, Park Y, Choi B, Song T, Lee H et al. Airway hyperresponsiveness with Delta;FEV0.5 and FEV0.75 in children. Journal of Allergy and Clinical Immunology. 2009; 123(2 SUPPL. 1):S6

1314 Park YB, Yoo KH, Lee W-Y. Characteristics of difficult to treat asthma in Korea; pilot study. Allergy. 2013; 68:373

1315 Parker AL. Airway reactivity is a determinant of bronchodilator responsiveness after methacholine-induced bronchoconstriction. Journal of Asthma. 2004; 41(6):671-677

1316 Parkerson J, Ledford D. Mannitol as an indirect bronchoprovocation test for the 21st century. Annals of Allergy, Asthma and Immunology. 2011; 106(2):91-96

1317 Pastorello EA, Incorvaia C, Ortolani C, Bonini S, Canonica GW, Romagnani S et al. Studies on the relationship between the level of specific IgE antibodies and the clinical expression of allergy: I. Definition of levels distinguishing patients with symptomatic from patients with asymptomatic allergy to common aeroallergens. Journal of Allergy and Clinical Immunology. 1995; 96(5 Pt 1):580-587

1318 Paterson NA, Peat JK, Mellis CM, Xuan W, Woolcock AJ. Accuracy of asthma treatment in schoolchildren in NSW, Australia. European Respiratory Journal. 1997; 10(3):658-664

1319 Paton JY. Asthma in childhood - making the diagnosis. Current Pediatric Reviews. 2010; 6(2):112-120

1320 Pattemore PK, Asher MI, Harrison AC, Mitchell EA, Rea HH, Stewart AW. The interrelationship among bronchial hyperresponsiveness, the diagnosis of asthma, and asthma symptoms. American Review of Respiratory Disease. 1990; 142(3):549-554

1321 Pearlman AN, Chandra RK, Chang D, Conley DB, Tripathi-Peters A, Grammer LC et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. American Journal of Rhinology and Allergy. 2009; 23(2):145-148

1322 Pearlman DS, Berger WE, Kerwin E, Laforce C, Kundu S, Banerji D. Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. Journal of Allergy and Clinical Immunology. 2005; 116(6):1206-1212

1323 Peat JK, Salome CM, Berry G, Woolcock AJ. Relation of dose-response slope to respiratory symptoms in a population of Australian schoolchildren. American Review of Respiratory Disease. 1991; 144(3 Pt 1):663-667

1324 Peat JK, Salome CM, Woolcock AJ. Longitudinal changes in atopy during a 4-year period: Relation to bronchial hyperresponsiveness and respiratory symptoms in a population sample of Australian schoolchildren. Journal of Allergy and Clinical Immunology. 1990; 85(1 I):65-74

1325 Peat JK, Toelle BG, Dermand J, van den Berg R, Britton WJ, Woolcock AJ. Serum IgE levels, atopy, and asthma in young adults: results from a longitudinal cohort study. Allergy. 1996; 51(11):804-810

1326 Peat JK, Tovey E, Mellis CM, Leeder SR, Woolcock AJ. Importance of house dust mite and Alternaria allergens in childhood asthma: an epidemiological study in two climatic regions of Australia. Clinical and Experimental Allergy. 1993; 23(10):812-820

1327 Peat JK, van den Berg RH, Green WF, Mellis CM, Leeder SR, Woolcock AJ. Changing prevalence of asthma in Australian children. BMJ. 1994; 308(6944):1591-1596

1328 Pecoud A, Ochsner M, Arrendal H, Frei PC. Improvement of the radioallergosorbent test (RAST) sensitivity by using an antibody specific for the determinant D epsilon 2. Clinical Allergy. 1982; 12(1):75-81

1329 Pedrosa M, Barranco P, Caminoa M, Botello MD, Quirce S. Comparison of methacholine and adenosine inhalation challenge in patients with suspected asthma. Journal of Asthma. 2009; 46(8):773-776

1330 Pedrosa M, Cancelliere N, Barranco P, Lopez-Carrasco V, Quirce S. Usefulness of exhaled nitric oxide for diagnosing asthma. Journal of Asthma. 2010; 47(7):817-821

1331 Peirsman EJ, Carvelli TJ, Hage PY, Hanssens LS, Pattyn L, Raes MM et al. Exhaled nitric oxide in childhood allergic asthma management a randomised controlled trial. Pediatric Pulmonology. 2013;

1332 Pekkarinen PT, von Hertzen L, Laatikainen T, Makela MJ, Jousilahti P, Kosunen TU et al. A disparity in the association of asthma, rhinitis, and eczema with allergen-specific IgE between Finnish and Russian Karelia. Allergy. 2007; 62(3):281-287

1333 Pelikan Z, Pelikan-Filipek M. A diagnostic study of immediate hypersensitivity in asthmatic patients: A comparison of bronchial challenge and serum RAST. Annals of Allergy. 1982; 49(2):112-117

1334 Pepys J, Roth A, Carroll KB. RAST, skin and nasal tests and the history in grass pollen allergy. Clinical Allergy. 1975; 5(4):431-442

1335 Pereira EAL, Silva DAO, Cunha-Junior JP, Almeida KC, Alves R, Sung SJ et al. IgE, IgG1, and IgG4 antibody responses to Blomia tropicalis in atopic patients. Allergy. 2005; 60(3):401-406

1336 Perpina M, Pellicer C, De Diego A, Compte L, Macian V. Diagnostic value of the bronchial provocation test with methacholine in asthma. A Bayesian analysis approach. Chest. 1993; 104(1):149-154

1337 Perrin B, Lagier F, L'Archeveque J, Cartier A, Boulet LP, Cote J et al. Occupational asthma: validity of monitoring of peak expiratory flow rates and non-allergic bronchial responsiveness as compared to specific inhalation challenge. European Respiratory Journal. 1992; 5(1):40-48

1338 Perrin LF, Sroussi J, Cea-Gil F, Deviller P, Lasne Y. Serum IgE levels and specific IgE antibodies in house dust mite allergy: predictive value. Journal of Asthma. 1983; 20(2):93-96

1339 Persaud DI, Barnett SE, Weller SC, Baldwin CD, Niebuhr V, McCormick DP. An asthma self-management program for children, including instruction in peak flow monitoring by school nurses. Journal of Asthma. 1996; 33(1):37-43

1340 Persky VW, Slezak J, Contreras A, Becker L, Hernandez E, Ramakrishnan V et al. Relationships of race and socioeconomic status with prevalence, severity, and symptoms of asthma in Chicago school children. Annals of Allergy, Asthma and Immunology. 1998; 81(3):266-271

1341 Pertseva TO, Botvinikova LA. Quality of life in patients with bronchial asthma impact of regular monitoring and good compliance [Abstract]. European Respiratory Journal. 2004; 24(Suppl 48):285s

1342 Perzanowski MS, Canfield SM, Chew GL, Mellins RB, Hoepner LA, Jacobson JS et al. Birth order, atopy, and symptoms of allergy and asthma among inner-city children attending Head Start in New York City. Clinical and Experimental Allergy. 2008; 38(6):968-976

1343 Perzanowski MS, Divjan A, Mellins RB, Canfield SM, Rosa MJ, Chew GL et al. Pediatric - Exhaled NO among inner-city children in New York City. Journal of Asthma. 2010; 47(9):1015-1021

1344 Perzanowski MS, Sporik R, Squillace SP, Gelber LE, Call R, Carter M et al. Association of sensitization to Alternaria allergens with asthma among school-age children. Journal of Allergy and Clinical Immunology. 1998; 101(5):626-632

1345 Perzanowski MS, Divjan A, Mellins RB, Canfield SM, Rosa MJ, Chew GL et al. Exhaled NO among inner-city children in New York City. Journal of Asthma. 2010; 47(9):1015-1021

1346 Petanjek BB, Grle SP, Pelicaric D, Vrankovic D. Bronchodilator response in patients with persistent allergic asthma could not predict airway hyperresponsiveness. Allergy, Asthma, and Clinical Immunology. 2007; 3(4):123-127

1347 Peters JM, Avol E, Navidi W, London SJ, Gauderman WJ, Lurmann F et al. A study of twelve Southern California communities with differing levels and types of air pollution. I. Prevalence of respiratory morbidity. American Journal of Respiratory and Critical Care Medicine. 1999; 159(3):760-767

1348 Petitto J, Jones SM. Adherence to inhaled corticosteroids: An ancillary study of the Childhood Asthma Management Program clinical trial. Pediatrics. 2012; 130(SUPPL.1):S37-S38

1349 Petrie KJ, Perry K, Broadbent E, Weinman J. A text message programme designed to modify patients' illness and treatment beliefs improves self-reported adherence to asthma preventer medication. British Journal of Health Psychology.: British Psychological Society, United Kingdom. 2012; 17(1):74-84

1350 Petsky H, Li AM, Kynaston JA, Turner C, Chang, AB. Dual-centre randomised trial on tailored asthma therapy based on exhaled nitric oxide (FeNO) [Abstract]. Paediatric Respiratory Reviews. 3/10 2010; 11(Suppl 1):S80-S81

1351 Petsky HL. Dual-centre randomised trial on tailored asthma therapy based on exhaled nitric oxide (FeNO) vs routine clinical care. Pediatric Pulmonology. 2014; 49:S57

1352 Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax. 2012; 67(3):199-208

1353 Petsky HL, Kynaston JA, Turner C, Li AM, Cates CJ, Lasserson TJ et al. Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database of Systematic Reviews. 2007; Issue 2:CD005603. DOI:10.1002/14651858.CD005603.pub2.

1354 Petsky HL, Li AM, Au CT, Kynaston JA, Turner C, Chang AB. Management based on exhaled nitric oxide levels adjusted for atopy reduces asthma exacerbations in children: A dual centre randomized controlled trial. Pediatric Pulmonology. 2014;

1355 Phakthongsuk P, Sangsupawanich P, Musigsan A, Thammakumpee G. Work-related respiratory symptoms among cotton-fabric sewing workers. International Journal of Occupational Medicine and Environmental Health. 2007; 20(1):17-24

1356 Piacentini GL, Bodini A, Costella S, Suzuki Y, Zerman L, Peterson CG et al. Exhaled nitric oxide, serum ECP and airway responsiveness in mild asthmatic children. European Respiratory Journal. 2000; 15(5):839-843

1357 Piacentini GL, Bodini A, Costella S, Vicentini L, Mazzi P, Sperandio S et al. Exhaled nitric oxide and sputum eosinophil markers of inflammation in asthmatic children. European Respiratory Journal. 1999; 13(6):1386-1390

1358 Piippo-Savolainen E, Remes S, Korppi M. Does blood eosinophilia in wheezing infants predict later asthma? A prospective 18-20-year follow-up. Allergy and Asthma Proceedings. 2007; 28(2):163-169

1359 Pijnenburg MW, Bakker EM, Hop WC, De Jongste JC. Titrating inhaled steroids on exhaled nitric oxide improves FEV1 in allergic asthmatic children. American Thoracic Society 2005 International Conference; May 20-25; San Diego, California. 2005;C47

1360 Pike K, Selby A, Price S, Warner J, Connett G, Legg J et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clinical Respiratory Journal. 2012;

1361 Pinnock H, Adlem L, Gaskin S, Harris J, Snellgrove C, Sheikh A. Accessibility, clinical effectiveness, and practice costs of providing a telephone option for routine asthma reviews: phase IV controlled implementation study. British Journal of General Practice. United Kingdom 2007; 57:714-722

1362 Pinnock H, Bawden R, Proctor S, Wolfe S, Scullion J, Price D et al. Accessibility, acceptability, and effectiveness in primary care of routine telephone review of asthma: pragmatic, randomised controlled trial. BMJ. 2003; 326(7387):477-479

1363 Pinnock H, McKenzie L, Price D, Sheikh A. Cost-effectiveness of telephone or surgery asthma reviews: economic analysis of a randomised controlled trial. British Journal of General Practice. 2005; 55:119-124:119-124

1364 Pinnock H, Burton C, Campbell S, Gruffydd-Jones K, Hannon K, Hoskins G et al. Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. Primary Care Respiratory Journal. 2012; 21(3):288-294

1365 Pino JM, Garcia-Rio F, Prados C, Alvarez-Sala R, Diaz S, Villasante C et al. Value of the peak expiratory flow in bronchodynamic tests. Allergologia Et Immunopathologia. 1996; 24(2):54-57

1366 Pinto LA, Depner M, Klopp N, Illig T, Vogelberg C, von Mutius E et al. MMP-9 gene variants increase the risk for non-atopic asthma in children. Respiratory Research. 2010; 11:23

1367 Pizzichini MM, Rennie D, Senthilselvan A, Taylor B, Habbick BF, Sears MR. Limited agreement between written and video asthma symptom questionnaires. Pediatric Pulmonology. 2000; 30(4):307-312

1368 Plaschke P, Janson C, Norrman E, Björnsson E, Ellbjär S, Järvholm B. Association between atopic sensitization and asthma and bronchial hyperresponsiveness in swedish adults: pets, and not mites, are the most important allergens. Journal of Allergy and Clinical Immunology. 1999; 104(1):58-65

1369 Plaschke P, Janson C, Norrman E, Bjornsson E, Lundback B, Lindholm N et al. Skin prick tests and specific IgE in adults from three different areas of Sweden. Allergy. 1996; 51(7):461-472

1370 Plebani M, Borghesan F, Faggian D. Clinical efficiency of in vitro and in vivo tests for allergic diseases. Annals of Allergy, Asthma and Immunology. 1995; 74(1):23-28

1371 Pless-Mulloli T, Howel D, King A, Stone I, Merefield J, Bessell J et al. Living near opencast coal mining sites and children's respiratory health. Occupational and Environmental Medicine. 2000; 57(3):145-151

1372 Pless-Mulloli T, Howel D, Prince H. Prevalence of asthma and other respiratory symptoms in children living near and away from opencast coal mining sites. International Journal of Epidemiology. 2001; 30(3):556-563

1373 Poder G, Kelemen J, Mezei G, Borzsonyi L. Results of bronchial challenge after infantile obstructive bronchitis. Acta Paediatrica Hungarica. 1987; 28(3-4):201-207

1374 Pogson ZEK, McKeever TM, Lewis SA, Britton JR, Fogarty AW. An evaluation of the use of bronchoconstriction induced by deep inspiration as a new epidemiological measure for asthma. Journal of Asthma. 2009; 46(4):319-321

1375 Pohunek P, Warner JO, Turzikova J, Kudrmann J, Roche WR. Markers of eosinophilic inflammation and tissue re-modelling in children before clinically diagnosed bronchial asthma. Pediatric Allergy and Immunology. 2005; 16(1):43-51

1376 Ponsonby AL, Couper D, Dwyer T, Carmichael A, Kemp A, Cochrane J. The relation between infant indoor environment and subsequent asthma. Epidemiology. 2000; 11(2):128-135

1377 Ponsonby AL, Couper D, Dwyer T, Carmichael A, Wood-Baker R. Exercise-induced bronchial hyperresponsiveness and parental ISAAC questionnaire responses. European Respiratory Journal. 1996; 9(7):1356-1362

1378 Ponsonby AL, Dwyer T, Trevillian L, Kemp A, Cochrane J, Couper D et al. The bedding environment, sleep position, and frequent wheeze in childhood. Pediatrics. 2004; 113(5):1216-1222

1379 Ponsonby AL, Glasgow N, Pezic A, Dwyer T, Ciszek K, Kljakovic M. A temporal decline in asthma but not eczema prevalence from 2000 to 2005 at school entry in the Australian Capital Territory with further consideration of country of birth. International Journal of Epidemiology. 2008; 37(3):559-569

1380 Popa V, Singleton J. Provocation dose and discriminant analysis in histamine bronchoprovocation. Are the current predictive data satisfactory? Chest. 1988; 94(3):466-475

1381 Popovic-Grle S, Mehulic M, Pavicic F, Babic I, Beg-Zec Z. Clinical validation of bronchial hyperresponsiveness, allergy tests and lung function in the diagnosis of asthma in persons with dyspnea. Collegium Antropologicum. 2002; 26 Suppl:119-127

1382 Porsbjerg C, Rasmussen L, Thomsen SF, Brannan JD, Anderson SD, Backer V. Response to mannitol in asymptomatic subjects with airway hyper-responsiveness to methacholine. Clinical and Experimental Allergy. 2007; 37(1):22-28

1383 Porsbjerg C, von Linstow ML, Ulrik CS, Nepper-Christensen S, Backer V. Risk factors for onset of asthma: a 12-year prospective follow-up study. Chest. 2006; 129(2):309-316

1384 Porsbjerg C, Backer V, Joos G, Kerstjens HAM, Rodriguez-Roisin R. Current and future use of the mannitol bronchial challenge in everyday clinical practice. Clinical Respiratory Journal. 2009; 3(4):189-197

1385 Postma DS, Lebowitz MD. Persistence and new onset of asthma and chronic bronchitis evaluated longitudinally in a community population sample of adults. Archives of Internal Medicine. 1995; 155(13):1393-1399

1386 Powell CV, Nolan TM, Carlin JB, Bennett CM, Johnson PD. Respiratory symptoms and duration of residence in immigrant teenagers living in Melbourne, Australia. Archives of Disease in Childhood. 1999; 81(2):159-162

1387 Powell CV, Primhak RA. Asthma treatment, perceived respiratory disability, and morbidity. Archives of Disease in Childhood. 1995; 72(3):209-213

1388 Powell CV, Primhak RA. Stability of respiratory symptoms in unlabelled wheezy illness and nocturnal cough. Archives of Disease in Childhood. 1996; 75(5):385-391

1389 Powell H, Murphy VE, Taylor DR, Hensley MJ, Mccaffery K, Giles W et al. Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial. Lancet. 2011; 378(9795):983-990

1390 Powell H, Gibson PG. Options for self-management education for adults with asthma. Cochrane Database of Systematic Reviews. 2002; Issue 3:CD004107. DOI:10.1002/14651858.CD004107

1391 Power C, Manor O. Asthma, enuresis, and chronic illness: long term impact on height. Archives of Disease in Childhood. 1995; 73(4):298-304

1392 Prabhakaran L, Chee J, Chua KC, Mun WW. The Use of Text Messaging to Improve Asthma Control: A Study of Short Message Service (SMS). Respirology. 2009; 14(Suppl 3):A217

1393 Prabhakaran L, Chee WY, Chua KC, Abisheganaden J, Wong WM. The use of text messaging to improve asthma control: a pilot study using the mobile phone short messaging service (SMS). Journal of Telemedicine and Telecare. 2010; 16(5):286-290

1394 Prabhu N, Smith N, Campbell D, Craig LC, Seaton A, Helms PJ et al. First trimester maternal tobacco smoking habits and fetal growth. Thorax. 2010; 65(3):235-240

1395 Prado OS, Perez-Yarza EG, Ruiz AA, Murua JK, Elosegui PC, Aramburu JM et al. Fraction of exhaled nitric oxide and asthma predictive index in infants less than two years-old. Archivos De Bronconeumologia. 2011; 47(5):234-238

1396 Prasad A, Langford B, Stradling JR, Ho LP. Exhaled nitric oxide as a screening tool for asthma in school children. Respiratory Medicine. 2006; 100(1):167-173

1397 Pratter MR, Curley FJ, Dubois J, Irwin RS. Cause and evaluation of chronic dyspnea in a pulmonary disease clinic. Archives of Internal Medicine. 1989; 149(10):2277-2282

1398 Pratter MR, Hingston DM, Irwin RS. Diagnosis of bronchial asthma by clinical evaluation. An unreliable method. Chest. 1983; 84(1):42-47

1399 Prehn A, Seger RA, Torresani T, Molinari L, Sennhauser FH. Evaluation of a clinical algorithm involving serum eosinophil cationic protein for guiding the anti-inflammatory treatment of bronchial asthma in childhood. Pediatric Allergy and Immunology. 2000; 11(2):87-94

1400 Press VG, Arora VM, Shah LM, Lewis SL, Charbeneau J, Naureckas ET et al. Teaching the use of respiratory inhalers to hospitalized patients with asthma or COPD: a randomized trial. Journal of General Internal Medicine. 2012; 27(10):1317-1325

1401 Price D, Saralaya D, Britton M, ike T, ohn H, ilary P et al. Asthma Costs In The UK By Asthma Control Status And Exacerbations. American Journal of Respiratory and Critical Care Medicine. American Thoracic Society International Conference Abstracts: American Thoracic Society. 2013; 187:A2145

1402 Price D, Berg J, Lindgren P. An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom. Allergy. 2009; 64(3):431-438

1403 Price JA, Reiser J, Longbottom JL, Warner JO. Inhalant allergy in asthmatic children: skin prick test, radioallergosorbent test and chemiluminescent assay compared with allergen levels in their mattress dusts. International Archives of Allergy and Applied Immunology. 1989; 88(1-2):183-184

1404 Prichard MG, Ryan G, Walsh BJ, Musk AW. Skin test and RAST responses to wheat and common allergens and respiratory disease in bakers. Clinical Allergy. 1985; 15(2):203-210

1405 Prieto L, Gutierrez V, Morales C, Marin J. Differences in sensitivity, maximal response and position of the concentration-response curve to methacholine between asthmatics, patients with allergic rhinitis and healthy subjects. Respiratory Medicine. 1998; 92(1):88-94

1406 Prieto L, Gutierrez V, Morales C, Perpinan J, Inchaurraga I. Variability of peak expiratory flow rate in allergic rhinitis and mild asthma: relationship to maximal airway narrowing. Annals of Allergy, Asthma and Immunology. 1998; 80(2):151-158

1407 Prieto L, Sanchez-Toril F, Brotons B, Soriano S, Casan R, Belenguer JL. Airway responsiveness to acetaldehyde in patients with asthma: relationship to methacholine responsiveness and peak expiratory flow variation. Clinical and Experimental Allergy. 2000; 30(1):71-78

1408 Prieto L, Esnal S, Lopez V, Barato D, Rojas R, Marin J. Maximal response plateau to adenosine 5'-monophosphate in asthma. Relationship with the response to methacholine, exhaled nitric oxide, and exhaled breath condensate pH. Chest. 2009; 135(6):1521-1526

1409 Profita M, Montuschi P, Bonanno A, Riccobono L, Montalbano AM, Ciabattoni G et al. Novel perspectives in the detection of oral and nasal oxidative stress and inflammation in pediatric united airway diseases. International Journal of Immunopathology and Pharmacology. 2010; 23(4):1211-1219

1410 Pronk-Admiraal CJ, Haitjema T, Horikx P, Bartels PC. Surplus value of eosinophil count and ECP to diagnose and monitor asthmatic patients. Netherlands Journal of Medicine. 2001; 58(1):9-17

1411 Prosperini G, Rajakulasingam K, Cacciola RR, Spicuzza L, Rorke S, Holgate ST et al. Changes in sputum counts and airway hyperresponsiveness after budesonide: monitoring anti-inflammatory response on the basis of surrogate markers of airway inflammation. Journal of Allergy and Clinical Immunology. 2002; 110(6):855-861

1412 Pruitt B. Spirometry and Response to Bronchodilator Studies. Journal of Asthma and Allergy Educators. 2012; 3(2):73-77

1413 Pujades-Rodriguez M, Lewis S, McKeever T, Britton J, Venn A. Effect of living close to a main road on asthma, allergy, lung function and chronic obstructive pulmonary disease. Occupational and Environmental Medicine. 2009; 66(10):679-684

1414 Pujades-Rodriguez M, McKeever T, Lewis S, Whyatt D, Britton J, Venn A. Effect of traffic pollution on respiratory and allergic disease in adults: cross-sectional and longitudinal analyses. BMC Pulmonary Medicine. 2009; 9:42

1415 Puolijoki H, Impivaara O, Liippo K, Tala E. Later development of asthma in patients with a negative methacholine inhalation challenge examined for suspected asthma. Lung. 1992; 170(4):235-241

1416 Purokivi M, Koskela HO, Koistinen T, Magga J, Peuhkurinen K, Kiviniemi V et al. Utility of hypertonic histamine challenge in distinguishing difficult-to-diagnose asthma. Clinical Respiratory Journal. 2007; 1(2):91-98

1417 Quadrelli SA, Roncoroni AJ, Montiel GC. Evaluation of bronchodilator response in patients with airway obstruction. Respiratory Medicine. 1999; 93(9):630-636

1418 Quiralte J, Llanes E, Barral P, Arias de Saavedra JM, Saenz de San Pedro B, Villalba M et al. Ole e 2 and Ole e 10: new clinical aspects and genetic restrictions in olive pollen allergy. Allergy. 2005; 60(3):360-365

1419 Quirce S, Contreras G, Dybuncio A, Chan-Yeung M. Peak expiratory flow monitoring is not a reliable method for establishing the diagnosis of occupational asthma. American Journal of Respiratory and Critical Care Medicine. 1995; 152(3):1100-1102

1420 Rachelefsky GS, Coulson A, Siegel SC, Stiehm ER. Aspirin intolerance in chronic childhood asthma: Detected by oral challenge. Pediatrics. 1975; 56(3):443-448

1421 Radon K, Busching K, Heinrich J, Wichmann HE, Jorres RA, Magnussen H et al. Passive smoking exposure: a risk factor for chronic bronchitis and asthma in adults? Chest. 2002; 122(3):1086-1090

1422 Radulovic M, Schilero GJ, Wecht JM, La Fountaine M, Rosado-Rivera D, Bauman WA. Exhaled nitric oxide levels are elevated in persons with tetraplegia and comparable to that in mild asthmatics. Lung. 2010; 188(3):259-262

1423 Raherison C, Nejjari C, Marty ML, Filleul L, Barberger-Gateau P, Dartigues JF et al. IgE level and Phadiatop in an elderly population from the PAQUID cohort: relationship to respiratory symptoms and smoking. Allergy. 2004; 59(9):940-945

1424 Raherison C, Abouelfath A, Le Gros V, Taytard A, Molimard M. Underdiagnosis of nocturnal symptoms in asthma in general practice. Journal of Asthma. 2006; 43(3):199-202

1425 Ram G, Puthenpura V, Cianferoni A. Prevalence of pediatric drug allergy based on drug provocation testing. Journal of Allergy and Clinical Immunology. 2013; 131(2 Suppl.1):AB175

1426 Ramirez D, Patel P, Casillas A, Cotelingam J, Boggs P, Bahna SL. Assessment of high-sensitivity C-reactive protein as a marker of airway inflammation in asthma. Annals of Allergy, Asthma and Immunology. 2010; 104(6):485-489

1427 Ramirez F, Pavon GF, Reyna JM, Garcia ML, Gonzalez MR, Ruiz K et al. Reliability of nasal provocation test using gradual increases of 25mgof lysineaspirin foraspirinexacerbated respiratory disease diagnostic.experience at the national institute of respiratory diseases. Annals of Allergy, Asthma and Immunology. 2011; 107(5 Suppl.1):A110

1428 Ramser M, Hammer J, Amacher A, Trachsel D. The value of exhaled nitric oxide in predicting bronchial hyperresponsiveness in children. Journal of Asthma. 2008; 45(3):191-195

1429 Rand CS, Wise RA. Measuring adherence to asthma medication regimens. American Journal of Respiratory and Critical Care Medicine. 1994; 149(2 Pt 2):S69-8

1430 Randolph C. Diagnostic exercise challenge testing. Current Allergy and Asthma Reports. 2011; 11(6):482-490

1431 Randolph C, Fraser B, Matasavage C. The free running athletic screening test as a screening test for exercise-induced asthma in high school. Allergy and Asthma Proceedings. 1997; 18(2):93-98

1432 Randolph CC. Treadmill challenge for confirmation of exercise-induced bronchoconstriction. Journal of Allergy and Clinical Immunology. 2011; 127(2 Suppl.1):AB9

1433 Randolph CC, Dreyfus DH, Kearney DM, Fraser BA. Mannitol challenge for diagnosis of exercise-induced bronch constriction. Journal of Allergy and Clinical Immunology. 2013; 131(2 Suppl. 1):AB195

1434 Randolph CC, Kaplan C, Randolph M, Asevica S. Mannitol challenge for diagnosis of exercise-induced brocnoconstriction: Experience in practice. Journal of Allergy and Clinical Immunology. 2012; 129(2 Suppl.1):AB3

1435 Rasmussen F, Taylor DR, Flannery EM, Cowan JO, Greene JM, Herbison GP et al. Outcome in adulthood of asymptomatic airway hyperresponsiveness in childhood: a longitudinal population study. Pediatric Pulmonology. 2002; 34(3):164-171

1436 Rasmussen LM, Phanareth K, Nolte H, Backer V. Can internet-based management improve asthma control? A long term randomised clinical study of 300 asthmatics. European Respiratory Journal. 2005; 26(Suppl.49)

1437 Ratnawati, Morton J, Henry RL, Thomas PS. Exhaled breath condensate nitrite/nitrate and pH in relation to pediatric asthma control and exhaled nitric oxide. Pediatric Pulmonology. 2006; 41(10):929-936

1438 Raza A, Kurukulaaratchy RJ, Grundy JD, Clayton CB, Mitchell FA, Roberts G et al. What does adolescent undiagnosed wheeze represent? Findings from the Isle of Wight Cohort. European Respiratory Journal. 2012; 40(3):580-588

1439 Razi E, Moosavi GA. Serum total IgE levels and total eosinophil counts: relationship with treatment response in patients with acute asthma. Jornal Brasileiro De Pneumologia. 2010; 36(1):23-28

1440 Razi SP, Piroozmand N, Zolfaghari M, Kazemnejad A, Firoozbakhsh S. Education of How-to-Use Peak Flow Meter and Following up via SMS on Asthma Self-Management. Hayat. 2012; 18(4):19-27

1441 Reddel HK. Peak flow monitoring in clinical practice and clinical asthma trials. Current Opinion in Pulmonary Medicine. 2006; 12(1):75-81

1442 Redline S, Larkin EK, Kercsmar C, Berger M, Siminoff LA. Development and validation of school-based asthma and allergy screening instruments for parents and students. Annals of Allergy, Asthma and Immunology. 2003; 90(5):516-528

1443 Reed CE. Asthma in the elderly: diagnosis and management. Journal of Allergy and Clinical Immunology. 2010; 126(4):681-689

1444 Regnier SA, Huels J. Association between respiratory syncytial virus hospitalizations in infants and respiratory sequelae: Systematic review and meta-analysis. Pediatric Infectious Disease Journal. 2013; 32(8):820-826

1445 Reid DW, Johns DP, Feltis B, Ward C, Walters EH. Exhaled nitric oxide continues to reflect airway hyperresponsiveness and disease activity in inhaled corticosteroid-treated adult asthmatic patients. Respirology. 2003; 8(4):479-486

1446 Reijula K, Leino M, Mussalo-Rauhamaa H, Nikulin M, Alenius H, Mikkola J et al. IgE-mediated allergy to fungal allergens in Finland with special reference to Alternaria alternata and Cladosporium herbarum. Annals of Allergy, Asthma and Immunology. 2003; 91(3):280-287

1447 Remes ST, Castro-Rodriguez JA, Holberg CJ, Martinez FD, Wright AL. Dog exposure in infancy decreases the subsequent risk of frequent wheeze but not of atopy. Journal of Allergy and Clinical Immunology. 2001; 108(4):509-515

1448 Remes ST, Pekkanen J, Remes K, Salonen RO, Korppi M. In search of childhood asthma: questionnaire, tests of bronchial hyperresponsiveness, and clinical evaluation. Thorax. 2002; 57(2):120-126

1449 Rennie DC, Lawson JA, Cockcroft DW, Senthilselvan A, McDuffie HH. Differences in respiratory symptoms and pulmonary function in children in 2 Saskatchewan communities. Annals of Allergy, Asthma and Immunology. 2004; 92(1):52-59

1450 Rensen ELJ, Straathof KCM, Veselic M, Zwinderman AH, Sterk PJ. Comparison of changes in exhaled nitric oxide, sputum eosinophils and histamine hyperresponsiveness in patients with mild asthma treated with inhaled steroids. American Journal of Respiratory and Critical Care Medicine. 1998; 157(3 Suppl):A608

1451 Renwick DS, Connolly MJ. Prevalence and treatment of chronic airways obstruction in adults over the age of 45. Thorax. 1996; 51(2):164-168

1452 Resano A, Sanz ML, Oehling A. Sensitization to Alternaria and Cladosporium in asthmatic patients and its in vitro diagnostic confirmation. Journal of Investigational Allergology and Clinical Immunology. 1998; 8(6):353-358

1453 Rhee CK, Lee HY, Kwon SS, Lee SY. The clinical features between asthma and overlap syndrome. Respirology. 2013; 18:26

1454 Ricci A, Barosi G, Gelmetti A, Esposito R, Tzialla C, Napoli A et al. A system of teleassistance for in-house monitoring respiratory function in children with bronchial asthma. Minerva Pediatrica. 2001; 53(5):466-467

1455 Riccioni G, Bucciarelli V, Verini M, Consilvio NP, Gallina S, Martini F et al. ADMA, SDMA, L-Arginine and nitric oxide in allergic pediatric bronchial asthma. Journal of Biological Regulators and Homeostatic Agents. 2012; 26(3):561-566

1456 Richter DC, Joubert JR, Nell H, Schuurmans MM, Irusen EM. Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma. International Journal of Chronic Obstructive Pulmonary Disease. 2008; 3(4):693-699

1457 Riedler J. Nonpharmacological challenges in the assessment of bronchial responsiveness. European Respiratory Monograph. 1997; 2(5):115-135

1458 Riedler J, Golser A, Huttegger I. Is 'free running' as a form of exercise challenge sensitive to assess bronchial hyperreactivity in children with mild asthma? Klinische Padiatrie. 1992; 204(5):373-377

1459 Riedler J, Reade T, Dalton M, Holst D, Robertson C. Hypertonic saline challenge in an epidemiologic survey of asthma in children. American Journal of Respiratory and Critical Care Medicine. 1994; 150(6 Pt 1):1632-1639

1460 Rietveld S, Dooijes EH. Characteristics and diagnostic significance of wheezes during exercise-induced airway obstruction in children with asthma. Chest. 1996; 110(3):624-631

1461 Rietveld S, Rijssenbeek-Nouwens LH. Diagnostics of spontaneous cough in childhood asthma: results of continuous tracheal sound recording in the homes of children. Chest. 1998; 113(1):50-54

1462 Rijcken B, Schouten JP, Weiss ST, Meinesz AF, De Vries K, van der Lende R. The distribution of bronchial responsiveness to histamine in symptomatic and in asymptomatic subjects. A population-based analysis of various indices of responsiveness. American Review of Respiratory Disease. 1989; 140(3):615-623

1463 Rikkers-Mutsaerts ERVM, Winters AE, Bakker MJ, van Stel HF, Jongste JC. Internet-based self-management compared with usual care in adolescents with asthma: A randomised controlled

trial. European Respiratory Society Annual Congress, Barcelona, Spain, September 18-22 2010. 2010;5396

1464 Rikkers-Mutsaerts ERVM, Winters AE, Bakker MJ, van Stel HF, van der Meer V, De Jongste JC et al. Internet-based self-management compared with usual care in adolescents with asthma: a randomized controlled trial. Pediatric Pulmonology. 2012; 47(12):1170-1179

1465 Rizwan S, Reid J, Kelly Y, Bundred PE, Pearson M, Brabin BJ. Trends in childhood and parental asthma prevalence in Merseyside, 1991-1998. Journal of Public Health. 2004; 26(4):337-342

1466 Robinson C, Baumann L, Gilman RH, Hansel NN, Gonzalvez G, Garcia H et al. Epidemiology of asthma in two peruvian cities: Differences in symptom reporting, spirometry, allergy skin testing, exhaled nitric oxide, and indoor air quality. American Journal of Respiratory and Critical Care Medicine. 2010; 181(1 MeetingAbstracts)

1467 Robinson CL, Baumann LM, Gilman RH, Romero K, Combe JM, Cabrera L et al. The Peru urban versus rural asthma (PURA) study: Methods and baseline quality control data from a cross-sectional investigation into the prevalence, severity, genetics, immunology and environmental factors affecting asthma in adolescence in Peru. BMJ Open. 2012; 2(1)

1468 Robroeks CMHH, van de Kant KDG, Jobsis Q, Hendriks HJE, van Gent R, Wouters EFM et al. Exhaled nitric oxide and biomarkers in exhaled breath condensate indicate the presence, severity and control of childhood asthma. Clinical and Experimental Allergy. 2007; 37(9):1303-1311

1469 Rodrigo GJ, Castro-Rodriguez JA. Daily vs. intermittent inhaled corticosteroids for recurrent wheezing and mild persistent asthma: a systematic review with meta-analysis. Respiratory Medicine. 2013; 107(8):1133-1140

1470 Rodriguez O, Celio R, Aboukhair F, Laurrabaquio AM, Tinoco IO, Cuevas HU et al. Skin test with allergen extracts from pollens and relation to clinical signs of allergic rhinitis and bronchial asthma in Camaguey, Cuba. VacciMonitor. 2013; 22(2):9-13

1471 Roduit C, Scholtens S, De Jongste JC, Wijga AH, Gerritsen J, Postma DS et al. Asthma at 8 years of age in children born by caesarean section. Thorax. 2009; 64(2):107-113

1472 Rogers L, Cassino C, Berger KI, Goldring RM, Norman RG, Klugh T et al. Asthma in the elderly: Cockroach sensitization and severity of airway obstruction in elderly nonsmokers. Chest. 2002; 122(5):1580-1586

1473 Rolla G, Guida G, Heffler E, Badiu I, Bommarito L, De Stefani A et al. Diagnostic classification of persistent rhinitis and its relationship to exhaled nitric oxide and asthma: a clinical study of a consecutive series of patients. Chest. 2007; 131(5):1345-1352

1474 Romberg K, Tufvesson E, Bjermer L. Including variability as a criteria, increases diagnostic accuracy in elite asthmatic swimmers after mannitol and exercise challenge. Allergy. 2011; 66:670

1475 Romberg K, Tufvesson E, Bjermer L. Extended diagnostic criteria used for indirect challenge testing in elite asthmatic swimmers. Respiratory Medicine. 2012; 106(1):15-24

1476 Rona RJ, Chinn S, Burney PG. Trends in the prevalence of asthma in Scottish and English primary school children 1982-92. Thorax. 1995; 50(9):992-993

1477 Roorda RJ, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. Journal of Allergy and Clinical Immunology. 2001; 108(4):540-546

1478 Rootmensen GN, van Keimpema ARJ, Looysen EE, van der Schaaf L, de Haan RJ, Jansen HM. The effects of additional care by a pulmonary nurse for asthma and COPD patients at a respiratory outpatient clinic: results from a double blind, randomized clinical trial. Patient Education and Counseling. 2008; 70(2):179-186

1479 Roquet A, Hallden G, Ihre E, Hed J, Zetterstrom O. Eosinophil activity markers in peripheral blood have high predictive value for bronchial hyperreactivity in patients with suspected mild asthma. Allergy. 1996; 51(7):482-488

1480 Rosa MJ, Divjan A, Hoepner L, Sheares BJ, Diaz D, Gauvey-Kern K et al. Fractional exhaled nitric oxide exchange parameters among 9-year-old inner-city children. Pediatric Pulmonology. 2011; 46(1):83-91

1481 Rosario NA, Vilela MM. Quantitative skin prick tests and serum IgE antibodies in atopic asthmatics. Journal of Investigational Allergology and Clinical Immunology. 1997; 7(1):40-45

1482 Rosias PPR, Dompeling E, Dentener MA, Pennings HJ, Hendriks HJE, Van Iersel MPA et al. Childhood asthma: exhaled markers of airway inflammation, asthma control score, and lung function tests. Pediatric Pulmonology. 2004; 38(2):107-114

1483 Rosier MJ, Bishop J, Nolan T, Robertson CF, Carlin JB, Phelan PD. Measurement of functional severity of asthma in children. American Journal of Respiratory and Critical Care Medicine. 1994; 149(6):1434-1441

1484 Ross JA, Clark NM, Baptist A. An asthma self-management intervention can improve outcomes for older adults. Journal of Allergy and Clinical Immunology. 2012; 129(2 Suppl.1):AB142

1485 Rottoli L, Rottoli P, Beltrami V, Murgia M, Carriero G. Hypersensitivity to pets in Italy. Allergologia Et Immunopathologia. 1989; 17(1):7-9

1486 Rouhos A, Ekroos H, Karjalainen J, Sarna S, Haahtela T, Sovijarvi ARA. Smoking attenuates increase in exhaled nitric oxide in atopic but not in nonatopic young adults with asthma. International Archives of Allergy and Immunology. 2010; 152(3):226-232

1487 Rouhos A, Kainu A, Karjalainen J, Lindqvist A, Piirila P, Sarna S et al. Atopic sensitization to common allergens without symptoms or signs of airway disorders does not increase exhaled nitric oxide. Clinical Respiratory Journal. 2008; 2(3):141-148

1488 Royal College of Physicians of London. Why asthma still kills: The national review of asthma deaths (NRAD) confidential enquiry report May 2014. London. Royal College of Physicians, 2014. Available from: https://www.rcplondon.ac.uk/sites/default/files/why-asthma-still-kills-full-report.pdf

1489 Rudzki E, Litewska D. RAST and PRIST in children with atopic dermatitis. Dermatologica. 1990; 180(2):82-85

1490 Rugina M, Serrano E, Klossek JM, Crampette L, Stoll D, Bebear JP et al. Epidemiological and clinical aspects of nasal polyposis in France; the ORLI group experience. Rhinology. 2002; 40(2):75-79

1491 Rundell KW, Anderson SD, Spiering BA, Judelson DA. Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes. Chest. 2004; 125(3):909-915

1492 Ruppel GL. What is the clinical value of lung volumes? Respiratory Care. 2012; 57(1):26-28

1493 Ryan D, Price D, Musgrave SD, Malhotra S, Lee AJ, Ayansina D et al. Clinical and cost effectiveness of mobile phone supported self monitoring of asthma: multicentre randomised controlled trial. BMJ. 2012; 344:e1756

1494 Rydjord B, Marton JH, Stromsnes H, Granum B, Bolle R, Nystad W et al. Mould-specific immunoglobulin antibodies quantified by flow cytometry reflect mould exposure in Norwegian children. Clinical and Experimental Allergy. 2008; 38(3):430-437

1495 Rydman RJ, Sonenthal K, Tadimeti L, Butki N, McDermott MF. Evaluating the outcome of two teaching methods of breath actuated inhaler in an inner city asthma clinic. Journal of Medical Systems. 1999; 23(5):349-356

1496 Rytila P, Metso T, Heikkinen K, Saarelainen P, Helenius IJ, Haahtela T. Airway inflammation in patients with symptoms suggesting asthma but with normal lung function. European Respiratory Journal. 2000; 16(5):824-830

1497 Sachs-Olsen C, Lodrup Carlsen KC, Mowinckel P, Haland G, Devulapalli CS, Munthe-Kaas MC et al. Diagnostic value of exhaled nitric oxide in childhood asthma and allergy. Pediatric Allergy and Immunology. 2010; 21(1 Pt 2):e213-e221

1498 Sachs-Olsen C, Berntsen S, Lodrup Carlsen KC, Anderssen SA, Mowinckel P, Carlsen KH. Time spent in vigorous physical activity is associated with increased exhaled nitric oxide in non-asthmatic adolescents. Clinical Respiratory Journal. 2013; 7(1):64-73

1499 Saito J, Inoue K, Sugawara A, Yoshikawa M, Watanabe K, Ishida T et al. Exhaled nitric oxide as a marker of airway inflammation for an epidemiologic study in schoolchildren. Journal of Allergy and Clinical Immunology. 2004; 114(3):512-516

1500 Sakai T, Sugiyama N, Hirai K, Muramatsu R, Hagiwara S, Oh Y et al. Consistently high levels of exhaled nitric oxide in children with asthma. Pediatrics International. 2010; 52(5):801-805

1501 Salam MT, Li YF, Langholz B, Gilliland FD, Children's Health Study. Early-life environmental risk factors for asthma: findings from the Children's Health Study. Environmental Health Perspectives. 2004; 112(6):760-765

1502 Sallaway K, Rae R, Road JD, Fitzgerald JM. The utility of a walk-in spirometry laboratory in the diagnosis of asthma and COPD. American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

1503 Salome CM, Peat JK, Britton WJ, Woolcock AJ. Bronchial hyperresponsiveness in two populations of Australian schoolchildren. I. Relation to respiratory symptoms and diagnosed asthma. Clinical Allergy. 1987; 17(4):271-281

1504 Salome CM, Roberts AM, Brown NJ, Dermand J, Marks GB, Woolcock AJ. Exhaled nitric oxide measurements in a population sample of young adults. American Journal of Respiratory and Critical Care Medicine. 1999; 159(3):911-916

1505 Sanchez-Garcia S, Fermin I, Andregnette V, Del Rio PR, Escudero C, Ibanez MD. Bronchial hyperresponsiveness in children with suggestive asthma symptoms. World Allergy Organization Journal. 2012; 5:S183-S184

1506 Sanchez-Sindin G, Barreiro-De AM, Iglesias-Rey M, Garcia CN, Ferreiro R, Lorenzo A et al. Asthma prevalence in patients with inflammatory bowel disease. Journal of Crohn's and Colitis. 2013; 7:S277

1507 Sandrini A, Taylor DR, Thomas PS, Yates DH. Fractional exhaled nitric oxide in asthma: an update. Respirology. 2010; 15(1):57-70

1508 Sangha HS, Kapoor BK, Kishan J. Effectiveness of self management plan of bronchial asthma using peak flow meter and symptom profile: a randomized controlled study [Abstract]. Chest. 2004; 126(4 Suppl):706S-706b

1509 Sano T, Ueda H, Bando H. A preliminary study of PEFR monitoring in patients with chronic cough. Lung. 2004; 182(5):285-295

1510 Santos DdO, Martins MC, Cipriano SL, Pinto RMC, Cukier A, Stelmach R. Pharmaceutical care for patients with persistent asthma: assessment of treatment compliance and use of inhaled medications. Jornal Brasileiro De Pneumologia. 2010; 36(1):14-22

1511 Santoso H. The value of a single skin prick testing for specific IgE Dermatophagoides pteronyssinus to distinguish atopy from non-atopic asthmatic children in the tropics. Asian Pacific Journal of Allergy and Immunology. 1998; 16(2-3):69-74

1512 Saraiva-Romanholo BM, Machado FS, Almeida FM, Nunes MdP, Martins MA, Vieira JE. Non-asthmatic patients show increased exhaled nitric oxide concentrations. Clinics. 2009; 64(1):5-10

1513 Sastre J, Ibanez MD, Lombardero M, Laso MT, Lehrer S. Allergy to cockroaches in patients with asthma and rhinitis in an urban area (Madrid). Allergy. 1996; 51(8):582-586

1514 Sato K, Sakamaki T, Sumino H, Sakamoto H, Hoshino J, Masuda H et al. Rate of nitric oxide release in the lung and factors influencing the concentration of exhaled nitric oxide. American Journal of Physiology - Lung Cellular and Molecular Physiology. 1996; 270(6 14-6):L914-L920

1515 Sato S, Saito J, Sato Y, Ishii T, Xintao W, Tanino Y et al. Clinical usefulness of fractional exhaled nitric oxide for diagnosing prolonged cough. Respiratory Medicine. 2008; 102(10):1452-1459

1516 Satouchi M, Maeda H, Yu Y, Yokoyama M. Clinical significance of the increased peak levels of exhaled nitric oxide in patients with bronchial asthma. Internal Medicine. 1996; 35(4):270-275

1517 Sauro A, Scalzitti F, Buono N, Siringano R, Petrazzuoli F, Diodati G et al. Spirometry is really useful and feasible in the GP's daily practice but guidelines alone are not. European Journal of General Practice. 2005; 11(1):29-31

1518 Savage I, Goodyear L. Providing information on metered dose inhaler technique: Is multimedia as effective as print? Family Practice. 2003; 20(5):552-557

1519 Savenije OE, Granell R, Caudri D, Koppelman GH, Smit HA, Wijga A et al. Comparison of childhood wheezing phenotypes in 2 birth cohorts: ALSPAC and PIAMA. Journal of Allergy and Clinical Immunology. 2011; 127(6):1505-1512

1520 Scarlett JF, Griffiths JM, Strachan DP, Anderson HR. Effect of ambient levels of smoke and sulphur dioxide on the health of a national sample of 23 year old subjects in 1981. Thorax. 1995; 50(7):764-768

1521 Schachter EN, Doyle CA, Beck GJ. A prospective study of asthma in a rural community. Chest. 1984; 85(5):623-630

1522 Schachter LM, Peat JK, Salome CM. Asthma and atopy in overweight children. Thorax. 2003; 58(12):1031-1035

1523 Schachter LM, Salome CM, Peat JK, Woolcock AJ. Obesity is a risk for asthma and wheeze but not airway hyperresponsiveness. Thorax. 2001; 56(1):4-8

1524 Schaper C, Glaser S, Obst A, Schmidt CO, Volzke H, Felix SB et al. Symptoms and diagnosis of asthma in a general population - longitudinal results from the SHIP database. Journal of Asthma. 2010; 47(8):860-864

1525 Schatz M, Zeiger RS. Ineffectiveness of telephone-based environmental control intervention to improve asthma outcomes. Journal of Allergy and Clinical Immunology. 2010; 126(4):873-875

1526 Schermer TRJ, Folgering HTM, Bottema BJAM, Jacobs JE, van Schayck CP, Van WC. The value of spirometry for primary care: Asthma and COPD. Primary Care Respiratory Journal. 2000; 9(3):51-55

1527 Schermer TR, Thoonen BP, van den Boom G, Akkermans RP, Grol RP, Folgering HT et al. Randomized controlled economic evaluation of asthma self-management in primary health care. American Journal of Respiratory and Critical Care Medicine. 2002; 166(8):1062-1072

1528 Schernhammer ES, Vutuc C, Waldhor T, Haidinger G. Time trends of the prevalence of asthma and allergic disease in Austrian children. Pediatric Allergy and Immunology. 2008; 19(2):125-131

1529 Scherr A, Jochmann A, Miedinger D, Maier S, Torok SS, Chhajed P. Airway hyperresponsiveness to mannitol as a predictor of treatment response to ciclesonide in patients with suspected asthma: A double-blind, randomised, placebo-controlled trial [Abstract]. European Respiratory Journal: European Respiratory Society Annual Congress, Vienna, Austria, September 1-5. 2012; 40(Suppl 56):862s

1530 Schleich FN, Asandei R, Manise M, Sele J, Seidel L, Louis R. Is FENO50 useful diagnostic tool in suspected asthma? International Journal of Clinical Practice. 2012; 66(2):158-165

1531 Schlunssen V, Kespohl S, Jacobsen G, Raulf-Heimsoth M, Schaumburg I, Sigsgaard T. Immunoglobulin E-mediated sensitization to pine and beech dust in relation to wood dust exposure levels and respiratory symptoms in the furniture industry. Scandinavian Journal of Work, Environment and Health. 2011; 37(2):159-167

1532 Schmidt LE, Thorne PS, Watt JL, Schwartz DA. Is an abbreviated bronchial challenge with histamine valid? Chest. 1992; 101(1):141-145

1533 Schneider A, Ay M, Faderl B, Linde K, Wagenpfeil S. Diagnostic accuracy of clinical symptoms in obstructive airway diseases varied within different health care sectors. Journal of Clinical Epidemiology. 2012; 65(8):846-854

1534 Schneider A, Faderl B, Schwarzbach J, Welker L, Karsch-Volk M, Jorres RA. Prognostic value of bronchial provocation and FENO measurement for asthma diagnosis --results of a delayed type of diagnostic study. Respiratory Medicine. 2014; 108(1):34-40

1535 Schneider A, Gindner L, Tilemann L, Schermer T, Dinant GJ, Meyer FJ et al. Diagnostic accuracy of spirometry in primary care. BMC Pulmonary Medicine. 2009; 9:31

1536 Schneider A, Schwarzbach J, Faderl B, Welker L, Karsch-Volk M, Jorres RA. FENO measurement and sputum analysis for diagnosing asthma in clinical practice. Respiratory Medicine. 2013; 107(2):209-216

1537 Schneider A, Tilemann L, Schermer T, Gindner L, Laux G, Szecsenyi J et al. Diagnosing asthma in general practice with portable exhaled nitric oxide measurement--results of a prospective diagnostic study: FENO < or = 16 ppb better than FENO < or =12 ppb to rule out mild and moderate to severe asthma. Respiratory Research. 2009; 10:15

1538 Schoefer Y, Schafer T, Meisinger C, Wichmann HE, Heinrich J, KORA study group. Predictivity of allergic sensitization (RAST) for the onset of allergic diseases in adults. Allergy. 2008; 63(1):81-86

1539 Scholtens S, Wijga AH, Brunekreef B, Kerkhof M, Hoekstra MO, Gerritsen J et al. Breast feeding, parental allergy and asthma in children followed for 8 years. The PIAMA birth cohort study. Thorax. 2009; 64(7):604-609

1540 Scholtens S, Wijga AH, Brunekreef B, Kerkhof M, Postma DS, Oldenwening M et al. Maternal overweight before pregnancy and asthma in offspring followed for 8 years. International Journal of Obesity. 2010; 34(4):606-613

1541 Scholtens S, Wijga AH, Seidell JC, Brunekreef B, de Jongste JC, Gehring U et al. Overweight and changes in weight status during childhood in relation to asthma symptoms at 8 years of age. Journal of Allergy and Clinical Immunology. 2009; 123(6):1312-1318

1542 Schonberger H, van Schayck O, Muris J, Bor H, van den Hoogen H, Knottnerus A et al. Towards improving the accuracy of diagnosing asthma in early childhood. European Journal of General Practice. 2004; 10(4):138-151

1543 Schulze J, Reinmuller W, Herrmann E, Rosewich M, Rose MA, Zielen S. Bronchial allergen challenges in children - safety and predictors. Pediatric Allergy and Immunology. 2013; 24(1):19-27

1544 Schumpert JC, Noonan CW, Sylvester J, Vanek D, Ward T, Holian A. Patterns of asthma symptoms and perceptions of harm from seasonal atmospheric events in rural Western Montana. International Journal of Occupational and Environmental Health. 2006; 12(1):52-58

1545 Schwaiblmair M, Vogelmeier C, Fruhmann G. Occupational asthma in hairdressers: results of inhalation tests with bleaching powder. International Archives of Occupational and Environmental Health. 1997; 70(6):419-423

1546 Schwartz J, Weiss ST. Relationship of skin test reactivity to decrements in pulmonary function in children with asthma or frequent wheezing. American Journal of Respiratory and Critical Care Medicine. 1995; 152(6 I):2176-2180

1547 Sciamanna C, Poger JM, Pool A, Stuckey H, Lehman EB, Craig T. Improving the quality of asthma care using the Internet. Journal of General Internal Medicine.: Springer New York. 2013; 28:S106-S107

1548 Scollo M, Zanconato S, Ongaro R, Zaramella C, Zacchello F, Baraldi E. Exhaled nitric oxide and exercise-induced bronchoconstriction in asthmatic children. American Journal of Respiratory and Critical Care Medicine. 2000; 161(3 Pt 1):1047-1050

1549 Scordamaglia A, Passalacqua G, Pisati P, Moscato G, Bertoletti R, Ruffoni S et al. A multi-allergen ELISA screening method. Comparison with Pharmacia CAP system and Phazet skin prick test. Allergologia Et Immunopathologia. 1992; 20(5):179-183

1550 Scott M, Raza A, Karmaus W, Mitchell F, Grundy J, Kurukulaaratchy RJ et al. Influence of atopy and asthma on exhaled nitric oxide in an unselected birth cohort study. Thorax. 2010; 65(3):258-262

1551 Scott S, Currie J, Albert P, Calverley P, Wilding JPH. Risk of misdiagnosis, health-related quality of life, and BMI in patients who are overweight with doctor-diagnosed asthma. Chest. 2012; 141(3):616-624

1552 Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline 101. London / Edinburgh. British Thoracic Society / Scottish Intercollegiate Guidelines Network, 2012. Available from: http://www.sign.ac.uk/pdf/SIGN101.pdf

1553 Searing DA, Bender BG. Short message service (SMS) for asthma management: a pilot study utilizing text messaging to promote asthma self-management. Journal of Allergy and Clinical Immunology. 2012; 129(2 Suppl.):AB142

1554 Sears MR, Holdaway MD, Flannery EM, Herbison GP, Silva PA. Parental and neonatal risk factors for atopy, airway hyper-responsiveness, and asthma. Archives of Disease in Childhood. 1996; 75(5):392-398

1555 See KC, Christiani DC. Normal values and thresholds for the clinical interpretation of exhaled nitric oxide levels in the US general population: results from the National Health and Nutrition Examination Survey 2007-2010. Chest. 2013; 143(1):107-116

1556 Seear M, Wensley D, West N. How accurate is the diagnosis of exercise induced asthma among Vancouver schoolchildren? Archives of Disease in Childhood. 2005; 90(9):898-902

1557 Seid M, D'Amico EJ, Varni JW, Munafo JK, Britto MT, Kercsmar CM et al. The In Vivo adherence intervention for at risk adolescents with asthma: Report of a randomized pilot study. Journal of Pediatric Psychology. United States 2012; 37(4):390-403

1558 Sekerel BE, Saraclar Y, Kalayci O, Cetinkaya F, Tuncer A, Adalioglu G. Comparison of four different measures of bronchial responsiveness in asthmatic children. Allergy. 1997; 52(11):1106-1109

1559 Selassie FG, Stevens RH, Cullinan P, Pritchard D, Jones M, Harris J et al. Total and specific IgE (house dust mite and intestinal helminths) in asthmatics and controls from Gondar, Ethiopia. Clinical and Experimental Allergy. 2000; 30(3):356-358

1560 Sennhauser FH, Kuhni CE. Prevalence of respiratory symptoms in Swiss children: is bronchial asthma really more prevalent in boys? Pediatric Pulmonology. 1995; 19(3):161-166

1561 Senthilselvan A, Chen Y, Dosman JA. Predictors of asthma and wheezing in adults. Grain farming, sex, and smoking. American Review of Respiratory Disease. 1993; 148(3):667-670

1562 Sethi JM, White AM, Patel SA, Dinella JV, Calhoun WJ, Choi AMK. Bronchoprovocation testing in asthma: effect on exhaled monoxides. Journal of Breath Research. 2010; 4(4):047104

1563 Shaheen SO, Newson RB, Henderson AJ, Headley JE, Stratton FD, Jones RW et al. Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood. Clinical and Experimental Allergy. 2005; 35(1):18-25

1564 Shaheen SO, Newson RB, Sherriff A, Henderson AJ, Heron JE, Burney PGJ et al. Paracetamol use in pregnancy and wheezing in early childhood. Thorax. 2002; 57(11):958-963

1565 Shaheen SO, Sterne JA, Montgomery SM, Azima H. Birth weight, body mass index and asthma in young adults. Thorax. 1999; 54(5):396-402

1566 Shaheen SO, Sterne JA, Songhurst CE, Burney PG. Frequent paracetamol use and asthma in adults. Thorax. 2000; 55(4):266-270

1567 Shaheen SO, Sterne JA, Tucker JS, Florey CD. Birth weight, childhood lower respiratory tract infection, and adult lung function. Thorax. 1998; 53(7):549-553

1568 Shakeri J, Paknejad O, Moghadam KG, Taherzadeh M. Logistic regression model for prediction of airway reversibility using peak expiratory flow. Tanaffos. 2012; 11(1):49-54

1569 Shankardass K, McConnell R, Jerrett M, Milam J, Richardson J, Berhane K. Parental stress increases the effect of traffic-related air pollution on childhood asthma incidence. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106(30):12406-12411

1570 Shanovich K, Sorkness CA, Wise M, Pulvermacher A, Bhattacharya A, Gustafson D. Internet telehealth for pediatric nurse case management improves asthma control. Journal of Allergy and Clinical Immunology. 2009; 123(2 Suppl.1):S43

1571 Shapiro GG, Furukawa CT, Pierson WE, Bierman CW. Methacholine bronchial challenge in children. Journal of Allergy and Clinical Immunology. 1982; 69(4):365-369

1572 Sharma S, Kathuria PC, Gupta CK, Nordling K, Ghosh B, Singh AB. Total serum immunoglobulin E levels in a case-control study in asthmatic/allergic patients, their family members, and healthy subjects from India. Clinical and Experimental Allergy. 2006; 36(8):1019-1027

1573 Shavit O, Swern A, Dong Q, Newcomb K, Sazonov Kocevar V, Taylor SD. Impact of smoking on asthma symptoms, healthcare resource use, and quality of life outcomes in adults with persistent asthma. Quality of Life Research. 2007; 16(10):1555-1565

1574 Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2007; 176(3):231-237

1575 Sherriff A, Maitra A, Ness AR, Mattocks C, Riddoch C, Reilly JJ et al. Association of duration of television viewing in early childhood with the subsequent development of asthma. Thorax. 2009; 64(4):321-325

1576 Sherrill D, Sears MR, Lebowitz MD, Holdaway MD, Hewitt CJ, Flannery EM et al. The effects of airway hyperresponsiveness, wheezing, and atopy on longitudinal pulmonary function in children: a 6-year follow-up study. Pediatric Pulmonology. 1992; 13(2):78-85

1577 Sherrill DL, Stein R, Halonen M, Holberg CJ, Wright A, Martinez FD. Total serum IgE and its association with asthma symptoms and allergic sensitization among children. Journal of Allergy and Clinical Immunology. 1999; 104(1):28-36

1578 Shibasaki M, Noguchi E, Takeda K, Takita H. Distribution of IgE and IgG antibody levels against house dust mites in schoolchildren, and their relation with asthma. Journal of Asthma. 1997; 34(3):235-242

1579 Shields MD, Brown V, Stevenson EC, Fitch PS, Schock BC, Turner G et al. Serum eosinophilic cationic protein and blood eosinophil counts for the prediction of the presence of airways inflammation in children with wheezing. Clinical and Experimental Allergy. 1999; 29(10):1382-1389

1580 Shimoda T, Obase Y, Kishikawa R, Iwanaga T, Miyatake A, Kasayama S. The fractional exhaled nitric oxide and serum high sensitivity C-reactive protein levels in cough variant asthma and typical bronchial asthma. Allergology International. 2013; 62(2):251-257

1581 Shin B, Cole SL, Park SJ, Ledford DK, Lockey RF. A new symptom-based questionnaire for predicting the presence of asthma. Journal of Investigational Allergology and Clinical Immunology. 2010; 20(1):27-34

1582 Shin HW, Schwindt CD, Aledia AS, Rose-Gottron CM, Larson JK, Newcomb RL et al. Exercise-induced bronchoconstriction alters airway nitric oxide exchange in a pattern distinct from spirometry. American Journal of Physiology Regulatory, Integrative and Comparative Physiology. 2006; 291(6):R1741-R1748

1583 Shirahata K, Fujimoto K, Arioka H, Shouda R, Kudo K, Ikeda S-I. Prevalence and clinical features of cough variant asthma in a general internal medicine outpatient clinic in Japan. Respirology. 2005; 10(3):354-358

1584 Shofer S, Haus BM, Kuschner WG. Quality of occupational history assessments in working age adults with newly diagnosed asthma. Chest. 2006; 130(2):455-462

1585 Shome GP, Starnes III JD, Shearer M, Kennedy R, Way A, Arif A et al. Exhaled nitric oxide in asthma: Variability, relation to asthma severity, and peripheral blood lymphocyte cytokine expression. Journal of Asthma. 2006; 43(2):95-99

1586 Short PM, McKinlay L, Jackson CM, Williamson PA, Burns P, Fardon TC et al. Steroid titration against mannitol PD10 confers benefits in mild to moderate asthmatics with no adverse effects on safety outcomes. American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

1587 Short PM, Lipworth SIW, Lipworth BJ. Relationships between airway hyperresponsiveness, inflammation, and calibre in asthma. Lung. 2011; 189(6):493-497

1588 Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000; 320(7246):1368-1373

1589 Sibbald B, Anderson HR, McGuigan S. Asthma and employment in young adults. Thorax. 1992; 47(1):19-24

1590 Siersted HC, Hansen HS, Hansen NC, Hyldebrandt N, Mostgaard G, Oxhoj H. Evaluation of peak expiratory flow variability in an adolescent population sample. The Odense Schoolchild Study. American Journal of Respiratory and Critical Care Medicine. 1994; 149(3 Pt 1):598-603

1591 Siersted HC, Mostgaard G, Hyldebrandt N, Hansen HS, Boldsen J, Oxhoj H. Interrelationships between diagnosed asthma, asthma-like symptoms, and abnormal airway behaviour in adolescence: The Odense Schoolchild Study. Thorax. 1996; 51(5):503-509

1592 Silkoff PE, Sylvester JT, Zamel N, Permutt S. Airway nitric oxide diffusion in asthma: Role in pulmonary function and bronchial responsiveness. American Journal of Respiratory and Critical Care Medicine. 2000; 161(4 Pt 1):1218-1228

1593 Silver EJ, Crain EF, Weiss KB. Burden of wheezing illness among U.S. children reported by parents not to have asthma. Journal of Asthma. 1998; 35(5):437-443

1594 Silvers KM, Frampton CM, Wickens K, Epton MJ, Pattemore PK, Ingham T et al. Breastfeeding protects against adverse respiratory outcomes at 15 months of age. Maternal and Child Nutrition. 2009; 5(3):243-250

1595 Silvers KM, Frampton CM, Wickens K, Pattemore PK, Ingham T, Fishwick D et al. Breastfeeding protects against current asthma up to 6 years of age. Journal of Pediatrics. 2012; 160(6):991-996

1596 Silvestri IC, Pereira CAdC, Rodrigues SCS. Comparison of spirometric changes in the response to bronchodilators of patients with asthma or chronic obstructive pulmonary disease. Jornal Brasileiro De Pneumologia. 2008; 34(9):675-682

1597 Silvestri M, Bontempelli M, Giacomelli M, Malerba M, Rossi GA, Di Stefano A et al. High serum levels of tumour necrosis factor-alpha and interleukin-8 in severe asthma: markers of systemic inflammation? Clinical and Experimental Allergy. 2006; 36(11):1373-1381

1598 Silvestri M, Oddera S, Crimi P, Rossi GA. Frequency and specific sensitization to inhalant allergens within nuclear families of children with asthma and/or rhinitis. Annals of Allergy, Asthma and Immunology. 1997; 79(6):512-516

1599 Silvestri M, Oddera S, Rossi GA, Crimi P. Sensitization to airborne allergens in children with respiratory symptoms. Annals of Allergy, Asthma and Immunology. 1996; 76(3):239-244

1600 Silvestri M, Sabatini F, Spallarossa D, Fregonese L, Battistini E, Biraghi MG et al. Exhaled nitric oxide levels in non-allergic and allergic mono- or polysensitised children with asthma. Thorax. 2001; 56(11):857-862

1601 Silvestri M, Spallarossa D, Battistini E, Brusasco V, Rossi GA. Dissociation between exhaled nitric oxide and hyperresponsiveness in children with mild intermittent asthma. Thorax. 2000; 55(6):484-488

1602 Silvestri M, Spallarossa D, Battistini E, Fregonese B, Rossi GA. How can we best read exhaled nitric oxide flow curves in asthmatic children? Monaldi Archives for Chest Disease. 2001; 56(5):384-389

1603 Silvestri M, Sabatini F, Sale R, Defilippi AC, Fregonese L, Battistini E et al. Correlations between exhaled nitric oxide levels, blood eosinophilia, and airway obstruction reversibility in childhood asthma are detectable only in atopic individuals. Pediatric Pulmonology. 2003; 35(5):358-363

1604 Simon MR, Chinchilli VM, Phillips BR, Sorkness CA, Lemanske RFJ, Szefler SJ et al. Forced expiratory flow between 25% and 75% of vital capacity and FEV1/forced vital capacity ratio in relation to clinical and physiological parameters in asthmatic children with normal FEV1 values. Journal of Allergy and Clinical Immunology. 2010; 126(3):527-528

1605 Simoni M, Biavati P, Baldacci S, Carrozzi L, Pedreschi M, Di Pede F et al. The Po River Delta epidemiological survey: reference values of total serum IgE levels in a normal population sample of North Italy (8-78 yrs). European Journal of Epidemiology. 2001; 17(3):231-239

1606 Simpson A, Soderstrom L, Ahlstedt S, Murray CS, Woodcock A, Custovic A. IgE antibody quantification and the probability of wheeze in preschool children. Journal of Allergy and Clinical Immunology. 2005; 116(4):744-749

1607 Simpson A, Tan VYF, Winn J, Svensen M, Bishop CM, Heckerman DE et al. Beyond atopy: multiple patterns of sensitization in relation to asthma in a birth cohort study. American Journal of Respiratory and Critical Care Medicine. 2010; 181(11):1200-1206

1608 Simpson JL, Wark PAB. The role of exhaled nitric oxide and exaheld breath condensates in evaluating airway inflammation in asthma. Expert Opinion on Medical Diagnostics. 2008; 2(6):607-620

1609 Sin BA, Akkoca O, Saryal S, Oner F, Misirligil Z. Differences between asthma and COPD in the elderly. Journal of Investigational Allergology and Clinical Immunology. 2006; 16(1):44-50

1610 Sin BA, Yildiz OA, Dursun AB, Misirligil Z, Demirel YS. Airway hyperresponsiveness: a comparative study of methacholine and exercise challenges in seasonal allergic rhinitis with or without asthma. Journal of Asthma. 2009; 46(5):486-491

1611 Sin DD, Jones RL, Man SFP. Obesity is a risk factor for dyspnea but not for airflow obstruction. Archives of Internal Medicine. 2002; 162(13):1477-1481

1612 Sinclair DG, Sims MM, Hoad NA, Winfield CR. Exercise-induced airway narrowing in army recruits with a history of childhood asthma. European Respiratory Journal. 1995; 8(8):1314-1317

1613 Singh D, Richards D, Knowles RG, Schwartz S, Woodcock A, Langley S et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. American Journal of Respiratory and Critical Care Medicine. 2007; 176(10):988-993

1614 Singh V, Meena P, Sharma BB. Asthma-like peak flow variability in various lung diseases. Lung India. 2012; 29(1):15-18

1615 Sippel JM, Holden WE, Tilles SA, O'Hollaren M, Cook J, Thukkani N et al. Exhaled nitric oxide levels correlate with measures of disease control in asthma. Journal of Allergy and Clinical Immunology. 2000; 106(4):645-650

1616 Siroux V, Oryszczyn MP, Paty E, Kauffmann F, Pison C, Vervloet D et al. Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study. Clinical and Experimental Allergy. 2003; 33(6):746-751

1617 Sistek D, Tschopp J-M, Schindler C, Brutsche M, Ackermann-Liebrich U, Perruchoud A-P et al. Clinical diagnosis of current asthma: Predictive value of respiratory symptoms in the SAPALDIA study. European Respiratory Journal. 2001; 17(2):214-219

1618 Sistek D, Wickens K, Amstrong R, D'Souza W, Town I, Crane J. Predictive value of respiratory symptoms and bronchial hyperresponsiveness to diagnose asthma in New Zealand. Respiratory Medicine. 2006; 100(12):2107-2111

1619 Sivan Y, Gadish T, Fireman E, Soferman R. The use of exhaled nitric oxide in the diagnosis of asthma in school children. Journal of Pediatrics. 2009; 155(2):211-216

1620 Skaer TL, Wilson CB, Sclar DA, Arnold TA, Garcia CF, Schmidt LN et al. Metered-dose inhaler technique and quality of life with airways disease: assessing the value of the Vitalograph in educational intervention. Journal of International Medical Research. 1996; 24(4):369-375

1621 Skovsted TA, Schlunssen V, Schaumburg I, Wang P, Staun-Olsen P, Skov PS. Only few workers exposed to wood dust are detected with specific IgE against pine wood. Allergy. 2003; 58(8):772-779

1622 Slader CA, Reddel HK, Spencer LM, Belousova EG, Armour CL, Bosnic-Anticevich SZ et al. Double blind randomised controlled trial of two different breathing techniques in the management of asthma. Thorax. 2006; 61(8):651-656

1623 Slader CA, Belousova EG, Reddel HK. Measuring peak flow enhances adherence to monitoring in asthma. Thorax. 2007; 62(8):741-742

1624 Slieker MG, van der Ent CK. The diagnostic and screening capacities of peak expiratory flow measurements in the assessment of airway obstruction and bronchodilator response in children with asthma. Monaldi Archives for Chest Disease. 2003; 59(2):155-159

1625 Smeeton NC, Rona RJ, Oyarzun M, Diaz PV. Agreement between responses to a standardized asthma questionnaire and a questionnaire following a demonstration of asthma symptoms in adults. American Journal of Epidemiology. 2006; 163(4):384-391

1626 Smit LAM, Heederik D, Doekes G, Wouters IM. Exhaled nitric oxide in endotoxin-exposed adults: effect modification by smoking and atopy. Occupational and Environmental Medicine. 2009; 66(4):251-255

1627 Smith AB, Bernstein DI, Aw TC, Gallagher JS, London M, Kopp S et al. Occupational asthma from inhaled egg protein. American Journal of Industrial Medicine. 1987; 12(2):205-218

1628 Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. New England Journal of Medicine. 2005; 352(21):2163-2173

1629 Smith AD, Cowan JO, Brassett KP, Filsell S, McLachlan C, Monti-Sheehan G et al. Exhaled nitric oxide: a predictor of steroid response. American Journal of Respiratory and Critical Care Medicine. 2005; 172(4):453-459

1630 Smith AD, Cowan JO, Filsell S, McLachlan C, Monti-Sheehan G, Jackson P et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. American Journal of Respiratory and Critical Care Medicine. 2004; 169(4):473-478

1631 Smith CM, Anderson SD. Inhalational challenge using hypertonic saline in asthmatic subjects: a comparison with responses to hyperpnoea, methacholine and water. European Respiratory Journal. 1990; 3(2):144-151

1632 Smith HE, Hogger C, Lallemant C, Crook D, Frew AJ. Is structured allergy history sufficient when assessing patients with asthma and rhinitis in general practice? Journal of Allergy and Clinical Immunology. 2009; 123(3):646-650

1633 Snider GL. Distinguishing among asthma, chronic bronchitis, and emphysema. Chest. 1985; 87(1 Suppl):35S-39S

1634 Snijders BEP, Thijs C, Dagnelie PC, Stelma FF, Mommers M, Kummeling I et al. Breast-feeding duration and infant atopic manifestations, by maternal allergic status, in the first 2 years of life (KOALA study). Journal of Pediatrics. 2007; 151(4):347-2

1635 Sobol BJ. Response to bronchodilator in the asthmatic: An alternative method of analysis. Annals of Allergy. 1985; 55(2):114-115

1636 Sockrider MM, Tortolero SR, Bartholomew LK, Markham CM, Abramson SL, Fernandez M et al. Pilot study of a screening questionnaire for asthma. Pediatric Asthma, Allergy and Immunology. 2001; 15(1):15-24

1637 Solomon C, Poole J, Jarup L, Palmer K, Coggon D. Cardio-respiratory morbidity and long-term exposure to particulate air pollution. International Journal of Environmental Health Research. 2003; 13(4):327-335

1638 Sonnappa S, Bastardo CM, Saglani S, Bush A, Aurora P. Relationship between past airway pathology and current lung function in preschool wheezers. European Respiratory Journal. 2011; 38(6):1431-1436

1639 Sonnappa S, Bastardo CM, Wade A, Saglani S, McKenzie SA, Bush A et al. Symptom-pattern phenotype and pulmonary function in preschool wheezers. Journal of Allergy and Clinical Immunology. 2010; 126(3):519-7

1640 Sonnenschein-van der Voort AMM, Jaddoe VWV, van der Valk RJP, Willemsen SP, Hofman A, Moll HA et al. Duration and exclusiveness of breastfeeding and childhood asthma-related symptoms. European Respiratory Journal. 2012; 39(1):81-89

1641 Sonnenschein-van der Voort A, Jaddoe VWV, Raat H, Moll HA, Hofman A, de Jongste JC et al. Fetal and infant growth and asthma symptoms in preschool children: the Generation R Study. American Journal of Respiratory and Critical Care Medicine. 2012; 185(7):731-737

1642 Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ. Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. American Journal of Respiratory and Critical Care Medicine. 1999; 159(4 Pt 1):1043-1051

1643 Sordillo JE, Webb T, Kwan D, Kamel J, Hoffman E, Milton DK et al. Allergen exposure modifies the relation of sensitization to fraction of exhaled nitric oxide levels in children at risk for allergy and asthma. Journal of Allergy and Clinical Immunology. 2011; 127(5):1165-1172

1644 Soriano JB, Anto JM, Sunyer J, Tobias A, Kogevinas M, Almar E et al. Risk of asthma in the general Spanish population attributable to specific immunoresponse. Spanish Group of the European Community Respiratory Health Survey. International Journal of Epidemiology. 1999; 28(4):728-734

1645 Soriano JB, Anto JM, Sunyer J, Tobias A, Kogevinas M, Almar E et al. Risk of asthma in the general Spanish population attributable to specific immunoresponse. International Journal of Epidemiology. 1999; 28(4):728-734

1646 Soriano JB, Tobias A, Kogevinas M, Sunyer J, Saez M, Moratalla J et al. Atopy and nonspecific bronchial responsiveness: A population-based assessment. American Journal of Respiratory and Critical Care Medicine. 1996; 154(6):1636-1640

1647 Soriano JB, Rabe KF, Vermeire PA. Predictors of poor asthma control in European adults. Journal of Asthma. 2003; 40(7):803-813

1648 Sotir M, Yeatts K, Miller W, Shy C. Comparison of asthma-related functional consequences and health care utilization among children with and without upper respiratory infection-triggered wheezing. Journal of Asthma. 2006; 43(8):629-632

1649 Soto-Ramirez N, Ziyab AH, Karmaus W, Zhang H, Kurukulaaratchy RJ, Ewart S et al. Epidemiologic methods of assessing asthma and wheezing episodes in longitudinal studies: measures of change and stability. Journal of Epidemiology. 2013; 23(6):399-410

1650 Soto-Ramos M, Castro-Rodriguez JA, Hinojos-Gallardo LC, Hernandez-Saldana R, Cisneros-Castolo M, Carrillo-Rodriguez V. Fractional exhaled nitric oxide has a good correlation with asthma control and lung function in latino children with asthma. Journal of Asthma. 2013; 50(6):590-594

1651 Souma R, Watanabe H, Wakayama T, Ochiai A, Sagara H. Comprehensive evaluation of coughing, transforming growth factor-beta, interleukin- 13, interleukin-8, and airway reversibility can facilitate the differential diagnosis of asthma. Allergy. 2011; 66:579

1652 Sovijarvi AR. Flow-volume response to inhaled methacholine in asthmatics; comparison of area under the curve (AFV) with conventional parameters. European Journal of Respiratory Diseases Supplement. 1986; 143:18-21

1653 Spallarossa D, Sacco O, Girosi D, Rossi GA. Blood eosinophil counts and arterial oxygen tension in acute asthma. Archives of Disease in Childhood. 1995; 73(4):333-337

1654 Spallarossa D, Battistini E, Silvestri M, Sabatini F, Fregonese L, Brazzola G et al. Steroid-naive adolescents with mild intermittent allergic asthma have airway hyperresponsiveness and elevated exhaled nitric oxide levels. Journal of Asthma. 2003; 40(3):301-310

1655 Spector SL, Tan RA. Is a single blood eosinophil count a reliable marker for "eosinophilic asthma?". Journal of Asthma. 2012; 49(8):807-810

1656 Spee-van der Wekke J, Meulmeester JF, Radder JJ, Verloove-Vanhorick SP. School absence and treatment in school children with respiratory symptoms in The Netherlands: data from the Child Health Monitoring System. Journal of Epidemiology and Community Health. 1998; 52(6):359-363

1657 Spencer M, Briggs AH, Grossman RF, Rance L. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease. Pharmacoeconomics. 2005; 23(6):619-637

1658 Spiering BA, Judelson DA, Rundell KW. An evaluation of standardizing target ventilation for eucapnic voluntary hyperventilation using FEV1. Journal of Asthma. 2004; 41(7):745-749

1659 Spiropoulos K, Stevens J, Eigen H, Spiropoulos A. Specificity and sensitivity of methacholine challenge test in children with normal and hyperreactive airways. Acta Paediatrica Scandinavica. 1986; 75(5):737-743

1660 Spitale N, Popat N, McIvor A. Update on exhaled nitric oxide in pulmonary disease. Expert Review of Respiratory Medicine. 2012; 6(1):105-115

1661 Sposato B, Mariotta S, Ricci A. When should a reversibility test be performed on patients with early stages of asthma and normal spirometry? Journal of Asthma. 2008; 45(6):479-483

1662 Sposato B, Scalese M, Migliorini MG, Di Tomassi M, Scala R. Small airway impairment and bronchial hyperresponsiveness in asthma onset. Allergy, Asthma and Immunology Research. 2014; 6(3):242-251

1663 Springer C, Godfrey S, Picard E, Uwyyed K, Rotschild M, Hananya S et al. Efficacy and safety of methacholine bronchial challenge performed by auscultation in young asthmatic children. American Journal of Respiratory and Critical Care Medicine. 2000; 162(3 Pt 1):857-860

1664 Spycher BD, Silverman M, Brooke AM, Minder CE, Kuehni CE. Distinguishing phenotypes of childhood wheeze and cough using latent class analysis. European Respiratory Journal. 2008; 31(5):974-981

1665 Spycher BD, Henderson J, Granell R, Evans DM, Smith GD, Timpson NJ et al. Genome-wide prediction of childhood asthma and related phenotypes in a longitudinal birth cohort. Journal of Allergy and Clinical Immunology. 2012; 130(2):503-509

1666 Spycher BD, Silverman M, Egger M, Zwahlen M, Kuehni CE. Routine vaccination against pertussis and the risk of childhood asthma: a population-based cohort study. Pediatrics. 2009; 123(3):944-950

1667 Sritipsukho P. Aeroallergen sensitivity among Thai children with allergic respiratory diseases: a hospital-based study. Asian Pacific Journal of Allergy and Immunology. 2004; 22(2-3):91-95

1668 Stafanger G, Kock AJ, Koch C. Specific diagnosis of exogenous bronchial asthma in children. Allergy. 1986; 41(2):110-117

1669 Stahl E, Lindberg A, Jansson SA, Ronmark E, Svensson K, Andersson F et al. Health-related quality of life is related to COPD disease severity. Health and Quality of Life Outcomes. 2005; 3:56

1670 Stahl MC, Arora R, Tucker M, Johnson T, Calabria C. A prospective evaluation of the fraction of exhaled nitric oxide and the subsequent diagnosis of asthma in military basic trainees. Annals of Allergy, Asthma and Immunology. 2009; 103(5 SUPPL. 3):A72

1671 Stahlman JE, Alghamdi K, Salmun LM, Borras IM, Bailey E, Schneider LC. Adherence with a hand-held electronic device versus conventional peak expiratory flow rate monitoring in children with asthma. Pediatric Asthma, Allergy and Immunology. 2006; 19(2):118-125

1672 Staikuniene J, Vaitkus S, Japertiene LM, Ryskiene S. Association of chronic rhinosinusitis with nasal polyps and asthma: clinical and radiological features, allergy and inflammation markers. Medicina. 2008; 44(4):257-265

1673 Stein RT, Holberg CJ, Morgan WJ, Wright AL, Lombardi E, Taussig L et al. Peak flow variability, methacholine responsiveness and atopy as markers for detecting different wheezing phenotypes in childhood. Thorax. 1997; 52(11):946-952

1674 Stelmach I, Jerzynska J, Stelmach W, Majak P, Chew G, Gorski P et al. Cockroach allergy and exposure to cockroach allergen in Polish children with asthma. Allergy. 2002; 57(8):701-705

1675 Stenius BS, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clinical Allergy. 1976; 6(2):119-129

1676 Stenton SC, Beach JR, Avery AJ, Hendrick DJ. The value of questionnaires and spirometry in asthma surveillance programmes in the workplace. Occupational Medicine. 1993; 43(4):203-206

1677 Stern DA, Morgan WJ, Halonen M, Wright AL, Martinez FD. Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study. Lancet. 2008; 372(9643):1058-1064

1678 Stevens W, Addo-Yobo E, Roper J, Woodcock A, James H, Platts-Mills T et al. Differences in both prevalence and titre of specific immunoglobulin E among children with asthma in affluent and poor communities within a large town in Ghana. Clinical and Experimental Allergy. 2011; 41(11):1587-1594

1679 Stevens WJ, van Schil L, Vermeire PA. Discriminatory role of history, skin testing and radio-allergo-sorbent test (RAST) in type I-mediated respiratory disease. Allergologia Et Immunopathologia. 1983; 11(4):243-249

1680 Stickland MK, Rowe BH, Spooner CH, Vandermeer B, Dryden DM. Accuracy of eucapnic hyperpnea or mannitol to diagnose exercise-induced bronchoconstriction: a systematic review. Annals of Allergy, Asthma and Immunology. 2011; 107(3):229-234

1681 Stingone JA, Claudio L. Disparities in allergy testing and health outcomes among urban children with asthma. Journal of Allergy and Clinical Immunology. 2008; 122(4):748-753

1682 Stingone JA, Ramirez OF, Svensson K, Claudio L. Prevalence, demographics, and health outcomes of comorbid asthma and overweight in urban children. Journal of Asthma. 2011; 48(9):876-885

1683 Stoddard JJ, Miller T. Impact of parental smoking on the prevalence of wheezing respiratory illness in children. American Journal of Epidemiology. 1995; 141(2):96-102

1684 Stokes JR, Hartel R, Ford LB, Casale TB. Cannabis (hemp) positive skin tests and respiratory symptoms. Annals of Allergy, Asthma and Immunology. 2000; 85(3):238-240

1685 Storms WW. Exercise-induced asthma: Making the diagnosis. Journal of Respiratory Diseases. 2000; 21(8):491-494

1686 Stout JW, Smith K, Zhou C, Solomon C, Dozor AJ, Garrison MM et al. Learning from a distance: effectiveness of online spirometry training in improving asthma care. Academic Pediatrics. 2012; 12(2):88-95

1687 Strachan DP. Wheezing presenting in general practice. Archives of Disease in Childhood. 1985; 60(5):457-460

1688 Strachan DP, Anderson HR, Bland JM, Peckham C. Asthma as a link between chest illness in childhood and chronic cough and phlegm in young adults. BMJ. 1988; 296(6626):890-893

1689 Strachan DP, Anderson HR, Limb ES, O'Neill A, Wells N. A national survey of asthma prevalence, severity, and treatment in Great Britain. Archives of Disease in Childhood. 1994; 70(3):174-178

1690 Strachan DP, Butland BK, Anderson HR. Incidence and prognosis of asthma and wheezing illness from early childhood to age 33 in a national British cohort. BMJ. 1996; 312(7040):1195-1199

1691 Strachan DP, Griffiths JM, Johnston ID, Anderson HR. Ventilatory function in British adults after asthma or wheezing illness at ages 0-35. American Journal of Respiratory and Critical Care Medicine. 1996; 154(6 Pt 1):1629-1635

1692 Strandbygaard U, Thomsen SF, Backer V. A daily SMS reminder increases adherence to asthma treatment: a three-month follow-up study. Respiratory Medicine. 2010; 104(2):166-171

1693 Strunk RC, Sternberg AL, Bacharier LB, Szefler SJ. Nocturnal awakening caused by asthma in children with mild-to-moderate asthma in the childhood asthma management program. Journal of Allergy and Clinical Immunology. 2002; 110(3):395-403

1694 Strunk RC, Szefler SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. Journal of Allergy and Clinical Immunology. 2003; 112(5):883-892

1695 Suarthana E, Vergouwe Y, Moons KG, de Monchy J, Grobbee D, Heederik D et al. A diagnostic model for the detection of sensitization to wheat allergens was developed and validated in bakery workers. Journal of Clinical Epidemiology. 2010; 63(9):1011-1019

1696 Subira ML, Oehling A, Crisci CD, Martin-Gil D. Evaluation of total IgE in diverse allergosis. Comparative study with other techniques. Part II. Allergologia Et Immunopathologia. 1976; 4(1):51-66

1697 Suetsugu S, Sakakibara H, Ishikawa H. A study on aspirin-induced asthma - its clinical feature and diagnosis. Japanese Journal of Medicine. 1981; 20(4):No

1698 Suman LG, Vijaya L, V, Surekha RH, Murthy KJR. Use of specific IgE to fractions of Gynandropsis gynandra pollen in in vitro diagnostic test. Indian Journal of Clinical Biochemistry. 2005; 20(2):170-173

1699 Sun Y, Sundell J. On associations between housing characteristics, dampness and asthma and allergies among children in Northeast Texas. Indoor and Built Environment. 2013; 22(4):678-684

1700 Sun Y, Sundell J. Life style and home environment are associated with racial disparities of asthma and allergy in Northeast Texas children. Science of the Total Environment. 2011; 409(20):4229-4234

1701 Sunyer J, Anto JM, Castellsague J, Soriano JB, Roca J. Total serum IgE is associated with asthma independently of specific IgE levels. The Spanish Group of the European Study of Asthma. European Respiratory Journal. 1996; 9(9):1880-1884

1702 Sunyer J, Jarvis D, Pekkanen J, Chinn S, Janson C, Leynaert B et al. Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study. Journal of Allergy and Clinical Immunology. 2004; 114(5):1033-1039

1703 Surange N, Hoyle J. Occupational asthma; Is this the cause of excess respiratory symptoms and COPD described in bitumen exposed workers? Thorax. 2011; 66:A5-A6

1704 Sutherland TJT, Taylor DR, Sears MR, Cowan JO, McLachlan CR, Filsell S et al. Association between exhaled nitric oxide and systemic inflammatory markers. Annals of Allergy, Asthma and Immunology. 2007; 99(6):534-539

1705 Sverrild A, Malinovschi A, Porsbjerg C, Backer V, Alving K. Predicting airway hyperreactivity to mannitol using exhaled nitric oxide in an unselected sample of adolescents and young adults. Respiratory Medicine. 2013; 107(1):150-152

1706 Sverrild A, Porsbjerg C, Backer V. The use of inhaled mannitol in the diagnosis and management of asthma. Expert Opinion on Pharmacotherapy. 2012; 13(1):115-123

1707 Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Airway hyperresponsiveness to mannitol and methacholine and exhaled nitric oxide: a random-sample population study. Journal of Allergy and Clinical Immunology. 2010; 126(5):952-958

1708 Sverrild A, Porsbjerg C, Thomsen SF, Backer V. Diagnostic properties of inhaled mannitol in the diagnosis of asthma: a population study. Journal of Allergy and Clinical Immunology. 2009; 124(5):928-932

1709 Syk J, Malinovschi A, Johansson G, UndéN A-L, Alving K. Improved asthma outcomes with FENO-guided anti-inflammatory treatment: A randomised controlled trial. 6th IPCRG World Conference, April 25-28, Edinburgh. 2012;Abstract

1710 Syk J, Malinovschi A, Johansson G, Unden A-L, Alving K. Lower incidence of asthma exacerbations with FENO-guided anti-inflammatory treatment: A randomised controlled trial [Abstract]. European Respiratory Journal. 2012; 40(Suppl 56):797s

1711 Syk J, Malinovschi A, Johansson G, Unden A-L, Andreasson A, Lekander M et al. Anti-inflammatory treatment of atopic asthma guided by exhaled nitric oxide: A randomized, controlled trial. Journal of Allergy and Clinical Immunology: In Practice. 2013; 1(6):639-648

1712 Szefler SJ, Mitchell H, Sorkness CA, Gergen PJ, O'Connor GT, Morgan WJ et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet. 2008; 372(9643):1065-1072

1713 Tagaya E, Tamaoki J, Nagai A, Murasugi H, Igi H. The role of a self-management program in the control of mild to moderate asthma: A randomized controlled study. Allergology International. 2005; 54(4):527-531

1714 Tagiyeva N, Devereux G, Semple S, Sherriff A, Henderson J, Elias P et al. Parental occupation is a risk factor for childhood wheeze and asthma. European Respiratory Journal. 2010; 35(5):987-993

1715 Tai A, Volkmer R, Burton A. Association between asthma symptoms and obesity in preschool (4-5 year old) children. Journal of Asthma. 2009; 46(4):362-365

1716 Taitel M, Jiang JZ, Rudkin K. Impact of pharmacist-call intervention program on new-to-therapy patients' medication adherence. Value in Health.: Elsevier Ltd. 2014; 17(3):A138-A139

1717 Taji B, Dolatabadi M, Fereidouni M. Determination of PEF and FEV1 normal volumes and assessment of portable digital peak flow meter in diagnosis of asthma in elementary school students of birjand city. Iranian Journal of Allergy, Asthma and Immunology. 2013; 12(1):S103-S104

1718 Takami S, Mochizuki H, Muramatsu R, Hagiwara S, Arakawa H. Relationship between bronchial hyperresponsiveness and lung function in children age 5 and 6 with and without asthma. Respirology. 2013; 18(4):682-687

1719 Takenoue Y, Kaneko T, Miyamae T, Mori M, Yokota S. Influence of outdoor NO2 exposure on asthma in childhood: meta-analysis. Pediatrics International. 2012; 54(6):762-769

1720 Tal A, Pasterkamp H, Serrette C, Leahy F, Chernick V. Response to cold air hyperventilation in normal and in asthmatic children. Journal of Pediatrics. 1984; 104(4):516-521

1721 Talini D, Benvenuti A, Carrara M, Vaghetti E, Martin LB, Paggiaro PL. Diagnosis of flour-induced occupational asthma in a cross-sectional study. Respiratory Medicine. 2002; 96(4):236-243

1722 Tamasi L, Bohacs A, Bikov A, Andorka C, Rigo JJ, Losonczy G et al. Exhaled nitric oxide in pregnant healthy and asthmatic women. Journal of Asthma. 2009; 46(8):786-791

1723 Tamura G, Satoh K, Chao C-L, Inoue H, Takishima T. Do diagnostic procedures other than inhalation challenge predict immediate bronchial responses to inhaled allergen? Clinical and Experimental Allergy. 1991; 21(4):497-502

1724 Tan WC, Bourbeau J, Hernandez P, Chapman KR, Cowie R, FitzGerald JM et al. Bronchodilator responsiveness and reported respiratory symptoms in an adult population. PloS One. 2013; 8(3):e58932

1725 Tang H, Fang Z, Sun Y, Li B, Shi Z, Chen J et al. YKL-40 in asthmatic patients, and its correlations with exacerbation, eosinophils and immunoglobulin E. European Respiratory Journal. 2010; 35(4):757-760

1726 Tang RB, Wu KK. Total serum IgE, allergy skin testing, and the radioallergosorbent test for the diagnosis of allergy in asthmatic children. Annals of Allergy. 1989; 62(5):432-435

1727 Tapp S, Lasserson TJ, Rowe BH. Education interventions for adults who attend the emergency room for acute asthma. Cochrane Database of Systematic Reviews. 2007; Issue 3:CD003000. DOI:10.1002/14651858.CD003000.pub2

1728 Tarlo SM, Broder I. Outcome of assessments for occupational asthma. Chest. 1991; 100(2):329-335

1729 Tarlo SM, Leung K, Broder I, Silverman F, Holness DL. Asthmatic subjects symptomatically worse at work: prevalence and characterization among a general asthma clinic population. Chest. 2000; 118(5):1309-1314

1730 Tarlo SM, Balmes J, Balkissoon R, Beach J, Beckett W, Bernstein D et al. Diagnosis and management of work-related asthma: American College Of Chest Physicians Consensus Statement. Chest. 2008; 134(3 Suppl):1S-41S

1731 Tarlo SM, Liss GM, Blanc PD. How to diagnose and treat work-related asthma: key messages for clinical practice from the American college of chest physicians consensus statement. Polskie Archiwum Medycyny Wewnetrznej. 2009; 119(10):660-666

1732 Taskinen T, Meklin T, Nousiainen M, Husman T, Nevalainen A, Korppi M. Moisture and mould problems in schools and respiratory manifestations in schoolchildren: clinical and skin test findings. Acta Paediatrica. 1997; 86(11):1181-1187

1733 Tauber E, Halmerbauer G, Frischer T, Gartner C, Horak FJ, Veiter A et al. Urinary eosinophil protein X in children: the relationship to asthma and atopy and normal values. Allergy. 2000; 55(7):647-652

1734 Taussig LM, Wright AL, Holberg CJ, Halonen M, Morgan WJ, Martinez FD. Tucson Children's Respiratory Study: 1980 to present. Journal of Allergy and Clinical Immunology. 2003; 111(4):661-676

1735 Taveras EM, Camargo CAJ, Rifas-Shiman SL, Oken E, Gold DR, Weiss ST et al. Association of birth weight with asthma-related outcomes at age 2 years. Pediatric Pulmonology. 2006; 41(7):643-648

1736 Taylor B, Wadsworth J, Golding J, Butler N. Breast feeding, eczema, asthma, and hayfever. Journal of Epidemiology and Community Health. 1983; 37(2):95-99

1737 Taylor DR, Cowan JO, Greene JM, Willan AR, Sears MR. Asthma in remission: can relapse in early adulthood be predicted at 18 years of age? Chest. 2005; 127(3):845-850

1738 Tee RD, Cullinan P, Welch J, Burge PS, Newman-Taylor AJ. Specific IgE to isocyanates: a useful diagnostic role in occupational asthma. Journal of Allergy and Clinical Immunology. 1998; 101(5):709-715

1739 Teeter JG. Use of pulmonary function tests in the diagnosis and management of asthma. Clinical Pulmonary Medicine. 1999; 6(4):211-217

1740 Terada A, Fujisawa T, Togashi K, Miyazaki T, Katsumata H, Atsuta J et al. Exhaled nitric oxide decreases during exercise-induced bronchoconstriction in children with asthma. American Journal of Respiratory and Critical Care Medicine. 2001; 164(10 Pt 1):1879-1884

1741 Terblanche E, Stewart RI. The prevalence of exercise-induced bronchoconstriction in Cape Town schoolchildren. South African Medical Journal. 1990; 78(12):744-747

1742 Ternesten-Hasseus E, Farbrot A, Lowhagen O, Millqvist E. Sensitivity to methacholine and capsaicin in patients with unclear respiratory symptoms. Allergy. 2002; 57(6):501-507

1743 Ternesten-Hasseus E, Johansson EL, Bende M, Millqvist E. Dyspnea from exercise in cold air is not always asthma. Journal of Asthma. 2008; 45(8):705-709

1744 Terzioglu E, Sin A, Kokuludag A, Kirmaz C, Erdem N, Sebik F et al. Sensitivity to Parietaria pollen in Izmir, Turkey as determined by skin prick and serum specific IgE values. Journal of Investigational Allergology and Clinical Immunology. 1998; 8(3):180-183

1745 Thiadens HA, De Bock GH, Dekker FW, Huysman JA, Van Houwelingen JC, Springer MP et al. Identifying asthma and chronic obstructive pulmonary disease in patients with persistent cough presenting to general practitioners: descriptive study. BMJ. 1998; 316(7140):1286-1290

1746 Thiadens HA, De Bock GH, Dekker FW, Huysman JA, Van Houwelingen JC, Springer MP et al. Value of measuring diurnal peak flow variability in the recognition of asthma: a study in general practice. European Respiratory Journal. 1998; 12(4):842-847

1747 Thiadens HA, De Bock GH, Van Houwelingen JC, Dekker FW, De Waal MW, Springer MP et al. Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV(1) in primary care patients presenting with a persistent cough? Thorax. 1999; 54(12):1055-1060

1748 Thomas M, Gruffydd-Jones K, Stonham C, Ward S, Macfarlane TV. Assessing asthma control in routine clinical practice: use of the Royal College of Physicians '3 questions'. Primary Care Respiratory Journal. 2009; 18(2):83-88

1749 Thomas M, Murray-Thomas T, Fan T, Williams T, Taylor S. Prescribing patterns of asthma controller therapy for children in UK primary care: a cross-sectional observational study. BMC Pulmonary Medicine. 2010; 10:29

1750 Thomas PS, Gibson PG, Wang H, Shah S, Henry RL. The relationship of exhaled nitric oxide to airway inflammation and responsiveness in children. Journal of Asthma. 2005; 42(4):291-295

1751 Thomson CD, Wickens K, Miller J, Ingham T, Lampshire P, Epton MJ et al. Selenium status and allergic disease in a cohort of New Zealand children. Clinical and Experimental Allergy. 2012; 42(4):560-567

1752 Thoonen BPA, Schermer TRJ, van Den Boom G, Molema J, Folgering H, Akkermans RP et al. Self-management of asthma in general practice, asthma control and quality of life: A randomised controlled trial. Thorax. 2003; 58(1):30-36

1753 Thorne PS, Kulhankova K, Yin M, Cohn R, Arbes SJJ, Zeldin DC. Endotoxin exposure is a risk factor for asthma: the national survey of endotoxin in United States housing. American Journal of Respiratory and Critical Care Medicine. 2005; 172(11):1371-1377

1754 Thurber LA, Kotses H, Zuber P, Evavold S, Harver A. Compliance with daily monitoring of asthma symptoms diary vs.electronic peak flow recordings [Abstract]. Proceedings of the American Thoracic Society. 2006;A599

1755 Tie ST, Wong JL, Beniyamin A, Ho A, Kannan SKK, Jamalul Azizi AR. Methacholine challenge test as an adjunctive investigative tool in patients with asthma-like symptoms: the Sabah experience. Medical Journal of Malaysia. 2012; 67(2):204-206

1756 Tilemann L, Gindner L, Meyer F, Szecsenyi J, Schneider A. Differences in local and systemic inflammatory markers in patients with obstructive airways disease. Primary Care Respiratory Journal. 2011; 20(4):407-414

1757 Timonen KL, Nielsen J, Schwartz J, Gotti A, Vondra V, Gratziou C et al. Chronic respiratory symptoms, skin test results, and lung function as predictors of peak flow variability. American Journal of Respiratory and Critical Care Medicine. 1997; 156(3 Pt 1):776-782

1758 Timonen KL, Schwartz J, Nielsen J, Brunekreef B. Associations between markers of respiratory morbidity in European children. European Respiratory Journal. 2002; 19(3):479-486

1759 Tinkelman DG, Price DB, Nordyke RJ, Halbert RJ, Isonaka S, Nonikov D et al. Symptom-based questionnaire for differentiating COPD and asthma. Respiration. 2006; 73(3):296-305

1760 To T, Dell S, Tassoudji M, Wang C. Health outcomes in low-income children with current asthma in Canada. Chronic Diseases in Canada. 2009; 29(2):49-55

1761 To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; 12:204

1762 To T, Vydykhan TN, Dell S, Tassoudji M, Harris JK. Is obesity associated with asthma in young children? Journal of Pediatrics. 2004; 144(2):162-168

1763 Toda R, Hoshino T, Kawayama T, Imaoka H, Sakazaki Y, Tsuda T et al. Validation of "lung age" measured by spirometry and handy electronic FEV1/FEV6 meter in pulmonary diseases. Internal Medicine. 2009; 48(7):513-521

1764 Todd DC, Davis BE, Hurst TS, Cockcroft DW. Dosimeter methacholine challenge: comparison of maximal versus submaximal inhalations. Journal of Allergy and Clinical Immunology. 2004; 114(3):517-519

1765 Toelle BG, Peat JK, Salome CM, Mellis CM, Woolcock AJ. Toward a definition of asthma for epidemiology. American Review of Respiratory Disease. 1992; 146(3):633-637

1766 Toelle B, Ram Felix SF. Written individualised management plans for asthma in children and adults. Cochrane Database of Systematic Reviews. 2011; Issue 7:CD002171. DOI:10.1002/14651858.CD002171.pub3

1767 Tokuyama K, Shigeta M, Maeda S, Takei K, Hoshino M, Morikawa A. Diurnal variation of peak expiratory flow in children with cough variant asthma. Journal of Asthma. 1998; 35(2):225-229

1768 Tokuyama K, Tamura H, Mitsuhashi M, Morikawa A, Mochizuki H, Tajima K et al. Nonimmunologic activity of Dermatophagoides farinae extract. Annals of Allergy. 1985; 55(4):601-604

1769 Tollerud DJ, O'Connor GT, Sparrow D, Weiss ST. Asthma, hay fever, and phlegm production associated with distinct patterns of allergy skin test reactivity, eosinophilia, and serum IgE levels. The Normative Aging Study. American Review of Respiratory Disease. 1991; 144(4):776-781

1770 Tolppanen AM, Sayers A, Granell R, Fraser WD, Henderson J, Lawlor DA. Prospective association of 25-hydroxyvitamin d3 and d2 with childhood lung function, asthma, wheezing, and flexural dermatitis. Epidemiology. 2013; 24(2):310-319

1771 Tomasiak-Lozowska MM, Zietkowski Z, Przeslaw K, Tomasiak M, Skiepko R, Bodzenta-Lukaszyk A. Inflammatory markers and acid-base equilibrium in exhaled breath condensate of stable and unstable asthma patients. International Archives of Allergy and Immunology. 2012; 159(2):121-129

1772 Tomassen P, Jarvis D, Newson R, van Ree R, Forsberg B, Howarth P et al. Staphylococcus aureus enterotoxin-specific IgE is associated with asthma in the general population: a GA(2)LEN study. Allergy. 2013; 68(10):1289-1297

1773 Tomita K, Sano H, Chiba Y, Sato R, Sano A, Nishiyama O et al. A scoring algorithm for predicting the presence of adult asthma: a prospective derivation study. Primary Care Respiratory Journal. 2013; 22(1):51-58

1774 Toop LJ. Active approach to recognising asthma in general practice. BMJ. 1985; 290(6482):1629-1631

1775 Toren K, Brisman J, Jarvholm B. Asthma and asthma-like symptoms in adults assessed by questionnaires. A literature review. Chest. 1993; 104(2):600-608

1776 Torrent M, Sunyer J, Munoz L, Cullinan P, Iturriaga MV, Figueroa C et al. Early-life domestic aeroallergen exposure and IgE sensitization at age 4 years. Journal of Allergy and Clinical Immunology. 2006; 118(3):742-748

1777 Torrent M, Sunyer J, Garcia R, Harris J, Iturriaga MV, Puig C et al. Early-life allergen exposure and atopy, asthma, and wheeze up to 6 years of age. American Journal of Respiratory and Critical Care Medicine. 2007; 176(5):446-453

1778 Torres Da CJ, Ferreira JA, Castro E, Vaz M, Barros H, Agostinho MJ et al. Occupational asthma in the cotton textile industry: Assessment by bronchial hyperreactivity and peak expiratory flow recording. Revista Portuguesa De Pneumologia. 2002; 8(2):115-129

1779 Torres-Rodriguez JM, Pulido-Marrero Z, Vera-Garcia Y. Respiratory allergy to fungi in Barcelona, Spain: clinical aspects, diagnosis and specific treatment in a general allergy unit. Allergologia Et Immunopathologia. 2012; 40(5):295-300

1780 Toungoussova O, Foschino Barbaro MP, Esposito LM, Carpagnano GE, Salerno FG, Dal Negro RW et al. Brittle asthma. Monaldi Archives for Chest Disease - Pulmonary Series. 2007; 67(2):102-105

1781 Townley RG, Hopp RJ, Bewtra AK, Nair NM. Predictive value of airway reactivity. Journal of Allergy and Clinical Immunology. 1990; 86(4 Pt 2):650-652

1782 Townley RG, Ryo UY, Kolotkin BM, Kang B. Bronchial sensitivity to methacholine in current and former asthmatic and allergic rhinitis patients and control subjects. Journal of Allergy and Clinical Immunology. 1975; 56(6):429-442

1783 Tran N, Coffman JM, Sumino K, Cabana MD. Patient reminder systems and asthma medication adherence: a systematic review. Journal of Asthma. 2014; 51(54):536-543

1784 Travers J, Marsh S, Aldington S, Williams M, Shirtcliffe P, Pritchard A et al. Reference ranges for exhaled nitric oxide derived from a random community survey of adults. American Journal of Respiratory and Critical Care Medicine. 2007; 176(3):238-242

1785 TreeAge Software Inc. TreeAge Pro 2009. 2009. Available from: http://www.treeage.com. [Last accessed: 24 November 2014]

1786 Troise C, Voltolini S, Delbono G, Negrini AC. Allergy to pollens from Betulaceae and Corylaceae in a Mediterranean area (Genoa, Italy)--a ten-year retrospective study. Journal of Investigational Allergology and Clinical Immunology. 1992; 2(6):313-317

1787 Tromp IIM, Kiefte-de Jong JC, de Vries JH, Jaddoe VWV, Raat H, Hofman A et al. Dietary patterns and respiratory symptoms in pre-school children: the Generation R Study. European Respiratory Journal. 2012; 40(3):681-689

1788 Tschopp JM, Sistek D, Schindler C, Leuenberger P, Perruchoud AP, Wuthrich B et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE,

skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy. 1998; 53(6):608-613

1789 Tse M, Cooper C, Bridges-Webb C, Bauman A. Asthma in general practice. Opportunities for recognition and management. Australian Family Physician. 1993; 22(5):736-741

1790 Tse SM, Gold DR, Sordillo JE, Hoffman EB, Gillman MW, Rifas-Shiman SL et al. Diagnostic accuracy of the bronchodilator response in children. Journal of Allergy and Clinical Immunology. 2013; 132(3):554

1791 Tsujino I, Nishimura M, Kamachi A, Makita H, Munakata M, Miyamoto K et al. Exhaled nitric oxide--is it really a good marker of airway inflammation in bronchial asthma? Respiration. 2000; 67(6):645-651

1792 Tsybulkina V, Kurmaeva N, Tsybulkin N, DuBuske L. Assessment of allergen sensitisation and bronchial reactivity in young patients with asthma. Allergy. 2011; 66:347-348

1793 Tsybulkina V, Kurmaeva N, Tsybulkin N, DuBuske LM. Allergen sensitization and bronchial reactivity inyoung patients withatopicasthma. Annals of Allergy, Asthma and Immunology. 2012; 109:A59

1794 Tsybulkina V, Skorohodkina O, Luntsov A, Tsybulkin N, DuBuske L. Diagnostic value of exercise testing in young patients with atopic asthma [Abstract]. European Respiratory Society Annual Congress, Berlin, Germany, October 4-8. 2008;1097

1795 Tsybulkina V, Skorohodkina O, Luntsov N, Tsybulkin N, DuBuske LM. Assessment of bronchial reactivity in young patients with atopic asthma. Journal of Allergy and Clinical Immunology. 2009; 123(2 Suppl.1):S5

1796 Tu Y-L, Tsai H-J, Chang S-W, Cheng J-H, Huang J-L, Yao T-C. Reference values of total serum IgE and their significance in the diagnosis of allergy in Asian children: PATCH study. Allergy. 2013; 68:447

1797 Tuchinda M, Habananada S, Vareenil J, Srimaruta N, Piromrat K. Asthma in Thai children: a study of 2000 cases. Annals of Allergy. 1987; 59(3):207-211

1798 Tufvesson E, Aronsson D, Ankerst J, George SC, Bjermer L. Peripheral nitric oxide is increased in rhinitic patients with asthma compared to bronchial hyperresponsiveness. Respiratory Medicine. 2007; 101(11):2321-2326

1799 Turbyville J, Gada S, Payne K, Laubach S, Callahan CW, Nelson M. Posttussive emesis as a symptom of asthma in children. Annals of Allergy, Asthma and Immunology. 2011; 106(2):140-145

1800 Turcotte H, Langdeau JB, Bowie DM, Boulet LP. Are questionnaires on respiratory symptoms reliable predictors of airway hyperresponsiveness in athletes and sedentary subjects? Journal of Asthma. 2003; 40(1):71-80

1801 Turgeon JP, St-Laurent-Gagnon T, Chabot G, Allard-Dansereau C, Gaudreault P, Thivierge RL et al. Teaching inhalation techniques to asthmatic children: A randomized clinical trial. Ambulatory Child Health. 1996; 1(3):205-213

1802 Turktas H, Oguzulgen K, Kokturk N, Memis L, Erbas D. Correlation of exhaled nitric oxide levels and airway inflammation markers in stable asthmatic patients. Journal of Asthma. 2003; 40(4):425-430

1803 Turner MO, Taylor D, Bennett R, Fitzgerald JM. A randomized trial comparing peak expiratory flow and symptom self-management plans for patients with asthma attending a primary care clinic. American Journal of Respiratory and Critical Care Medicine. 1998; 157(2):540-546

1804 Turner S, McNamee R, Roberts C, Bradshaw L, Curran A, Francis M et al. Agreement in diagnosing occupational asthma by occupational and respiratory physicians who report to surveillance schemes for work-related ill-health. Occupational and Environmental Medicine. 2010; 67(7):471-478

1805 Turner SW, Craig LCA, Harbour PJ, Forbes SH, McNeill G, Seaton A et al. Early rattles, purrs and whistles as predictors of later wheeze. Archives of Disease in Childhood. 2008; 93(8):701-704

1806 Turner SW, Campbell D, Smith N, Craig LCA, McNeill G, Forbes SH et al. Associations between fetal size, maternal {alpha}-tocopherol and childhood asthma. Thorax. 2010; 65(5):391-397

1807 Turner-Warwick M. Epidemiology of nocturnal asthma. American Journal of Medicine. 1988; 85(1B):6-8

1808 Uasuf CG, Jatakanon A, James A, Kharitonov SA, Wilson NM, Barnes PJ. Exhaled carbon monoxide in childhood asthma. Journal of Pediatrics. 1999; 135(5):569-574

1809 Ulrik CS, Backer V, Hesse B, Dirksen A. Risk factors for development of asthma in children and adolescents: findings from a longitudinal population study. Respiratory Medicine. 1996; 90(10):623-630

1810 Ulrik CS, Postma DS, Backer V. Recognition of asthma in adolescents and young adults: which objective measure is best? Journal of Asthma. 2005; 42(7):549-554

1811 Uysal MA, Mungan D, Yorgancioglu A, Yildiz F, Akgun M, Gemicioglu B et al. Asthma control test via text messaging: could it be a tool for evaluating asthma control? Journal of Asthma. England: Informa Healthcare (52 Vanderbilt Ave., New York 10017, United States). 2013; 50(10):1083-1089

1812 Vagic D, Ferencic Z, Drvis P, Geber G, Dzidic S, Baudoin T et al. Local IgE and inflammation in chronic rhinosinusitis of asthmatics and non-asthmatics. European Archives of Oto-Rhino-Laryngology. 2008; 265(10):1205-1209

1813 Vaidyanathan S, Williamson PA, Lipworth BJ. Is a positive nasal lysine-aspirin challenge test associated with a more severe phenotype of chronic rhinosinusitis and asthma? American Journal of Rhinology and Allergy. 2012; 26(3):e89-e93

1814 Valencia M, Randazzo L, Tapias G, Granel C, Olive A. Allergy to Alternaria. II. Diagnostic comparison of skin-tests and RAST. Allergologia Et Immunopathologia. 1993; 21(2):84-87

1815 Valery PC, Chang AB, Shibasaki S, Gibson O, Purdie DM, Shannon C et al. High prevalence of asthma in five remote indigenous communities in Australia. European Respiratory Journal. 2001; 17(6):1089-1096

1816 Valery PC, Masters IB, Chang AB. Snoring and its association with asthma in Indigenous children living in the Torres Strait and Northern Peninsula Area. Journal of Paediatrics and Child Health. 2004; 40(8):461-465

1817 Valery PC, Purdie DM, Chang AB, Masters IB, Green A. Assessment of the diagnosis and prevalence of asthma in Australian indigenous children. Journal of Clinical Epidemiology. 2003; 56(7):629-635

1818 van Amsterdam JGC, Janssen NAH, De MG, Fischer PH, Nierkens S, Van LH et al. The relationship between exhaled nitric oxide and allergic sensitization in a random sample of school children. Clinical and Experimental Allergy. 2003; 33(2):187-191

1819 Van Asch CJJ, Balemans WAF, Rovers MM, Schilder AGM, van der Ent CK. Atopic disease and exhaled nitric oxide in an unselected population of young adults. Annals of Allergy, Asthma and Immunology. 2008; 100(1):59-65

1820 Van Bever HP, Wieringa MH, Weyler JJ, Nelen VJ, Fortuin M, Vermeire PA. Croup and recurrent croup: their association with asthma and allergy. An epidemiological study on 5-8-year-old children. European Journal of Pediatrics. 1999; 158(3):253-257

1821 Van De Ven MOM, van den Eijnden RJJM, Engels RCME. Atopic diseases and related risk factors among Dutch adolescents. European Journal of Public Health. 2006; 16(5):549-558

1822 van der Gugten AC, Koopman M, Evelein AMV, Verheij TJM, Uiterwaal CSPM, van der Ent CK. Rapid early weight gain is associated with wheeze and reduced lung function in childhood. European Respiratory Journal. 2012; 39(2):403-410

1823 van der Mark LB, van Wonderen KE, Mohrs J, van Aalderen WMC, Ter Riet G, Bindels PJE. Predicting asthma in preschool children at high risk presenting in primary care: development of a clinical asthma prediction score. Primary Care Respiratory Journal. 2014; 23(1):52-59

1824 van der Meer V, Bakker MJ, van den Hout WB, Rabe KF, Sterk PJ, Kievit J et al. Internet-based self-management plus education compared with usual care in asthma: a randomized trial. Annals of Internal Medicine. 2009; 151(2):110-120

1825 van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL, Seydel ER. Evaluation of the long-term effectiveness of three instruction modes for inhaling medicines. Patient Education and Counseling. 1997; 32(1 Suppl):S87-S95

1826 van der Palen J, Klein JJ, Zielhuis GA, Van Herwaarden CLA. The role of self-treatment guidelines in self-management education for adult asthmatics. Respiratory Medicine. 1998; 92(4):668-675

1827 van der Palen J, Klein JJ, Zielhuis GA, Van Herwaarden CLA, Seydel ER. Behavioural effect of self-treatment guidelines in a self-management program for adults with asthma. Patient Education and Counseling. 2001; 43(2):161-169

1828 van der Valk RJP, Baraldi E, Stern G, Frey U, De Jongste JC. Daily exhaled nitric oxide measurements and asthma exacerbations in children. Allergy. 2012; 67(2):265-271

1829 van der Valk RJP, Caudri D, Savenije O, Koppelman GH, Smit HA, Wijga AH et al. Childhood wheezing phenotypes and FeNO in atopic children at age8. Clinical and Experimental Allergy. 2012; 42(9):1329-1336

1830 van der Valk RJP, Duijts L, Kerkhof M, Willemsen SP, Hofman A, Moll HA et al. Interaction of a 17q12 variant with both fetal and infant smoke exposure in the development of childhood asthma-like symptoms. Allergy. 2012; 67(6):767-774

1831 van der Valk RJP, Kiefte-de Jong JC, Sonnenschein-van der Voort AMM, Duijts L, Hafkamp-de Groen E, Moll HA et al. Neonatal folate, homocysteine, vitamin B12 levels and methylenetetrahydrofolate reductase variants in childhood asthma and eczema. Allergy. 2013; 68(6):788-795

1832 van Gaalen JL, Bakker MJ, van Bodegom-Vos L, Snoeck-Stroband JB, Assendelft WJJ, Kaptein AA et al. Implementation strategies of internet-based asthma self-management support in usual care. Study protocol for the IMPASSE cluster randomized trial. Implementation Science. 2012; 7:113

1833 van Gaalen JL, Beerthuizen T, van der Meer V, van Reisen P, Redelijkheid GW, Snoeck-Stroband JB et al. Long-term outcomes of internet-based self-management support in adults with asthma. Journal of Medical Internet Research. 2013; 15(9):e188

1834 van Gent R, van Essen-Zandvliet LEM, Rovers MM, Kimpen JLL, de Meer G, van der Ent CK. Poor perception of dyspnoea in children with undiagnosed asthma. European Respiratory Journal. 2007; 30(5):887-891

1835 Van Gysel D, Govaere E, Verhamme K, Doli E, De Baets F. The influence of bedroom environment on sensitization and allergic symptoms in schoolchildren. Journal of Investigational Allergology and Clinical Immunology. 2007; 17(4):227-235

1836 van Maanen A, Wijga AH, Gehring U, Postma DS, Smit HA, Oort FJ et al. Sleep in children with asthma: results of the PIAMA study. European Respiratory Journal. 2013; 41(4):832-837

1837 van Nimwegen FA, Penders J, Stobberingh EE, Postma DS, Koppelman GH, Kerkhof M et al. Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy. Journal of Allergy and Clinical Immunology. 2011; 128(5):948-3

1838 van Schayck CP. Diagnosis of asthma and chronic obstructive pulmonary disease in general practice. British Journal of General Practice. 1996; 46(404):193-197

1839 van Schayck CP, van Der Heijden FM, van Den Boom G, Tirimanna PR, van Herwaarden CL. Underdiagnosis of asthma: is the doctor or the patient to blame? The DIMCA project. Thorax. 2000; 55(7):562-565

1840 van Schayck CP, Van Weel C, Harbers HJ, van Herwaarden CL. Do physical signs reflect the degree of airflow obstruction in patients with asthma or chronic obstructive pulmonary disease? Scandinavian Journal of Primary Health Care. 1991; 9(4):232-238

1841 van Zaane B, Droog RP, Stouthard MEA, van Aalderen WMC. QUOTAC: QUestionnaire On day and night Time respiratory symptoms in Asthmatic Children -- a validity study. Journal of Asthma. 2007; 44(2):107-111

1842 Vandenplas O, Binard-Van Cangh F, Brumagne A, Caroyer JM, Thimpont J, Sohy C et al. Occupational asthma in symptomatic workers exposed to natural rubber latex: evaluation of diagnostic procedures. Journal of Allergy and Clinical Immunology. 2001; 107(3):542-547

1843 Vanto T, Viander M, Koivikko A, Schwartz B, Lowenstein H. RAST in the diagnostic of dog dander allergy. A comparison between three allergen preparations using two variants of RAST. Allergy. 1982; 37(2):75-85

1844 Varela S, Mendez J, Gonzalez de la Cuesta C, Iglesias I, Gonzalez C, Menendez M. Characteristics of pollinosis caused by Betula in patients from Ourense (Galicia, Spain). Journal of Investigational Allergology and Clinical Immunology. 2003; 13(2):124-130

1845 Vargas MH, Ruiz-Gutierrez HH, Espinosa-Serafin C, Zuniga-Vazquez G, Furuya MEY. Underestimation of the peak flow variability in asthmatic children: Evaluation of a new formula. Pediatric Pulmonology. 2005; 39(4):325-331

1846 Vargas PA, Perry TT, Robles E, Jo CH, Simpson PM, Magee JM et al. Relationship of body mass index with asthma indicators in head start children. Annals of Allergy, Asthma and Immunology. 2007; 99(1):22-28

1847 Vasar M, Braback L, Julge K, Knutsson A, Riikjarv MA, Bjorksten B. Prevalence of bronchial hyperreactivity as determined by several methods among Estonian schoolchildren. Pediatric Allergy and Immunology. 1996; 7(3):141-146

1848 Vasbinder EC, Janssens HM, Rutten-van Molken MPMH, van Dijk L, de Winter BCM, de Groot RCA et al. e-Monitoring of Asthma Therapy to Improve Compliance in children using a real-time medication monitoring system (RTMM): the e-MATIC study protocol. BMC Medical Informatics and Decision Making. 2013; 13(1):38

1849 Vazquez MI, Buceta JM. Effectiveness of self-management programmes and relaxation training in the treatment of bronchial asthma: relationships with trait anxiety and emotional attack triggers. Journal of Psychosomatic Research. 1993; 37(1):71-81

1850 Vedal S, Petkau J, White R, Blair J. Acute effects of ambient inhalable particles in asthmatic and nonasthmatic children. American Journal of Respiratory and Critical Care Medicine. 1998; 157(4 Pt 1):1034-1043

1851 Vellinga A, Droste JHJ, Vermeire PA, Desager K, De Backer WA, Nelen VJ et al. Changes in respiratory and allergic symptoms in schoolchildren from 1996 to 2002, results from the ISAAC surveys in Antwerp (Belgium). Acta Clinica Belgica. 2005; 60(5):219-225

1852 Venables KM, Burge PS, Davison AG, Newman Taylor AJ. Peak flow rate records in surveys: reproducibility of observers' reports. Thorax. 1984; 39(11):828-832

1853 Venables KM, Farrer N, Sharp L, Graneek BJ, Newman Taylor AJ. Respiratory symptoms questionnaire for asthma epidemiology: validity and reproducibility. Thorax. 1993; 48(3):214-219

1854 Venn A, Lewis S, Cooper M, Hubbard R, Hill I, Boddy R et al. Local road traffic activity and the prevalence, severity, and persistence of wheeze in school children: combined cross sectional and longitudinal study. Occupational and Environmental Medicine. 2000; 57(3):152-158

1855 Venn AJ, Lewis SA, Cooper M, Hubbard R, Britton J. Living near a main road and the risk of wheezing illness in children. American Journal of Respiratory and Critical Care Medicine. 2001; 164(12):2177-2180

1856 Ventura MT, Gelardi M, Di Gioia R, Buquicchio R, Accettura G, Tummolo RA et al. Statistical evaluation and parameters of phlogosis in patients sensitized to cypress. Journal of Biological Regulators and Homeostatic Agents. 2007; 21(1-2):41-48

1857 Verini M, Consilvio NP, Di PS, Cingolani A, Spagnuolo C, Rapino D et al. FeNO as a marker of airways inflammation: The possible implications in childhood asthma management. Journal of Allergy. 2010; 2010:691425

1858 Verleden GM, Dupont LJ, Verpeut AC, Demedts MG. The effect of cigarette smoking on exhaled nitric oxide in mild steroid-naive asthmatics. Chest. 1999; 116(1):59-64

1859 Verver S, Poelman M, Bogels A, Chisholm SL, Dekker FW. Effects of instruction by practice assistants on inhaler technique and respiratory symptoms of patients. A controlled randomized videotaped intervention study. Family Practice. 1996; 13(1):35-40

1860 Vervloet D, de Andrade AD, Pascal L, Lanteaume A, Dutau H, Armengaud A et al. The prevalence of reported asthma is independent of exposure in house dust mite-sensitized children. European Respiratory Journal. 1999; 13(5):983-987

1861 Vial Dupuy A, Amat F, Pereira B, Labbe A, Just J. A simple tool to identify infants at high risk of mild to severe childhood asthma: the persistent asthma predictive score. Journal of Asthma. 2011; 48(10):1015-1021

1862 Viander M, Valovirta E, Vanto T, Koivikko A. Cross-reactivity of cat and dog allergen extracts. RAST inhibition studies with special reference to the allergenic activity in saliva and urine. International Archives of Allergy and Applied Immunology. 1983; 71(3):252-260

1863 Vieira T, Fonseca J, Cruz L, Silva R, Ferreira A, Leblanc A et al. Results of a school-based asthma assessment from the upKids questionnaire validation study. Allergy. 2009; 64:441-442

1864 Vieira T, Fonseca JA, Silva R, Cruz L, Ferreira AR, Leblanc A et al. Validity of a questionnaire in a school-based allergic asthma screening- comparison with exhaled nitric oxide fraction and skin prick tests. Revista Portuguesa De Imunoalergologia. 2011; 19(4):215-221

1865 Vila-Indurain B, Munoz-Lopez F, Martin-Mateos M. Evaluation of blood eosinophilia and the eosinophil cationic protein (ECP) in the serum of asthmatic children with varying degree of severity. Allergologia Et Immunopathologia. 1999; 27(6):304-308

1866 Vilozni D, Bentur L, Efrati O, Barak A, Szeinberg A, Shoseyov D et al. Exercise challenge test in 3- to 6-year-old asthmatic children. Chest. 2007; 132(2):497-503

1867 Vilozni D, Livnat G, Dabbah H, Elias N, Hakim F, Bentur L. The potential use of spirometry during methacholine challenge test in young children with respiratory symptoms. Pediatric Pulmonology. 2009; 44(7):720-727

1868 Visser MJ, de Wit MC, van Aalderen WM, Postma DS, Brand PL. Exhaled nitric oxide in children measured by tidal breathing method: differences between asthmatics and nonasthmatic controls. Pediatric Pulmonology. 2000; 29(6):434-437

1869 Vogelmeier C, Baur X, Fruhmann G. Isocyanate-induced asthma: results of inhalation tests with TDI, MDI and methacholine. International Archives of Occupational and Environmental Health. 1991; 63(1):9-13

1870 Vogelmeier CF, Hering T, Lewin T, Sander P, Bethke TD. Efficacy and safety of ciclesonide in the treatment of 24,037 asthmatic patients in routine medical care. Respiratory Medicine. 2011; 105(2):186-194

1871 Volbeda F, Broekema M, Lodewijk ME, Hylkema MN, Reddel HK, Timens W et al. Clinical control of asthma associates with measures of airway inflammation. Thorax. 2013; 68(1):19-24

1872 Volkmer RE, Ruffin RE, Wigg NR, Davies N. The prevalence of respiratory symptoms in South Australian preschool children. II. Factors associated with indoor air quality. Journal of Paediatrics and Child Health. 1995; 31(2):116-120

1873 Vollmer WM, Kirshner M, Peters D, Drane A, Stibolt T, Hickey T et al. Use and impact of an automated telephone outreach system for asthma in a managed care setting. American Journal of Managed Care. 2006; 12(12):725-733

1874 Vollmer WM, Feldstein A, Smith DH, Dubanoski JP, Waterbury A, Schneider JL et al. Use of health information technology to improve medication adherence. American Journal of Managed Care. 2011; 17(12 Spec No.):SP79-SP87

1875 Von Ehrenstein OS, von Mutius E, Illi S, Baumann L, Bohm O, von Kries R. Reduced risk of hay fever and asthma among children of farmers. Clinical and Experimental Allergy. 2000; 30(2):187-193

1876 von Mutius E, Illi S, Hirsch T, Leupold W, Keil U, Weiland SK. Frequency of infections and risk of asthma, atopy and airway hyperresponsiveness in children. European Respiratory Journal. 1999; 14(1):4-11

1877 Vooren PH, Kramps JA, Franken C, Dijkman JH. Diagnostic relevance of the modified RAST using D epsilon 2 specific anti-IgE antibodies. European Journal of Respiratory Diseases. 1983; 64(2):90-101

1878 Voorend-van BS, Vaessen-Verberne A, Landstra A, Brackel H, van den Berg N, De JJ et al. FeNO and web-based monitoring in paediatric asthma managemant; the BATMAN study [Abstract]. European Respiratory Society Annual Congress, 2013 Sept 7-11, Barcelona, Spain. 2013; 42(Suppl 57):629s

1879 Voutilainen M, Malmberg LP, Vasankari T, Haahtela T. Exhaled nitric oxide indicates poorly athlete's asthma. Clinical Respiratory Journal. 2013; 7(4):347-353

1880 Vries TW, Berg PB, Duiverman EJ, Jong-van Den Berg LTW. Effect of a minimal pharmacy Intervention on adherence to asthma medication guidelines for children. Pharmaceutisch Weekblad. 2010; 145(50):195-197

1881 Vugt Sv, Broekhuizen L, Zuithoff N, Butler C, Hood K, Coenen S et al. Airway obstruction and bronchodilator responsiveness in adults with acute cough. Annals of Family Medicine. 2012; 10(6):523-529

1882 Wakamori T, Katoh N, Hirano S, Kishimoto S, Ozasa K. Atopic dermatitis, dry skin and serum IgE in children in a community in japan. International Archives of Allergy and Immunology. 2009; 149(2):103-110

1883 Wake M, Clifford SA, Patton GC, Waters E, Williams J, Canterford L et al. Morbidity patterns among the underweight, overweight and obese between 2 and 18 years: population-based cross-sectional analyses. International Journal of Obesity. 2013; 37(1):86-93

1884 Walamies MA. Diagnostic role of residual volume in paediatric patients with chronic symptoms of the lower airways. Clinical Physiology. 1998; 18(1):49-54

1885 Walders N, Kercsmar C, Schluchter M, Redline S, Kirchner HL, Drotar D. An interdisciplinary intervention for undertreated pediatric asthma. Chest. 2006; 129(2):292-299

1886 Walraven GE, Nyan OA, Van Der Sande MA, Banya WA, Ceesay SM, Milligan PJ et al. Asthma, smoking and chronic cough in rural and urban adult communities in The Gambia. Clinical and Experimental Allergy. 2001; 31(11):1679-1685

1887 Walters GI, Moore VC, Robertson AS, Burge CBSG, Vellore AD, Burge PS. An outbreak of occupational asthma due to chromium and cobalt. Occupational Medicine. 2012; 62(7):533-540

1888 Wang C, Salam MT, Islam T, Wenten M, Gauderman J, Gilliland FD. Effects of in utero and childhood tobacco smoke exposure and beta2-adrenergic receptor genotype on childhood asthma and wheezing. Pediatrics. 2008; 122(1):e107-e114

1889 Wang HY, Pizzichini MMM, Becker AB, Duncan JM, Ferguson AC, Greene JM et al. Disparate geographic prevalences of asthma, allergic rhinoconjunctivitis and atopic eczema among adolescents in five Canadian cities. Pediatric Allergy and Immunology. 2010; 21(5):867-877

1890 Wang HY, Wong GWK, Chen YZ, Ferguson AC, Greene JM, Ma Y et al. Prevalence of asthma among Chinese adolescents living in Canada and in China. CMAJ. 2008; 179(11):1133-1142

1891 Wang J, Visness CM, Calatroni A, Gergen PJ, Mitchell HE, Sampson HA. Effect of environmental allergen sensitization on asthma morbidity in inner-city asthmatic children. Clinical and Experimental Allergy. 2009; 39(9):1381-1389

1892 Wang JY, Chen WY. Inhalant allergens in asthmatic children in Taiwan: comparison evaluation of skin testing, radioallergosorbent test and multiple allergosorbent chemiluminescent assay for specific IgE. Journal of the Formosan Medical Association. 1992; 91(12):1127-1132

1893 Wang W, Huang K, Wu B, Wang Y, Wang D. Correlation of eosinophil counts in induced sputum and fractional concentration of exhaled nitric oxide and lung functions in patients with mild to moderate asthma. Chinese Medical Journal. 2012; 125(17):3157-3160

1894 Wanich NH, Kaplan MS. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: A randomised controlled trial. Pediatrics. United States: American Academy of Pediatrics (141 Northwest Point Blvd, P.O. Box 927, Elk Grove Village IL 60007-1098, United States). 2009; 124(SUPPL. 2):S147

1895 Wardman AG, Binns V, Clayden AD, Cooke NJ. The diagnosis and treatment of adults with obstructive airways disease in general practice. British Journal of Diseases of the Chest. 1986; 80(1):19-26

1896 Warke TJ, Fitch PS, Brown V, Taylor R, Lyons JDM, Ennis M et al. Exhaled nitric oxide correlates with airway eosinophils in childhood asthma. Thorax. 2002; 57(5):383-387

1897 Wassall HJ, Devenny AM, Daud Khan S, Ninan TK, Russell G. A comparison of virus-associated and multi-trigger wheeze in school children. Journal of Asthma. 2005; 42(9):737-744

1898 Watelet JB, Van Zele T, Brusselle G. Chronic cough in upper airway diseases. Respiratory Medicine. 2010; 104(5):652-657

1899 Weber RW, Hoffman M, Raine DAJ, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. Journal of Allergy and Clinical Immunology. 1979; 64(1):32-37

1900 Wedner HJ, Zenger VE, Lewis WH. Allergic reactivity of Parthenium hysterophorus (Santa Maria feverfew) pollen: An unrecognized allergen. International Archives of Allergy and Applied Immunology. 1987; 84(2):116-122

1901 Weinberger M, Murray MD, Marrero DG, Brewer N, Lykens M, Harris LE et al. Effectiveness of pharmacist care for patients with reactive airways disease: a randomized controlled trial. JAMA. 2002; 288(13):1594-1602

1902 Weinmayr G, Gehring U, Genuneit J, Buchele G, Kleiner A, Siebers R et al. Dampness and moulds in relation to respiratory and allergic symptoms in children: results from Phase Two of the International Study of Asthma and Allergies in Childhood (ISAAC Phase Two). Clinical and Experimental Allergy. 2013; 43(7):762-774

1903 Weinmayr G, Weiland SK, Bjorksten B, Brunekreef B, Buchele G, Cookson WOC et al. Atopic sensitization and the international variation of asthma symptom prevalence in children. American Journal of Respiratory and Critical Care Medicine. 2007; 176(6):565-574

1904 Weintraub JM, Sparrow D, Weiss ST. Receiver operating characteristics curve analysis of cutaneous skin test reactions to predict hay fever and asthma symptoms in the Normative Aging Study. Allergy. 2001; 56(3):243-246

1905 Welsh L, Lercher P, Horak E. Exhaled nitric oxide: interactions between asthma, hayfever, and atopic dermatitis in school children. Pediatric Pulmonology. 2007; 42(8):693-698

1906 Wensley D, Silverman M. Peak flow monitoring for guided self-management in childhood asthma: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine. 2004; 170(6):606-612

1907 West JV, Robertson CF, Roberts R, Olinsky A. Evaluation of bronchial responsiveness to exercise in children as an objective measure of asthma in epidemiological surveys. Thorax. 1996; 51(6):590-595

1908 Wever-Hess J, Kouwenberg JM, Duiverman EJ, Hermans J, Wever AM. Prognostic characteristics of asthma diagnosis in early childhood in clinical practice. Acta Paediatrica. 1999; 88(8):827-834

1909 White SK, Cox-Ganser JM, Benaise LG, Kreiss K. Work-related peak flow and asthma symptoms in a damp building. Occupational Medicine. 2013; 63(4):287-290

1910 Whitrow MJ, Harding S. Asthma in Black African, Black Caribbean and South Asian adolescents in the MRC DASH study: a cross sectional analysis. BMC Pediatrics. 2010; 10:18

1911 Wickens K, Barry D, Friezema A, Rhodius R, Bone N, Purdie G et al. Fast foods - are they a risk factor for asthma? Allergy. 2005; 60(12):1537-1541

1912 Wickens K, Ingham T, Epton M, Pattemore P, Town I, Fishwick D et al. The association of early life exposure to antibiotics and the development of asthma, eczema and atopy in a birth cohort: confounding or causality? Clinical and Experimental Allergy. 2008; 38(8):1318-1324

1913 Wickman M, Lilja G, Soderstrom L, van Hage-Hamsten M, Ahlstedt S. Quantitative analysis of IgE antibodies to food and inhalant allergens in 4-year-old children reflects their likelihood of allergic disease. Allergy. 2005; 60(5):650-657

1914 Wickman M, Nordvall SL, Pershagen G, Sundell J, Schwartz B. House dust mite sensitization in children and residential characteristics in a temperate region. Journal of Allergy and Clinical Immunology. 1991; 88(1):89-95

1915 Wieslander G, Janson C, Norback D, Bjornsson E, Stalenheim G, Edling C. Occupational exposure to water-based paints and self-reported asthma, lower airway symptoms, bronchial hyperresponsiveness, and lung function. International Archives of Occupational and Environmental Health. 1994; 66(4):261-267

1916 Wijga AH, Smit HA, Kerkhof M, De Jongste JC, Gerritsen J, Neijens HJ et al. Association of consumption of products containing milk fat with reduced asthma risk in pre-school children: the PIAMA birth cohort study. Thorax. 2003; 58(7):567-572

1917 Willems DC, Joore MA, Hendriks JJ, van Duurling RA, Wouters EF, Severens JL. Process evaluation of a nurse-led telemonitoring programme for patients with asthma. Journal of Telemedicine and Telecare. 2007; 13(6):310-317

1918 Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of self-management in asthma: A systematic review of peal flow monitoring interventions. Internation Journal of Technical Assessment in Health Care. 2006; 22:436-442:436-442

1919 Willems DC, Joore MA, Hendriks JJ, Wouters EF, Severens JL. Cost-effectiveness of a nurse-led telemonitoring intervention based on peak expiratory flow measurements in asthmatics: results of a randomised controlled trial. Cost Effectiveness and Resource Allocation. 2007; 5:10

1920 Willers SM, Devereux G, Craig LCA, McNeill G, Wijga AH, Abou El-Magd W et al. Maternal food consumption during pregnancy and asthma, respiratory and atopic symptoms in 5-year-old children. Thorax. 2007; 62(9):773-779

1921 Willers SM, Wijga AH, Brunekreef B, Kerkhof M, Gerritsen J, Hoekstra MO et al. Maternal food consumption during pregnancy and the longitudinal development of childhood asthma. American Journal of Respiratory and Critical Care Medicine. 2008; 178(2):124-131

1922 Williams LK, Peterson EL, Wells K, Campbell J, Wang M, Chowdhry VK et al. A cluster-randomized trial to provide clinicians inhaled corticosteroid adherence information for their patients with asthma. Journal of Allergy and Clinical Immunology. 2010; 126(2):225-4

1923 Williamson PA, Vaidyanathan S, Clearie K, Stewart M, Lipworth BJ. Relationship between fractional exhaled nitric oxide and nasal nitric oxide in airways disease. Annals of Allergy, Asthma and Immunology. 2010; 105(2):162-167

1924 Wing A, Upton J, Svensson K, Weller P, Fletcher M, Walker S. The standardized and mini versions of the PAQLQ are valid, reliable, and responsive measurement tools. Journal of Clinical Epidemiology. 2012; 65(6):643-650

1925 Wismol P, Putivoranat P, Buranapraditkun S, Pinnobphun P, Ruxrungtham K, Klaewsongkram J. The values of nasal provocation test and basophil activation test in the different patterns of ASA/NSAID hypersensitivity. Allergologia Et Immunopathologia. 2012; 40(3):156-163

1926 Withers NJ, Low L, Holgate ST, Clough JB. The natural history of respiratory symptoms in a cohort of adolescents. American Journal of Respiratory and Critical Care Medicine. 1998; 158(2):352-357

1927 Wittczak T, Dudek W, Walusiak-Skorupa J, Swierczynska-Machura D, Cader W, Kowalczyk M et al. Metal-induced asthma and chest X-ray changes in welders. International Journal of Occupational Medicine and Environmental Health. 2012; 25(3):242-250

1928 Witteman AM, Stapel SO, Perdok GJ, Sjamsoedin DHS, Jansen HM, Aalberse RC et al. The relationship between RAST and skin test results in patients with asthma or rhinitis: A quantitative study with purified major allergens. Journal of Allergy and Clinical Immunology. 1996; 97(1 I):16-25

1929 Wjst M, Dold S, Roell G, Reitmeir P, Fritzsch C, Von ME et al. Bronchial hyperreactivity and history of wheezing in children. European Journal of Pediatrics. 1994; 153(9):682-686

1930 Wjst M, Hoelscher B, Frye C, Wichmann HE, Dold S, Heinrich J. Early antibiotic treatment and later asthma. European Journal of Medical Research. 2001; 6(6):263-271

1931 Wjst M, Popescu M, Trepka MJ, Heinrich J, Wichmann HE. Pulmonary function in children with initial low birth weight. Pediatric Allergy and Immunology. 1998; 9(2):80-90

1932 Wojnarowski C, Storm Van's GK, Riedler J, Eichler I, Gartner C, Frischer T. Comparison of bronchial challenge with ultrasonic nebulized distilled water and hypertonic saline in children with mild-to-moderate asthma. European Respiratory Journal. 1996; 9(9):1896-1901

1933 Wolf RL, Berry CA, Quinn K. Development and validation of a brief pediatric screen for asthma and allergies among children. Annals of Allergy, Asthma and Immunology. 2003; 90(5):500-507

1934 Wolfe I, Cass H, Thompson MJ, Craft A, Peile E, Wiegersma PA et al. Improving child health services in the UK: insights from Europe and their implications for the NHS reforms. BMJ. 2011; 342:d1277

1935 Wolff PT, Arison L, Rahajamiakatra A, Raserijaona F, Niggemann B. High asthma prevalence and associated factors in urban malagasy schoolchildren. Journal of Asthma. 2012; 49(6):575-580

1936 Wongtim S, Mogmeud S, Limthongkul S, Chareonlap P, Udompanich V, Nuchprayoon C et al. The role of the methacholine inhalation challenge in adult patients presenting with chronic cough. Asian Pacific Journal of Allergy and Immunology. 1997; 15(1):9-14

1937 Woo SI, Lee JH, Kim H, Kang JW, Sun YH, Hahn YS. Utility of fractional exhaled nitric oxide (F(E)NO) measurements in diagnosing asthma. Respiratory Medicine. 2012; 106(8):1103-1109

1938 Woodmansee D. CAP-RAST vs. skin prick testing in suspected aeroallergen sensitization. Annals of Allergy, Asthma and Immunology. 2009; 103(5 Suppl.3):A54-A55

1939 Woods RK, Abramson M, Bailey M, Walters EH. International prevalences of reported food allergies and intolerances. Comparisons arising from the European Community Respiratory Health Survey (ECRHS) 1991-1994. European Journal of Clinical Nutrition. 2001; 55(4):298-304

1940 Woods RK, Burton DL, Wharton C, McKenzie GH, Walters EH, Comino EJ et al. Asthma is more prevalent in rural New South Wales than metropolitan Victoria, Australia. Respirology. 2000; 5(3):257-263

1941 Woods RK, Walters EH, Wharton C, Watson N, Abramson M. The rising prevalence of asthma in young Melbourne adults is associated with improvement in treatment. Annals of Allergy, Asthma and Immunology. 2001; 87(2):117-123

1942 Woods RK, Thien F, Raven J, Walters EH, Abramson M. Prevalence of food allergies in young adults and their relationship to asthma, nasal allergies, and eczema. Annals of Allergy, Asthma and Immunology. 2002; 88(2):183-189

1943 Woolcock AJ, Salome CM, Yan K. The shape of the dose-response curve to histamine in asthmatic and normal subjects. American Review of Respiratory Disease. 1984; 130(1):71-75

1944 Wright AL, Holberg CJ, Taussig LM, Martinez FD. Factors influencing the relation of infant feeding to asthma and recurrent wheeze in childhood. Thorax. 2001; 56(3):192-197

1945 Wright AL, Stern DA, Kauffmann F, Martinez FD. Factors influencing gender differences in the diagnosis and treatment of asthma in childhood: the Tucson Children's Respiratory Study. Pediatric Pulmonology. 2006; 41(4):318-325

1946 Wu F, Gao Y, An J-Y, Xie Y-Q, Liu W-T, Yu X-X et al. Is bronchial provocation test induced by adenosine monophosphate (AMP) superior to histamine for identifying patients with asthma? Respirology. 2011; 16:221

1947 Wuthrich B, Schindler C, Leuenberger P, Ackermann-Liebrich U. Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Swiss Study on Air Pollution and Lung Diseases in Adults. International Archives of Allergy and Immunology. 1995; 106(2):149-156

1948 Xu F, Zou Z, Yan S, Li F, Kan H, Norback D et al. Fractional exhaled nitric oxide in relation to asthma, allergic rhinitis, and atopic dermatitis in Chinese children. Journal of Asthma. 2011; 48(10):1001-1006

1949 Xu X, Niu T, Chen C, Wang B, Jin Y, Yang J et al. Association of airway responsiveness with asthma and persistent wheeze in a Chinese population. Chest. 2001; 119(3):691-700

1950 Yang CL, Simons E, Foty RG, Marshall L, Nelligan K, To T et al. Questionnaire diagnosis of asthma leads to misclassification compared to guideline-based diagnosis. American Journal of Respiratory and Critical Care Medicine. 2011; 183(1 MeetingAbstracts)

1951 Yang YW, Tseng KC, Chen YH, Yang JY. Associations among eczema, asthma, serum immunoglobulin E and depression in adults: a population-based study. Allergy. 2010; 65(6):801-802

1952 Yao TC, Ou LS, Lee WI, Yeh KW, Chen LC, Huang JL et al. Exhaled nitric oxide discriminates children with and without allergic sensitization in a population-based study. Clinical and Experimental Allergy. 2011; 41(4):556-564

1953 Yartsev SS. Analysis of diagnostic efficiency of lung ventilation parameters in patients with bronchial asthma. Biomedical Engineering. 2006; 40(1):21-24

1954 Yavuz ST, Civelek E, Sahiner UM, Buyuktiryaki AB, Tuncer A, Karabulut E et al. Identifying uncontrolled asthma in children with the childhood asthma control test or exhaled nitric oxide measurement. Annals of Allergy, Asthma and Immunology. 2012; 109(1):36-40

1955 Yazicioglu M, Sayinbas P, Ones U, Saltik A, Tugrul M. Alatop: a new in vitro screening test for atopy. Journal of International Medical Research. 1994; 22(6):313-322

1956 Yeatts K, Maier W, Shy C. Asthma inhaler use and barriers in a population-based sample of African-American and white adolescents. Annals of Allergy, Asthma and Immunology. 2000; 84(1):94-100

1957 Yeatts K, Shy C, Wiley J, Music S. Statewide adolescent asthma surveillance. Journal of Asthma. 2000; 37(5):425-434

1958 Yeatts K, Davis KJ, Sotir M, Herget C, Shy C. Who gets diagnosed with asthma? Frequent wheeze among adolescents with and without a diagnosis of asthma. Pediatrics. 2003; 111(5 Pt 1):1046-1054

1959 Yoo Y, Kim DK, Yu J, Choi SH, Kim CK, Koh YY. Relationships of methacholine and AMP responsiveness with peak expiratory flow variability in children with asthma. Clinical and Experimental Allergy. 2007; 37(8):1158-1164

1960 Yoo Y, Ko HK, Han JJ, Lee Y, Seo KJ, Choung JT et al. The prevalence of atopy and asthma among university freshmen in Seoul, Korea: association with obesity. Journal of Asthma. 2007; 44(1):45-49

1961 Yoon J-Y, Woo S-I, Kim H, Sun Y-H, Hahn Y-S. Fractional exhaled nitric oxide and forced expiratory flow between 25% and 75% of vital capacity in children with controlled asthma. Korean Journal of Pediatrics. 2012; 55(9):372-379

1962 Yoon R, McKenzie DK, Bauman A, Miles DA. Controlled trial evaluation of an asthma education programme for adults. Thorax. 1993; 48(11):1110-1116

1963 Yoos HL, Kitzman H, McMullen A, Henderson C, Sidora K. Symptom monitoring in childhood asthma: a randomized clinical trial comparing peak expiratory flow rate with symptom monitoring. Annals of Allergy, Asthma and Immunology. 2002; 88(3):283-291

1964 Young HN, Havican SN, Griesbach S, Thorpe JM, Chewning BA, Sorkness CA. Patient and phaRmacist telephonic encounters (PARTE) in an underserved rural patient population with asthma: results of a pilot study. Telemedicine Journal and E-Health. 2012; 18(6):427-433

1965 Yu ITS, Wong TW, Li W. Using child reported respiratory symptoms to diagnose asthma in the community. Archives of Disease in Childhood. 2004; 89(6):544-548

1966 Yun TJ, Arriaga RI. A text message a day keeps the pulmonologist away. Proceedings of the SIGCHI Conference on Human Factors in Computing Systems 2013;1769-1778

1967 Yunginger JW, Reed CE, O'Connell EJ, Melton LJ, O'Fallon WM, Silverstein MD. A community-based study of the epidemiology of asthma. Incidence rates, 1964-1983. American Review of Respiratory Disease. 1992; 146(4):888-894

1968 Yurdakul AS, Dursun B, Canbakan S, Cakaloglu A, Capan N. The assessment of validity of different asthma diagnostic tools in adults. Journal of Asthma. 2005; 42(10):843-846

1969 Zacharasiewicz A, Erin EM, Bush A. Noninvasive monitoring of airway inflammation and steroid reduction in children with asthma. Current Opinion in Allergy and Clinical Immunology. 2006; 6(3):155-160

1970 Zaghloul MA, Barakat MM, Khalifah MA, Khattab G. Diagnostic evaluation of patients with chronic non-productive cough: Saudi experience. Annals of Thoracic Medicine. 2009; 4(2):101

1971 Zambonino MA, Torres MJ, Munoz C, Requena G, Mayorga C, Posadas T et al. Drug provocation tests in the diagnosis of hypersensitivity reactions to non-steroidal anti-inflamatory drugs in children. Journal of Allergy and Clinical Immunology. 2013; 131(2 Suppl.1):AB168

1972 Zaragoza RH. Update in the prevalence of atopic conditions, IgE levels and skin test sensitization to aeroallergens in Northern Puerto Rico. Journal of Allergy and Clinical Immunology. 2014; 133(2 Suppl.1):AB188

1973 Zedan M, Settin A, El-Chennawi F, El-Desouky T, Nasef N, Fouda A. Eosinophilic cationic protein: is it useful in assessing control of childhood asthma? Eastern Mediterranean Health Journal. 2010; 16(10):1045-1049

1974 Zemek RL, Bhogal SK, Ducharme FM. Systematic review of randomized controlled trials examining written action plans in children: what is the plan? Archives of Pediatrics and Adolescent Medicine. 2008; 162(2):157-163

1975 Zetterquist W, Marteus H, Hedlin G, Alving K. Increased exhaled nitrite in children with allergic asthma is not related to nitric oxide formation. Clinical Respiratory Journal. 2008; 2(3):166-174

1976 Zetterström O, Fagerberg E, Wide L. An investigation of pollen extracts from different deciduous trees in patients with springtime allergy in Sweden. Acta Allergologica. 1972; 27(1):15-21

1977 Zhao Z, Huang C, Zhang X, Xu F, Kan H, Song W et al. Fractional exhaled nitric oxide in Chinese children with asthma and allergies--a two-city study. Respiratory Medicine. 2013; 107(2):161-171

1978 Zhou C, Baiz N, Banerjee S, Charpin DA, Caillaud D, De BF et al. The relationships between ambient air pollutants and childhood asthma and eczema are modified by emotion and conduct problems. Annals of Epidemiology. 2013; 23(12):778-783

1979 Ziaee V, Nourian R, Mehrkhani F. Sensitivity and specificity of self-reported symptoms for exercise-induced bronchospasm diagnosis in children. Annals of Allergy, Asthma and Immunology. 2009; 103(5 Suppl.3):A63-A64

1980 Zietkowski Z, Bodzenta-Lukaszyk A, Tomasiak MM, Skiepko R, Szmitkowski M. Comparison of exhaled nitric oxide measurement with conventional tests in steroid-naive asthma patients. Journal of Investigational Allergology and Clinical Immunology. 2006; 16(4):239-246

1981 Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A. Endothelin-1 in exhaled breath condensate of stable and unstable asthma patients. Respiratory Medicine. 2008; 102(3):470-474

1982 Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A. Soluble CD40 ligand and soluble P-selectin in allergic asthma patients during exercise-induced bronchoconstriction. Journal of Investigational Allergology and Clinical Immunology. 2008; 18(4):272-278

1983 Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Mroczko B, Szmitkowski M, Bodzenta-Lukaszyk A. RANTES in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction. Respiration. 2010; 80(6):463-471

1984 Zietkowski Z, Tomasiak MM, Skiepko R, Bodzenta-Lukaszyk A. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respiratory Medicine. 2008; 102(8):1198-1202

1985 Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Zietkowska E, Bodzenta-Lukaszyk A. Eotaxin-1 in exhaled breath condensate of stable and unstable asthma patients. Respiratory Research. 2010; 11:110

1986 Zietkowski Z, Skiepko R, Tomasiak MM, Bodzenta-Lukaszyk A. Endothelin-1 in exhaled breath condensate of allergic asthma patients with exercise-induced bronchoconstriction. Respiratory Research. 2007; 8:76

1987 Zietkowski Z, Tomasiak-Lozowska MM, Skiepko R, Mroczko B, Szmitkowski M, Bodzenta-Lukaszyk A. High-sensitivity C-reactive protein in the exhaled breath condensate and serum in stable and unstable asthma. Respiratory Medicine. 2009; 103(3):379-385

1988 Zilmer M, Steen NP, Zachariassen G, Duus T, Kristiansen B, Halken S. Prevalence of asthma and bronchial hyperreactivity in Danish schoolchildren: no change over 10 years. Acta Paediatrica. 2011; 100(3):385-389

1989 Zimmerman B, Forsyth S. Diagnosis of allergy in different age groups of children: use of mixed allergen RAST discs, Phadiatop and Paediatric Mix. Clinical Allergy. 1988; 18(6):581-587

1990 Zollner IK, Weiland SK, Piechotowski I, Gabrio T, von Mutius E, Link B et al. No increase in the prevalence of asthma, allergies, and atopic sensitisation among children in Germany: 1992-2001. Thorax. 2005; 60(7):545-548

1991 Zuidgeest MGP, van Dijk L, Smit HA, van der Wouden JC, Brunekreef B, Leufkens HGM et al. Prescription of respiratory medication without an asthma diagnosis in children: a population based study. BMC Health Services Research. 2008; 8:16

1992 Zuidgeest MGP, van Dijk L, Spreeuwenberg P, Smit HA, Brunekreef B, Arets HGM et al. What drives prescribing of asthma medication to children? A multilevel population-based study. Annals of Family Medicine. 2009; 7(1):32-40

1993 Zureik M, Liard R, Segala C, Henry C, Korobaeff M, Neukirch F. Peak expiratory flow rate variability in population surveys: Does the number of assessments matter? Chest. 1995; 107(2):418-423

1994 Zwar NA, Marks GB, Hermiz O, Middleton S, Comino EJ, Hasan I et al. Predictors of accuracy of diagnosis of chronic obstructive pulmonary disease in general practice. Medical Journal of Australia. 2011; 195(4):168-171